[
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease cystic fibrosis. The ICD-10 codes associated with this disease are ['E84.9', 'Z14.1', 'E84.0', 'E84.11', 'E84.8', 'E84.19', 'P09.4']. The drugs being studied in this trial are sildenafil and placebo. The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include having a confirmed diagnosis of cystic fibrosis, being at least 18 years old, having a FEV1 (forced expiratory volume in 1 second) of at least 50% predicted, being clinically stable without respiratory tract infection or exacerbation, being able to perform spirometry, understanding and signing an informed consent, and being willing and able to perform nasal potential difference testing. The exclusion criteria include having a history of hypersensitivity to sildenafil, recent use of an investigational agent, being pregnant or breastfeeding, having certain medical conditions or impairments, inability to swallow pills, previous lung transplantation, use of certain medications, and other conditions or abnormalities that may compromise safety or data quality.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include Ewing's sarcoma/soft tissue sarcoma, neuroblastoma, and brain tumors. The corresponding ICDCodes for these diseases are C71.7, C71.9, C79.31, D33.0, D33.1, D33.2, and D49.6. The drugs being used in the trial are plerixafor. \n\nThe eligibility criteria for this trial include:\n- Age between 2 to less than 18 years during stage 1 and 1 to less than 18 years during stage 2.\n- Patients with Ewing's sarcoma, soft tissue sarcoma, lymphoma, neuroblastoma, brain tumors, or other malignancy (excluding leukemia) requiring high dose chemotherapy and autologous transplant as rescue therapy.\n- Eligible for autologous transplantation.\n- Recovered from all acute significant toxic effects of prior chemotherapy.\n- Adequate performance status.\n- Specific blood count requirements.\n- Specific liver function requirements.\n- Patient and/or their parent/legal guardian willing and able to provide informed consent.\n- Patients who are sexually active must be willing to abstain from sexual intercourse or use contraception while receiving plerixafor treatment.\n\nThe exclusion criteria for this trial include:\n- Any form of leukemia.\n- High-risk co-morbid condition.\n- Previous stem cell transplantation.\n- Prohibited marrow involvement prior to mobilization.\n- Ongoing toxicities from prior chemotherapy.\n- Acute infection or fever.\n- Known HIV seropositivity, AIDS, hepatitis C, or active hepatitis B infections.\n- Positive pregnancy test in post-pubertal girls.\n- History of clinically significant cardiac abnormality or arrhythmia.\n- Use of investigational drugs not approved in any indication within 2 weeks prior to the first dose of G-CSF.\n- Inability to adhere to the study requirements, as determined by the investigator.",
    "The sample from the table is for a phase 2 clinical trial. The diseases being studied are nausea, vomiting, and glioma. The corresponding ICD-10 codes for these diseases are 'R11.0', 'R11.11', 'R11.2' for nausea, 'R11.10', 'R11.12', 'R11.14', 'R11.11', 'K91.0', 'O21.2', 'O21.8' for vomiting, and unspecified codes for glioma. The drugs being used in the trial are aprepitant and ondansetron. The eligibility criteria for the trial include having a confirmed diagnosis of glioma, being either chemotherapy na\u00efve or non-na\u00efve and scheduled to receive temozolomide-based +/- Bevacizumab-based chemotherapy, age \u2265 18 years, having received \u2264 2 prior chemotherapeutic regimens, and meeting certain laboratory and clinical criteria. The sample also includes exclusion criteria such as pregnancy or breastfeeding, prior use of nitrosourea drugs, inability or unwillingness to cooperate with study procedures, and concurrent use of certain medications.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of glioblastoma multiforme, a type of brain tumor. The trial is investigating the effectiveness of the drugs axitinib and axitinib plus lomustine. The eligibility criteria for participants include having a histopathological diagnosis of glioblastoma, either \"de novo\" or \"secondary,\" and having experienced glioma recurrence or progression after prior treatment with surgery, radiation therapy, and alkylating chemotherapy. Other criteria include the presence of a measurable tumor lesion, specific characteristics of the glioblastoma on imaging tests, no contraindications for evaluation by certain imaging techniques, availability of archival glioma tissue, and certain organ function requirements. Additional criteria include specific requirements for corticosteroid use, performance status, life expectancy, and resolution of prior treatment effects. Women of childbearing potential must have a negative pregnancy test and agree to use contraception. The sample also includes exclusion criteria related to gastrointestinal abnormalities, hypertension, concurrent treatments, and certain medical conditions. Participants must provide informed consent and be willing to comply with the study procedures.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on ovarian cancer and fallopian tube cancer. The diseases are represented by their respective ICD-10 codes. The drug being studied is called \"bibf 1120\". The sample also includes the eligibility criteria for participants in the trial, including age, previous treatments, organ function, and other medical conditions. The inclusion criteria specify that female subjects must have histologically proven recurrent advanced epithelial ovarian, fallopian tube, or primary peritoneal carcinomas. The exclusion criteria list various conditions and factors that would make a patient ineligible for the trial, such as certain types of tumors, significant cardiovascular diseases, and laboratory values indicating an increased risk for adverse events.",
    "The sample from the table represents a phase 2 clinical trial for patients with Philadelphia positive, BCR-ABL positive, and acute lymphoblastic leukemia (ALL). The trial is focused on the drug ponatinib. The eligibility criteria for the trial include having >20% blasts in the bone marrow at the time of diagnosis and no prior history of chronic myeloid leukemia (CML). Patients must be either 60 years or older or 18 years or older but unfit for intensive therapy and allogeneic stem cell transplantation. Adequate hepatic and pancreatic function is required, as well as negative pregnancy test for females of childbearing potential. Patients must also agree to use contraception during the study and for 4 months after treatment. The exclusion criteria include poor performance status, active hepatitis, history of pancreatitis or alcohol abuse, ongoing infections, uncontrolled hypertriglyceridemia, and various cardiovascular conditions. Other exclusion criteria include uncontrolled hypertension, certain medications, impaired kidney function, gastrointestinal issues, recent major surgery, pregnancy or breastfeeding, history of another significant malignancy, and unwillingness or inability to comply with the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is prostate cancer. The ICDCodes associated with this disease are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']. The drugs being used in the trial are abiraterone acetate, androgen deprivation, and prednisone. The eligibility criteria for this trial include various factors such as Gleason Score, PSA levels, clinical stage, ECOG Performance Status, laboratory values, age, ability to swallow medication, and willingness to adhere to study restrictions. There are also exclusion criteria listed, which include factors such as metastasis, prior therapy for prostate cancer, testosterone levels, previous malignancies, hypertension, gastrointestinal disorders, and various other medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this particular sample, the phase of the trial is phase 2. The disease being studied is \"breast neoplasms\" and its corresponding ICD-10 codes are listed as \"C79.81\", \"D24.1\", \"D24.2\", \"D24.9\", \"D49.3\", \"C44.501\", and \"D48.60\". The drugs being tested are \"erismodegib\" and \"placebo\". The eligibility criteria for this trial include a diagnosis of pathologic stage II or III ER, PR, and HER2 negative primary invasive ductal or invasive lobular breast carcinoma, completion of all surgery for breast cancer, completion of axillary lymph node surgery, completion of (neo) adjuvant chemotherapy and radiation therapy, completion of the most recent cancer therapy no less than 3 and no more than 24 weeks prior to registration, being at least 18 years of age, having an ECOG performance status of \u2264 1, and being able to understand and sign an IRB approved informed consent document.\n\nThe exclusion criteria for this trial include concurrent treatment with any other standard therapy within 3 weeks of starting sonidegib, treatment with investigational anti-cancer agents within 4 weeks or 5 half-lives of initializing treatments with sonidegib, previous treatment with systemic sonidegib or other Hh pathway inhibitors, diagnosis of a neuromuscular disorder or concomitant treatment with drugs that cause rhabdomyolysis, being HIV-positive on combination antiretroviral therapy, and other specific medical conditions or medications that may interfere with participation in the study.\n\nAdditionally, there are registration inclusion and exclusion criteria listed. The inclusion criteria for registration include the presence of bone marrow DTCs after completion of all intended breast cancer therapy, having an ECOG performance status of \u2264 1, and meeting specific normal bone marrow and organ function requirements. The exclusion criteria for registration include evidence of distant metastasis within one year prior to the trial, history of other malignancy within the past 5 years (with exceptions), history of allergic reactions to similar compounds, planning to embark on a new strenuous exercise regimen, diagnosis of a medical condition that affects the upper gastrointestinal tract or causes malabsorption syndrome, taking specific medications that interact with sonidegib, having concurrent uncontrolled medical conditions, impaired cardiac function or clinically significant heart disease, and being pregnant or breastfeeding.\n\nIt is important to note that this description is based on the provided sample and may not encompass all possible information in the table.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on diabetes mellitus, specifically type 1 diabetes. The trial involves the use of the drug imatinib mesylate, with a placebo also being administered. The eligibility criteria for participants are listed, including age requirements, diagnosis timeline, C-peptide levels, and the need for effective birth control for sexually active participants. The exclusion criteria are also outlined, which include prior cardiac disease, abnormal blood counts, history of severe drug reactions, active infections, use of certain diabetes medications, and liver or kidney dysfunction, among others. The sample concludes with a list of conditions or factors that may affect study participation or the interpretation of results.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2, and the disease being studied is glioblastoma multiforme (gbm). The icd-10 codes associated with this disease are 'L51.0', 'L51.8', and 'L51.9'. The drug being used in the trial is fluciclitite, pet imaging, and bevacizumab. The eligibility criteria for this trial include being 18 years or older, having a histologically proven GBM and scheduled for Avastin therapy, having a tumor volume of > 2.0 cm, having a recent MRI of the brain within 28 days, agreeing to have clinical and radiographic endpoints entered into a research database, signing informed consent and HIPAA authorization, meeting certain requirements for female patients, and having pre-treatment laboratory tests performed. The exclusion criteria include known allergies to radiopharmaceuticals, requiring monitored anesthesia for PET scanning, being claustrophobic, having a calculated GFR of less than 30 ml/min, being HIV positive, and being unable to undergo MRI imaging due to exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is \"untreated adult acute myeloid leukemia.\" The ICDCodes associated with this disease are \"C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01.\" The drugs being used in the trial are \"cytarabine, daunorubicin hydrochloride, nilotinib.\" The eligibility criteria for this trial include various medical conditions, such as specific blood test results, normal organ function, and absence of certain illnesses. Additionally, there are exclusion criteria, which include factors like pregnancy, certain medical conditions, and use of specific medications.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as a phase 1/phase 2 trial. The disease being studied is cancer, specifically grade four Glioblastoma Multiforme. The trial is looking for patients who have experienced tumor progression following radiation and first-line chemotherapy with Temozolomide. The inclusion criteria include being 18 years or older, having a confirmed diagnosis of Glioblastoma Multiforme, having a Karnofsky performance scale of 60% or greater, and being willing to comply with all study requirements. The exclusion criteria include having Glioblastoma Multiforme secondary to low-grade glioma or anaplastic glioma, currently receiving treatment for recurrent Glioblastoma Multiforme, and having undergone certain surgeries or treatments within specific time intervals. Other exclusion criteria include having certain medical conditions, substance abuse or dependence disorders, and significant psychiatric disorders. The sample also mentions criteria related to pregnancy, contraception, and allergies to certain medications.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on smoking cessation. The associated diseases are chronic cough associated with long-term smoking, non-obstructive chronic bronchitis (NCB), and physician-diagnosed chronic obstructive pulmonary disease (COPD). The ICD-10 codes for these diseases are ['Y36.881S', 'Y36.891S', 'Y36.880S', 'Y36.881A', 'Y36.881D', 'Y36.890S', 'Y36.891A'].\n\nThe drugs being studied are nadolol and placebo. The eligibility criteria for potential study participants are listed, including being an active cigarette-smoking male or female between the ages of 18-70 with chronic cough associated with long-term smoking. Participants must have a committed desire to quit smoking and be enrolled in an approved smoking cessation program. Other criteria include a diagnosis of COPD or NCB, certain lung function measurements, baseline blood pressure and heart rate, smoking intensity, prior failed attempts to quit smoking, ability to comply with study procedures, and certain requirements for female participants of childbearing age.\n\nThe exclusion criteria are also listed, which include having certain medical conditions, allergies, history of alcohol or drug abuse, recent participation in another research trial, inability to comply with study procedures, pregnancy or nursing, and use of certain medications or substances.\n\nOverall, this sample provides information about the phase, diseases, drugs, and eligibility criteria for potential participants in a smoking cessation clinical trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is \"staphylococcal infection.\" The ICDCodes associated with this disease are ['G00.3', 'M00.09', 'A05.0', 'M00.08', 'L00', 'M00.00', 'M00.011']. The drugs mentioned are 'mupirocin calcium' and 'mupirocin calcium'. The eligibility criteria are listed under \"Inclusion Criteria\" and \"Exclusion Criteria,\" which include factors such as age, colonization with SA, anticipated duration of stay in the ICU, previous participation in the trial, current use of mupirocin, presence of certain congenital abnormalities, nasal intubation, hypersensitivity to the trial product, immune deficiency, and any other conditions that may jeopardize safety or compliance with the protocol.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2, and the diseases being studied are Crohn's disease and Crohn disease. The corresponding ICD-10 codes for these diseases are provided. The drug being tested is high-dose cyclophosphamide. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Participants must be at least 18 years old, both males and females are eligible.\n- Participants must have moderate to severe Crohn's Disease with a CDAI (Crohn's Disease Activity Index) score greater than 220. Additionally, evidence of ulceration on ileocolonoscopy or active disease on small bowel imaging is required (except for patients with an ostomy).\n- Participants must have experienced disease progression despite treatment with at least one anti-tumor necrosis factor (TNF) agent (such as infliximab, adalimumab, certolizumab pegol). They must also have had disease progression despite treatment with one of the following immunosuppressant drugs: azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, natalizumab, vedolizumab.\n- Participants must be willing to participate in a clinical trial.\n- Approval by an Enrollment Panel is required to determine the appropriateness of potential study participants.\n\nThere are also exclusion criteria for the trial, which include:\n- Pregnant or nursing women.\n- Sexually active men and women who do not agree to use effective means of birth control during the treatment period.\n- Evidence of primarily fibrostenosing disease without active inflammatory disease on disease staging.\n- Co-morbid conditions including cardiac disease with an ejection fraction of less than 45%, chronic renal failure with serum creatinine greater than 2.0, liver disease with total bilirubin greater than 2.0 (excluding hyperbilirubinemia secondary to Gilbert's disease), or transaminitis greater than 3 times the upper limit of normal.\n- History of serious allergic reaction to cyclophosphamide.\n- History of malignancy in the last 5 years (excluding non-melanomatous skin cancers).\n- Patients who are pre-terminal.\n- Toxic megacolon.\n- Active infection.\n- White blood cell count less than 3000 cells/ul, platelets less than 100K/ul, hemoglobin less than 10.0 g/dL.\n- Any use of thiopurines, methotrexate, or anti-TNF agents in the previous four weeks prior to treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is metastatic colorectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are 5-fluorouracile, leucovorin l, oxaliplatin, irinotecan, and cetuximab. The eligibility criteria for this trial include being at least 18 years old, having an ECOG performance status of 0 or 1, having a confirmed diagnosis of adenocarcinoma of the colon or rectum with wild-type RAS and B-RAF tumor status, having potentially resectable metastatic disease, and meeting certain hematological, renal, and hepatic function requirements. There are also exclusion criteria listed, such as having definitively non-resectable metastatic colorectal cancer, having received prior chemotherapy or systemic therapy for mCRC, and having concurrent central nervous system metastases.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is acute myeloid leukemia. The ICDCodes associated with this disease are C92.A1, C92.A2, C92.61, C92.62, C92.A0, and C92.60. The drug mentioned is midostaurin. The eligibility criteria for this trial include age between 18 and 60, ECOG Performance Status of less than 2, a documented diagnosis of AML according to WHO 2008 classification, presence of FLT3 ITD mutation, and previous allogeneic HSCT in CR1 from a matched related or matched unrelated donor. The sample also includes exclusion criteria such as failed prior attempts at allogeneic HSCT, autologous transplant, Acute GVHD Grade III-IV, confirmed diagnosis of HIV infection or active viral hepatitis, and impaired cardiac function. Additionally, it mentions criteria related to pulmonary infiltrate, treatment with specific inhibitors or inducers, and pregnancy or nursing status.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is breast cancer. The ICDCodes associated with breast cancer are listed as C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are placebo and valproic acid (VPA). \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n1. Patients with symptomatic pleural effusion requiring the presence of an IPC or new placement of an IPC.\n2. Pathologic documentation of breast cancer.\n3. Performance status 0 to 3 (ECOG scale).\n4. Signed informed consent.\n5. Subject must be female or male age 18 years or over.\n6. At least one prior line of chemotherapy in the metastatic setting.\n7. Positive effusion cytology.\n\nExclusion Criteria:\n1. Other prior malignancy (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer) from which the patient has been disease-free for at least two years.\n2. Laboratory results sustained at: Neutrophils less than 1.5 \u00d7 109/L; Serum bilirubin >1.5 x the upper limit of reference range (ULRR); Serum creatinine >1.5 x ULRR or creatinine clearance < 30 mL/minute (calculated by Cockcroft-Gault formula).\n3. Patients with a history of existing hypercalcemia, hypocalcemia, hypermagnesemia or hypomagnesemia that is not corrected despite supplementation. Known Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 \u00d7 ULRR or alkaline phosphatase (ALP) >2 x ULRR, or > 4x ULRR if judged by the investigator to be related to liver metastases.\n4. Serious underlying medical condition that would impair the ability of the patient to receive protocol treatment, specifically cardiac diseases, uncontrolled hypertension or renal diseases.\n5. Diagnosis of an infection requiring IV antibiotics 14 days prior to registration.\n6. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.\n7. Women who are currently pregnant or breastfeeding.\n8. Known hypersensitivity to VPA, valproate sodium, disodium valproate, or any ingredient in the respective formulation.\n9. Known urea cycle disorders based on history.\n10. Known HIV infection based on history.\n11. Active or recent pancreatitis (within last 6 months).\n12. Any of the following interventions on the affected hemithorax: prior IPC, prior chest tube placement, history of chemical or mechanical pleurodesis, history of thoracotomy within 4 weeks and incompletely healed surgical incision before randomization.\n13. Evidence of empyema or history of empyema of the affected hemithorax.\n14. Non-correctable bleeding diathesis.\n15. Clinical evidence of skin infection at the potential site of IPC placement.\n16. Patients currently taking valproic acid.\n17. History of hepatitis or liver disease.\n18. The following drugs will not be administered concurrently with VPA: Carbapenem antibiotics; Clonazepam; Topiramate; Felbamate; Lorazepam; Barbiturates; Barbiturates; CarBAMazepine; ChlorproMAZINE; Ethosuximide; GuanFACINE; LamoTRIgine; MethylfolateOXcarbazepine; Paliperidone; Phenytoin; Primidone; Protease Inhibitors; Rifampin; Risperidone; Rufinamide; Salicylates; Temozolomide; Tricyclic Antidepressants; Vorinostat; Zidovudine.\n19. History of seizures.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of treatment-resistant depression. The trial includes patients who have been diagnosed with Major Depressive Disorder (MDD) and are currently experiencing a Major Depressive Episode (MDE) of at least eight weeks in duration. The eligibility criteria include being between 18-70 years old, able to provide informed consent, having a history of treatment-resistant depression during the current MDE, and meeting a certain threshold on the MADRS score.\n\nThe sample also includes a list of exclusion criteria, such as being pregnant or breastfeeding, having a history of substance use disorder, bipolar disorder, schizophrenia, or eating disorders, and having certain medical conditions like hypertension, recent myocardial infraction, or congestive heart failure. It also mentions specific lab abnormalities and exclusionary medications.\n\nOverall, the sample provides detailed information about the eligibility and exclusion criteria for participants in the clinical trial.",
    "The sample provided is for a phase 2 clinical trial for breast cancer. The trial is specifically targeting postmenopausal women with operable breast cancer (T1c-T3, any N, M0). The patients must have measurable disease and a confirmed diagnosis of breast cancer through histological and/or cytological analysis. They should also have a diagnostic biopsy available for the analysis of PIK3CA mutation and Ki67 level.\n\nIn terms of eligibility criteria, the patients must be adult females aged 18 or older at the time of informed consent. They should have estrogen-receptor and/or progesterone positive breast cancer, as well as HER2 negative breast cancer. Exclusion criteria include having locally recurrent or metastatic disease, receiving any prior systemic therapy or radiotherapy for the current breast cancer, and having uncontrolled hypertension or a history of acute pancreatitis within the past year.\n\nThe drugs being tested in this trial are alpelisib, buparlisib, and a placebo.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on knee osteoarthritis. The ICD-10 codes associated with the disease are listed as well. The drugs being studied in the trial include tpx-100 in various dosages and a placebo. The eligibility criteria for participants are also provided, including age restrictions, specific knee conditions, and requirements for using certain medications. Additionally, there are exclusion criteria listed, such as contraindications to MRI, previous knee surgeries, and certain medical conditions. The sample also includes information about birth control requirements for female participants, as well as other restrictions and medical history considerations.",
    "The sample from the table is for a phase 2 trial. The disease being studied is HIV-1 infection. The ICD-10 codes associated with the disease are B20, Z71.7, O98.72, Z21, O98.73, R75, and Z11.4. The drug being tested is telmisartan. The eligibility criteria for the trial include having documented HIV-1 infection, being on antiretroviral therapy for at least 48 weeks, having HIV-1 RNA levels below a certain threshold, and not having made any recent changes to the antiretroviral therapy regimen. Other criteria include having a specific body mass index range, negative pregnancy test for females of reproductive potential, providing informed consent, and willingness to undergo certain biopsies. There are also exclusion criteria such as having certain blood pressure levels, liver or heart diseases, being pregnant or breastfeeding, using certain medications, having certain laboratory values outside the normal range, and having certain medical conditions or illnesses.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes information about the diseases being studied, the ICDCodes associated with those diseases, the drugs being used, and the eligibility criteria for participants.\n\nIn this particular sample, the phase of the trial is phase 2. The diseases being studied are colorectal neoplasms and adenocarcinoma. The ICDCodes associated with these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2 for colorectal neoplasms and C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31 for adenocarcinoma.\n\nThe drugs being used in the trial are metformin and irinotecan. The eligibility criteria for participants include being 18 years or older, having biopsy-proven colorectal adenocarcinoma, being ineligible for curative intent therapy such as surgery or radiation, having disease progression after specific previous treatments, and having assessable disease according to RECIST v1.1.\n\nThere are also exclusion criteria, which include known hypersensitivity to metformin or irinotecan, uncontrolled central nervous system metastasis, and acute or chronic severe infection.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has several columns including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases, \"icdcodes\" which lists the ICDCodes (ICD-10 codes) associated with the diseases, \"drugs\" which lists the names of drugs, and \"criteria\" which provides the eligibility criteria for the trial.\n\nThe sample data in the table includes information for different cohorts and steps within the trial. It includes details such as the inclusion criteria, exclusion criteria, and specific requirements for each cohort and step. The inclusion criteria include factors such as HIV-1 infection, specific medication history, laboratory values, and negative test results for certain diseases. The exclusion criteria include factors such as a history of malignancy, active infections, autoimmune disorders, and certain medication use. The sample also mentions requirements for pregnancy testing, contraception, and performance scores.\n\nOverall, the table provides a structured way to store and organize information about clinical trial phases, diseases, drugs, and eligibility criteria, allowing for easy retrieval and analysis of the data.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease gastroparesis. The associated ICD-10 code for gastroparesis is K31.84. The trial involves several drugs, including gsk962040 50 mg, metoclopramide 10 mg, placebo ng, and placebo iv. \n\nThe eligibility criteria for participants in this trial include being between 18 and 85 years old, being admitted to the participating ICU within the previous 48 hours, being intubated and invasively mechanically ventilated, and being indicated to receive early enteral nutrition (EN) or already receiving EN. Additionally, participants must meet certain clinical criteria such as having cardiovascular dysfunction requiring vasopressor agents or having a poly-trauma with an injury severity score (ISS) of at least 15 points.\n\nThere are also exclusion criteria, such as not being expected to be in the ICU and alive for at least 48 hours from the screening point, having acute hepatitis or severe chronic liver disease, having certain liver function test results, having received a gastric prokinetic agent in the previous 12 hours, having a prolonged QT duration corrected for heart rate, using strong Cyp3A4 inhibitors, requiring renal replacement therapy or having a low estimated glomerular filtration rate (GFR), having a history of major esophageal or gastric surgery, having absolute contraindications to enteral nutrition, having a gastric pacemaker, being pregnant or lactating, having a history of sensitivity to the study medications, being concurrently enrolled in another interventional study involving a novel chemical or biopharmaceutical entity, having been previously randomized in this study, being admitted to the ICU due to an overdose, having an untreated pheochromocytoma, having a past history of a seizure disorder and currently receiving anti-epileptic treatment, or taking drugs likely to cause extrapyramidal reactions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the treatment of heart failure. The trial includes patients who have been diagnosed with acute decompensated heart failure within the last 24 hours and exhibit symptoms such as dyspnea, respiratory distress, or tachypnea. The patients must also show evidence of elevated cardiac filling pressure or pulmonary congestion.\n\nOther criteria for inclusion in the trial include left ventricular systolic dysfunction, age of 18 years or older, willingness and ability to provide written informed consent, and screening plasma C-reactive protein levels above 5 mg/L.\n\nThere are also exclusion criteria that would make patients ineligible for the trial. These include having a primary diagnosis other than decompensated heart failure, having comorbidities that would interfere with the study, recent cardiac procedures or surgeries, chronic use of intravenous inotropes, recent use of immunosuppressive or anti-inflammatory drugs, chronic inflammatory disorders, active infections, chronic/recurrent infectious diseases, prior or current malignancy, comorbidities limiting survival or ability to complete the study, end-stage kidney disease, neutropenia or thrombocytopenia, pregnancy, and angina, arrhythmias, or ECG changes that limit maximum exertion during exercise testing.\n\nOverall, the sample provides specific details about the phase, diseases, ICDCodes, drugs, and eligibility criteria for the clinical trial.",
    "The sample from the table is for a phase 2 clinical trial for breast cancer. The eligibility criteria for the trial include being 18 years or older, having histologically proven infiltrating carcinoma of the breast with specific characteristics, having unresected and untreated breast cancer of certain clinical stages, having a performance status of 0-1, and having adequate organ and cardiac function. The patient should also be willing to undergo baseline and follow-up imaging and biopsy procedures, use effective contraception, and understand and consent to the study. The exclusion criteria include receiving prior or ongoing local or systemic treatment for the current breast cancer, recent systemic treatment for other cancers, pregnancy or nursing, current use of investigational agents, known hypersensitivity to certain drugs, and certain medical conditions that may put the patient at risk.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is seasonal allergic rhinitis. The icd-10 code associated with this disease is J30.2. The drugs being used in the trial are sparc placebo, sparc1310 i, sparc1310 ii, and sparc1310 iii. The eligibility criteria for participants include being male or female aged 18 to 65 years with a history of seasonal allergic rhinitis and being able to understand and sign the informed consent form. Exclusion criteria include having significant nasal septum deviations, being pregnant or nursing, having positive serology for infectious diseases (Hepatitis B or C, HIV), participating in another current investigational study or participating in a study within the last 30 days prior to study entry, or having previously participated in the same study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of external genital warts. The ICD-10 codes associated with the disease are provided. The drugs being studied are \"15% as101 gel\" and \"vehicle.\" The eligibility criteria for participants are listed, including age requirements, the need to sign an informed consent form, and the agreement to avoid sexual contact while using the gel. Inclusion criteria also include a clinical diagnosis of external genital warts and specific characteristics of the warts being treated. Exclusion criteria are also listed, such as recent participation in other trials, previous participation in a trial involving AS101, recent topical treatment for genital warts, and various medical conditions or allergies that could interfere with participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is diabetic macular edema. The ICDCodes associated with this disease are ['E10.311', 'E10.319', 'E11.311', 'E11.319', 'E13.311', 'E13.319', 'E10.3513']. The drugs being used in the trial are 'intravitreal ranibizumab 0.3 mg' and 'dexamethasone intravitreal implant'. \n\nThe eligibility criteria for this trial include being at least 18 years old, having a diagnosis of diabetes mellitus (type 1 or type 2), and meeting specific ocular criteria related to the study eye. Exclusion criteria include having chronic renal failure, unstable medical status, recent initiation of intensive insulin treatment, participation in other investigational trials, known allergies to study drugs, and certain medical conditions such as high blood pressure, recent cardiac events, and recent use of certain medications. \n\nThere are also specific exclusion criteria related to the study eye, such as the presence of macular edema due to causes other than diabetic macular edema, certain ocular conditions that may affect visual acuity, and a history of certain eye treatments or surgeries.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is HIV infections. The ICDCodes associated with this disease are ['Z21']. The drugs being used in the trial are 'ldmtx' and 'placebo'. The eligibility criteria for participants in this trial include having documented HIV-1 infection, being on continuous antiretroviral therapy (ART) for at least 24 weeks, having specific laboratory values within normal ranges, and meeting certain cardiovascular disease (CVD) risk factors. There are also criteria related to reproductive potential, completion of specific assessments, and prior receipt of pneumococcal vaccination. The exclusion criteria include various medical conditions, recent treatments, allergies, substance use, recent changes in medication, and certain health conditions such as congestive heart failure and uncontrolled diabetes.",
    "The sample from the table represents a clinical trial for the treatment of acute myocardial infraction. The trial is in phase 2/phase 3. The disease being studied is acute myocardial infraction. The ICD-10 codes associated with this disease are 'I21.9', 'I23.8', 'I23.0', 'I24.0', 'I23.1', 'I23.2', and 'I23.4'. The drugs being tested in the trial are anakinra 100 mg and placebo. The eligibility criteria for the trial are as follows:\n\nInclusion Criteria:\n1. Patients must have acute ST-segment elevation myocardial infraction (STEMI) defined as chest pain (or equivalent) with an onset within 12 hours and ECG evidence of ST segment elevation (>1 mm) in 2 or more anatomically contiguous leads that is new or presumably new.\n2. Patients must have planned or completed coronary angiogram for potential intervention.\n3. Patients must be above the age of 21.\n\nExclusion Criteria:\n- Patients who are unable to give informed consent.\n- Pregnant patients.\n- Patients with preexisting congestive heart failure (American Heart Association/American College of Cardiology class C-D, New York Heart Association III-IV).\n- Patients with preexisting severe left ventricular dysfunction (EF<20%).\n- Patients with preexisting severe valvular heart disease.\n- Patients with active infections (acute or chronic), excluding Hepatitis C Virus (HCV)+ with undetectable RNA.\n- Patients who have recently (<14 days) or actively used anti-inflammatory drugs (excluding non-steroidal anti-inflammatory drugs [NSAIDs] or corticosteroids used for IV dye allergy only).\n- Patients with chronic inflammatory disease, including but not limited to rheumatoid arthritis and systemic lupus erythematosus.\n- Patients with active malignancy, excluding carcinoma in situ [any organ] and non-melanoma skin cancer.\n- Patients who are anticipated to need cardiac surgery.\n- Patients with neutropenia (absolute neutrophil count<1,800/mm3).",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on studying the effectiveness of certain drugs in treating hepatocellular carcinoma and lung metastasis. The diseases being targeted are hepatocellular carcinoma and lung metastasis. The corresponding ICD-10 codes for these diseases are provided as well.\n\nThe drugs being investigated in this trial are 5-fluorouracil and mitomycin. The eligibility criteria for participants in this trial are listed, including requirements such as having received previous local therapy treatments for intrahepatic hepatocellular carcinoma, having measurable lung metastasis, and having risk factors for hepatocellular carcinoma.\n\nOther criteria include age range (18 to 80 years), ECOG Performance Status of 0 to 2, Child-Pugh class A or B, and specific laboratory requirements for bone marrow and liver function. The exclusion criteria are also listed, which include factors such as a Child-Pugh score greater than 10, ECOG Performance Status greater than 3, history of organ allograft, and prior systemic chemotherapy except sorafenib.\n\nOverall, this sample provides information about the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is acute ischemic stroke. The ICD-10 codes associated with this disease are I25.5, H47.013, H93.013, G45.9, H47.011, H47.012, and H47.019. The drugs being tested in the trial are natalizumab and placebo. The eligibility criteria for participants include having a diagnosis of acute ischemic stroke, a score of at least 6 points on the National Institute of Health Stroke Scale (NIHSS) at screening, and the presence of at least one acute infarct with a diameter of more than 2 cm on baseline brain diffusion-weighted imaging (DWI). Other criteria include the ability to undergo baseline study magnetic resonance imaging (MRI) after reperfusion therapy (if received), practicing effective contraception for subjects of childbearing potential, and not having certain exclusion criteria such as intracranial hemorrhage, stroke isolated to the brainstem, coma, or contraindications to MRI.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is relapsed / recurrent germ cell tumors. The corresponding ICD-10 codes for these diseases are G47.13, J01.41, K11.22, K12.0, N96, F33.8, and G03.2. The drugs being investigated in this trial are erlotinib and sirolimus. The eligibility criteria for participants include being between 12 months and 50 years of age, having histologic verification of an extracranial germ cell tumor that is not a pure mature teratoma, having relapsed or refractory disease after at least two prior cisplatin-containing chemotherapy regimens, having measurable or evaluable disease according to RECIST criteria, and having a performance status score of at least 50. Other criteria include having a life expectancy of more than 8 weeks, fully recovering from previous anti-cancer therapy, having adequate bone marrow, renal, liver, and central nervous system function, and meeting certain requirements for cholesterol and triglyceride levels. Exclusion criteria include having active brain metastases, being pregnant or breastfeeding, taking certain medications, having uncontrolled infection, having received prior therapy targeting EGFR or mTOR inhibitors, having had major surgery within 3 weeks prior to enrollment, and not being able to comply with safety monitoring requirements.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is sickle cell disease, and the corresponding ICDCodes are ['D57.1', 'D57.20', 'D57.212', 'D57.219', 'D57.211', 'D57.213', 'D57.218']. The drug being investigated is hydroxyurea. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include pediatric patients aged 1.00-9.99 years with documented sickle cell anemia, a minimum weight of 10.0 kg, and consent from a parent or guardian. Exclusion criteria include known medical conditions that make participation ill-advised, severe malnutrition, pre-existing severe hematological toxicity, recent blood transfusion, and recent use of hydroxyurea.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of metastatic castration-resistant prostate cancer. The trial involves the use of drugs such as olaparib, placebo, abiraterone, and prednisone or prednisolone. The eligibility criteria for participants include being male, aged 18 years or older, having a histologically or cytologically proven diagnosis of prostate cancer, and being a candidate for abiraterone therapy with evidence of metastatic castration-resistant prostate cancer. Other criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, a life expectancy of at least 12 weeks, and willingness to comply with the study protocol. Participants must also have a stable concomitant medication regimen and have received at least 2 cycles of chemotherapy with docetaxel. Exclusion criteria include previous treatment in the present study, previous exposure to certain medications, unresolved toxicities from prior therapy, spinal cord compression or brain metastases, severe or uncontrolled systemic diseases, certain cardiac criteria, and other malignancies within the last 5 years. Inadequate bone marrow reserve or organ function, refractory nausea and vomiting, and certain medical conditions or surgeries are also exclusion criteria. The sample also includes exclusion criteria for genetic research.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is melanoma. The ICD-10 codes associated with the disease are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4. The drugs being used in the trial are dabrafenib and trametinib. The eligibility criteria for participants include being at least 18 years old, having histologically confirmed AJCC Stage IIIB or IIIC cutaneous melanoma with BRAF V600 mutation, being able to swallow oral medication, having an ECOG Performance Status of 0-1, having adequate organ function, and meeting certain requirements for pregnancy prevention. The exclusion criteria include having mucosal or ocular melanoma, evidence of distant metastatic disease, prior anti-cancer treatment for melanoma (except surgery), recent use of investigational drugs, use of prohibited medications, known hypersensitivity reactions to study treatments, HIV infection, glucose-6-phosphate dehydrogenase deficiency, history of other malignancies (with some exceptions), history or evidence of cardiovascular risk, history or current evidence/risk of retinal vein occlusion or central serous retinopathy, serious or unstable pre-existing medical conditions or psychiatric disorders, and breastfeeding.",
    "The sample is for a phase 2 clinical trial. The disease being studied is bacteremia due to Staphylococcus aureus. The ICD-10 codes associated with this disease are A41.2, J15.20, J15.29, P23.2, A41.1, A41.01, and A41.02. The drugs being tested in the trial are daptomycin and vancomycin. The eligibility criteria for inclusion in the trial include being over 21 years old, being an inpatient at the time of enrollment, having MRSA bacteremia due to MRSA isolates with a vancomycin MIC (minimum inhibitory concentration) greater than 1.5 ug/ml, and being willing to undergo all treatments and procedures as per the trial protocol. The exclusion criteria include having allergies to any of the study medications, being pregnant or breastfeeding, being unable to provide consent or having no legally authorized representatives, having participated in an interventional antibiotic or vaccine trial within the past three months, having a confirmation of MRSA vancomycin MIC greater than or equal to 1.5 ug/ml more than 48 hours after the microbiology laboratory report, being on palliative care or having less than 24 hours of life expectancy, having polymicrobial bacteremia or pneumonia, being on treatment with linezolid, tigecycline, or ceftaroline immediately prior to enrollment, having previous blood cultures positive for MRSA in the preceding one month, being on vancomycin or daptomycin treatment for more than 96 hours prior to enrollment, having BSI (bloodstream infection) due to MRSA with vancomycin MIC greater than or equal to 4 ug/ml, having baseline serum creatine kinase more than 1.5 times the upper limit of normal, having prosthetic heart valves, or having any other significant condition that, in the opinion of the investigator, would compromise the patient's safety or outcome in the trial. Additionally, there are two additional criteria for exclusion related to the presence of other organisms in blood cultures or signs and symptoms consistent with pneumonia.",
    "The sample is a phase 2 trial that focuses on three diseases: diabetes mellitus type 2, non-alcoholic fatty liver disease, and obesity. The diseases are identified by their corresponding ICD-10 codes. The trial involves two drugs, amlexanox and placebo. The eligibility criteria for participants include being at least 18 years old, having a confirmed diagnosis of diabetes mellitus, having a BMI between 27 and 45 kg/m2, and not being on insulin or other injectables for diabetes treatment. Other criteria include having a liver ultrasound confirming fatty infiltration, being able to read and understand the informed consent form, and being willing to comply with the study requirements. Exclusion criteria include having advanced liver disease, other viral hepatitis etiologies, hematologic abnormalities, HIV infection, inability to give informed consent, presence of certain medical conditions like active cancer or congestive heart failure, and other conditions that may impede data collection.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease phenylketonuria (PKU). The ICD-10 code for PKU is E70.0. The trial involves the drugs sapropterin and placebo. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include providing written informed consent, having a documented diagnosis of PKU with phenylalanine levels equal to or greater than 600 micromole per liter (mcmol/L), negative pregnancy test for women of childbearing potential, age between 18 and 29 years, mean blood phenylalanine levels between 600 and 1000 mcmol/L in the 12 months prior to inclusion, IQ score greater than or equal to 85, and willingness to comply with study procedures and dietary recommendations.\n\nExclusion criteria include having tetrahydrobiopterin (BH4) deficiency, previous exposure to sapropterin or BH4 for more than 30 days (or exposure within the previous 6 months), inability to comply with study procedures and neuropsychological testing, significant illnesses or conditions that may interfere with participation, significant illnesses, medications or substance abuse that may affect cognitive function, concomitant use of forbidden medications, hypersensitivity to sapropterin or BH4, recent cognitive neuropsychological testing, pregnancy or lactation, current or recent participation in another clinical trial, and legal incapacity or limited legal capacity.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 2. The disease mentioned is \"melanoma and brain metastases.\" The icd-10 codes associated with this disease are \"C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4.\" The drugs being used in the trial are \"dabrafenib 150 mg\" and \"trametinib 2.0 mg.\" The eligibility criteria for participants are listed, including requirements such as signed informed consent, specific mutation status, presence of certain lesions, age, organ function, and more. There are also exclusion criteria listed, which include factors such as uncontrolled neurological symptoms, previous treatments, presence of certain diseases or conditions, and allergies or contraindications to certain medications.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of chronic heart failure. The ICD-10 codes associated with this disease are ['I50.812', 'I50.22', 'I50.32', 'I50.813', 'I50.23', 'I50.33', 'I50.42']. The drugs being tested in this trial are 'rlx030 (serelaxin)' and 'placebo'. The eligibility criteria for participants include having a body weight of \u2264 160 kg, being diagnosed with compensated CHF (NYHA Class II - III), having a prior documented history of chronic heart failure, having an NT-proBNP level >300 pg/ml, being treated with appropriate CHF standard of care, and being able to comply with all requirements of the trial. The exclusion criteria include having current acute decompensated HF, being a major solid organ transplant recipient or planning to have an organ transplant within 1 year, having a history of untreated ventricular arrhythmia with syncopal episodes, having significant mitral and/or aortic valve disease, and having severe renal impairment.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on diabetic macular edema.\n- ICD Codes: The ICD-10 codes associated with the disease are ['E10.311', 'E10.319', 'E11.311', 'E11.319', 'E13.311', 'E13.319', 'E10.3513'].\n- Drugs: The drugs being studied are ranibizumab.\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include factors such as providing informed consent, age over 18, specific visual acuity range, willingness to attend clinic visits, and previous bevacizumab injections for diabetic macular edema. The exclusion criteria include factors such as pregnancy or lactation, lack of adequate contraception, recent steroid or laser treatments, history of certain eye conditions or surgeries, and participation in other clinical studies.\n\nOverall, this sample record provides information about a clinical trial focusing on diabetic macular edema, the drugs being studied, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating renal cell carcinoma, a type of kidney cancer. The trial includes patients with unresectable advanced or metastatic renal cell carcinoma that has not been previously treated with any systemic agents. The sample also includes a list of ICD-10 codes associated with the disease.\n\nThe trial involves the use of three drugs: atezolizumab (mpdl3280a), bevacizumab, and sunitinib. The eligibility criteria for the trial are listed, including requirements such as measurable disease, a Karnofsky performance score of 70 or higher, and adequate hematologic and end-organ function. Participants of childbearing potential must agree to use highly effective contraception methods.\n\nThe sample also includes exclusion criteria, which specify conditions that would disqualify a participant from the trial. These include recent radiotherapy for renal cell carcinoma, active malignancies or metastasis of the brain or spinal cord, uncontrolled pleural effusion or ascites, uncontrolled hypercalcemia, and certain other malignancies within the past 5 years. General medical exclusions include a life expectancy of less than 12 weeks, pregnancy or lactation, severe allergies to certain antibodies, history of autoimmune disease, and certain medical conditions such as pulmonary fibrosis or active pneumonitis.\n\nExclusion criteria related to medications include prior treatment with specific therapeutic antibodies or pathway-targeting agents, recent treatment with immunostimulatory or immunosuppressive medications, and specific exclusions related to the drugs bevacizumab and sunitinib, such as inadequately controlled hypertension or recent cardiovascular events.\n\nOverall, the sample provides information about the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for a clinical trial focused on treating renal cell carcinoma.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The disease being studied is pain. The ICD-10 codes associated with this disease are 'N50.82', 'R07.2', 'R07.82', 'R10.13', 'R10.33', 'R14.1', and 'R52'. The drugs being used in the trial are clonidine and ropivacaine. The eligibility criteria for participants are listed, including requirements such as undergoing foot or ankle surgery with a planned popliteal nerve block for postoperative pain relief, being 19 years of age or older, and being classified as American Society of Anesthesiology (ASA) class 1, 2, or 3. There are also exclusion criteria listed, such as not meeting the ASA classification, having allergies or intolerance to certain medications, having a history of continuous opioid use, having a pre-existing neurologic deficit in the lower extremity, having a clinically significant coagulopathy, or not following the UAB Department of Anesthesiology Algorithm for the Preoperative Management of an Angiotensin Converting Enzyme Inhibitor (ACEI) or an Angiotensin Receptor Blocker (ARB).",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is HCV infection, which is represented by the ICD-10 codes ['K94.02', 'K94.12', 'K94.22', 'K94.32', 'N99.511', 'A02.9', 'A31.0']. The drugs being used in the trial are ldv/sof and rbv. The eligibility criteria for participants are listed, including requirements such as providing written informed consent, having HCV genotype 1, and having HCV RNA levels above a certain threshold. There are also exclusion criteria, such as being pregnant or having co-infections with HIV or hepatitis B virus. The sample concludes with a note that there may be additional inclusion/exclusion criteria defined in the protocol.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is a combination of phase 1 and phase 2.\n- Diseases: The specific disease being targeted in the trial, which in this case is \"carcinoma, hepatocellular.\"\n- ICD Codes: The ICD-10 codes associated with the disease, which are listed as \"C22.0\", \"C4A.9\", \"C7B.1\", \"C4A.0\", \"C4A.31\", \"C4A.51\", and \"C4A.8\".\n- Drugs: The drugs being used in the trial, which include \"tepotinib 300 mg\", \"tepotinib 500 mg\", \"tepotinib 1000 mg\", \"tepotinib\", and \"sorafenib\".\n- Criteria: The eligibility criteria for participants in the trial, which are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". These criteria include factors such as confirmed diagnosis of hepatocellular carcinoma, specific disease progression or treatment history, MET status, liver function, age, performance status, and various medical history and condition considerations.\n\nOverall, this sample record provides information about a clinical trial targeting hepatocellular carcinoma, involving a combination of phase 1 and phase 2, and using specific drugs and eligibility criteria for participant selection.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on ovarian cancer. The ICD-10 codes associated with the disease are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drugs being studied in the trial are 'dnib0600a' and 'pld'. The eligibility criteria for participants are listed, including requirements such as having a performance status of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG), having a documented diagnosis of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, and having advanced cancer that has progressed or relapsed after previous treatment with a platinum-containing chemotherapy regimen. There are also exclusion criteria listed, such as having primary platinum-refractory disease, recent anti-tumor therapy, or significant concomitant diseases.",
    "The sample from the table represents a clinical trial for the treatment of estrogen receptor positive breast cancer. The trial is in phase 1/phase 2. The diseases being studied are limited to estrogen receptor positive breast cancer. The corresponding ICD-10 codes for these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being tested in the trial are azd5363, placebo, and fulvestrant. \n\nThe eligibility criteria for the trial include being a post-menopausal woman with a life expectancy of at least 3 months. The participant must have histological confirmation of estrogen receptor positive breast cancer and either metastatic or locally advanced disease that cannot be surgically removed. The participant must also have measurable or non-measurable disease and adequate bone marrow, renal, and hepatic function. The Eastern Cooperative Oncology Group (ECOG) performance status must be less than or equal to 2. The participant must have experienced progressive disease while receiving an aromatase inhibitor for metastatic breast cancer or relapsed with metastatic disease while receiving an aromatase inhibitor in the adjuvant setting. The participant can have up to 3 prior lines of endocrine therapy for advanced breast cancer and up to 1 line of chemotherapy for advanced breast cancer. The participant must be willing to donate an archival tumor sample and a baseline blood sample. They must also be suitable for further endocrine therapy.\n\nThe exclusion criteria for the trial include previous treatment with fulvestrant or PI3K/mTOR/Akt inhibitor therapy, recent treatment with chemotherapy, immunotherapy, targeted therapy, biologic therapy, or tumor embolization within 21 days of the study drug administration. Palliative radiotherapy within 7 days of the study drug is also excluded. Participants with clinically significant abnormalities in glucose metabolism, rapidly progressive visceral disease not suitable for further endocrine therapy, known brain or leptomeningeal metastases, or any other co-existing medical condition that would prevent trial entry are excluded. Concomitant medication that is unsuitable for combination with the trial medication is also excluded.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of severe community-acquired pneumonia (CAP). The diseases column specifies the disease being studied, while the icdcodes column provides the corresponding ICD-10 codes for the disease. The drugs column lists the drugs being used in the trial, which in this case are ticagrelor and placebo. The criteria column contains the eligibility criteria for the trial, including both inclusion and exclusion criteria. The inclusion criteria specify the conditions that patients must meet to be eligible for the trial, such as having new severe CAP and certain symptoms or laboratory findings. The exclusion criteria outline the conditions or factors that would disqualify a patient from participating in the trial, such as certain underlying diseases, age, pregnancy, or inability to receive the study drug. Overall, this sample provides a snapshot of the trial's phase, diseases being studied, drugs used, and the criteria for participant eligibility.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease called alpha-1 antitrypsin deficiency. The ICD-10 code for this disease is E88.01. The trial involves the use of drugs, specifically \"kamada-aat for inhalation, 80mg\", \"placebo\", and \"kamada-aat for inhalation, 160mg\". The eligibility criteria for participants in this trial include being between 18 and 65 years old, having a diagnosis of alpha1-antitrypsin deficiency (specifically individuals with a ZZ or Z null classification), having a forced expiratory volume in one second (FEV1) of at least 50% of predicted post bronchodilator, and not having had any respiratory exacerbations within 6 weeks of baseline. There are also exclusion criteria, such as having significant intercurrent illnesses, a history of life-threatening allergies or transfusion reactions, a history of lung transplant, current or previous use of AAT augmentation therapy, and current use of high-dose glucocorticoids. Other exclusion criteria include pregnancy or lactation, psychiatric or mental disorders, alcohol or drug abuse, and inability to undergo bronchoscopy. The sample also includes additional criteria and factors that may prevent a patient from complying with the study protocol.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial is evaluating the effectiveness of concurrent platinum-based chemotherapy in patients with locally advanced Stage IIIA or IIIB lung carcinoma. The eligibility criteria for inclusion in the trial include being 18 years or older, providing informed consent, having an ECOG performance status of 0-2, having histologically confirmed non-small cell lung carcinoma, having a history of at least 10-pack-years of smoking, and not undergoing surgical resection. The patients must also be assessed by a medical oncologist and radiation oncologist to ensure adequate bone marrow, hepatic, and renal function for the administration of platinum-based chemotherapy. The exclusion criteria include contraindications to MRI, serious medical comorbidities or contraindications to radiotherapy or chemotherapy, a prior history of lung cancer within 5 years, prior thoracic radiation at any time, metastatic disease (unless all metastases have been ablated and the patient is receiving chemoradiotherapy to the thoracic disease with curative intent), inability to attend the full course of radiotherapy or follow-up visits, and being pregnant or lactating.",
    "The sample provided is for a phase 2 clinical trial for Huntington's disease. The inclusion criteria for participants include having a diagnosis of Huntington's disease based on the presence of at least 36 CAG repeats, being male or female aged 21 or older with an onset of Huntington's disease after 18 years old, using adequate birth control for females of childbearing potential, having a body weight of at least 50 kg, scoring at least 25 points on the UHDRS-TMS (Unified Huntington's Disease Rating Scale - Total Motor Score), having a UHDRS Independence Score below 90%, providing written informed consent, willing to provide a blood sample for genetic analyses, able to take oral medication and comply with study procedures, being ambulatory and able to travel to the study center, and having a caregiver, informant, or family member available and willing to accompany the patient to the clinic. Exclusion criteria include having clinically significant heart disease, receiving treatment with tetrabenazine within 6 weeks of study screening, having a history of epilepsy or seizures within the last 5 years, having other serious medical illnesses that may put the patient at risk or influence the study results, receiving medications that prolong the QT interval or are metabolized by CYP2D6 and have the potential to reduce seizure threshold within 6 weeks prior to screening, and other criteria that can be obtained by contacting the investigator.",
    "The sample is a phase 2 trial for the treatment of schizophrenia and schizophrenia-related psychotic disorders. The trial includes participants who have given written informed consent and are between the ages of 18 and 65. They must be diagnosed with schizophrenia or a related disorder according to the Diagnostic and Statistical Manual of Mental Disorders Version 4. Participants must have been on a stable dose of their current antipsychotic medication for at least four weeks and have shown some response to first-line antipsychotic medication. They must remain stable on their medication throughout the study.\n\nThe inclusion criteria also state that participants must be willing to have their name notified to the responsible authorities and allow their primary care practitioner and consultant to be notified of their participation. \n\nExclusion criteria include known or suspected hypersensitivity to cannabinoids or any of the investigational medicinal product's excipients. Participants with a Positive and Negative Symptom Scale total score of less than 60 at Day 1 are also excluded. Other exclusion criteria include current or historical clinical pictures consistent with delirium or dementia, acute drug-induced psychosis, or bipolar disorder. Participants taking more than one antipsychotic medication, pregnant or lactating females, participants who have received an investigational medicinal product within 30 days prior to the screening visit, and participants with any other significant disease or disorder that may put them at risk or influence the study results are also excluded.\n\nAdditionally, participants with physical abnormalities that prevent safe participation in the study, those unwilling to abstain from blood donation during the study, those who have traveled outside their country of residence during the study, and those who have previously been randomized into this study are excluded.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 2 trial for the treatment of follicular lymphoma. The trial is evaluating the drug \"beeam\" and includes eligibility criteria for participants.\n\nThe inclusion criteria for the trial include patients with histologically confirmed relapsed follicular lymphoma, aged between 18 and 65 years, and who have experienced first or second chemosensitive relapses after salvage therapy. Patients must also be eligible for autologous stem cell transplantation (ASCT) and have a minimum number of CD34+ cells for transplantation. Other criteria include Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2, a minimum life expectancy of 3 months, and specific cardiovascular and organ function requirements.\n\nExclusion criteria for the trial include transformed follicular lymphoma, prior autologous or allogeneic transplantation, presence of non-chemosensitive disease, contraindication to any drug in the chemotherapy regimens, and various other medical conditions or treatments that may interfere with therapy.\n\nThe record also includes information about women of childbearing potential, who must have a negative serum pregnancy test and agree to use contraception during the study and for 6 months after treatment. Additionally, participants must have the ability to understand and sign a written informed consent document, be covered by medical insurance, and have signed informed consent.\n\nOverall, the record provides detailed information about the phase 2 trial, including the specific eligibility and exclusion criteria for potential participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 2 and phase 3. The disease being studied is \"myelodysplastic syndromes.\" The ICDCodes associated with this disease are \"D46.9,\" \"D46.C,\" and \"D46.Z.\" The drugs being tested in this trial are \"galunisertib\" and \"placebo.\" The eligibility criteria for participants include having a confirmed diagnosis of MDS based on WHO criteria, being in the very low, low, or intermediate-risk category according to IPSS-R, and having anemia with or without RBC transfusion dependence. There are also exclusion criteria, such as no history of moderate or severe cardiac disease and no prior history of acute myeloid leukemia.",
    "The sample is from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being tested, and \"criteria\" which provides the eligibility criteria for participants.\n\nIn this specific sample, the phase of the trial is phase 2. The disease being studied is schizophrenia, and the corresponding ICD-10 codes are listed as well. The drugs being tested are \"valacyclovir hci 500 mg tablets\" and \"placebo\". The eligibility criteria for participants are then listed, including age requirements, diagnosis confirmation, stability of the condition, language fluency, and other factors. There are also exclusion criteria listed, such as certain medical conditions, previous participation in other clinical trials, and pregnancy or breastfeeding.\n\nOverall, this sample provides specific details about the phase, diseases, drugs, and eligibility criteria for a clinical trial focused on schizophrenia.",
    "The sample is a phase 2 clinical trial for multiple sclerosis (MS). The trial is evaluating the effectiveness of a drug called \"95% pure ecgc capsules 200mg\" compared to a placebo. The eligibility criteria for participants include having a diagnosis of MS according to the McDonald criteria, having relapsing-remitting MS or secondary progressive MS, and being on stable therapy with specific medications for at least six months. Other criteria include having an EDSS score of less than or equal to 7.0, being between the ages of 18-60, and having normal organ and marrow function. There are also exclusion criteria, such as recent MS relapse, primary progressive form of MS, previous treatments not included in the inclusion criteria, history of renal or liver disease, recent consumption of green tea or tea extract, and participation in other clinical trials involving investigational agents. The sample also lists additional exclusion criteria related to allergies, contraindications for MRI, uncontrolled active illnesses, and other conditions that would make a subject unsuitable for the study. Pregnant women and individuals with underlying predisposition to gastrointestinal bleeding are also excluded.",
    "The sample from the table represents a clinical trial with a phase 1/phase 2 designation. The trial focuses on two diseases, namely chronic lymphocytic leukemia and mantle cell lymphoma. The corresponding ICD-10 codes for these diseases are provided as well. The trial involves the use of two drugs, ublituximab and ibrutinib. The eligibility criteria for participants are outlined, including requirements such as confirmed mantle cell lymphoma, refractory or relapsed after prior treatment, and an Eastern Cooperative Oncology Group (ECOG) score of 0 to 2. The exclusion criteria specify factors such as recent major surgery, chemotherapy, or immunotherapy, as well as the presence of certain infections or recent hematologic stem cell transplants. Additionally, the exclusion criteria mention specific conditions like Richter's transformation, prolymphocytic leukemia, or primary central nervous system lymphoma.",
    "The sample from the table represents a clinical trial for a drug called \"pralatrexate injection\" in patients with peripheral T-cell lymphoma. The trial is in phase 1/phase 2. The eligibility criteria for inclusion in the trial include being a Japanese patient at least 20 years of age, having a histological diagnosis of peripheral T-cell lymphoma, being relapsed or refractory with a treatment history of at least one regimen, having a clearly measurable enlarged lymph node or extranodal mass lesion, and being expected to survive for at least 3 months. Other criteria include having an ECOG performance status of 0-2, having adequate hemopoietic efficacy, liver and kidney function, and providing written consent for the study. Exclusion criteria include recent chemotherapy or high-dose systemic adrenocorticosteroid use, recent radiation therapy or other study drug use, history of stem cell transplantation, presence of cerebral metastasis or central nervous system lesion, active multiple primary cancer, severe cardiovascular disease, positive results for certain viral antibodies, presence of infectious disease requiring intravenous treatment, and presence of interstitial pneumonia or pulmonary fibrosis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is sickle cell disease, and the corresponding ICDCodes are ['D57.1', 'D57.20', 'D57.212', 'D57.219', 'D57.211', 'D57.213', 'D57.218']. The drugs being tested in this trial are alemtuzumab, cyclophosphamide, and sirolimus. \n\nThe eligibility criteria for patients participating in this trial are as follows:\n- Patients with sickle cell disease are eligible if they have any of the following complications: stroke or central nervous system event lasting longer than 24 hours, frequent vaso-occlusive pain episodes (\u2265 3 per year) requiring emergency room, acute care center, or hospital admissions, recurrent episodes of priapism (\u2265 2 per year) requiring emergency room visits, acute chest syndrome with recurrent hospitalizations (\u2265 2 lifetime events), red-cell alloimmunization (\u2265 2 antibodies) during long-term transfusion therapy, bilateral proliferative retinopathy with major visual impairment in at least one eye, osteonecrosis of 2 or more joints, sickle cell nephropathy defined by a GFR < 90mL/min/1.73m2 or the presence of macroalbuminuria (urine albumin > 300 mg/g creatinine), and pulmonary hypertension defined by a mean pulmonary artery pressure > 25mmHg.\n- The age range for eligible patients is 16-60 years.\n- Patients must have a Karnofsky performance status of 60 or higher.\n- Adequate cardiac function is required, defined as a left ventricular ejection fraction \u2265 40%.\n- Adequate pulmonary function is required, defined as diffusion lung capacity of carbon monoxide \u2265 50% predicted (after adjustment for hemoglobin concentration).\n- Estimated GFR (glomerular filtration rate) must be \u2265 50mL/min as calculated by the modified MDRD equation.\n- ALT (alanine aminotransferase) levels must be \u2264 3 times the upper limit of normal.\n- Patients must be HIV-negative.\n- Pregnant patients are not eligible.\n- Patients must be able and willing to sign informed consent.\n- Patients must have an HLA-haploidentical relative.\n\nThis sample provides a specific example of a clinical trial in Phase 2 that focuses on sickle cell disease and tests the effectiveness of alemtuzumab, cyclophosphamide, and sirolimus in eligible patients meeting the specified criteria.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"epidermolysis bullosa\". The associated ICD-10 codes for this disease are \"Q81.0\", \"Q81.1\", \"Q81.2\", \"Q81.8\", \"Q81.9\", \"L12.30\", and \"L12.35\". The drugs being studied in this trial are \"sd-101 dermal cream (3%)\", \"sd-101 dermal cream (6%)\", and \"vehicle (sd-101 0%)\". \n\nThe eligibility criteria for participants in this trial are as follows:\n- The participant or their legal representative must have signed an informed consent form.\n- The participant (or caretaker) must be willing to comply with all protocol requirements.\n- The participant must have a diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB.\n- Participants must be 6 months of age or older.\n- Participants must have 1 target wound within a specified size range at the start of the study.\n- The target wound must be at least 21 days old.\n\nThe exclusion criteria for participants in this trial are as follows:\n- Participants who do not meet all the entry criteria outlined in the inclusion criteria.\n- The selected target wound shows clinical evidence of local infection.\n- The participant has used any investigational drug within 30 days prior to enrollment.\n- The participant has undergone immunotherapy or cytotoxic chemotherapy within 60 days prior to enrollment.\n- The participant has used systemic or topical steroidal therapy within 30 days prior to enrollment, except for inhaled steroids and ophthalmic drops containing steroids.\n- The participant has used systemic antibiotics within 7 days prior to enrollment.\n- The participant has a current or past history of malignancy.\n- The participant has an arterial or venous disorder resulting in ulcerated wounds.\n- The participant has diabetes mellitus.\n- The participant is pregnant or breastfeeding during the study (a urine pregnancy test was performed for female participants of childbearing potential).\n- Female participants of childbearing potential who are not abstinent and not practicing a medically acceptable method of contraception.\n- The participant has a known history of cardiac, hepatic, or renal disease.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is primary open angle glaucoma. The icd-10 codes associated with this disease are H40.1130, H40.1131, H40.1132, H40.1133, H40.1134, H40.1110, and H40.1111. The drug mentioned is mitomycin-c. The eligibility criteria for this trial include being 18 years or older, having a diagnosis of chronic angle-closure glaucoma or open-angle glaucoma, being a suitable candidate for trabeculectomy with Ex-PRESS glaucoma filtration device with MMC in the superonasal quadrant in the study eye, and being capable and willing to provide consent. There are also exclusion criteria listed, such as being unable or unwilling to provide consent, having previous ocular surgeries preventing placement of the trabeculectomy device, having previous glaucoma drainage devices, having any abnormality other than glaucoma in the study eye that could affect tonometry, having certain ocular infections or inflammations, having significant unstable cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric diseases, being pregnant or breastfeeding, and having certain physical and laboratory findings that may affect the study.",
    "The sample in the table represents a phase 2 clinical trial for the treatment of various diseases, including desmoplastic/nodular medulloblastoma, medulloblastoma, medulloblastoma with extensive nodularity, nevoid basal cell carcinoma syndrome, and untreated childhood medulloblastoma. The trial aims to evaluate the effectiveness of the drugs carboplatin, cyclophosphamide, etoposide, methotrexate, and vincristine sulfate in treating these diseases.\n\nThe eligibility criteria for the trial include being newly diagnosed with nodular desmoplastic or medulloblastoma with extensive nodularity, having negative lumbar cerebrospinal fluid (CSF) cytology, and undergoing specific imaging tests such as pre-operative cranial MRI or CT, post-operative cranial MRI, and spinal MRI. Patients must be enrolled within 31 days of surgery and have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2.\n\nOther criteria include having a life expectancy of at least 8 weeks, being on a stable dose of dexamethasone for at least 1 week prior to enrollment, and meeting certain blood count and kidney function requirements. Patients with metastatic disease or those who have received prior tumor-directed therapy other than surgery and corticosteroids are not eligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is chronic thromboembolic pulmonary hypertension. The ICDCodes associated with this disease are \"I27.24\". The drugs being tested in this trial are macitentan and placebo. The eligibility criteria for this trial include requirements such as written informed consent, being diagnosed with CTEPH (WHO Group 4) that is deemed inoperable due to the location of the obstruction, and female participants of childbearing potential needing to have a negative pregnancy test and agree to use two reliable methods of contraception. There are also exclusion criteria listed, such as previous pulmonary endarterectomy, recurrent thromboembolism despite sufficient oral anticoagulants, and various lung diseases or conditions that may limit the ability to comply with study requirements.",
    "The sample from the table is for a phase 2 trial. The diseases being studied are anemia and chronic renal insufficiency. The corresponding ICD-10 codes for these diseases are provided. The drugs being tested are bay85-3934 and a placebo. The eligibility criteria for the trial include being a woman without childbearing potential, being at least 18 years old with anemia of chronic kidney disease, having a certain glomerular filtration rate, not being on dialysis, not having been treated with any erythropoiesis-stimulating agent within 8 weeks before randomization, having a certain mean screening Hb concentration, and having a body weight within a specific range. The exclusion criteria include having significant acute or chronic bleeding, having certain chronic inflammatory diseases, having a history of cancer except for specific cases, having been treated with any erythropoiesis-stimulating agent or received a red blood cell transfusion within 8 weeks before randomization, having a history of certain cardio-vascular events, having severe rhythm or conduction disorders, having New York Heart Association Class III or IV congestive heart failure, and having severe hepatic insufficiency or active hepatitis.",
    "The sample is a phase 2 trial for the treatment of depression. The trial focuses on patients with documented coronary heart disease and a diagnosis of major depression. The trial excludes patients with moderate to severe cognitive impairment, those who meet DSM-5 criteria for depressive disorder due to a general medical condition or medication, and those with major Axis I psychiatric disorders other than unipolar depression or an anxiety disorder. Patients who are at high risk of suicide or have current substance abuse other than tobacco are also excluded. Additionally, patients who are not expected to survive one year or are physically unable to tolerate the study protocol, those with known sensitivity to sertraline or omega-3, or those with allergies to fish oil or shellfish are excluded. Patients who are already taking an antidepressant or an omega-3 supplement at baseline are also excluded. Patients who have been exempted by their cardiologist or primary care physician, refuse to provide informed consent, or are participating in a competing protocol or trial are not eligible for the study. The trial involves the use of an omega-3 supplement and a placebo as the drugs being tested.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 2. The disease being studied is \"prostatic neoplasms.\" The ICDCodes associated with this disease are \"B38.81,\" \"N42.31,\" \"Z87.430,\" \"N40.0,\" and \"N40.1.\" The drug being tested is \"radium-223 dichloride (xofigo, bay88-8223).\" \n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- The patient must have histologically or cytologically confirmed adenocarcinoma of the prostate.\n- The patient must have castration-resistant disease, which is defined as a serum testosterone level of \u2264 50 ng/dL (1.7 nmol/L) and either bilateral orchiectomy or maintenance on androgen ablation therapy.\n- The patient must have serum PSA progression or radiographic evidence of disease progression in the bone.\n- The patient must have an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2, or if ECOG PS is 2, it must be due to metastatic prostate cancer to the bone.\n- The patient must have two or more skeletal metastases on bone scintigraphy within 8 weeks of randomization.\n\nThe exclusion criteria for this trial include:\n- History of visceral metastasis or current presence of visceral metastases.\n- Lymphadenopathy with lymph nodes exceeding 3 cm in short axis diameter.\n- Central nervous system (CNS) metastases.\n- Recent treatment with cytotoxic chemotherapy for prostate cancer or planned treatment with cytotoxic chemotherapy agents during the trial.\n- Chronic conditions associated with non-malignant abnormal bone growth, such as confirmed Paget's disease of bone.\n- Prior treatment with radium-223 dichloride.\n- Prior systemic radiotherapy and hemibody external radiotherapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is \"spinal and bulbar muscular atrophy.\" The ICDCodes associated with this disease are \"G71.00, G71.02, G71.11, G12.9, G71.09, N36.44, G12.1.\" The drugs being used in the trial are \"bvs857\" and \"placebo.\" The eligibility criteria for this trial include specific requirements for inclusion and exclusion. Some of the key inclusion criteria are a genetic diagnosis of SBMA with symptomatic muscle weakness, the ability to complete a 2-minute timed walk, and a serum IGF-1 level less than or equal to 170 ng/mL. Some of the key exclusion criteria are medically treated diabetes mellitus or a known history of hypoglycemia, a history of Bell's palsy, recent treatment with certain medications, a history of cancer (excluding non-melanomatous skin cancer), retinopathy, and papilledema. Other inclusion/exclusion criteria may also apply as defined by the protocol.",
    "The sample from the table represents a phase 2 clinical trial. The trial is focused on studying the effectiveness of a drug called selinexor in treating various types of cancer, including ovarian carcinoma, endometrial carcinoma, and cervical carcinoma. The diseases are identified by their respective ICD-10 codes. \n\nThe eligibility criteria for participants in the trial include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, adequate hematologic function, adequate liver function, renal function, and having recovered from previous treatments. Other criteria include a negative pregnancy test for women of childbearing potential, agreement to use contraception during treatment, and a life expectancy of at least 12 weeks. Participants must also be able to swallow and retain oral medication and provide informed consent.\n\nThe sample also includes exclusion criteria, such as evidence of bowel obstruction or the need for total parenteral nutrition. Pregnant or breastfeeding individuals, those who have undergone radiation or chemotherapy within the past three weeks, and those with a recent diagnosis or recurrence of invasive cancer are excluded. Other exclusions include unstable cardiovascular function, uncontrolled active infection, significantly diseased or obstructed gastrointestinal tract, and concurrent therapy with other anti-cancer treatments.\n\nAdditionally, participants with known brain metastases, non-epithelial cancers of the specified organs, or neuro-endocrine tumors are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is focused on kidney transplantation and is in phase 2. The diseases being studied are related to kidney transplantation, and the corresponding ICD-10 codes are provided. The drugs being used in the trial include fludarabine, cyclophosphamide, acetaminophen, diphenhydramine, methylprednisolone, mesna, mycophenolate mofetil, prednisone, and filgrastim. The eligibility criteria for participants are listed, including age requirements, HLA compatibility, blood group compatibility, antibody testing, cardiac and pulmonary health, viral infection history, contraception requirements, ability to receive oral medication, and negative tuberculosis testing. The exclusion criteria for participants are also listed, including specific renal diseases, certain medical conditions, history of certain infections, autoimmune diseases, recent use of investigational drugs or live vaccines, and other medical conditions deemed incompatible with participation. The eligibility criteria for donors are also provided, including HLA compatibility, age requirements, renal function, and absence of certain medical conditions. The exclusion criteria for donors include diabetes, severe cardiovascular disease, history of blood product donation to the recipient, certain infections, autoimmune diseases, and other medical conditions deemed incompatible with participation.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on patients with chronic obstructive pulmonary disease (COPD). The trial involves the use of drugs such as olodaterol, tiotropium, and a placebo. The eligibility criteria for the trial are listed, including requirements for patients to have a diagnosis of COPD, be 40 years of age or older, and have a smoking history of more than 10 pack years. The criteria also specify that patients must be able to perform pulmonary function tests, inhale medication properly, and meet certain spirometric criteria. The sample also includes exclusion criteria, such as having significant diseases other than COPD, abnormal lab values, a history of asthma, and various other medical conditions. Additionally, patients who are pregnant or nursing, women of childbearing potential not using effective birth control, and those who have previously been randomized in this study or are currently participating in another study are excluded. Patients who are unable to comply with pulmonary medication restrictions prior to randomization are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are invasive bladder cancer and bladder cancer. The corresponding ICDCodes for these diseases are ['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']. The drug being used in the trial is gemcitabine and fractionated cisplatin (combination treatment). \n\nThe eligibility criteria for this trial include:\n1. Pathologically confirmed muscle-invasive urothelial (transitional cell) carcinoma of the bladder or upper genitourinary tract.\n2. Stage T2-T4a. Patients may have nodal disease but there must be no evidence of distant metastases and patients must be candidates for radical cystectomy as determined by a urologic surgeon.\n3. No prior systemic therapy for urothelial carcinoma. Prior intravesical therapy is allowed.\n4. Patients are determined by their treating oncologist to not be a candidate for high dose cisplatin (> 70mg/m2) due to medical comorbidities.\n5. Creatinine Clearance (CrCL or eCCr)) > 25 mL/min calculated using the Cockcroft-Gault formula.\n6. Patients without serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive the protocol treatment of this study with gemcitabine and weekly fractionated cisplatin.\n7. Preexisting neuropathy < grade 2.\n8. No prior invasive malignancy within the prior two years. However, prior history of non-muscle invasive bladder cancer and patients with an early stage malignancy that is not expected to require treatment in the next 2 years are eligible.\n9. ECOG performance status 0 or 1.\n10. Age \u2265 18 years of age.\n11. Not pregnant and not nursing. Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to beginning treatment.\n12. Required Initial Laboratory Values: Neutrophils \u2265 1,000/\u03bcl, Platelet count \u2265 100,000/\u03bcl, Total bilirubin \u2264 1.5 x ULN, AST (SGOT) & ALT (SGPT) \u2264 3.0 x ULN.\n\nThe exclusion criteria for this trial include:\n1. Metastatic disease.\n2. Prior hypersensitivity to platinums that, in the investigator's opinion, would put the patient at risk if re-exposed.\n3. Small cell cancer of the bladder or pure adenocarcinoma. Patients with mixed histologies such as urothelial carcinoma with sarcomatoid features, squamous differentiation, or adenocarcinoma are allowed as long as transitional cell cancer is the predominant pathologic subtype.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"gastroesophageal reflux.\" The corresponding ICD-10 codes for this disease are \"K21.9,\" \"K21.00,\" and \"K21.01.\" The trial involves two drugs, \"iw-3718\" and a matching placebo. The eligibility criteria for participants include being between 18 and 65 years old, not being pregnant or breastfeeding, having a confirmed diagnosis of gastroesophageal reflux disease, currently taking a proton pump inhibitor, and experiencing GERD symptoms as specified in the protocol. There are also exclusion criteria, such as not meeting any excluded conditions specified in the protocol, experiencing alarm symptoms like GI bleeding or unexpected weight loss, and having hypersensitivity or allergies to any of the active ingredients or excipients in the study medication.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is described as \"phase 2/phase 3\". The diseases being studied are \"gastroparesis\" and \"diabetes mellitus\". The corresponding ICD-10 codes for these diseases are \"K31.84\" and \"P70.2\", \"O24.92\", \"Z83.3\", \"E10.65\", \"E10.9\", \"E11.65\", \"E11.9\" respectively. The drugs being tested in the trial are \"prucalopride\" and \"placebo\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being between the ages of 18-64, having a clinical diagnosis of gastroparesis for at least one year, experiencing symptoms of gastroparesis, having delayed gastric emptying, and having a normal upper endoscopy. Exclusion criteria include having significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric, or other diseases that may interfere with the study objectives, being pregnant or breastfeeding, having certain heart conditions or abnormal ECG results, having abnormal blood electrolyte levels, using specific medications that cannot be stopped prior to the study, having certain gastrointestinal surgeries or major surgeries within the past 3 months, having a low estimated GFR, and having a history of cardiovascular disorders.\n\nOverall, this sample provides information about the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for a clinical trial related to gastroparesis and diabetes mellitus.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of Crohn's disease. The diseases column specifies the disease being studied, and in this case, it is Crohn's disease. The icdcodes column contains a list of ICD-10 codes associated with the disease. The drugs column lists the drugs being used in the trial, including risankizumab iv, risankizumab sc, and placebo. The criteria column provides the eligibility criteria for participants in the trial, including age requirements, diagnosis of Crohn's disease, disease severity, previous treatment history, and other medical conditions. The inclusion criteria specify the conditions that must be met for a patient to be eligible for the trial, while the exclusion criteria outline the conditions that would disqualify a patient from participating.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug mentioned is atezolizumab. The eligibility criteria for this trial include being an adult participant aged 18 or above, having locally advanced or metastatic NSCLC, having representative FFPE tumor specimens, having PD-L1-positive tumor status, having measurable disease, and having an ECOG performance status of 0 or 1. The exclusion criteria include recent use of approved anti-cancer therapy, CNS disease, other malignancies within the past 5 years, history of autoimmune disease, history of certain lung conditions, active hepatitis B or C, HIV positive status, and prior treatment with specific therapeutic antibodies or pathway-targeting agents.",
    "The sample is a phase 2 clinical trial for patients with metastatic low or intermediate grade pancreatic neuroendocrine tumors. The trial is focused on evaluating the effectiveness of the drug everolimus. The eligibility criteria include having confirmed metastatic tumors to the liver, having undergone surgery to remove all disease, and being within 4 to 8 weeks from the completion of surgery. Other criteria include having available tumor tissue for review, specific imaging requirements, and certain blood test results within normal ranges. Patients must not have received certain vaccines or other investigational agents, and they must have a performance status of 1 or lower. Exclusion criteria include previous use of everolimus, central nervous system metastases, pregnancy or breastfeeding, and certain medical conditions or history of allergic reactions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of idiopathic dilated cardiomyopathy. The trial involves the use of two drugs: infusion of autologous mononuclear bone marrow cells and a placebo infusion. The eligibility criteria for participants are listed, including age range, diagnosis requirements, minimum duration of the disease, absence of coronary injury, prior medical therapy, specific cardiac measurements, sinus rhythm, and normal laboratory parameters. There are also exclusion criteria, such as secondary dilated cardiomyopathy, recent myocarditis, eligibility for cardiac resynchronization therapy, being on a heart transplantation waiting list, presence of other serious systemic diseases or blood diseases, pregnancy or breastfeeding, recent participation in other clinical trials, presence of malignant or pre-malignant tumors, positive serology for certain viruses, and use of prohibited medications.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is urothelial cancer. The ICD-10 codes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are nab-paclitaxel and paclitaxel. The eligibility criteria for the trial include having a confirmed diagnosis of TCC of the urinary tract, evidence of metastatic disease, and a performance status of \u2264 2. Other criteria include having adequate hematological, renal, and hepatic functions, not having had prior therapy with a taxane, and being able to complete the required questionnaires. There are also exclusion criteria, such as being a candidate for potentially curative surgery or radiotherapy, having brain metastases, and having serious illnesses or medical conditions that would prevent adherence to the protocol.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The disease being studied is Prader-Willi syndrome, which is confirmed through genetic testing. The ICD-10 code for this disease is Q87.11. The drugs being tested are DCCR and placebo. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being children, adolescents, or young adults with Prader-Willi syndrome, aged between 10 and 22 years. Participants should be generally healthy based on medical history, physical examination, vital signs, ECG, and clinical laboratory assessments. Their BMI should exceed the 95th percentile for their age according to CDC BMI charts, and fasting glucose levels should be below 126 mg/dL. HbA1c levels should be below 6.5%.\n\nExclusion criteria include recent use of investigational drugs, anticipated need for prohibited medications, history of allergic reactions to certain drugs, anticipated disruptive changes in care, congestive heart failure or compromised cardiac reserve, and any other clinically significant diseases that may interfere with the assessment of the investigational drug, as determined by the investigator.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is advanced prostate cancer. The ICDCodes associated with this disease are \"C61\", \"D29.1\", \"D40.0\", \"Z15.03\", \"Z80.42\", \"Z85.46\", and \"Z12.5\". The drugs being used in the trial are \"bkm 120\" and \"cabazitaxel\". The eligibility criteria for this trial include various requirements such as confirmation of adenocarcinoma of the prostate, metastatic disease, previous treatment with docetaxel, castrate-resistant status, Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 2, and progressive metastatic prostate cancer based on specific criteria. The sample also includes exclusion criteria such as previous treatment with PI3K inhibitors, hypersensitivity to certain drugs, recent use of investigational drugs, previous chemotherapy with agents other than docetaxel, recent radiation therapy or surgery, certain medical conditions, and various other factors that may affect eligibility for the trial. Additionally, there are requirements related to age, ability to provide tissue samples, understanding of the study, and written informed consent. The sample also mentions the need for contraception for fertile male patients during the study and a certain period after the final dose of study therapy.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating Merkel Cell Carcinoma and skin cancer. The diseases are represented by their names and corresponding ICD-10 codes. The drug being studied is cabozantinib. \n\nThe eligibility criteria for participants in the trial are listed, including having confirmed metastatic or unresectable Merkel Cell Carcinoma, measurable disease, prior treatment with platinum-based chemotherapy, and no prior use of a MET inhibitor. Other criteria include specific time intervals since prior treatments, normal organ and marrow function, and the ability to understand and sign an informed consent document. \n\nThere are also exclusion criteria, such as recent chemotherapy or radiotherapy, active brain metastases or epidural disease, history of allergic reactions to similar compounds, and certain medical conditions that carry a high risk of bleeding. Other factors that would exclude a participant from the trial include chronic concomitant treatment with certain medications, inability to swallow tablets, and specific cardiac or pulmonary conditions. \n\nThe sample also mentions that pregnant women and individuals with a history of other malignancies are not eligible for the trial, unless they have been disease-free for at least 5 years and are considered at low risk for recurrence. HIV-positive individuals on combination antiretroviral therapy are also excluded. \n\nOverall, this sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for a clinical trial focused on Merkel Cell Carcinoma and skin cancer.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"adenocarcinoma of the pancreas.\" The ICDCodes associated with this disease are \"C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31.\" The drugs being used in the trial are \"mk-1775\" and \"gemcitabine.\" \n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- Patients must have pathologically confirmed adenocarcinoma of the pancreas.\n- Patients must have unresectable disease, defined radiographically as >180 degrees involvement of the superior mesenteric artery or celiac trunk or SMV/portal vein impingement that cannot be surgically reconstructed, in the absence of distant metastasis.\n- Patients must have a Zubrod performance status of <2.\n- Patients must have adequate organ function, including specific requirements for absolute neutrophil count, platelets, serum creatinine, total bilirubin, and AST levels.\n- Patients of reproductive potential must agree to use effective contraception during the trial and for 6 months after.\n- Patients must be at least 18 years old and provide written informed consent.\n\nThe exclusion criteria for this trial include:\n- Other serious uncontrolled concomitant systemic disorders or psychiatric conditions that would interfere with the safe delivery of protocol therapy.\n- History of previous chemotherapy for pancreatic cancer or abdominal radiation therapy.\n- Use of any investigational agent in the month before enrollment into the study.\n- Inability to discontinue certain prescription or non-prescription drugs or other products known to be metabolized by CYP3A4, or to inhibit or induce CYP3A4 prior to Day 1 of dosing and throughout the study until 2 weeks after the last dose of study medication. Specific medications of concern are listed.\n\nThis description provides an overview of the sample record and the information it contains.",
    "The sample from the table represents a clinical trial for a drug called allopurinol. The trial is in phase 2/phase 3 and is focused on patients with pre-hypertension or stage I hypertension. The diseases being studied include pre-hypertension and jnc 7 stage I hypertension. The corresponding ICD-10 codes for these diseases are provided as well.\n\nThe eligibility criteria for the trial are as follows:\n- Participants must have pre-hypertension or stage I hypertension, as defined by specific blood pressure measurements.\n- Participants must have a certain level of serum urate.\n- Participants must be between the ages of 18 and 40.\n\nThere are also exclusion criteria, which include:\n- Participants currently receiving pharmacological treatment for hypertension, except for stable doses of calcium channel blockers.\n- Participants with a low estimated glomerular filtration rate.\n- Participants currently using urate-lowering therapy or statins.\n- Participants with a prior diagnosis of gout or previous use of urate-lowering therapy for gout.\n- Participants with a prior diagnosis of diabetes.\n- Pregnant individuals or those who have recently given birth.\n- Active smokers.\n- Immune-suppressed individuals or those currently using azathioprine.\n- Individuals with certain blood cell count abnormalities.\n- Individuals of Han Chinese or Thai descent with a specific genetic phenotype.\n- Individuals with a serious medical condition that would prevent them from taking a fixed dose of allopurinol.\n\nOverall, this sample provides information about the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for a clinical trial involving allopurinol and patients with pre-hypertension or stage I hypertension.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of small cell lung cancer (SCLC). The ICD-10 codes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being studied in this trial are alisertib, placebo, and paclitaxel.\n\nThe sample also includes the eligibility criteria for participants to be enrolled in the study. Inclusion criteria include being 18 years or older, having a confirmed diagnosis of SCLC, having received and progressed after a platinum-based standard chemotherapy regimen for first-line treatment of SCLC, having measurable disease, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion criteria include having received any prior therapy for second-line treatment of SCLC, relapsing more than 180 days after the response to first-line treatment, prior treatment with specific-targeted or pan-Aurora-targeted agents, prior treatment with paclitaxel or any other taxane agent, known hypersensitivity to certain components, having comorbid conditions or unresolved toxicity that would prevent administration of the drugs, and various other medical or psychiatric conditions.\n\nThe sample also mentions specific restrictions and requirements related to enzyme inducers, ability to swallow medications, administration of certain medications, history of other malignancies, cardiac conditions, infectious diseases, recent surgeries, and contraception for female participants.\n\nOverall, the sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for participants in a clinical trial focused on small cell lung cancer.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is \"myelodysplastic syndromes\". The ICDCodes associated with this disease are \"D46.9\", \"D46.C\", and \"D46.Z\". The drugs mentioned in this sample are \"deferasirox + azacitidine\" and \"azacitidine\". The eligibility criteria for this trial include various conditions such as age, specific MDS classification, previous treatment cycles, ferritin levels, blood counts, ECOG performance status, and kidney function. The exclusion criteria include factors such as elevated ALT levels, uncontrolled infection, HIV positivity, pregnancy or breastfeeding, previous or concurrent iron chelation, and concurrent use of certain medications.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The disease mentioned is \"melanoma and brain metastases.\" The ICDCodes associated with this disease are \"C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4.\" The drugs being used in this trial are \"dabrafenib\" and \"trametinib.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having an ECOG Performance Status range of 0-2, having histologically confirmed cutaneous metastatic melanoma of specific variations, and being able to undergo MRI with at least one measurable intracranial lesion. \n\nExclusion criteria include prior treatment with specific inhibitors, previous anti-cancer therapy or chemotherapy within a specific timeframe, treatment with stereotactic radiosurgery or whole-brain radiation within a specific timeframe, presence of leptomeningeal disease or parenchymal brain metastasis, history of another malignancy, and history or evidence of cardiovascular risk or retinal vein occlusion.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is chronic graft-versus-host disease. The ICDCodes associated with this disease are 'D89.811' and 'D89.812'. The drugs being tested in this trial are 'r348 ophthalmic solution, 0.2%' and 'r348 ophthalmic solution, 0.5%'. The eligibility criteria for participants in this trial include having received an allogeneic hematologic stem cell transplantation at least 3 months prior, experiencing post-transplantation onset or worsening of dry eye symptoms for at least 1 month, using eye drops for dry eye symptoms within the past month, having specific corneal fluorescein staining and lissamine green conjunctival staining scores, and meeting certain exclusion criteria such as not having clinically unstable graft versus host disease, not using specific eye drops or steroids within certain timeframes.",
    "The sample is a phase 2 clinical trial for breast cancer. The eligibility criteria include having hormone receptor positive (HR+) HER2 negative stage II or stage III invasive breast cancer. Both men and women are eligible, and participants must have previously completed at least 1 month of tamoxifen or aromatase inhibitor therapy without significant adverse events. Other criteria include having an ECOG performance status of 0-1, being at least 18 years old, having normal organ and marrow function, and a baseline QTc of \u2264 480 ms. Participants must also use adequate contraception if they are capable of becoming pregnant. Exclusion criteria include concurrent therapy with other investigational agents, prior therapy with any CDK4/6 inhibitor, history of allergic reactions to similar compounds, and use of medications that prolong the QT interval. Other exclusion criteria include uncontrolled intercurrent illness, pregnancy or breastfeeding, history of a different malignancy (except for specific circumstances), and no ongoing combination antiretroviral therapy.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"non-small cell lung cancer\" and its corresponding ICDCodes are ['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']. The drug mentioned is \"ldk378\". The eligibility criteria for this trial include various inclusion and exclusion criteria. Some of the inclusion criteria are a confirmed diagnosis of NSCLC with ALK rearrangement, age 18 years or older, and stage IIIB or IV NSCLC. Some of the exclusion criteria are hypersensitivity to LDK378, symptomatic central nervous system metastases, history of carcinomatous meningitis, presence or history of another malignant disease, and clinically significant, uncontrolled heart disease.",
    "The sample from the table is for a phase 2 clinical trial. The diseases being studied are differentiated thyroid cancer (DTC) and poorly differentiated thyroid cancer. The corresponding ICD-10 codes for these diseases are C73, D34, D44.0, and Z85.850. The drug being tested in the trial is cabozantinib. \n\nThe eligibility criteria for the trial include having a histologic or cytologic diagnosis of a DTC tumor that is metastatic or unresectable, having progressive disease based on RECIST 1.1 criteria, and having RAI-refractory disease. Other criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, meeting certain organ and marrow function and laboratory value requirements, being capable of understanding and complying with the protocol, and using medically accepted barrier methods of contraception for sexually active subjects.\n\nExclusion criteria include having received cytotoxic chemotherapy, biologic agents, or any other anti-cancer systemic therapy, prior treatment with cabozantinib, recent radiation therapy or radionuclide treatment, and recent use of any other investigational agent. Other exclusion criteria include not having recovered from toxicity due to prior therapies, having a primary brain tumor or active brain metastases, and having certain cardiovascular, gastrointestinal, or other disorders. The subject must also be able to swallow tablets and not have a corrected QT interval above a certain threshold. Pregnancy or breastfeeding is also an exclusion criterion, as well as having a known allergy or hypersensitivity to the study treatment formulation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are ischemic stroke and transient ischemic attack. The ICDCodes associated with these diseases are provided as well. The drugs being investigated in this trial are rivaroxaban and warfarin. The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The criteria include factors such as the type and severity of the stroke, presence of atrial fibrillation, age, informed consent, and various medical conditions or circumstances that may exclude a participant from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is lymphoma. The ICDCodes associated with this disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drug being tested in this trial is carfilzomib. \n\nThe eligibility criteria for this trial include:\n1. Confirmed diagnosis of mantle cell lymphoma.\n2. Patients must have relapsed or refractory MCL.\n3. Understand and voluntarily sign an IRB-approved informed consent form.\n4. Age >/= 18 years at the time of signing the informed consent.\n5. Patients must have bi-dimensional measurable disease (bone marrow only involvement is acceptable).\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.\n7. Various blood test results must be within specific ranges.\n8. Females of childbearing potential must have a negative pregnancy test and agree to use effective birth control.\n9. Males must agree to use a condom with spermicide during the study.\n10. Patients must be willing to receive transfusions of blood products.\n\nThe exclusion criteria for this trial include:\n1. Any serious medical condition that would prevent the subject from signing the informed consent form.\n2. Pregnant or breastfeeding females.\n3. Known HIV infection or active hepatitis B infection.\n4. Patients with active central nervous system lymphoma.\n5. Significant neuropathy within 14 days prior to enrollment.\n6. Known history of allergy to Captisol\u00ae.\n7. Contraindication to required concomitant drugs or supportive treatments.\n8. Patients with active pulmonary embolism or deep vein thrombosis.\n9. Patients with symptomatic bradycardia.\n10. Recent use of anti-lymphoma drug therapy or experimental non-drug therapy.\n11. Patients with certain heart conditions.\n12. Patients with a prior or concurrent malignancy that presents a greater risk than the MCL.\n13. Acute active infection requiring treatment within 14 days prior to enrollment.\n14. Patients who have received previous Carfilzomib treatment.",
    "The sample from the table represents a clinical trial that is in phase 2/phase 3. The trial focuses on patients with acute coronary syndrome who are undergoing percutaneous coronary intervention. The trial aims to evaluate the effectiveness of ticagrelor, prasugrel, and clopidogrel as potential treatments. \n\nThe eligibility criteria for inclusion in the trial are as follows: patients must be between the ages of 18 and 75, weigh more than 60 kg (unless they are over 75 years old and weigh less than 60 kg, in which case prasugrel is reduced to 5mg daily if randomized to personalized therapy arm), and be undergoing non-ST elevation myocardial infraction (NSTEMI) with percutaneous coronary intervention (PCI).\n\nPatients will be excluded from the trial if they have any of the following: a contraindication for clopidogrel, prasugrel, or ticagrelor; an intolerance to aspirin; an absolute requirement for ticagrelor or prasugrel (such as stent thrombosis or allergic reaction to clopidogrel); a requirement for anticoagulation treatment; a history of stroke, transient ischemic attack (TIA), or intracranial hemorrhage; a platelet count less than 100,000/\u03bcl; a known bleeding diathesis; a hematocrit less than 30% or greater than 52%; severe liver dysfunction; renal insufficiency with creatinine clearance less than 30ml/min; or adjuvant therapy with a glycoprotein IIbIIIa inhibitor.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 2 and phase 3. The disease mentioned is \"urinary bladder, neurogenic\" and its corresponding ICDCodes are ['G98.0', 'K59.2', 'M48.061', 'M48.062']. The drugs being studied are \"mirabegron\" and \"placebo\". The eligibility criteria are listed under inclusion and exclusion criteria. The inclusion criteria include a diagnosis of suprasacral spinal cord injury or multiple sclerosis, age over 18 years, stable bladder management for more than 3 months, bothersome urinary symptoms, and ability to read and speak English. The exclusion criteria include recent participation in another study, previous urologic surgery, current use of certain catheters, unstable cardiac disease, abnormal ECG, renal or liver dysfunction, history of pelvic radiation or bladder cancer, history of other malignancies, interstitial cystitis/pelvic pain syndrome, urinary retention, tachyarrhythmia, glaucoma, noncompliance with the study protocol, active urinary tract infection, pregnancy or breastfeeding, and refusal to provide consent or complete study visits. Additionally, certain medications and physical exam results are also considered for exclusion.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include acute biphenotypic leukemia, de novo myelodysplastic syndrome, previously treated myelodysplastic syndrome, recurrent adult acute myeloid leukemia, untreated adult acute myeloid leukemia, and secondary acute myeloid leukemia. The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs being used in the trial are cladribine, cytarabine, and mitoxantrone hydrochloride. The eligibility criteria for the trial are listed, including specific requirements for patients with newly diagnosed disease and those with relapsed/refractory disease. Other criteria include the use of hydroxyurea prior to study registration, previous chemotherapy regimens, and the need to be off any active systemic therapy for at least 14 days prior to study registration.\n\nExclusion criteria are also mentioned, such as the presence of myeloid blast crisis of chronic myeloid leukemia, concomitant illnesses with a likely survival of less than 1 year, and active systemic infections. Other exclusion criteria include known hypersensitivity to any study drug, pregnancy or lactation, and treatment with any other investigational agent.",
    "The sample provided is for a phase 2 clinical trial focused on smoking cessation. The trial aims to test the effectiveness of the drug \"apd356-lorcaserin hydrochloride\" compared to a placebo. The eligibility criteria for participants include being between the ages of 18-65, smoking at least 10 cigarettes per day with no extended periods of abstinence, and being motivated to quit smoking. Female participants must not be pregnant or lactating and must agree to use contraception during the study. Male participants must also agree to use contraception if sexually active with a female partner who is not using birth control. Participants must weigh at least 50 kg (110 pounds) and be considered to be in stable health. \n\nExclusion criteria include prior or current use of lorcaserin HCl, previous participation in a nicotine vaccination study, and use of other smoking cessation therapies within 3 months prior to screening. Other exclusion criteria include the use of tobacco products other than cigarettes, prior use of fenfluramine or dexfenfluramine, serious or unstable medical conditions, recent participation in another clinical study, severe allergies or hypersensitivity, significant cardiovascular conditions, significant medical conditions, significant risk of suicide, anticipated use of agents associated with valvulopathy and/or pulmonary hypertension, positive test results for HIV, hepatitis B, or hepatitis C, recent history of alcohol or drug/solvent abuse, concurrent participation in the study by multiple members of the same household, and being deemed unsuitable to participate by the investigator.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"multiple myeloma.\" The ICD-10 codes associated with this disease are \"C90.01,\" \"C90.02,\" and \"C90.00.\" The drug being studied in this trial is \"pomalidomide and dexamethasone.\" \n\nThe eligibility criteria for this trial include having a documented diagnosis of multiple myeloma with measurable disease, having undergone at least one prior antimyeloma regimen with documented progression, and having impaired renal function. The impaired renal function must be confirmed by a kidney biopsy and have an estimated Glomerular Filtrate Rate of less than 45 mL/min/1.73 m2.\n\nThere are also exclusion criteria, such as having any significant medical condition or psychiatric illness that would prevent participation, having renal insufficiency due to reasons other than multiple myeloma or hypocalcemia, and having a history of malignancies other than multiple myeloma, unless the subject has been disease-free for at least 5 years.\n\nAdditionally, previous therapy with pomalidomide, hypersensitivity to thalidomide, lenalidomide, or dexamethasone, and eligibility for or planning for stem cell transplant are also exclusion criteria for this trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of plaque psoriasis. The table includes columns for the phase of the trial, the diseases being studied, the corresponding ICD-10 codes for those diseases, the drugs being used in the trial, and the eligibility criteria for participants.\n\nIn this specific sample, the phase of the trial is phase 2, and the disease being studied is plaque psoriasis. The ICD-10 codes associated with this disease are 'L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', and 'L40.50'. The drugs being used in the trial are 'idp-118 lotion', 'idp-118 monad hp lotion', 'idp-118 monad taz lotion', and 'idp-118 vehicle lotion'. \n\nThe eligibility criteria for participants include being at least 18 years old, providing informed consent, having an area of plaque psoriasis that covers at least 3% but no more than 12% of the body surface area (excluding certain areas), being willing to avoid prolonged exposure to ultraviolet radiation, and having a clinical diagnosis of psoriasis with a specific severity score. \n\nThere are also exclusion criteria, such as having rapidly improving or deteriorating psoriasis, previous treatment failure with prescription medication, concurrent skin conditions that could interfere with evaluation, pregnancy or planning a pregnancy, and recent participation in other clinical studies with investigational drugs or devices.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"ankylosing spondylitis (AS)\". The ICD-10 codes associated with this disease are \"L40.53\", \"M08.1\", \"M45.6\", \"M45.2\", \"M45.3\", \"M45.4\", and \"M45.5\". The drugs being studied in this trial are \"placebo for risankizumab\" and \"risankizumab\". \n\nThe eligibility criteria for this trial are as follows:\n- Male and female patients\n- Age between 18 and 70 years\n- Definite AS based on the modified New York criteria (1984)\n- Documented disease duration of at least 3 months at screening\n- Active disease at screening, defined as a BASDAI score (0-10) of at least 4 and spinal pain level assessed by the 2nd BASDAI question (0-10) of at least 4\n- Inadequate response to two non-steroidal anti-inflammatory drugs (NSAIDs) or documented intolerance to NSAIDs\n- Female patients must meet certain contraception criteria\n- Patients receiving background MTX or Leflunomide therapy must follow national regulatory guidelines regarding contraception\n- Signed and dated written informed consent prior to admission to the study\n\nThe exclusion criteria for this trial are as follows:\n- Radiographic evidence of total ankylosis of the spine at screening or before\n- Previous treatment with any biological immunomodulating agent for AS\n- Previous or current participation in a clinical trial testing an investigational drug for AS within 12 weeks prior to randomization\n- Usage of any investigational drug within 30 days prior to randomization or planned use during the study\n- Active uveitis or inflammatory bowel disease at screening\n- Diagnosed psoriatic arthritis at screening, satisfying the modified New York criteria\n- Recent intraarticular injection(s) with corticosteroids\n- Need or desire to continue restricted medications or any drug that may interfere with the study\n- Major surgery performed within 8 weeks prior to screening or planned within 12 months after screening\n- Chronic or relevant acute infections including HIV, viral hepatitis, and tuberculosis\n- Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except for certain types of skin or uterine cervix cancers\n- Evidence of current or previous clinically significant disease, medical condition other than AS, abnormal medical examination findings, or laboratory values outside the reference range that may compromise patient safety or data quality\n- History of allergy/hypersensitivity to a systemically administered biologic agent or its excipients\n- History of alcohol or drug abuse within the last 12 months\n\nThis information provides a detailed description of the sample record from the table, including the phase of the trial, the disease being studied, the associated ICD-10 codes, the drugs involved, and the eligibility and exclusion criteria for participants in the trial.",
    "The sample is a phase 2 trial for the treatment of glioblastoma multiforme, a type of brain tumor. The trial is investigating the effectiveness of two drugs, tpi 287 and bevacizumab. The eligibility criteria for participants include having histologically proven GBM, disease progression following radiation and TMZ treatment, and a minimum life expectancy of 12 weeks. Other criteria include specific time intervals between prior therapies and the start of the trial, adequate bone marrow, liver, and renal function, and the absence of certain medical conditions. Exclusion criteria include the presence of certain types of tumors, prior treatment with specific drugs, recent major surgical procedures, and various medical conditions that could pose risks or interfere with the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial is Phase 2.\n- Diseases: The trial is focused on treating metastatic castration-resistant prostate cancer.\n- ICD Codes: The ICD-10 codes associated with the disease are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5'].\n- Drugs: The drugs being used in the trial are carfilzomib, dexamethasone, and acyclovir.\n- Criteria: The eligibility criteria for participants in the trial are listed, including requirements such as having histologically proven adenocarcinoma of the prostate, metastatic disease, progressive disease following previous treatments, and meeting certain health and age requirements. There are also exclusion criteria listed, such as having certain medical conditions or being unable to comply with study requirements.\n\nOverall, this record provides information about a Phase 2 clinical trial for metastatic castration-resistant prostate cancer, including the specific drugs being used and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on three diseases: functional iron deficiency, trauma, and anemia. The diseases are associated with specific ICD-10 codes. The trial involves the use of four drugs: iron sucrose, oxandrolone, IV iron placebo, and oxandrolone placebo. The eligibility criteria for the trial are listed, including inclusion criteria such as informed consent, trauma patient status, anemia, functional iron deficiency, and specific timeframes and expected length of stay in the ICU. Exclusion criteria are also listed, including age restrictions, active bleeding, iron overload, infection, chronic inflammatory conditions, pre-existing hematologic disorders, pre-existing hepatic dysfunction, recent use of immunosuppressive agents, recent use of erythropoietin, known or suspected carcinoma, nephrosis, hypercalcemia, pregnancy or lactation, legal arrest or incarceration, prohibition of blood transfusion, stay in another ICU, history of intolerance or hypersensitivity to iron or oxandrolone, and being in a moribund state.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 2, and the disease is brain cancer. The icd-10 codes associated with the disease are C71.7, C71.9, C79.31, D33.0, D33.1, D33.2, and D49.6. The drug mentioned is dacomitinib. The eligibility criteria for this trial include having a documented extracranial diagnosis of primary lung cancer, melanoma, HER2-amplified breast cancer, or HER2-amplified gastric cancer with brain metastasis detected by MRI or CT. Other criteria include having progression and measurable brain disease, stable or no evidence of extracranial disease, and meeting certain age, organ function, and performance status requirements. The sample also includes exclusion criteria such as current or planned use of systemic therapy for the primary tumor, presence of uncontrolled seizures, and certain medical disorders. Additionally, pregnant or nursing individuals are excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is Crohn's disease. The corresponding ICD-10 codes for Crohn's disease are K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, and K50.919. The drugs being tested in this trial are glpg0634 and placebo. The eligibility criteria for participants in this trial include being between 18 and 75 years old, having a documented history of ileal, colonic, or ileocolonic CD, having a CDAI score between 220 and 450, and having evidence of active inflammation confirmed by endoscopy. Participants must also meet certain requirements regarding previous exposure to anti-TNF treatment and concurrent use of certain medications. There are also exclusion criteria, such as having a diagnosis of indeterminate colitis or ulcerative colitis, having certain surgical or medical conditions, or having certain infections or malignancies. Additionally, participants must not be pregnant, lactating, or unwilling to use highly effective birth control methods during the study and for 12 weeks afterward.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease called idiopathic pulmonary fibrosis (IPF). The ICDCodes column contains the ICD-10 code for IPF, which is \"J84.112\". The drugs being studied in this trial are \"fostair\" and \"placebo\". The criteria column provides the eligibility criteria for participants in the trial.\n\nThe inclusion criteria for this trial include being a male or female between the ages of 40 and 85, having a definite diagnosis of IPF according to the American Thoracic Society / European respiratory symposium (ATS/ERS) Consensus Statement, having a carbon monoxide transfer factor (TLco) of at least 30% predicted, being able to maintain oxygen saturation of at least 89% while at rest, having a forced vital capacity (FVC) of 50-80% predicted value, having a negative pregnancy test for female subjects of childbearing potential, and having the competency to understand the information provided in the Ethics Committee approved Patient Information Sheet and Consent Form.\n\nThe exclusion criteria for this trial include having clinically significant respiratory diseases other than IPF, having clinically significant heart disease, being a current smoker, using any inhaled long-acting beta-agonist or inhaled steroid within the 3 months prior to screening, using any medication to treat or possibly indicated in the treatment of IPF, using any antiplatelet therapy that may alter assessment of study endpoints, having a history of cancer or precancerous state within 5 years prior to screening, having a history or evidence of a clinically significant disorder, condition, or disease that may pose a risk to subject safety or interfere with the study evaluations, procedures, or completion, and participating in an investigational drug or device trial within 30 days prior to screening.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 2 and involves the study of two diseases: venous thromboembolism and cancer. The corresponding ICD-10 codes for these diseases are also provided. The trial involves the use of two drugs: apixaban and a placebo drug. The eligibility criteria for participants are listed, including requirements such as a newly diagnosed cancer or progression of a malignant disease, initiation of a new course of chemotherapy, a VTE risk stratification score of at least 2, being 18 years or older, and providing written informed consent. The exclusion criteria are also listed, which include conditions at increased risk of bleeding, liver insufficiency, certain types of cancer, planned stem cell transplant, a life expectancy of less than 6 months, renal insufficiency, pregnancy, continuous anticoagulation with certain medications, low weight, low platelet count, allergies to apixaban ingredients, and use of contraindicated medications with apixaban.",
    "The sample from the table represents a clinical trial for the treatment of depression. The trial is divided into two phases, phase 1 and phase 2. The disease being studied is depression, and it is identified by the ICD-10 codes F32.A, F53.0, P91.4, Z13.31, and Z13.32. The drugs being tested are diazoxide and placebo.\n\nThe eligibility criteria for participants include being between 18 and 65 years old, women of childbearing potential must have a negative pregnancy test and use two effective methods of contraception. Participants must be capable of understanding the tests and examinations required and must provide informed consent. They must also meet the DSM-IV criteria for major depressive disorder (MDD) without psychotic features, have a current major depressive episode lasting at least four weeks, and have a minimum score of 20 on the MADRS (Montgomery-\u00c5sberg Depression Rating Scale) at screening and baseline.\n\nExclusion criteria include having current or past psychotic features, a diagnosis of schizophrenia or any other psychotic disorder, a history of drug or alcohol dependency or abuse within the past three months, a head injury resulting in loss of consciousness exceeding five minutes, a diagnosis of borderline or antisocial personality disorder, pregnancy or nursing, serious unstable medical illnesses, hyperthyroidism or clinical hypothyroidism, unexplained seizures, abnormal laboratory tests, diabetes, fasting plasma glucose concentration above 120 mg/dl, low diastolic blood pressure, recent treatment with certain medications, lifetime history of deep brain stimulation, current serious suicidal or homicidal risk, positive HIV test, and contraindications to MRI.\n\nThe study does not allow structured psychotherapy during the trial. Treatment resistance is defined as having previously failed to respond to two adequate antidepressant trials, which will be determined using the clinician-administered modified Antidepressant Treatment History Form (ATHF).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is thalassemia major. The ICDCodes associated with this disease are ['D56.0', 'D56.1', 'D56.3', 'D56.9', 'D56.2', 'D56.5', 'D57.40']. The drug being used in the trial is ruxolitinib. \n\nThe eligibility criteria for this trial are as follows:\n- Patients must have thalassemia and be on a regular and stable transfusion regimen for at least 24 weeks prior to screening.\n- Patients must have spleen enlargement, confirmed by MRI or CT scan, with a spleen volume of at least 450 cm3.\n- Patients must be on iron chelation treatment (deferoxamine or deferasirox) for at least four weeks prior to screening.\n\nThe exclusion criteria for this trial are as follows:\n- Patients who have had a splenectomy or are planning to have one during the study.\n- Patients with active serious bacterial, mycobacterial, fungal, parasitic, or viral infections that require therapy.\n- Patients with a hemoglobin level below 65 g/L at screening.\n- Patients with a platelet count below 75\u00d7109/L or an absolute neutrophil count below 1.5\u00d7109/L at screening.\n- Patients with an estimated MDRD (glomerular filtration rate) below 30 mL/min/1.73 m2 at screening.\n- Patients with ALT (SGPT) levels greater than 5 times the upper limit of normal at screening.\n- Patients with hepatocellular diseases such as hepatitis B, hepatitis C, or liver cirrhosis.\n- Patients who are HIV positive.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this particular sample, the phase of the trial is phase 2. The disease being studied is breast cancer, and the corresponding ICD-10 codes are provided. The drugs being tested are sapanisertib, fulvestrant, and exemestane. The eligibility criteria are listed in a detailed format, including criteria related to the patient's medical history, laboratory values, performance status, and ability to swallow oral medications. There are also specific criteria for the phase 1b and phase 2 portions of the study.\n\nAdditionally, the sample includes exclusion criteria, which are conditions that would disqualify a patient from participating in the trial. These criteria include recent prior treatments, certain medical conditions, and a history of certain events or diseases.\n\nOverall, the sample provides a comprehensive description of the trial phase, diseases, drugs, and eligibility and exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is \"super-refractory status epilepticus.\" The ICDCodes associated with this disease are \"G40.803, G40.804, G40.823, G40.824, G40.833, G40.834, G40.911.\" The drug being tested is \"sage-547.\" \n\nThe eligibility criteria for this trial include subjects who are 2 years of age or older and have been diagnosed with super-refractory status epilepticus confirmed by an EEG. They must also be under concomitant therapy with a continuous IV AED (third-line agent) for at least 24 hours. The inclusion criteria also specify the failure to respond to first-line and second-line agents, as well as the presence of breakthrough seizures after initiation of the continuous IV AED/third-line agent.\n\nThe exclusion criteria state that subjects with SRSE due to anoxic/hypoxic encephalopathy or children with an encephalopathy due to an underlying progressive neurological disorder are not eligible. Subjects with clinically significant ECG abnormalities or other medical or surgical conditions that may compromise vital organ systems are also excluded. Additionally, subjects who are receiving a continuous IV AED for seizure suppression or burst-suppression that will require more than 24 hours to wean are not eligible for this trial.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is squamous cell carcinoma of the head and neck. The ICD-10 codes associated with this disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drugs being used in the trial are cetugex\u2122, cetuximab, and chemotherapy. \n\nThe eligibility criteria for the trial include patients with confirmed recurrent and/or metastatic SCCHN who are not eligible for local treatment. Patients must have measurable disease according to RECIST 1.1 and be at least 18 years old. They must also have an ECOG performance status of 0 or 1 and a minimum life expectancy of 3 months. Tissue samples must be available for specific disease and therapy-related biological assessments. Female patients of childbearing potential must have negative pregnancy test results and either be non-lactating or use highly effective contraceptives. Male patients with partners of childbearing potential must also use highly effective contraceptives. Patients must be willing and able to comply with the protocol and provide written informed consent.\n\nExclusion criteria for the trial include prior systemic chemotherapy or treatment with cetuximab or other EGFR-targeting agents within the past 6 months. Patients who have had surgery or irradiation within 30 days before randomization are also excluded. Concomitant antitumor therapy, immunotherapy, live vaccines, and corticosteroid treatment are not allowed unless specified in the protocol. Patients with brain metastasis, nasopharyngeal tumors, concomitant malignant disease (except for adequately treated tumors with a high likelihood of being cured), renal or hepatic impairment, abnormal hematology parameters, impaired auditory function or platinum-related neuropathy, clinically active infections, known active hepatitis B or C, known HIV infection, recent myocardial infraction or significant cardiac conditions, history of keratitis or interstitial lung disease, or any other disorder that may interfere with the study are also excluded. Patients with unstable conditions, recent history of drug or alcohol abuse, or who are thought to be unreliable or incapable of complying with the study requirements are not eligible. Patients who have been institutionalized by official means or court order, received any other investigational medicinal product within the past 30 days, or had a previous allergic reaction to a monoclonal antibody are also excluded. Additionally, patients with known sensitivity to any component of the investigational medicinal product or medication used in the study, or known dihydropyrimidine dehydrogenase deficiency (France only), are not eligible.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 2.\n- Diseases: The trial is focused on the disease \"diabetes mellitus, type 2\".\n- ICD Codes: The ICD-10 codes associated with the disease are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\".\n- Drugs: The trial involves the drugs \"gwp42004\" and \"placebo\".\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". These criteria include factors such as age, diagnosis, medication history, medical conditions, and willingness to comply with study requirements.\n\nOverall, this sample provides specific information about a Phase 2 clinical trial focused on diabetes mellitus, type 2, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 2 and focuses on two diseases: non-small cell lung cancer and malignant pleural effusion. The diseases are associated with specific ICD-10 codes. The trial involves the drug bevacizumab. The eligibility criteria for participants are listed, including requirements such as a histological or cytological diagnosis of non-small cell lung cancer, symptomatic malignant pleural or pericardial effusion, and being unsuitable for or rejecting systemic therapy. There are also exclusion criteria, such as recent use of platelet function inhibitors or anticoagulants, allergies to bevacizumab, pregnancy or lactation, and pleural or pericardial infection.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is specified as \"phase 1/phase 2\". The disease mentioned in this record is \"squamous cell carcinoma of the head and neck\". The corresponding ICD-10 codes for this disease are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']. The drugs being studied in this trial are 'cetuximab' and 'methotrexate'. The eligibility criteria for participants in this trial include having a cytologically/histologically-proven SCCHN, recurrent or metastatic SCCHN, and at least one measurable lesion as determined by RECIST v1.1. There are also additional criteria related to prior treatment, primary site, time between prior treatment and inclusion, medical co-morbidities, performance status, age, organ function, and laboratory parameters. The exclusion criteria include serious active infections, lack of adequate contraceptive measures, prior treatment with EGFR inhibitors or MTX, concurrent administration of other experimental drugs, concurrent treatment with any other anti-cancer therapy, central nervous system involvement, lung fibrosis, pleural effusion or ascites or other third space effusions, history of another malignancy within 2 years, pregnancy or lactation, and any other condition that would preclude participation in the clinical study.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug mentioned is finasteride 5mg oral daily. The eligibility criteria for this trial include being male, being over 18 years old, having biopsy-proven non-small cell lung cancer, and having a planned surgical intervention. The exclusion criteria include not currently using a 5-alpha reductase inhibitor, not having a previous diagnosis of prostate cancer, and not having a previous hypersensitivity to a 5-alpha reductase inhibitor.",
    "The sample from the table is a clinical trial for the treatment of advanced, progressive, recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. The trial is in phase 1/phase 2 and involves the drugs pazopanib and fosbretabulin. The eligibility criteria for participants include having measurable disease, a World Health Organisation performance status of 0 or 1, and a life expectancy of at least 12 weeks. Other criteria include specific ranges for hemoglobin, neutrophil count, platelet count, and various other blood and urine measurements. Exclusion criteria include recent radiotherapy, surgery, or tumor embolization, ongoing toxic manifestations of previous treatments, and certain cardiovascular conditions. Participants must also not be pregnant or lactating and must agree to use contraception during and after the trial. Other exclusion criteria include certain medical conditions, history of certain cardiovascular events, and hypersensitivity to pazopanib or its excipients.",
    "The sample provided is a record from a table that contains information about clinical trials. \n\nIn this particular sample, the trial is in phase 2 and focuses on the disease \"hypercholesterolemia.\" The associated ICD-10 codes for this disease are \"E78.01,\" \"E78.00,\" and \"Z83.42.\" \n\nThe drugs being tested in this trial include \"bococizumab (pf-04950615;rn316),\" \"placebo,\" and \"ezetimibe.\" \n\nThe eligibility criteria for this trial are as follows: \n- Inclusion Criteria: \n  - Subjects whose LDL-C (low-density lipoprotein cholesterol) is not controlled by a stable dose of atorvastatin (Population A).\n  - Subjects who are new to lipid-lowering drug treatment and have uncontrolled LDL-C (Population B).\n- Exclusion Criteria: \n  - Severe acute or chronic medical or psychiatric conditions or laboratory abnormalities.\n  - Pregnant or breastfeeding females, as well as males and females of childbearing potential who are unwilling or unable to use highly effective contraception.\n  - Subjects who have previously been administered or exposed to PF-04950615 and/or an antibody targeting PCSK9.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 1/Phase 2. The disease being studied is multiple myeloma, and its corresponding ICD-10 codes are C90.01, C90.02, and C90.00. The drug being used in the trial is carfilzomib. The eligibility criteria for participants in the trial are listed, including age requirements, consent, contraception methods for female participants, and the need for two negative pregnancy tests. Other criteria include the patient's medical history, performance status, life expectancy, and various laboratory values. The exclusion criteria include pregnancy or lactation, certain medical conditions, allergies to specific substances, and recent history of other malignancies.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on patients with type 2 diabetes. The ICD-10 codes associated with the disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being studied are hm11260c, liraglutide, and a placebo. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- Age: 18 to 74 years\n- Gender: Male and Female\n- Diagnosis of type 2 diabetes\n- Previous treatment with diet and exercise therapy, with or without metformin monotherapy\n- HbA1c levels between 7.0% and 10.0%\n- Females of childbearing potential must not be pregnant and agree to use a reliable method of birth control\n- Written informed consent is required\n\nThe exclusion criteria for the trial are as follows:\n- Pregnant or nursing (lactating) women\n- Diagnosis of type 1 diabetes mellitus\n- Uncontrolled diabetes, defined as a fasting plasma glucose (FPG) level of over 240 mg/dL\n- Significant change in body weight in the 3 months before screening\n- History of gastrointestinal (GI) intolerance\n- Personal or family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC\n- Known history of chronic pancreatitis\n- History of alcohol or drug abuse or addiction",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 2 and is focused on advanced solid tumors. The associated ICD-10 codes for these tumors are 'K74.02', 'G47.22', 'H35.3133', 'H35.3134', 'H35.3113', 'H35.3114', and 'H35.3123'. The drugs being used in this trial are linsitinib, erlotinib, paclitaxel, bortezomib, and dexamethasone. The eligibility criteria for participants include currently participating in a previous linsitinib trial sponsored by Astellas, not meeting criteria for discontinuation or progression in the previous trial, and deriving benefit from continued treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 2. The diseases being studied are \"open angle glaucoma\" and \"ocular hypertension\". The corresponding icd-10 codes for these diseases are \"H40.10X0\", \"H40.10X1\", \"H40.10X2\", \"H40.10X3\", \"H40.10X4\", \"H40.1130\", \"H40.1131\" for open angle glaucoma, and \"H40.053\", \"H40.051\", \"H40.052\", \"H40.059\" for ocular hypertension.\n\nThe drugs being investigated in this trial are \"pg324 ophthalmic solution 0.01%\", \"pg324 ophthalmic solution 0.02%\", \"netarsudil (ar-13324) ophthalmic solution 0.02%\", and \"latanoprost ophthalmic solution 0.005%\".\n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being 18 years of age or older, having a diagnosis of open angle glaucoma or ocular hypertension, having corrected visual acuity equivalent to 20/200 or better, and being able and willing to give informed consent and follow study instructions. Exclusion criteria include having certain types of glaucoma, high intraocular pressure, hypersensitivity to certain components, previous glaucoma surgeries or laser procedures, recent ocular trauma or surgeries, ocular infections or inflammation, significant ocular diseases, abnormal corneal thickness, and any abnormality preventing reliable tonometry. Systemic exclusion criteria include significant abnormalities in laboratory tests, systemic diseases, recent participation in other investigational studies, changes in systemic medication, and women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is prostate cancer. The ICDCodes associated with the disease are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']. The drugs being used in the trial are enzalutamide and androgen deprivation. The eligibility criteria for participants in this trial include having a histologically confirmed diagnosis of prostate adenocarcinoma, a Gleason sum of 7, 8, 9, or 10 at the time of prostatectomy, PSA relapse within 4 years of prostatectomy, evidence of disease recurrence or progression as evidenced by a PSA > 0.20, and meeting various age, performance status, and laboratory parameter requirements. The sample also includes exclusion criteria such as radiographic evidence of metastatic disease, PSA > 4.0 ng/mL, and prior exposure to certain hormones or chemotherapy.",
    "The sample from the table represents a phase 2 clinical trial for prostate cancer. The diseases included in the trial are adenocarcinoma of the prostate, recurrent prostate cancer, and stage IV prostate cancer. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being studied in the trial are enzalutamide, bicalutamide, leuprolide acetate, and goserelin acetate. The eligibility criteria for the trial include having a confirmed diagnosis of prostate adenocarcinoma with metastasis and being on or recently started on LHRH analogue therapy. Other criteria include specific PSA levels, previous hormone therapy history, absence of concomitant treatments, performance status, absence of prior malignancies, and willingness to provide informed consent. There are also exclusion criteria related to medical conditions, laboratory values, cardiovascular disease, gastrointestinal disorders, previous treatments, and other factors that may interfere with the trial or pose risks to the patient.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2, and the disease being studied is prostate cancer. The icd-10 codes associated with this disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs being used in the trial are ibrance, bicalutamide, zoladex, and lupron depot. The eligibility criteria for this trial include having a pathologic diagnosis of prostate cancer, hormone-sensitive metastatic disease, a minimum PSA level, agreeing to undergo a biopsy for RB status evaluation, having an ECOG performance status of 0-2, meeting organ and marrow function requirements, being able to take oral medication, meeting certain time requirements for prior treatments, agreeing to use contraception, and providing informed consent. The exclusion criteria include receiving androgen deprivation therapy for more than 14 days prior to enrollment, currently being treated with certain medications, using proton pump inhibitors, having known brain metastases, having uncontrolled intercurrent illness, having a currently active second malignancy, and being HIV-positive on combination antiretroviral therapy.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which includes the eligibility criteria for participants.\n\nIn this particular sample, the phase of the trial is listed as \"phase 2/phase 3\". The disease being studied is ADHD (Attention-Deficit/Hyperactivity Disorder), specifically the predominantly inattentive type. The corresponding ICD-10 code for ADHD is \"F90.0\". The drugs being tested are \"mg01ci (1400 mg)\" and \"placebo\". \n\nThe eligibility criteria for participants are listed under \"criteria\". Inclusion criteria include being a man or non-pregnant, non-lactating woman between the ages of 18 and 55, having a diagnosis of ADHD based on the DSM-IV and DSM-5 criteria, having at least moderate clinical severity of ADHD, and meeting certain scores on the CAARS-Inv assessment. Female subjects of childbearing potential must agree to use effective contraception throughout the study. Other criteria include being able to attend the clinic regularly, being able to swallow tablets and capsules, being able to understand and communicate in English fluently (or Hebrew for Israeli subjects), and being able to provide informed consent.\n\nExclusion criteria include not responding to previous adequate trials of stimulant or atomoxetine treatments, having clinically significant psychiatric or medical conditions, having certain infectious diseases, having allergies or sensitivities to B-complex vitamins, having a history of intellectual disability or autism spectrum disorder, having certain other psychiatric diagnoses, and having used certain medications or supplements within specific timeframes before the study. Other exclusion criteria include having a current drug or alcohol dependence or substance abuse disorder, having a history of suicidal behavior, having used certain ADHD medications within specific timeframes before the study, having significant visual impairment, having a relationship with the sponsor, investigator, or study staff, having any condition that may place the subject at risk or influence the study, being unable to comprehend or comply with the study requirements, being pregnant, lactating, or using inadequate contraception, and certain changes in CAARS-Inv assessment results.\n\nOverall, this sample provides information about a clinical trial for ADHD, including the phase of the trial, the diseases being studied, the drugs being tested, and the eligibility criteria for participants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on genitourinary cancer and kidney cancer. The ICD-10 codes associated with these diseases are ['D17.71', 'D30.00', 'D30.01', 'D30.02', 'D41.00', 'D41.01', 'D41.02']. The drug being studied in this trial is sunitinib. The eligibility criteria for participants in this trial include having histologically or cytologically-confirmed metastatic renal cell carcinoma of clear cell histology, being at least 18 years old, having measurable or evaluable metastatic disease, having an ECOG performance status of 0-1, and meeting certain organ and bone marrow function requirements. There are also exclusion criteria, such as prior treatment with sunitinib or any other systemic therapy in the metastatic setting, uncontrolled hypertension, and a history of certain medical conditions. Pregnant or breastfeeding women and individuals with HIV or AIDS-related illness are also excluded from the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are melanoma and skin cancer. The corresponding icd-10 codes for these diseases are provided as well. The drugs being used in the trial are pimonidazole hydrochloride (hypoxyprobe\u2122-1) and an optional 18f-fmiso pet scan (18f-fluoromisonidazole). The eligibility criteria for participants are listed, including age requirements, tumor size, pregnancy status, kidney and liver function, ability to undergo MRI scans, and willingness to comply with study procedures. Exclusion criteria are also mentioned, such as pregnancy or breastfeeding, contraindications for MRI, presence of other malignancies, and any other co-existing condition that may increase the risk to the participant.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 2.\n- Diseases: The trial is focused on treating squamous cell carcinoma of the head and neck.\n- ICD Codes: The ICD-10 codes associated with the disease are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8'].\n- Drugs: The drugs being used in the trial are cisplatin, docetaxel xrp6976, and dexamethasone.\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion criteria\" and \"Exclusion criteria\". The criteria include factors such as the stage of the disease, prior treatment history, age, organ function, and other health conditions. The information also mentions that the provided details may not cover all considerations relevant to a patient's potential participation in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on treating metastatic cancer, specifically metastatic melanoma. The trial involves the use of drugs such as aldesleukin, cyclophosphamide, and fludarabine. The eligibility criteria for participants include having measurable metastatic melanoma that expresses ESO, confirmation of diagnosis by the National Cancer Institute, having a certain clinical performance status, and being within a certain age range. Other criteria include being HLA-A*0201 positive, practicing birth control, and having certain serology and hematology values within normal ranges. There are also exclusion criteria, such as being pregnant or breastfeeding, having certain medical conditions or infections, receiving concurrent systemic steroid therapy, and having a history of severe hypersensitivity reactions or cardiac issues.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on various diseases such as esophageal carcinoma, hypopharyngeal carcinoma, laryngeal carcinoma, lymphoma, mesothelioma, and others. The diseases are associated with specific ICD-10 codes. The trial also involves the use of a drug called doxepin hydrochloride. The eligibility criteria for participants include having a confirmed diagnosis of thoracic malignancies, planned radiation therapy, experiencing esophageal pain related to esophagitis, and being able to swallow the study medication. There are also exclusion criteria, such as allergies to doxepin or tricyclic antidepressants, presence of certain medical conditions, and pregnancy or nursing.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of mild persistent asthma. The diseases column lists the specific disease being studied. The icdcodes column contains the corresponding ICD-10 codes for the disease. The drugs column lists the names of the drugs being used in the trial. Lastly, the criteria column provides the eligibility criteria for subjects participating in the trial, including age, medical history, medication usage, and other factors. The inclusion criteria specify the requirements for subjects to be included in the study, while the exclusion criteria outline the conditions that would disqualify subjects from participating.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes information about the diseases being studied, the associated ICD-10 codes, the drugs being used, and the eligibility criteria for participants.\n\nIn this particular trial, the diseases being studied are obesity, over-weight, hypothalamic injury, and craniopharyngioma. The ICD-10 codes associated with these diseases are \"E66.8\", \"E66.9\", \"E66.1\", \"O99.214\", \"O99.215\", \"O99.210\", and \"O99.211\". The drugs being used in the trial are \"zgn-440 sterile diluent\" and \"zgn-440 for injectable suspension\".\n\nThe eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having obesity as a consequence of acquired anatomical hypothalamic damage, being greater than 6 months post-treatment with resulting hypothalamic and/or pituitary injury, having stable body weight for at least 3 months, and having type 2 diabetes mellitus. Exclusion criteria include being male and taking gonadotropin replacement therapy, planning fertility treatment within 6 months, using weight loss agents or narcotics/opiates in the past 3 months, having a history of severe psychiatric disorders or type 1 diabetes mellitus, having metabolic or genetic disorders linked to obesity, having a history of bariatric surgery, participating in any other clinical study with an investigational drug or device within the past 3 months, experiencing blood loss or donation over 500 mL in the past 3 months, and being pregnant, nursing, or intending to become pregnant during the study.\n\nOverall, this sample provides information about a phase 2 clinical trial focusing on obesity and related conditions, the drugs being used, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a trial in phase 2/phase 3 for the treatment of involutional osteoporosis. The trial focuses on patients aged 50 years or older who have been diagnosed with involutional osteoporosis. Women included in the trial must have gone through menopause at least 2 years prior to the trial. \n\nThe record also includes exclusion criteria, which are conditions that would disqualify a patient from participating in the trial. These criteria include patients with secondary osteoporosis or other diseases that cause decreased bone mass. Patients with certain medical conditions or a history of specific treatments, such as radiotherapy to the lumbar spine or the pelvis, treatment with certain medications, or disorders affecting the esophagus or gastrointestinal system, are also excluded from the trial.\n\nAdditionally, patients with serious renal, hepatic, or cardiac disease, as well as those who have unresolved dental problems requiring surgical dental procedures, are not eligible for the trial.\n\nThe record also lists the drugs being tested in the trial, which include \"ne-58095 ir,\" \"ne-58095 ir placebo,\" \"ne-58095 dr,\" and \"ne-58095 dr placebo.\" The eligibility criteria provided in the record are categorized into inclusion criteria (conditions that must be met for a patient to be included in the trial) and exclusion criteria (conditions that would disqualify a patient from participating in the trial).",
    "The sample from the table is for a phase 2 clinical trial for the treatment of gout. The eligibility criteria for participants include being between 18 and 75 years old, having a known diagnosis of gout, experiencing at least three documented flares in the past year, not using any urate-lowering therapy or colchicine for at least two weeks prior to screening, having a usual level of resting pain of three or less on a numerical rating scale, having a serum uric acid level between 7.5 mg/dL and 12 mg/dL, and meeting various other medical and laboratory requirements.\n\nFemale participants must meet additional criteria related to contraception, surgical sterility, or post-menopausal status. Exclusion criteria include recent use of certain medications, history of certain medical conditions (such as kidney stones or viral infections), history of drug or alcohol abuse, history of certain cardiovascular events, history of cancer within the past five years (with some exceptions), and various other conditions that may compromise the safety or compliance of the participant.\n\nThe sample also includes a list of drugs being tested in the trial, including arhalofenate 600 mg, allopurinol 300 mg, colchicine 0.6 mg, placebo, and arhalofenate 800 mg.",
    "The sample from the table represents a phase 2 clinical trial for Alzheimer's disease. The trial is investigating the effectiveness of different drugs, including placebo and donepezil. The eligibility criteria for participants include having a probable diagnosis of Alzheimer's disease, a documented history of cognitive decline, a reliable caregiver, normal physical examination and laboratory test results, good communication skills, adequate reading ability, and a negative MRI scan ruling out non-AD conditions. Exclusion criteria include previous use of certain AD treatments, significant medical conditions or recent surgery, positive HIV or active hepatitis B infection, history of malignancy or stroke, presence of non-AD neurological disorders, recent head trauma or infectious disease affecting the brain, psychiatric disorders, vitamin deficiencies, pregnancy or nursing, recent participation in other trials, history of alcoholism or drug abuse, and contraindications to donepezil.",
    "The sample is a record from a table that contains information about clinical trials. It includes the following details:\n\n- Phase: The trial is in Phase 2.\n- Diseases: The trial is focused on three diseases - post-herpetic neuralgia (PHN), neuropathic pain, and painful diabetic peripheral neuropathy (PDPN).\n- ICD Codes: The ICD-10 codes associated with these diseases are ['E85.1', 'E85.0', 'N31.0', 'N31.1', 'N31.2', 'E10.610', 'E11.610'].\n- Drugs: The trial involves two drugs - 'asp8477' and 'placebo'.\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include having a diagnosis of diabetes with painful diabetic peripheral neuropathy, stable glycemic control, a history of DPN pain, and stable symptoms. The exclusion criteria include having pain unrelated to the specified diseases, certain medical conditions, previous investigational therapy, and various other factors.\n\nOverall, this sample provides information about the phase, diseases, ICD codes, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are metastatic melanoma and brain metastases. The ICDCodes associated with these diseases are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4. The drugs being used in the trial are nab-paclitaxel, temozolomide, and bevacizumab. The eligibility criteria for participants include having histologically or cytologically confirmed malignant melanoma with clinical evidence of metastatic disease to the brain, newly developed inoperable brain metastases without associated hemorrhage or midline shift, and inoperable or metastatic extra cranial stage III or IV disease. There are additional criteria related to diagnostic imaging, prior therapy, age, peripheral neuropathy, pregnancy test, contraception, performance status, estimated life expectancy, and organ function. The exclusion criteria include prior surgical resection for brain metastases, history of allergic reactions to certain compounds, uncontrolled intercurrent illness, history of myocardial infraction or stroke, history of abdominal fistula or abscess, serious non-healed wounds or fractures, history of hepatitis B, C or HIV, uncontrolled hypertension or chronic renal disease, known hypersensitivity to human albumin, recent surgery or chemotherapy, evidence of other concurrent active malignancy, pregnancy or nursing, and not receiving any other investigational agent.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"rheumatoid arthritis.\" The ICD-10 codes associated with this disease are \"M06.9,\" \"M05.9,\" \"M06.08,\" \"M06.00,\" \"M06.011,\" \"M06.012,\" and \"M06.019.\" The drugs being studied in this trial are \"placebo\" and \"upadacitinib.\" \n\nThe eligibility criteria for participants in this trial include being diagnosed with rheumatoid arthritis for at least 3 months, having active rheumatoid arthritis based on specific criteria, receiving methotrexate therapy for at least 3 months, discontinuing certain other medications prior to the trial, having a negative tuberculosis screening, and meeting certain requirements for the use of other medications. \n\nThere are also exclusion criteria, such as being pregnant or breastfeeding, prior exposure to certain medications, recent use of investigational drugs, and certain laboratory values not meeting the specified criteria.",
    "The sample is a phase 2 trial for the treatment and prevention of chronic migraine. The trial focuses on patients who have a history of at least 5 attacks of migraine without aura and/or migraine with visual sensory, speech and/or language, retinal or brainstem aura. These patients also have a history of at least 15 headache days per month, with at least 8 of those days being assessed as migraine days by the patients themselves. The trial requires patients to have at least 4 distinct headache episodes, each lasting at least 4 hours or shorter if associated with the use of a triptan or ergot-derivative on the same day. Patients must also demonstrate at least 80% compliance with an eDiary.\n\nThere are certain exclusion criteria for the trial, such as a history of cluster headache or hemiplegic migraine headache, inability to differentiate migraine from other headaches, failure of more than 3 medication categories for prophylactic treatment of migraine, receiving botulinum toxin in the head or neck region within 4 months prior to screening, and using a prohibited migraine prophylactic medication, device, or procedure within 2 months prior to the start of the baseline phase. The only drug mentioned in the sample is a placebo.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of basal cell carcinomas. The ICD-10 codes associated with the disease are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']. The drugs being studied are vismodegib and placebo. The sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being at least 18 years old, having a history of 3 or more biopsy confirmed BCCs in the preceding 2 years, and agreeing to comply with the study procedures. Exclusion criteria include being pregnant or lactating, having uncontrolled illnesses or infections, and currently receiving certain medications or treatments. The sample also mentions other requirements such as using contraception and understanding and signing an informed consent document in English.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 2, and the disease is major depressive disorder. The icd-10 codes associated with the disease are F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, and F33.40. The drugs being tested in this trial are nrx-1074 1 mg, placebo, nrx-1074 5 mg, and nrx-1074 10 mg. The eligibility criteria include age between 18 and 65, meeting the diagnostic criteria for major depressive disorder, having a current episode lasting at least 8 weeks, specific HDRS-17 scores, negative pregnancy test for female subjects, and the ability to understand and comply with the study requirements. There are also exclusion criteria listed, such as certain psychiatric disorders, substance abuse, allergies to medications, recent participation in other clinical trials, and more.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for participants in the trial.\n\nIn this specific sample, the phase of the trial is phase 2. The diseases being studied are \"painful diabetic neuropathy\", \"diabetic neuropathy\", and \"neuropathy\". The corresponding ICD-10 codes for these diseases are provided. The drugs being tested are \"clonidine gel 0.1%\" and \"placebo\". The eligibility criteria for participants in this trial are listed, including requirements such as providing written informed consent, having stable glycemic control, experiencing chronic pain in the feet due to neuropathy, and meeting certain pain score criteria.\n\nAdditionally, there are exclusion criteria listed, which specify conditions or factors that would disqualify a participant from the trial. These include having neuropathy secondary to non-diabetic causes, having significant neurological disorders or conditions that mimic peripheral neuropathy, having other sustained pain that is equal to or greater than the neuropathic pain in the feet, and having certain medical or psychiatric conditions that would interfere with participation in the study.\n\nOverall, this sample provides a snapshot of a specific clinical trial, including the phase, diseases being studied, drugs being tested, and the eligibility and exclusion criteria for participants.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is atopic dermatitis. The corresponding ICD-10 codes for atopic dermatitis are 'L20.89' and 'L20.9'. The drugs being tested in this trial are 'opa-15406' and 'placebo'. The eligibility criteria for participants include being between 10-70 years old, having a diagnosis of atopic dermatitis for at least 3 years, having AD affecting between 5% and 40% of the total body surface area, and having a disease severity score of 2 (mild) or 3 (moderate) in the selected treatment area(s) according to the Investigator's Global Assessment. Exclusion criteria include having a contact or atopic dermatitis flare within 28 days of the baseline visit, and having concurrent diseases/conditions or a history of other diseases/conditions in the selected treatment area(s) that may affect the study assessments.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on patients with osteoarthritis of the knee. The ICD-10 codes associated with this disease are ['M15.4', 'M15.0', 'M16.9', 'M17.9', 'M19.011', 'M19.012', 'M19.019']. The trial involves two drugs, 'tv-45070' and 'placebo'. The eligibility criteria for inclusion in the trial include being between 40 and 85 years old, having primary osteoarthritis in a single knee (confirmed by American College of Rheumatology criteria), and having acceptable visual analog scale (WAS) pain scores. Patients with secondary or inflammatory arthritis, symptomatic chondrocalcinosis, fibromyalgia, or other conditions that may confound pain assessment are excluded from the trial. Patients with certain medical disorders, edema or skin disorders in the knee area, previous knee surgeries, or intolerance to the study drug are also excluded. Additionally, patients using certain medications or with other specific criteria may be excluded. For more information, it is advised to contact the investigator.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating advanced breast cancer. The trial involves the use of drugs such as dexamethasone based mouthwash, everolimus, and exemestane. The eligibility criteria for participants include being adult women with metastatic or locally advanced breast cancer that cannot be treated with surgery or radiotherapy. They must also have hormone-receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer and be postmenopausal. The trial requires the participants to take everolimus 10mg plus exemestane 25mg treatment on Cycle 1 Day 1. Other criteria include having an ECOG Performance status of \u2264 2, adequate renal function, and willingness to self-report oral pain levels using a Visual Analog Scale (WAS) and the Normalcy Diet Scale (NDS). The exclusion criteria include patients currently receiving anticancer therapies, those with stomatitis/oral mucositis/mouth ulcers, known intolerance or hypersensitivity to everolimus or other rapamycin analogs, and patients with certain medical conditions such as uncontrolled diabetes mellitus or severe cardiac disease. The sample also includes additional exclusion criteria related to medical conditions, treatment history, and participation in other clinical investigations.",
    "The sample provided is for a phase 2 clinical trial for the treatment of bladder cancer using the drug mitomycin c. The eligibility criteria for participants include having a recurrence of non-muscle invasive bladder cancer (NMIBC) following a low-risk diagnosis, being diagnosed with transitional-cell carcinoma (TCC), being 16 years or older, having satisfactory blood test results, and not being pregnant. \n\nExclusion criteria include having a history of high-grade or advanced stage bladder cancer, having a history of non-TCC bladder cancer, having a recurrence within 11.5 months of the original diagnosis, having received prior treatment for the recurrence, having a known allergy to mitomycin c, having carcinoma involving the prostatic urethra or upper urinary tract, having a reduced bladder capacity, having a bleeding disorder, being a breastfeeding woman or a sexually active male without contraception, having an active urinary tract infection, having a urethral stricture or any obstruction preventing catheter insertion, having large narrow neck diverticula, having significant urinary incontinence, or having any other condition that the Principal Investigator deems incompatible with the study.\n\nThis description provides an overview of the phase 2 trial, the disease being targeted (bladder cancer), the drug being tested (mitomycin c), and the eligibility and exclusion criteria for participants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"cystic fibrosis\". The ICD-10 codes associated with this disease are \"E84.9\", \"Z14.1\", \"E84.0\", \"E84.11\", \"E84.8\", \"E84.19\", and \"P09.4\". The drugs being studied in this trial are \"vx-661\", \"ivacaftor\", \"placebo matched to vx-661\", and \"placebo matched to ivacaftor\". The eligibility criteria for participants in this trial include being homozygous for the F508del CFTR mutation, having a FEV1 (forced expiratory volume in one second) between 40% and 90% of predicted normal for age, sex, and height, and having stable CF (cystic fibrosis) disease. There are also exclusion criteria, such as having comorbidities that could affect the study results or pose additional risks, being pregnant or nursing without a negative pregnancy test, not following contraception requirements for sexually active participants of reproductive potential, and having a close relative involved in the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is pulmonary hypertension. The ICDCodes associated with this disease are ['I27.0', 'I27.20', 'I27.21', 'I27.24', 'I27.29', 'P29.30', 'I27.22']. The drugs being tested in this trial are macitentan and placebo. The eligibility criteria for this trial include specific inclusion and exclusion criteria. Inclusion criteria include being male or female aged 18 years or older, having combined pre-and post-capillary pulmonary hypertension due to left ventricular dysfunction (subset of WHO groups 2.1 and 2.2), and being on optimized diuretic therapy. Exclusion criteria include having types of pulmonary hypertension other than WHO groups 2.1 and 2.2 (Nice classification) and receiving specific PAH-specific therapies such as endothelin receptor antagonists (ERAs), prostanoids, phosphodiesterase 5 (PDE-5) inhibitors, or guanylate cyclase stimulators.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 2 and is focused on chronic lymphocytic leukemia (CLL). The trial is looking at the effectiveness of the drugs bendamustine and obinutuzumab. The eligibility criteria for participants include being 18 years or older, having a diagnosis of CD20+ B- CLL according to NCI criteria, having active disease that meets certain criteria for treatment, having refractory or relapse CLL, having received prior purine analogue or bendamustine therapy, having a life expectancy of more than 6 months, and using effective contraception. The exclusion criteria include having had a prior allogenic bone marrow transplant, having received three or more previous lines of chemotherapy and/or immunotherapy for CLL, having received a previous obinutuzumab-containing regimen, having treatment failure or progression within 6 months of a bendamustine-containing regimen, having CLL transformed to aggressive non-Hodgkin lymphoma (Richter's transformation), having active hemolytic anemia, having inadequate liver function, having a history of other malignancy that could affect compliance with the protocol or interpretation of results, having evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, having recent major surgery, regular treatment with corticosteroids, known active infection or any infection requiring treatment, having HIV, HTLV-1, hepatitis B or hepatitis C, being pregnant or breastfeeding, having received a live vaccine within 4 weeks prior to the baseline visit, and having received any other study drug within 4 weeks prior to the study start.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is hypercholesterolemia. The ICD-10 codes associated with this disease are E78.01, E78.00, and Z83.42. The drugs being tested in the trial are etc-1002, placebo, and statin therapy. \n\nThe eligibility criteria for inclusion in the trial are:\n- Fasting, calculated mean LDL-C (low-density lipoprotein cholesterol) levels between 130 mg/dL and 220 mg/dL\n- Fasting mean TG (triglyceride) levels below 400 mg/dL\n- Stable statin therapy for at least 3 months prior to screening, with specific statin medications listed (atorvastatin, simvastatin, rosuvastatin, or pravastatin)\n\nThe exclusion criteria for the trial are:\n- Clinically significant cardiovascular disease within the past 12 months\n- Current muscle-related symptoms possibly caused by ongoing statin therapy or previous lab abnormalities during statin therapy\n- Type 1 diabetes or uncontrolled type 2 diabetes\n- Recent use of metformin or thiazolidinediones (TZD)\n- History of chronic musculoskeletal symptoms like fibromyalgia\n- Uncontrolled hypothyroidism\n- Liver disease or dysfunction\n- Renal dysfunction or nephritic syndrome\n- Gastrointestinal conditions, procedures, or surgeries\n- Hematologic or coagulation disorders or low hemoglobin levels\n- HIV or AIDS\n- History of malignancy\n- History of drug or alcohol abuse within the past 2 years\n- Use of experimental or investigational drugs within the past 30 days\n- Previous use of ETC-1002 in a previous clinical study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are metastatic melanoma, stage III melanoma, and stage IV melanoma. The corresponding ICDCodes for these diseases are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4.\n\nThe drugs being investigated in this trial are indoximod, ipilimumab, nivolumab, and pembrolizumab. \n\nThe eligibility criteria for this trial include:\n- Patients must have unresectable Stage III or Stage IV melanoma.\n- Patients must have measurable disease, with specific size requirements for lesions.\n- Patients should not have received any systemic treatment in the previous 28 days.\n- Patients must be at least 18 years old.\n- Patients' ECOG performance status should be \u22642 (Karnofsky \u226560%).\n- Patients with brain metastases are eligible if their tumors have been treated and they are neurologically stable.\n- There are also exclusion criteria, such as recent molecular targeted therapy or radiotherapy, prior therapy with immune checkpoint inhibition or indoximod, presence of other cancers, laboratory evidence of pancreatitis, autoimmune disease, and chronic use of immune-suppressive drugs.\n\nThis sample provides a specific example of the data stored in the table, showcasing the phase, diseases, ICDCodes, drugs, and eligibility criteria for a particular clinical trial.",
    "The sample from the table is for a phase 2 clinical trial for breast cancer. The trial is specifically for patients with invasive breast cancer that is over 1 cm in diameter and has no evidence of metastasis, except for isolated supra-clavicular node involvement. The patients must have overexpression and/or amplification of HER2 in the primary tumor, as confirmed by a certified laboratory. The trial also requires knowledge of the patient's hormone receptor status.\n\nIn terms of eligibility criteria, the patients must be female, at least 18 years old, and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. They must also meet certain hematopoietic, hepatic, renal, and cardiovascular requirements. Additionally, they must have a negative pregnancy test and use effective contraception if they are fertile. Patients must provide informed consent and agree to make tumor samples available for translational studies.\n\nThere are also exclusion criteria for the trial. Patients with a history of certain malignant neoplasms within the past 5 years, preexisting peripheral neuropathy grade 2 or higher, and certain cardiovascular conditions are excluded. Other exclusion criteria include concurrent diseases or conditions that would make the patient inappropriate for the study, unresolved or unstable adverse events from prior investigational drug administration, and certain psychiatric or gastrointestinal conditions. Patients currently undergoing neoadjuvant cancer therapy or participating in another therapeutic clinical trial are also excluded. Patients with known hypersensitivity reactions to certain drugs or components, pregnant or lactating women, and those unable to comply with the protocol are also excluded.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease tuberculosis. The associated ICD-10 codes for tuberculosis are ['A18.39', 'P37.0', 'Z22.7', 'A15.0', 'A15.7', 'A15.8', 'A15.9']. The drug being used in this trial is a placebo. \n\nThe sample also includes the eligibility criteria for participants in the trial. The inclusion criteria state that participants must have completed the informed consent process, be between the ages of 12 and 17, agree to stay in contact with the study site, and have good general health. They must also have received a BCG vaccination at least 5 years ago and test negative for QFT-GIT at screening.\n\nThe exclusion criteria list factors that would disqualify a participant from the trial, such as acute illness, high oral temperature, abnormal laboratory values, evidence of systemic or local disease, history of active TB or latent Mtb infection, autoimmune disease or immunosuppression, recent use of immunosuppressive medication or blood products, and recent receipt of investigational drugs or vaccines. Other factors include a history of alcohol or drug abuse, current pregnancy or lactation, recent TST test, and any medical, psychiatric, or substance abuse problems that would make it unlikely for the subject to comply with the protocol.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is anemia, and the associated ICD-10 codes are D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, and D61.9. The drugs being tested are gsk1278863 and placebo. The eligibility criteria for participants include being on a stable hemodialysis regimen for at least 12 weeks, having a dialysis adequacy measure (Kt/Vurea) of at least 1.2, meeting specific criteria for rhEPO hyporesponsiveness, having a small difference in hemoglobin levels, being at least 18 years old, having a QTc interval within a certain range, and meeting certain gender requirements. There are also exclusion criteria, such as planned changes in dialysis modality, recent use of certain medications, and various medical conditions that could impact the study. Additionally, there are specific laboratory eligibility criteria that will be assessed. Subjects who fail the initial screening may be rescreened, with specific timeframes for rescreening based on certain criteria.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which includes the eligibility criteria for the trial.\n\nIn this particular sample, the phase of the trial is phase 2. The disease being studied is \"respiratory disorders\". The corresponding ICD-10 codes for the disease are \"J98.9\", \"Z13.83\", \"J95.89\", \"J98.8\", and \"J99\". The drug being tested is a \"nacl placebo\". The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include age requirements, confirmed diagnosis of COPD, smoking history, history of exacerbations, and other specific conditions. The exclusion criteria include factors such as participation in other clinical studies, use of other investigational products, previous vaccination with certain antigens, and various medical conditions or treatments that may affect the study.\n\nOverall, this sample provides specific details about the phase, diseases, drugs, and eligibility criteria for a clinical trial related to respiratory disorders.",
    "The sample provided is a record from a clinical trial table. It belongs to phase 2 of the trial and focuses on the disease \"infection, human immunodeficiency virus\" with the corresponding ICD-10 code \"Z21\". The drugs being tested in this phase include \"744 tablet\", \"744 la injection\", \"placebo tablet\", and \"placebo injection\". The eligibility criteria for participants are listed, including requirements such as a non-reactive HIV test, being between 18 and 65 years old, having engaged in casual sex in the past 24 months, being in good health, and agreeing to use condoms if engaging in sexual activity with a female partner. There are also exclusion criteria, such as having a reactive HIV test, being at high risk for HIV infection, co-enrollment in other HIV research studies, recent use of antiretroviral therapy, and various medical conditions or abnormalities. The sample also includes specific laboratory values and cardiac conditions that would exclude a participant from the trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the diseases mentioned are nonalcoholic steatohepatitis and non-alcoholic fatty liver disease. The ICDCodes associated with these diseases are K75.81 and a combination of Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, and K70.0. The drug mentioned is idn-6556. The eligibility criteria for this sample include various conditions such as being of legal age, having a diagnosis of non-alcoholic fatty liver disease, specific levels of ALT and AFP, and certain blood counts. There are also exclusion criteria, including infections with HIV, HCV, or HBV, severe liver disease, inflammatory bowel disease, systemic lupus erythematosus (SLE) and/or rheumatoid arthritis (RA), hepatocellular carcinoma (HCC), history of non-liver malignancies, significant systemic or major illnesses, and history or presence of alcohol or substance abuse.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of prostate cancer. The trial is focused on patients with metastatic prostate cancer who have shown progression of the disease. The eligibility criteria for the trial include being a male aged 18 years and above, having histologically or cytologically confirmed adenocarcinoma of the prostate, and having documented metastatic disease. The patients should also be asymptomatic or mildly symptomatic from prostate cancer and have medically castrated testosterone levels. Other criteria include having a certain performance status, specific blood counts and levels, and meeting certain liver function requirements. The patients should be able to swallow the study drug whole as a tablet and have a life expectancy of at least 6 months. Patients with partners of childbearing potential must be willing to use a method of birth control during the study and for 1 week after the last study drug administration. The exclusion criteria include surgical castration, recent use of LHRH-therapy, active infections or medical conditions contraindicating the use of corticosteroids, certain pathological findings, liver or visceral organ metastasis, known brain metastasis, and use of certain analgesics for cancer-related pain. Other exclusion criteria include prior treatments for prostate cancer, recent radiation therapy, prior treatment with specific drugs, and certain medical conditions such as uncontrolled hypertension, liver disease, heart disease, and other malignancies with a high probability of recurrence. The sample also includes criteria related to the administration of other medications and the overall suitability of the patient for participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are metastatic pancreatic adenocarcinoma and metastatic pancreatic cancer. The ICDCodes associated with these diseases are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31 for the first disease, and C25.3 for the second disease. The drugs being used in the trial are nab-paclitaxel, gemcitabine, and indoximod. The eligibility criteria for this trial include having a definitive histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas, with the initial diagnosis of metastatic disease occurring within the past 8 weeks. Patients must have one or more measurable metastatic tumors, be at least 18 years old, and have a Karnofsky performance status of 70 or higher. Patients should not have received any previous radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease. Prior treatment with gemcitabine and/or nab-paclitaxel in the adjuvant setting is allowed if certain conditions are met. Patients should not have received any other immunomodulatory therapies for this or any other cancer. There are also exclusion criteria, such as not receiving any other investigational agents for metastatic disease, not having known brain metastases, and not having only locally advanced disease. Other exclusion criteria include having a history of malignancy in the last 3 years (except for certain cases), having any active autoimmune disease, and having undergone major surgery within 4 weeks prior to the start of the treatment in this study.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The disease being studied in this trial is Alzheimer's disease. The corresponding ICD-10 codes for this disease are G30.8, G30.9, G30.0, and G30.1. The drugs being tested in this trial are iti-007 and placebo. \n\nThe eligibility criteria for this trial are divided into two parts. In Part 1, the trial is looking for healthy geriatric volunteers with a minimum MMSE score of 26 at screening. The volunteers should have a BMI between 19.0 and 40.0 kg/m2 and a minimum body weight of 50 kg at screening. \n\nIn Part 2, the trial is targeting geriatric patients with a clinical diagnosis of dementia and an MMSE score of less than 26 at screening. The same BMI and body weight requirements apply.\n\nThe exclusion criteria for this trial include having any clinically significant illness within 6 months before screening, a history of cancer within the last 5 years, a history of Hepatitis B or C infection, and elevated ALT, AST, or bilirubin levels above the upper limit of normal. Additionally, any subject considered to be an imminent danger to themselves or others is excluded from the trial.",
    "The sample from the table is for a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating glioblastoma, specifically adult brain glioblastoma and glioblastoma multiforme. The trial requires patients to meet certain eligibility criteria, including being 18 years or older, having histologically confirmed GBM or WHO Grade IV variants, and having evidence of tumor recurrence or progression. Patients who have undergone resection of recurrent or progressive tumor must have recovered from the effects of surgery, and those who have not had resection must have measurable disease. Other criteria include specific imaging requirements, recovery from prior therapy toxicity, specific time intervals from prior treatments, HLA-A2 positivity, and adequate organ function. Female patients of childbearing potential must have a negative pregnancy test and agree to use contraception. The exclusion criteria include prior use of certain treatments, specific characteristics of the tumor, requirement of high-dose corticosteroid therapy, recent surgical or radiation therapy, active infection, history of certain cancers, significant cardiovascular disease, immunosuppressive or autoimmune diseases, and other conditions that make the patient unsuitable for the study. The sample also includes criteria related to anticoagulation therapy and bleeding events.",
    "The sample from the table is for a clinical trial in the field of oncology. The trial is in phase 1/phase 2 and focuses on the treatment of chronic myeloid leukemia. The trial includes patients who have been diagnosed with Philadelphia chromosome (Ph) positive chronic myelogenous leukemia in either chronic phase or accelerated phase. The eligibility criteria include having failed or demonstrated intolerance to at least 2 prior treatments with tyrosine kinase inhibitors (TKIs). Failure of TKI treatment can be primary (no response) or secondary resistance (loss of response). Intolerance to TKI therapy can be due to nonhematologic toxicity, hematologic toxicity, or any unacceptable toxicity. Patients must have completed all previous anticancer therapy and have adequate hepatic and renal function. The trial also has exclusion criteria, such as uncontrolled cardiac conditions, recent myocardial infraction, concurrent illnesses that would affect the study, recent stem cell transplant, and active viral infections. The sample does not mention the duration or other details of the trial.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is Alzheimer's disease. The ICD-10 codes associated with the disease are G30.8, G30.9, G30.0, and G30.1. The drugs being tested in the trial are t-817ma-h, t-817ma-l, and a placebo. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- The patient must be male or female, post-menopausal or surgically sterile.\n- The patient must have mild to moderate Alzheimer's disease and be receiving donepezil (Aricept\u00ae) or rivastigmine transdermal system (Exelon\u00ae Patch). Memantine (Namenda\u00ae) is allowed only if prescribed in combination with donepezil or rivastigmine transdermal system.\n- The patient must be between the ages of 55 and 85.\n- The patient must be living in the community.\n- The patient must have an eligible informant or study partner (caregiver).\n- Both the patient and the caregiver must be able to read and understand English.\n- Informed consent must be obtained from both the patient and the caregiver.\n\nThe exclusion criteria for the trial are as follows:\n- Patients with clinically significant cardiac, hepatic, or renal impairment.\n- Patients with a dementia not of the Alzheimer's type, as defined by the protocol.\n- Patients who are taking any drug other than donepezil or rivastigmine transdermal system for Alzheimer's disease, including olal rivastigmine (Exelon\u00ae) and galantamine (Razadyne\u00ae).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are lupus erythematosus and graft-versus-host disease. The ICDCodes associated with these diseases are D89.810, D89.811, D89.813, and D89.812. The drugs being used in the trial include cyclophosphamide, fludarabine, tacrolimus, mycophenolate mofetil, and rabbit antithymocyte globulin. The eligibility criteria for this trial include specific criteria for inclusion, such as meeting certain classification criteria for lupus erythematosus, involvement of specific organ systems, and a lack of response to certain treatments. There are also exclusion criteria, such as age restrictions, pregnancy risk, and patients who are preterminal or moribund.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on pancreatic cancer. The ICD-10 code for pancreatic cancer is C25.3. The drug being studied is regorafenib. The record includes the eligibility criteria for participants in the trial, including requirements such as having adenocarcinoma of the exocrine pancreas with metastatic disease, progression on prior chemotherapy, measurable disease on imaging, and a life expectancy of at least 8 weeks. The record also includes exclusion criteria, such as uncontrolled hypertension, active cardiac disease, and previous assignment to treatment in this study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on prostate cancer. The ICD-10 codes associated with the disease are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']. The drugs being studied are 'relugolix' and 'leuprorelin'. The eligibility criteria for participants are listed, including requirements such as being male, having a confirmed diagnosis of prostate adenocarcinoma, and being a candidate for androgen deprivation therapy. The sample also includes exclusion criteria, such as having certain medical conditions or receiving certain treatments.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is metastatic colorectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are sym004 (12 mg/kg), sym004 (9/6 mg/kg), fluorouracil (5-fu), and capecitabine. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include obtaining written informed consent, being at least 18 years old, having histologically or cytologically confirmed metastatic colorectal cancer with Kirsten rat sarcoma wild-type (KRAS WT) at initial diagnosis, failure of or intolerance to 5-FU, Oxaliplatin, and Irinotecan, acquired resistance to marketed anti-EGFR monoclonal antibodies (mAbs), having measurable disease according to RECIST, having a life expectancy of at least 3 months, having an Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1, and meeting any other protocol-defined inclusion criteria.\n\nExclusion criteria include pretreatment with regorafenib, subjects who would benefit more from regorafenib treatment (except where regorafenib is not reimbursed in the country), having a skin rash Common Terminology Criteria for Adverse Events (CTCAE) Grade greater than 1 from previous anti-EGFR therapy at the time of randomization, having magnesium levels less than 0.9 milligram per deciliter (mg/dL), known hypersensitivity to any of the treatment ingredients, known previous Grade 3-4 infusion-related reactions with anti-EGFR monoclonal antibodies, and meeting any other protocol-defined exclusion criteria.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on head and neck cancer. The trial includes patients who are scheduled for definitive or postoperative chemoradiotherapy. The eligibility criteria for inclusion in the trial include having a histopathological diagnosis of head and neck cancer in specific regions, no previous history of chemotherapy or radiotherapy for head and neck cancer, an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, ability to hold fluid in the mouth and swallow the investigational medicinal product (IMP), expected survival of at least 3 months, written informed consent, ability to stay at or visit the hospital for scheduled examinations and observations, and ability to take contraceptive measures. Exclusion criteria include having primary malignant tumors other than head and neck cancer, symptomatic viral, bacterial, or fungal infection, serious renal impairment, distant metastasis, severe complications, and abnormal laboratory test results. The sample also mentions specific laboratory test result thresholds for neutrophil count, platelet count, hemoglobin, AST, ALT, serum bilirubin, serum albumin, serum creatinine, and creatinine clearance. Additional exclusion criteria include complications with autoimmune disease, requirement for continuous systemic administration of glucocorticoid, pregnancy or lactation, recent participation in another clinical trial, history of drug allergy to specific compounds, and being deemed inappropriate for inclusion by the investigator or sub-investigator.",
    "The sample from the table represents a phase 2 clinical trial for patients with relapsed or refractory indolent B cell non-Hodgkin lymphomas. The trial aims to evaluate the effectiveness of the drugs \"imprime pgg\" and \"rituximab\" in treating these types of lymphomas. The eligibility criteria for participants include having histologically determined indolent NHL that has relapsed or is refractory after initial therapy, having received 1-3 prior lines of chemoimmunotherapy and/or monotherapy with rituximab, and having measurable disease that has not been previously irradiated. Other criteria include specific performance status, blood count, organ function, and age requirements. The exclusion criteria include current or recent anticancer therapies, previous use of PGG-Betafectin or Imprime PGG, major surgery or traumatic injury within 4 weeks, known leptomeningeal or brain metastases, severe allergies or hypersensitivity to monoclonal antibody therapy or baker's yeast, HIV or hepatitis B or C infection, uncontrolled infections, history of other malignancies (except for certain types), and other medical conditions that could affect participation in the study. Female participants must not be pregnant or breastfeeding and must use effective birth control methods. The sample also includes additional details about the study requirements and restrictions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on various types of lymphomas, including adult diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma, Waldenstrom macroglobulinemia, small lymphocytic lymphoma, chronic lymphocytic leukemia, and T-cell lymphoma. The corresponding ICD-10 codes for these diseases are also included. The trial is investigating the use of the drug doxycycline. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include having relapsed aggressive or indolent non-Hodgkin lymphoma (NHL) following prior treatment, being at least 18 years old, having a Karnofsky Performance Status (KPS) of at least 60% or an Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or lower, having a life expectancy of at least 3 months, having measurable disease in at least one target lesion, and having adequate organ function. Adequate organ function is defined by specific criteria for blood cell counts, renal function, and hepatic function.\n\nExclusion criteria include known sensitivity or allergy to tetracyclines, lack of measurable disease by computed tomography (CT) or positron emission tomography (PET), a KPS of less than 60% or an ECOG PS higher than 2, curative treatment being indicated or possible, inadequate organ function, and pregnancy or breastfeeding.\n\nOverall, the sample provides information about the phase, diseases, ICD-10 codes, drug, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of schizophrenia. The ICD-10 codes associated with the disease are ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drug being studied is risperidone ism. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being capable of providing informed consent, being between the ages of 18 and 65, having a current diagnosis of schizophrenia, having a body mass index (BMI) between 17 and 35 kg/m2, being medically and psychiatrically stable, being on a stable dosage of oral risperidone of at least 4 mg daily, having a total score of 70 or less on the Positive and Negative Syndrome Scale, using a medically accepted contraceptive method, and agreeing to washout prohibited medications prior to baseline.\n\nExclusion criteria include obtaining informed consent from a third party, being a prisoner or compulsorily detained patient, being a breastfeeding female or having a positive pregnancy test, having an uncontrolled or unstable clinically significant medical condition, testing positive for Hepatitis B, Hepatitis C, or anti-HIV 1 and 2, having a history of neuroleptic malignant syndrome or tardive dyskinesia, having a positive urine drug or alcohol screen finding, being at risk of self-harm or harm based on the Columbia Suicidal Rating Scale, taking more than one antidepressant, using depot antipsychotics within the last three months, using strong or moderate cytochrome P450 isoenzyme 3A4 inducers, undergoing electroconvulsive therapy (ETC) within the last three months, receiving any investigational drugs within the last three months, having a known or suspected allergy or hypersensitivity to risperidone, or being a previous non-responder to risperidone treatment.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on patients with dermatitis, specifically atopic dermatitis. The ICD-10 codes associated with the disease are 'L20.89' and 'L20.9'. The drugs being tested in the trial are apremilast and placebo. \n\nThe eligibility criteria for participants include being 18 years or older (20 years or older for Japanese subjects), having a diagnosis of atopic dermatitis for at least 12 months, having moderate to severe atopic dermatitis that cannot be adequately controlled by topical therapy, meeting the laboratory criteria defined in the protocol, and having a negative pregnancy test for females of childbearing potential. \n\nFemales of childbearing potential who are sexually active must use approved contraceptive options while on the study medication and for at least 28 days after the last dose. Male subjects who engage in activities where conception is possible must use barrier contraception during the study and for at least 28 days after the last dose.\n\nThe exclusion criteria include having active tuberculosis or a history of inadequately treated tuberculosis, testing positive for hepatitis B surface antigen or hepatitis C antibody, being pregnant or breastfeeding, having a history of allergy to any component of the study medication, and having an active skin infection requiring systemic antimicrobials at baseline.",
    "The sample is a phase 2 clinical trial for the treatment of acute myeloid leukemia (AML). The trial is specifically for patients aged 60 years or older who have relapsed or refractory AML, excluding acute promyelocytic leukemia (APL). These patients must have previously undergone at least one AML therapy but are not eligible for stem cell transplantation and are currently unfit for intensive chemotherapy. The Eastern Cooperative Oncology Group (ECOG) score must be 2 or lower.\n\nTo be eligible for the trial, patients must have available bone marrow biopsy or tumor tissue for central review. They must also meet the criteria for relapsed or refractory AML, which includes either a recurrence of the disease after complete remission or failure to achieve complete remission with initial therapy. Patients must have received at least one prior line of AML therapy, including a hypomethylating agent with at least two cycles.\n\nThere should be a minimum of two weeks since the last anti-leukemia treatment (excluding hydroxyurea) before the first dose of the study drug.\n\nExclusion criteria for the trial include recent treatment with any investigational agent, presence of central nervous system (CNS) leukemia, blast transformation of chronic myeloid leukemia (CML), major surgery within two weeks of the first dose, concurrent active malignancy under treatment, known active hepatitis B virus (HBV) or C virus (HCV) infection, known HIV infection, inability to swallow tablets or significant gastrointestinal dysfunction, and AML classified as favorable according to the European LeukemiaNet (ELN) disease risk assessment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are locally advanced renal cell carcinoma and metastatic renal cell carcinoma. The ICDCodes associated with these diseases are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drug being used in the trial is pazopanib. The eligibility criteria for this trial include various factors such as age, histologically confirmed renal cell carcinoma, ECOG score, previous therapy, organ function, pregnancy test, and contraception. The exclusion criteria include conditions related to the central nervous system, gastrointestinal conditions, infections, cardiovascular diseases, previous surgeries or traumas, bleeding disorders, and other medical or psychiatric conditions that may affect patient safety. Additionally, the criteria state that patients should not be on certain anti-tumor therapies and should not have any present toxicity from prior treatments.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"type 2 diabetes mellitus\". The ICD-10 codes associated with this disease are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\". The drugs being studied in this trial are \"ly2409021\", \"placebo\", and \"metformin\". The eligibility criteria for participants in this trial include having type 2 diabetes mellitus, meeting certain glycated hemoglobin (HbA1c) values, having specific blood pressure ranges, and stable body weights. Participants must also be motivated and capable of reliably administering the oral study drug, maintaining a study diary, performing self-monitored blood glucose testing, and wearing an ambulatory blood pressure monitoring device. Women must be not of child-bearing potential, and men who are sexually active must use reliable methods of birth control during the study. The exclusion criteria include having severe gastrointestinal disease, previous histories or active diagnoses of pancreatitis, liver disease, abnormal resting pulse rate, and certain medical conditions.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is metastatic castration-resistant prostate cancer. The corresponding ICD-10 codes for this disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drug being tested is mln0128. The eligibility criteria for this trial include having histologically confirmed castration-resistant metastatic prostate cancer with evidence of disease progression. Patients must have been in a castrate state either by orchiectomy or by GnRH analogues. Other criteria include detectable metastases by bone scan, CT-scan, or MRI, ongoing androgen depletion therapy, castrate levels of serum testosterone, progression of disease off anti-androgen therapy, and specific time intervals since the use of certain medications or treatments. There are also criteria related to prior surgery, toxicities, performance status, age, and willingness to comply with study procedures. The sample also includes exclusion criteria such as brain metastases, history of other malignancies, prior treatment with PI3K/mTOR pathway inhibitors, and certain medical conditions that could impair the patient's ability to comply with study procedures.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is primary myelofibrosis. The corresponding ICD-10 codes for the disease are D75.81, C94.41, C94.42, and C94.40. The drug being used in the trial is ruxolitinib. \n\nThe sample also includes the eligibility criteria for the trial. The inclusion criteria state that patients must have a confirmed diagnosis of primary myelofibrosis, PPV MF, or PET-MF, regardless of their JAK2 mutational status. Their peripheral blast count must be less than 10%. They must require therapy for myelofibrosis as determined by the investigator. They must have previously received monotherapy treatment with ruxolitinib for at least 12 consecutive weeks but had to discontinue due to loss of response or adverse events. Patients must adhere to the screening phase assessments and undergo a ruxolitinib-free washout period of 1 to 8 weeks. Their ECOG performance status must be 0, 1, 2, or 3. They must also have adequate bone marrow function and provide written informed consent.\n\nThe exclusion criteria state that patients who did not initially respond to ruxolitinib therapy, underwent a splenectomy or spleen radiation, are scheduled for a bone marrow transplant, or discontinued ruxolitinib less than 14 days prior to screening are not eligible for the trial. Patients who cannot receive a starting dose of at least 15 mg of ruxolitinib per day, have leukemic transformation, inadequate renal function, clinically meaningful active infections, a previous history of Progressive Multifocal Leuko-encephalopathy (PML), clinically significant cardiac disease, or significant concurrent medical conditions are also excluded from the trial.",
    "The sample from the table represents a clinical trial for the treatment of hepatitis C virus (HCV) infection. The trial is in phase 2/phase 3 and focuses on patients with chronic HCV genotype 1 infection. The eligibility criteria include having documented chronic HCV infection, evidence or no evidence of liver cirrhosis, and specific HCV treatment history. Patients with chronic kidney disease or on hemodialysis are also included. Female participants of reproductive potential must agree to use contraception during the study. The exclusion criteria include decompensated liver disease, co-infection with hepatitis B or HIV, recent malignancy, substance abuse, pregnancy or breastfeeding, and certain medical conditions such as uncontrolled hypertension or cardiovascular disorders.",
    "The sample provided is for a phase 2 clinical trial. The trial is focused on the disease \"clostridium difficile infection\" and the associated ICD-10 codes are \"A05.2\", \"A04.71\", \"A04.72\", and \"B96.7\". The drugs being studied are \"smt19969\" and \"vancomycin\". \n\nThe eligibility criteria for this trial include the requirement of informed consent, a clinical diagnosis of CDAD (Clostridium difficile-associated disease) along with a laboratory diagnostic test, no more than 24 hours of antimicrobial treatment for the current CDAD episode, no more than 3 episodes of CDAD in the prior 12 months, and no previous episode of CDAD within 30 days of study enrollment. Female subjects of childbearing potential must also use adequate contraception.\n\nThe exclusion criteria for this trial include having life-threatening or fulminant colitis, concurrent use of antibiotics or any other treatments for CDAD, a history of inflammatory bowel disease (ulcerative colitis, Crohn's disease), and participation in other clinical research studies within one month of screening.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on non-small cell lung cancer. The trial includes eligibility criteria for patients to participate. Inclusion criteria include being 18 years or older, having stage IIIB or IV non-squamous NSCLC, and having recurrent or progressive disease after prior chemotherapy treatment. The criteria also specify that certain prior treatments, such as neoadjuvant/adjuvant chemotherapy or targeted kinase inhibitors, will or will not be counted as prior treatments. Other criteria include having measurable disease, a performance status of 0-1, and adequate organ function. Female patients of childbearing potential must have a negative pregnancy test. Exclusion criteria include having small cell carcinoma, squamous cell carcinoma, or unspecified NSCLC, prior therapy with pemetrexed, and inability or unwillingness to take certain medications. Other exclusion criteria include certain medical conditions, concurrent active malignancy, pregnancy or breastfeeding, and taking medications that may prolong QT interval or are strong inducers/inhibitors of CYP3A4.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug mentioned is azd9291. \n\nThe eligibility criteria for this trial include being at least 18 years old (or 20 years old for Japanese patients), having locally advanced or metastatic NSCLC that is not amenable to curative surgery or radiotherapy, and radiological documentation of disease progression. The disease progression should have occurred following 1st line EGFR TKI treatment or prior therapy with an EGFR TKI and a platinum-based doublet chemotherapy. The patients must also have confirmation that their tumor harbors an EGFR mutation associated with EGFR TKI sensitivity, as well as a World Health Organization (WHO) performance status of 0-1 and a minimum life expectancy of 12 weeks. \n\nOther criteria include having at least one measurable lesion that has not been previously irradiated and is suitable for accurate repeated measurements, using contraception for females of child-bearing potential, and having negative pregnancy test results. \n\nExclusion criteria for this trial include recent treatment with an EGFR-TKI, cytotoxic chemotherapy, investigational agents, or other anticancer drugs, as well as previous treatment with AZD9291 or 3rd generation TKIs. Major surgery within 4 weeks, radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks, and current treatment with certain inhibitors are also excluded. Other exclusions include unresolved toxicities from prior therapy, unstable spinal cord compression or brain metastases, severe/uncontrolled systemic diseases, refractory nausea/vomiting, chronic gastrointestinal diseases or bowel resection, cardiac disease, past history of ILD or radiation pneumonitis, and inadequate bone marrow reserve or organ function.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is \"respiratory syncytial virus infections.\" The ICDCodes associated with this disease are \"R09.2,\" \"A15.7,\" \"A15.8,\" \"A15.9,\" \"J98.9,\" \"R06.03,\" and \"J12.1.\" The drugs mentioned in this sample are \"als-008176\" and \"vehicle.\" The eligibility criteria for this trial include age between 18 and 45 years, good health with no major medical conditions, a total body weight of at least 50 kg, and a body mass index (BMI) greater than 18 kg/m2. The exclusion criteria include acute or chronic medical illness, positive status for Human Immunodeficiency Virus (HIV), Hepatitis B or C, nose or nasopharynx abnormalities, and abnormal lung function.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2. The diseases being studied are hepatitis C and liver disease. The icd-10 codes associated with these diseases are B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9 for hepatitis C, and K76.9, K71.8, K70.9, K71.9, K75.9, P78.84, Q44.6 for liver disease. The drugs being used in the trial are alisporivir and ribavirin. The eligibility criteria for participants include obtaining written informed consent, having HCV genotype 2 or 3 infection, being aged 18 years or older, and being diagnosed with chronic hepatitis C virus infection. Exclusion criteria include the use of other investigational drugs, hypersensitivity to study drugs or similar drugs, testing positive for hepatitis B surface antigen (HBsAg), and being HIV positive. The sample also mentions that there are other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is non-small cell lung cancer. The trial is specifically targeting patients with locally advanced or metastatic non-small cell lung cancer that has a specific genetic mutation called anaplastic lymphoma kinase (ALK+). The trial is testing the effectiveness of a drug called brigatinib.\n\nThe eligibility criteria for the trial include having confirmed ALK rearrangement through a positive result from a specific test or having documented ALK positivity through a different test. Patients must have experienced disease progression while on a previous treatment called crizotinib. They must also have at least one measurable lesion according to RECIST v1.1 criteria.\n\nOther criteria include recovering from any toxicities related to previous anticancer therapy, being at least 18 years old with a life expectancy of at least 3 months, and having adequate organ and hematologic function. Participants must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower and a normal QT interval on an electrocardiogram (ECG) evaluation.\n\nFemale participants of childbearing potential must have a negative pregnancy test and both male and female participants who are fertile must agree to use contraception throughout the study. Participants must provide informed consent and be willing and able to comply with scheduled visits and study procedures.\n\nExclusion criteria include having received any other ALK-targeted TKI besides crizotinib, receiving crizotinib within 3 days of starting brigatinib, receiving certain treatments within specific timeframes, having certain medical conditions or illnesses, and being pregnant or breastfeeding.\n\nOverall, the sample describes the specific criteria and requirements for patients to be eligible for the phase 2 clinical trial studying brigatinib as a treatment for non-small cell lung cancer with ALK rearrangement.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of autism. The trial is specifically looking at patients aged 4 to 10 years who have been diagnosed with Autism Spectrum Disorder (ASD) and exhibit frequent epileptiform discharges on an EEG. The patients' intelligence quotient (IQ) should fall within the range of 40 to 100, and their weight should be equal to or greater than 12.5 kg. The trial is open to English-speaking families.\n\nThere are also exclusion criteria listed, which specify conditions that would disqualify a patient from participating in the trial. These include a history of epilepsy, certain neurogenetic disorders or chromosomal abnormalities, and structural brain lesions. Patients who have previously been treated with divalproex sodium for more than 6 months, within the last 12 months, or experienced significant side effects leading to termination of treatment are also excluded. Additionally, patients who have undergone general anesthesia within the past six months or sedation within the past two weeks, or have recently initiated a behavioral therapy program or started a new psychotropic medication, are not eligible. Patients with certain medical conditions or dysfunctions, such as carnitine deficiency, urea cycle disorder, or renal, hepatic, pancreatic, or hematologic dysfunction, are also excluded. Concomitant use of specific medications contraindicated with divalproex sodium, as well as severe behavioral management issues, and the absence of a primary care physician are also exclusion criteria.\n\nThis sample provides a detailed description of the inclusion and exclusion criteria for the clinical trial, which helps to define the specific patient population being targeted for the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied include various types of adult acute myeloid leukemia, recurrent adult acute lymphoblastic leukemia, and recurrent childhood acute lymphoblastic leukemia. The ICDCodes associated with these diseases are also provided. The drugs being used in the trial are etoposide and cyclophosphamide. The eligibility criteria for participants are listed, including requirements such as signed informed consent, specific performance status, previous treatment history, HLA matching, and various medical tests and measurements. There are also exclusion criteria listed, which include prior stem cell therapy, certain medical conditions, and plans to receive other investigational agents during the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is Phase 2.\n- Diseases: The specific disease being targeted in the trial, which is \"non-small-cell lung cancer\".\n- ICD Codes: The ICD-10 codes associated with the disease, which are \"C78.00\", \"C78.01\", \"C78.02\", \"D14.30\", \"D14.31\", \"D14.32\", and \"C34.2\".\n- Drugs: The drug or combination of drugs being tested in the trial, which is an \"intercalated combination of chemotherapy and erlotinib\".\n- Criteria: The eligibility criteria for patients to participate in the trial.\n\nThe eligibility criteria include various factors such as histological documentation of the disease, specific genetic mutations, performance status, previous treatments, organ function, age, and written informed consent. There are also exclusion criteria, which include prior chemotherapy or targeted therapy, history of other malignancies, brain metastasis or spinal cord compression, risk of transmitting HIV, nursing or lactating, unwillingness to practice contraception, unwillingness to provide informed consent, and unwillingness to accept follow-up.\n\nOverall, this sample provides specific information about a Phase 2 clinical trial for non-small-cell lung cancer, including the disease, drugs, and eligibility criteria.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on two diseases: peripheral nerve injuries and pain. The corresponding ICD-10 codes for these diseases are listed as well. The drug being studied in this trial is rufinamide. \n\nThe sample also includes the eligibility criteria for participants in the trial. The inclusion criteria for the run-in phase include age between 18 and 75 years, weight between 50 and 100kg, height between 155 and 195cm, sufficient command of the German language, patient after thoracotomy, pain duration of more than 6 months, diagnosis of neuropathic pain using the DN4 questionnaire, average baseline mean last week pain intensity of 5 on the NRS (numerical rating scale), and signed and dated informed consent.\n\nThe inclusion criteria for the treatment phase include a stable analgesic regimen for at least 7 days prior to randomization and patients not reaching a pain intensity of 3 on the NRS with the baseline individually dose-adjusted treatment (oxycodone).\n\nThe exclusion criteria for the trial include contraindications to the class of drugs being studied (rufinamide and oxycodone), hypersensitivity to certain antifungal drugs, lactose intolerance or other related conditions, recent use of topical analgesics or nerve blocks, pregnancy or breastfeeding, certain concomitant disease states, low creatinine clearance, known drug or alcohol abuse, inability to follow study procedures, participation in another study with investigational drugs, enrollment of certain individuals, known neurological diseases or sensory changes, epilepsy, abnormal electrocardiogram, presence of another pain condition with greater intensity, repeated thoracic surgeries, pneumonectomy or chest wall resection, and bilateral thoracic surgery.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 designation. The trial focuses on the treatment of leukemia. The specific diseases included in the trial are not mentioned. However, the ICD-10 codes associated with the diseases are provided. The drugs being tested in the trial are brentuximab vedotin and 5-azacytidine. The eligibility criteria for the trial are listed, including requirements such as confirmation of AML diagnosis, CD30 expression in AML blasts, age 18 or older, specific performance status score, and baseline laboratory data within certain ranges. Inclusion and exclusion criteria are also provided, outlining factors that would make a patient eligible or ineligible for the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"multiple sclerosis\". The ICD-10 codes associated with this disease are \"G35\" and \"C81.18\". The drug being studied is \"cholecalciferol\". The sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being female, having relapsing remitting MS, being in clinical remission for at least 6 weeks, being over 18 years old, being premenopausal, and either not receiving any immune-modulating treatment or receiving specific registered MS modulating treatments. Exclusion criteria include contraindications to vitamin D, recent use of systemic glucocorticosteroids, supplementation of high doses of vitamin D, medical history of disturbed vitamin D/calcium metabolism, presence of clinical depression or treatment with certain medications, treatment with high-dose dexamethasone for MS exacerbation, and pregnancy or intention to become pregnant during the study period.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on colorectal neoplasms. The ICD-10 codes associated with these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being studied in this trial are rrx-001, regorafenib, and irinotecan. The eligibility criteria for participants include having a histological or cytological documentation of adenocarcinoma of the colon or rectum, having received specific previous treatments, having measurable disease, meeting certain criteria for brain metastasis, having a life expectancy of at least 12 weeks, having an Eastern Cooperative Group (ECOG) performance status of 0 or 1, and having adequate organ function. There are also exclusion criteria, such as having clinically significant cardiovascular disease, unresolved toxicity from previous therapy, active bleeding, active brain metastases, allergic reaction or intolerance to irinotecan, and other specific conditions. Additionally, pregnant or lactating individuals or those planning to become pregnant during the study are excluded.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The disease being studied in this sample is Parkinson's disease. The corresponding ICD-10 code for Parkinson's disease is G20. The drugs being used in the trial are \"levodopa and carbidopa sc solution\" and \"oral levodopa and carbidopa\". The eligibility criteria for participants in the trial are listed under both inclusion and exclusion criteria. Inclusion criteria include being a male or female Parkinson's disease patient between the ages of 30 and 80, having a PD diagnosis consistent with the UK PD Society Brain Bank criteria, stable doses of anti-PD drugs for at least 30 days, well-defined morning \"OFF\" and a good response to LD, MMSE score greater than 26, and no clinically significant medical, psychiatric, or laboratory abnormalities. Exclusion criteria include having atypical or secondary Parkinsonism, acute psychosis or hallucinations, being treated with neuroleptics, having a history of melanoma or significant skin disorders, prior neurosurgical procedure for PD, history of drug abuse or alcoholism, clinically significant ECG abnormalities, renal or liver dysfunction, and having participated in another clinical study within 30 days.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2, and the disease being studied is prostate cancer. The icd-10 codes associated with the disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drug being used in the trial is a combination of radium ra 223 dichloride and abiraterone acetate plus prednisone. \n\nThe eligibility criteria for this trial include:\n1. The subject must be able to understand and sign the informed consent form.\n2. The subject must be willing and able to comply with the protocol and all study visits.\n3. The subject must be a male over 18 years old.\n4. The subject must have a life expectancy of at least 9 months.\n5. The subject must have histologically documented prostate cancer.\n6. The subject must have initiated a stable dose of daily abiraterone acetate plus prednisone within 90 days of enrollment or plans to initiate it within 30 days of the first radium ra 223 dichloride treatment.\n7. The subject must plan to receive all 6 radium ra 223 dichloride injections and daily oral doses of abiraterone plus prednisone during the trial.\n8. The subject must have a history of bone metastasis from prostate cancer confirmed by imaging.\n9. The subject must have castrate-resistant prostate cancer.\n10. The subject must have bone pain requiring treatment with external beam radiation therapy (EBRT) or analgesic medications.\n11. The subject must have an ECOG performance status of 0-2.\n12. The subject must have acceptable hematology and serum biochemistry screening values.\n13. The subject must have normal liver and renal function tests.\n14. The subject must have been on stable doses of anti-resorptive medications for at least 90 days prior to enrollment.\n15. Subjects of childbearing potential must agree to use adequate contraception.\n\nThe exclusion criteria for this trial include:\n1. The subject has known malignant pleural effusion, lung, liver, or brain metastasis.\n2. The subject has a history of visceral metastatic disease.\n3. The subject has received previous treatment with abiraterone acetate for longer than 90 days prior to enrollment or any prior treatment with radium ra 223 dichloride.\n4. The subject has a known medical contraindication to prednisone, abiraterone acetate, or radium ra 223 dichloride.\n5. The subject is not willing to initiate or receive the required doses of abiraterone acetate plus prednisone and radium ra 223 dichloride.\n6. The subject has received previous treatment with certain other medications for bone metastasis.\n7. The subject has received investigational products or experimental therapy within 4 weeks of enrollment.\n8. The subject has had treatment with cytotoxic chemotherapy within the previous 4 weeks or has not recovered from adverse events due to cytotoxic chemotherapy administered more than 4 weeks prior to enrollment.\n9. The subject has a history of certain medical conditions or illnesses.\n10. The subject has any condition that would impair their ability to comply with study procedures.\n11. The subject is unable to swallow the study treatment capsules.\n12. The subject has unmanageable fecal incontinence.\n13. The subject has a history of pelvic lymphadenopathy that may contribute to current hydronephrosis.\n\nThis sample provides detailed information about the trial phase, disease, drugs, and eligibility criteria for the study.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is eosinophilic esophagitis. The corresponding ICD-10 code for this disease is K20.0. The drugs being tested in this trial are rpc4046 and placebo. The eligibility criteria for participants in this trial include having histologic evidence of EoE and experiencing clinical symptoms such as dysphagia. The exclusion criteria state that individuals with primary causes of esophageal eosinophilia other than EoE will be excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial focuses on the disease \"myocardial reperfusion injury.\"\n- ICD Codes: The ICD-10 codes associated with the disease are \"I51.5,\" \"I25.2,\" \"I25.6,\" \"I21.9,\" \"I21.A1,\" \"I21.A9,\" and \"P29.4.\"\n- Drugs: The trial involves the drugs \"milrinone,\" \"esmolol,\" and \"saline infusion.\"\n- Criteria: The eligibility criteria for the trial are provided, including both inclusion and exclusion criteria.\n\nThe inclusion criteria state that men and women who are 18 years of age or older, present within 12 hours after the onset of chest pain, have ST-segment elevation of more than 0.1 mV in two contiguous leads, and are recommended for treatment with PCI (percutaneous coronary intervention) are eligible for enrollment.\n\nThe exclusion criteria state that patients with cardiac arrest, ventricular fibrillation, cardiogenic shock, previous acute myocardial infraction, occlusion of the left main, baseline heart rate less than 50 beats/min, systolic blood pressure less than 90 mmHg, pregnant patients, and patients with any disorder associated with immunologic dysfunction within the past 6 months will be excluded from the study.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is Phase 2. The diseases being studied are acute chest syndrome and sickle cell disease. The corresponding ICD-10 codes for these diseases are D57.1, D57.20, D57.212, D57.219, D57.211, D57.213, and D57.218. The drug being tested is unfractionated heparin. The eligibility criteria for participants are listed, including a diagnosis of acute chest syndrome, confirmation of HbSS, SC, or B0 through hemoglobin electrophoresis, and age greater than or equal to 18. There are also exclusion criteria, such as absolute contraindications to heparin, platelet count less than 50 per microliter, historical diagnoses of moyamoya disease or proliferative retinopathy, current participation in a chronic exchange transfusion program, underlying hypercoagulable disorder other than sickle cell disease, current use of therapeutic anticoagulation or antiplatelet agents, and current use of estrogen-containing oral contraceptives. Additionally, a chest CT scan documenting pulmonary embolism must have been performed prior to study enrollment.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on various diseases, including contiguous stage II small lymphocytic lymphoma, noncontiguous stage II small lymphocytic lymphoma, stage 0 chronic lymphocytic leukemia, stage I chronic lymphocytic leukemia, stage I small lymphocytic lymphoma, and stage II chronic lymphocytic leukemia. The diseases are associated with specific ICD-10 codes. The trial involves the use of the drug curcumin. \n\nThe eligibility criteria for participants in this trial include having a diagnosis of CLL or SLL, a performance status of 0-2, no prior treatment for CLL or SLL, being in stage 0-II based on Rai staging system, and meeting certain blood count and organ function requirements. Other criteria include being off steroids, curcumin, turmeric, or vitamin D supplements prior to treatment, and being able to take oral medications. \n\nExclusion criteria include having had systemic treatment for another malignancy within the past 3 years, any indication to start treatment for CLL based on NCI-WG criteria, prior therapy for CLL/SLL, pregnancy or breastfeeding, certain medical conditions, inability to take oral medications, receiving other investigational agents, history of allergic reactions to similar compounds, being on therapeutic anticoagulation, and being HIV-positive and on combination antiretroviral therapy.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is acute pain, which is associated with the ICD-10 codes G89.12, G89.18, G89.11, and G89.3. The drugs being tested in this trial are trv130, morphine, and placebo. The sample also includes the eligibility criteria for participants. Inclusion criteria include having undergone a specific type of surgery, experiencing a pain intensity rating of at least 4 on a scale, and being able to provide written informed consent. Exclusion criteria include having a certain classification in the ASA Physical Status Classification System, having surgical or post-surgical complications, having significant medical conditions that may interfere with the trial, or having previously participated in another TRV130 clinical study.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of various types of ovarian cancer. The diseases included in the trial are ovarian brenner tumor, ovarian carcinosarcoma, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian mucinous cystadenocarcinoma, ovarian seromucinous carcinoma, ovarian serous cystadenocarcinoma, ovarian serous surface papillary adenocarcinoma, ovarian undifferentiated carcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, and recurrent primary peritoneal carcinoma. The corresponding ICD-10 codes for these diseases are also provided.\n\nThe drugs being tested in the trial are adavosertib and gemcitabine hydrochloride. The eligibility criteria for the trial include having histologically or cytologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma, being platinum-resistant or having platinum-refractory disease, having measurable disease, and meeting certain laboratory and medical criteria. The criteria also specify that patients must have completed any prior chemotherapy, radiotherapy, or major surgery at least 4 weeks before receiving study treatment.\n\nThere are also exclusion criteria, such as previous use of gemcitabine for recurrent disease, receiving any other investigational agents, having clinically or radiologically unstable brain metastases, and having certain allergies or medical conditions. Pregnant and breastfeeding women, as well as HIV-positive patients on combination antiretroviral therapy, are also excluded from the study.\n\nOverall, the sample provides detailed information about the phase 2 clinical trial, including the diseases being targeted, the drugs being tested, and the eligibility criteria for participation.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, the disease is metastatic breast cancer, the ICDCodes are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60, and the drug is abemaciclib. The eligibility criteria are listed under \"Inclusion Criteria\" and \"Exclusion Criteria,\" which include specific requirements and restrictions for participants in the clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on Tourette's Syndrome. The disease is identified by the ICD-10 code \"F95.2\". The drug being studied is called \"ecopipam\". The sample also includes the eligibility criteria for participants in the trial.\n\nThe inclusion criteria state that subjects must have a diagnosis of Tourette's Syndrome, exhibit both motor and vocal tics, and have a minimum score of 20 on the Yale Global Tic Severity Scale. They must also be between the ages of 7 and 18 and weigh at least 20 kg. Female participants who are sexually active must be using effective contraception and agree to continue using it throughout the study and for 30 days after the last dose of the study drug. Male participants must use a barrier method of contraception during the study and for at least 30 days after the last dose of the study drug. Written informed consent and assent are required from the subject and their parent or legal guardian.\n\nThe exclusion criteria state that subjects with unstable medical illness, abnormal laboratory tests, or abnormal ECG at screening are not eligible. Subjects with a major depressive episode in the past 2 years, a history of attempted suicide, or clinically significant suicidality are also excluded. Subjects with a first-degree relative who had a major depressive episode resulting in psychiatric hospitalization or attempted/completed suicide are excluded, except for post-partum depression hospitalization. Subjects with a history of seizures, recent myocardial infraction, current pregnancy or lactation, or a need for medication that may affect TS symptoms are also excluded. Subjects with certain psychiatric disorders, substance abuse or dependence, positive urine drug screen for specific substances, previous treatment with ecopipam, or recent treatment with certain medications are also excluded.\n\nOverall, the sample provides specific details about the phase, disease, drug, and eligibility criteria for participants in the clinical trial.",
    "The sample is a phase 2 trial for the treatment of colorectal neoplasms. The trial is testing a drug called abi-007. The eligibility criteria for participants include being at least 18 years old, having a histological or cytological diagnosis of adenocarcinoma of the colon or rectum with evidence of metastasis, having a known KRAS mutation status, and having documented disease progression within 2 months after the last administration of the last standard therapy. Other criteria include having received prior treatment or not being a candidate for prior treatment with specific drugs, having a performance status of 0 or 1, having radiographically-documented measurable disease, and having adequate organ and bone marrow function. Female participants of child-bearing potential must commit to abstinence or use effective contraception, and male participants must practice abstinence or use a condom during sexual contact with a pregnant female or a female of childbearing potential. The sample also includes exclusion criteria such as having current or a history of brain metastasis, having grade 2 peripheral neuropathy, having had prior treatment with regorafenib, and having certain medical conditions or infections. The sample does not include pregnant or nursing females.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"non stemi\" and \"unstable angina\". The ICDCodes associated with these diseases are \"I20.0\", \"I25.110\", \"I25.750\", \"I25.700\", \"I25.790\", \"I25.710\", and \"I25.720\". The drugs being tested in this trial are \"cmx-2043\" and \"placebo comparator\". The eligibility criteria for this trial include being at least 18 years old, having acute coronary syndrome (excluding STEMI), undergoing coronary angiography with the possibility of going on to PCI, meeting certain eGFR criteria, meeting certain criteria for female subjects, being free of non-cardiac acute injuries or illnesses, being willing to undergo pre-and post-study tests and exams, and providing signed written informed consent. The exclusion criteria include undergoing elective coronary angiography, having end-stage renal disease, having STEMI, experiencing cardiac arrest or life-threatening arrhythmia associated with the current admission, weighing over 125 kg, having a history of certain psychiatric disorders or substance abuse, having uncorrected clinically significant abnormalities in laboratory tests, having non-cardiac acute illness or injuries, having chronic diseases that make the subject unfit for the procedure or increase the risk, and being currently enrolled or having participated in another clinical study within a certain timeframe.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The disease being studied is ventricular arrhythmia. The corresponding ICDCodes for this disease are ['I47.0']. The drugs being used in the trial are eleclazine and a placebo to match eleclazine. \n\nThe eligibility criteria for this trial are listed under \"Key Inclusion Criteria\" and \"Key Exclusion Criteria\". Some of the key inclusion criteria include having an implanted ICD or CRT-D for primary or secondary prevention and experiencing at least one ICD intervention for ventricular tachycardia/ventricular fibrillation (VT/VF) within 60 days prior to screening. Other criteria include the use of highly effective contraception methods for females of childbearing potential or sexually active males, and being hemodynamically stable.\n\nSome of the key exclusion criteria include having New York Heart Association (NYHA) Class IV heart failure, recent myocardial infraction or coronary artery bypass graft (CABG) surgery, significant primary obstructive valvular disease, history of congenital heart disease, and being on a cardiac transplant list. Other exclusion criteria include a history of seizures or epilepsy, recent cardiac ablation, severe renal impairment, abnormal liver function tests, and current use of certain medications.\n\nIt is important to note that there may be additional inclusion and exclusion criteria defined by the protocol of the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of multiple sclerosis. The diseases column lists the disease names, in this case, only \"multiple sclerosis\" is mentioned. The icdcodes column contains the corresponding ICD-10 codes for the diseases, which in this case are \"G35\" and \"C81.18\". The drugs column lists the names of the drugs being used in the trial, which are \"oxcarbazepine\" and \"placebo\". The criteria column provides the eligibility criteria for participants in the trial, including both inclusion and exclusion criteria. The inclusion criteria specify that participants must have a definite diagnosis of multiple sclerosis, have been treated with disease-modifying drugs for at least 6 months prior to the baseline visit, have a certain level of CSF NFL (neurofilament light chain) in their cerebrospinal fluid, have an EDSS (Expanded Disability Status Scale) score between 3.5 and 6.0, have no history of relapses in the 6 months prior to the baseline visit, have a history of slow progression of disability, and be between the ages of 18 and 60. The exclusion criteria specify that participants cannot be pregnant or breastfeeding, cannot have a diagnosis of primary progressive or primary relapsing multiple sclerosis, cannot have had a clinical relapse or received steroids in the 6 months prior to the baseline assessment, cannot have certain severe or unstable medical disorders, cannot have certain infections, cannot have been exposed to any other investigational drug within 30 days of enrollment, cannot be judged to have a suicidal risk, cannot have a prior history of malignancy (unless granted an exception), cannot have a history of uncontrolled drug or alcohol abuse within 6 months prior to screening, cannot have had past untoward reactions to oxcarbazepine or carbamazepine, and cannot have received oxcarbazepine or carbamazepine in the previous 12 weeks from baseline. The criteria also mention the requirement for participants to use adequate contraception, specifying that non-hormonal methods are preferred, but additional barrier methods are required for female participants using hormonal contraception.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the disease HIV. The ICD-10 codes associated with HIV are ['B20', 'Z71.7', 'O98.72', 'Z21', 'O98.73', 'R75', 'Z11.4']. The drug being studied is rilpivirine/emtricitabine/tenofovir. The eligibility criteria for participants are listed, including requirements such as having a documented HIV-1 infection, a stable first-line antiretroviral therapy, and meeting certain laboratory values. There are also exclusion criteria, such as a history of virologic failure, current breastfeeding, and active tuberculosis.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease of asthma. The ICD-10 codes associated with the disease are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being studied in the trial are 'bd mdi 320 \u00b5g', 'bd mdi 160 \u00b5g', 'bd mdi 80 \u00b5g', 'bd mdi 40 \u00b5g', and 'placebo mdi'. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Participants must be between 18 and 65 years old.\n- They must have a diagnosis of mild to moderate persistent asthma, made at least 6 months prior to screening.\n- Participants must currently be receiving treatment with a low to medium dose of an inhaled corticosteroid (ICS) or a combination of controller medications for at least 4 weeks before screening.\n- Their pre-albuterol FEV1 (forced expiratory volume in 1 second) must be greater than 60% and less than 85% of the predicted normal value.\n- Participants must show reversibility, with an increase in FEV1 of at least 12% and 200 mL over the pre-albuterol FEV1 within 30-60 minutes after inhaling 4 puffs of Ventolin hydrofluoroalkane (HFA).\n- They must have required albuterol use on at least two of the last seven days and have an Asthma Control Questionnaire (ACQ) total score of at least 1.5 before randomization.\n\nThere are also exclusion criteria for the trial, including:\n- Participants must not have had a life-threatening asthma episode requiring intubation, hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episodes within the 12 months before screening.\n- They must not have experienced a worsening of asthma that involved an emergency department visit, hospitalization, or use of oral/parenteral corticosteroids within 6 weeks of screening.\n- Participants with only intermittent, seasonal, or exercise-induced asthma are not eligible for the study.\n- Concurrent respiratory diseases, pregnancy, nursing, current diagnosis of Chronic Obstructive Pulmonary Disease (COPD), current smoking, respiratory tract infection within 6 weeks prior to the first visit, documented myocardial infraction within a year from the screening visit, clinically significant abnormal ECG, abnormal liver function tests, cancer that has not been in complete remission for at least 5 years, and a history of hypersensitivity to any component of the metered-dose inhaler (MDI) are also exclusion criteria for the trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is Hepatitis C Virus. The ICDCodes associated with the disease are B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, and B17.2. The drugs mentioned in the sample are Grazoprevir (GZR), Elbasvir (EBR), and Ribavirin (RBV). The eligibility criteria for this trial are listed under inclusion and exclusion criteria, which include specific requirements related to the disease, previous treatments, reproductive potential, liver conditions, co-infections, history of malignancy, participation in other studies, drug or alcohol abuse, pregnancy or breastfeeding, organ transplants, venous access, gastric surgery or malabsorption disorders, hemoglobinopathy, corticosteroid administration, and chronic hepatitis not caused by HCV.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"relapsed peripheral T-cell lymphoma\" and \"refractory peripheral T-cell lymphoma.\" The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial are \"folotyn and leucovorin,\" \"folic acid,\" and \"vitamin b12.\" The eligibility criteria for participants in this trial include being diagnosed with hematological malignancies, being at least 18 years old, providing informed consent, recovering from prior therapy, and having adequate hematologic, hepatic, and renal function. Additional criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower, practicing contraception for females of childbearing potential, and using a barrier method of contraception for male patients. The exclusion criteria include having congestive heart failure, uncontrolled hypertension, HIV-positive diagnosis, symptomatic central nervous system (CNS) metastases, uncontrolled infection or serious illness, recent major surgery, previous exposure to Folotyn within 6 months, and being pregnant or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is pancreatic cancer. The ICDCodes associated with this disease are C25.3. The drugs being used in the trial are nab-paclitaxel and gemcitabine. \n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- The patient must provide written informed consent according to ICH/GCP and national/local regulations.\n- The patient must be at least 18 years old.\n- The patient must have unresectable locally advanced or metastatic pancreatic cancer.\n- The cancer must be histologically or cytologically confirmed as adenocarcinoma of the pancreas (excluding islet cell neoplasms).\n- The patient must have evaluable or measurable disease that has not been previously irradiated.\n- The patient must have a life expectancy of at least 12 weeks.\n- The patient's WHO ECOG performance status must be \u2264 2.\n- The patient must have adequate organ function, including bone marrow, hepatic, and renal function, as well as acceptable coagulation levels.\n- The patient must not have clinically significant abnormalities in urinalysis.\n- Effective contraception is required for both male and female patients of childbearing potential, and women must have a negative blood pregnancy test at the screening visit.\n\nThe exclusion criteria for this trial include:\n- Prior chemotherapy, radiotherapy, surgery, or other investigational therapy for the treatment of metastatic disease, unless at least 6 months have elapsed since the last dose of gemcitabine or 5-FU.\n- Major surgery within 4 weeks of the start of the study.\n- Irradiation within 3 weeks prior to study entry.\n- Known or suspected brain metastasis.\n- Serious medical risk factors involving major organ systems, including high cardiovascular risk and psychiatric disorders.\n- Historical or active infection with HIV, hepatitis B, or C.\n- History of connective tissue disorders, interstitial lung disease, or peripheral artery disease.\n- Previous or concurrent malignancies at other sites, except for surgically cured or adequately treated carcinoma in-situ of the cervix and basal cell carcinoma of the skin.\n- Known allergy or adverse reaction to any of the drugs or related compounds.\n- Use of Coumadin.\n- Organ allografts requiring immunosuppressive therapy.\n- Pregnancy or breastfeeding.\n- Medical, social, or psychological conditions that would prevent the patient from completing the study or providing meaningful informed consent.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on two diseases: acute lung injury and sepsis. The diseases are associated with specific ICD-10 codes. The trial involves the use of two drugs: ascorbic acid and a placebo called 5% dextrose in water. The eligibility criteria for participants are listed, including requirements related to infection, systemic inflammatory response, sepsis-induced organ dysfunction, and acute respiratory distress syndrome (ARDS). The inclusion criteria specify the presence of suspected or proven infection, as well as meeting specific criteria for SIRS, sepsis-induced organ dysfunction, and ARDS. The exclusion criteria outline factors that would disqualify potential participants, such as known allergy to Vitamin C, inability to obtain consent, age under 18, and various medical conditions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on bladder cancer. The ICD-10 codes associated with the disease are D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, and D41.4. The drug being studied is atezolizumab. The eligibility criteria for participants are listed, including requirements such as having locally advanced or metastatic transitional cell carcinoma of the urothelium, a performance status of 0 or 1, and measurable disease. There are also specific inclusion and exclusion criteria for participants in Cohort 2. The exclusion criteria include factors such as recent treatment with other anti-cancer therapies, active central nervous system metastases, uncontrolled tumor-related pain, and certain medical conditions.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on lung cancer, specifically non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The trial is looking for patients with advanced or metastatic lung cancer who have specific genetic alterations or mutations in genes such as FGFR1, FGFR2, FGFR3, VEGFA, or PDGFR\u03b1. The trial requires a tumor tissue sample for confirmation of the genetic alteration. Patients must have an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 and measurable disease according to RECIST 1.1 criteria. Patients must also have documented radiographic disease progression after at least one line of therapy in the advanced/metastatic setting. \n\nThere are exclusion criteria as well, such as tumors invading a major vessel, uncontrolled hypertension or hypothyroidism, symptomatic or untreated central nervous system metastases, presence of another active cancer, ongoing adverse events from prior anti-cancer therapies, and pregnancy or breastfeeding.\n\nThe only drug mentioned in the sample is lucitanib.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the treatment of metastatic pancreatic cancer. The ICD-10 code for this specific cancer is C25.3. The drug being studied is paclitaxel bound albumin. \n\nThe eligibility criteria for participants in this trial include being male or female between the ages of 18 and 75, having a confirmed diagnosis of pancreatic ductal adenocarcinoma, providing written informed consent, having measurable metastatic disease that has not been previously treated with chemotherapy, having an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, not having received previous abdominal radiotherapy on target lesions (except for radiation therapy for pain relief if it has not been performed on measurable targets), not having heart failure, angina, or a heart attack within the past 12 months, and having adequate organ function.\n\nAdequate organ function is defined as having an absolute neutrophil count (ANC) of at least 1.5 x 10^9/L, platelets of at least 100 x 10^9/L, a bilirubin level within 1.5 times the upper limits of normal (ULN), and a serum creatinine level within normal limits and no more than 1.5 times the ULN.\n\nThe exclusion criteria for this trial include being 76 years of age or older, having endocrine or acinar pancreatic carcinoma, having received previous radiotherapy for measurable lesions, having central nervous system metastasis, having any other concomitant cancer or a history of cancer outside of carcinoma in situ of the cervix or basal or squamous cell of the skin, already being enrolled in another clinical trial with experimental drugs, having a current active infection, having serious pre-existing medical conditions or serious concomitant systemic disorders that would compromise the safety of the patient or their ability to complete the study (such as unstable angina pectoris, clinically significant history of cardiac disease, or uncontrolled diabetes mellitus), being pregnant or lactating, being unable to undergo medical tests for geographical, social, or psychological reasons, and having a known deficiency of dihydropyrimidine dehydrogenase (DPD).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is metastatic cancer of the pancreas. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are pf-03084014, gemcitabine, and nab-paclitaxel. The eligibility criteria for this trial include a histologically or cytologically diagnosed metastatic ductal adenocarcinoma of the pancreas, no prior radiotherapy, surgery, chemotherapy, or investigational therapy for metastatic disease, availability of tumor tissue, measurable disease as per RECIST 1.1, and a performance status (ECOG) of 0 or 1. The exclusion criteria include symptomatic brain metastases requiring steroids, prior therapy with gamma secretase inhibitors or other Notch pathway inhibitors, major surgery within 4 weeks of registration, known hypersensitivity to gemcitabine or nab-paclitaxel or any of the excipients, current or anticipated need for food or drugs that are strong/moderate CYP3A4 inhibitors or inducers, and diagnosis of any second malignancy within 3 years prior to registration.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on patients with coronary artery disease. The ICD-10 codes associated with the disease are ['I25.10', 'I25.110', 'I25.119', 'I25.111', 'I25.118']. The drugs being studied are ticagrelor and placebo. The record also includes the eligibility criteria for the trial. The inclusion criteria state that patients must be aged 40 or older with angiographically proven multivessel coronary artery disease. The exclusion criteria include recent acute coronary syndrome, indication for dual anti-platelet therapy, inability to take aspirin, and recent percutaneous coronary intervention or coronary artery bypass graft surgery. Other exclusion criteria include hypersensitivity to ticagrelor, active pathological bleeding, significant thrombocytopenia, history of intracranial hemorrhage, liver impairment, and renal dysfunction. The record also mentions contraindications to certain medications and planned coronary revascularization or major non-cardiac surgery in the next 12 months.",
    "The sample is a phase 2 trial for the treatment of myasthenia gravis. The trial is testing the effectiveness of rituximab compared to a placebo. The eligibility criteria for participants include being between 21 and 90 years old, having generalized MG, elevated AChR antibody titer, and being on a stable immunosuppressive regimen. Participants must also be willing to complete the study and return for follow-up visits. Exclusion criteria include having other chronic or debilitating illnesses, being pregnant or breastfeeding, having altered levels of consciousness or abnormal mental status, recent thymectomy, recent medication with certain immunosuppressive drugs, recent IVIg or PLEX treatment, and other medical conditions that may contraindicate the use of the investigational drug or put the participant at high risk. The sample also includes general safety and laboratory exclusion criteria such as abnormal blood counts, positive serology for hepatitis B or C, history of positive HIV, recent treatment with investigational agents or live vaccines, and previous treatment with rituximab or natalizumab.",
    "The sample is a phase 2 trial for the treatment of type 2 diabetes mellitus. The trial is testing the effectiveness of several drugs, including ly2409021, sitagliptin, placebo, metformin, and sulfonylurea. The eligibility criteria for participants include being treated with a stable dose of metformin for at least 3 months and an optimally effective and stable dose of a sulfonylurea for at least 6 months prior to screening. Participants must also have an HbA1c value between 7.0% and 10.0%, a body mass index (BMI) between 20 and 45 kg/m^2, and meet certain exclusion criteria such as not having type 1 diabetes, not experiencing severe hypoglycemia or poor glucose control, and not having certain gastrointestinal or liver diseases. Additionally, participants should not have a history of neuroendocrine tumors or contraindications for magnetic resonance imaging.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating melanoma and skin cancer. The diseases are represented by their respective ICD-10 codes. The drugs being used in the trial are aldesleukin, fludarabine, and cyclophosphamide. The eligibility criteria for participants are listed, including requirements such as having measurable metastatic melanoma, being between 18 and 70 years old, and having a clinical performance status of Easter Cooperative Oncology Group (ECOG) 0 or 1. There are also specific serology and hematology requirements, as well as criteria related to prior treatments and medical history. The sample also includes exclusion criteria, such as prior treatment with an anti-4-1BB antibody and concurrent systemic steroid therapy.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of multiple myeloma, a type of cancer. The trial is specifically targeting patients who have symptomatic multiple myeloma and have received at least two cycles of initial therapy within the past 2-12 months.\n\nTo be eligible for the trial, patients must be at least 18 years old and have an adequate amount of autologous stem cells collected. They must also have adequate organ function, including cardiac, hepatic, renal, and pulmonary function. Additionally, patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, indicating their ability to carry out daily activities.\n\nPatients who have evidence of multiple myeloma disease progression, have previously undergone a stem cell transplant, have smoldering multiple myeloma not requiring therapy, or have certain other conditions such as plasma cell leukemia or systemic amyloid light chain amyloidosis, are excluded from the trial.\n\nOther exclusion criteria include having active bacterial, viral, or fungal infections, being seropositive for HIV, having active hepatitis A, B, or C infections, being pregnant or breastfeeding, receiving other concurrent anticancer therapy within 7 days prior to the trial, being hypersensitive or intolerant to any component of the study drug formulation, and receiving growth factors or undergoing apheresis within 14 days prior to the start of treatment on the trial.\n\nOverall, this sample provides specific details about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial focused on multiple myeloma treatment.",
    "The sample from the table represents a phase 2 clinical trial. The trial focuses on the treatment of various stages of uterine serous carcinoma, including endometrial serous adenocarcinoma and different stages of uterine corpus cancer. The trial involves the use of two drugs, paclitaxel and carboplatin. The eligibility criteria for the trial include having histologically or cytologically documented primary stage 3C1, 3C2, stage 4A, or 4B uterine serous carcinoma. Certain stage 3A and B diseases are also allowed. Patients must have residual disease after primary surgery, and specific criteria determine whether they are eligible or not. All patients must have a procedure to determine the diagnosis of high-risk uterine cancer. The trial also has exclusion criteria, such as distant metastasis to the lung, bone, or brain, and certain medical conditions that may affect the patient's ability to participate in the study.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is primary central nervous system lymphoma. The ICD-10 codes associated with this disease are 'S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', and 'S33.131S'. The drug being tested in this trial is rituximab plus temozolomide. \n\nThe eligibility criteria for this trial include: \n1. The patient must have histologically confirmed CD20 positive primary B-cell CNS lymphoma.\n2. There should be no evidence of systemic non-Hodgkin's lymphoma.\n3. The patient must be 60 years of age or older, or 18 years of age or older and decline methotrexate-based treatment.\n4. The disease should be measurable by MRI of the brain and/or spine with contrast enhancement.\n5. The patient's ECOG performance status should be 2 or less.\n6. The patient should have received no more than 2 prior chemotherapy regimens.\n7. The patient should have adequate hematologic, renal, and hepatic function.\n8. The patient should be able to swallow oral medications.\n9. Female patients who are not of childbearing potential, or female patients of childbearing potential who agree to use adequate contraceptive measures, should have a negative serum pregnancy test within 72 hours prior to treatment.\n10. Male patients should be willing to use adequate contraceptive measures.\n11. The patient's life expectancy should be 8 weeks or greater.\n12. The patient should be HIV negative.\n13. The patient should have archival tumor block or unstained slides for biomarker testing.\n14. The patient should be willing and able to comply with study and follow-up procedures.\n15. The patient should be able to understand the nature of the study and give written informed consent.\n16. Bone marrow biopsy must be negative for lymphoma.\n\nThe exclusion criteria for this trial include:\n1. Previous treatment with rituximab or other monoclonal antibodies, or temozolomide.\n2. Prior bone marrow or organ transplantation.\n3. Chemotherapy or investigational drug therapy for cancer within 21 days prior to the start of the study.\n4. T-cell primary CNS lymphoma.\n5. Known hypersensitivity to dacarbazine (DTIC).\n6. Active, clinically serious infection greater than CTCAE grade 2.\n7. Positive test results for chronic hepatitis BsAg infection.\n8. Chronic treatment with steroids or other immunosuppressive agents for medical conditions other than cancer.\n9. History of other malignancy within 5 years prior to study entry that could affect compliance with the protocol or interpretation of results.\n10. History of unstable or newly diagnosed angina pectoris, recent myocardial infraction, or New York Heart Association Classification III or IV.\n11. Vaccination with a live-virus vaccine within 4 weeks prior to the start of the study treatment.\n12. Impairment of gastrointestinal function or GI disease that may significantly alter the absorption of the study drug.\n13. Significant, concurrent, uncontrolled medical condition that may interfere with patient participation in the study.\n14. Pregnant or lactating females.",
    "The sample from the table is for a phase 2 clinical trial for the treatment of eosinophilic esophagitis. The trial is testing the effectiveness of the drugs mometasone furoate and placebo. The eligibility criteria for participants include being over 18 years old, having a newly diagnosed case of EoE with specific diagnostic criteria, and providing informed consent. There are also exclusion criteria, such as having certain infections, recent trauma or surgery, dehydration, glaucoma, hypersensitivity to the treatments, and other medical conditions that may interfere with the study. Participants who are pregnant or planning to become pregnant, or those who are not using contraception during the study period, are also excluded.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is metastatic alveolar soft part sarcoma. The corresponding ICD-10 codes for this disease are J84.09, J84.01, J84.02, M26.70, M26.71, M26.72, and M26.73. The drug being tested in this trial is pazopanib. \n\nThe eligibility criteria for this trial include a confirmed diagnosis of alveolar soft part sarcoma with TFE3 fusion at stage IV or relapse, being at least 18 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, having a measurable lesion as defined by RECIST v1.1, being chemo-na\u00efve or having received prior chemotherapies, and having adequate organ function.\n\nThe exclusion criteria for this trial include having prior malignancies, having active CNS disease, being at high risk for gastrointestinal bleeding, having significant cardiovascular disease, having uncontrolled hypertension, and having a bleeding diathesis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease mentioned is thyroid carcinoma. The corresponding ICDCodes for this disease are 'D09.3'. The drug being used in this trial is sorafenib (also known as nexavar or bay43-9006). \n\nThe eligibility criteria for this trial are as follows:\n- The trial is open to Japanese patients with anaplastic thyroid carcinoma (ATC) or locally advanced or metastatic medullary thyroid carcinoma (MTC).\n- Patients who are not suitable candidates for surgery or radiotherapy with curative intent are eligible.\n- The diagnosis of ATC or MTC must be confirmed histologically or cytologically.\n- The disease must be measurable or non-measurable but clinically evaluable according to RECIST 1.1 criteria.\n- Patients must be at least 18 years old.\n- Adequate bone marrow, liver, and renal function is required, which will be assessed within 14 days prior to treatment.\n- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n- The expected life expectancy of patients must be at least 12 weeks.\n\nThe exclusion criteria for this trial are as follows:\n- Patients with histologic subtypes of thyroid cancer other than anaplastic or medullary carcinoma are not eligible.\n- Patients who have received prior anti-cancer treatment with tyrosine kinase inhibitors, monoclonal antibodies (licensed or investigational) that target VEGF or VEGF receptors, or other targeted agents are not eligible.\n- Patients who have received prior chemotherapy for thyroid cancer (only one regimen allowed) are not eligible.\n- Patients who have undergone major surgery, open biopsy, or significant traumatic injury within 30 days prior to enrollment in the study are not eligible.\n- Patients with tracheal, bronchial, or esophageal infiltration with a significant risk of bleeding, but without having received local treatment prior to enrollment in the study, are not eligible.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 2. The diseases being studied are melanoma and brain metastases. The icd-10 codes associated with these diseases are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4. The drug being used in the trial is ipilimumab. The eligibility criteria for participants in this trial include having a histologic diagnosis of melanoma, being over the age of 18, having a specific classification of brain metastases, and meeting certain organ function requirements. There are also exclusion criteria listed, such as prior progression of melanoma to an ipilimumab-containing regimen, prior radiation therapy to the brain, and other specific medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 2 and phase 3. The disease being studied is chronic hepatitis C. The ICDCodes associated with this disease are B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, and K71.4. The drugs being used in the trial are grazoprevir, elbasvir, and mk-5172a. \n\nThe eligibility criteria for this trial include having documented chronic HCV GT1 infection (or GT4 or GT6 infection for Arm 4 participants), clinical evidence of hepatic cirrhosis with a Child-Pugh scale score from 7 to 9 (except for Arm 2 participants who should have no evidence of cirrhosis), and not anticipating a liver transplant within the next 36 weeks (for Arm 1, Arm 3, and Arm 4). Other inclusion criteria include agreeing to remain abstinent or using an acceptable method of birth control, and exclusion criteria include being co-infected with hepatitis B or HIV, having received previous direct-acting antiviral therapy for HCV, having a history of malignancy within the last 5 years (except for certain types of adequately treated cancer), and having cirrhosis with evidence of hepatocellular carcinoma or under evaluation for it. \n\nAdditional exclusion criteria include current or recent participation in another study with an investigational compound, clinically-relevant drug or alcohol abuse within the last 12 months, pregnancy or breastfeeding, having received organ transplants (except for cornea and hair), poor venous access, history of gastric surgery or malabsorption disorders, requirement or likelihood of chronic systemic administration of corticosteroids during the trial, and evidence or history of chronic hepatitis not caused by HCV.",
    "The sample provided is for a phase 2 clinical trial for lung cancer. The trial is specifically for patients with unresected and pathologically proven Stage 3a or Stage 3b non-small cell lung cancer (NSCLC) of adenocarcinoma, squamous cell, large cell, or mixed histology. The patients must be diagnosed within three months of study randomization and have non-metastatic disease.\n\nThe inclusion criteria for the trial include being between the ages of 18 and 80, having undergone specific diagnostic tests within a certain timeframe, and having a certain performance status. The exclusion criteria include having a high ECOG performance status, significant weight loss, diabetes or current use of certain medications, low pulmonary function test results, abnormal blood count or organ function, high fasting blood sugar levels, prior lung cancer treatments, prior radiotherapy that overlaps with the planned treatment area, recent invasive malignancy, AIDS, increased risk for lactic acidosis, hypersensitivity or allergy to Metformin, pregnancy or lactation, geographic inaccessibility for follow-up, and inability to provide informed consent.\n\nThe trial treatment involves the use of metformin in combination with chemo-radiotherapy.",
    "The sample from the table represents a clinical trial for wound infection treatment. The trial is in phase 1/phase 2 and focuses on patients with burn wounds in a hospital burn unit. The eligibility criteria include being an adult with informed consent, having signs of infection in the burn wound or graft harvesting area, and having a microbiologically documented infection caused by Escherichia coli or Pseudomonas aeruginosa. The patients must have been treated with povidone-iodine. Pregnant or breastfeeding women, patients with certain medical conditions or treatments, those currently participating in other research protocols, and individuals with allergies to Silver Sulfadiazine are excluded from the trial.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 2. The disease being studied is depressive disorder, major. The corresponding ICD-10 codes for this disease are F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, and F33.40. The drug being tested is normal saline. The eligibility criteria for this trial include having moderate to severe major depressive disorder as an inclusion criteria, and having prior treatment with botulinum toxin, use of antidepressant medication for depression within 2 weeks of the study, or a diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, or Amyotrophic Lateral Sclerosis as exclusion criteria.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on HIV infections. The ICD-10 code for this disease is 'Z21'. The trial involves the use of multiple drugs, including raltegravir (mk-0518), nevirapine, lamivudine, tenofovir, emtricitabine, lopinavir, ritonavir, atazanavir, and darunavir. The eligibility criteria for participants are listed, including requirements such as being male or non-pregnant/non-breastfeeding female, having no previous history of virological failure, and not having been exposed to certain types of drugs before. The criteria also include specific HIV-1 RNA levels, previous treatment regimens, and genotype testing results. Additionally, there are exclusion criteria, such as having hepatitis B or C, liver cirrhosis, diabetes mellitus, or any other cancer. The sample also mentions restrictions for female participants who are nursing, pregnant, or planning to become pregnant. It also states that participants should not have any active AIDS-defining events or have participated in other clinical trials recently.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is metastatic pancreatic adenocarcinoma. The ICDCodes associated with this disease are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drugs being tested in this trial are z-360 and placebo. The eligibility criteria for this trial include having histological or cytological evidence of metastatic pancreatic adenocarcinoma, a life expectancy of at least 12 weeks, an Eastern cooperative oncology group performance status (ECOG PS) of 0, 1, or 2, and meeting certain organ function requirements. The exclusion criteria include previous therapies for pancreatic adenocarcinoma such as surgery, radiation, chemoradiation, and specific chemotherapy treatments within certain timeframes.",
    "The sample is a phase 2 clinical trial for the treatment of nonsquamous non-small cell lung carcinoma (NSCLC). The trial is investigating the effectiveness of a combination of drugs including ruxolitinib, placebo, pemetrexed, and cisplatin. The eligibility criteria for participants include having a confirmed diagnosis of nonsquamous NSCLC, measurable or evaluable disease, a life expectancy of at least 12 weeks, and a tumor without activating driver mutations. Participants must also have a modified Glasgow Prognostic Score (mGPS) of 1 or 2, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and adequate renal, hepatic, and bone marrow function. Exclusion criteria include having squamous or mixed histology NSCLC, previous systemic therapy for advanced or metastatic disease, known active central nervous system metastases, and current or previous other malignancies within 2 years. Participants with uncontrolled cardiac or other medical conditions are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The disease being studied is colorectal cancer (CRC). The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are ruxolitinib, regorafenib, and placebo.\n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The patient must have histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum.\n- The patient must have received previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as well as an anti-VEGF therapy (if no contraindication) and, if KRAS wild type and no contraindication, an anti-EGFR therapy.\n- The patient must have radiographically measurable or evaluable disease according to RECIST v1.1.\n- The patient must have a life expectancy of at least 12 weeks.\n- The patient's Eastern Cooperative Oncology Group (ECOG) performance status must be between 0 and 2.\n- At least three weeks must have passed since the completion of the previous treatment regimen, and the patient must have recovered or be at a new stable baseline from any related toxicities.\n- Prior radiotherapy to disease sites is allowed with certain protocol-defined restrictions.\n\nExclusion Criteria:\n- The patient must not have received prior treatment with regorafenib.\n- The patient must not have any active gastrointestinal disease or other condition that significantly interferes with drug absorption.\n- The patient must not have active peptic ulcer disease, inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease), diverticulitis, or other gastrointestinal conditions with an increased risk of perforation or gastrointestinal bleeding.\n- The patient must not have had a recent history (within the past 3 months) or ongoing partial or complete bowel obstruction, unless it is due to the disease under study and corrected with surgery.\n- The patient's blood pressure must not be equal to or higher than 140/90 mmHg.\n- The patient must not have any active bleeding diathesis or a history of major bleeding within the past 6 months, such as requiring transfusion of red blood cells (RBCs), central nervous system (CNS) bleeding, or significant hemoptysis. However, subjects with bleeding secondary to underlying disease that has been corrected by surgery or alternative procedure may be included.\n- The patient must not have any clinically significant cardiac disease, including unstable angina, acute myocardial infraction within 6 months from Day 1 of study drug administration, New York Heart Association Class II, III, or IV congestive heart failure, and arrhythmia requiring therapy.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is diabetes mellitus, type 2. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs mentioned in this sample are ly2944876, exenatide extended-release, and placebo. The eligibility criteria for this trial include specific requirements for participants, such as having diabetes mellitus type 2, a certain range of HbA1c levels, a specific BMI range, and not meeting certain exclusion criteria, such as being a woman of childbearing potential or having used certain medications within a specified time frame.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is chronic HCV infection. The ICDCodes associated with this disease are \"K94.02\", \"K94.12\", \"K94.22\", \"K94.32\", \"N99.511\", \"A02.9\", and \"A31.0\". The drugs being used in the trial are \"ldv/sof\", \"sof\", and \"rbv\". The eligibility criteria for this trial include having Hemophilia A, B, or C, or Von Willebrand's disease, having chronic genotype 1, 2, 3, or 4 HCV infection, having HCV RNA \u2265 1000 IU/mL at screening, using specified contraception methods if female of childbearing potential or sexually active male, having screening laboratory values within defined thresholds, and meeting specific requirements for HIV-1/HCV co-infected individuals. There are also exclusion criteria listed, such as having a clinically-significant illness or major medical disorder that may interfere with treatment, having certain medical conditions like hepatic decompensation or hepatocellular carcinoma, being pregnant or nursing, having prior treatment with specific inhibitors, or having chronic use of immunosuppressive agents.",
    "The sample from the table is for a phase 2 clinical trial. The diseases being studied are \"infection, human immunodeficiency virus\" and \"hiv infections\". The corresponding ICD-10 codes for these diseases are \"Z21\" and \"Z21\" respectively. The drugs being tested in the trial are \"gsk744\", \"gsk744 la\", \"tmc278 la\", \"abc/3tc\", and \"rpv\". The eligibility criteria for the trial include being HIV-1 infected and at least 18 years old, having a negative pregnancy test for female participants, having a CD4+ cell count of at least 200 cells/mm^3, being ART-naive, and not having certain pre-existing conditions or allergies to the study drugs. There are also exclusion criteria such as breastfeeding, certain diseases or conditions, and recent exposure to certain medications or treatments.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on esophageal carcinoma. The ICD-10 codes associated with the disease are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']. The drugs being studied are pertuzumab and trastuzumab. The eligibility criteria for participants include having histologically proven adenocarcinoma of the intrathoracic esophagus or gastroesophageal junction, being HER2-positive, being surgically resectable, having specific tumor characteristics, meeting certain age and performance status requirements, and having adequate hematological, renal, and hepatic functions. There are also exclusion criteria, such as having certain types of tumors, a history of malignancy, or certain medical conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"keratoconjunctivitis sicca\" (dry eye syndrome). The associated ICD-10 codes for this disease are 'H16.223', 'H16.221', 'H16.222', and 'H16.229'. The trial involves testing three different drugs: \"low dose 0.155\u00b5g/ml skq1 ophthalmic solution\", \"high dose 1.55\u00b5g/ml skq1 ophthalmic solution\", and \"placebo (vehicle) ophthalmic solution\". \n\nThe sample also includes the eligibility criteria for participants. The inclusion criteria state that participants can be of any race, at least 18 years old, and have a reported history of dry eye syndrome. They should also have a history of using or desiring to use eye drops for dry eye. \n\nOn the other hand, the exclusion criteria specify conditions that would disqualify participants from the trial. These include having clinically significant eye findings that require treatment, having had LASIK surgery within the last 12 months, or using Restasis\u00ae within 30 days of the first visit. Other exclusion criteria include being pregnant, nursing, or planning a pregnancy, having allergies or sensitivities to the test article or its components, currently participating in another investigational study, or having a condition that may put the participant at significant risk or interfere with their participation in the trial.",
    "The sample from the table represents a clinical trial with a phase 1/phase 2 study design. The trial focuses on HIV infection and involves the evaluation of the drugs dipyridamole and placebo. The eligibility criteria for participants include being diagnosed with HIV-1 infection, being on antiretroviral therapy for at least 12 months, having a plasma HIV-1 RNA level below 50 copies/mL, and having a stable ART regimen for at least 8 weeks. Other criteria include providing informed consent, having no medical or mental health conditions that would prevent participation, and meeting specific laboratory values within 60 days prior to entry.\n\nExclusion criteria for the trial include pregnancy or breastfeeding, known allergies or hypersensitivity to the study drugs, history of cardiovascular disease, uncontrolled type II diabetes mellitus, and chronic inflammatory conditions. Other exclusions include a history of asthma requiring treatment, recent serious illness or hospitalization, use of certain medications within the past 60 days, recent vaccinations, participation in other HIV immunotherapy or therapeutic vaccination trials, active drug or alcohol use, and use of investigational therapies within 30 days prior to entry.\n\nFor the subset of participants undergoing rectal tissue analysis, additional criteria and exclusions apply. These include abstaining from certain sexual practices before and after rectal biopsy, absence of colorectal abnormalities or symptoms, and absence of active untreated gonorrhea or chlamydia infection.\n\nFor participants enrolled under Version 2.0, there are additional exclusions for spirometry testing, such as recent abdominal or cataract surgery, recent myocardial infraction or stroke, acute respiratory symptoms or fever, uncontrolled hypertension, and prior adverse reactions to albuterol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"chronic graft-versus-host disease\" and \"oral mucosal disease due to graft-versus-host disease\". The corresponding ICDCodes for these diseases are \"D89.811\" and \"D89.812\" for the first disease, and \"D89.810\", \"D89.811\", \"D89.813\", and \"D89.812\" for the second disease. The drug being tested in this trial is \"sirolimus\". \n\nThe eligibility criteria for this trial include:\n- Patients must be on a stable immunomodulatory medication regimen for 7 days prior to the study.\n- Patients must be 4 years of age or older.\n- Patients must have symptomatic oral chronic graft-versus-host disease with a sensitivity score of 4 or higher.\n- Patients must have been on stable topical steroid therapy for 7 days prior to enrollment.\n- Patients must have been on a stable systemic cGVHD medication regimen for 7 days prior to enrollment.\n- Women of child-bearing potential and men must agree to use adequate contraception during the study and for 4 months after completion of topical sirolimus administration.\n- Patients already using topical sirolimus therapy, patients with an allergy/intolerance to sirolimus, patients with a sensitivity score of 3 or lower, patients unable to comply with study instructions, pregnant or breastfeeding women, and patients with uncontrolled intercurrent illness are excluded from the trial.\n\nThis sample provides detailed information about the trial phase, diseases being studied, ICDCodes, the drug being tested, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on pancreatic adenocarcinoma. The trial includes patients with borderline unresectable advanced pancreatic adenocarcinoma who meet certain criteria. The eligibility criteria include having a documented diagnosis of pancreatic ductal adenocarcinoma, being 18 years or older, having an ECOG performance status of 0-1, and having a life expectancy of at least 12 weeks. Other criteria include adequate hematological, renal, and hepatic function. Patients must not have received prior therapy for their disease and must have measurable disease according to RECIST 1.1 criteria. Additionally, patients must agree to use effective contraception methods if they are sexually active. The exclusion criteria include patients with metastatic pancreatic adenocarcinoma or disease amenable to resection with curative intent. Other exclusion criteria include known allergy or hypersensitivity to certain drugs, routine use of specific oral anti-oxidant supplements, pre-existent ischemic heart disease, significant medical or psychiatric conditions, and certain medical history such as venous thromboembolic events or significant cardiovascular events. Patients who are pregnant, plan to become pregnant, or are lactating are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic castration-resistant prostate cancer. The trial is evaluating the effectiveness of two drugs, abiraterone acetate and enzalutamide. The eligibility criteria for participants include being adult males over 18 years old, having a history of adenocarcinoma of the prostate without neuroendocrine or small cell differentiation, evidence of metastatic disease on bone scan or CT scan, and evidence of biochemical or imaging progression in the setting of surgical or medical castration. Other criteria include having an ECOG performance status of 0-2, being eligible for treatment with either abiraterone acetate or enzalutamide as per standard of care guidelines, and having adequate organ function. Exclusion criteria include severe concurrent illness or co-morbid disease, prior therapy with certain inhibitors or experimental anti-androgens, prior systemic chemotherapy for mCRPC, life expectancy less than 6 months, active concurrent malignancy (except non-melanomatous skin cancer), recent radiotherapy or radioisotope treatment, brain metastases or active epidural disease, use of herbal products that may lower PSA level, contraindication to prednisone therapy, history of seizure or cerebrovascular event, gastrointestinal disorder affecting absorption, and major surgery within 4 weeks of starting study treatment.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is asthma, and the corresponding ICD-10 codes for asthma are provided. The drugs being tested in this trial are \"chf 5259 plus foster 100/6 \u00b5g\" and \"foster 100/6 \u00b5g\". The eligibility criteria for participants are listed, including age, asthma control, lung function, and exclusion criteria such as pregnancy, COPD diagnosis, recent asthma exacerbations, therapy for gastroesophageal reflux disease, and clinically significant cardiovascular conditions.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on diseases related to angina pectoris, myocardial infraction, reperfusion injury, and coronary heart disease. The corresponding ICD-10 codes for these diseases are also listed. The trial involves the use of the drugs glp-1 and placebo. The eligibility criteria for participants include undergoing elective PCI, being over 18 years old, and being able to provide informed consent. Exclusion criteria include severe co-morbidity with a life expectancy of less than 6 months, the use of certain medications, being a woman of childbearing age or breastfeeding, having had a myocardial infraction within the previous 3 months, baseline elevation of Troponin I before PCI, and having chronic renal impairment with a serum creatinine level above 160 \u03bcmol/l.",
    "The sample from the table represents a phase 2 clinical trial. The trial focuses on the treatment of gout and moderate renal impairment. The diseases are represented by their corresponding ICD-10 codes. The drugs being studied include febuxostat ir, febuxostat xr, febuxostat placebo, colchicine, naproxen, and lansoprazole. \n\nThe eligibility criteria for participants include being capable of understanding and complying with the study requirements, providing informed consent, having a history or presence of gout, being at least 18 years old, using adequate contraception if sexually active, having a serum urate level of at least 8.0 mg/dL, having an estimated Glomerular Filtration Rate (eGRF) between 30 mL/min and 60 mL/min, and experiencing at least one gout flare within the past 12 months.\n\nExclusion criteria include recent use of investigational compounds, being a family member or dependent of a study site employee, being pregnant or breastfeeding, having secondary hyperuricemia or xanthinuria, recent use of urate lowering therapy, hypersensitivity to the study drugs or components, active peptic ulcer disease, history of cancer within the past 5 years, elevated liver enzyme levels, rheumatoid arthritis requiring treatment, significant medical conditions that may interfere with the study, history of cardiovascular events, history of drug or alcohol abuse, recent participation in another investigational study, history of hepatitis B, hepatitis C, or HIV infection, and requirement to take excluded medications.",
    "The sample is a phase 2 clinical trial for the treatment of HIV-related cognitive impairments. The trial focuses on patients with diseases such as AIDS dementia complex, HIV-1-associated cognitive motor complex, and human immunodeficiency virus. The diseases are identified by their corresponding ICD-10 codes. The drug being tested in the trial is cenicriviroc. \n\nThe sample includes the eligibility criteria for the trial. Inclusion criteria include documentation of HIV-1 infection, being on antiretroviral medication for at least 1 year, having a low plasma HIV RNA level, willingness to use effective contraception, being between the ages of 18 and 70, and having mild to moderate cognitive impairment. Exclusion criteria include recent use of a CCR5 antagonist, high plasma HIV RNA level, presence of HIV-2, chronic hepatitis B or C, active or chronic liver disease, active tuberculosis, and other specific medical conditions. \n\nThe sample also mentions additional criteria related to medication use, laboratory values, and other medical conditions that would disqualify a patient from participating in the trial. It also mentions specific criteria for MRI and lumbar puncture substudies.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of hepatocellular carcinoma (HCC), a type of liver cancer. The trial is specifically targeting patients with advanced HCC that is refractory to standard therapies or has metastasized, and for whom no curative treatments are expected. \n\nThe sample includes details about the eligibility criteria for participants. Inclusion criteria include being at least 18 years old, having a diagnosis of HCC confirmed through cytology and/or histology, and meeting specific requirements related to previous treatment and disease progression. Other criteria include performance status, cirrhosis classification, and various laboratory values. \n\nExclusion criteria are also listed, which outline conditions that would make a subject ineligible for the trial. These include receiving multiple prior systemic drug therapies for HCC, recent use of certain medications, unresolved toxicities from previous chemotherapy, recent locoregional treatment or major surgery, and various medical conditions or infections. \n\nOverall, this sample provides a snapshot of the trial's phase, the targeted disease, the drugs being studied, and the specific eligibility criteria that potential participants must meet.",
    "The sample is a phase 2 trial for the treatment of adult B acute lymphoblastic leukemia. The trial is specifically targeting patients with relapsed or refractory B-ALL who are eligible to receive salvage therapy. The eligibility criteria include having a certain performance status, specific laboratory values within normal range, and no contraindications for the study drug, ibrutinib. The sample also includes exclusion criteria such as recent chemotherapy or radiotherapy, active central nervous system leukemia, and certain medical conditions that may put the patient at risk. The sample provides detailed information on the inclusion and exclusion criteria, as well as other important information for potential participants in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is metastatic colorectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are aflibercept, irinotecan, 5-fluorouracil, and folinic acid. The eligibility criteria for participants in this trial include having histologically proven adenocarcinoma of the colon and/or rectum, confirmed metastatic disease, and no prior therapy for metastatic disease. Other criteria include specific age requirements, Eastern Cooperative Oncology Group (ECOG) Performance status, adequate hematological, renal, and liver function, regular follow-up feasibility, and baseline evaluations. The exclusion criteria include the exclusive presence of bone metastasis, uncontrolled hypercalcemia, uncontrolled hypertension, and various other conditions and medical history factors.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of ulcerative colitis. The trial involves the use of a drug called \"sb012\" and a placebo. The eligibility criteria for participants include being adults aged 18 to 75 with active ulcerative colitis. Other criteria include having a certain Mayo Score, body mass index, and negative pregnancy test for female subjects. There are also exclusion criteria, such as having certain medical conditions, recent use of specific medications, and prior participation in the trial.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial includes patients between the ages of 40 and 70 who have a history of COPD exacerbations. The inclusion criteria also require a diagnosis of symptomatic COPD with mild to moderate airflow obstruction. Other criteria include specific lung function measurements, body weight, smoking history, respiratory symptoms, and liver function. Female participants must meet certain criteria related to their reproductive status. The exclusion criteria include the presence of other lung diseases, low oxygen levels, recent antibiotic or corticosteroid use, and various medical conditions that could affect the safety of the participants. The sample also mentions specific drugs that should not be used during the study and certain medical tests that should be within normal ranges.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 2. The disease being studied is diabetic gastroparesis. The ICDCodes associated with this disease are \"K31.84\". The drugs being tested are promethazine and a sugar pill. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The trial is open to adult patients between the ages of 18 and 65.\n- Patients must have a clinical diagnosis of diabetic gastroparesis.\n- An EGD (Esophagogastroduodenoscopy) must have been performed within the past five years, showing no evidence of gastric outlet obstruction.\n- A gastric emptying scintigraphy test must have been conducted within the past three years, demonstrating more than 10% solid food retention at 4 hours.\n\nExclusion Criteria:\n- Patients who are unable or unwilling to provide informed consent are not eligible.\n- Pregnant or breastfeeding individuals are excluded.\n- Patients who have had a gastric stimulator placed previously are not eligible.\n- Patients who have received pyloric botulinum toxin injection within the past 12 months are excluded.\n- Individuals with a history of prior gastric surgery are not eligible.\n- Patients with a connective tissue disorder are excluded.\n- Use of narcotic medication within the past four weeks disqualifies patients.\n- Hemoglobin A1C levels above 12 mg/dL within the past 3 months make patients ineligible.\n- Current or recent (within the past 4 weeks) use of promethazine, metoclopramide, or domperidone disqualifies patients.\n- Patients with a known hypersensitivity or prior adverse reaction to promethazine are excluded.\n- Concomitant use of phenothiazines (such as prochlorperazine or chlorpromazine) or other agents likely to increase extrapyramidal reactions disqualifies patients.\n- Concomitant use of tiotropium or ipratropium makes patients ineligible.\n- Patients with narrow-angle glaucoma are excluded.\n- Individuals with urinary retention are not eligible.\n- Patients with Parkinson's disease are excluded.\n- Individuals with significant psychiatric disease are not eligible.\n- Patients with a history of seizures are excluded.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is chronic obstructive pulmonary disease (COPD). The ICD-10 codes associated with COPD are J44.9, J44.1, and J44.0. The drugs being tested in the trial are gsk2269557 100 mcg, gsk2269557 500 mcg, and a placebo. The eligibility criteria for participants include having a confirmed diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, being between 40 and 75 years old, having specific lung function measurements within a certain range, having a smoking history of at least 10 pack years, being able to produce a certain amount of sputum, and meeting certain weight and BMI requirements. Female participants must meet specific criteria related to their reproductive status, and male participants with female partners of child-bearing potential must agree to use contraception. There are also exclusion criteria, such as having certain medical conditions, diseases, or sensitivities, having a positive test for HIV or hepatitis, being pregnant or lactating, and having participated in other clinical trials within a certain time period. The sample also includes additional exclusion criteria related to COPD control and recent respiratory infections or treatments. Finally, the sample specifies that participants must be able to understand and communicate in German or their native language.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"leiomyoma,\" which is documented with the ICD-10 codes \"D25.0,\" \"D25.1,\" \"D25.2,\" and \"D25.9.\" The drugs being studied in this trial are \"bay1002670\" and \"placebo.\" \n\nThe eligibility criteria for participants in this trial include having a diagnosis of uterine fibroid(s) with at least one fibroid measuring 3.0 cm in diameter, being between 18 and 50 years old, experiencing heavy menstrual bleeding (>80 mL), having a normal cervical smear, and having a normal endometrial biopsy. Participants must also use a non-hormonal barrier method of contraception throughout the study and be in good general health, except for findings related to uterine fibroids.\n\nExclusion criteria for this trial include being pregnant or lactating, having a uterine fibroid with a diameter larger than 10.0 cm, having a hypersensitivity to any ingredient in the study drug, having laboratory values outside the acceptable range, having hemoglobin values below 6 g/dL or requiring immediate blood transfusion (participants with hemoglobin values below 10.9 g/dL will receive iron supplementation), and having any diseases or conditions that could affect the absorption, accumulation, metabolism, or excretion of the study drug.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is neuroendocrine tumors. The ICDCodes associated with this disease are C7A.1, C7A.8, C7B.8, and D3A.8. The drug being used in the trial is fosbretabulin tromethamine. The eligibility criteria for participants in this trial include being able to read and provide written consent, being at least 18 years old, having a biopsy-proven well-differentiated, low-to-intermediate-grade PNET or GI-NET with elevated biomarkers, having a life expectancy of more than 12 weeks, having received or currently receiving therapies including octreotide or other somatostatin analogues, having confirmed progressive disease within 18 months of enrollment, having recovered from prior radiation therapy or surgery, having an ECOG performance score of 0-2, having adequate blood counts and renal and hepatic function, having a disease that can be assessed with imaging, and using effective birth control for women of childbearing potential and fertile men and their partners. The exclusion criteria include inadequately controlled hypertension, history of cardiovascular diseases, CNS diseases, certain cardiac conditions, bleeding disorders, intolerance or hypersensitivity to fosbretabulin, history of organ transplant, and any other medical condition that may interfere with the study or interpretation of results.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating patients with non-small cell lung cancer (NSCLC) and brain metastases. The trial is specifically looking at the effectiveness of the drug cabozantinib. The eligibility criteria for the trial are listed, including requirements for previous treatment, availability of tumor tissue for testing, assessment of disease sites, and various organ and marrow function parameters. There are also exclusion criteria listed, such as recent treatments, prior use of cabozantinib or other c-MET directed therapy, and evidence of certain medical conditions or complications.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial is looking for male and female participants with locally advanced, inflammatory, or early-stage breast cancer. The participants must have a primary tumor larger than 2 centimeters or greater than 5 millimeters in diameter and node-positive. They must also have HER2-positive breast cancer confirmed by a central laboratory and have a tumor tissue specimen available. Other eligibility criteria include a baseline left ventricular ejection fraction (LVEF) of 55% or higher, an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or lower, and at least 4 weeks since major unrelated surgery with full recovery.\n\nExclusion criteria include participants with metastatic disease or bilateral breast cancer, those who have had an incisional biopsy or excision of the primary tumor, and those who have had previous systemic therapy or radiation therapy for cancer. Participants with a history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) are not allowed to enter the study if they have received any systemic therapy or radiation therapy to the ipsilateral breast. Other exclusion criteria include inadequate bone marrow, renal, or liver function, history or evidence of cardiovascular condition, dyspnea at rest or other diseases requiring continuous oxygen therapy, severe uncontrolled systemic disease, poorly controlled diabetes or clinically significant diabetic vascular complications, pregnancy or breastfeeding, recent investigational treatment, known infection with HIV, hepatitis B, or hepatitis C, current chronic daily treatment with corticosteroids, and known hypersensitivity to any of the study drugs or excipients.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of major depressive disorder. The ICD-10 codes associated with this disease are F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, and F33.40. The drugs being studied in this trial are esketamine and placebo. The sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include meeting the DSM-IV diagnostic criteria for major depressive disorder, having current suicidal ideation with intent, and being in need of acute psychiatric hospitalization due to the risk of suicide. Exclusion criteria include having a diagnosis of bipolar or related disorders, intellectual disability, or cluster b personality disorder. Participants with a current or prior diagnosis of a psychotic disorder, MDD with psychosis, or obsessive-compulsive disorder are also excluded. Additionally, participants with certain medical conditions such as liver or renal insufficiency, significant cardiac or neurological disturbances, or uncontrolled hypertension are excluded from the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on diseases such as bacteremia, healthcare-associated pneumonia, and ventilator-associated pneumonia. The corresponding ICD-10 code for the disease is \"J95.851\". The trial involves the use of drugs like polymyxin b and polymyxin b + doripenem. The eligibility criteria for participants include having monomicrobial XDR-GNB bacteremia, monomicrobial XDR-GNB ventilator-associated pneumonia or healthcare-associated pneumonia. There are also exclusion criteria such as allergy to study medications, pregnancy for female patients, inability to provide consent, current enrollment in another trial, more than 48 hours after XDR-GNB confirmation, palliative care with less than 24 hours of life expectancy, co-infection with other aerobic Gram-negative bacteria, and severe renal impairment. The presence of a concurrent infection not involving the lungs or bloodstream is not an exclusion criterion for the study.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on diseases related to end-stage renal disease, kidney failure, delayed graft function, and ischemic reperfusion injury. The diseases are identified using ICD-10 codes. The trial involves the use of two drugs, namely c1 esterase inhibitor and placebo. The eligibility criteria for participants include being between 18-70 years old, being a recipient of a specific type of donor allograft, having received meningococcal vaccination before the transplant, and providing written consent. The criteria also include a risk index based on factors such as donor age, cold ischemia time, recipient race, and donor death due to a cerebrovascular accident. There are also exclusion criteria, such as having a prothrombotic disorder, history of thrombosis or hypercoagulable state, and contraindications to treatment with C1INH. Other exclusion criteria include abnormal coagulation function, active presence of malignancies, and positive PCR results for hepatitis B, hepatitis C, or HIV. Additionally, recipients of preemptive kidney transplantation, multi-organ transplants, and certain types of kidney allografts are excluded from the trial. Pregnant or lactating female subjects are also excluded.",
    "The sample from the table is for a phase 2 clinical trial. The trial is focused on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The diseases are identified by their respective ICD-10 codes. The drugs being studied are idelalisib and ofatumumab. \n\nThe eligibility criteria for participants include having CLL/SLL with specific characteristics, such as a certain B cell count and expression of certain markers. Participants must also have measurable disease and meet certain indications for treatment. Other criteria include having a certain performance status, being at least 18 years old, and having normal organ and marrow function.\n\nExclusion criteria include having received prior systemic therapy for CLL, having severe allergic reactions to similar compounds, having certain active hepatic or biliary diseases, and being on certain non-marketed drugs or experimental therapies. Other exclusion criteria include having certain past or current malignancies, chronic or current infectious diseases, significant cerebrovascular disease, being HIV positive, having significant cardiac disease, and having other concurrent uncontrolled medical conditions. \n\nAdditional exclusion criteria include positive serology for Hepatitis B or Hepatitis C, being pregnant or lactating, and not using adequate contraception for women of childbearing potential or not using adequate contraception for male subjects. Participants using concomitant corticosteroids are allowed as long as they meet certain dosage and stability requirements.",
    "The sample is a phase 2 clinical trial for the treatment of prostate cancer. The trial is specifically targeting patients with localized prostate adenocarcinoma of intermediate risk. The eligibility criteria include being male and 18 years of age or older, having a confirmed diagnosis of intermediate-risk prostate cancer, and being scheduled for external beam radiation therapy (EBRT) at least 12 weeks after the baseline visit. Other criteria include having certain laboratory values within normal ranges, having a suitable venous access for blood sampling, and providing voluntary written consent.\n\nThe exclusion criteria include having metastatic disease, previous or current use of certain hormone therapies, recent diagnosis or treatment of another malignancy, abnormal laboratory values suggesting underlying disease, history of certain cardiac conditions, abnormal electrocardiogram (ECG) results, uncontrolled hypertension, certain viral infections, recent use of investigational products, and having a primary family member involved in the study or being a study site employee. Other exclusion criteria include having gastrointestinal (GI) conditions that may interfere with the absorption of the study drug, recent use of certain medications or dietary products, and evidence of alcohol or drug abuse.\n\nThe sample also includes a list of diseases, in this case, only prostate cancer, and their corresponding ICD-10 codes. Additionally, there is a list of drugs being used in the trial, which includes \"tak-385\" and \"degarelix\".",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is respiratory syncytial virus infection. The corresponding ICD-10 codes for this disease are 'R09.2', 'A15.7', 'A15.8', 'A15.9', 'J98.9', 'R06.03', and 'J12.1'. The drugs being tested in the trial are presatovir and presatovir placebo. The eligibility criteria for participants are listed under key inclusion and exclusion criteria. The key inclusion criteria include being a current inpatient, having new onset or acute worsening of respiratory symptoms, and being documented as RSV-positive. The key exclusion criteria include certain medication use, medical history factors, medical conditions at screening, and allergies to components of the study drug. It is also noted that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is a phase 2 trial for metastatic breast cancer. The trial is specifically targeting postmenopausal females between the ages of 18 and 70. The participants must have an ECOG performance status of 1 or less and a life expectancy of more than 3 months. The trial requires confirmation of histologically confirmed metastatic breast cancer, with ER and/or PR positive status and HER2-negative status. Participants must have experienced disease progression during adjuvant or first-line endocrine therapy, or be endocrine naive but unsuitable for endocrine therapy alone. They should not have received pretreated chemotherapy for metastatic disease and must have at least one target lesion according to RECIST 1.1 criteria. Participants should not have received any therapy (chemotherapy, endocrine therapy, target therapy, or operation) within 4 weeks before enrollment. They must also meet certain health criteria, including specific levels of hemoglobin, absolute neutrophil count, platelet count, serum bilirubin, ALT and AST levels, serum creatinine, and endogenous creatinine clearance. \n\nExclusion criteria include being pregnant or lactating, having evidence of CNS metastasis, having a seriously uncontrolled infection, having a history of other malignancies (except for cured basal cell carcinoma of the skin and carcinoma in-situ of the uterine cervix), having been pretreated with Fulvestrant, or having been pretreated with two or more lines of endocrine therapy.",
    "The sample in the table is for a phase 2 clinical trial. The diseases being studied are liver fibrosis, hepatic fibrosis, liver cirrhosis, and hepatic cirrhosis. The corresponding ICD-10 codes for these diseases are provided. The drugs being tested in the trial are idn-6556 and placebo. The eligibility criteria for the trial include being a male or female of minimum adult legal age, having a history of orthotopic liver transplantation for HCV-induced liver disease, being diagnosed with HCV infection and liver fibrosis or incomplete cirrhosis post-transplantation, achieving a sustained virologic response with anti-viral HCV treatment within 18 months, having liver fibrosis within a certain range on histology, and being willing to use contraception during the study. The exclusion criteria include having infections with hepatitis B or HIV, having a history of renal transplant or severe renal impairment, having tumor burden beyond certain criteria or evidence of vascular invasion in the liver, having hepatocellular carcinoma, using sirolimus, having cardiac arrhythmias or prolonged QT interval, having systemic lupus erythematosus or rheumatoid arthritis, and being pregnant or breastfeeding.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of idiopathic interstitial pneumonias and pulmonary hypertension. The diseases are described using a list of disease names and their corresponding ICD-10 codes. The drugs being studied are riociguat (adempas, bay63-2521) and a placebo. The eligibility criteria for participants include age, specific diagnoses, lung function measurements, and confirmation of pulmonary hypertension. There are also criteria related to blood pressure, functional class, and contraception for women of childbearing potential. The exclusion criteria include certain heart conditions, recent hemoptysis or pulmonary hemorrhage, lung function measurements, recent use of specific medications, and pregnancy or breastfeeding.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is \"diabetes mellitus, type 1\". The ICDCodes associated with this disease are \"E10.65\", \"E10.9\", \"E10.21\", \"E10.36\", \"E10.41\", \"E10.42\", and \"E10.44\". The drugs being tested in this trial are \"canagliflozin 100 mg\", \"canagliflozin 300 mg\", and \"placebo\". The eligibility criteria for this trial include having type 1 diabetes mellitus for at least 1 year, inadequate glycemic control, a specific body mass index range, a minimum daily dose of insulin, and being on a stable insulin regimen for at least 8 weeks prior to screening. The exclusion criteria include a history of type 2 diabetes mellitus, pancreas or \u03b2-cell transplantation, severe hypoglycemia, diabetic ketoacidosis, hereditary glucose-galactose malabsorption, and inadequately controlled thyroid disorder.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3, and the diseases being studied are carpal tunnel syndrome and compression neuropathy. The corresponding ICD-10 codes for these diseases are 'G56.00', 'G56.01', 'G56.02', and 'G56.03'. The drugs being tested in the trial are acetyl-l-carnitine and placebo. \n\nThe eligibility criteria for the trial are as follows:\nInclusion Criteria:\n- Patients will be recruited from the University of Alberta Hospital referred for CTS.\n- Adult patients (over age 18) with at least one of the following symptoms:\n  1. Numbness and parenthesis in the median nerve distribution.\n  2. Precipitation of those symptoms by repetitive motions that are relieved by rubbing and or shaking the hands.\n  3. Nocturnal awakening by those sensory symptoms.\n  4. Weakness of thumb abduction and thenar atrophy.\n\nExclusion Criteria:\n1. Motor unit loss in the median nerve less than 2 SD below the mean for the age as determined by nerve conduction studies.\n2. The presence of other neurologic conditions.\n3. Previous carpal tunnel release surgery.\n4. Cognitive impairment that renders the patient unable to provide informed consent.\n5. Pregnancy.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on colorectal cancer. The ICD-10 codes associated with the disease are provided. The trial involves several drugs, including 5-fu, bevacizumab, folinic acid, oxaliplatin, and vanucizumab. The eligibility criteria for participants are listed, including requirements for confirmed mCRC, performance status, and adequate organ function. There are also exclusion criteria, such as prior systemic therapy, other malignancies within the past 5 years, and certain medical conditions.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2 and the disease is lupus nephritis. The icd-10 codes associated with this disease are B26.83, A51.44, N11.8, N11.9, and N12. The drugs being studied are voclosporin high dose, voclosporin low dose, and placebo. The eligibility criteria include being aged 18 to 75 years, having a diagnosis of systemic lupus erythematosus (SLE) according to the American College of Rheumatology criteria, and having a kidney biopsy within 6 months prior to screening with a histologic diagnosis of lupus nephritis. There are also specific laboratory evidence requirements for active nephritis. The sample also includes exclusion criteria such as certain medical conditions, previous kidney transplant, and pregnancy.",
    "The sample provided is for a phase 2 clinical trial. The trial is focused on the treatment of primary open-angle glaucoma and ocular hypertension. The diseases are represented by their respective ICD-10 codes. The drug being tested in this trial is bimatoprost. \n\nThe eligibility criteria for this trial include having completed a previous study (FSV5-002), providing written informed consent, and being willing to comply with the visit schedule. \n\nOn the other hand, the exclusion criteria include recent participation in another investigational drug or device study, the need for contact lens use during the trial, and any condition or situation that may confound the study results, pose significant risk, or interfere with the subject's ability to participate.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the treatment of delayed graft function. The diseases associated with the trial are specified as \"delayed graft function\" and are represented by a list of ICD-10 codes. The drugs being studied are eculizumab and placebo. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being 18 years or older, having dialysis-dependent renal failure, and being willing to comply with the study protocol. Exclusion criteria include receiving a multi-organ transplant, receiving a kidney from donors under 6 years of age, and having a history of certain infections or illnesses. Female participants of child-bearing potential must have a negative pregnancy test and use contraception. The sample provides a detailed description of the criteria that determine whether a participant is eligible for the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the treatment of diabetes and peripheral arterial disease. The diseases are represented by their respective ICD-10 codes. The drugs being studied are dlbs1033 and a placebo. The sample also includes the eligibility criteria for the trial, including inclusion and exclusion criteria. Inclusion criteria include having a signed informed consent, being between 40-65 years old, having a diagnosis of diabetes mellitus, and having peripheral arterial disease with a specific ankle-brachial index range. Exclusion criteria include being a female of childbearing potential who is pregnant, breastfeeding, or intending to become pregnant, recent stroke or heart-related events, impaired liver or renal function, use of certain medications, concurrent use of herbal medicines or food supplements, presence of other diseases or infections that could interfere with the trial, high risk of bleeding, prior experience with dlbs1033 or similar products, known or suspected allergies to study medications or aspirin.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is prostate cancer. The ICDCodes associated with the disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drug being tested is selinexor. \n\nThe eligibility criteria for participants in this trial include having a histologically proven adenocarcinoma of the prostate with evidence of skeletal metastases, having received at least one agent known to impact survival, having an Eastern Cooperative Oncology Group (ECOG) score of \u2264 2 or a Karnofsky Performance Status (KPS) \u2265 60%, having serum testosterone levels < 50 ng/ml, ongoing gonadal androgen deprivation therapy, and progression of disease despite androgen ablation. \n\nThere are also various laboratory requirements and exclusions, such as not having histologic variants other than adenocarcinoma, not requiring urgent treatment with docetaxel, and not having abnormal hepatic function. Other exclusions include not having therapy with other hormonal therapy or certain medications within a specific timeframe, not having uncontrolled infection or concomitant illness, and not having certain medical conditions or situations that may put the participant at significant risk or interfere with their participation in the study. \n\nAdditionally, there are requirements related to contraception for men with female partners of child-bearing potential and a restriction on body mass index (BMI) to prevent participants from receiving a dose of selinexor greater than 70 mg/m^2.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of detectable prostate nodules. The associated ICD-10 codes for the diseases are A18.14, N41.2, N42.0, N42.83, C61, D29.1, and N42.30. The drug being used in the trial is bicalutamide plus finasteride, which is a combination therapy. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Must be willing and able to provide written informed consent.\n- Must be at least 18 years old.\n- Must have an Eastern Cooperative Group (ECOG) performance status of 2 or lower.\n- Must have a documented histologically confirmed adenocarcinoma of the prostate, with a minimum of 12 core prostate biopsies completed within 90 days of screening.\n- Must have very low-risk prostate cancer, as defined by specific criteria such as Gleason score, PSA density, PSA level, clinical tumor stage, and involvement of prostate cores.\n- Must be willing and qualified for active surveillance at Johns Hopkins.\n- Must have at least one MRI significant visible prostate tumor that has been biopsy proven to be prostatic adenocarcinoma.\n- Must have a serum testosterone level of at least 150 ng/dL.\n- Must be able to swallow the study drugs whole as a tablet.\n\nThe exclusion criteria for participants in the trial are as follows:\n- Prior local therapy to treat prostate cancer, such as radical prostatectomy or radiation therapy.\n- Prior use of bicalutamide.\n- Prior use of finasteride within the past year.\n- Prior or ongoing systemic therapy for prostate cancer, including hormonal therapy, CYP-17 inhibitors, antiandrogens, second-generation antiandrogens, immunotherapy, and chemotherapy.\n- Evidence of serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with patient safety or provision of informed consent.\n- Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule.\n- Abnormal bone marrow function, liver function, kidney function, or cardiac function.\n\nThis information provides details about the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for participants in the clinical trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, the disease is microvascular angina, the ICDCodes is H35.09, the drugs are ranolazine and placebo, and the eligibility criteria are listed under inclusion and exclusion criteria. The inclusion criteria include having a history of typical angina or effort-induced anginal symptoms, abnormal stress ECG or imaging, and non-obstructive coronary artery disease. The exclusion criteria include inability to provide informed consent, active myocardial infraction, history of coronary artery bypass grafting, diagnosis of other specific cardiac diseases, low left ventricular ejection fraction, known renal insufficiency or on dialysis, and contraindications to the use of ranolazine.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 2, and the disease being studied is rheumatoid arthritis. The icd-10 codes associated with this disease are M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, and M06.019. The drugs being tested in this trial are tofacitinib and placebo. The eligibility criteria for participants include having moderate to severe rheumatoid arthritis that is not adequately controlled by methotrexate, having certain levels of C-reactive protein (CRP) and painful and swollen joint counts, having active disease, and being at least 50 years of age or older. The exclusion criteria include a history of receiving any varicella-zoster virus vaccine, receiving any vaccines within 6 weeks of the study treatment, having current or past infections, and a history of recurrent or disseminated episodes of herpes zoster or herpes simplex.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating two diseases: myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The diseases are identified by their respective ICD-10 codes. The trial involves the use of three drugs: birinapant, azacitidine, and a placebo. The eligibility criteria for participants in the trial are listed, including requirements such as a confirmed diagnosis of MDS/CMML, a specific prognostic score, no prior treatment with certain agents, a certain performance status, and adequate renal and liver function. There are also exclusion criteria, such as being relapsed or refractory to certain agents, having acute myeloid leukemia (except for specific cases), recent participation in other studies, and various medical conditions that would prevent participation.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"asthma\". The associated ICD-10 codes for asthma are listed as ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being studied in this trial are \"beclometasone dipropionate 100 \u00b5g + formoterol fumarate 6 \u00b5g\", \"beclometasone dipropionate 200 \u00b5g + formoterol fumarate 6 \u00b5g\", and \"placebo\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include obtaining the patient's written informed consent, being between the ages of 18 and 65, having evidence of \"partially controlled\" or \"uncontrolled\" asthma, being on a medium daily dose of previous inhaled corticosteroids treatment, having FEV1 (forced expiratory volume in 1 second) between 60% and 85% of predicted normal values, having a positive response to the reversibility test, being a non-smoker or ex-smoker, and having a cooperative attitude and ability to be trained in the proper use of a DPI (dry powder inhaler).\n\nExclusion criteria include being pregnant or lactating, having significant seasonal variation in asthma, having a history of near-fatal asthma or asthma exacerbation requiring intensive care unit treatment within the past year, experiencing asthma exacerbations or respiratory tract infections in the 4 weeks prior to screening, having a diagnosis of chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, or alpha-1 antitrypsin deficiency, having a diagnosis of restrictive lung disease, being treated with oral or parenteral corticosteroids in the previous 8 weeks, having intolerance or contraindication to treatment with beta2-agonists and/or inhaled corticosteroids, having allergies or intolerance to the study drugs or excipients, having received any investigational drug within the last 8 weeks, taking non-permitted concomitant medication, being unlikely to comply with the study protocol, having any clinically relevant abnormal value or physical finding at screening, having a significant medical history, having an abnormal and clinically significant 12-lead electrocardiogram, or having low compliance with QVAR intake.\n\nThis sample provides a detailed description of the trial phase, the disease being studied, the associated ICD-10 codes, the drugs being tested, and the eligibility criteria for participants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on primary sj\u00f6gren's syndrome. The icd-10 codes associated with this disease are D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, and E34.0. The drugs being studied are vay736 and placebo. The eligibility criteria for participants include fulfilling the revised European US consensus criteria for pSS, having an ESSDAI value of at least 6, elevated serum titers of ANA (\u2265 1:160), being seropositive for anti-SSA and/or anti-SSB antibodies, and having a stimulated whole salivary flow rate of more than 0 mL/min. Exclusion criteria include prior or previous use of certain therapies, active or recent history of clinically significant infection, recent vaccination, and a history of primary or secondary immunodeficiency. The use of hydroxychloroquine or methotrexate in a consistent dose for at least 3 months prior to randomization is allowed.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease mentioned is \"diabetes mellitus, type 2.\" The ICDCodes associated with this disease are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The drugs mentioned in this sample are 'placebo' and 'bi 187004'. The eligibility criteria for this trial include specific requirements related to gender, age, BMI, previous treatments, laboratory values, medical history, medication usage, surgery or trauma history, and other medical conditions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of type 2 diabetes mellitus. The trial includes a list of diseases, which in this case is only type 2 diabetes mellitus. The icd-10 codes associated with the disease are also provided. The trial involves testing different drugs, including low metformin, metformin, mid metformin, and high metformin. The eligibility criteria for participants are listed, including age requirements, gender restrictions, pregnancy test results, and the need for birth control. Participants must have type 2 diabetes that is not adequately controlled by diet and exercise alone or with a single, first-line treatment. They must also meet certain health criteria, such as fasting plasma glucose levels, HbA1c levels, and BMI. The sample also includes exclusion criteria, such as renal dysfunction, use of certain medications, history of cardiovascular or cerebrovascular disease, gastrointestinal disorders, and various other medical conditions. Additionally, there are restrictions on recent weight loss or gain, history of alcohol or substance abuse, participation in other clinical trials, and allergies to specific medications. The sample concludes with a restriction on employment or affiliation with NuSirt Biopharma.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of schizophrenia. The trial is specifically targeting patients with a primary diagnosis of schizophrenia who are currently experiencing an acute exacerbation with prominent \"active phase\" symptoms. The trial requires participants to have a well-documented diagnosis of schizophrenia for at least 1 year before the screening visit, with no more than 2 hospitalizations per year since the diagnosis.\n\nThe inclusion criteria also state that participants should have had a maximum of 3 acute psychotic episodes requiring hospitalization or change of antipsychotic medication in the year before the trial. They should have shown adequate clinical response to previous treatment courses during acute episodes, which involves receiving antipsychotic treatment with usual doses for at least 4 weeks.\n\nFor the current acute episode, participants must have a PANSS total score between 70 and 120, as well as a rating of at least 4 (moderate) on at least 2 of the 4 PANSS positive symptoms. The CGI-S score should be 4 or higher (moderate or severe). Participants should have initiated antipsychotic treatment for the current episode and/or be on ongoing chronic antipsychotic treatment, with a maximum of 2 antipsychotics needing to be changed due to inefficacy or safety reasons. They should have been hospitalized and/or receiving treatment for the current psychotic episode for less than 2 weeks prior to the trial. Additionally, there should be no significant improvement in PANSS total score between enrollment and inclusion visits.\n\nThe exclusion criteria include patients in their first acute episode of psychosis, those with current schizophrenic episodes with predominant negative symptoms, and patients known to be refractory to treatment despite adequate courses with at least 3 different antipsychotics. Other exclusion criteria include various psychiatric disorders, cognitive disorders, personality disorders, history of certain symptoms or conditions, and ongoing or previous treatments that may interfere with the trial.\n\nIt is important to note that this description is based on the provided sample and may not encompass all the details and requirements of the complete table.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is \"depressive disorder, treatment-resistant.\" The corresponding ICD-10 codes for this disease are ['F25.1', 'F32.89', 'F33.8', 'F33.0', 'F33.1', 'F33.9', 'F32.0']. The drugs being tested in this trial are 'avp-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)' and 'placebo'. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The patient must have a clinical diagnosis of a major depressive episode that has lasted for a maximum of 24 months.\n- The patient's HAM-D17 score (a depression severity rating scale) must be equal to or greater than 20.\n- The patient should not have experienced a significant (25% or greater) change in QIDS-SR16 score (another depression rating scale) between the screening and baseline visits.\n- The patient must have had an inadequate response (less than 50% symptom reduction) to at least one but no more than three adequate antidepressant trials during the current depressive episode.\n- The patient must be receiving ongoing treatment with an adequate dose of antidepressants.\n- The patient's Body Mass Index (BMI) must be between 18 and 35 kg/m\u00b2.\n\nExclusion Criteria:\n- The patient must not have a history of myasthenia gravis (a neuromuscular disease).\n- The patient must not have any cardiovascular concerns such as complete heart block, prolonged QT interval corrected for heart rate (QTc), or torsades de points. Additionally, the patient must not have any family history of congenital QT interval prolongation syndrome.\n- The patient must not have any known hypersensitivity or intolerance to DM (dextromethorphan), Q (quinidine), opiate drugs, or any other ingredient in the study medication.\n- The patient must not pose a current suicide risk, as determined by the investigator or based on specific criteria related to suicide attempts or suicidal thoughts.\n- The patient must not have any other current DSM-IV-TR Axis I disorders, except for generalized anxiety disorder (GAD), social anxiety disorder, dysthymic disorder, or specific phobia. However, patients with co-morbid GAD, social anxiety disorder, or specific phobia are ineligible if the co-morbid condition is clinically unstable or has been the primary focus of treatment within the 6-month period prior to screening.\n- The patient must not have a diagnosis of delirium, dementia, amnestic disorder, other cognitive disorder, schizophrenia, bipolar I or II disorder, or any clinically significant Axis II (DSM-IV-TR) personality disorder.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied in this trial include breast cancer, cervical cancer, renal cancer, melanoma, and bladder cancer. The ICDCodes associated with these diseases are also provided. The drugs being used in the trial are aldesleukin, fludarabine, and cyclophosphamide.\n\nThe eligibility criteria for participants in this trial are listed in a numbered format. These criteria include having metastatic or locally advanced refractory/recurrent cancer that expresses MAGE-A3, having previously received prior first-line standard therapy, being HLA-A A serotype positive, being between the ages of 18 and 70, having a good understanding of the trial and willingness to sign the informed consent document, having a clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1, and practicing birth control during the trial and for up to four months after treatment.\n\nOther eligibility criteria include being seronegative for HIV antibody, hepatitis B antigen, and hepatitis C antibody (if positive for hepatitis C antibody, being tested negative for HCV RNA), having a negative pregnancy test for women of child-bearing potential, meeting certain hematology and chemistry requirements, having a certain time elapsed since prior systemic therapy, and being co-enrolled in another protocol.\n\nThere are also exclusion criteria listed, which include being pregnant or breastfeeding, having active systemic infections or major medical illnesses, having primary immunodeficiency, concurrent opportunistic infections or systemic steroid therapy, a history of severe immediate hypersensitivity reaction to any of the agents used in the study, a history of cardiac events or a documented low left ventricular ejection fraction, having central nervous system metastases or symptomatic CNS involvement, presenting with lesions that may harbor an occult infectious source, having a documented forced expiratory volume 1 (FEV1) less than or equal to 60% predicted, and receiving any other investigational agents.",
    "The sample from the table represents a clinical trial for lung cancer patients in phase 1/phase 2. The trial is specifically targeting patients with advanced (non-operable or metastatic) biopsy-proven stage IV or recurrent lung cancer. The patients must have a documented somatic activating mutation in EGFR, such as Exon 19 deletion or L858R. They should also have experienced radiographic progression during treatment with erlotinib, and prior chemotherapy regimens are allowed.\n\nThe inclusion criteria also state that patients must have received erlotinib or other EGFR TK treatment for at least 2 weeks prior to enrollment. They should have a measurable indicator lesion that has not been previously irradiated. Additionally, patients must have undergone a biopsy after developing acquired resistance to erlotinib, with adequate tissue to determine EGFR T790M and tumor histology.\n\nOther eligibility criteria include a Karnofsky Performance Status (KPS) of at least 70%, age over 18 years old, and adequate organ function. Organ function is determined by criteria such as AST, ALT, and Alk phos levels being within 3.0 times the upper limit of normal, total bilirubin being within 2.0 times the upper limit of normal, and creatinine levels being below 2.0 times the upper limit of normal or a creatinine clearance of at least 60ml/min. The patient's ANC should be at least 1,000 cells/mm\u00b3, platelet count should be at least 100,000/mm\u00b3, and hemoglobin should be at least 9.0g/dL.\n\nOn the other hand, there are exclusion criteria that would disqualify patients from participating in the trial. These include concurrent therapy with a potent CYP3A4 inducer or inhibitor, symptomatic brain metastasis requiring escalating doses of steroids, any systemic therapy (except erlotinib or other EGFR TKI) within 3 weeks of starting treatment, any radiation within 2 weeks prior to starting treatment, grade 2 or greater diarrhea despite maximal medical management, inadequate recovery from prior treatment toxicities, pregnancy or lactation, prior treatment with JAK inhibitor, previous or current malignancies at other sites within the last 2 years (with some exceptions), clinically significant cardiac disease, chronic or current active infections requiring systemic antibiotics, antifungals, or antiviral therapy, and known human immunodeficiency virus infection or hepatitis B or C virus viremia.\n\nIn summary, the sample represents a clinical trial for lung cancer patients in phase 1/phase 2, targeting those with specific genetic mutations and treatment history. The trial has specific inclusion and exclusion criteria to ensure the safety and eligibility of participants.",
    "The sample is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the ICD-10 codes associated with the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this particular sample, the phase of the trial is phase 2. The disease being studied is \"HIV-1 infection\" and its associated ICD-10 codes are \"B20\", \"Z71.7\", \"O98.72\", \"Z21\", \"O98.73\", \"R75\", and \"Z11.4\". The drugs being tested are \"aspirin\" and \"placebo\". The eligibility criteria for the trial include being currently on continuous antiretroviral therapy (ART) for at least 48 weeks prior to study entry, having no change in ART regimen within the 12 weeks prior to study entry, and having a screening HIV-1 RNA test result of less than 50 copies/mL. There are also several other laboratory values and conditions that need to be met for eligibility.\n\nThe sample also includes exclusion criteria, such as having a current malignancy (except non-melanoma cancer of the skin), current use or indication for use of non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin that cannot be interrupted for clinical reasons, and current diagnosis of diabetes with HbA1c level of 8% or higher within 24 weeks prior to screening. There are several other exclusion criteria listed, including various medical conditions, medication use, and history of certain diseases or disorders.",
    "The sample from the table represents a phase 2 clinical trial for heart failure. The diseases included in the trial are heart failure, decompensated heart failure, and acute heart failure. The corresponding ICD-10 codes for these diseases are provided. The drugs being studied are cxl-1427 and placebo. The eligibility criteria for participants are listed, including age requirements, left ventricular ejection fraction, hospitalization reasons, pulmonary artery catheter placement, cardiac index, blood pressure, stability, body weight, vein access, understanding of the trial, and willingness to participate. The exclusion criteria are also listed, which include specific medical conditions, medications, history of cardiac events, electrolyte abnormalities, liver or kidney function, pregnancy, previous use of investigational drugs, and other relevant factors.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is cystic fibrosis. The ICD-10 codes associated with the disease are E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, and P09.4. The drug being tested is alginate oligosaccharide. The eligibility criteria for participants are listed, including requirements such as a confirmed diagnosis of cystic fibrosis, age 18 or older, positive microbiological finding of Pseudomonas aeruginosa, FEV1 between 40%-100%, and no significant pulmonary illness other than cystic fibrosis. There are also exclusion criteria listed, such as recent changes in therapy, pulmonary exacerbation, lactose intolerance/milk allergy, and history of organ transplantation. The sample also includes additional criteria specific to certain sites involved in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is chronic lymphocytic leukemia. The ICDCodes associated with this disease are C91.11, C91.12, and C91.10. The drugs being used in the trial are ipi-145, fludarabine, cyclophosphamide, and rituximab. The eligibility criteria for participants in this trial include having a confirmed diagnosis of CLL, no prior therapy for CLL, being between the ages of 18 and 65 with an ECOG performance status of \u22641. There are also exclusion criteria listed, such as not receiving any other study agents, having known CNS involvement, and having uncontrolled intercurrent illnesses. Other exclusion criteria include being pregnant, having a history of a different malignancy (with some exceptions), being HIV-positive, having inadequate hepatic or renal function, having a baseline QTcF >480 ms, and having a history of active tuberculosis or venous thromboembolic events. Additional exclusion criteria include a history of alcohol abuse, chronic hepatitis, or other chronic liver disease, taking certain foods or medications that may interact with the study treatment, and being unable to receive prophylactic treatment for pneumocystis.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is multiple myeloma. The ICD-10 codes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are elotuzumab, lenalidomide, and dexamethasone. The eligibility criteria for participants include having an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower, having documented evidence of active multiple myeloma (either newly diagnosed and not a candidate for transplant, or relapsed/refractory with up to 3 prior lines of therapy), and meeting specific criteria for prior lenalidomide exposure. There are also exclusion criteria, such as certain target disease exceptions and the presence of primary amyloidosis or POEMS syndrome.",
    "The sample is a phase 2 trial for a drug called \"isis-apo(a)rx\" and a placebo. The trial is focused on the disease \"elevated lipoprotein(a)\". The eligibility criteria for participants include being aged 18-65, having a body mass index (BMI) \u226440 kg/m2, and having specific lipoprotein(a) levels at the time of screening. There are also exclusion criteria, such as having certain medical conditions, infections, or a history of drug or alcohol abuse. Participants must not have received certain medications or undergone specific procedures within a certain timeframe. The sample also includes additional criteria and conditions that would make a participant unsuitable for inclusion or could interfere with their participation in the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of diffuse cutaneous systemic sclerosis, a specific disease. The trial uses the drugs abatacept and placebo. The eligibility criteria for participants are listed, including requirements such as a diagnosis of systemic sclerosis, specific disease duration, and certain medical conditions or treatments that would exclude someone from participating. The sample also includes exclusion criteria, which outline additional factors that would disqualify someone from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is small cell lung carcinoma. The corresponding ICD-10 codes for this disease are 'D02.20', 'D02.21', and 'D02.22'. The drugs being tested in this trial are roniciclib (bay1000394) and a placebo. The eligibility criteria for this trial include being male or female aged 18 years or older, having histologically or cytologically confirmed extensive-stage disease small cell lung cancer, having at least one measurable solid tumor lesion, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The exclusion criteria state that prior systemic anticancer therapy for SCLC, including previous therapy with a cyclin-dependent kinase (CDK) inhibitor, is not allowed.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on two diseases: schizophrenia and alcohol use disorder. The corresponding ICD-10 codes for these diseases are provided. The trial involves two drugs: samidorphan + olanzapine (alks 3831) and a placebo + olanzapine. The eligibility criteria for participants are listed, including having a BMI between 18.0 and 40.0 kg/m2, a diagnosis of schizophrenia, a diagnosis of alcohol use disorder, and experiencing an acute exacerbation of schizophrenia within the past 6 months. There are also exclusion criteria, such as being pregnant or breastfeeding, having a known intolerance or allergy to olanzapine, having pending legal charges with potential incarceration, and testing positive for opiates. Additional criteria may also apply.",
    "The sample is a phase 2 trial for the treatment of breast neoplasms. The trial is specifically targeting triple-negative adenocarcinoma of the breast that is inoperable locally advanced or metastatic and not amenable to resection with curative intent. The eligibility criteria include having a histologically documented triple-negative adenocarcinoma, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, availability of a tumor specimen, measurable disease according to RECIST v1.1, adequate hematologic and organ function, and agreement to use contraception for female participants of childbearing potential. The exclusion criteria include previous therapy for inoperable locally advanced or metastatic triple-negative adenocarcinoma, recent radiation treatment to metastatic sites, presence of HER2 positive, ER positive, or PR positive breast cancer, previous therapy with Akt, PI3K, and/or mTOR inhibitors, recent major surgical procedures or significant traumatic injuries, and known presence of brain or spinal cord metastasis.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease cholangiocarcinoma. The ICD-10 codes associated with this disease are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']. The trial involves the drugs regorafenib/active and regorafenib/placebo. The eligibility criteria for participants include having histologically proven intra-hepatic or hilum cholangiocarcinoma, documented progression after specific chemotherapy treatments, being over 18 years old, having a certain performance status, having measurable disease, and meeting certain laboratory requirements. There are also exclusion criteria, such as inability to take oral medication, certain medical conditions, and previous exposure to certain therapies.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"migraine headache\". The associated ICD-10 codes for this disease are ['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']. The trial involves two drugs, \"galcanezumab\" and \"placebo\". The eligibility criteria for participants are listed, including requirements such as having a history of migraine for at least 1 year, migraine onset before the age of 50, and exclusion criteria such as not currently being enrolled in another clinical trial or having a history of certain migraine subtypes. Additionally, participants must not have a medical illness that would prevent their participation, must have failed to respond to at least two other migraine prevention treatments, and must not have significant active psychiatric disease. Lastly, pregnant or nursing women are excluded from the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on patients with chronic obstructive pulmonary disease (COPD) with evidence of an asthmatic component. The trial aims to evaluate the efficacy of certain drugs in treating this condition.\n\nThe inclusion criteria for the trial include being 18 years of age or older, having COPD with evidence of an asthmatic component as demonstrated by spirometry, reversibility, and current therapy. The spirometry measurements should show a post-bronchodilator morning (AM) FEV1 between 50% and 80% of the predicted normal value at Visit 1. The pre- and post-bronchodilator FEV1/FVC ratio should be less than 0.7. The patient should also demonstrate reversibility with at least a 12% and 200 mL increase in FEV1 following albuterol at Visit 1. Additionally, the patient should have been on regular controller therapy for at least 12 weeks prior to Visit 1.\n\nThe exclusion criteria include a history of life-threatening respiratory events within the last 5 years, unresolved respiratory infection, recent severe COPD or asthma exacerbation, risk factors for pneumonia, hospitalization for pneumonia within 3 months, concurrent respiratory disease other than COPD or asthma, uncontrolled conditions or diseases that may put the subject's safety at risk or confound the interpretation of efficacy results, viral hepatitis or HIV, current or chronic history of liver disease or hepatic/biliary abnormalities, drug or milk protein allergy, administration of medications that significantly affect COPD or asthma or interact with the study drug, lung volume reduction surgery within 12 months prior to screening, requirement for long-term oxygen therapy or nebulized therapy, participation in the acute phase of a pulmonary rehabilitation program within 4 weeks, unstable or life-threatening cardiac disease, abnormal and clinically significant 12-Lead Electrocardiogram (ECG) findings, and diseases that prevent the use of anticholinergics.\n\nThis sample provides specific details about the phase, diseases, ICDCodes, drugs, and eligibility criteria for the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2, and the disease being studied is colorectal cancer. The icd-10 codes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are irinotecan hydrochloride and vemurafenib. The eligibility criteria for this sample include specific requirements for patient selection, such as documented BRAFV600E mutant status, prior chemotherapy treatment, absence of certain prior treatments, completion of previous therapies, and various medical parameters within acceptable ranges. The sample also includes information about specimen submission criteria and regulatory criteria for patient consent. Additionally, it mentions the possibility of crossover registration in case of disease progression while on the trial.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of schizophrenia. The trial is looking at the effectiveness of the drug sodium nitroprusside. The eligibility criteria for participants include being between the ages of 18-65, having a primary diagnosis of schizophrenia, providing written informed consent, and meeting certain symptom severity criteria. Participants must also have been on antipsychotic treatment for at least 8 weeks with a stable dose for at least 4 weeks. Exclusion criteria include having certain medical conditions, taking specific medications, being pregnant or breastfeeding, having a recent history of substance use disorder, and being at risk of suicide or self-harm. The sample also includes additional criteria and reasons for exclusion as determined by the investigator.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is human immunodeficiency virus (HIV). The ICD-10 codes associated with the disease are B20, Z71.7, O98.72, Z21, O98.73, R75, and Z11.4. The drugs being tested are rilpivirine and placebo. The eligibility criteria for participants include being female, aged 18-45, willing to provide informed consent, having no evidence of an active sexually transmitted infection (STI), using an acceptable form of contraception, and having normal laboratory values. There are also additional inclusion criteria for a subset of participants at US sites who will undergo more intensive sampling of vaginal tissue. Exclusion criteria include experiencing early menopause, recent use of pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) for HIV, pregnancy or recent childbirth, breastfeeding, intent to become pregnant during the study, uncontrolled depression or suicidal ideation, history of certain allergies or diseases, abnormal laboratory values, recreational injection drug use, participation in other research studies involving study drugs or vaccines, and various other conditions that may interfere with study participation or safety. The exclusion criteria for the tissue subset include unwillingness to abstain from certain medications before a biopsy procedure, presence of certain medical conditions or symptoms, and previous hysterectomy.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 2, and the disease being studied is chronic hepatitis B. The icd-10 codes associated with this disease are B18.0, B18.1, B18.2, B18.8, and B18.9. The drugs being used in the trial are vesatolimod and placebo. The eligibility criteria for participants include having the ability to understand and sign a consent form, having documented evidence of CHB infection, being on approved HBV OAV treatment for at least 1 year, currently taking an approved HBV OAV with no recent change in regimen, and being willing to provide blood samples for assessment. There are also exclusion criteria, such as having extensive bridging fibrosis or cirrhosis, abnormal laboratory parameters, coinfection with other viruses, evidence of hepatocellular carcinoma, recent malignancy, significant cardiovascular, pulmonary, or neurological disease, certain conditions that may worsen with interferon treatment, recent organ or bone marrow transplant, recent therapy with immunomodulators or biologics, use of other investigational agents, current alcohol or substance abuse, and pregnancy or potential pregnancy.",
    "The sample provided is for a clinical trial study. The trial is in phase 1/phase 2 and focuses on the treatment of scleroderma and systemic sclerosis. The diseases are represented by the names \"scleroderma\" and \"systemic sclerosis\" and their corresponding ICD-10 codes are ['L94.1', 'L94.0'] and ['M34.0', 'M34.89', 'M34.9', 'M34.82', 'M34.83', 'M34.81', 'M34.2'] respectively. The drug being tested in the trial is \"divalproex sodium\". \n\nThe eligibility criteria for participants in the trial are as follows:\n- Participants must be 18 years of age or older.\n- Participants must have a diagnosis of scleroderma as defined by the American College of Rheumatology (ACR).\n- Participants must have at least one digital manifestation occurring within the past 6 months, such as digital swelling/edema, digital ulcer, calcinosis cutis, or restricted digital range of motion.\n- Female participants of childbearing potential must use an oral contraceptive pill or equivalent birth control method during the study.\n\nThe exclusion criteria for participants in the trial are as follows:\n- Participants must not be under 18 years old.\n- Participants must not be using high dose steroids (>10 mg/day) or have an unstable steroid dose in the past 4 weeks.\n- Participants must not have started an investigational drug or disease-modifying agent within the past 6 months, including systemic corticosteroids, methotrexate, cyclosporine, azathioprine, cyclophosphamide, bosentan, mycophenolate mofetil, thalidomide, or colchicine.\n- Participants must not be taking a medication with a significant drug-drug interaction with divalproex sodium, such as clomipramine and lamotrigine.\n- Participants must not have another connective tissue disease or condition that could affect rest pain and hand function, such as systemic lupus erythematosus, rheumatoid arthritis, or osteoarthritis.\n- Participants must not have uncontrolled diabetes, chronic kidney disease, or chronic hepatitis.\n- Participants must not have certain laboratory abnormalities at baseline, such as anemia, thrombocytopenia, abnormal INR, low estimated GFR, elevated serum creatinine, hyperbilirubinemia, or elevated AST or ALT.\n- Participants must not be pregnant or breastfeeding.\n- Participants must not have a history of severe depression, suicidal ideation, epilepsy, bipolar disorder, or schizophrenia.",
    "The sample is a phase 2 clinical trial for patients with stage IV lung or breast cancer who have progressive or recurrent brain metastases. The trial is evaluating the effectiveness of the drug cabazitaxel. The eligibility criteria for inclusion in the trial include being an adult patient, having a confirmed diagnosis of stage IV lung or breast cancer with brain metastases, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, having received prior external beam radiotherapy, having at least one measurable lesion on brain MRI, having a life expectancy of at least 3 months, and meeting certain requirements for contraception for females and males. The exclusion criteria include having received prior chemotherapy or targeted therapy for brain metastases, recent chemotherapy or targeted tumor therapy, recent antihormonal tumor treatment, a short time interval since prior external beam radiotherapy, suspected or known leptomeningeal disease, peripheral neuropathy of grade 2 or higher, inadequate organ and bone marrow function, history of hypersensitivity reaction to docetaxel or polysorbate 80 containing drugs, uncontrolled severe illness or medical condition, concurrent or planned treatment with certain medications, recent vaccination against yellow fever, pregnancy or breastfeeding, participation in other clinical trials or treatment with experimental drugs, and previous or concurrent tumors other than the underlying lung or breast cancer.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is Duchenne muscular dystrophy. The ICDCodes associated with this disease are \"G71.01\". The drug being used in the trial is prednisolone. The eligibility criteria for inclusion in the trial include having an appropriate degree of weakness for age, creatine kinase levels greater than 20 times the upper limit of normal, and a known genetic mutation causative for Duchenne muscular dystrophy. Additionally, inclusion criteria also include having an appropriate degree of weakness for age, creatine kinase levels greater than 20 times the upper limit of normal, and either genetic or biopsy confirmation of Duchenne muscular dystrophy in a primary relative (e.g. brother or maternal uncle). De-identified genetic studies will be reviewed by collaborator Kevin Flanigan, MD before enrolling subjects. The age range for entry into the trial is one month through 30 months. The exclusion criteria state that prior treatment with corticosteroids is not allowed.",
    "The sample from the table is for a phase 2 clinical trial focused on Alzheimer's disease. The trial is testing multiple drugs, including \"azd0530 100mg daily,\" \"azd0530 125mg daily,\" and a placebo. The eligibility criteria for participants include having a diagnosis of probable Alzheimer's disease based on NIA-Alzheimer's Association core clinical criteria, evidence of elevated A\u03b2 on an 18F-Florbetapir scan, being between the ages of 55 and 85, having a MMSE score between 18 and 26, and having stable medication doses for at least 4 weeks. Other criteria include having a Geriatric Depression Scale score less than 6, having a study partner available for frequent contact and accompanying visits, having adequate visual and auditory acuity for testing, being in good general health with no interfering diseases, not being pregnant or of childbearing potential, having a Modified Hachinski score less than or equal to 4, having completed at least six grades of education or having a good work history, and being fluent in English or Spanish.\n\nExclusion criteria include having any significant neurologic disease other than Alzheimer's disease, having certain MRI scan findings, having contraindications for MRI studies, having major depression or bipolar disorder within the past year, having a history of schizophrenia or alcohol/substance abuse within the past 2 years, having clinically significant or unstable medical conditions, having a history of certain malignant diseases within the past 5 years, having clinically significant abnormalities in B12 or TFTs, residing in a skilled nursing facility, using any excluded medication, having recent exposure to radiation, having neutropenia or thrombocytopenia, having blood clotting or bleeding disorders for CSF sub-study participants, having clinically significant abnormalities in screening laboratories, having a history of interstitial lung disease, or being deemed ineligible by the principal investigator.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is mantle cell lymphoma. The ICD-10 codes associated with this disease are S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, and S33.131S. The drug being tested in this trial is ibrutinib. The eligibility criteria for participants in this trial include a diagnosis of mantle cell lymphoma, previous treatment for the disease, measurable disease, failure to achieve a partial response with the most recent treatment, and an Eastern Cooperative Oncology Group performance status score of 0 or 1. The exclusion criteria include recent chemotherapy, prior treatment with ibrutinib or other BTK inhibitors, more than 5 previous lines of therapy for mantle cell lymphoma, known central nervous system lymphoma, and pregnancy or plans to become pregnant.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is lymphoma. The ICDCodes associated with the disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drug being tested is brentuximab vedotin. The sample also includes the eligibility criteria for the trial, including age range, performance status, laboratory values, and previous exposure to brentuximab. It also lists the exclusion criteria, such as pregnancy, presence of steroid-refractory acute graft-versus-host disease, and dual refractory CMV reactivation.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of psoriasis. The diseases column specifies that the trial is targeting psoriasis. The icdcodes column provides a list of ICD-10 codes associated with psoriasis. The drugs column lists the different drugs being tested in the trial, including xp23829 at various dosages and a placebo. The criteria column outlines the eligibility criteria for participants in the trial. It includes inclusion criteria such as being 18 years or older, having stable moderate-to-severe plaque-type psoriasis, and meeting specific severity criteria. It also includes exclusion criteria such as having certain types of psoriasis, other skin conditions that may confound the study, recent use of certain medications or treatments, and previous treatment failures with multiple approved systemic agents for psoriasis.",
    "The sample is a phase 2 trial for the treatment of chronic hepatitis B. The trial focuses on the drug \"tenofovir disoproxil fumarate\". The eligibility criteria for participants include having a documented chronic hepatitis B infection, a screening HBV DNA level of at least 2000 IU/mL, and a negative pregnancy test for females. Exclusion criteria include having cirrhosis, inadequate liver function, co-infection with hepatitis C virus (HCV), HIV or hepatitis D virus (HDV), recent antiviral treatment for HBV, hepatocellular carcinoma, significant cardiovascular, pulmonary, or neurological disease, pregnancy or plans to become pregnant during the study, recent solid organ or bone marrow transplant, recent therapy with immunomodulators or biologics, use of investigational agents, current alcohol or substance abuse, recent receipt of immunoglobulin or blood products, history of certain diseases or allergies, known hypersensitivity to study drugs, metabolites or formulation excipients, and malignancy within the past 5 years (except for specific cured cancers).",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"diabetes mellitus, type II.\" The corresponding ICD-10 codes for this disease are ['E23.2', 'N25.1', 'P70.2', 'O24.92', 'Z83.3', 'Z86.32', 'E10.65']. The drugs being studied in this trial are 'placebo' and 'pf-06291874'. \n\nThe eligibility criteria for this trial are as follows:\n- The trial is open to male subjects and non-childbearing potential female subjects between the ages of 18 and 70 years old.\n- The subjects must have a Body Mass Index (BMI) between 18.0 and 45.4 kg/m2 and a total body weight of more than 50 kg.\n- The HbA1c value at the screening visit must meet one of the following criteria:\n  - Currently taking acceptable oral antiglycemic drug therapy within the range of 6.5 to 9.5%.\n  - Not currently taking any oral antiglycemic drug therapy within the range of 7 to 10.5%.\n- Fasting plasma glucose concentrations should be less than 270mg/dL at the screening and run-in visit, confirmed by a single repeat if necessary.\n- Subjects must be willing and able to perform self-tests of blood glucose at least 4 times per day and maintain a diary throughout the study. Therefore, subjects must be literate.\n\nThe exclusion criteria for this trial are as follows:\n- History of Type 1 diabetes mellitus or secondary forms of diabetes.\n- One or more self-reported hypoglycemic episodes of severe intensity within 3 months of screening, or 2 or more self-reported hypoglycemic episodes of severe intensity within the previous 6 months.\n- History of myocardial infraction, unstable angina, arterial revascularization, stroke, New York Heart Association Functional Class II-IV heart failure, or transient ischemic attack within 6 months of screening.\n- History or evidence of diabetic complications with significant end organ damage, such as proliferative retinopathy and/or macular edema, or diabetic neuropathy complicated by neuropathic ulcers.\n- Screening seated systolic blood pressure >160 mm Hg and/or diastolic blood pressure >100 mm Hg after at least a 5-minute seated rest. If the blood pressure exceeds this limit, it may be repeated 2 more times, and the median of the 3 values should be used to determine subject eligibility.\n- Male subjects with partners currently pregnant, or male subjects capable of conceiving children who are unwilling or unable to use a highly effective method of contraception as outlined in the protocol for the duration of the study and for at least 28 days after the last dose of the investigational product.",
    "The sample is a record from a table that contains information about clinical trials. It provides details about a specific trial, including the phase (phase 2), the diseases being studied (metastatic breast cancer and human epidermal growth factor 2 negative carcinoma of breast), the corresponding ICD-10 codes for the diseases, the drugs being used (bevacizumab and eribulin), and the eligibility criteria for participants.\n\nThe eligibility criteria are divided into inclusion and exclusion criteria. Inclusion criteria include requirements such as signed informed consent, being a female patient aged 18 or older, having confirmed human epidermal growth factor receptor 2-negative adenocarcinoma of the breast with documented disease progression, and having received specific treatments in the first-line setting. Other criteria include performance status, time since prior radiation therapy or surgery, presence of measurable disease, and estimated life expectancy.\n\nExclusion criteria include factors such as previous use of anti-angiogenic therapy other than bevacizumab, exclusive use of endocrine treatment in combination with bevacizumab until disease progression, unknown or positive human epidermal growth factor receptor 2/neu status, recent participation in experimental drug studies, active malignancy within the last 5 years, certain laboratory values at baseline, psychiatric or addictive disorders, serious active infection, and contraindications or high risk for treatment-related complications.\n\nThe sample also mentions that there are specific exclusions related to bevacizumab and eribulin, which are detailed in the protocol.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating colorectal neoplasms and metastatic disease. The diseases are identified by their ICD-10 codes. The drug being studied is regorafenib. The eligibility criteria for participants are listed, including requirements such as signing an informed consent form, being at least 18 years old, having a documented adenocarcinoma of the colon or rectum, and having received specific previous treatments. Other criteria include having measurable lesions, a certain performance level, and adequate bone marrow, renal, and hepatic function. The exclusion criteria are also listed, which include factors such as prior treatment with regorafenib, presence of other neoplastic diseases, history of brain metastases, recent major surgery or biopsy, and various medical conditions or complications.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is hepatitis C. The ICD-10 codes associated with the disease are B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, and B15.9. The drugs being used in the trial are dcv/asv/bms-791325, ribavirin, sofosbuvir, and peginterferon \u03b1-2a. The eligibility criteria for the trial are listed, including age requirements, specific genotype of chronic HCV infection, non-cirrhotic condition, and treatment-naive status. There are also exclusion criteria listed, such as different genotypes of HCV, hepatocellular carcinoma, decompensated liver disease, and contraindications to Peg/RBV therapy. The record also includes a website for more information about participating in the clinical trial.",
    "The sample from the table is for a phase 2 trial. The diseases being studied are depression and major depressive disorder. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being tested in the trial are buprenorphine and placebo. The eligibility criteria for the trial include being at least 50 years old, having a diagnosis of major depressive disorder, having a Montgomery-\u00c5sberg Depression Rating Scale (MADRS) score of 15 or higher, having a clinical relationship with a primary care physician, and having an available informant. The exclusion criteria include inability to provide informed consent, having a MADRS score below 15, having dementia, having a diagnosis of bipolar disorder, schizophrenia, or other psychotic disorders, having a history of alcohol or substance abuse, being at high risk for suicide, having contraindications to the study drugs, inability to communicate in English, having significant sensory impairment, having unstable medical illnesses, taking certain psychotropic medications, having a history of opiate abuse or dependence, experiencing severe pain, using certain medications that interact with the study drugs, having hepatic impairment, having a low estimated glomerular filtration rate, refusing to identify an emergency contact, being pregnant, and having contraindications to MRI.",
    "The sample is a phase 2 clinical trial for bladder cancer. The trial is looking for patients with histologically proven bladder cancer, specifically excluding pure small cell carcinoma, pure adenocarcinoma, and pure squamous cell carcinoma histologies. The patients must have stage cT2-T4a N0 M0 disease and documented muscle invasive disease with a tumor measuring at least 10 mm on imaging or the presence of tumor-associated hydronephrosis. Staging scans and tests must have been done within 56 days prior to registration.\n\nThe patients must have a performance status of 0 or 1 and be 18 years of age or older. They must also have tumor tissue from transurethral resection of the bladder tumor available for testing and agree to submit the required slides. Collection of tissue, urine, and whole blood is also required, as well as participation in the translational medicine studies outlined in the protocol.\n\nExclusion criteria include prior systemic cytotoxic chemotherapy or systemic anthracycline, peripheral neuropathy grade 2 or higher, class III/IV heart failure or known left ventricular ejection fraction (LVEF) less than 50%, clinically relevant hearing impairment grade 2 or higher, renal function with calculated creatinine clearance less than 60 mL/min, hepatic function with total bilirubin greater than 1.5 times the institutional upper limit of normal (IULN) or greater than 2.5 times IULN with Gilbert's disease, AST and ALT greater than 2 times IULN, hematologic function with absolute neutrophil count (ANC) less than 1,500/mcL, hemoglobin less than 9 g/dL, and platelets less than 100,000/mcL, hypersensitivity to specific drugs, incidence of or uncontrolled medical illness, pregnancy or nursing, and no other prior malignancy except for specific exceptions.\n\nOverall, the trial aims to study the effectiveness of gemcitabine, cisplatin, methotrexate, vinblastine, doxorubicin, and filgrastim in treating bladder cancer patients who meet the inclusion criteria and do not have any of the exclusion criteria.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is \"diabetic kidney disease.\" The ICDCodes associated with this disease are ['E10.22', 'E11.22', 'E13.22', 'E08.22', 'E09.22']. The drugs mentioned in this sample are 'selonsertib' and 'placebo to match selonsertib'. The eligibility criteria for this trial include being an adult male or female with a prior diagnosis of Diabetic Kidney Disease, having a Type 2 diabetes mellitus diagnosis for at least 6 months, having a specific range of eGFR (MDRD) at screening, and meeting certain urine albumin to creatinine ratio (UACR) requirements based on the stage/stratum. Additionally, participants must be receiving angiotensin-converting-enzyme inhibitor (ACEi) or angiotensin receptor blockers (ARB) at a minimum dose deemed appropriate by the investigator. There are also exclusion criteria, such as having Type 1 diabetes mellitus, having HbA1c > 9.5%, having non-diabetic kidney disease, and being pregnant or lactating.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the trial is in phase 2 and focuses on two diseases: hypercholesterolemia and hypertension. The corresponding ICD-10 codes for these diseases are provided as well. The trial involves two drugs, etc-1002 and placebo. The eligibility criteria for participants are listed, including specific requirements for blood pressure, LDL-C levels, triglycerides, and body mass index. There are also exclusion criteria, such as having secondary hypertension, taking multiple anti-hypertension medications, or having a history of cardiovascular disease or diabetes.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for participants.\n\nIn this particular sample, the phase of the trial is phase 2. The diseases being studied include metastatic ureter carcinoma, metastatic urethral carcinoma, stage III bladder urothelial carcinoma, stage III ureter cancer, stage III urethral cancer, stage IV bladder urothelial carcinoma, stage IV ureter cancer, stage IV urethral cancer, ureter urothelial carcinoma, and urethral urothelial carcinoma. The corresponding ICD-10 codes for these diseases are also provided.\n\nThe drugs being used in the trial are eribulin mesylate and gemcitabine hydrochloride. The eligibility criteria for participants include having locally advanced or metastatic predominantly urothelial carcinoma of the bladder, ureter, or urethra that is not amenable to curative surgical treatment, having histologically confirmed predominantly urothelial carcinoma, and having measurable disease according to specific criteria. There are also additional criteria related to eligibility for treatment with cisplatin, prior systemic therapy, performance status, life expectancy, blood counts, liver function, kidney function, contraception, and ability to provide informed consent.\n\nThe exclusion criteria include having a small cell component in the histology, having received chemotherapy for advanced or unresectable urothelial cancer of the bladder, receiving other investigational agents, having known brain metastases, having a history of allergic reactions to similar compounds, having uncontrolled intercurrent illness, being pregnant or breastfeeding, having HIV with certain conditions, having baseline corrected QT prolongation, having congenital long QT syndrome, and taking other medications known to prolong QT interval.\n\nOverall, this sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 2. The disease being studied is psoriasis, and the corresponding ICD-10 codes for psoriasis are provided. The drugs being used in the trial are \"las41004\" and a control drug. The eligibility criteria for participants are also listed, including requirements for the severity and type of psoriasis, previous treatments, and any allergies or contraindications. Female participants of childbearing potential must agree to use contraception. The sample also mentions exclusion criteria, such as severe forms of psoriasis, recent use of certain medications, and allergies to the active ingredients. Additionally, it states that pregnancy or nursing is a contraindication according to the summary of product characteristics for the active comparator drug.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is metastatic colorectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being used in the trial is folfir + aflibercept. \n\nThe eligibility criteria for this trial include being at least 18 years old, having an overall state as per WHO \u2264 2, having a life expectancy of more than 3 months, having histologically proven metastatic adenocarcinoma of the rectum or colon, being unresectable or inoperable, being eligible for a first-line treatment of 5 FU-Irinotecan (FOLFIRI) and aflibercept, having at least one measurable target lesion according to RECIST criteria v1.1, not having received prior treatment for metastatic disease (except for completed adjuvant chemotherapy at least 12 months before diagnosis), and having satisfactory laboratory panel results.\n\nThe exclusion criteria for this trial include having primary tumor symptoms, brain metastases, Gilbert's syndrome, uncontrolled hypercalcemia, uncontrolled hypertension, any unbalanced active disease in the last 6 months, recent significant surgical intervention, presence of active gastroduodenal ulcer, non-healed wound or bone fracture, receiving antitumor treatments other than those included in the study, history of malignant hemopathy or cancer (except for certain cases), being pregnant or breastfeeding, not meeting contraception requirements, having contraindications to the drugs used in the study, and being unable to meet the medical follow-up requirements for various reasons.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is cholangiocarcinoma. The ICDCodes associated with this disease are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']. The drug being used in the trial is nab-paclitaxel and gemcitabine. The eligibility criteria for this trial include various factors such as the stage of the disease, previous treatments received, age, organ function, performance status, and other medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is Hodgkin disease. The ICD-10 codes associated with the disease are C81.77, C81.97, C81.17, C81.27, C81.37, C81.47, and C81.70. The drugs being used in the trial are nivolumab, doxorubicin, vinblastine, and dacarbazine. The eligibility criteria for participants include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, having received prior high-dose conditioning chemotherapy followed by autologous stem cell transplant (ASCT) as salvage therapy for cHL (cohort A, B & C - enrollment closed), and being newly diagnosed and previously untreated with classical Hodgkin Lymphoma (cohort D). The exclusion criteria include having known central nervous system lymphoma, nodular lymphocyte-predominant Hodgkin Lymphoma, prior allogeneic stem cell transplantation (SCT), chest radiation within 24 weeks prior to the first dose, and receiving carmustine \u2265 600 mg/m\u00b2 as part of the pre-transplant conditioning regimen.",
    "The sample from the table is for a phase 2 clinical trial. The trial is focused on lung cancer, specifically adenocarcinoma and non-small cell lung cancer (NSCLC). The trial is testing the drug crizotinib. The eligibility criteria for the trial include patients with locally advanced or metastatic adenocarcinoma of the lung, positive for ROS1 translocation, ability to swallow pills, age over 18 years, ECOG performance status 0 to 2, life expectancy of at least 12 weeks, measurable disease per RECIST criteria, and specific laboratory requirements for bone marrow, liver, and renal function. The sample also includes exclusion criteria such as previous treatment with specific ALK or ROS1 inhibitors, current participation in another clinical trial, ongoing malignancy that could interfere with efficacy interpretation, pregnancy or breastfeeding, use of certain drugs that interact with CYP3A4 enzymes, active CNS metastases, and various medical conditions that would prevent completion of the study or understanding of the patient information.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is liver cancer. The ICD-10 codes associated with the disease are D13.4, Z85.05, C22.8, C78.7, C22.9, and D37.6. The drug being tested is idarubicin. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- The patient must have a histologically diagnosed hepatocellular carcinoma (HCC) or HCC diagnosed according to the EASL criteria.\n- The patient must have measurable targets according to the mRECIST v1.1 criterion.\n- The patient must have preserved liver function, specifically Child-Pugh A or B7 cirrhosis.\n- The tumor should not have undergone interventive care such as liver transplant, surgical resection, or percutaneous destruction.\n- The patient should have BCLC A/B stage without portal or extra-hepatic invasion.\n- The patient should not have received prior treatment with chemotherapy, radiotherapy, or transarterial embolization (with or without chemotherapy).\n- The patient should be at least 18 years old.\n- The patient should have a WHO performance status of 0 or 1.\n- The patient should meet certain laboratory test criteria, including platelets \u2265 50,000 mm3, neutrophil count \u2265 1,000/mm3, creatinine level \u2264 150 \u00b5mol/L, and prothrombin time (PT) \u2265 50%.\n- The patient should not have heart failure (isotope or ultrasound ventricular ejection fraction > 50%).\n\nThe exclusion criteria for the trial are as follows:\n- The patient should not have advanced tumor with vascular or extra-hepatic invasion, including brain metastasis or diffuse HCC with liver invasion > 50%.\n- The patient should not have a history of other types of cancer, except for cancer known to be in remission for more than 5 years (in which case, HCC histological proof is required), basal-cell carcinoma, or in situ cervix uteri cancer properly treated with curative treatment.\n- The patient should not have advanced liver disease, specifically Child B8, B9, and C, bilirubin level > 3 mg/dL, SGOT and SGPT levels > 5 times the upper limit of normal (ULN) or 250 U/L.\n- The patient should not have received previous treatment with idarubicin and/or doxorubicin.\n- The patient should not have contraindications to idarubicin, such as cardiopathy with myocardial failure, serious kidney or liver failure, or yellow fever vaccine.\n- The patient should not have any concurrent disease or uncontrolled severe clinical condition.\n- The patient should not have uncontrolled severe infection.\n- The patient should not require long-term anticoagulant treatment.\n- The patient should not have thrombosis of the portal vein or a 3-segment region or more.\n- The patient should not have hepatofugal portal venous flow.\n- The patient should not have serious atheromatosis.\n- The patient should not have collateral vascular ways potentially affecting the normal regions during embolization.\n- The patient should not have arthritis of the hepatic artery branches to be treated.\n- The patient should not have arterioportal or arterial subhepatic fistula that cannot be embolized by coils.\n- The patient should not be pregnant or breastfeeding.\n- The patient should have effective contraception if of childbearing age.\n- The patient should be able to be regularly monitored, without any psychological, social, family, or geography-related reasons that would hinder regular monitoring.\n- The patient should not be concurrently participating in another study.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is macular edema. The corresponding ICD-10 codes for macular edema are ['H59.033', 'H34.8130', 'H59.031', 'H59.032', 'H59.039', 'H34.8110', 'H34.8120']. The drugs being tested in this trial are abicipar pegol and ranibizumab. The eligibility criteria for this trial include a diagnosis of diabetes mellitus (Type 1 or 2), decreased vision due to diabetic macular edema in at least one eye, and specific visual acuity requirements for the study eye and fellow eye. The exclusion criteria include recent stroke or heart attack, history of certain eye surgeries, and recent laser photocoagulation of the study eye.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is multiple myeloma, and the corresponding ICDCodes are C90.01, C90.02, and C90.00. The drugs being used in the trial are selinexor, liposomal doxorubicin, and dexamethasone. \n\nThe eligibility criteria for this trial include:\n- Patients must have relapsed and refractory multiple myeloma, having received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor. The disease must be refractory to the most recent therapy.\n- Patients must have previously received or be ineligible for (or refused) autologous stem cell transplant.\n- Patients must have measurable myeloma paraprotein levels in serum or urine, or by free light chain.\n- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, with ECOG 2 allowed if due to bone disease.\n- Patients must have a certain level of left ventricular ejection fraction (LVEF) as indicated by an echocardiogram or multigated acquisition (MUGA) scan.\n- Patients must have adequate hematological, hepatic, and renal function.\n- Female patients of child-bearing potential must agree to use dual methods of contraception, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential.\n- There are also various exclusion criteria, such as pregnancy or lactation, recent radiation or chemotherapy, certain heart conditions, prior cumulative exposure to doxorubicin, uncontrolled infections, HIV seropositivity, active hepatitis A, B, or C infection, and other underlying conditions or medical conditions that could interfere with treatment.\n\nIt is important to note that this is just a sample record, and there may be additional records in the table with different phases, diseases, drugs, and eligibility criteria.",
    "The sample is a phase 2 trial for non-small cell lung cancer. The diseases included in the trial are adenosquamous lung carcinoma, bronchioloalveolar carcinoma, large cell lung carcinoma, lung adenocarcinoma, non-small cell lung carcinoma, recurrent non-small cell lung carcinoma, squamous cell lung carcinoma, stage IIIA non-small cell lung cancer, and stage IIIB non-small cell lung cancer. The trial also includes specific icd-10 codes for each disease. The drugs being tested in the trial are carboplatin, metformin, and paclitaxel. The eligibility criteria for the trial include having a confirmed diagnosis of stage IIIA or IIIB non-small cell lung cancer, having measurable disease, being medically inoperable or unwilling to undergo surgery, and meeting certain diagnostic requirements such as CT scans, MRI, and PET/CT imaging. Other criteria include specific blood counts, renal and hepatic function, and pregnancy status. There are also exclusion criteria such as having mixed small cell and non-small cell histologies, distant metastasis, prior chemotherapy for the study cancer, and certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is gastroparesis, and its corresponding ICDCodes is \"K31.84\". The drugs being tested are \"tc-6499\" and \"placebo\". The eligibility criteria for this trial include having a diagnosis of gastroparesis or symptoms consistent with gastroparesis for at least 6 months, confirmation of gastroparesis using the GEBT, having type 1 or type 2 diabetes with a Hemoglobin A1c \u2264 10%, specific fasting blood glucose levels, a body mass index (BMI) \u2264 40, willingness to stay in the clinical research facility for the required duration, willingness to use birth control, ability to understand study procedures and provide informed consent. The exclusion criteria include a history of abdominal surgery, chronic parenteral feeding or feeding through a tube, persistent daily vomiting, history of eating disorder, recent poor control of diabetes, acute severe gastroenteritis, use of certain medications, allergies or intolerance to specific substances, pregnancy or lactation, presence of clinically significant medical conditions or abnormalities in laboratory findings, physical exam findings, or vital signs, and participation in another investigational drug study within 30 days of screening.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating metastatic renal cell carcinoma, a type of kidney cancer. The trial is looking at the effectiveness of three drugs: crlx101, bevacizumab, and a standard of care treatment chosen by the investigator. The eligibility criteria for participants include having confirmed renal cell carcinoma, having unresectable metastatic disease, and having received 2 or 3 prior lines of conventional molecularly targeted therapy. Other criteria include having a good performance status, being at least 18 years old, having a life expectancy of at least 3 months, and having normal organ and marrow function. Participants must also be willing to sign an informed consent document and be able to comply with the study visit schedule and assessments. There are also exclusion criteria, such as recent treatment with other therapies, major surgery, or topoisomerase I therapy. Patients with certain medical conditions, active malignancies, or brain metastasis are also excluded. Additionally, patients with certain cardiac conditions, uncontrolled hypertension, uncontrolled concurrent illness, history of non-healing wounds or ulcers, pregnancy, inadequate contraception, or known HIV or solid organ transplant are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The diseases being studied are \"dry eye syndromes\" and \"keratoconjunctivitis sicca\". The corresponding ICD-10 codes for these diseases are \"H04.121\", \"H04.122\", \"H04.123\", \"H04.129\" for dry eye syndromes and \"H16.223\", \"H16.221\", \"H16.222\", \"H16.229\" for keratoconjunctivitis sicca. The drugs being tested in this trial are \"kpi-121\" and \"placebo\". The eligibility criteria for this trial include having a documented clinical diagnosis of dry eye disease in both eyes as an inclusion criteria, and exclusion criteria include known hypersensitivity/contraindication to study products or components, history of glaucoma, ongoing ocular infection, severe/serious ocular condition, severe/serious systemic disease or uncontrolled medical condition, exposure to an investigational drug within the past 30 days, and unwillingness or inability to comply with the study protocol or instill eye drops successfully.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease myeloma. The ICD-10 codes associated with the disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are nelfinavir, bortezomib, and dexamethasone. The eligibility criteria for participants include giving written informed consent, being diagnosed with multiple myeloma based on standard criteria, having received at least one previous line of chemotherapy, being exposed to or intolerant to at least one IMID drug, and meeting certain health requirements such as adequate hematological values and hepatic function. There are also exclusion criteria, such as having ongoing uncontrolled systemic infections, a history of chronic active HCV or HBV, or evidence of myeloma within the CNS. The sample also includes additional criteria and restrictions for participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are ovarian cancer and endometrial cancer. The ICDCodes associated with these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2 for ovarian cancer, and N85.00, N85.01, N85.02, N99.85 for endometrial cancer. The drug being used in the trial is a combination of everolimus and letrozole. \n\nThe eligibility criteria for this trial include being post-menopausal or post-oophorectomy, having a performance status of less than or equal to ECOG 2, having relapsed or refractory or persistent epithelial ovarian, fallopian tube, primary peritoneal carcinoma, or endometrial cancer, and having received treatment with a platinum-based chemotherapeutic regimen. Other criteria include having platinum-resistant or platinum-sensitive disease, allowing for additional cytotoxic regimens or biologic/targeted therapy, and meeting certain exclusion criteria such as not currently receiving anticancer therapies or having known intolerance or hypersensitivity to the drugs being used.\n\nOverall, this sample provides specific details about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is chronic obstructive pulmonary disease (COPD). The ICD-10 codes associated with COPD are 'J44.9', 'J44.1', and 'J44.0'. The drugs being tested in the trial are 'chf 5259' and 'placebo'. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- Participants must be male or female adults between the ages of 40 and 80 with a diagnosis of COPD.\n- Participants must be current smokers or ex-smokers.\n- Participants must have a post-bronchodilator FEV1 (forced expiratory volume in 1 second) less than 60% of the predicted normal value and a post-bronchodilator FEV1/FVC (forced vital capacity) ratio less than 0.7.\n- Participants must have a positive response to the reversibility test at screening, defined as a change in FEV1 of at least 5%.\n- Participants must have a BDI (Baseline Dyspnea Index) score of 10 or less.\n- Participants must have been free of exacerbations for at least 1 month.\n\nThe exclusion criteria for the trial are as follows:\n- Pregnant or lactating women.\n- Participants with a diagnosis of asthma.\n- Participants who have been treated for exacerbations in the 4 weeks prior to the screening visit.\n- Participants who are being treated with long-acting antihistamines, unless they have been on a stable regimen for at least 2 months prior to screening and will maintain a constant dosage during the study, or if taken as needed.\n- Participants who require long-term (at least 12 hours daily) oxygen therapy for chronic hypoxemia.\n- Participants with known respiratory disorders other than COPD.\n- Participants who have clinically significant cardiovascular conditions.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"melanoma.\" The associated ICD-10 codes for melanoma are listed as \"C43.0,\" \"C43.31,\" \"D03.9,\" \"C43.51,\" \"C43.9,\" \"D03.0,\" and \"C43.4.\" The trial involves the drugs \"metformin,\" \"melatonin,\" and \"dacarbazine.\" \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Age greater than 18.\n- Obtained informed consent.\n- Morphologically confirmed disseminated Stage IV melanoma.\n- Eastern Collaborative Oncology Group Performance Status Scale of 0-2.\n- Expected survival of more than 3 months.\n\nExclusion Criteria:\n- Evidence of active brain lesions (brain lesions after stereotaxic ray therapy allowed).\n- Evidence of liver and bone marrow clinically meaningful dysfunction.\n- Severe uncontrolled concomitant conditions and diseases.\n- Pregnancy or lactation.\n- Systemic therapy for disseminated melanoma.\n- Second malignancy.\n- Diabetes mellitus requiring drug therapy.\n- Any condition preventing study participation by investigator opinion.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is osteoarthritis of the knee. The corresponding ICD-10 codes for the disease are M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, and M17.30. The drugs being tested in the trial are ly2951742 and celecoxib. The eligibility criteria for participants in the trial include having a confirmed diagnosis of knee osteoarthritis based on American College of Rheumatology criteria, being on a stable dose of certain pain medications for at least 20 days, experiencing a certain level of pain while walking, and not having certain allergies or medical conditions.",
    "The sample from the table represents a clinical trial for the treatment of non-small cell lung cancer (NSCLC) in different phases (phase 1 and phase 2). The trial focuses on patients with specific mutations in the EGFR gene, namely del ex19, L858R, G719X, or L861Q. The eligibility criteria include a confirmed diagnosis of NSCLC, a life expectancy of at least 12 weeks, and previous treatment with EGFR tyrosine-kinase inhibitors (EGFR-TKIs) for phase 1 patients. For phase 2 patients, eligibility criteria include confirmed progressive disease after previous treatment with EGFR-TKIs and the presence of the EGFR-T790M mutation. The sample also mentions the requirement for at least one measurable lesion based on RECIST criteria. The exclusion criteria include previous antitumor treatment-related toxicity, history of interstitial lung disease, recent treatment with reversible EGFR-TKIs, previous treatment with other antitumor therapies or investigational drugs, previous treatment with specific EGFR-TKIs, planned surgical procedures, and symptomatic central nervous system lesions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The specific disease being studied in this sample is \"dry eye.\" The corresponding ICD-10 codes for this disease are \"H04.121,\" \"H04.122,\" \"H04.123,\" \"H04.129,\" \"H35.3111,\" \"H35.3112,\" and \"H35.3121.\" The drugs being tested in this trial are \"dnase\" and \"vehicle.\" The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being 18 years or older, having documented dry eye disease for at least 6 months, specific measurements for Schirmer I and corneal/conjunctival staining, and experiencing annoying or activity-limiting ocular symptoms. Women must meet certain post-menopausal or contraceptive requirements. Exclusion criteria include allergies to specific eye drops, recent use of experimental systemic medication, active ocular infection or allergies, recent eyelid or ocular surgery, certain corneal conditions, recent use of specific eye medications, and a history of drug/alcohol dependence or abuse.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the diseases being studied are HIV infections and hepatitis C. The ICDCodes associated with these diseases are Z21 for HIV infections and a list of codes including B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, and B15.9 for hepatitis C. The drugs being used in the trial are paritaprevir/ritonavir/ombitasvir (ptv/r/obt), dasabuvir (dsv), and ribavirin (rbv). The eligibility criteria for participants in this trial include age between 18 and 70, specific body mass index (BMI) range, HIV-1 infection, certain CD4+ cell count and percentage, being on a stable ART regimen, specific HIV-1 RNA levels, chronic HCV infection, specific HCV treatment history, HCV genotype 1a or 1b infection, specific laboratory values, absence of certain liver conditions, negative pregnancy test for females, agreement to contraception methods, and willingness to provide informed consent. The sample also includes exclusion criteria such as breastfeeding, allergies/sensitivities to study drugs, certain illnesses or medical conditions, active drug or alcohol use, history of certain infections or malignancies, abnormal EKG or QT interval, recent use of certain medications, and other specific medical history.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease mentioned is \"colorectal neoplasms.\" The ICDCodes associated with this disease are \"C05.2,\" \"C10.0,\" \"C16.0,\" \"C16.4,\" \"C17.0,\" \"C17.1,\" and \"C17.2.\" The drug mentioned is \"regorafenib.\" \n\nThe eligibility criteria for this trial include:\n1. Histologically confirmed metastatic adenocarcinoma of the colon or rectum.\n2. Patients who have been previously treated with or are not candidates for fluorouracil, oxaliplatin, irinotecan, and if Kras wild-type, anti EGFR therapy.\n3. Considered an appropriate candidate for regorafenib therapy.\n4. Measurable disease or evaluable disease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n5. Measurable computed tomography (CT) scan evidence of liver metastases which are not treatable by surgical resection or local ablation with curative intent at the time of study entry.\n6. ECOG Performance Status score of 0-1.\n7. Adequate hematologic, renal and liver function.\n8. Male patients with female partners of childbearing potential and female patients of childbearing potential are required to use two forms of acceptable contraception, including one barrier method, during their participation in the study and for 30 days following the last dose.\n9. Life expectancy \u2265 3 months.\n10. Ability to understand the nature of this study and give written informed consent.\n\nThe exclusion criteria for this trial include:\n1. Most recent chemotherapy \u226414 days and \u2265Grade 1 chemotherapy-related side effects, with the exception of alopecia.\n2. Use of a study drug \u226421 days or 5 half-lives (whichever is shorter) prior to initiation of study treatment.\n3. Wide field radiotherapy administered \u226428 days or limited field radiation for palliation \u22647 days prior to starting study drug or has not recovered from side effects of such therapy.\n4. Previous radiation delivered to the upper abdomen.\n5. Major surgical procedures \u226428 days of beginning study drug, or minor surgical procedures \u22647 days.\n6. Previously untreated brain metastases.\n7. Leptomeningeal metastases or spinal cord compression due to disease.\n8. Pregnant or lactating.\n9. Evidence of ascites, cirrhosis, portal hypertension, or thrombosis as determined by clinical or radiologic assessment.\n10. History of abdominal fistula or gastrointestinal perforation \u22646 months prior to beginning study treatment.\n11. Serious non-healing wound, active ulcer, or untreated bone fracture.\n12. Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy.\n13. Any of the specified cardiac diseases currently or within the last 6 months.\n14. Inadequately controlled hypertension.\n15. Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.\n16. Known diagnosis of human immunodeficiency virus, hepatitis B, or hepatitis C.\n17. Presence of other active cancers, or history of treatment for invasive cancer \u22645 years.\n18. Use of strong CYP34A inducers or inhibitors.\n19. The use of certain herbal medications is not allowed during study treatment.\n20. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.\n21. Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and is focused on the disease called tardive dyskinesia. The associated ICD-10 codes for this disease are \"K22.4\" and \"G24.01\". The drugs being studied are \"sd-809\" and \"placebo\". The eligibility criteria for participants are listed, including requirements such as having a history of using a dopamine receptor antagonist for at least 3 months, a clinical diagnosis of tardive dyskinesia with symptoms lasting at least 3 months, and being in good general health. There are also exclusion criteria, such as currently receiving medication for tardive dyskinesia, having other neurological conditions that may interfere with assessing the severity of dyskinesias, and having serious untreated or undertreated psychiatric illness.",
    "The sample provided is a record from a table that contains information about clinical trials. \n\nIn this particular record, the trial is in phase 2 and is focused on the disease \"stroke\". The corresponding ICD-10 codes for this disease are \"G46.4\", \"G46.3\", and \"Z82.3\". The drugs being studied in this trial are \"pioglitazone\" and \"placebo\". \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n1. The patient must have experienced an acute ischemic stroke within 48 hours.\n2. The patient must be at least 20 years old.\n3. The stroke severity must be such that the patient has at least one point for limb weakness on the National Institutes of Health Stroke Scale (NIHSS).\n4. Patients with no known history of diabetes must have an admission serum glucose level of at least 130 mg/dl.\n\nExclusion Criteria:\n1. Patients with a history of urinary bladder cancer or hematuria are not eligible.\n2. Patients with a history of congestive heart failure or myocardial infraction are not eligible.\n3. Patients with a known history of using pioglitazone before the onset of stroke are not eligible.\n4. Patients with a modified Rankin Scale (mRS) score of at least 3 before stroke onset are not eligible.",
    "The sample from the table represents a clinical trial for the treatment of graft versus host disease (GVHD) in patients who are steroid dependent or refractory. The trial is in phase 1/phase 2. The disease being studied is GVHD, and the corresponding ICD-10 codes are D89.810, D89.811, D89.813, and D89.812. The drug being tested is ibrutinib. \n\nThe inclusion criteria for the trial include being steroid dependent or refractory classic chronic GVHD, having received no more than 3 previous treatments for cGVHD, currently receiving baseline systemic glucocorticoid therapy, being at least 18 years old, and having a Karnofsky performance status of at least 60.\n\nThe exclusion criteria include having known or suspected active acute GVHD, currently being treated with sirolimus and either cyclosporine or tacrolimus, having a history of treatment with a tyrosine kinase inhibitor, purine analogs, or other cancer chemotherapy in the 4 weeks prior to starting the study drug, having currently active, clinically significant cardiovascular disease, having uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicines, having a recent infection requiring systemic treatment completed within 14 days before the first dose of the study drug, having progressive underlying malignant disease including post-transplant lymphoproliferative disease, having a history of other malignancy (excluding the underlying malignancy that was the indication for transplant), concomitant use of warfarin or other Vitamin K antagonists, having known bleeding disorders or hemophilia, having a history of stroke or intracranial hemorrhage within 6 months prior to enrollment, having a known history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV), and concurrent use of a strong cytochrome P450(CYP) 3A inhibitor.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of chronic obstructive pulmonary disease (COPD). The trial involves several drugs, including \"bff mdi 320/9.6 \u03bcg,\" \"bff mdi 160/9.6 \u03bcg,\" \"bff mdi 80/9.6 \u03bcg,\" \"bd mdi 320 \u03bcg,\" and \"ff mdi 9.6 \u03bcg.\" The eligibility criteria for participants include providing informed consent, having a clinical diagnosis of COPD, being a current or former smoker with a history of at least 10 pack years of cigarette smoking, and meeting specific severity criteria for COPD. Other criteria include acceptable screening clinical laboratory tests, ECG, and chest x-ray or CT scan. The exclusion criteria include having significant diseases other than COPD, being pregnant or nursing, having asthma as the primary diagnosis, having alpha 1 antitrypsin deficiency as the cause of COPD, and having various other medical conditions that may interfere with participation in the study.",
    "The sample from the table represents a phase 2 clinical trial for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). The trial aims to evaluate the effectiveness of the drugs cisplatin and wee1 inhibitor azd1775 in treating this type of cancer. The eligibility criteria for the trial include having histologically or cytologically confirmed SCCHN that is not amenable to curative surgery or radiation, no prior systemic chemotherapy or wee1 kinase inhibitor therapy for metastatic or recurrent disease, and having measurable disease that can be accurately measured. Other criteria include having completed any previous surgery or radiotherapy at least 4 weeks prior to enrollment, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and meeting certain laboratory values such as leukocyte count, platelet count, and liver function. Patients with certain medical conditions or taking certain medications are excluded from the trial. Women of childbearing potential and men must use two forms of contraception during the study. The sample includes a list of diseases and their corresponding ICD-10 codes, as well as the inclusion and exclusion criteria for the trial.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is colorectal cancer. The ICD-10 codes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being tested in this trial are fruquintinib and placebo. \n\nThe eligibility criteria for participants in this trial include being between the ages of 18 and 75, weighing at least 40 kg, having histological or cytological confirmation of metastatic colorectal cancer, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, having failed 2 or more lines of chemotherapy, having adequate hepatic, renal, heart, and hematologic functions, having at least one measurable lesion larger than 10 mm in diameter, and providing signed and dated informed consent. Participants must also be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.\n\nExclusion criteria for this trial include being pregnant or lactating, having any factors that influence the usage of oral administration, having central nervous system (CNS) metastasis, having non-controlled hypertension, coronary artery disease, arrhythmia, or heart failure, abusing alcohol or drugs, being less than 4 weeks from the last clinical trial, having previous treatment with VEGFR inhibition, having a disability of serious uncontrolled intercurrent infection, having proteinuria \u2265 2+ (1.0g/24hr), having evidence or a history of bleeding tendency within two months of enrollment, having a history of artery/venous thromboembolic events in the past 12 months, such as cerebral vascular accident or transient ischemic attack, having a history of acute myocardial infraction, acute coronary syndrome, or coronary artery bypass graft (CABG) in the past 6 months, having a bone fracture or wounds that have not healed for a long time, having coagulation dysfunction, hemorrhagic tendency, or receiving anticoagulant therapy.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on three diseases: hip fracture, myocardial ischemia, and inflammation. The corresponding ICD-10 codes for these diseases are also provided. The trial involves two drugs, atorvastatin and placebo. The eligibility criteria for participants are listed, including inclusion criteria such as age 65 or older and a life expectancy of more than 3 months, and exclusion criteria such as a history of certain medical conditions or taking specific medications. The sample record provides specific details about the trial's phase, diseases, ICD-10 codes, drugs, and eligibility criteria.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on bladder cancer. The ICD-10 codes associated with the disease are ['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']. The drug being studied is tamoxifen citrate. The eligibility criteria for participants are listed, including age requirements, histologic evidence of urothelial carcinoma of the bladder, and specific tumor size requirements. There are also exclusion criteria, such as certain types of tumors, concurrent use of certain medications, and medical or psychological conditions that could jeopardize the participant's safety. Additionally, there are specific exclusion criteria for women, including pregnancy or lactation, history of endometrial cancer or abnormal uterine bleeding, and previous or concurrent treatment with certain medications.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease mentioned is \"hematological malignancies,\" and the corresponding ICDCodes are ['P61.9', 'P61.8', 'O28.0', 'T45.8X6S', 'T45.96XS', 'T45.8X3S', 'T45.8X4S']. The drugs being used in the trial are 'cyclophosphamide', 'thiotepa', 'fludarabine', 'melphalan', 'mesna', 'mycophenolate mofetil', 'tacrolimus', and 'methylprednisolone'. The eligibility criteria for the trial are listed, including age restrictions, donor availability, HLA-matching requirements, and specific high-risk hematologic malignancies that qualify for the trial. There are also exclusion criteria listed, such as the presence of other active malignancies, pregnancy, breastfeeding, Down Syndrome, and uncontrolled infections. Additionally, there are inclusion criteria for haploidentical donors, including age, HIV status, and pregnancy status.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on prostate cancer. The ICD-10 codes associated with the disease are provided. The trial involves the use of two drugs, radium ra 223 dichloride and enzalutamide. The eligibility criteria for participants are listed, including requirements such as histologically documented adenocarcinoma of the prostate, metastatic disease, castration-resistant prostate cancer, evidence of disease progression, and adequate hematologic, renal, and liver function. The sample also includes exclusion criteria, such as the presence of brain metastases or visceral metastases, prior treatment with certain therapies, and certain medical conditions that could compromise the study's objectives.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is advanced non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being used in the trial is pemetrexed with bevacizumab. The eligibility criteria for this trial include being 20 years or older, having a PS0-2 status, having advanced non-squamous non-small cell lung cancer, and having received more than 4 cycles of pemetrexed therapy before the study. The exclusion criteria include having interstitial pneumonia and abnormal blood test results.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 2 and phase 3. The disease being studied is hepatitis C. The ICDCodes associated with this disease are B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, and B15.9. The drugs being tested in this trial are grazoprevir, elbasvir, placebo to grazoprevir, and placebo to elbasvir. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having documented chronic Japanese HCV genotype 1, being treatment-na\u00efve or having a history of intolerance or non-response to prior anti-HCV interferon-based treatment, and agreeing to use contraception if a female of reproductive potential. Exclusion criteria include having evidence of decompensated liver disease, being coinfected with hepatitis B virus or HIV, having a history of malignancy within the past 5 years (except for certain types of adequately treated cancer), having cirrhosis and evidence of hepatocellular carcinoma, having recent drug or alcohol abuse, being pregnant or breastfeeding, and having certain medical conditions or undergoing specific treatments.\n\nOverall, this sample provides information about the phase, disease, ICDCodes, drugs, and eligibility criteria for a clinical trial focused on hepatitis C.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"endometriosis.\" The ICD-10 codes associated with this disease are \"N80.8,\" \"N80.9,\" \"N80.0,\" \"N80.1,\" \"N80.5,\" \"N80.2,\" and \"N80.3.\" The drugs being studied in this trial are \"placebo,\" \"levonorgestrel,\" \"anastrozole,\" and \"lupron / leuprolide acetate.\" \n\nThe eligibility criteria for participants in this trial include being a premenopausal woman aged 18 or above, having a confirmed diagnosis of endometriosis within the last ten years, experiencing moderate to severe endometriosis-associated pelvic pain (EAPP) in the last 28 days, adhering to study procedures during the screening period, and being willing to use only ibuprofen as rescue pain medication if needed. Participants must also use a non-hormonal barrier method of contraception and not have any conditions that could compromise the function of the body systems or interfere with the study.\n\nExclusion criteria for this trial include pregnancy or lactation, any conditions that could affect the absorption, accumulation, metabolism, or excretion of the study drug, any conditions that could interfere with the study or interpretation of results, any conditions that may worsen under hormonal treatment, undiagnosed abnormal genital bleeding, a wish for pregnancy during the study, regular use of pain medication for other underlying diseases, and non-responsiveness of EAPP to GnRH-a or surgery.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on diabetes, specifically type 2 diabetes. The trial includes participants aged 18 to 70 years who have been diagnosed with type 2 diabetes for at least 3 months. Female participants of childbearing potential and male participants with female partners of childbearing potential must agree to use highly effective contraceptive measures. Participants must also be on a stable dose of metformin for at least 8 weeks prior to the trial and have certain criteria such as specific levels of hemoglobin A1c, fasting plasma glucose, C-peptide, and body mass index. They must also have a stable weight and be willing to maintain their existing diet and exercise habits throughout the study. Participants should be capable of performing self-injections on a daily basis. \n\nExclusion criteria include pregnancy or lactation in females, history of type 1 diabetes or other forms of diabetes, history of acute metabolic complications, clinically significant diabetic complications, severe hypoglycemia, certain gastrointestinal conditions, history of weight loss surgery or procedures, eating disorders, malignancy within the past 5 years, personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, history of pancreatitis or hemochromatosis, significant cardiovascular disease, renal or liver disease, hypersensitivity or intolerance to certain analogues, elevated lipase or amylase levels, positive tests for HIV, hepatitis B, or hepatitis C, recent use of investigational drugs, and any other condition or abnormal laboratory findings that could interfere with the study or pose risks to the participant.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is knee osteoarthritis. The ICDCodes associated with this disease are M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, and M17.30. The drugs being tested in this trial are fasitibant- low dose, fasitibant- intermediate dose, fasitibant- high dose, and a placebo comparator. The eligibility criteria for this trial include age between 40 to 80 years, BMI less than 30 kg/m\u00b2, Kellgren-Lawrence Grade 2 to 3 osteoarthritis, moderate to severe pain, and exclusion criteria such as hypersensitivity/allergy to certain drugs, recent changes in medication, use of corticosteroids or immunosuppressant drugs, and various other medical conditions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as a combination of phase 1 and phase 2. The trial is focused on studying the effects of the drugs \"per977,\" \"placebo,\" and \"enoxaparin\" on a group of individuals with the disease \"healthy.\" The eligibility criteria for participants in the trial are listed, including age requirements, normal laboratory values, no significant abnormalities in electrocardiogram results, specific body mass index range, contraception requirements for males and females, and agreement to comply with the study requirements. The exclusion criteria are also listed, which include a history of certain diseases or conditions, hypersensitivity to specific medications, recent bleeding or surgical procedures, clotting disorders, pregnancy or breastfeeding, recent hormone therapy, recent use of certain medications, positive serologic tests for certain infections, recent blood donation, previous participation in studies involving the drug PER977, recent participation in other investigational studies, and active drug or alcohol dependence or any condition that may interfere with adherence to the study protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is obsessive-compulsive disorder (OCD). The ICDCodes associated with this disease are \"F42.8\", \"F42.9\", and \"F60.5\". The drugs being used in the trial are intranasal ketamine and intranasal midazolam. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Age between 18 and 55\n- Physically healthy and not currently pregnant\n- Primary diagnosis of OCD\n- Sufficient severity of symptoms\n- Stable medication dose for at least 6 weeks prior to enrollment\n- Able to provide consent\n\nExclusion Criteria:\n- First-degree relative with schizophrenia\n- Psychiatric conditions that would make participation unsafe, as determined by the study doctor\n- Female patients who are either pregnant or nursing\n- Planning to start exposure and response prevention (EX/RP) during the study period or have completed an adequate dose of EX/RP within 8 weeks prior to enrollment\n- Nasal obstruction or history of nasal surgery\n- Currently on psychotropic medication or other medication likely to interact with the glutamate system\n- Medical conditions that make participation unsafe\n- Allergy or intolerance to ketamine or midazolam",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of sarcoma, a type of high-grade soft tissue cancer. The trial excludes certain types of sarcoma, such as embryonal rhabdomyosarcoma and gastrointestinal stromal tumors. Patients who have undergone previous surgery with inadequate margins are eligible if they have started thermochemotherapy within 8 weeks after surgery. The trial requires patients to have completed 4 to 8 cycles of thermochemotherapy with specific drugs (doxorubicin and ifosfamide) prior to study entry. Patients must also have no evidence of disease following completion of first-line thermochemotherapy. Other eligibility criteria include a specific performance status, no prior chemotherapy except thermochemotherapy, and adequate organ system function.\n\nThe exclusion criteria include no prior or concurrent second primary malignant tumors, no symptomatic or known central nervous system metastases, and no clinically significant gastrointestinal abnormalities that may increase the risk for bleeding or affect absorption of the investigational product. Other exclusion criteria include specific cardiovascular conditions, poorly controlled hypertension, history of cerebrovascular accident or untreated deep venous thrombosis within the past 6 months, recent major surgery or trauma, evidence of active bleeding or bleeding diathesis, and any serious pre-existing medical, psychiatric, or other condition that could interfere with the subject's safety or compliance to study procedures. The trial also excludes patients who have received certain anti-cancer therapies within specific timeframes.\n\nOverall, the sample provides detailed information about the phase, diseases, icd-10 codes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of essential tremor of the upper limbs. The diseases column specifies the disease being studied, and the icdcodes column provides the corresponding ICD-10 codes for the disease. The drugs column lists the drugs being used in the trial, which in this case are \"incobotulinumtoxina\" and \"placebo\". The criteria column contains the eligibility criteria for participants in the trial, including requirements such as a definite diagnosis of essential tremor, stability of symptoms, and specific tremor ratings. The sample also includes exclusion criteria, such as the presence of other neurological signs, exposure to certain drugs, recent trauma or surgery, and relevant concomitant disorders.",
    "The sample is a phase 2 trial with various diseases and corresponding ICD-10 codes. The trial involves testing different drugs for the treatment of these diseases. The eligibility criteria for participants include age restrictions, specific disease conditions, planned conditioning regimen, and the requirement of a related or unrelated peripheral blood stem cell donor. Other criteria include cardiac, renal, and pulmonary function, as well as liver function. Female participants must practice contraception, and male participants must agree to certain measures to prevent pregnancy. Exclusion criteria include prior transplant, low performance score, active central nervous system involvement, uncontrolled infections, and certain medical conditions. The sample also mentions restrictions on the use of specific medications and the exclusion of certain types of leukemia.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease gastroparesis. The associated ICD-10 code for gastroparesis is \"K31.84\". The drugs being studied in this trial are placebo and camicinal. The eligibility criteria for participants in this trial include having type 1 or type 2 diabetes with an HbA1c level of 11.0% or lower, being between 18 and 80 years old, and having gastroparesis as determined by specific criteria related to gastric emptying and symptoms. Other criteria include having a certain severity of symptoms, meeting certain requirements for female participants regarding pregnancy prevention, having a specific body mass index range, and meeting certain criteria related to heart function and liver enzymes. The exclusion criteria include having acute severe gastroenteritis, having a gastric pacemaker, being on chronic enteral or parenteral feeding, having a recent history of poor diabetes control, having severe cardiovascular autonomic neuropathy, having a history of eating disorders, using medications that affect gastrointestinal motility or appetite, having received intrapyloric botox injections within the past 6 months, having had certain gastric surgeries or obstructions, having unstable medication dosages, having a low glomerular filtration rate, using opiates daily, using prohibited medications, having significant gastrointestinal, hepatic, or renal disease, being enrolled in another study involving experimental drugs, having a sensitivity or allergy to the study medications, being pregnant or lactating, or having a positive result for Hepatitis B or Hepatitis C.",
    "The sample is a phase 2 clinical trial for the treatment of atopic dermatitis. The trial is testing the effectiveness of the drug dupilumab compared to a placebo. The eligibility criteria for participants include being adults between the ages of 18 and 64 with chronic atopic dermatitis for at least 3 years. Participants must also have had an inadequate response to topical medication or have reasons why topical therapies are not advisable. They must have a certain severity of atopic dermatitis based on the Eczema Area and Severity Index (EASI) score and the Investigator's Global Assessment (IGA) score. Additionally, participants must have at least 10% of their body surface area affected by atopic dermatitis. There are also exclusion criteria, such as prior treatment with dupilumab, the need for high-dose systemic corticosteroids, a history of Guillain-Barre syndrome, severe allergic reactions to vaccines or vaccine components, severe reactions to natural rubber latex products, recent treatment with biologics, and current infections requiring treatment. It is important to note that the information provided is not exhaustive and there may be additional criteria not listed.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is atopic dermatitis, which is a skin condition. The ICD-10 codes associated with this disease are 'L20.89' and 'L20.9'. The drugs being tested in this trial are called ds107g and placebo. The eligibility criteria for participants include being 18 years or older and having moderate to severe atopic dermatitis. Some exclusion criteria include having significant impairment of renal or hepatic function, a history of hypersensitivity to the drugs being tested, recent treatment with any experimental drug, and excessive sun exposure or use of UV light sources.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is prostate cancer. The ICD-10 codes associated with this disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs being used in the trial are leuprolide acetate fluidcrystal\u00ae injection depot and leuprolide acetate. The eligibility criteria for participants in the trial are listed under both inclusion and exclusion criteria. Inclusion criteria include being a man between the ages of 40 and 85, having histological or cytological proven adenocarcinoma of the prostate requiring hormone therapy, having a life expectancy of over 12 months, having a WHO/ECOG performance status of 0, 1, or 2, and having adequate and stable renal and hepatic function. Exclusion criteria include having evidence of brain metastasis, spinal cord compression, or urinary tract obstruction, having serum testosterone levels below 150 ng/dL at the screening visit, having received medical or radiological prostate cancer treatments within 2 months prior to the screening visit, having undergone surgical treatment of prostate cancer within 2 weeks prior to the screening visit, having undergone prior orchiectomy, hypophysectomy, or adrenalectomy, and having prior use of LHRH agonists within 12 months prior to the screening visit and during the study.",
    "The sample is a phase 2 clinical trial for HIV-1 infection. The trial is testing the effectiveness of the drugs raltegravir and etravirine. The eligibility criteria for participants include being at least 45 years old, having documented HIV-1 infection, being naive to integrase inhibitor and etravirine, and having at least 6 months of stable antiretroviral therapy. Other criteria include having a HIV-RNA plasma viral load of \u2264 50 copies/mL, having a genotype that shows sensitivity to ETR or no genotype available with no virological failure on NNRTI, and meeting certain health parameters such as CD4+ lymphocytes count, creatinine level, liver enzyme levels, hemoglobin level, and platelet count. Exclusion criteria include previous exposure to raltegravir or etravirine, presence of certain mutations or infections, history of non-compliance or irregular follow-up, and use of certain medications. Pregnant or breastfeeding women are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the treatment of squamous cell carcinoma. The ICD-10 codes associated with this disease are C44.520, C44.92, C44.02, C44.321, C44.521, C44.82, and C44.42. The drug being tested in this trial is selinexor (kpt-330). The eligibility criteria for this trial include being 18 years of age or older, having confirmed SCC of the head and neck, lung, or esophagus, having received 1 to 2 prior therapies, and having measurable disease with documented progression within the past 6 weeks. The exclusion criteria include patients requiring total parenteral nutrition, those with unstable cardiovascular function, substantially impaired gastrointestinal function, symptomatic brain metastases, and those with another malignancy within 3 years, except for adequately treated in situ carcinoma of any type, basal or non-melanomatous skin cancer.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on breast cancer, specifically HER2 positive breast cancer. The trial includes patients with locally advanced or metastatic breast cancer that cannot be surgically removed. The eligibility criteria include having confirmed HER2-positive breast cancer, having progressed on or being intolerant to pertuzumab and ado-trastuzumab emtansine, and having previously been treated with trastuzumab. The patients must also have an ECOG Performance Status of 0 or 1. The exclusion criteria include previous treatment with certain anthracycline derivatives, presence of central nervous system metastases, certain heart conditions, and a history of cardiac arrhythmias or cardiac toxicity related to trastuzumab. Additionally, patients with a history of decline in left ventricular ejection fraction (LVEF) below 50% during or after prior trastuzumab or other HER2 directed therapy are excluded.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on castration levels of testosterone, hormone-resistant prostate cancer, metastatic prostate carcinoma in the soft tissue, prostate carcinoma metastatic in the bone, PSA progression, and stage IV prostate adenocarcinoma AJCC v7. The associated ICD-10 codes for these diseases are also provided. The only drug mentioned in this sample is selinexor. The eligibility criteria for the trial include various requirements such as confirmed adenocarcinoma of the prostate, castrate levels of testosterone, progressive disease, resistance to certain therapies, presence of bone metastasis, and specific laboratory values within normal limits. There are also exclusion criteria, such as untreated brain metastases, prior chemotherapy for metastatic castration-resistant prostate cancer, active viral hepatitis or chronic liver disease, and certain medical conditions that may interfere with the absorption of the study agents. The sample also includes additional details about the trial protocol, including the need for informed consent, life expectancy, and ability to swallow oral medication.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 2, and the disease mentioned is \"diabetes mellitus, type 1\". The icd-10 codes associated with this disease are \"E10.65\", \"E10.9\", \"E10.21\", \"E10.36\", \"E10.41\", \"E10.42\", and \"E10.44\". The drugs involved in this trial are \"anti-thymocyte globulin (atg)\", \"granulocyte colony stimulating factor (gcsf)\", \"placebo (for atg)\", and \"placebo (for gcsf)\". The eligibility criteria for this trial include age restrictions, a recent diagnosis of T1D, positive islet cell autoantibodies, specific C-peptide levels, negative Epstein-Barr virus status, and compliance with diabetes management. The exclusion criteria include immunodeficiency, active infection, tuberculosis infection, pregnancy or lactation, use of other immunosuppressive agents, HIV or hepatitis infection, complicating medical issues, history of malignancies, liver or renal dysfunction, recent live virus vaccination, recent use of non-insulin pharmaceuticals affecting glycemic control, participation in another T1D treatment study, prior treatment with abatacept or anti-cd3, known allergies to GCSF or ATG, and any condition that may adversely affect study participation or compromise the study results.",
    "The sample from the table is for a phase 2 clinical trial for Huntington's disease. The trial is testing the effectiveness of the drugs laquinimod and placebo. The eligibility criteria for participants include having a positive genetic test or clinical diagnosis of Huntington's disease, having a specific number of CAG repeats in the huntingtin gene, being between 21-55 years old with onset of HD at or after 18 years old, practicing birth control for women of child-bearing potential, having a certain score on the UHDRS-TMS, providing informed consent, being able to take oral medication, being ambulatory and able to travel to the study center, having a caregiver available, and having stable antidepressant medication dosing. The exclusion criteria include recent use of certain medications, previous use of laquinimod, pregnancy or breastfeeding, having certain medical conditions or disorders, having abnormal laboratory results, being unsuitable for MRI, having a history of alcohol or drug abuse, having active suicidal ideation, having certain intracranial conditions, having drug hypersensitivity, having swallowing difficulties, recent use of other investigational products, recent use of tetrabenazine or antipsychotic medication, and other criteria that may apply.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 2. The disease being studied is post-traumatic stress disorder (PTSD), and the corresponding ICD-10 codes for PTSD are \"F43.10\", \"F43.11\", and \"F43.12\". The drugs being tested in this trial are \"pf-04457845\" and \"placebo\". The eligibility criteria for participants include being men and women between the ages of 18 and 60 with a primary psychiatric diagnosis of PTSD. However, individuals with other psychiatric illnesses requiring current treatment with medication are excluded from the trial.",
    "The sample provided is for a phase 2 clinical trial. The diseases being studied in this trial are esophagus cancer, stomach cancer, small bowel cancer, colon cancer, and rectum cancer. The corresponding ICD-10 codes for these diseases are also provided. The drugs being tested in this trial are s-1, capecitabine, and oxaliplatin. \n\nThe eligibility criteria for participants in this trial include giving written informed consent, being at least 18 years old, having advanced or metastatic gastrointestinal tract adenocarcinoma, not having received previous cancer chemotherapy, having measurable or evaluable lesions according to RECIST v1.1 criteria, being able to take medications orally, having an ECOG performance status of 0 or 1, having a life expectancy of at least 3 months, and having adequate organ function.\n\nThe exclusion criteria for this trial include cancer that is considered operable without prior chemotherapy, previous chemotherapy for cancer, previous therapy with fluoropyrimidines or anthracyclines for any indication, inability to swallow tablets, known brain metastasis or leptomeningeal metastasis, history of myocardial infraction, coronary stenting/graft, unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack, pulmonary embolism or deep vein thrombosis, symptomatic congestive heart failure, ongoing cardiac dysrhythmias, any cardiac disease that requires regular medication, hypertensive crisis or severe hypertension that is not controlled, being a pregnant or lactating female, and inability to perform cardiac arterial flow tests.",
    "The sample is a phase 2 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH). The trial is investigating the effectiveness of the drugs cenicriviroc and placebo. The eligibility criteria for participants include being between the ages of 18-75, having histological evidence of NASH with a Nonalcoholic fatty liver disease Activity Score (NAS) of at least 4, having evidence of liver fibrosis, and meeting certain criteria related to type 2 diabetes, body mass index, metabolic syndrome, and liver fibrosis. Participants must also agree to undergo liver biopsies at various points during the study. Exclusion criteria include having certain viral infections, prior liver transplantation, other causes of chronic liver disease, history of cirrhosis or hepatic decompensation, excessive alcohol consumption, HIV infection, recent weight reduction surgery, pregnancy or breastfeeding, and any other disorders or prior therapies that would make the participant unsuitable for the study.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 2. The disease being studied is anxiety disorders (or anxiety and phobic neuroses). The corresponding ICD-10 codes for these diseases are F20.81, F21, F34.0, F34.1, F42.3, F45.0, and F51.5. The drugs being tested in the trial are cerc-501 and placebo. The eligibility criteria for participants include being between the ages of 21 and 65, meeting specific diagnostic criteria for certain mental disorders, having a Snaith-Hamilton Pleasure Scale (SHAPS) score of at least 20, being reliable and willing to participate for the duration of the study, giving written informed consent, being able to understand and follow instructions, and meeting certain requirements for contraception. There are also exclusion criteria, such as a history of certain medical conditions, substance abuse or dependence, unstable mental health conditions, and use of certain medications. Other exclusion criteria include contraindications to magnetic resonance imaging procedures, positive urine drug screen, recent use of investigational medication, known hypersensitivity to the study drug, and various other conditions that may prevent participation in the study. Smoking, pregnancy, and lactation are also exclusion criteria.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease being studied is asthma. The ICDCodes associated with asthma are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being tested are 'placebo' and 'pf-03715455'. The eligibility criteria for this trial include having a physician-documented history or diagnosis of persistent asthma, a pre-bronchodilator FEV1 within a specific range, being on a stable dose of certain combination therapies, and having a specific score on the Juniper Asthma Control Questionnaire. There are also exclusion criteria, such as having chronic pulmonary diseases or being a current smoker.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is Hepatitis C Virus Infection. The ICDCodes associated with this disease are B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, and B17.2. The drugs being tested in this trial are ldv/sof and placebo. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having chronic HCV infection, being genotype 1, meeting specific laboratory values, and using contraception if applicable. Exclusion criteria include having significant medical disorders, cirrhosis, contraindication to MRI, being pregnant or nursing, and having received certain prior treatments.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of lymphoma. The ICD-10 codes associated with the disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drugs being used in the trial are 'plerixafor gz316455' and 'filgrastim'. The eligibility criteria for participants are listed, including age requirements, specific diagnosis, response to previous treatment, and various exclusion criteria such as other malignancies, hypersensitivity to certain medications, and certain health conditions. The sample also mentions the need for contraception for sexually active participants and the requirement for participants to comply with study procedures and restrictions.",
    "The sample from the table is for a clinical trial that is in phase 1/phase 2. The trial is focused on the disease of obesity, which is identified by the ICD-10 codes ['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99.215', 'O99.210', 'O99.211']. The drugs being tested in the trial are 'pp1420' and 'placebo'. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Participants must be healthy males, as determined by a medical evaluation including history, physical examination, vital signs, laboratory tests, and 12-lead ECG.\n- Participants must be between 18 and 50 years of age.\n- Participants must have a body weight of 70 kg and a body mass index (BMI) within the range of 25 - 35 kg/m2.\n- Participants must be capable of giving written informed consent and willing to comply with the requirements and restrictions listed in the consent form.\n- Participants must be willing and able to comply with the protocol for the duration of the study.\n\nThere are also exclusion criteria for participants in the trial, which include:\n- Participants who are considered unsuitable for the study based on medical evaluation, physical examination, or screening investigations.\n- Participants who test positive for drugs or alcohol in a pre-study screening.\n- Participants who test positive for Hepatitis B surface antigen or Hepatitis C antibody within 3 months of screening.\n- Participants who test positive for HIV antibody.\n- Participants with a history of migraine.\n- Participants with a history or evidence of abnormal eating behavior.\n- Participants with a history of excessive alcohol consumption.\n- Participants with urinary cotinine levels indicative of smoking or a history of regular tobacco or nicotine use.\n- Participants with QTc (a measure of heart rate) greater than 450 msec at screening.\n- Participants with blood pressure or heart rate outside the specified ranges.\n- Participants who have participated in another clinical trial and received an investigational product within a certain time period prior to the current study.\n- Participants who have been exposed to more than four new chemical entities within 12 months prior to the study.\n- Participants who have used prescription or non-prescription drugs, including vitamins, herbal and dietary supplements, within a certain time period prior to the study.\n- Participants with a history of sensitivity or allergy to any of the study medications or their components.\n- Participants who would donate blood in excess of 500 mL within 3 months before or after the study.\n- Participants who are unwilling to abstain from certain substances (caffeine, illicit drugs, alcohol, smoking) during specific time periods related to the study.\n- Participants who are unwilling or unable to use a condom during sexual activity throughout the study.\n- Participants who are vegans or have milk or wheat intolerance or allergy.\n- Participants who are unwilling or unable to follow the procedures outlined in the protocol.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of macular degeneration. The trial includes patients with specific ICD-10 codes related to macular degeneration. The drugs being tested in the trial are regorafenib, ophthalmic oily suspension (bay73-4506), ranibizumab, and a placebo. \n\nThe eligibility criteria for the trial are as follows:\n- Participants must be able to read or have the ability to understand the informed consent form.\n- Both men and women aged 50 or above are eligible.\n- Participants must have active primary subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea.\n- The area of CNV must occupy at least 50% of the total lesion.\n- Evidence of intraretinal and/or subretinal fluid on OCT is required.\n- The study eye must have an Early Treatment Diabetic Retinopathy Study BCVA of 73 to 25 letters (20/40 to 20/320 Snellen equivalent).\n- Participants must be willing and able to attend all clinic visits and complete all study-related procedures.\n- Women of childbearing potential and men must agree to use adequate contraception during the study period.\n\nThe exclusion criteria for the trial are as follows:\n- Participants with concurrent diseases in the study eye, other than AMD, that could compromise visual acuity or require medical or surgical intervention during the study period.\n- Total lesion size in the study eye is greater than 12 disc areas.\n- Participants with only one functional eye, even if that eye is otherwise eligible for the study.\n- Prior ocular or systemic treatment or surgery for neovascular AMD in the study eye, except dietary supplements or vitamins.\n- Prior treatment with any systemic anti-VEGF agent.\n- Use of systemic or ocular treatment with an investigational drug within 12 weeks prior to the start of study treatment.\n- Any other condition that would require frequent chronic co-administration of other topical eye medications that would interfere with study drug administration.\n- Symptoms or conditions consistent with contraindications listed in the current local label for ranibizumab.\n- Participation in an investigational study within 30 days prior to the start of study treatment that involved treatment with any drug or device.\n- Lactating women and women of childbearing potential with either a positive pregnancy test result or no pregnancy test at screening are excluded. Postmenopausal women must be amenorrheic for at least 12 months to not be considered of childbearing potential.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on patients with type 2 diabetes mellitus. The ICD-10 codes associated with the disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in the trial are 10mg ds-8500a tablet, 75mg ds-8500a tablet, and a placebo. \n\nThe inclusion criteria for the trial are as follows:\n- Patients must be aged 20 years or older at the time of informed consent.\n- Patients must be Japanese and have type 2 diabetes.\n- Patients must have HbA1c levels between 7.0% and 10.0% if untreated with antidiabetic agents, or between 6.5% and 9.5% if treated with antidiabetic agents.\n\nThe exclusion criteria for the trial are as follows:\n- Patients must not be aged 70 years or older at the time of informed consent.\n- Patients must not have a history of type 1 diabetes or diabetic ketoacidosis.\n- Patients must not be receiving or requiring treatment with insulin.\n- Patients must not have a body mass index (BMI) below 18.5 kg/m2 or above 35.0 kg/m2.\n- Patients must not have an estimated glomerular filtration rate (eGFR) below 45 mL/min per 1.73 m2.\n- Patients must not have a fasting plasma glucose level of 240 mg/dL or higher.",
    "The sample is a phase 2 trial for the treatment of hypertension. The trial includes subjects who are 19-70 years old and have a mean clinic-measured sitting diastolic blood pressure (siDBP) of 90-109 mmHg and mean clinic-measured sitting systolic blood pressure (siSBP) of 140-179 mmHg. The subjects must have a difference of \u226410 mmHg in sitting DBP between before and after a washout period of prior antihypertensive medications. Inclusion criteria also include subjects who are willing to participate in the study and provide written informed consent, as well as those who are considered cooperative and able to be followed-up until the end of the study.\n\nExclusion criteria for the trial include subjects with severe hypertension (mean siDBP \u2265110 mmHg or mean siSBP \u2265180 mmHg), orthostatic hypotension with clinically significant signs or symptoms, secondary hypertension, and those who are unable to stop taking other antihypertensive medications throughout the entire study period. Other exclusion criteria include clinically significant abnormal laboratory test results, conditions that may affect the absorption, distribution, metabolism, and excretion of the study drugs, severe insulin-dependent or uncontrolled diabetes mellitus, severe cardiovascular diseases within 6 months of screening, history of percutaneous transluminal coronary angiography or coronary artery bypass graft, chronic debilitating disease, autoimmune disease, connective tissue disease, positive results for hepatitis B, hepatitis C, or HIV antibodies, history or evidence of alcohol or drug abuse within 2 years, known allergic reaction to any angiotensin receptor blockers, chronic inflammation disease requiring chronic anti-inflammation therapy, women of childbearing potential without contraceptive measures or breastfeeding mothers, prior participation in a clinical trial of any investigational products within 12 weeks from screening, serum potassium levels below 3.5 mmol/L or above 5.5 mmol/L at any time during the study period, depletion of sodium ion or body fluid that cannot be easily corrected during the study period, evidence of hereditary diseases, and subjects considered unsuitable to participate in the study under the discretion of the principal investigator.",
    "The sample is a phase 2 trial for the treatment of ischemic stroke. The trial is testing the effectiveness of a drug called placebo. The eligibility criteria for participants include having an acute ischemic stroke, being able to receive IV tPA or mechanical thrombectomy, having a National Institutes of Health Stroke Scale (NIHSS) score of 5 or higher, providing signed informed consent, and meeting certain time requirements for mechanical thrombectomy subjects. There are also exclusion criteria, such as having a history of stroke or head injury within the past 90 days, having certain conditions like Moyamoya disease or cerebral arterio-venous malformation (AVM), having other co-morbidities that may worsen neurological status, having certain baseline CT scan results, and having certain medical conditions like prolonged prothrombin time or severe hypertension.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 2 and focuses on the disease \"relapsing-remitting multiple sclerosis\". The associated ICD-10 codes for this disease are \"G35\", \"G93.81\", \"K74.1\", \"Q85.1\", \"G12.21\", \"G12.23\", and \"M34.0\". The trial involves the drugs \"vatelizumab\" and \"placebo (for vatelizumab)\". The eligibility criteria for this trial include having a diagnosis of relapsing-remitting multiple sclerosis, experiencing at least one documented relapse in the past 12 months, having at least one contrast-enhancing lesion on MRI in the past 12 months or at screening, and having at least three T2 lesions on screening MRI. There are also exclusion criteria, such as having a diagnosis of primary progressive or secondary progressive MS, having an EDSS score greater than 5.5, experiencing a relapse within 30 days prior to enrollment, and having certain medical conditions or treatments that could adversely affect participation in the study. Additionally, pregnancy or breastfeeding is also an exclusion criterion. It is important to note that there may be other inclusion/exclusion criteria defined by the protocol.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is venous thromboembolism. The corresponding ICD-10 codes for this disease are 'O88.22', 'O88.23', 'O88.211', 'O88.212', 'O88.213', and 'O88.219'. The drug being tested in this trial is dabigatran. The eligibility criteria for inclusion in the trial are as follows: the patient must be a neonate or infant aged less than 12 months at Visit 1, have an objective diagnosis of VTE, have completed a planned treatment course with anticoagulant therapy as per standard of care at the investigator site, and have provided written informed consent from their parent(s) or legal guardian. The exclusion criteria include a weight less than 3 kg at Visit 1, conditions associated with an increased risk of bleeding, renal dysfunction, hepatic disease, and anemia or thrombocytopenia at screening.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"progressive solid malignancies,\" \"refractory solid malignancies,\" and \"cancer.\" The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial are \"cyclophosphamide pill\" and \"imiquimod topical cream.\" The eligibility criteria for participants include factors such as providing informed consent, having a confirmed diagnosis of progressive and/or refractory SM, expression of specific TAPAs, presence of measurable or evaluable disease, absence of active infectious processes, and not receiving active immunosuppressive therapy, among others. There are also exclusion criteria listed, such as not having confirmed progressive and/or refractory SM, not having measurable or evaluable disease, receiving cytotoxic therapy or radiation therapy within three weeks of vaccination, and having active autoimmune diseases or active second invasive malignancies, among others.",
    "The sample from the table represents a phase 2 clinical trial for prostate cancer. The trial is focused on patients with metastatic disease and aims to evaluate the effectiveness of the drug combination of radium-223 and enzalutamide. The eligibility criteria for the trial include factors such as age, performance status, confirmed adenocarcinoma of the prostate, documented disease progression, specific PSA levels, medical condition stability, life expectancy, presence of osseous metastases, ability to swallow the study drug, and adequate hematological, hepatic, and renal function. The sample also includes exclusion criteria, such as not receiving any other investigational agents, gastrointestinal tract disease affecting oral medication intake, active hepatic or biliary disease, prior therapy with certain drugs, prior chemotherapy or radiation therapy, history of other systemic malignancies, certain cardiac conditions, history of seizures or brain injuries, certain infections or serious medical/psychiatric illnesses, and prohibited medications.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is Hepatitis C Virus Infection. The ICDCodes associated with this disease are B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, and B17.2. The drugs mentioned in this sample are ldv/sof, vdv, and rbv. The eligibility criteria for this trial include age being 18 years or older, being a treatment-experienced individual with chronic HCV genotype 1 infection, having compensated cirrhosis, meeting specific screening laboratory values, using specific contraceptive methods if applicable, and not being pregnant or nursing. The exclusion criteria include co-infection with HIV or hepatitis B virus, current or prior history of clinical hepatic decompensation, chronic use of systemic immunosuppressive agents, and a history of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is diffuse large B-cell lymphoma. The ICDCodes associated with this disease are 'S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', and 'S33.131S'. The drug being tested in this trial is selinexor. \n\nThe eligibility criteria for this trial are as follows:\n- The patient must be at least 18 years old.\n- The Eastern Cooperative Oncology Group (ECOG) performance status should be 2 or lower.\n- The patient must have pathologically confirmed de novo DLBCL.\n- There should be objective, documented evidence of disease progression at the time of study entry.\n- The patient must have received at least 2 but no more than 5 previous systemic regimens for the treatment of DLBCL.\n- The patient must have measurable disease.\n- If the patient's most recent anti-DLBCL therapy induced a partial response (PR) or complete response (CR), at least 60 days must have passed since the end of that therapy. For all other patients, at least 14 weeks must have elapsed since their most recent systemic anti-DLBCL therapy.\n\nThe exclusion criteria for this trial are as follows:\n- DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma, composite lymphoma (HL+NHL), or DLBCL transformed from diseases other than indolent NHL.\n- The patient must not be eligible for high-dose therapy with autologous stem cell transplantation rescue.\n- Primary mediastinal (thymic) large B-cell lymphoma (PMBL).\n- Known central nervous system (CNS) lymphoma.\n- Active Hepatitis B or C infection.\n- Known human immunodeficiency virus (HIV) infection.\n- The patient must not have difficulty swallowing tablets, malabsorption syndrome, or any other gastrointestinal (GI) disease or GI function that could interfere with the absorption of the study treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"catheter-related bloodstream infection (crbsi) nos,\" \"bloodstream infection due to central venous catheter,\" and \"bloodstream infection due to hickman catheter.\" The corresponding ICDCodes for these diseases are \"T80.211S,\" \"T80.211A,\" and \"T80.211D.\" \n\nThe drugs being used in the trial are \"ethanol,\" \"heparin lock,\" and \"normal saline.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The inclusion criteria include being newly started on Home Parenteral Nutrition with an anticipated duration of more than 3 months, not previously being on Home Parenteral Nutrition, providing consent, having non-medicare insurance or medicare insurance with a supplementary insurance, having single lumen Hickman\u00ae catheters, and no known alcohol addiction. \n\nThe exclusion criteria include failure to provide consent, having medicare insurance without any supplemental private insurance, having a catheter type other than a single lumen Hickman\u00ae, being on Home Parenteral Nutrition for less than three months, being pregnant, having previous proven addiction and dependence to alcohol, lacking capacity to provide consent, and not being managed by the Home Parenteral Nutrition team at the investigator's institution.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on peripheral artery disease (PAD). The associated ICD-10 codes for PAD are listed as ['A18.2', 'H11.043', 'H11.053', 'H18.463', 'H35.40', 'H81.393', 'I73.9']. The drugs being studied are ticagrelor and a comparator drug. The eligibility criteria for participants are listed, including requirements such as written informed consent, being aged 50 or older, having planned revascularization within 5 weeks, and having a diagnosis of PAD confirmed by specific criteria. The exclusion criteria are also listed, which include factors such as previous participation in the study, certain medical conditions, use of specific medications, and pregnancy or lactation for women of childbearing potential.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on asthma. The diseases associated with the trial include asthma, chronic asthma, bronchial asthma, and asthmatic. The ICD-10 codes for these diseases are J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, and J45.40. The drugs involved in the trial are z7200, symbicort\u00ae turbohaler\u00ae, placebo of test product, and placebo of reference drug. The sample also includes the eligibility criteria for the trial, including age, informed consent, diagnosis of asthma, ability to use the DPI (dry powder inhaler), contraception for female patients, adherence to GINA guidelines, non-smoking status, understanding of the protocol, and more. The exclusion criteria are also listed, which include pregnancy or lactation, recent asthma exacerbation or airway infection, inability to perform pulmonary function testing, uncontrolled disease, allergies or intolerance to study drugs, non-compliance with the protocol, recent use of corticosteroids or investigational drugs, history of alcohol or substance abuse, diagnosis of COPD, lactose intolerance or allergy to milk proteins, and use of certain medications or herbal medicines.",
    "The sample is a record from a table that contains information about clinical trials. In this particular record, the phase of the trial is phase 2. The disease being studied is secondary progressive multiple sclerosis. The corresponding ICD-10 codes for this disease are A81.2, G12.22, G60.3, I67.3, M34.0, Q78.3, and G12.25. The drug being tested in this trial is saline. \n\nThe record also includes the eligibility criteria for participants in the trial. The inclusion criteria are as follows:\n1. The participant must have a historical or current cranial MRI scan showing T2-hyperintense lesions consistent with MS.\n2. The participant must have secondary progressive multiple sclerosis as determined by the 2010 Update to the McDonald Criteria.\n3. The participant must have an Expanded Disability Status Scale (EDSS) score of 3.0 to 6.5 at the screening.\n4. The participant's secondary progressive multiple sclerosis must have been clinically active and functionally progressive within the 2 years prior to screening.\n5. The participant must not have experienced an MS relapse for at least two years prior to the baseline.\n6. The participant must have been neurologically stable for at least four weeks prior to screening.\n7. The participant must have specific laboratory values within three days prior to starting the investigational product.\n8. The participant must have provided written informed consent to participate.\n\nThe exclusion criteria are as follows:\n1. The participant must not have primary Progressive MS (PPMS), Relapsing Remitting (RRMS), or progressive relapsing MS as determined by the 2010 update to the McDonald Criteria.\n2. The participant must have completed the discontinuation period for approved and/or investigational multiple sclerosis disease modifying therapies prior to screening.\n3. The participant must not have received any other immunomodulatory drug therapy or immunosuppressive therapy within four weeks prior to screening, or systemic corticosteroids within the eight weeks prior to screening.\n4. The participant must not have had any previous exposure to investigational MS therapeutic vaccines.\n5. The participant must not have used cell-depleting monoclonal antibodies such as Rituximab or Ocrelizumab.\n6. The participant must not have a diagnosis or history of certain diseases including collagen vascular disease, sarcoidosis, vasculitis, and Lyme disease.\n7. The participant must not have a contraindication to MRI, such as having a pacemaker or allergy to gadolinium.\n8. The participant must not have a history of alcohol or drug abuse within two years prior to screening.\n9. The participant must not have had major surgery or radiation therapy within four weeks prior to screening.\n10. The participant must not have an active infection requiring antibiotics within two weeks prior to screening.\n11. The participant must not have had active malignancy within two years of screening, except for basal cell carcinoma and squamous cell carcinoma of the skin.\n12. The participant must not have certain cardiovascular conditions, such as uncontrolled congestive heart failure or recent myocardial infraction.\n13. The participant must not have symptomatic cardiac dysrhythmias requiring treatment or prolonged QTcF interval.\n",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on Parkinson's disease. The associated ICD-10 code for Parkinson's disease is \"G20\". The drug being studied is called \"apl-130277\". \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being 18 years or older, having a clinical diagnosis of idiopathic PD, receiving stable doses of L-dopa or other PD therapy for at least 4 weeks, experiencing at least one OFF episode per day with a total daily OFF time of more than 2 hours, having predictable OFF episodes in the morning before receiving the morning dose of levodopa, being in stage I to III on the Hoehn and Yahr scale in the \"ON\" state, and meeting certain requirements for birth control, compliance, and consent.\n\nExclusion criteria include having atypical or secondary parkinsonism, recent changes in L-dopa or other PD drug dosing regimens, past treatment with apomorphine within 30 days, being pregnant or lactating, having contraindications or hypersensitivity to the study drug or its ingredients, recent participation in another clinical trial or receipt of investigational medication, currently taking certain medications, having drug or alcohol dependency in the past 6 months, having clinically significant orthostatic hypotension, having a history of malignant melanoma within 5 years, having clinically significant medical, surgical, or laboratory abnormalities, having certain psychiatric disorders or dementia, having potential for lack of compliance or follow-up, having any other condition or therapy that would make the subject unsuitable for the study, previous neurosurgery for PD, recent donation of blood or plasma, and presence of cankers or mouth sores.",
    "The sample from the table represents a clinical trial with a phase 1/phase 2 study design. The trial focuses on two diseases, diffuse large B-cell lymphoma (DLBCL) and Kaposi sarcoma (KS). The diseases are identified by their respective International Classification of Diseases, Tenth Revision (ICD-10) codes. The trial involves the use of a drug called abc294640.\n\nThe eligibility criteria for the trial are as follows:\n1. Patients must have a confirmed diagnosis of DLBCL or KS that is refractory to standard therapy or has relapsed after standard therapy.\n2. Patients with DLBCL must not be eligible for hematopoietic stem cell transplantation or have failed the transplantation.\n3. Patients must have tumor progression after receiving standard/approved chemotherapy or be ineligible for standard therapy.\n4. Patients must have one or more measurable tumors on PET-CT scan (for DLBCL) or CT scan/clinical examination of the skin (for KS).\n5. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 3 or lower.\n6. Patients must have a life expectancy of at least 3 months.\n7. Patients must be 18 years or older.\n8. Patients must provide signed, written informed consent approved by the Institutional Review Board (IRB).\n9. Female patients must have a negative pregnancy test.\n10. Patients must have acceptable liver function, acceptable hematologic status, and no clinically significant abnormalities in urinalysis or PT/PTT levels.\n11. Patients of child-producing potential must be willing to use effective contraceptive methods during the study.\n\nThe exclusion criteria for the trial are as follows:\n1. Patients with severe cardiac disease, recent myocardial infraction, unstable arrhythmia, or evidence of ischemia on ECG.\n2. Pregnant or nursing women.\n3. Patients with active, life-threatening bacterial or fungal infections.\n4. Patients who have received radiation therapy, surgery, chemotherapy, or investigational therapy within one month prior to study entry.\n5. Patients unwilling or unable to comply with study procedures.\n6. Patients with serious nonmalignant diseases that could compromise the study objectives.\n7. Patients currently receiving any other investigational agent.\n8. Patients receiving drugs that interact with specific enzymes or substrates and cannot be stopped before starting treatment with abc294640.\n9. Patients currently taking Coumadin or Coumadin derivatives.\n10. Patients who have received antineoplastic therapy within one month of starting treatment with abc294640 or have not adequately recovered from previous therapy's side effects.\n11. Patients currently participating in any other clinical trial of an investigational product.\n12. Patients with an allergy to radiographic contrast.\n\nThis description provides an overview of the sample data and the criteria for eligibility and exclusion in the clinical trial.",
    "The sample from the table describes a clinical trial in phase 2 for the treatment of active melanoma brain metastases. The trial focuses on patients with metastatic melanoma carrying the BRAF V600-mutation. The eligibility criteria include having a measurable intracranial target lesion, being previously untreated or having progressive disease, and having a largest diameter of the lesion between 0.5cm and 4cm. Prior therapies for extracranial metastatic melanoma are allowed, except for prior BRAF or MEK treatments. Other criteria include specific age, bone marrow function, renal function, liver function, ability to swallow pills, and negative pregnancy test for premenopausal women. Exclusion criteria include active infection, prior therapy with BRAFi and/or MEKi, leptomeningeal disease, and symptomatic brain metastases requiring immediate interventions. The sample also lists other exclusion criteria related to corticosteroid use, medication, toxicity from previous therapy, conditions interfering with drug absorption, and various medical conditions. The use of certain foods/supplements is prohibited during the study. Additionally, there are criteria related to retinal pathology, glaucoma, serum cholesterol, hypertriglyceridemia, hyperglycemia, and cardiac dysfunction.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on Huntington's disease. The disease is identified by its ICD-10 code, which is \"G10\". The trial involves two drugs, \"bn82451b\" and \"placebo\". The eligibility criteria for participants are listed, including age range, confirmation of Huntington's disease diagnosis, specific symptom scores, ability to swallow medication, and other factors. There are also exclusion criteria, such as the presence of other forms of chorea, history of seizures or convulsive disorders, and certain medical conditions. The sample also includes information about prohibited medications and substances.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is hypertension. The ICD-10 codes associated with the disease are I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, and I10. The drugs being tested are abatacept and placebo. The eligibility criteria for participants include being between 18 and 65 years old, having hypertension treated with three or more anti-hypertensive drugs (including a diuretic), and having a systolic blood pressure above 150 mmHg in the clinic and during daytime monitoring. There are also exclusion criteria, such as having a medical history of secondary causes of hypertension, severe obesity, severe psychiatric disorders, recent cancer, or recent herpes zoster or cytomegalovirus infection. Other exclusion criteria include inability to return for treatment and follow-up, inability to understand or complete study-related assessments, current drug or alcohol abuse, recent live vaccine receipt, active or latent infections, risk for tuberculosis, and abnormal laboratory values.",
    "The sample from the table is for a phase 2 clinical trial focused on obsessive-compulsive disorder (OCD). The trial is investigating the effectiveness of ketamine compared to a placebo. The eligibility criteria for participants include being aged 18 to 55, meeting the DSM-IV criteria for OCD, and having a Y-BOCS score of at least 18 at screening. \n\nExclusion criteria include unwillingness or inability to provide informed consent, active suicidal ideation, a lifetime history of psychotic disorder or autism spectrum disorder, recent alcohol or substance dependence, intolerance or hypersensitivity to ketamine, nasal/sinus anomalies or dysfunction, and clinically significant medical or neurologic diseases. \n\nFemale participants must have a negative pregnancy test and use effective contraception. Lactating females are also excluded. Other exclusion criteria include significant laboratory abnormalities, current use of certain medications, recent participation in another drug trial, and contraindication to having an MRI.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease mentioned is \"pulmonary arterial hypertension\" and its corresponding ICDCodes is \"I27.21\". The drugs being tested in this trial are \"placebo\" and \"selonsertib\". The eligibility criteria for this trial include a diagnosis of idiopathic pulmonary arterial hypertension (IPAH), heritable pulmonary arterial hypertension (HPAH), drug- and toxin-induced PAH, or PAH associated with connective tissue disease, HIV infection, or congenital heart defects. The criteria also include specific hemodynamic measurements, the ability to walk a certain distance, specific symptoms, and certain pulmonary function test results. There are also exclusion criteria listed, such as certain types of pulmonary hypertension, specific heart conditions, uncontrolled hypertension, severe liver disease, and end-stage renal disease. It is mentioned that individuals may be rescreened once with prior notification and approval from the sponsor.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is heart failure. The ICD-10 codes associated with the disease are I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, and I11.0. The drugs being tested are spironolactone and placebo. The eligibility criteria for the trial are listed, including age, symptoms and signs of congestion, timing of randomization, estimated GFR, serum K+ levels, NT-proBNP or BNP levels, and medication usage. The exclusion criteria are also listed, including medication usage, eGFR levels, systolic blood pressure, arrhythmias, recent acute coronary syndrome, liver disease, infection, gastrointestinal bleeding, malignancy, mechanical circulatory support, cardiac transplant, inotrope use, specific heart conditions, previous adverse reactions, and enrollment in another clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are bendamustine, bortezomib, and prednisone. \n\nThe eligibility criteria for this trial include being newly diagnosed with multiple myeloma and requiring systemic treatment, having measurable disease as defined by specific criteria, being over 18 years old, having a WHO performance status of 0-3, and having a negative pregnancy test for women of childbearing potential. Other criteria include the ability to understand the trial and its consequences, providing written informed consent, and agreeing to abstain from donating blood during the study.\n\nExclusion criteria for this trial include known hypersensitivity to the drugs being used, systemic AL amyloidosis (except for certain cases), recent chemotherapy or radiotherapy, plasma cell leukemia, severe cardiac dysfunction, significant hepatic dysfunction, HIV-positive status, active uncontrolled infections, peripheral neuropathy of a certain grade, and certain types of second malignancies. Other exclusion criteria include specific medical conditions and participation in other clinical trials within a certain timeframe.\n\nIt is also mentioned that no subject can enroll in this trial more than once.",
    "The sample is a phase 2 trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial is testing a drug called AZD7624, along with a placebo. The eligibility criteria for participants include being aged 40-85 years, having a diagnosis of COPD for more than 1 year, and currently receiving COPD maintenance treatment with at least ICS/LABA. Participants must also have a post-bronchodilator FEV1/FVC ratio of less than 0.70 and a post-bronchodilator FEV1 of less than or equal to 70% of the predicted normal value. They must have a history of 2 or more moderate to severe COPD exacerbations within the past 12 months, but not within the last 6 weeks before randomization. Other criteria include being a current or ex-smoker with a smoking history of at least 10 pack-years and having a weight of at least 50 kg. Exclusion criteria include involvement in the planning and conduct of the study, previous randomization in the present study, participation in another clinical study with any investigational medicinal product within 3 months of randomization, and participation in or scheduled for an intensive COPD rehabilitation program during the study. Other exclusion criteria include significant disease or disorder other than COPD, clinically relevant abnormal findings in various medical tests, positive results on screening for certain infections, history or family history of muscle diseases, abnormal vital signs, prolonged QTcF interval, and various cardiovascular conditions. Additionally, participants must not have a history of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity to drugs with a similar chemical structure or class to AZD7624. They must not have had any exacerbation or respiratory infection within 6 weeks of randomization, and must not have donated plasma or had significant blood loss within a certain timeframe. Other exclusion criteria include a history of or current alcohol or drug abuse, treatment with certain medications within specific timeframes, and treatment with strong CYP3A inhibitors within 4 weeks prior to randomization.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this particular sample, the phase of the trial is phase 2. The disease being studied is amyotrophic lateral sclerosis (ALSO), and its corresponding ICD-10 code is G12.21. The drugs being tested are placebo (for mn-166), mn-166, and riluzole. The eligibility criteria for this trial include obtaining written informed consent, being between the ages of 18 and 80, having a diagnosis of familial or sporadic ALSO according to specific research diagnostic criteria, having an ALSO onset of less than or equal to 5 years from first clinical weakness, having a slow vital capacity of at least 60% of predicted within 1 month prior to treatment, currently being on a stable dose of riluzole or starting on a stable dose prior to screening, and meeting certain requirements for females of childbearing potential. There are also additional criteria related to the ability to swallow study medication, compliance with the protocol, absence of allergies to the study drug, and having received a pneumococcal vaccine within the past 4 years.\n\nThe exclusion criteria for this trial include the use of tracheostomy or invasive mechanical ventilation, significant loss in vital capacity or ALSFRS-R total score, hepatic or renal insufficiency, clinically significant psychiatric or medical conditions, history of malignancy within the past 5 years (with exceptions), prolonged QTcB interval on ECG, history of HIV or other active infection, history of stomach or intestinal surgery or conditions that could interfere with drug absorption, history of alcohol or substance abuse or dependence, poor peripheral venous access, recent participation in another study, inability to cooperate with study procedures, and specific criteria for the advanced ALSO group.\n\nOverall, this sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for a specific clinical trial related to amyotrophic lateral sclerosis.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of various diseases, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS). The trial is investigating the drug cpx-351. The eligibility criteria for participants include being able to understand and sign an informed consent form, being between the ages of 18 and 80, having a life expectancy of at least 3 months, and meeting specific pathological confirmation criteria for the diseases being studied. Other criteria include having a certain performance status, adhering to the study schedule, and meeting certain laboratory values. There are also exclusion criteria, such as being ineligible for a previous study or taking medications that can prolong the QTc interval. The sample also includes additional exclusion criteria related to cardiac health, previous diagnoses, and medical conditions that could prevent informed consent.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in both phase 2 and phase 3.\n- Diseases: The trial is focused on \"diarrhea predominant irritable bowel syndrome.\"\n- ICD Codes: The ICD-10 codes associated with the disease are ['C81.07', 'C81.00', 'C81.02', 'C81.06', 'C81.03', 'D83.1', 'C81.08'].\n- Drugs: The drugs being tested in the trial are \"ranolazine\" and \"placebo.\"\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The inclusion criteria include having a diagnosis of IBS-D, being between 18-70 years old, being a U.S. resident, and being English-speaking. The exclusion criteria include having certain structural or metabolic diseases, being unable to withdraw specific medications prior to the study, being pregnant or breastfeeding, having severe depression, having significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric, or other diseases, having a Corrected QT Interval (QTc) greater than 490 msec, being an active alcoholic or substance abuser, having liver cirrhosis or clinically significant hepatic disease, experiencing major cardiovascular events in the last 6 months, participating in another clinical trial within the last 30 days, or being incarcerated.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease is Alzheimer's disease. The ICDCodes associated with the disease are G30.8, G30.9, G30.0, and G30.1. The drugs being used in the trial are bi 409306 and placebo. The eligibility criteria include age requirements, body weight, specific neuropsychological testing scores, abnormal markers of AD pathology, no previous treatment for AD, education level, written informed consent, the presence of a study partner, and various exclusion criteria such as other cognitive impairments, medical history, psychiatric disorders, drug dependence, HIV infection, and more.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"resectable pancreatic cancer\" and \"pancreatic ductal carcinoma.\" The ICDCodes associated with these diseases are \"C25.3.\" The drugs being used in the trial are \"folfirinox,\" \"gemcitabine/nab-paclitaxel,\" and \"capecitabine.\" \n\nThe eligibility criteria for this trial include the requirement of cytologic or histologic proof of pancreatic ductal carcinoma before study entry. Patients must not have evidence of metastatic disease and must be potentially resectable. Other criteria include age (18 years or older), ECOG Performance Status (0 or 1), life expectancy (greater than 3 months), and specific lab values within normal ranges. \n\nThere are also exclusion criteria, such as the presence of metastatic disease, serious concomitant systemic disorders, pregnancy or lactation, prior chemotherapy or radiation for pancreatic tumor, and other uncontrolled medical conditions. The sample also includes criteria related to participation in the study, history of seizures or psychiatric disability, recent major surgery, and participation in other investigational drug studies.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease of obesity. The associated ICD-10 codes for obesity are ['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99.215', 'O99.210', 'O99.211']. The drugs being studied in this trial are canagliflozin, phentermine, matching placebo to canagliflozin, and matching placebo to phentermine. The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having a BMI of at least 30 kg/m2 and less than 50 kg/m2 (or BMI of at least 27 kg/m2 and less than 50 kg/m2 with comorbidity of hypertension and/or dyslipidemia), stable weight, and agreement to use effective birth control. Exclusion criteria include a diagnosis of diabetes mellitus, obesity with a known secondary cause, certain medical conditions, recent cardiovascular events, high glycated hemoglobin levels, and elevated blood pressure readings.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is divided into different phases, and this particular record is from phase 1/phase 2. The trial is focused on the treatment of classical Hodgkin lymphoma. The ICD-10 codes associated with this disease are provided. The drugs being used in the trial include brentuximab vedotin, etoposide, soludomerin, cisplatin, and ara c. The record also includes the eligibility criteria for patients to participate in the trial, such as age restrictions, performance status, organ function, and absence of prior malignant diseases. Inclusion and exclusion criteria are listed, including factors like medical history, pregnancy or breastfeeding status, and concurrent medical conditions.",
    "The sample from the table represents a phase 2 clinical trial for patients with multiple myeloma in their first relapse. The trial is specifically for patients who have previously been treated in the first line within the IFM/DFCI 2009 trial and are now being treated within the PCD trial in the second line. \n\nThe eligibility criteria for the trial include being able to understand and voluntarily sign an informed consent form, adhering to the study visit schedule and other protocol requirements, being between the ages of 18-70, having a life expectancy of more than 6 months, and having progressive myeloma as defined by specific criteria such as an increase in serum M-component, urine M-component, bone marrow plasma cell percentage, or the development of new bone lesions or soft tissue plasmacytomas. \n\nPatients must also have a clearly detectable and quantifiable monoclonal M-component value, meet certain performance status and organ function requirements, have a washout period of at least 2 weeks from previous antitumor therapy or any investigational treatment, and be able to take antithrombotic medicines. \n\nFemale subjects of childbearing potential must agree to use two reliable forms of contraception simultaneously or practice complete abstinence during specific time periods related to the study. Male subjects must practice complete abstinence or use a condom during sexual contact with a pregnant female or a female of childbearing potential. \n\nThere are also exclusion criteria, such as having any uncontrolled medical condition or comorbidity that might interfere with participation, having primary amyloidosis or myeloma complicated by amyloidosis, being pregnant or breastfeeding, using any other experimental drug or therapy within 2 weeks before study treatment initiation, and having certain medical conditions or toxicities.",
    "The sample from the table represents a clinical trial for the treatment of ovarian carcinoma. The trial is a combination of phase 1 and phase 2. The diseases being studied are ovarian carcinoma, fallopian tube carcinoma, and primary peritoneal carcinoma. The corresponding ICD-10 codes for these diseases are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']. The drug being tested in the trial is paclitaxel. \n\nThe eligibility criteria for the trial include: \n1. Confirmation of histologically or cytologically confirmed ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma.\n2. Recurrent ovarian cancer with any number of prior therapies.\n3. Age 18 and older.\n4. Life expectancy of at least 12 weeks.\n5. Measurable disease according to the revised RECIST criteria version 1.1.\n6. ECOG score 0-1.\n7. Adequate bone marrow, liver, and renal functions.\n8. Ability to operate the NovoTTF-100L(O) System independently or with the help of a caregiver.\n9. No concurrent anti-tumor therapy (beyond weekly paclitaxel and NovoTTF Therapy as per protocol).\n10. At least 4 weeks since major surgery.\n\nThe exclusion criteria for the trial include:\n1. Meningeal carcinomatosis or known brain metastases which have not been treated, require steroid treatment, or are symptomatic.\n2. Any other malignancy requiring anti-tumor treatment in the past three years, except resected non-melanomatous skin cancer, breast carcinoma in situ, adequately treated stage I breast cancer, or in situ cervical cancer.\n3. Chemotherapy within 4 weeks prior to treatment start.\n4. Radiotherapy within 4 weeks prior to treatment start.\n5. Significant comorbidity which is expected to affect the patient's prognosis or ability to receive the combined therapy.\n6. Implantable electronic medical devices including pacemaker, implantable automatic defibrillator, etc.\n7. Known history of sensitivity to taxanes or drugs containing Cremophor.\n8. Grade 2 or greater peripheral neuropathy.\n9. Known allergies to medical adhesives or hydrogel.\n10. Pregnant or breastfeeding.\n\nThis sample provides an overview of the trial, including the phase, diseases being studied, drugs being tested, and the eligibility and exclusion criteria for participants.",
    "The sample is from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being tested, and \"criteria\" which provides the eligibility criteria for participants in the trial.\n\nIn this specific sample, the phase of the trial is phase 2. The disease being studied is Alzheimer's disease, and the corresponding ICD-10 codes are G30.8, G30.9, G30.0, and G30.1. The drugs being tested are \"anavex2-73 oral\" and \"anavex2-73 intravenous\", with \"anavex2-73 oral\" appearing multiple times. The eligibility criteria for participants include a diagnosis of probable Alzheimer's disease according to NINCDS-ADRDA criteria, a brain CT or MRI scan consistent with the diagnosis, age between 55 and 85 years, MMSE score of 16-28, Rosen Modified Hachinski Ischemic score <=4, having a caregiver with regular contact and ability to oversee medication compliance, fluency in English, ability to read, write, and speak clearly for cognitive tests, stable doses of medications for non-excluded medical conditions, and several exclusion criteria such as not having other forms of dementia, neurodegenerative diseases, major psychiatric disorders, or clinically significant systemic illnesses.",
    "The sample is a phase 2 trial for the treatment of nonalcoholic fatty liver disease (NAFLD). The trial is testing a combination therapy called ez-urso. The eligibility criteria for participants include having steatosis (accumulation of fat in the liver), ALT (liver enzyme) levels higher than 1.5 times the normal range, an ALT/AST (another liver enzyme) ratio higher than 1.0, and normal kidney function. \n\nExclusion criteria include having normal ALT levels within the last 6 months, advanced fibrosis in the liver (stage 3 or 4 NAFLD) based on biopsy, imaging, or lab results (platelet count below 150,000), daily alcohol use above certain limits, prescription use of specific medications, significant weight loss in the past year, being pregnant or breastfeeding, having a body mass index (BMI) above 50, having a largest body circumference above 160 cm, claustrophobia, and having allergies to ezetimibe or ursodiol.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this sample, the phase of the trial is a combination of phase 2 and phase 3. The diseases being studied are HIV and pregnancy. The ICDCodes associated with these diseases are provided as well. The drugs being tested are \"dolutegravir 50mg od\" and \"standard of care\". The eligibility criteria for this sample include being able to provide informed consent, being willing to participate, being a woman aged 18 years and above, being pregnant, and having untreated HIV infection in late pregnancy at 28-36 weeks gestation. There are also exclusion criteria listed, such as having received antiretroviral drugs in the previous 6 months, having ever received integrase inhibitors, having certain abnormal blood test results, having a low eGFR (a measure of kidney function), having active Hepatitis B infection or severe liver disease, having severe pre-eclampsia or other pregnancy-related abnormalities, having paternal non-consent, or having clinical depression or an increased risk of suicidality based on clinical judgment.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on colorectal neoplasms. The ICD-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are 5-fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin. The eligibility criteria for participants in the trial are listed, including requirements for written informed consent, a histopathologically proven diagnosis of colorectal cancer, and the presence of measurable lesions. There are also exclusion criteria, such as previous treatment with irradiation to bone marrow, untreated brain metastases, and chronic systemic corticosteroid treatment.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"gout.\" The ICD-10 codes associated with gout are listed as well. The drugs being studied in this trial include \"rdea3170 15 mg,\" \"rdea3170 10 mg,\" \"rdea3170 2.5,\" \"rdea3170 5 mg,\" \"febuxostat 40 mg,\" and \"febuxostat 80 mg.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being able to understand the study procedures and risks, meeting the criteria for the diagnosis of gout, having a certain body weight and body mass index, and having a screening serum urate level above a certain threshold. Exclusion criteria include being unable to take colchicine for gout flare prophylaxis, having a history or suspicion of kidney stones, having gastrointestinal disorders that affect motility and/or absorption, having certain heart conditions or receiving anticoagulants, having abnormal screening laboratory parameters, having a low estimated creatinine clearance, taking certain medications, and being unable or unwilling to comply with the study requirements or having a condition that may interfere with participation.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as phase 2. The specific disease being studied is respiratory syncytial virus infections. The corresponding ICD-10 codes for this disease are listed as 'R09.2', 'A15.7', 'A15.8', 'A15.9', 'J98.9', 'R06.03', and 'J12.1'. The drugs being used in the trial are 'saline placebo (0.5ml injection)' and 'rsv f vaccine (0.5ml injection)'. \n\nThe eligibility criteria for pregnant women to participate in the trial are listed under \"Inclusion Criteria\". These criteria include being between 18 and 40 years of age, having a singleton pregnancy of 33 to 35 weeks gestation, and being in good general maternal health. The health assessment includes medical history, physical examination, and clinical laboratory parameters. The documentation requirements for eligibility are also specified.\n\nThe \"Exclusion Criteria\" list conditions that would disqualify pregnant women from participating in the trial. These conditions include cardiac or pulmonary disease requiring chronic drug therapy, certain body mass index ranges, hemoglobinopathy or blood dyscrasias, hepatic or renal dysfunction, seizure disorder, auto-immune disease or immunodeficiency syndrome, endocrine disorders, history of major surgeries, certain infections, alcohol or drug abuse, and various other conditions.\n\nOverall, the sample provides a detailed description of the phase 2 clinical trial, including the disease being studied, the drugs being used, and the eligibility criteria for pregnant women to participate.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 2 and phase 3. The disease being studied is chronic hepatitis B. The ICDCodes associated with this disease are B18.0, B18.1, B18.2, B18.8, and B18.9. The drug being tested is called \"abx203 therapeutic hepatitis B vaccine treatment arm\". \n\nThe eligibility criteria for this trial are as follows:\n- The subject must be between 18 and 65 years old.\n- The subject must be HBeAg negative and anti-HBe Abs positive for at least 1 year prior to screening and at screening.\n- The subject must have HBV DNA levels below 40 IU/mL for at least 1 year prior to screening and at screening.\n- The subject's ALT and AST levels must be within the normal range for at least 1 year prior to screening and at screening.\n- The subject must be HBsAg positive at screening.\n- The subject must have been treated with NUCs (nucleoside/nucleotide analogues) for at least 2 years prior to screening.\n- The subject must not have been treated with PEG-IFN (pegylated interferon) or IFN (interferon) for at least 1 year prior to screening.\n- Female subjects must have a negative serum pregnancy test at screening and must use adequate contraception during the study and for 6 months after the study.\n- The subject must have provided written informed consent.\n\nThe exclusion criteria for this trial are as follows:\n- The subject has elevated blood levels of alpha-fetoprotein (AFP) (> 500 ng/mL).\n- The subject has cirrhosis, as defined by specific criteria related to platelet count, esophageal varices, spleen size, liver stiffness, or AST to Platelet Ratio Index (APRI).\n- The subject has hepatocellular carcinoma (HCC) diagnosed by ultrasonography.\n- The subject has liver decompensation, indicated by low albumin levels and high bilirubin levels.\n- The subject is positive for Hepatitis C virus (HCV) antibodies at screening.\n- The subject is positive for Hepatitis delta virus (HDV) antibodies at screening.\n- The subject is positive for Human Immunodeficiency Virus (HIV) antibodies at screening.\n- The subject has an immune suppressive disorder or is undergoing treatment with immunosuppressive drugs.\n- The subject has been treated with corticosteroids within 12 weeks prior to the first administration of the study product, except for topical or inhaled corticosteroids.\n- The subject has been treated with rituximab.\n- The subject has other hepatic diseases of different etiology, such as auto-immune hepatitis, toxic hepatitis, Wilson disease, alcoholic or hemochromatosis.\n- The subject has a history of allergic disease or reactions that may be worsened by any component of the study products.\n- The subject has a history of substance abuse (drug or alcohol) within the previous 3 years.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"allogeneic hematopoietic stem cell transplantation\" and its corresponding ICDCodes is \"M31.11\". The drug mentioned is \"mln9708\". \n\nThe sample also includes detailed inclusion and exclusion criteria for the trial. The inclusion criteria specify the requirements for patients to be eligible for the trial, such as having a history of a hematological malignancy or bone marrow failure syndrome, being aged 18 or older, having received or planning to receive an allograft from a suitable donor, and meeting certain health criteria. The exclusion criteria outline the conditions or situations that would disqualify a patient from participating in the trial, such as having peripheral neuropathy, allergies or intolerance to the drug, certain medical conditions, or recent surgeries or treatments.\n\nOverall, this sample provides specific information about the trial phase, disease, drug, and the criteria that determine eligibility for participation.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for participants.\n\nIn this specific sample, the phase of the trial is phase 2. The disease being studied is \"carcinoma, non-small-cell lung\". The corresponding ICD-10 codes for this disease are \"D02.20\", \"D02.21\", and \"D02.22\". The drugs being used in the trial are \"nab-paclitaxel iv\", \"cc-486\", and \"duravalumab\". The eligibility criteria for participants are listed in a detailed format, including age requirements, consent, ability to adhere to the study schedule, confirmation of advanced NSCLC, absence of other active malignancies, presence of measurable disease, prior chemotherapy treatment, blood count and liver function requirements, performance status, pregnancy and contraception requirements for females, and abstinence or condom use requirements for males.\n\nAdditionally, the sample includes exclusion criteria, which are conditions or factors that would prevent a subject from participating in the trial. These criteria include refractory to prior taxane therapy, active brain metastases, specific gene mutations, preexisting peripheral neuropathy, unresolved toxicities from previous therapy, certain medical conditions or infections, history of lung diseases, malabsorption syndrome or bowel obstruction, recent cancer treatment, allergies to study drugs, recent major surgeries, enrollment in other clinical trials, and other medical conditions that may interfere with the therapy or data interpretation. There are also criteria related to pregnancy, breastfeeding, and immunosuppressive medications.\n\nOverall, this sample provides a detailed description of a specific trial phase, the disease being studied, the drugs used, and the eligibility and exclusion criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trials. The record belongs to a trial in phase 2 and focuses on the diseases \"open angle glaucoma\" and \"ocular hypertension\". The corresponding ICD-10 codes for these diseases are provided as well. The trial involves the use of multiple drugs, including \"1 drop of 0.375% syl040012 (bamosiran)\" and \"1 drop of 0.5% timolol maleate\". The eligibility criteria for this trial are listed, including age requirements, general health assessment, informed consent, specific diagnoses, visual acuity, visual field stability, corneal thickness, and gonioscopic grade. The exclusion criteria are also mentioned, which include pregnancy, certain medical conditions, medication changes, hypersensitivity, inability to comply with trial requirements, abnormal laboratory tests, severe visual field defect, and various ocular conditions or surgeries.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on chronic lymphocytic leukemia and leukemia. The diseases are represented by their names and corresponding ICD-10 codes. The trial involves the use of drugs such as ibrutinib, fludarabine, cyclophosphamide, and rituximab. The eligibility criteria for participants are listed, including specific requirements related to the diagnosis, symptoms, blood counts, age, performance status, and organ function. There are also exclusion criteria, which outline conditions or circumstances that would prevent someone from participating in the trial.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is hepatitis C virus infection. The corresponding ICD-10 codes for this disease are B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, and B17.2. The drug being tested in the trial is ldv/sof. The eligibility criteria for participants include having genotype 1 or 4 chronic HCV infection, having received a kidney transplant more than 6 months prior to the baseline visit, having a determination of cirrhosis, having screening laboratory parameters within defined thresholds, and using two effective contraception methods if female of childbearing potential or sexually active male. The exclusion criteria include being pregnant or nursing, having hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers), having a history of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol, and having a planned or anticipated second kidney transplant. It is noted that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is alcohol use disorder. The ICDCodes associated with this disease are F10.94, F10.980, F10.982, F10.988, F10.99, F10.959, and F10.96. The drugs being tested in this trial are gabapentin enacarbil and placebo. The eligibility criteria include being at least 21 years old, having a current diagnosis of alcohol use disorder according to DSM-5, having a breathalyzer test result of 0.000 when signing the informed consent, and seeking treatment for alcohol-related problems. Additional evaluations will be conducted in the clinic, and there are exclusion criteria that will also be evaluated in the clinic.",
    "The sample is a phase 2 trial for the treatment of gout and hyperuricemia. The trial is testing the effectiveness of drugs such as arhalofenate, febuxostat, and colchicine. The eligibility criteria for participants include being 18 to 75 years old, having a known diagnosis of gout, having a serum uric acid level of at least 7.5 mg/dL, and having normal liver and kidney function. Female participants must either be surgically sterile or post-menopausal, or use two forms of contraception. The trial also excludes individuals who have recently used other gout medications, have certain medical conditions or diseases, or are taking specific medications. The purpose of the trial is to evaluate the safety and efficacy of the drugs in treating gout and hyperuricemia.",
    "The sample in the table is for a phase 2 trial. The disease being studied is mucositis. The ICD-10 codes associated with this disease are J34.81, K92.81, K12.30, K12.39, K12.33, N76.81, and K12.31. The drugs being tested in this trial are bupivacaine and a standard treatment which includes lidocaine viscous solution, morphine, paracetamol, NSAID, and gabapentin. The eligibility criteria for participants include being diagnosed with head/neck cancer and starting radiotherapy treatment, being between the ages of 18 and 80, being able to speak, read, and understand Danish, and being able to give informed consent. The exclusion criteria include known hypersensitivity to bupivacaine or other local anesthetics of the amide type, pregnancy, and breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are glioblastoma, glioma, and brain tumor. The ICDCodes associated with these diseases are C71.7, C71.9, C79.31, D33.0, D33.1, D33.2, and D49.6. The drug being used in the trial is carboplatin. \n\nThe eligibility criteria for this trial include being over 18 years old, having recurrent glioma that has not responded to standard treatments, being eligible for carboplatin-based chemotherapy, having a contrast-enhanced tumor less than 35 mm in diameter, having no risk of cerebral herniation, being able to tolerate pre/post procedure steroid treatment, being affiliated with social security in France, being able and willing to give signed and informed consent, having normal biological status, having a hemoglobin level of at least 10 g/dl, having platelets of at least 100000/mm3, having neutrophils of at least 1500/mm3, having normal creatine clearance of at least 60ml/mn, having ASAT levels less than 3 times the normal range, having ALAT levels less than 3 times the normal range, having a normal bilirubin level less than 1.5 times the normal range, having alkaline phosphatase levels less than 3 times the normal range, having an INR less than 1.5, and having a prothrombin level of at least 70%.\n\nThe exclusion criteria for this trial include being allergic to iodine, gadolinium, or xylocain, having contraindications to echographic contrast agent (microbubbles), having severe renal insufficiency, having hepatic insufficiency, receiving possible toxic treatment for CNS, having a previously infected surgical field, having uncontrolled epilepsy, having MRI contraindications, having hemostasis troubles such as thrombopenia less than 75,000, TP less than 60%, INR greater than 1.5, or ongoing anti-platelet or anticoagulant therapy, having active phlebitis or active pulmonary embolism, being pregnant or currently breastfeeding, and being under judicial protection.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the treatment of keratoconjunctivitis sicca (dry eye disease). The diseases column lists the specific diseases being studied, and the icdcodes column provides the corresponding ICD-10 codes for each disease. The drugs column lists the names of the drugs being tested in the trial. \n\nThe criteria column contains the eligibility criteria for participants in the trial. The inclusion criteria include being 18 years or older, providing written consent, having a history of KCS for at least 6 months, having a clinical diagnosis of bilateral KCS, and meeting certain scoring criteria for conjunctival staining and symptom severity. Other inclusion criteria include having a certain level of visual acuity, being willing to discontinue current dry eye therapy, and meeting certain requirements for female subjects of childbearing potential.\n\nThe exclusion criteria include recent use of specific medications, certain medical conditions, previous treatment failure, and participation in other clinical investigations. The sample also includes additional exclusion criteria related to specific eye conditions, surgeries, and medical history.\n\nOverall, the sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for participants in a clinical trial for the treatment of keratoconjunctivitis sicca.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of oropharyngeal squamous cell carcinoma. The diseases included in the trial are stage III oropharyngeal squamous cell carcinoma, stage IVA oropharyngeal squamous cell carcinoma, stage IVB oropharyngeal squamous cell carcinoma, stage IVC oropharyngeal squamous cell carcinoma, and tongue carcinoma. The corresponding ICD-10 codes for these diseases are provided as well. The drug being tested in the trial is cisplatin. The eligibility criteria for the trial include specific requirements related to the diagnosis, staging, smoking history, performance status, age, hematologic function, renal function, hepatic function, HIV status, pregnancy, and prior allergic reactions. The sample also includes exclusion criteria for the trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is respiratory syncytial virus. The ICDCodes associated with this disease are J12.1, J20.5, J21.0, Z29.11, and B97.4. The drugs mentioned are presatovir and placebo. The eligibility criteria are listed under \"Inclusion Criteria\" and \"Exclusion Criteria,\" which include requirements such as having received an autologous or allogeneic HCT, being RSV-positive, having specific respiratory symptoms, having no evidence of lower respiratory tract infection, and meeting various other medical and laboratory conditions.",
    "The sample from the table is for a phase 2 trial. The disease being studied is respiratory syncytial virus infection. The corresponding ICD-10 codes for this disease are 'R09.2', 'A15.7', 'A15.8', 'A15.9', 'J98.9', 'R06.03', and 'J12.1'. The drugs being tested in the trial are presatovir and placebo. The eligibility criteria for participants include having received an autologous or allogeneic HCT, evidence of new abnormalities on chest X-ray consistent with LRTI, documented RSV in both the upper and lower respiratory tract, signed informed consent, negative pregnancy test for females, agreement to contraceptive requirements, willingness to complete study procedures, and availability of a working telephone or email. The exclusion criteria include recent use of investigational agents or monoclonal anti-RSV antibodies, use of certain cytochrome P450 enzyme inducers, pregnancy or breastfeeding, inability to tolerate nasal sampling, history of HIV/AIDS with low CD4 count, history of drug/alcohol abuse, requiring invasive mechanical ventilation, positive for other respiratory viruses, recent bacteremia/fungemia or pneumonia, excessive nausea/vomiting or inability to swallow pills, any condition that would prevent full participation, and abnormal laboratory results.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are lde225 and bortezomib. The eligibility criteria for this trial include measurable MM requiring systemic therapy, progression during or after at least two previous treatment regimens, ECOG Performance Status score of 0-2, adequate bone marrow, liver and renal function, ability to swallow and retain oral medication, and willingness and ability to comply with study and follow-up procedures. There are also exclusion criteria listed, such as recent treatment for myeloma, refractory to bortezomib, previous treatment with systemic LDE225 or other Hedgehog pathway inhibitors, and various medical conditions or medications that may interfere with the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease called Friedreich ataxia. The trial is investigating the effects of a drug called omaveloxolone capsules at various dosages, as well as a placebo. The eligibility criteria for participants are listed, including having genetically confirmed Friedreich's ataxia, a specific score range on a modified FARS score, and being within a certain age range. Other criteria include not having certain medical conditions or taking specific medications, and being able to swallow capsules. The sample also includes exclusion criteria, such as having uncontrolled diabetes or a history of certain heart diseases. The sample provides detailed information about the inclusion and exclusion criteria for potential participants in the clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on restless legs syndrome. The trial is specifically looking at the effects of vitamin D on patients with primary restless legs syndrome and vitamin D deficiency. \n\nThe inclusion criteria for the trial are as follows:\n1. Patients must be newly diagnosed or already diagnosed with primary restless legs syndrome and vitamin D deficiency.\n2. Patients should not be currently receiving any treatment for restless legs syndrome or vitamin D replacement therapy.\n3. Patients must be between 18 and 75 years old.\n4. Patients should be in good general health.\n\nThe exclusion criteria for the trial are as follows:\n1. Patients diagnosed with secondary restless legs syndrome, such as those with iron deficiency anemia, end-stage renal disease, diabetes mellitus, peripheral neuropathy, multiple sclerosis, or pregnancy.\n2. Patients with other disorders or primary sleep disorders that mimic restless legs syndrome, such as arthritis, deep venous thrombosis, varicose veins or venous insufficiency, or habitual foot tapping.\n3. Patients currently taking medications that can trigger restless legs syndrome, such as certain anti-hypertensive medications, anti-convulsion medications, antinausea drugs, antipsychotic drugs, anti-depressants, or antihistamines.\n4. Patients with current medications or conditions that would interfere with vitamin D absorption, such as celiac disease, Crohn's disease, chronic pancreatitis, cystic fibrosis, weight-loss drugs, or cholesterol-lowering drugs.\n5. Patients with contraindications for vitamin D supplements, such as hyperparathyroidism, kidney stones, liver diseases, or granulomatous disorders.\n6. Patients who are 17 years old and younger.\n7. Patients who have used supplements containing vitamin D at doses higher than 1000 IU/day within 12 weeks of the baseline visit and are unwilling to limit supplementation dosage to no higher than 1000 IU/day for the duration of the study.\n8. Patients who have used supplements containing calcium at doses higher than 600 mg/day within 1 week of the baseline visit and are unwilling to limit calcium supplementation dosage to no more than 600 mg/day for the duration of the study.\n9. Patients with a history of intolerance to vitamin D supplements.\n10. For women only: a) Pregnancy within the past year or intent to become pregnant in the next 4 years, or unprotected intercourse. History of gestational diabetes is not an exclusion criterion. b) Currently breastfeeding. c) Use of oral contraceptives or menopausal hormone therapy started within 3 months of baseline. Stable regimen of oral contraceptives or any other hormonal method of contraception is allowed.\n\nThis sample provides specific details about the eligibility criteria for patients participating in the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The disease being studied is \"idiopathic pulmonary fibrosis\". The corresponding ICD-10 code for this disease is \"J84.112\". The drugs being tested in the trial are \"inhaled td139\" and \"placebo\". The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include factors such as age, lung function, oxygen saturation, and diagnosis of IPF. The exclusion criteria include conditions that would make the patient at risk for bronchoscopy, active smoking, significant co-morbidities, certain medical conditions, use of specific medications, history of malignancy, asthma, and recent participation in other clinical studies.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is non-small cell lung carcinoma (NSCLC). The ICD-10 codes associated with this disease are D02.20, D02.21, and D02.22. The drugs being tested in this trial are itacitinib and docetaxel. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n1. The patient must have a confirmed diagnosis of NSCLC that is Stage IIIb, IV, or recurrent.\n2. The patient must have received only one prior systemic chemotherapy regimen for Stage IIIb, IV, or recurrent disease, excluding neoadjuvant and/or adjuvant therapy. Exceptions may be allowed based on prior treatment regimens and tumor types.\n3. The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n4. The patient must have a life expectancy of at least 12 weeks.\n\nThe exclusion criteria for the trial are as follows:\n1. The patient must not have received prior treatment with docetaxel.\n2. The patient must not have known active central nervous system (CNS) metastases, unless they have completed a course of therapy and are clinically stable for at least 1 month prior to study entry.\n3. The patient must not have peripheral neuropathy of grade 3 or higher.\n4. The patient must not have had any other malignancy within 2 years of study entry, except for certain cured or noninvasive cancers.\n5. The patient must not have any significant, concurrent, uncontrolled medical conditions.\n6. The patient must be willing to be transfused with blood components if necessary.",
    "The sample from the table is for a phase 2 clinical trial. The diseases being studied are follicular lymphoma and small lymphocytic lymphoma. The corresponding ICD-10 codes for these diseases are provided. The drug being tested in the trial is idelalisib. The eligibility criteria for the trial include a confirmed diagnosis of B-cell lymphoma, no previous systemic treatment for lymphoma, the need for treatment, specific disease stage and radiographic requirements, adequate performance status, and certain baseline laboratory data. There are also exclusion criteria, such as a history of certain types of lymphoma, ongoing infections, liver diseases, inflammatory bowel disease, HIV infection, prior transplantation, and ongoing immunosuppressive therapy. It is noted that there may be additional inclusion/exclusion criteria defined in the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 2. The diseases listed are \"human papilloma virus infection,\" \"stage iii squamous cell carcinoma of the oropharynx,\" \"stage iva squamous cell carcinoma of the oropharynx,\" and \"stage ivb squamous cell carcinoma of the oropharynx.\" The corresponding ICDCodes for these diseases are provided as well. The drugs mentioned in the sample are \"paclitaxel albumin-stabilized nanoparticle formulation,\" \"carboplatin,\" \"paclitaxel,\" \"fluorouracil,\" \"hydroxyurea,\" and \"cisplatin.\" The eligibility criteria for this trial include specific requirements for HPV testing, availability of slides, tumor stage, previous treatments, performance status, blood counts, liver and kidney function, and other medical conditions. The sample also includes exclusion criteria such as distant metastases, certain medical illnesses, pregnancy or nursing, other malignancies, prior surgical therapy, use of other investigational agents, and peripheral neuropathy.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on non-small cell lung cancer. The ICD-10 codes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being studied is nivolumab. The eligibility criteria for participants include having histologically proven non-small cell lung cancer, being at a high risk for the disease, having an ECOG performance status of 0-1, and meeting certain organ function requirements. There are also exclusion criteria, such as having an active autoimmune disease, receiving systemic treatment with corticosteroids or immunosuppressive medications, or having a history of certain medical conditions. The sample also includes information about contraception requirements for women of child-bearing potential and the need for informed consent from participants.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes two diseases, namely anemia and end stage renal disease. The corresponding ICD-10 codes for these diseases are also provided. The trial involves the use of a drug called akb-6548. The eligibility criteria for participants in this trial include being between 18 and 79 years old, having chronic kidney disease stage 5, being on chronic hemodialysis for at least 3 months, and having anemia secondary to CKD treated with erythropoiesis stimulating agent and intravenous iron. There are also exclusion criteria such as having a BMI greater than 44.0 kg/m2, recent transfusion, abnormal liver function, uncontrolled hypertension, congestive heart failure, and recent cardiovascular events.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is metastatic colorectal cancer. The ICD-10 codes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are pembrolizumab and azacitidine. The eligibility criteria for participants include being 18 years or older, having a confirmed diagnosis of metastatic colorectal cancer, having previously received standard therapies, having measurable disease, and having a performance status of 0 or 1 on the ECOG Performance Scale. There are also additional criteria related to organ function, pregnancy status, contraception, and exclusion criteria such as participation in other trials, immunodeficiency, prior treatments, other malignancies, and various medical conditions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on breast cancer and brain tumors that have spread to other parts of the body. The diseases are represented by their names and corresponding ICD-10 codes. The trial involves the use of two drugs, cabozantinib and trastuzumab. The eligibility criteria for participants are listed, including requirements such as having stage IV breast cancer, new or progressive CNS lesions, and a certain performance status. Other criteria include normal organ and marrow function, the use of contraception during the study, and recent assessments of disease sites. The exclusion criteria specify conditions that would make a participant ineligible, such as prior use of cabozantinib, uncontrolled illness, contraindications to MRI, and certain medical conditions or complications.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"lupus nephritis.\" The trial includes a list of ICDCodes, which are specific codes used to classify diseases. In this case, the ICDCodes associated with lupus nephritis are \"B26.83,\" \"A51.44,\" \"N11.8,\" \"N11.9,\" and \"N12.\"\n\nThe trial also involves several drugs, including cyclophosphamide, prednisone, methylprednisolone, diphenhydramine, and acetaminophen. These drugs are likely being tested for their effectiveness in treating lupus nephritis.\n\nThe eligibility criteria for participants in this trial are listed, including requirements such as a diagnosis of systemic lupus erythematosus (SLE) according to specific criteria, positive antinuclear antibody (ANA) or positive anti-ds DNA test results, and active proliferative lupus nephritis as defined by kidney biopsy documentation or active urinary sediment.\n\nThere are also exclusion criteria listed, which outline factors that would disqualify someone from participating in the trial. These include conditions such as new onset lupus nephritis, certain blood disorders, severe infections, certain chronic infections, and various other medical conditions.\n\nOverall, this sample provides a snapshot of the phase 2 trial for lupus nephritis, including the diseases being studied, the drugs involved, and the eligibility and exclusion criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is heart failure. The ICDCodes associated with heart failure are \"I50.814\", \"I09.81\", \"I50.82\", \"I50.89\", \"I50.9\", \"T86.22\", and \"I11.0\". The drug being tested is sodium nitrite inhalation solution. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The patient must have Heart Failure with preserved Ejection Fraction (HFpEF) and exhibit clinical symptoms of dyspnea and fatigue.\n- The patient must have a normal left ventricular ejection fraction (50% or higher).\n- The patient must have elevated Left Ventricular (LV) filling pressure at cardiac catheterization, defined as resting Pulmonary Capillary Wedge Pressure (PCWP) greater than 15 mmHg and/or PCWP of 25 mmHg or higher during exercise.\n\nExclusion Criteria:\n- The patient must not have a systolic blood pressure below 120 mmHg during catheterization.\n- The patient must not have received prior nitrate therapy within the previous 2 weeks.\n- The patient must not have Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.\n- The patient must not have other \"non-HFpEF\" specific causes of heart failure, such as significant valvular disease, severe pulmonary disease, unstable coronary disease or coronary spasm, primary renal or hepatic disease, constrictive pericarditis, or infiltrative, restrictive, or hypertrophic cardiomyopathies.\n- The patient must not be pregnant.",
    "The sample is a phase 2 trial for the treatment of chronic hepatitis C. The trial focuses on patients with HCV genotype 1 or 4 infection and a plasma level of HCV RNA greater than 10,000 IU/mL. The inclusion criteria include having documented chronic HCV infection, presence of cirrhosis, and being treatment-naive or treatment-experienced with a previous course of non-direct-acting antiviral therapy. Decompensated liver disease is also considered for inclusion. The exclusion criteria include co-infection with any HCV genotype, HIV-1 or -2, or hepatitis B virus. Patients with liver disease of non-HCV etiology or those who have used disallowed therapies before the study drugs are also excluded. The study drugs being used in this sample are simeprevir, daclatasvir, and sofosbuvir.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating metastatic breast cancer. The trial includes patients with histologically confirmed metastatic or recurrent breast cancer who are HER2-negative and over 18 years old. The patients should have an ECOG performance status of 0-2 and a life expectancy of at least 3 months. They should not have received prior chemotherapy for metastatic or recurrent breast cancer, although prior neoadjuvant or adjuvant taxane regimens are allowed if completed 12 months before enrollment. Prior hormonal therapy for metastatic disease is allowed but must be terminated before enrollment. Prior radiation therapy is allowed as long as less than 25% of the bone marrow has been treated and the patient has recovered from the acute toxic effects. Bisphosphonates for bone metastases should not be initiated after the first dose of randomized therapy. Adequate bone marrow, renal, and liver function is required. Patients with serious uncontrolled infections, medical or psychiatric illnesses, active cardiac disease, pregnancy or breastfeeding, documented brain metastasis, peripheral neuropathy grade 2 or higher, prior treatment with gemcitabine, or HER-2 overexpressing breast cancer with concomitant trastuzumab treatment are excluded from the trial. Women of childbearing potential must be willing to use contraception during the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are recurrent melanoma and stage IV melanoma. The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are raf kinase inhibitor lgx818 and binimetinib. The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" These criteria include factors such as signed informed consent, specific medical conditions, laboratory values, and other considerations that determine whether a patient is eligible to participate in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease lupus. The icd-10 codes associated with lupus are provided. The trial involves two drugs, namely \"bms-931699\" and \"placebo matching bms-931699\". The eligibility criteria for participants are listed, including age range, diagnosis of active systemic lupus erythematosus, presence of the disease in joints or on the skin, and certain restrictions on other medications. The exclusion criteria state that individuals with active lupus nephritis, multiple sclerosis, rheumatoid arthritis, tuberculosis, or ongoing infections with bacteria or viruses are not eligible for the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"angina\". The corresponding ICD-10 codes for angina are listed as \"I20.0\", \"I23.7\", \"I20.9\", \"I20.1\", \"I20.8\", \"I25.10\", and \"I25.810\". The trial involves two drugs, \"ranolazine\" and a \"sugar pill\". The eligibility criteria for the trial are listed, including inclusion criteria such as being an adult patient referred for cardiac catheterization and having at least one indeterminate stenosis, and exclusion criteria such as recent coronary revascularization, acute coronary syndrome, and certain medication usage.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of soft tissue sarcoma. The trial includes eligibility criteria for participants, such as being at least 18 years old, having histological documentation of soft tissue sarcoma, and having advanced and/or metastatic malignant soft tissue sarcoma of intermediate or high histologic grade. The sample also includes exclusion criteria, such as not being eligible for potentially curative therapy, having prior primary chemotherapy, or having received certain treatments within 28 days prior to the start of the trial. The sample provides detailed information about the inclusion and exclusion criteria, as well as other requirements for participation, such as adequate cardiac function and the use of reliable birth control for female participants.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 2. The disease being studied is gastroparesis. The icd-10 code associated with gastroparesis is K31.84. The drugs being tested are velusetrag and placebo. The eligibility criteria for participants in this trial include experiencing symptoms of gastroparesis for at least 3 months, having a certain composite score on the GCSI-2W questionnaire, having delayed gastric emptying confirmed by tests, ruling out upper gastrointestinal obstruction, and abstaining from certain medications. There are also exclusion criteria, such as having a high HbA1c level for diabetic participants, having a history of gastric surgery, recent botulinum toxin injection or electric stimulator implantation, and a history of alcohol or drug abuse or dependence.",
    "The sample is a phase 2 trial for rectal carcinoma. The eligibility criteria for this trial include having a biopsy-proven newly diagnosed primary rectal adenocarcinoma, a locally advanced tumor, and being at least 18 years old. The patient must also have a WHO Performance Status of 0-2 and be mentally and physically fit for chemotherapy. Adequate hematological, hepatic, and renal function is required. There are also exclusion criteria, such as having an inoperable tumor, metastatic or recurrent rectal cancer, or other co-existing malignancies. Pregnant or lactating patients, those with chronic bowel inflammatory disease, or significant heart disease are also excluded. Patients who are unable to sign the consent form due to physical or psychological disabilities are also not eligible for the trial. The drug being tested in this trial is capecitabine.",
    "The sample from the table represents a phase 2 clinical trial for prostate adenocarcinoma, prostate cancer, and high-risk prostate cancer. The trial is investigating the effectiveness of drugs such as enzalutamide, abiraterone acetate, prednisone, and leuprolide acetate. The eligibility criteria for participants include being male, 18 years of age or older, having histologically confirmed adenocarcinoma of the prostate without certain histological variants, and having available tissue from a pre-treatment diagnostic biopsy. Other criteria include specific features of the disease, no evidence of metastatic or nodal disease, being a candidate for RP (radical prostatectomy), having a certain performance status, and meeting certain organ and marrow function requirements. There are also exclusion criteria, such as prior hormone therapy, chemotherapy, radiation therapy, or immunotherapy for prostate cancer, certain cardiovascular diseases, and other medical conditions. Major surgery or radiation therapy within 30 days of screening is also an exclusion criterion.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating head and neck squamous cell carcinoma. The trial includes a list of diseases, which in this case is only head and neck squamous cell carcinoma. It also includes a list of ICD-10 codes associated with the diseases. The trial involves several drugs, including cisplatin, 5-fluorouracile, docetaxel, cetuximab, and granulocyte colony-stimulating factor (g-csf). The eligibility criteria for the trial are listed, including requirements such as histologically confirmed diagnosis, measurable lesions, specific age range, and various health function requirements. There are also exclusion criteria, which specify conditions or factors that would make a patient ineligible for the trial. These include prior chemotherapy or radiation therapy, certain medical conditions, and pregnancy or breastfeeding.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is bacterial infections. The ICDCodes associated with this disease are A49.9, A04.9, A04.8, and A49.8. The drugs mentioned are mrx-i and linezolid. The eligibility criteria for this trial include patients with systemic signs of infection diagnosed with acute bacterial skin and skin structure infection (ABSSSI), specifically cellulitis/erysipelas, major cutaneous abscess, or wound infections. The exclusion criteria include uncomplicated skin infections, severe sepsis or septic shock, ABSSSI solely due to gram-negative pathogens, and prior systemic antibiotics within 96 hours of randomization.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of nasopharyngeal neoplasms, a type of cancer. The trial is specifically targeting patients with undifferentiated or poorly differentiated nasopharyngeal carcinoma that is locally advanced or metastatic.\n\nThe inclusion criteria for the trial include being 18 years or older, having a histological or cytological diagnosis of the specified type of cancer, experiencing disease progression after previous treatments, receiving a platinum-containing regimen, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and having radiographically-documented measurable disease. Additionally, patients must have adequate organ and bone marrow functions and be willing to follow pregnancy precautions.\n\nOn the other hand, the exclusion criteria for the trial include having a history of or current brain metastasis, having any other malignancy within the past 5 years (with some exceptions), having previous treatment with specific medications, having a history of gastrointestinal disorder or defect, having impaired ability to swallow oral medication or experiencing persistent diarrhea or malabsorption, having active cardiac disease or HIV infection, having active bleeding or a pathological condition that carries a high risk of bleeding, having a major surgery within 14 days prior to starting the investigational product or not having recovered from major side effects, having received another investigational therapy within a specific timeframe, not having recovered from the acute toxic effects of prior anticancer therapy, radiation, or major surgery/significant trauma, having received radiotherapy or limited field radiation within a specific timeframe, being pregnant or breastfeeding, or having any condition that places the patient at unacceptable risk or confounds the ability to interpret data from the study.\n\nOverall, this sample provides specific details about the phase, diseases, icd-10 codes, drugs, and eligibility criteria for a clinical trial focused on treating nasopharyngeal neoplasms.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of opioid-induced constipation. The associated ICD-10 codes for this condition are listed as ['F11.14', 'F11.181', 'F11.182', 'F11.188', 'F11.19', 'F11.24', 'F11.281']. The drugs being studied in this trial are 'linaclotide 145 micrograms', 'linaclotide 290 micrograms', and 'placebo'. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include having chronic non-cancer pain for at least 3 months, receiving a stable oral dose of a full-opioid agonist for at least 4 days per week for 8 consecutive weeks, meeting the protocol criteria for opioid-induced constipation, meeting colonoscopy requirements, successfully completing protocol procedures, being compliant with daily diary reporting, having less than 6 spontaneous bowel movements in the 14 days before randomization, and having adequate pain relief with the current opioid dose.\n\nExclusion criteria include using opioids for abdominal pain, having symptoms or a diagnosis of chronic constipation or chronic idiopathic constipation prior to starting opioid treatment, having symptoms or a diagnosis of Irritable Bowel Syndrome (IBS) prior to starting opioid treatment, having a history of loose or watery stools for more than 25% of bowel movements in the absence of laxatives, suppositories, or enemas, having a structural abnormality of the gastrointestinal tract or a condition that can affect GI motility, and having any medical or surgical history that could limit the patient's ability to complete or participate in the trial or confound the study assessments.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is Parkinson's disease, which is represented by the ICD-10 code \"G20\". The drugs being used in the trial are CD-LD IR, IPX203 180 mg, IPX203 270 mg, Rytary 195 mg, and Rytary 145 mg. The eligibility criteria for participants include being diagnosed with idiopathic PD with motor complications, currently being treated with stable regimens of CD-LD, requiring a specific dosage of LD per day, having a certain dosing frequency of IR CD-LD, and experiencing a certain amount of \"off\" time per day based on a PD diary. There are also exclusion criteria, such as not using controlled-release CD-LD or Rytary for at least 4 weeks prior to the trial, being a breastfeeding or lactating female, having undergone neurosurgical treatment for PD, having allergies to the study drugs, and having certain medical conditions or surgical procedures that could interfere with LD absorption. Other exclusion criteria include a history of peptic ulcer disease, narrow angle glaucoma, myocardial infraction with certain arrhythmias, neuroleptic malignant syndrome, nontraumatic rhabdomyolysis, or psychosis. Additionally, employees or family members of the investigator, study site, or sponsor are excluded, as well as subjects who, in the opinion of the clinical investigator, should not participate in the study. Lastly, subjects who do not adequately comprehend the terminology needed to complete the PD diary are also excluded.",
    "The sample from the table represents a phase 2 clinical trial for lung cancer. The eligibility criteria for patients to participate in the trial include having histologically confirmed non-small cell lung cancer (NSCLC) and being deemed surgical candidates by standard criteria. Patients with stage IA to IIB disease are eligible, and select patients with resectable stage IIIA disease may also be considered if approved by the principal investigator. Other criteria include having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1, measurable disease according to RECIST 1.1 criteria, and undergoing complete surgical staging when clinically indicated. Patients must also have controlled serious, active infections and be able and willing to take oral medications. Exclusion criteria include preexisting interstitial lung disease, N2 nodal disease or distant metastatic disease, clinically relevant cardiovascular abnormalities, certain lab values outside the normal range, active hepatitis B or C infection, known or suspected active drug or alcohol abuse, significant or recent acute gastrointestinal disorders, baseline cardiac left ventricular function below 50%, receiving other investigational agents, history of allergic reactions to certain drugs, uncontrolled intercurrent illness, psychiatric illness or social situations that would limit compliance, pregnancy or lactation, and inability to comply with study procedures. Patients who are not surgical candidates or refuse surgery are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"chronic obstructive pulmonary disease\" (COPD). The associated ICD-10 codes for COPD are \"J44.9\", \"J44.1\", and \"J44.0\". The trial involves testing three drugs: \"ypl-001 low dose\", \"ypl-001 high dose\", and a placebo. The eligibility criteria for participants are listed, including age range, history and diagnosis of COPD, severity classification, and other factors. There are also exclusion criteria, such as a history of life-threatening COPD, recent hospitalizations, exacerbations, and other medical conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of lymphoma. The ICD-10 codes associated with the disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drug being studied is ibrutinib. The eligibility criteria for participants in the trial are listed, including requirements for blood counts, liver function, kidney function, age, performance status, and ability to understand and consent to the study. There are also exclusion criteria, such as recent chemotherapy or surgery, history of other malignancies, cardiovascular disease, and certain medication use.",
    "The sample is a record from a table that contains information about clinical trials. It is for a phase 2 trial and the disease being studied is multiple myeloma. The ICD-10 codes associated with the disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are lenalidomide and dexamethasone. The sample also includes the eligibility criteria for the trial, including requirements such as being newly diagnosed with symptomatic multiple myeloma, not having received any prior systemic anti-myeloma therapy, and having measurable disease. There are also exclusion criteria listed, such as non-secretory myeloma, smoldering MM, and certain infections.",
    "The sample from the table represents a phase 2 clinical trial. The diseases being studied include estrogen receptor-positive breast cancer, gastrinoma, glucagonoma, her2-negative breast cancer, insulinoma, mucositis, oral complications, pancreatic polypeptide tumor, progesterone receptor-positive breast cancer, recurrent breast cancer, recurrent islet cell carcinoma, recurrent renal cell cancer, somatostatinoma, stage iii renal cell cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer, and stage iv renal cell cancer. The corresponding ICD-10 codes for these diseases are also provided. The drug being tested in the trial is everolimus. The eligibility criteria for the trial include specific performance status, confirmed diagnosis of certain diseases, adequate bone marrow, renal, and liver function, signed informed consent, and adequate birth control. The exclusion criteria include patients currently receiving anticancer therapies, known intolerance or hypersensitivity to everolimus, uncontrolled diabetes mellitus, severe and/or uncontrolled medical conditions, chronic treatment with corticosteroids or other immunosuppressive agents, history of HIV seropositivity, history of non-compliance to medical regimens, pregnant or nursing women, and women of child-bearing potential who are not using highly effective contraception. Male patients whose sexual partners are women of child-bearing potential and are not willing to use adequate contraception are also excluded.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial is specifically targeting postmenopausal women with estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The eligibility criteria include having a primary tumor of at least 2 centimeters in diameter, being at stage I to operable stage III breast cancer, and having no distant metastases. Other criteria include having a confirmed evaluable tumor tissue for PIK3CA mutation status, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and meeting certain hematological, renal, and hepatic function requirements. Exclusion criteria include prior treatment for primary invasive breast cancer, certain tumor stages, bilateral or metastatic breast cancer, and certain medical conditions such as diabetes requiring medication or gastrointestinal inflammation. The sample also lists other exclusion criteria related to cardiovascular disease, liver disease, and recent surgical procedures. Participants must be willing and able to comply with the study protocol and follow-up procedures.",
    "The sample provided is a schema definition of a table that contains information about different phases of a clinical trial, diseases, ICDCodes, drugs, and eligibility criteria. The table has three cohorts: Cohort A for Soft Tissue Sarcoma, Cohort B for Myxoid Liposarcoma, and Cohort C for Retroperitoneum Sarcoma.\n\nFor each cohort, there are inclusion and exclusion criteria listed. The inclusion criteria specify the requirements for patients to be eligible for the trial, such as age, specific disease diagnosis, tumor characteristics, disease progression, performance status, organ function, and other medical conditions. The exclusion criteria list the factors that would disqualify patients from participating in the trial, such as previous treatments, certain medical conditions, infections, pregnancy, and participation in other clinical trials.\n\nThe sample also includes additional details about the specific histological subtypes that can be included, the need for measurable disease according to RECIST criteria, the requirement for normal cardiac function, and the need for HBV and HCV serologies.\n\nOverall, the sample provides a comprehensive overview of the different cohorts, their inclusion and exclusion criteria, and the specific requirements for patients to participate in the clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is focused on the treatment of malignant melanoma, a type of cancer. The phase of the trial is a combination of phase 1 and phase 2. The diseases column specifies the disease being studied, which in this case is malignant melanoma. The icdcodes column contains a list of ICD-10 codes associated with the disease. The drugs column lists the drug being used in the trial, which is ipilimumab. The criteria column provides the eligibility criteria for participants in the trial, including requirements such as confirmed diagnosis of unresectable or metastatic malignant melanoma, specific stage of melanoma, performance status, age, and various health parameters. The exclusion criteria are also listed, which include factors such as autoimmune diseases, active brain metastasis, uncontrolled infectious diseases, pregnancy, breastfeeding, and other medical or psychiatric conditions that may make the administration of the study drug hazardous.",
    "The sample from the table represents a phase 2 trial with two diseases, \"compliance\" and \"chronic pain\". The corresponding ICD-10 codes for these diseases are 'G89.29', 'G89.4', 'R39.82', 'G89.22', 'G89.28', 'G89.21', and 'G89.3'. The trial involves the use of three drugs, namely acetazolamide, quinine, and riboflavin. \n\nThe eligibility criteria for this trial include being an English-speaking literate adult between the ages of 18 and 50, having a medically diagnosed chronic pain condition, being on a stable dose of buprenorphine, having a history of prescription opioid abuse, having adequate venous access, and for females, having a negative pregnancy test. Individuals who are unstable in buprenorphine treatment, as evidenced by continued illicit drug use and irregular clinic attendance in the previous trial, will not be accepted. Additionally, participants should be in good physical health or under the care of a physician who is willing to take responsibility for their treatment. The same conditions apply to patients with a psychiatric disorder needing ongoing treatment.\n\nThe exclusion criteria for this trial include having physiologic drug dependence on benzodiazepines, barbiturates, and/or alcohol that would require medical management, having significant ongoing medical problems such as diabetes, a history of head injury or seizure, serious psychiatric illness outside of drug use such as schizophrenia, recent use of any agent that inhibits or induces cytochrome P450 3A4 or 2D6, being a nursing or pregnant female, or a female or male who does not agree to not become pregnant or father a child during the course of the study and three months following completion, having a cardiac conduction or blood clotting disorder, having donated blood within the past 30 days prior to screening, having clinically significant laboratory results as judged by the investigator/sub-investigator, having moderate to severe COPD, renal impairment, or severe renal hepatic impairment.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on colorectal cancer. The trial is specifically for patients with refractory colorectal cancer, meaning that standard treatments have not been effective. The trial requires patients to have measurable disease and be refractory to or intolerant of standard systemic therapy. The inclusion criteria also specify that patients must be at least 18 years old, have an ECOG performance status of less than 2, and have a life expectancy of at least 12 weeks. Normal bone marrow and organ function are also required.\n\nThe exclusion criteria state that patients who have previously received a JAK2 or FLT3 inhibitor or have a history of other malignancies within the past 5 years (with some exceptions) are not eligible for the trial. Patients who have received any chemotherapeutic or targeted agent for metastatic colorectal cancer within two weeks of starting the study drug, those currently receiving other investigational agents, and those with known brain metastases are also excluded. Other exclusion criteria include a history of allergic reactions to similar compounds, uncontrolled intercurrent illness, pregnancy or breastfeeding, HIV-positivity on combination antiretroviral therapy, recent use of a potent cytochrome P450 3A4 inhibitor, CTCAE grade 2 cardiac arrhythmias (unless stable and asymptomatic), gastrointestinal or metabolic conditions that could interfere with medication absorption, and active viral hepatitis.",
    "The sample in the table is for a phase 2 clinical trial. The disease being studied is essential tremor, which is indicated by the presence of symptoms in at least one upper limb. The ICD-10 code for essential tremor is G25.0. The drugs being tested in the trial are sage-547 and placebo. The eligibility criteria for participants include being between 35-75 years old, having a diagnosis of essential tremor with symptoms present for at least 2 years, and either being off medication or on a stable dose for at least 28 days prior to screening. The exclusion criteria include having any recent or active clinically significant manifestations of various disorders, such as metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, dermatological, urogenital, eyes, ears, nose, or throat, psychiatric, or neurological disorders (other than essential tremor), as well as a medical history of seizures.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of hepatitis C. The diseases column specifies the disease being studied, which in this case is hepatitis C. The icdcodes column provides the ICD-10 codes associated with the disease. The drugs column lists the names of the drugs being used in the trial, which are simeprevir and sofosbuvir. The criteria column contains the eligibility criteria for participants in the trial, including requirements such as having a confirmed HCV genotype 4 infection, a certain level of HCV RNA, and a recent hepatic imaging procedure. The inclusion criteria also include requirements for female participants of childbearing potential to have negative pregnancy tests and to use effective contraception during the trial. The exclusion criteria include factors such as evidence of hepatic decompensation, presence of liver diseases other than HCV, and history of malignancy within the past 5 years.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on patients with hypertension and hyperlipidemia. The ICD-10 codes associated with these diseases are provided as well. The trial involves the use of a drug called \"polypill\" which contains atorvastatin, amlodipine, losartan, and hydrochlorothiazide. \n\nThe inclusion criteria for the trial include being enrolled at the SCCS site in Mobile, Alabama, obtaining care at Franklin Primary Health Center, or living in the surrounding area. Patients must be aged between 45 and 75 years and have a baseline systolic blood pressure of at least 120 mm Hg. The study physicians are allowed to prescribe additional medication to achieve blood pressure control.\n\nThe exclusion criteria for the trial include a history of coronary heart disease or stroke, history of cancer (except for basal cell skin cancer), history of liver disease (excluding chronic, clinically-stable hepatitis), laboratory evidence of hepatic dysfunction, known renal disease with estimated creatinine clearance less than 60, current use of more than 2 anti-hypertensive medications, LDL cholesterol levels of 190 mg/dl or higher, insulin-dependent diabetes, known intolerance to any of the components of the polypill, potassium levels below 3.4 or above 5.5 mEq/L, use of medications that interact with statins, current use of diuretics for indications other than hypertension, comorbidities that might limit lifespan during the 12-month follow-up period, and inability to provide consent.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. The ICDCodes associated with these diseases are provided as well. The drug being tested in this trial is regorafenib. The eligibility criteria for participants in this trial include age greater than or equal to 18 years, a life expectancy of at least 12 weeks, a diagnosis of recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer, and the presence of measurable disease. Other criteria include prior therapy with platinum-based chemotherapeutic regimens, ECOG score of 0-1, and adequate bone marrow, liver, and renal function. The exclusion criteria include patients who have progressed during initial platinum-based therapy, recent major surgical procedures or traumatic injuries, recent radiation therapy, recent chemotherapy or targeted anticancer therapy, active concurrent primary malignancy, use of investigational drugs within 28 days prior to enrollment, and various other medical conditions or factors that could pose safety risks or compromise compliance with the protocol.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of pulmonary arterial hypertension (PAH). The diseases column specifies the disease being studied, which in this case is \"pulmonary arterial hypertension.\" The icdcodes column provides the corresponding ICD-10 code for the disease, which is \"I27.21.\" The drugs column lists the drugs being used in the trial, which are \"apd811\" and \"placebo.\" The criteria column contains the eligibility criteria for participants in the trial, including age range, specific subgroups of PAH, confirmation of diagnosis, symptomatology, previous therapy, and various medical and laboratory requirements. The exclusion criteria are also listed, which include factors such as recent participation in other clinical studies, certain medical conditions, and use of specific medications.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is \"t2 diabetes and fatty liver disease (non-alcoholic origin)\". The ICDCodes associated with this disease are \"Z52.6\", \"K71.8\", \"K71.7\", \"A06.4\", \"C22.0\", \"C22.3\", and \"K70.0\". The drugs being tested in this trial are \"placebo\", \"omega-3 carboxylic acids\", and \"dapagliflozin\". The eligibility criteria for inclusion in the trial include providing informed consent, being between 40 and 75 years old, having suitable veins for cannulation or repeated venepuncture, having a liver fat content assessed by MRI greater than 5.5%, and having a diagnosis of Type 2 diabetes for at least 6 months according to WHO criteria. The exclusion criteria include contraindications for MRI, such as having a pacemaker or claustrophobia, a diagnosis or signs of Type 1 diabetes, and a creatinine clearance less than 60 mL/min at screening according to the Cockcroft-Gault formula.",
    "The sample provided is a record from a table that contains information about a clinical trial. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for participants in the trial.\n\nIn this specific sample, the phase of the trial is listed as \"phase 2/phase 3\". The disease being studied is \"fatty liver\". The corresponding ICD-10 codes for the disease are listed as \"['K70.0', 'K76.0']\". The drug being tested is \"aramchol\". The eligibility criteria for participants are then listed, including age requirements, BMI or waist circumference ranges, criteria for type II Diabetes Mellitus or pre-Diabetes, histological criteria for Steatohepatitis, liver fat concentration requirements, liver function requirements, informed consent, pregnancy test and contraception requirements, hypertension control requirements, previous treatments restrictions, and glycaemia control requirements for patients with type II Diabetes.\n\nThe exclusion criteria are also provided, which include exclusion of patients with other active liver diseases, liver cirrhosis, alcohol or drug abuse, certain medical conditions, familial hypertriglyceridemia and hypercholesterolemia, certain diseases or conditions that may interfere with drug absorption or metabolism, certain medical devices, recent surgeries, significant weight loss, history of bariatric surgery, uncontrolled hypertension, pregnancy or breastfeeding, other types of Diabetes Mellitus, HIV infection, excessive alcohol intake, certain anti-diabetic medications, certain other medications, chronic antibiotic treatment, homeopathic or alternative treatments, uncontrolled hypothyroidism, renal dysfunction, elevated serum creatine phosphokinase levels, conditions that make NMRS testing unsuitable, hypersensitivity to Aramchol or bile acid sequestrants.\n\nOverall, this sample provides specific information about the phase, diseases, drugs, and eligibility criteria for participants in a clinical trial focused on fatty liver.",
    "The sample from the table is for a phase 2 clinical trial for the treatment of non-Hodgkin lymphoma. The disease being studied is non-Hodgkin lymphoma, and the ICDCodes associated with it are \"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", and \"S33.131S\". The drug being tested is brentuximab vedotin. \n\nThe eligibility criteria for the trial include having histologically confirmed non-Hodgkin lymphoma with CD30 expression, relapsed or progressed disease after two or more salvage chemotherapy treatments, fully recovering from prior treatments, having measurable disease, a life expectancy of greater than 3 months, an ECOG performance status of 2 or lower, being between 18 and 75 years old, and meeting certain criteria for contraception for female patients or effective barrier contraception for male patients. \n\nThe sample also includes exclusion criteria such as having Hodgkin lymphoma, anaplastic large cell lymphoma, being pregnant or breastfeeding, having certain medical or psychiatric illnesses that could interfere with treatment, having certain neurological diseases or neuropathy, having active infections, having received recent chemotherapy or investigational agents, having known hypersensitivity to the drug being tested, being HIV positive or having active hepatitis B or C infection, having been diagnosed or treated for another malignancy within the past 3 years, and having certain cardiovascular conditions.",
    "The sample from the table is for a phase 2 trial. The diseases being studied are \"ddp\", \"head and neck cancer\", and \"adverse effect\". The corresponding ICD-10 codes for these diseases are \"C76.0\", \"C47.0\", \"C49.0\", \"C77.0\", \"D17.0\", \"D21.0\", \"D36.11\" for the first disease and \"T36.0X5S\", \"T36.3X5S\", \"T36.4X5S\", \"T36.5X5S\", \"T36.6X5S\", \"T37.0X5S\", \"T37.4X5S\" for the second disease. The drug being tested is \"trans-tympanic injection of a sodium thiosulfate gel\". The eligibility criteria for inclusion include patients with newly diagnosed locally advanced squamous cell carcinoma of the mouth, oropharynx, hypopharynx, or larynx who are scheduled to be treated with concomitant chemoradiation including Cisplatin 100 mg/m2 three times. The patients should also have normal otoscopic findings and symmetrical hearing. The exclusion criteria include patients with a Karnofsky score below 70.",
    "The sample from the table is for a phase 2 clinical trial for the treatment of schizophrenia. The trial is testing multiple drugs, including \"bi 409306 100 mg qd\", \"bi 498306 50 mg qd\", \"placebo\", \"bi 498306 25 mg qd\", and \"bi 409306 10 mg qd\". The eligibility criteria for the trial include patients with established diagnoses of schizophrenia who are clinically stable and in the residual phase of their illness for at least 8 weeks. They must also meet certain criteria regarding their current antipsychotic and psychotropic medications. The patients must be between the ages of 18 and 55 and have the capability to comply with all protocol procedures. Informed consent is required, and patients must have a consistent informant throughout the study. There are also exclusion criteria, such as patients treated with more than two antipsychotic medications, patients with cognitive impairment that would compromise the validity of the cognitive outcome measures, and patients with a history of suicidal behavior or clinically significant medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"carcinoma, squamous cell\", \"head and neck neoplasms\", and \"oropharyngeal neoplasms\". The corresponding ICDCodes for these diseases are ['C44.520', 'C44.92', 'C44.02', 'C44.321', 'C44.521', 'C44.82', 'C44.42'], ['C76.0', 'C47.0', 'C49.0', 'C77.0', 'D17.0', 'D21.0', 'D36.11'], and ['R13.12'] respectively. The drug being used in the trial is \"cisplatin (or alternative)\". The eligibility criteria for participants include age, specific cancer type, HPV and/or p16 positivity, smoking history, absence of hematogenous metastasis, performance status, blood counts, renal and hepatic function, pregnancy test for women, contraception, ability to comply with the treatment plan, and informed consent. The exclusion criteria include prior history of radiation therapy or head and neck cancer, unresectable disease, current use of Disease Modifying Rheumatoid Drugs (DMRDs), severe active co-morbidities, HIV positive status, and others.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on breast adenocarcinoma. The trial is specifically targeting patients with certain characteristics, such as having a confirmed primary invasive adenocarcinoma of the breast with a tumor size of at least 1 cm. The patients must also test negative for the human epidermal growth factor receptor 2 (HER-2)/neu disease. The trial is investigating the use of the drug talazoparib.\n\nThe eligibility criteria for the trial are listed, including requirements such as signed written informed consent, specific performance status, certain blood counts and levels, and various medical conditions that would exclude a patient from participating. The criteria also specify that women of childbearing potential must use contraception throughout the study.\n\nThe sample also includes exclusion criteria, which outline conditions that would disqualify a patient from participating in the trial. These include pregnancy, recent major surgery, certain medical conditions, and known hypersensitivity to talazoparib.\n\nOverall, the sample provides detailed information about the phase 2 trial, the targeted disease, the drug being investigated, and the eligibility and exclusion criteria for potential participants.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of ovarian, fallopian tube, or primary peritoneal carcinoma in post-menopausal women. The diseases included in the trial are ovarian endometrioid adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous cystadenocarcinoma, ovarian serous surface papillary adenocarcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent ovarian germ cell tumor, recurrent primary peritoneal carcinoma, and undifferentiated ovarian carcinoma. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being tested in the trial are everolimus and letrozole. The eligibility criteria for the trial include specific requirements related to the patient's disease, biopsy, disease measurement, performance status, blood counts, liver function, kidney function, cholesterol and triglyceride levels, informed consent, follow-up, and tissue sample provision. The exclusion criteria include factors such as pregnancy, nursing, severe concurrent diseases, HIV positivity, ongoing or active severe infection, liver disease, heart failure, lung function impairment, bleeding diathesis, psychiatric illness, prior malignancy, ongoing or recent anticancer therapies, intolerance or hypersensitivity to the drugs being tested, gastrointestinal function impairment, uncontrolled diabetes, chronic corticosteroid or immunosuppressive treatment, recent live attenuated vaccines, history of non-compliance, prior therapy with the drugs being tested, brain metastasis, and active and chronic viral hepatitis.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease scleroderma, systemic. The trial is looking at the effectiveness of the drug riociguat (adempas, bay63-2521) compared to a placebo. The eligibility criteria for participants include being 18 years or older, having systemic sclerosis as defined by ACR/EULAR criteria, having dcSSc (diffuse cutaneous systemic sclerosis) according to the LeRoy criteria, having a disease duration of 18 months or less, having a mRSS (modified Rodnan skin score) between 10 and 22 units, having a FVC (forced vital capacity) of at least 45% of predicted, having a DLCO (diffusion capacity of the lung for carbon monoxide) of at least 40% of predicted, having a negative pregnancy test for women of childbearing potential, and agreeing to use adequate contraception. There are also exclusion criteria, such as having limited cutaneous SSc, recent major surgery, hepatic insufficiency, certain renal conditions, certain cardiovascular conditions, pulmonary disease, active hemoptysis or pulmonary hemorrhage, and not meeting medication or pregnancy requirements.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes information about the diseases being studied, the associated ICD-10 codes, the drugs being tested, and the eligibility criteria for participants.\n\nIn this particular trial, the diseases being studied are \"kidney failure, chronic\" and \"prediabetic state.\" The corresponding ICD-10 codes for these diseases are listed as \"N99.0,\" \"I13.0,\" \"I13.10,\" \"I13.11,\" and \"I13.2.\" The drugs being tested in the trial are \"liraglutide\" and \"placebo.\"\n\nThe eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having end-stage renal disease treated with chronic maintenance dialysis and impaired glucose tolerance or impaired fasting glucose. Exclusion criteria include having diabetes mellitus type 1 or type 2, chronic pancreatitis, known or suspected hypersensitivity to trial products, and various other conditions that could interfere with the trial results.\n\nThe record also includes additional information about contraceptive methods for female participants and exclusions for certain individuals who are unable to give informed consent.\n\nOverall, this sample provides a snapshot of the phase 2 trial, including the diseases being studied, the drugs being tested, and the eligibility criteria for participants.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is primary progressive multiple sclerosis. The ICD-10 codes associated with this disease are A81.2, G12.22, G60.3, I67.3, M34.0, Q78.3, and G12.25. The drugs being used in the trial are placebo and laquinimod. The eligibility criteria for the trial are listed, including requirements for confirmed diagnosis, MRI findings, disability scores, age range, birth control usage, and willingness to comply with the study requirements. The exclusion criteria are also listed, which include previous treatments, use of certain medications, medical conditions, and hypersensitivities.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is lupus erythematosus, systemic. The ICDCodes associated with this disease are M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, and M32.8. The drug being used in the trial is rituximab with belimumab. The eligibility criteria for participants in this trial include being 18 years or older, having a diagnosis of systemic lupus erythematosus according to the American College of Rheumatology (ACR) criteria, experiencing a severe flare of lupus symptoms, having refractory disease despite previous treatment, being ANA seropositive, being anti-DNA seropositive, having immune-complex mediated complement usage, and using effective contraception. The exclusion criteria include active pregnancy, significant B-cell depletion, significant hypogammaglobulinemia, recent immunization with a live vaccine, and active infection at the time of screening.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is postpartum depression, and the corresponding ICDCodes for this disease is F53.0. The drug being tested is sage-547. \n\nThe eligibility criteria for this trial are as follows:\n- The trial is open to adult females between the ages of 18 and 45 who have experienced a Major Depressive Episode in the postpartum period within the first 4 weeks following delivery.\n- The patient must have stopped lactating, or if still lactating, they must agree to cease giving breast milk to their infant before entering the study.\n\nThere are also exclusion criteria, which include:\n- Any recent history or active clinically significant manifestations of various disorders related to metabolism, liver, kidney, blood, lungs, heart, digestive system, muscles, skin, urinary system, or eyes, ears, nose, and throat.\n- Active psychosis.\n- A medical history of seizures.",
    "The sample is a phase 2 clinical trial for lung cancer patients. The trial is focused on the use of the drug metformin in combination with hypofractionated radiation therapy. The inclusion criteria for the trial include patients with a pathologic diagnosis of lung non-small cell carcinoma or squamous cell carcinoma, who are not surgical candidates due to medical comorbidities or patient refusal. The patients must plan to receive treatment at MD Anderson and must have adequate renal function. Exclusion criteria include patients with high random glucose levels or those taking oral hypoglycemic agents or insulin, patients with a history of lactic acidosis or chronic kidney disease, pregnant or breastfeeding women, and patients with a history of allergic reaction to metformin.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is gout. The ICDCodes associated with gout are provided as well. The drugs mentioned in the sample are placebo, ac-201, and febuxostat. The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The criteria include age requirements, specific criteria for the classification of acute arthritis of primary gout, serum uric acid levels, and restrictions on medication usage.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating rectal cancer. The trial includes the use of drugs such as dexamethasone, regorafenib, placebo, and a proton pump inhibitor. The eligibility criteria for participants are listed, including requirements such as being able to provide informed consent, having a histological diagnosis of adenocarcinoma, and having normal bone marrow, hepatic, and renal functions. There are also exclusion criteria listed, such as having previously used regorafenib, having certain medical conditions or illnesses, or being pregnant or nursing.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 2. The disease being studied is schizophrenia, and its corresponding ICD-10 codes are ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drug being tested is iti-007. The sample also includes the eligibility criteria for the trial. The inclusion criteria state that patients must have schizophrenia, be drug-free from antipsychotic medication, be in clinical remission, and be in good health. The exclusion criteria state that patients with clinically significant medical conditions that are considered inappropriate for trial participation will be excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is hormone-refractory prostate cancer. The ICDCodes associated with this disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drug being used in the trial is enzalutamide. The eligibility criteria for this trial include various factors such as age, confirmation of prostate adenocarcinoma without certain characteristics, androgen deprivation therapy, specific serum levels, stable bisphosphonate therapy, disease progression, metastatic disease, previous treatments, patient symptoms, life expectancy, ability to follow the protocol, and more. The exclusion criteria include factors such as active infections, brain metastasis, other malignancies, abnormal hematologic and liver function, renal function, history of epilepsy, cardiovascular disease, gastrointestinal disease, recent surgeries or radiation therapies, prior treatments with specific drugs, and other conditions that may preclude participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are mk-3475, pomalidomide, and dexamethasone. \n\nThe eligibility criteria for this trial include:\n1. Confirmed diagnosis of relapsed and/or refractory multiple myeloma.\n2. Having received two lines of prior therapy, including an IMiD (lenalidomide or thalidomide) and a proteasome inhibitor (bortezomib and/or carfilzomib).\n3. Measureable disease as defined by the protocol.\n4. Willingness and ability to provide written informed consent/assent for the trial.\n5. Being over 18 years of age.\n6. Having a performance status of 2 on the ECOG Performance Scale.\n7. Demonstrating adequate organ function.\n8. Female subjects of childbearing potential should have a negative serum pregnancy test.\n9. Male subjects should agree to use contraception.\n\nThe exclusion criteria for this trial include:\n1. Currently participating in or having participated in another investigational study within 4 weeks of the first dose of treatment.\n2. Having immunodeficiency (HIV) or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.\n3. Having received a prior monoclonal antibody within 4 weeks prior to study Day 1 or not having recovered from adverse events due to agents administered more than 4 weeks earlier.\n4. Having received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not having recovered from adverse events due to a previously administered agent.\n5. Having a known additional malignancy that is progressing or requires active treatment, except for certain types of skin cancer or situ cervical cancer that has undergone potentially curative therapy.\n6. Having known active central nervous system disease and/or carcinomatous meningitis.\n7. Having an active autoimmune disease requiring systemic treatment within the past 3 months or a history of clinically severe autoimmune disease.\n8. Having evidence of interstitial lung disease or active, non-infectious pneumonitis.\n9. Having an active infection requiring systemic therapy.\n10. Having a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the trial or interfere with the subject's participation.\n11. Having known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n12. Being pregnant or breastfeeding, or expecting to conceive or father children during study participation.\n13. Having received prior therapy with certain antibodies as per the protocol.\n14. Having known active Hepatitis B or Hepatitis C.\n15. Having a known history of Human Immunodeficiency Virus (HIV).\n16. Having received a live vaccine within 30 days prior to the first dose of trial treatment.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"ulcerative colitis.\" The ICD-10 codes associated with this disease are provided as well. The trial involves the drugs \"apremilast\" and \"placebo.\" The eligibility criteria for participants are listed, including age requirements, the duration of ulcerative colitis diagnosis, specific scores on the Mayo scale, and previous treatment failures or contraindications. The exclusion criteria are also listed, which include specific diagnoses, prior use of certain medications, recent use of corticosteroids or immunosuppressants, and various medical conditions that would prevent participation in the study.",
    "The sample is a phase 2 clinical trial for the treatment of non-small-cell lung carcinoma. The trial is evaluating the effectiveness of the drugs nab-paclitaxel and carboplatin. The eligibility criteria for participants include being at least 18 years old, having confirmed stage IIIB or IV non-small-cell lung cancer, having measurable disease, and not having received prior anti-cancer therapy for metastatic disease. Other criteria include specific blood counts and liver function, performance status, and certain requirements for females of childbearing potential and male subjects. The exclusion criteria include the presence of active brain metastases, history of leptomeningeal disease, pre-existing peripheral neuropathy, recent radiotherapy or limited field radiation, venous thromboembolism, congestive heart failure, and various other medical conditions. The sample also specifies that pregnant or breastfeeding females and subjects with an ECOG PS other than 2 are excluded from the trial.",
    "The sample from the table represents a phase 2 clinical trial for non-small cell lung cancer. The trial is focused on evaluating the effectiveness of the drug trastuzumab emtansine. The eligibility criteria for participants include having a histologically or cytologically documented diagnosis of Stage IIIB or Stage IV NSCLC, with a specific subtype classification. Participants must also have a HER2 status of IHC 2+ or 3+ and have received prior treatment with platinum-based chemotherapy. Additionally, participants with specific genetic mutations (ALK fusion oncogene or EGFR gene) must have experienced disease progression or intolerance with previous treatments. Other criteria include having measurable disease, a life expectancy of at least 12 weeks, adequate organ function, an ECOG performance status of 0 or 1, and a left ventricular ejection fraction of at least 50%. Participants must also use highly effective contraception. \n\nExclusion criteria include recent anti-cancer therapy, participation in another clinical study with therapeutic intent, recent irradiation, untreated or symptomatic brain metastases, history of intolerance or hypersensitivity to trastuzumab or murine proteins, exposure to certain cumulative doses of anthracyclines, peripheral neuropathy of Grade 3 or higher, history of other malignancy within the last 5 years (with some exceptions), uncontrolled pleural effusion, severe dyspnea at rest, active hemoptysis or pneumonitis, unstable ventricular arrhythmia, history of congestive heart failure or recent myocardial infraction, decrease in left ventricular ejection fraction, current severe, uncontrolled systemic disease, recent major surgical procedure or traumatic injury, current pregnancy or lactation, and current active infection with HIV, HBV, or HCV.",
    "The sample is a phase 2 trial for the treatment of diabetic gastroparesis. The eligibility criteria for patients to participate in the trial include being 18 years or older, having a confirmed diagnosis of type 1 or type 2 diabetes mellitus, and a diagnosis of DGP with no history or evidence of mechanical obstruction. Patients must also have delayed gastric emptying of solids documented within 2 years of the screening visit and a normal EGD with no evidence of structural or organic disease that may explain the gastroduodenal symptoms. Other criteria include being compliant with eDiary completion, refraining from making major lifestyle changes, and being fluent and literate in English.\n\nExclusion criteria for the trial include having a history or current symptoms of any organic or structural disease that can cause abdominal pain or discomfort, having rumination syndrome, cyclic vomiting syndrome, anorexia nervosa, or bulimia. Patients who are currently using a gastric electric stimulator or have had endoscopic pyloric injections of botulinum toxin within the 6 months prior to the screening visit are also excluded. Additionally, patients who have been hospitalized within the 2 months prior for uncontrolled diabetes mellitus, DGP, or associated malnutrition, or who have reported significant diarrhea during the four weeks prior to the screening visit are not eligible. Patients who have had surgery of the GI tract, appendectomy or cholecystectomy during the 3 months before the screening visit, non-GI surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months, or other major non-GI surgery during the 30 days before the screening visit are also excluded. Patients with a history of cancer, except for resected basal cell or squamous cell carcinoma of the skin, are not eligible to participate in the trial.",
    "The sample from the table represents a phase 2 clinical trial for pancreatic cancer. The eligibility criteria for participants include having confirmed metastatic pancreatic ductal adenocarcinoma, not having received prior chemotherapy or radiotherapy for the disease, having available tumor tissue for analysis, being at least 21 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, having measurable disease according to RECIST v1.1 criteria, having adequate organ and marrow function, and signing an informed consent form. Women of childbearing potential must agree to use two effective forms of contraception. \n\nOn the other hand, the exclusion criteria include having a neuroendocrine tumor, acinar tumor, or pancreatic tumor with mixed histologies, receiving certain anticoagulant medications, having brain metastases, leptomeningeal disease, uncontrolled seizure disorder, or active neurologic disease, having peripheral neuropathy of grade >2, having clinically significant ascites, having had other malignancies successfully treated within the past 3 years (with some exceptions), having significant intercurrent illness that may limit participation or result in death within the next 18 months, having a history of significant allergic reaction to humanized or human monoclonal antibody therapy, having known clinically significant gastrointestinal disease, being pregnant or nursing, having known HIV infection, or having a known bleeding disorder or coagulopathy.",
    "The sample from the table is for a phase 2 trial. The diseases being studied are gout and hyperuricemia. The corresponding ICD-10 codes for gout are M10.9, M10.08, M10.00, M10.011, M10.012, M10.019, and M10.021, while the ICD-10 code for hyperuricemia is E79.0. The drugs being tested in this trial are urc102 0.25mg, urc102 0.5mg, urc102 1.0mg, urc102 2.0mg, and a placebo. The eligibility criteria for inclusion in the trial is being diagnosed with gout, while the exclusion criteria include having participated in another clinical study within 12 weeks prior to enrollment and having received an investigational product, including placebo.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease mentioned is \"primary Sj\u00f6gren's syndrome,\" and its corresponding ICDCodes are ['D68.61', 'D69.41', 'D81.4', 'E24.1', 'E26.01', 'E26.81', 'E34.0']. The drugs involved in this trial are 'cfz533 active - cohort 1', 'cfz533 placebo- cohort 1', 'cfz533 active - cohort 2', 'cfz533 placebo - cohort 2', 'cfz533 active -cohort 3', and 'cfz533 active - cohort 3'. The eligibility criteria for this trial include specific inclusion and exclusion criteria. Inclusion criteria include a diagnosis of primary Sj\u00f6gren's syndrome and an ESSDAI score of 6 or higher. Exclusion criteria include secondary Sj\u00f6gren's syndrome, receiving certain medications, being at significant risk for thromboembolic events or clinically significant systemic infection, and having a significantly elevated risk for infection.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which includes the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is described as \"phase 1/phase 2\". The disease being studied is \"liver cancer\" and the corresponding ICD-10 codes are provided as \"['D13.4', 'Z85.05', 'C22.8', 'C78.7', 'C22.9', 'D37.6']\". The drug being tested is \"bleomycin phc 15 e. (united states pharmacopeia - usp)\". \n\nThe eligibility criteria for this trial are then listed, including specific conditions that patients must meet in order to be included in the trial. These conditions include having primary liver tumors such as hepatocellular carcinoma or intrahepatic cholangiocarcinoma, having disease progression after treatment with TACE, RFA, or percutaneous alcohol ablation, having tumors that are not suitable for standard treatment procedures, having tumors smaller than 4 cm in diameter, having a life expectancy of more than 3 months, and meeting certain performance status and age requirements. \n\nThe exclusion criteria are also provided, which outline conditions that would disqualify a patient from participating in the trial. These conditions include having secondary primary tumors, having metastases, having life-threatening infections or severe systemic pathologies, having certain medical conditions or allergies, being pregnant, and not being capable of understanding the purpose of the study or disagreeing with participating in the clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on hypertrophic cardiomyopathy, a heart condition characterized by thickening of the heart muscle. The trial is investigating the effectiveness of the drugs eleclazine and placebo. The eligibility criteria for participants include having a diagnosis of hypertrophic cardiomyopathy with a left ventricular wall thickness of at least 15 mm, experiencing exertional symptoms such as dyspnea or angina, having a screening peak VO2 (a measure of exercise capacity) below 80% of predicted values, and being able to perform a treadmill cardiopulmonary exercise test. Some exclusion criteria include having aortic valve stenosis, coronary artery disease, left ventricular systolic dysfunction, or having undergone a septal reduction procedure within the past six months.",
    "The sample is from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (in this case, phase 2), \"diseases\" which lists the names of the diseases being studied (in this case, \"chronic hepatitis c virus infection\"), \"icdcodes\" which provides the icd-10 codes associated with the diseases, \"drugs\" which lists the names of the drugs being used in the trial, and \"criteria\" which includes the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is phase 2 and the disease being studied is chronic hepatitis c virus infection. The icd-10 codes associated with this disease are listed as \"B00.81\", \"B25.1\", \"B26.81\", \"B58.1\", \"K75.4\", \"A51.45\", and \"B17.2\". The drugs being used in the trial are \"obv/ptv/r\", \"sofosbuvir\", and \"ribavirin (rbv)\". The eligibility criteria for the trial are provided, including inclusion criteria such as having chronic HCV infection, specific HCV genotype, absence or presence of cirrhosis, and exclusion criteria such as positive screen for hepatitis B or HIV, recent history of drug or alcohol abuse, and current or previous enrollment in other clinical studies or use of certain anti-HCV therapies. Additionally, there are criteria related to cirrhosis, abnormal lab tests, and pregnancy or breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with Hodgkin lymphoma. The trial is focused on patients with supradiaphragmatic Ann Arbor clinical stage I or II, previously untreated, and with certain unfavorable characteristics according to the classic EORTC/LYSA clinical prognostic factors. The trial aims to evaluate the effectiveness of a combination of drugs including doxorubicin, bleomycin, vinblastine, dacarbazine, and brentuximab vedotin. \n\nThe eligibility criteria for the trial include being histologically confirmed with CD30+ classical Hodgkin lymphoma, having a PET scan without IV contrast at diagnosis available for central review, having an ECOG performance status of 0-2, and having a life expectancy of more than 6 months. Other criteria include being between the ages of 18 and 60, having certain baseline laboratory data within specified ranges, and providing written informed consent.\n\nExclusion criteria for the trial include having a histological diagnosis different from classical Hodgkin lymphoma, having known cerebral or meningeal disease, having sensory or motor peripheral neuropathy of grade 2 or higher, and having certain cardiovascular conditions. Other exclusion criteria include having unstable diabetes mellitus, being HIV positive, being HCV positive, having certain types of cancer within the last 5 years, having dementia or altered mental status, being pregnant or breastfeeding, and having previous treatment with any anti-CD30 antibody.\n\nIt is important to note that this description is based on the provided sample and may not represent the complete information or requirements of the clinical trial.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is acute coronary syndrome. The ICD-10 code for this disease is I24.0. The drugs being used in the trial are acetylsalicylic acid, rivaroxaban, clopidogrel, and ticagrelor. The eligibility criteria for participants include having symptoms suggestive of acute coronary syndrome within 48 hours of hospital presentation, or developing ACS while being hospitalized. Participants must also have a diagnosis of either ST segment elevation myocardial infraction (STEMI) or non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Participants who are 54 years of age or younger must also have either diabetes mellitus or a history of a prior myocardial infraction (MI). Participants must be randomized within 10 days after hospital admission for the index ACS event and must have received acute phase treatment for the index ACS. Participants must also agree to provide a pharmacogenomics DNA sample. Exclusion criteria include contraindications to anticoagulant therapy, prior stroke or transient ischemic attack (TIA), receiving thrombolytic therapy for the index ACS event, anticipated need for chronic administration of omeprazole or esomeprazole with clopidogrel, and known allergy or intolerance to ASA or rivaroxaban.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease influenza. The ICD-10 codes associated with influenza are ['J11.81', 'J11.82', 'J10.01', 'J10.81', 'J10.82', 'J11.08', 'J11.2']. The drugs being studied in this trial are 'mhaa4549a', 'oseltamivir', and 'placebo'. The eligibility criteria for participants are listed, including requirements for diagnosis, markers of severity, pregnancy testing, contraceptive measures, and exclusion criteria such as hypersensitivity to certain substances, prior therapy, and specific medical conditions.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is chronic obstructive pulmonary disease (COPD). The ICD-10 codes associated with this disease are J44.9, J44.1, and J44.0. The drugs being tested in the trial are gsk2269557 and a placebo. The eligibility criteria for participants include being between 40 and 80 years old, having a confirmed diagnosis of COPD for at least 6 months, having specific lung function measurements, experiencing an acute exacerbation of COPD, being a smoker or ex-smoker with a certain smoking history, having a certain body weight and body mass index, and meeting certain criteria for female participants regarding reproductive potential and contraception. There are also exclusion criteria, such as severe COPD exacerbation, certain medical conditions or diseases, certain liver or cardiac abnormalities, certain medications or treatments, history of alcohol consumption, allergies to study medications, and certain infectious diseases. The sample also includes criteria related to previous clinical trial participation and blood donation.",
    "The sample from the table represents a phase 2 clinical trial for patients with transient ischemic attack (TIA) or minor ischemic stroke. The trial is investigating the effectiveness of two drugs, dabigatran and acetylsalicylic acid, in treating these conditions. \n\nThe inclusion criteria for the trial are as follows:\n1. Patients can be male or female.\n2. Patients must be over 18 years of age.\n3. Patients must have TIA or ischemic stroke with a NIHSS score less than 9.\n4. Symptom onset must be within 72 hours prior to enrollment, or study therapy must be initiated within 48 hours of symptom onset. If the exact onset time is unknown, it will be considered the time when the patient was last known to be well.\n5. Informed consent must be obtained from the patient or their substitute decision maker before any study-related procedures are performed.\n6. All patients will undergo an MRI, including diffusion-weighted imaging (DWI), before randomization.\n7. The DWI lesion volume must be less than 25ml.\n8. Patients without DWI lesions but with a clinical history consistent with TIA, as determined by the attending physician, can also be included.\n\nThe exclusion criteria for the trial are as follows:\n1. Patients with stroke mimics such as seizures or migraines.\n2. Patients with contraindications to MRI, including metallic implants.\n3. Patients with a past sensitivity to gadolinium contrast media, who will not undergo certain optional sequences.\n4. Patients with renal failure, defined as a Glomerular Filtration Rate (GFR) less than 30 ml/min.\n5. Patients deemed by the attending stroke physician to have ongoing bleeding risks or unsuitability for dabigatran therapy.\n6. Patients with additional pathology shown on MRI, such as arteriovenous malformations, intracranial aneurysms, tumors, or abscesses, which may increase the risk of bleeding. However, patients with small incidental lesions at low risk of bleeding, such as meningiomas, may be included at the investigator's discretion.\n7. Patients with an acute DWI lesion volume greater than 25 ml.\n8. Patients under 18 years of age.\n9. Pregnant or breastfeeding women.\n10. Patients with severe dysphagia requiring naso-gastric (NG) feeding, as dabigatran cannot be delivered via NG tube.\n11. Patients with planned thrombolysis or endovascular intervention for the index event.\n12. Patients who have undergone thrombolysis for ischemic stroke within the past 7 days.\n13. Patients with a planned carotid endarterectomy or carotid artery stent within 30 days. Carotid investigations will be completed before enrollment, and patients with symptomatic stenoses and a planned carotid procedure will be excluded.\n14. Patients with a history of spontaneous intracranial bleeding.\n15. Patients with a clear indication for anticoagulation, including atrial fibrillation, mechanical cardiac valves, deep venous thrombosis, pulmonary embolism, or known hypercoagulable state.\n16. Patients with a co-morbid illness and an expected life expectancy of less than 90 days.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 2, and the disease being studied is psoriasis. The icd-10 codes associated with psoriasis are 'L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', and 'L40.50'. The drugs being tested in this trial are 'jnj-38518168 60 mg', 'jnj-38518168 30 mg', 'jnj-38518168 3 mg', and 'placebo'. The eligibility criteria for participants include having a diagnosis of plaque-type psoriasis for at least 6 months, specific scores on the Psoriasis Area and Severity Index (PASI) and Investigator's Global Assessment (IGA), negative pregnancy test for women of childbearing potential, and agreement to use birth control for men. The exclusion criteria include having severe or uncontrolled diseases, current or recent history of malignancy, history of lymphoproliferative disease, chronic or recurrent infectious diseases, history of infected joint prosthesis, and previous use of biologic therapy for psoriasis or psoriatic arthritis.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is paroxysmal supraventricular tachycardia (PSVT). The ICD-10 code for this disease is I47.1. The drugs being tested are etripamil and a placebo. The eligibility criteria for participants include being 18 years or older, having a history of PSVT, and being scheduled for an electrophysiology study and catheter ablation. Participants must also provide written informed consent and agree to use contraception or practice abstinence during the study period. Exclusion criteria include having a serious allergic reaction to verapamil, currently participating in another drug or device study, and having any clinically significant cardiovascular, endocrine, gastrointestinal, hematologic, hepatic, immunologic, neurologic, oncologic, pulmonary, psychiatric, or renal disease. Other exclusion criteria include being pregnant or planning to become pregnant, having certain nasal cavity conditions, having low blood pressure, hepatic or renal impairment, recent use of certain medications, and having certain cardiac conditions. Additionally, participants who do not meet certain criteria at the treatment visit or require continuous sedation or analgesia may also be excluded from the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 2. The disease being studied is metastatic colorectal cancer. The icd-10 codes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are cetuximab and irinotecan. The eligibility criteria for this trial include having a histologically proven diagnosis of colorectal adenocarcinoma, RAS and BRAF wild-type status, and having received first-line irinotecan-based cetuximab-containing therapy that produced at least a partial response. Other criteria include specific timeframes between treatments, measurable disease according to RECIST criteria, availability of tumor tissue for biomarker analysis, and certain health and demographic requirements. The exclusion criteria include active uncontrolled infections, history of other malignancies, pregnancy or breastfeeding, and previous severe reactions to cetuximab.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being tested, and \"criteria\" which provides the eligibility criteria for participants in the trial.\n\nIn this particular sample, the phase of the trial is described as \"phase 1/phase 2\". The diseases being studied are \"acute myelogenous leukemia\" and \"myelodysplastic syndrome\". The corresponding ICD-10 codes for these diseases are provided as well. The drug being tested is \"bvd-523\". The eligibility criteria for participants include having a confirmed diagnosis of acute myeloid leukemia (AML) or intermediate-2 or high-grade risk myelodysplastic syndrome (MDS), having received at least one prior therapy, having an ECOG performance status of 0 to 2, having a predicted life expectancy of at least 3 months, and having adequate liver, renal, and cardiac function.\n\nThere are also specific exclusion criteria listed, such as having concomitant malignancies (except for certain types), having gastrointestinal conditions that could impair absorption of the study medication, having uncontrolled or severe intercurrent medical conditions, and having received certain cancer-directed therapies or investigational drugs within a specified timeframe. Other exclusion criteria include recent major surgery, pregnancy or breastfeeding, evidence of serious active infections, and any medical illness or abnormal laboratory finding that would increase the risk of participating in the study.\n\nAdditionally, there are specific criteria mentioned for a particular group within the study, such as being positive for RAS mutation at a certified laboratory prior to study entry.\n\nOverall, this sample provides information about the phase, diseases, drugs, and eligibility criteria for a clinical trial related to acute myelogenous leukemia and myelodysplastic syndrome.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes details about the diseases being studied, the associated ICD-10 codes, the drugs being used, and the eligibility criteria for participants.\n\nIn this particular trial, the diseases being studied are breast cancer, breast carcinoma, and breast tumors. The corresponding ICD-10 codes for these diseases are also provided. The drugs being used in the trial are letrozole and palbociclib.\n\nThe eligibility criteria for participants include being a postmenopausal woman, having operable ER-positive/HER2-negative invasive early breast cancer, and having a breast tumor with an ultrasound size of at least 2.0 cm. Other criteria include the ability to swallow oral medication, a performance status of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG), and meeting certain blood count and liver function criteria.\n\nThe exclusion criteria for participants include having active hepatitis B or hepatitis C, being HIV positive and receiving antivirals, being premenopausal or peri-menopausal, having inflammatory/inoperable breast cancer, and being HER2-positive. Other exclusion criteria include prior endocrine therapy for breast cancer, having any invasive malignancy within the previous 5 years (except for basal cell carcinoma or cervical carcinoma in situ), and having certain nonmalignant systemic diseases or conditions.\n\nAdditionally, the sample includes criteria related to previous treatments, medication usage, cardiac health, and psychiatric or addictive disorders that may preclude a participant from meeting the study requirements.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is malignant melanoma. The ICD-10 codes associated with the disease are C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, and C43.10. The drug being tested is a combination of dabrafenib and trametinib. The eligibility criteria for the trial include being 18 years of age or older, having histologically confirmed cutaneous melanoma that is either Stage IIIC or Stage IV and is BRAF V600E/K mutation-positive, having failed at least two prior systemic anti-cancer treatments, having documented progression of disease, having at least one measurable lesion, meeting certain time intervals between prior therapies and recruitment, not having ocular melanoma, having no significant prior treatment-related toxicities, being able to swallow and retain oral medication, having a negative pregnancy test for women of childbearing potential, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and having adequate baseline organ function. The exclusion criteria include having grade 4 or repetitive grade 3 adverse events related to prior treatment with a BRAF- and/or MEK inhibitor, having any contraindication for evaluation by whole body CT and MRI of the brain, having taken an investigational drug within a certain timeframe, having current use of prohibited medications, having a history of another malignancy (except for certain exceptions), having serious or unstable pre-existing medical conditions or psychiatric disorders, having known HIV, HBV, or HCV infection, having progressive symptoms from active brain metastasis or needing an increase in corticosteroids dose, not having taken enzyme inducing anticonvulsants for a certain timeframe, having a history or evidence of cardiovascular risk, having uncorrectable electrolyte abnormalities or long QT syndrome, having known hypersensitivity reaction to related drugs, being pregnant or nursing, having interstitial lung disease or pneumonitis, and having a prior history of certain ocular conditions.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2. The diseases being studied are \"allergic rhinoconjunctivitis\" and \"healthy volunteers\". The ICDCodes associated with these diseases are \"D69.0\", \"L50.0\", \"B44.81\", \"J30.89\", \"J30.9\", \"L20.84\", and \"H10.45\". The drug being used in this trial is a placebo. The eligibility criteria for inclusion include having IgE-mediated seasonal allergic rhinitis/rhinoconjunctivitis with or without allergic asthma, a positive skin prick test, specific IgE levels of at least 0.70 kU/L to a mixture of grass pollen allergens, and a symptom score of at least 4 per day during the week following the peak-pollen count in the baseline season. The exclusion criteria include having undergone specific immunotherapy with grass pollen allergens in any formulation less than 5 years prior to the screening date, currently undergoing any sort of immunotherapy or having undergone specific immunotherapy with an unknown allergen, having allergens that are expected to interfere with the grass pollen season, having uncontrolled or partly controlled asthma, and having contraindications for SIT (specific immunotherapy).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are acromegaly and neuroendocrine tumors. The corresponding ICDCodes for these diseases are 'E22.0' for acromegaly and ['C7A.1', 'C7A.8', 'C7B.8', 'D3A.8'] for neuroendocrine tumors. The drug being used in the trial is octreotide fluidcrystal\u00ae injection depot.\n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- For patients with acromegaly: they must be male or female and at least 18 years old, and currently treated with Sandostatin LAR.\n- For patients with neuroendocrine tumors (NET): they must be male or female and at least 18 years old, have functional, well-differentiated (Grade 1 or Grade 2) NET with symptoms of carcinoid syndrome (number of bowel movements and/or flushing), and currently treated with Sandostatin LAR for symptom control.\n\nExclusion Criteria:\n- For patients with acromegaly: they should not have inadequate bone marrow function, abnormal coagulation or chronic treatment with warfarin or coumarin derivates, impaired liver, cardiac and/or renal function, known gallbladder, bile duct disease or pancreatitis, diabetes with poorly controlled blood glucose levels despite adequate therapy, or hypothyroidism not adequately treated.\n- For patients with neuroendocrine tumors (NET): they should not have poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, pancreatic islet cell carcinoma, insulinoma, glucagonoma, gastrinoma, goblet cell carcinoid, typical and atypical lung carcinoids, large cell neuroendocrine carcinoma, small cell carcinoma, carcinoid syndrome refractory to treatment with conventional doses of somatostatin analogues (SSAs), inadequate bone marrow function, abnormal coagulation or chronic treatment with warfarin or coumarin derivates, impaired liver, cardiac and/or renal function, known gallbladder, bile duct disease or pancreatitis, short-bowel syndrome, diabetics with poorly controlled blood glucose levels despite adequate therapy, or hypothyroidism not adequately treated.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is chronic obstructive pulmonary disease (COPD). The ICD-10 codes associated with COPD are J44.9, J44.1, and J44.0. The drugs being tested in the trial are losmapimod tablets, placebo tablets, and salbutamol mdi. The eligibility criteria for participants include having a diagnosis of COPD, a history of COPD exacerbations, receiving COPD maintenance treatment for at least 3 months, being a current or former smoker, being of a certain age, having a certain ECG QT interval, and being capable of giving written informed consent. The exclusion criteria include having high blood eosinophils, being on certain medications, having other respiratory disorders, requiring certain medical devices, having undergone lung reduction surgery, having recently completed a course of antibiotics or oral corticosteroids for a COPD exacerbation, having certain abnormalities on chest X-ray or CT scan, participating in a pulmonary rehabilitation program, having certain liver or kidney conditions, having a current or previous history of cancer, having certain cardiovascular, pulmonary, metabolic, neurological, endocrine, renal, hepatic, hematological, or gastrointestinal conditions, having certain viral infections, being pregnant or lactating, having a history of drug or alcohol abuse, having recently used other investigational drugs, having an affiliation with the investigator site, being unable to read or comply with study procedures, or having conditions that may limit the validity of informed consent.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"triple negative breast neoplasms\". The associated ICD-10 codes for this disease are \"C79.81\", \"D24.1\", \"D24.2\", \"D24.9\", \"D49.3\", \"C44.501\", and \"D48.60\". The trial involves the use of the drug \"pf-03084014\" for treatment. \n\nThe eligibility criteria for this trial include having a histological or cytological diagnosis of triple negative breast cancer with evidence of metastatic or locally recurrent advanced disease that cannot be treated with surgery or radiotherapy. Additionally, the availability of tumor tissue or biopsies for genomic profiling of Notch receptors is required.\n\nThere are also exclusion criteria, which state that individuals with known brain metastases or prior treatment with a gamma secretase inhibitor or other Notch signaling inhibitor are not eligible for the trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is Hepatitis C Virus Infection. The ICDCodes associated with this disease are B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, and B17.2. The drugs mentioned are Sof/Vel and RBV. The eligibility criteria include requirements such as providing written informed consent, having a specific HCV genotype, having detectable HCV RNA at screening, and having completed a previous HCV treatment study. There are also exclusion criteria, such as having clinically significant illnesses or medical disorders, abnormal screening ECG results, and infections with hepatitis B virus or human immunodeficiency virus.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is mucositis, and the corresponding ICDCodes associated with this disease are J34.81, K92.81, K12.30, K12.39, K12.33, N76.81, and K12.31. The drugs being used in the trial are curcumin-mtd, mouthwash-standard pharmacy preparation, and curcumin. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- The participant must have grade 2 or higher oral mucositis related to chemotherapy for cancer.\n- The participant must be able to understand and willing to review and sign a written informed consent document.\n- The participant must be 18 years of age or older.\n- The participant must be willing to use adequate contraception before study entry, during the study, and for 30 days after the last dose for women of child-bearing potential and men.\n\nExclusion Criteria:\n- The participant must not be currently using therapeutic doses of anticoagulants such as warfarin or antiplatelet agents (prophylactic doses and agents are acceptable).\n- The participant must not have biliary tract obstruction or cholelithiasis.\n- The participant must not have a history of gastric or duodenal ulcers or hyperacidity syndromes.\n- The participant's AST or ALT levels must not be greater than 2 times the upper limit of normal (ULN).\n- The participant's total bilirubin levels must not be equal to or greater than 2 times the ULN.\n- The participant's INR must not be greater than 1.5.\n- The participant must not have undergone a previous stem cell transplant (allogeneic or autologous).\n- The participant must not have any preexisting oral disease, such as active oral infection, trauma to the oral mucosa, or oral ulceration prior to chemotherapy.\n- The participant must not have a known allergy or hypersensitivity to curcumin, yellow food coloring, or other members of the Zingiberaceae (ginger) family.\n- The participant must not be pregnant or breastfeeding.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is pancreatic neoplasms, and the corresponding ICD-10 code is C25.3. The drugs being tested in this trial are nab-paclitaxel, gemcitabine, chemoradiation, and capecitabine. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- Patients must have non-metastatic, unresectable adenocarcinoma pancreatic cancer.\n- Patients must not have received any prior anticancer therapy for pancreatic cancer.\n- Patients must be at least 18 years old with a performance status of 0 or 1.\n- Patients must have adequate complete blood counts, hepatic function, and renal function.\n- Patients must have signed informed consent.\n\nThe exclusion criteria for the trial are as follows:\n- Patients with active bacterial, viral, or fungal infections.\n- Patients with hepatitis B or C, or a history of HIV infection, or receiving immunosuppressive or myelosuppressive treatment.\n- Patients with sensory neuropathy, ascites, or a plastic biliary stent.\n- Patients with serious medical risk factors involving major organ systems or serious psychiatric disorders.\n- Women who are pregnant or breastfeeding are also excluded from the trial.",
    "The sample is a phase 2 trial for patients with lymphoma, primary central nervous system lymphoma, and recurrent/refractory secondary central nervous system lymphoma. The trial is testing the drug buparlisib (bkm120). The eligibility criteria include being at least 18 years old, having histologically documented PCNSL or SCNSL, having relapsed/refractory PCNSL or SCNSL, and having received at least one prior CNS directed therapy. Other criteria include having a Karnofsky performance status of at least 50, meeting certain bone marrow and organ function requirements, being able to take oral medication, and being able to tolerate MRI scans and lumbar puncture. Exclusion criteria include actively receiving treatment for extra-CNS disease, prior treatment with a PI3K inhibitor, concurrent use of other antineoplastic agents, recent chemotherapy or targeted anticancer therapy, and certain medical conditions or medications that may interfere with the study. The sample also includes exclusion criteria related to cardiac function, gastrointestinal function, diabetes, recent surgery, pregnancy or nursing, and prior allogenic stem cell transplants.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes information about the diseases being studied, the ICDCodes associated with those diseases, the drugs being used, and the eligibility criteria for participants.\n\nIn this particular trial, the diseases being studied are \"stomach neoplasms\", \"neoadjuvant therapy\", \"chemoradiotherapy\", and \"chemotherapy\". The ICDCodes associated with these diseases are provided as well.\n\nThe drugs being used in the trial are \"s-1\" and \"sox\". \n\nThe eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having locally advanced gastric adenocarcinoma, no distant metastasis in specific organs, no prior abdominal or pelvic radiotherapy, a certain level of performance status and life span, and normal organ and marrow function. Exclusion criteria include having prior chemotherapy or other cancer treatment, having a history of certain types of cancer, having distant metastasis in specific organs, having a history of allergic reactions to certain drugs, having uncontrolled illness or certain medical conditions, having a history of certain cardiac events, having prior radiation to the abdomen, and being pregnant or lactating.\n\nOverall, this sample provides information about a phase 2 clinical trial focusing on specific diseases, using certain drugs, and having specific eligibility criteria for participants.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on the disease melanoma, which is a type of skin cancer. The trial includes patients with AJCC stage III or IV completely resectable melanoma, meaning the cancer can be surgically removed. The eligibility criteria include being 18 years or older, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and being clinically disease-free after surgery. The trial also requires patients to have approximately 1 mg of accessible and dispensable tumor for testing purposes. Patients must have completed standard-of-care (SoC) adjuvant therapy as per NCCN guidelines, which may include chemotherapy, radiation therapy, and/or biologic therapy. Vaccinations for the trial should be initiated between 3 weeks and 3 months after completing SoC treatment. Patients must also meet certain laboratory value requirements for organ function, such as ANC, platelet count, hemoglobin level, creatinine level, total bilirubin level, and ALT/AST levels. Women of child-bearing potential must agree to use adequate birth control methods. The sample also includes exclusion criteria, such as evidence of residual disease after surgery and SoC adjuvant therapies, insufficient tumor available for vaccine production, ECOG performance status greater than 2, immune deficiency diseases or history of HIV/HBV/HCV, receiving immunosuppressive therapy, pregnancy or breastfeeding, active pulmonary disease requiring medication, and involvement in other experimental protocols without permission.",
    "The sample provided is for a phase 2 clinical trial for breast cancer. The trial is specifically targeting premenopausal or postmenopausal women with triple-negative carcinoma of the breast. The primary tumor size should be equal to or greater than 1.5 centimeters. Participants should have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Adequate hematologic and organ function is required, and tumor tissue from a core biopsy is needed for analysis. Female participants of childbearing potential must agree to use effective contraception during the study and for at least 6 months after the last dose of treatment. \n\nExclusion criteria include having HER2-positive, estrogen receptor (ER)-positive, or progesterone receptor (PgR)-positive breast cancer, prior treatment for the current primary invasive breast cancer, cT4 or cN3 stage breast tumors, metastatic (Stage IV) breast cancer, bilateral invasive breast cancer, and multicentric breast cancer. Participants with any contraindications to the investigational drug or any conditions that may affect the interpretation of results or pose a high risk of treatment complications are also excluded.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of diabetes mellitus and diabetic macular edema. The diseases are represented by their names and corresponding ICD-10 codes. The drugs being studied are asp8232, ranibizumab, and placebo. The eligibility criteria for participants are listed, including requirements for diabetes diagnosis, retinal thickening, visual acuity, and other factors. There are also exclusion criteria, such as the presence of other ocular diseases, infections, prior surgeries or treatments, and uncontrolled glaucoma.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is Phase 2.\n- Diseases: The disease being studied, which in this case is leukemia.\n- ICD codes: The ICD-10 codes associated with the disease, which are \"C95.91\", \"C95.92\", \"Z80.6\", \"Z85.6\", \"C90.11\", \"C90.12\", and \"C91.01\".\n- Drugs: The drug being tested in the trial, which is ixazomib.\n- Criteria: The eligibility criteria for participating in the trial.\n\nThe eligibility criteria are divided into two sections: Inclusion Criteria and Exclusion Criteria. The Inclusion Criteria specify the requirements that patients must meet in order to be eligible for the trial. These include factors such as age, consent, contraception for female patients, medical history, treatment history, performance status, and laboratory criteria.\n\nThe Exclusion Criteria list the factors that would disqualify a patient from participating in the trial. These include factors such as pregnancy or lactation, incomplete recovery from prior chemotherapy, recent major surgery or radiotherapy, central nervous system involvement, active infections, cardiovascular conditions, ongoing systemic infections or viral infections, and other medical or psychiatric illnesses that could interfere with treatment.\n\nOverall, this sample provides a snapshot of a Phase 2 clinical trial for leukemia, including the specific eligibility criteria that patients must meet in order to participate.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of various diseases. The diseases listed include \"carcinoma, basal cell,\" \"recurrent skin cancer,\" \"skin neoplasms,\" and \"basal cell nevus syndrome.\" The corresponding ICD-10 codes for these diseases are also provided. The drugs being tested in this trial are \"buparlisib\" and \"sonidegib.\" \n\nThe eligibility criteria for this trial are listed under \"INCLUSION CRITERIA\" and \"EXCLUSION CRITERIA.\" Inclusion criteria include being able to understand and sign informed consent, having a certain performance status, having metastatic or locally advanced disease, and meeting specific laboratory values. \n\nExclusion criteria include prior treatment with a P13K inhibitor, known hypersensitivity to the drugs being tested, untreated brain metastases, certain cardiac diseases, poorly controlled diabetes, and other concurrent severe medical conditions. \n\nThe sample also includes criteria related to mood disorders, gastrointestinal function, prior treatments, and use of certain medications. It further specifies criteria related to pregnancy and contraception for female participants. \n\nOverall, the sample provides detailed information about the phase 2 clinical trial, including the diseases being targeted, the drugs being tested, and the specific eligibility criteria that participants must meet.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are macular edema and retinal vein occlusion. The ICDCodes associated with these diseases are provided as well. The drugs being tested in this trial are 4 mg cls-ta, sham, and ivt aflibercept. The eligibility criteria for this trial include specific inclusion and exclusion criteria related to the diagnosis, history, visual acuity, previous treatments, and ophthalmic conditions of the study eye.",
    "The sample is a clinical trial for phase 1/phase 2 of a drug study. The trial is focused on the disease leukemia, specifically acute myeloid leukemia (AML). The trial is for patients who are newly diagnosed with AML and are considered inappropriate for intensive remission induction therapy. Patients who are not eligible for stem cell transplantation are also included. However, patients with acute promyelocytic leukemia, current myelodysplastic syndrome only subjects, unstable angina or uncontrolled congestive heart failure, any other malignancy (excluding specific types), and respiratory disease requiring continuous supplemental oxygen are excluded from the trial. The sample also mentions that there may be other protocol-defined inclusion/exclusion criteria that could apply.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is acute myeloid leukemia. The ICDCodes associated with this disease are C92.A1, C92.A2, C92.61, C92.62, C92.A0, and C92.60. The drugs being used in the trial are gmi-1271, mitoxantrone, etoposide, cytarabine, and idarubicin. The eligibility criteria for inclusion in the trial include specific age requirements, prior treatment history, blast count, ECOG performance status, and organ function. There are also exclusion criteria listed, such as specific types of leukemia, CNS involvement, prior use of certain medications, and certain medical conditions.",
    "The sample provided is for a phase 2 clinical trial. The trial is focused on rheumatoid arthritis (RA) as the disease being studied. The ICD-10 codes associated with RA are ['M06.9', 'M05.9', 'M06.08', 'M06.00', 'M06.011', 'M06.012', 'M06.019']. The drug being tested in this trial is methotrexate. \n\nThe inclusion criteria for participants in this trial are:\n- Diagnosis of RA for at least 6 months prior to screening, and American College of Rheumatology (ACR) functional class I-III.\n- Subjects who are currently being treated with and tolerating methotrexate.\n- Active RA.\n- Other criteria as defined in the protocol.\n\nThe exclusion criteria for participants in this trial are:\n- Individuals who have been treated with disease-modifying antirheumatic drugs (DMARDs)/systemic immunosuppressives other than methotrexate.\n- Individuals who have received approved or investigational biological or targeted synthetic DMARD therapies for RA less than 6 months prior to screening.\n- Individuals with a history of toxicity, non-tolerance, primary non-response, or inadequate response to a biological therapy or targeted synthetic DMARDs for RA.\n- Individuals who have received prior therapy blocking the interleukin-6 (IL-6) pathway, at any time.\n- Other criteria as defined in the protocol.",
    "The sample from the table is for a phase 2 clinical trial. The diseases being studied are \"monoclonal b-cell lymphocytosis\", \"stage 0 chronic lymphocytic leukemia\", \"stage i chronic lymphocytic leukemia\", and \"stage i small lymphocytic lymphoma\". The corresponding ICD-10 codes for these diseases are \"C91.11\", \"C91.12\", \"C91.10\", \"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", and \"S33.131S\". The drug being tested is \"lenalidomide\". The eligibility criteria for the trial include specific diagnosis criteria for CLL, SLL, and MBL, as well as certain disease-related symptoms and stage requirements. Other criteria include performance status, blood counts, liver function, and consent to participate in the study. There are also exclusion criteria such as certain comorbid conditions, recent surgeries or radiation therapy, and current use of corticosteroids.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on the treatment of infertility. The specific disease being targeted is infertility, and the associated ICD-10 codes are N46.8, N46.9, N97.9, N97.0, N97.1, N97.2, and N97.8. The drugs being used in the trial are fe 999049 and follitropin beta. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Women diagnosed with tubal infertility, unexplained infertility, infertility related to endometriosis stage I/II, or with partners diagnosed with male factor infertility.\n- Women eligible for IVF and/or ICSI treatment.\n- Women aged 20-39 years.\n- Women with a body mass index (BMI) of 17.5-32.0 kg/m2.\n\nThe exclusion criteria for participants in the trial are as follows:\n- Women with polycystic ovary syndrome (PCOS) associated with anovulation, or endometriosis stage III/IV.\n- Women with a history of recurrent miscarriage.\n- Women with contraindications to controlled ovarian stimulation with gonadotropins.\n- Women who have undergone three or more controlled ovarian stimulation cycles.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease Duchenne muscular dystrophy. The ICD-10 code for this disease is G71.01. The drug being used in this trial is a placebo. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being an ambulatory boy between the ages of 6 and 16 who has been diagnosed with DMD and is able to perform a specific stair climb test. Participants must also have been receiving glucocorticosteroids for at least 6 months prior to the trial and have stable dosage and dosing regimen. Adequate hepatic and renal function, as well as no underlying disposition for iron accumulation, are also required.\n\nExclusion criteria include cognitive impairment or behavioral issues that would impede the ability to follow instructions, recent major surgical procedures, injuries that may impact functional testing, and the presence or history of other musculoskeletal or neurologic diseases. Compromised cardiac function, clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, or allergic diseases, and documented history of iron overload are also exclusion criteria. Additionally, participants must be willing and able to undergo examination with a closed MRI without sedation and should not have participated in other studies involving investigational drugs within a certain timeframe. Treatment with specific therapies, such as anti-myostatin, exon skipping, nonsense mutation targeted therapies, androgens, human growth hormone, immunosuppressant therapies, aminoglycosides, multi vitamins with iron, iron supplements, and other investigational therapies, is also not allowed during the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease of infertility. The associated ICD-10 codes for this disease are 'N46.8', 'N46.9', 'N97.9', 'N97.0', 'N97.1', 'N97.2', and 'N97.8'. The trial involves the use of drugs named 'obe001 dose 1', 'obe001 dose 2', 'obe001 dose 3', and a placebo. The eligibility criteria for participants include being a woman undergoing IVF or ICSI using her own oocytes, following a specific protocol, and having evidence of uterine contractions. There are also exclusion criteria, such as not being at the blastocyst stage or having certain medical abnormalities or conditions.",
    "The sample is a phase 2 trial for patients with myeloproliferative neoplasm, primary myelofibrosis, essential thrombocythemia, or polycythemia vera. The trial is specifically for patients with a JAK2-V617F positive mutation. The inclusion criteria include a confirmed diagnosis of one of the specified diseases, a JAK2-V617F mutant allele burden of more than 20% in the peripheral blood, written informed consent, a WHO performance status of 0-2, age of 18 years or older, adequate hematological and hepatic function, adequate renal function, and compliance with contraception for women of child-bearing potential. The exclusion criteria include leukemic transformation, diabetic neuropathy, severe or uncontrolled cardiovascular disease, uncontrolled hypertension, recent treatment with IFN\u03b1 or JAK inhibitors, previous malignancy within 5 years (except for certain cases), psychiatric disorders affecting understanding or compliance, previous hematopoietic stem cell transplantation, recent treatment with cytoreductive drugs or other anti-cancer therapy, serious underlying medical conditions, known hypersensitivity to the trial drug, and concomitant use of drugs contraindicated with the trial drug.",
    "The sample is a phase 2 trial for the treatment of Prader-Willi syndrome. The eligibility criteria include having a confirmed diagnosis of PWS due to chromosome 15 micro-deletion, maternal uniparental disomy, or imprinting defect. The participants must be obese males or females weighing at least 50 kg with a BMI of \u226527 kg/m\u00b2 and aged between 16-65 years. If a participant has type 2 diabetes, specific criteria regarding HbA1c levels and fasting plasma glucose must be met. Vital signs such as blood pressure and pulse rate must be within certain ranges. Stable body weight at home for approximately 2 months is required. The participant's parent or guardian must be able to communicate well with the investigator and provide informed consent. Screening clinical laboratory tests must be within normal range or accepted as not clinically significant. Females of child-bearing potential must use contraception, while males with female partners of child-bearing potential must use a double barrier method. Participants must be on a stable dose of allowed chronic concomitant medications. Exclusion criteria include recent use of weight loss agents, certain mental disorders, clinically significant illnesses, certain medical conditions, and history of drug abuse or alcoholism. The sample must not have participated in any other clinical study with an investigational drug/device within the past 3 months.",
    "The sample is a phase 2 trial for the treatment of glaucoma and ocular hypertension. The trial is testing the drugs otx-tp and timolol. The eligibility criteria for participants include having a documented diagnosis of ocular hypertension or open angle glaucoma, with specific baseline intraocular pressure (IOP) measurements. The inclusion criteria require a mean baseline IOP of at least 24mmHg at certain time points, and a mean baseline IOP of at least 22mmHg at other time points. The washout IOP must be no higher than 34mmHg. Exclusion criteria include having any form of glaucoma other than open angle glaucoma, having a mean baseline IOP higher than 34mmHg, having a visual acuity worse than 0.6 logMAR (20/80 Snellen), and having allergies or hypersensitivity to certain substances.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease of obesity. The ICD-10 codes associated with obesity are provided. The drugs being studied in the trial are dapagliflozin, exenatide, and a placebo. The eligibility criteria for participants are listed, including age, body mass index (BMI), and specific requirements for female subjects. The exclusion criteria are also listed, which include previous enrollment in the study, participation in another clinical study, and various medical conditions or abnormalities.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"peripheral T-cell lymphoma (PTCL)\" and \"cutaneous T-cell lymphoma (CTCL)\". The corresponding ICDCodes for these diseases are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drug being tested in this trial is \"selinexor\". The eligibility criteria for this trial include specific requirements such as an ECOG performance status of \u22642, relapsed or refractory disease to at least one prior systemic regimen, measurable disease according to specific guidelines, and objective evidence of disease progression on study entry. There are also exclusion criteria listed, such as known active central nervous system (CNS) lymphoma, active graft-versus-host disease after allogeneic stem cell transplantation, and inability to swallow tablets or having a gastrointestinal function significantly affected by a disease.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"diabetic macular edema\" and \"age-related macular degeneration\". The corresponding ICDCodes for these diseases are provided as well.\n\nThe drug being tested in this trial is \"mtp-131\". The eligibility criteria for participants are listed, including age requirements, pregnancy testing for women of childbearing potential, and the specific criteria for the DME Treatment Group and AMD Treatment Group.\n\nThe exclusion criteria are also listed, which include factors such as the inability to self-administer eye drops, use of medications toxic to the eye, and medical conditions that may interfere with study participation.\n\nOverall, this sample provides a snapshot of the information stored in the table, including the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease of myocardial ischemia. The associated ICD-10 codes for this disease are 'I25.6' and 'P29.4'. The drugs being studied in this trial are heme arginate 3mg/kg, heme arginate 1mg/kg, and a placebo. The eligibility criteria for participants in this trial include signing informed consent, being between the ages of 40 and 85, having a body mass index of less than 35 kg/m2, and being able to communicate well with the investigator and understand the study requirements. There are also exclusion criteria, such as having a known hypersensitivity to the study drug, recent treatment with another investigational drug, or having certain medical conditions that could interfere with the study drug. Other exclusion criteria include severe renal failure, impaired ventricular function, high systolic pulmonary pressure, recent myocardial infraction, and being of childbearing potential.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is phase 2. The diseases being studied are neuroendocrine tumors, neuroendocrine carcinoma, neuroendocrine neoplasms, carcinoma neuroendocrine, and neuroendocrine tumors of the gastrointestinal tract and pancreas. The corresponding ICD-10 codes for these diseases are also provided. The drugs being used in the trial are sunitinib and everolimus.\n\nThe eligibility criteria for the trial are listed under the \"criteria\" column. The criteria include requirements such as histologically or cytologically diagnosed low or intermediate grade neuroendocrine tumors, age greater than or equal to 18 years, measurable disease according to RECIST criteria, willingness to undergo tumor biopsy, Eastern Cooperative Oncology Group (ECOG) performance status less than 2, normal organ and bone marrow function, specific cholesterol and triglyceride levels, agreement to use contraception for women of childbearing potential, full recovery from prior treatments, ability to understand and sign a consent document, and several exclusion criteria such as uncontrolled hypertension, prior radiation or chemotherapy, severe medical conditions, pregnancy or nursing, and others.\n\nOverall, this sample provides a detailed description of a specific clinical trial, including the phase, diseases being studied, drugs being used, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is \"healthy,\" which seems to indicate that the trial is focused on testing a drug or treatment on individuals who are considered healthy. The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drug being used in this trial is a placebo.\n\nThe eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being healthy based on physical examination, medical history, ECG, and laboratory criteria, as well as having negative HIV test results. Female participants of childbearing potential must also have negative pregnancy tests. Participants must also be assessed as being at low risk for HIV infection.\n\nExclusion criteria include having certain infections or diseases such as chronic active hepatitis B or active hepatitis C, syphilis, chlamydia, gonorrhea, or trichomonas. Participants with a history of certain infections or diseases in the 12 months prior to enrollment are also excluded. Other exclusion criteria include having significant medical conditions, recent major surgery, thyroid disease, heart conditions, abnormal ECG findings, history of adverse reactions to vaccines or vaccine products, neomycin, streptomycin, or egg products.\n\nOverall, this sample provides a snapshot of the trial phase, disease, ICDCodes, drug, and eligibility criteria for participants.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are liver metastasis and colorectal cancer. The ICDCodes associated with these diseases are provided as well. The drug being tested in this trial is decitabine. The eligibility criteria for participants are listed under inclusion and exclusion criteria. Inclusion criteria include having histological documentation of colorectal adenocarcinoma stage IV with unresectable liver metastases, meeting certain performance status and laboratory value requirements, and having progressive disease following standard palliative chemotherapy. Exclusion criteria include not having prior radiotherapy to liver lesions, no previous history of gastric or hepatobiliary surgery, no concurrent liver disease or serious medical condition, no use of other investigational drugs, no pre-existing neuropathy above grade 1, no previous or concurrent malignancies except for certain treated cases, not being pregnant or breastfeeding, and not being a candidate for resection of all colorectal cancer metastases with curative intent.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is multiple myeloma. The icd-10 codes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are daratumumab. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- The patient must have a diagnosis of smoldering multiple myeloma (SMM) for less than 5 years.\n- The patient must have a confirmed diagnosis of intermediate or high-risk SMM and an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\nExclusion Criteria:\n- The patient must not have active multiple myeloma requiring treatment as defined by the study protocol.\n- The patient must not have primary systemic AL (immunoglobulin light chain) amyloidosis.\n- The patient must not have prior or concurrent exposure to approved or investigational treatments for SMM or multiple myeloma, daratumumab or other anti CD-38 therapies, treatment with corticosteroids with a dose greater than 10 milligram (mg) prednisone per day or equivalent and bone-protecting agents (eg, bisphosphonates, denosumab) unless given in a stable dose and for a nonmalignant condition, or received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 4 weeks before Cycle 1, Day 1.\n- The patient must not have a history of malignancy (other than SMM) within 3 years before the date of randomization, except for specific cases that have been treated and are not currently active.\n- The patient must not have known chronic obstructive pulmonary disease (COPD) or moderate or severe persistent asthma within the past 2 years.\n- The patient must not have any concurrent medical or psychiatric condition or disease that is likely to interfere with the study procedures or results, or that would be considered a hazard for participating in the study, as determined by the investigator.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating metastatic colorectal cancer. The diseases column specifies the disease being studied, and the icdcodes column provides the corresponding ICD-10 codes for the disease. The drugs column lists the medications being used in the trial, which are cetuximab and irinotecan. The criteria column describes the eligibility criteria for participants in the trial, including requirements such as signed informed consent, confirmation of metastatic adenocarcinoma of the colon or rectum, specific genetic mutations, previous treatment regimens, measurable lesions, age, performance status, and organ function. The exclusion criteria are also listed, which include factors such as previous chemotherapy, specific mutations, cardiovascular disease, central nervous system metastasis, allergies, other concurrent malignancies, infections, HIV/AIDS, pregnancy, breastfeeding, recent use of other investigational drugs, and certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes information about the diseases being studied, the corresponding ICD-10 codes, the drugs being tested, and the eligibility criteria for participants.\n\nIn this particular sample, the trial is focused on chronic kidney disease and type 2 diabetes. The ICD-10 codes associated with these diseases are provided. The drugs being tested are \"rta 402\" and \"placebo\". The eligibility criteria for participants are listed under both inclusion and exclusion criteria. Inclusion criteria include being a CKD patient with type 2 diabetes, having eligible estimated GFR levels, and being treated with stable doses of ACE inhibitors and/or ARBs. Exclusion criteria include having type 1 diabetes, having known non-diabetic renal disease, having a history of renal transplantation, having high blood pressure, having high Hemoglobin A1c levels, and having specified cardiovascular diseases as outlined in the study protocol.",
    "The sample in the table represents a clinical trial for the treatment of gastric carcinoma, specifically for patients in phase 1/phase 2 of the trial. The trial aims to evaluate the effectiveness of the drug combination oxaliplatin+s-1. \n\nThe eligibility criteria for participants in this sample include having histologically confirmed gastric carcinoma at clinical stage III, having undergone radical resection, being able to read and understand the informed consent document, and being between the ages of 18 and 75. Additionally, participants must have at least 0.5 g of tumor sample available, have an ECOG score of \u22641, have a life expectancy of at least 12 weeks, and be able to comply with study-related procedures. Adequate bone marrow, liver, renal, and heart function are also required.\n\nExclusion criteria for this sample include being unable to provide informed consent, being pregnant or breastfeeding, having disease progression prior to treatment, being a transplant recipient, having a current diagnosis of Human Immunodeficiency Virus or other active uncontrolled infection, having unstable or severe intercurrent medical conditions, having an allergic constitution, or requiring treatment with immunosuppressants or corticosteroids for any systemic disease.\n\nThis sample provides a snapshot of the trial's phase, the disease being targeted, the associated ICD-10 codes, the drug being tested, and the specific eligibility criteria for participants.",
    "The sample is a phase 2 clinical trial for the treatment of septic shock. The trial is investigating the effectiveness of a drug called lb1148 compared to a placebo. The eligibility criteria for participants include having a first episode of documented or suspected sepsis, receiving antimicrobial therapy, and having septic shock requiring vasopressors despite adequate fluid resuscitation. Participants must also meet certain requirements for vasopressor support. There are several exclusion criteria, such as age limitations, time elapsed since onset of shock, and certain medical conditions. The sample also includes detailed information on the inclusion and exclusion criteria for the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on non-small cell lung cancer. The ICD-10 codes associated with the disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being studied in the trial are ficlatuzumab, erlotinib, and a placebo. The sample also includes the eligibility criteria for participants in the trial, including requirements such as having a confirmed diagnosis of Stage IV NSCLC, measurable disease, specific genetic mutations, and a performance status of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale. The sample also lists exclusion criteria, such as a history of severe allergic reactions, brain metastases, previous treatment with investigational drugs, and significant cardiovascular disease. Additionally, the sample mentions other criteria related to prior malignancies, interstitial lung disease, and unresolved toxicity from previous radiation therapy.",
    "The sample is from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for participants in the trial.\n\nIn this specific sample, the phase of the trial is phase 2. The disease being studied is psoriatic arthritis. The corresponding ICD-10 code for psoriatic arthritis is \"L40.52\". The drugs being tested are guselkumab, ustekinumab, and placebo. The eligibility criteria for participants include having had psoriatic arthritis for at least 6 months and meeting the classification criteria for psoriatic arthritis (CASPAR) at the screening. Participants should also have active psoriatic arthritis with a certain number of swollen and tender joints, and a specific level of C-reactive protein (CRP) in their blood. Additionally, participants should have certain subsets of psoriatic arthritis, plaque psoriasis with a certain body surface area involvement, and active psoriatic arthritis despite previous non-biologic treatments. There are also exclusion criteria, such as having other inflammatory diseases, previous use of guselkumab or ustekinumab, and receiving certain types of biologic anti-tumor necrosis factor (TNF) agents within a specific timeframe.",
    "The sample from the table is for a phase 2 clinical trial for the treatment of melanoma. The trial is investigating the use of the drugs ipilimumab and nivolumab. The eligibility criteria for the trial include having histologically confirmed malignant melanoma with measurable metastases in the brain. Both asymptomatic and symptomatic patients are eligible. There are specific requirements for the size and previous treatment of brain metastases. Prior stereotactic radiotherapy and excision of up to 3 melanoma brain metastases are permitted under certain conditions. Tumor tissue must be available for biomarker analysis. There are also criteria related to neurologic signs and symptoms, steroid use, and prior therapies. Exclusion criteria include leptomeningeal involvement, recent radiotherapy, certain brain lesion characteristics, and various medical conditions. The sample also mentions specific exclusion criteria related to hepatitis B, hepatitis C, HIV, allergies, and adverse drug reactions. The sample concludes by stating that other protocol-defined inclusion/exclusion criteria may apply.",
    "The sample is a phase 2 trial for the treatment of chronic lymphocytic leukemia. The trial includes participants who meet specific eligibility criteria outlined in the iwCLL NCI-WG guidelines. The criteria include evidence of progressive marrow failure, splenomegaly, lymphadenopathy, progressive lymphocytosis, autoimmune anemia or thrombocytopenia, constitutional symptoms, and specific blood count requirements. Participants must also have a life expectancy of more than 6 months and an ECOG PS of 0, 1, or 2. They should be willing to use contraception during and after the study. Exclusion criteria include pregnancy or lactation, previous CLL therapy, transformation of CLL to aggressive non-Hodgkin's lymphoma, inadequate renal or liver function, history of other malignancy, active infections, positive hepatitis serology, severe allergic reactions to monoclonal antibodies, significant cardiovascular or pulmonary diseases, recent live vaccination, and use of investigational agents within 30 days prior to the study treatment.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is urinary tract infections. The ICDCodes associated with this disease are P39.3, N39.0, O86.20, O86.29, N99.531, O03.38, and N99.521. The drugs mentioned are cefiderocol and imipenem/cilastatin. The eligibility criteria for this trial include being a hospitalized male or female patient aged 18 or above, having a clinical diagnosis of complicated urinary tract infections (cUTI) with or without pyelonephritis or acute uncomplicated pyelonephritis, and meeting specific inclusion criteria such as having certain signs or symptoms and urinalysis evidence of pyuria. There are also exclusion criteria mentioned, such as having a urine culture that identifies only a Gram-positive pathogen or a Gram-negative uropathogen resistant to imipenem, or being a patient receiving hemodialysis or peritoneal dialysis.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease and dementia. The trial is testing the effectiveness of the drugs e2609 and placebo. The eligibility criteria for participants include meeting specific clinical research criteria for mild cognitive impairment (MCI) or Alzheimer's disease (AD), having a positive amyloid PET scan, being between the ages of 50 and 85, having a caregiver or informant, and being on stable doses of certain medications. Exclusion criteria include having neurological conditions other than AD, history of stroke or epilepsy, depression or psychiatric diagnoses, certain medical conditions or diseases, visual or hearing impairments, immunodeficiency disorders, and recent use of live vaccines or active infections. Other factors such as cardiac health, diabetes, neoplasms, and drug or alcohol dependency are also considered. Pregnant or lactating females and males who do not meet the requirements for avoiding pregnancy are excluded from the trial.",
    "The sample from the table is for a phase 2 clinical trial. The diseases being studied are chronic graft vs. host disease, graft vs host disease, and graft-versus-host disease. The corresponding ICD-10 codes for these diseases are D89.810, D89.811, D89.813, and D89.812. The drug being tested in the trial is methoxsalen. The eligibility criteria for the trial include being at least 18 years old, having the ability to understand and sign a consent document, being enrolled in an NCI allogeneic transplant protocol, and agreeing to practice effective contraception. The exclusion criteria include having any physical or mental condition that would make participation in the trial unacceptable, having unstable hemodynamics, uncontrolled infection, inability to maintain venous access, uncontrolled or uncorrectable coagulopathy, being pregnant or breastfeeding, having a history of allergic reactions to methoxsalen or light-sensitive cutaneous disease, and having aphakia.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease is \"essential hypertension.\" The ICDCodes associated with this disease are \"I10,\" \"O10.02,\" \"O10.03,\" \"O10.011,\" \"O10.012,\" \"O10.013,\" and \"O10.019.\" The drugs being studied are \"qgc001\" and \"placebo.\" The eligibility criteria for this trial include specific age requirements, body weight and BMI ranges, a signed informed consent form, and a diagnosis of essential grade I or II hypertension. There are also exclusion criteria listed, such as significant medical conditions, recent acute diseases, history of certain cardiovascular events, and various other factors that may affect the participant's ability to comply with the study requirements or pose risks. Additionally, there are restrictions on the use of certain medications prior to the trial.",
    "The sample from the table is for a phase 2 clinical trial. The trial is focused on postmenopausal women with metastatic breast cancer. The diseases are specified as \"postmenopausal\" and \"metastatic breast cancer\" with corresponding ICD-10 codes. The drugs being studied are tamoxifen and ralimetinib (ly2228820 dimesylate). \n\nThe eligibility criteria for the trial include women with histologically confirmed breast cancer, aged between 18 and 80 years old. Menopausal status is determined based on criteria such as spontaneous amenorrhea for 12 months, or 6 months of amenorrhea with specific hormone levels. ER-positive status and HER2-negative status are also required.\n\nThe trial is for patients with inoperable locally advanced or metastatic breast cancer that has not responded to aromatase inhibitors. Patients who have previously received fulvestrant are eligible. The trial allows a maximum of 2 previous lines of chemotherapy for metastatic breast cancer.\n\nOther criteria include a performance status of 2 or lower, ability to swallow and retain oral medication, and the presence of measurable or evaluable lesions as per RECIST 1.1 criteria. Adequate bone marrow and organ function are required, as defined by specific laboratory values.\n\nExclusion criteria for the trial include previous treatment with p38 MAPK inhibitors or tamoxifen in the metastatic setting (adjuvant treatment with tamoxifen is allowed), more than 2 lines of chemotherapy for locally advanced and/or metastatic breast cancer, brain metastasis, and other concurrent malignancies. Clinically significant cardiovascular disease, major bowel resection, and inflammatory bowel disease are also exclusion criteria. Concurrent participation in other therapeutic clinical trials and inability or unwillingness to comply with the protocol are also reasons for exclusion.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on the treatment of gastroparesis and diabetes mellitus. The diseases are represented by their respective ICD-10 codes. The drugs being tested are sitagliptin and a placebo. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- The participant must have type 2 diabetes managed by diet or metformin alone.\n- The participant's body mass index (BMI) should be between 20 and 40 kg/m2.\n- Both males and females can participate, but females of reproductive potential must be using appropriate contraceptive methods.\n- The participant's glycated hemoglobin (HbA1c) level should be less than or equal to 8.5%.\n- The participant's hemoglobin level should be above the lower limit of the normal range (i.e., >135g/L for men and 115g/L for women), and ferritin level should be above the lower limit of normal (i.e., >10mcg/L).\n\nThe exclusion criteria for the trial are as follows:\n- Subjects with gastrointestinal disease, significant upper or lower gastrointestinal symptoms, or previous gastrointestinal surgery (except for uncomplicated appendicectomy or cholecystectomy) cannot participate.\n- Participants with other significant illnesses such as epilepsy, cardiovascular or respiratory disease are excluded.\n- Individuals with a history of unexplained pancreatitis, chronic pancreatitis, or pancreatectomy are not eligible.\n- Participants with impaired renal or liver function, as assessed by calculated creatinine clearance < 50 mL/min or abnormal liver function tests (> 2 times upper limit of normal range), are excluded.\n- Individuals requiring medication known to influence blood pressure, heart rate, or gastrointestinal function, or drugs with anticholinergic effects cannot participate.\n- Participants who consume more than 20g of alcohol per day or smoke more than 10 cigarettes per day are excluded.\n- Pregnant or lactating individuals are not eligible.\n- Vegetarians, individuals with allergies to sitagliptin or any other 'gliptin', and those who have donated blood or participated in other research studies within the previous 3 months are excluded.\n- Individuals who have been exposed to ionizing radiation for research purposes in the previous 12 months or are unable to give informed consent are not eligible for the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating head and neck neoplasms and mucositis. The diseases are identified by their ICD-10 codes. The drug being used in the trial is brilacidin. The sample also includes the eligibility criteria for participants in the trial, including requirements such as recently diagnosed non-metastatic squamous cell carcinoma, specific radiation and chemotherapy plans, Eastern Cooperative Oncology Group (ECOG) Performance Status, and various health conditions that would exclude someone from participating.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are obesity and type 2 diabetes. The ICDCodes associated with these diseases are \"E66.8\", \"E66.9\", \"E66.1\", \"O99.214\", \"O99.215\", \"O99.210\", \"O99.211\" for obesity, and \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", \"E11.44\" for type 2 diabetes. The drugs being tested are \"zgn-440 for injectable suspension\" and \"zgn-440 placebo for injectable suspension\". The eligibility criteria for this trial include specific requirements such as having a BMI of 30 or higher, having type 2 diabetes with an HbA1c level between 7-11%, and being treated with certain medications or combinations of medications. There are also exclusion criteria, such as not currently or recently using insulin and not having certain metabolic or genetic disorders linked to obesity.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in either phase I, phase II, or phase III. The disease being studied is seizures. The ICD-10 codes associated with this disease are 'G40.89', 'R56.1', 'F44.5', 'G40.501', 'G40.509', 'G40.111', and 'G40.119'. The drug being tested is cannabidiol oral solution. The sample also includes the eligibility criteria for participants in the trial. The inclusion criteria include having a treatment-resistant seizure disorder, being able to understand the study procedures and requirements, and providing informed consent. The exclusion criteria include having commitments that would interfere with attending study visits, using medications outside of the specified parameters, and having conditions that could compromise safety or the analysis of results.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of renal cell carcinoma, a type of kidney cancer. The trial is specifically targeting patients with locally advanced or metastatic renal cell carcinoma who have not received prior systemic therapy for their condition.\n\nThe eligibility criteria for participants in this trial include having a diagnosis of renal cell carcinoma with clear-cell component histology, having a measurable lesion on physical examination or as seen on CT/MRI scans, having a Karnofsky performance scale score of at least 70, being at least 18 years old, and having adequate organ function. Female participants must either be non-childbearing or agree to use adequate contraception, while male participants with female partners of childbearing potential must have undergone a vasectomy or agree to use effective contraception.\n\nExclusion criteria for the trial include being pregnant or lactating, having a history of another malignancy (unless disease-free for at least 3 years), having central nervous system metastases (unless previously treated and meeting specific criteria), having clinically significant gastrointestinal abnormalities, having moderate to severe hepatic impairment, having serious pre-existing medical, psychiatric, or other conditions that could interfere with the study, receiving chronic treatment with corticosteroids or other immunosuppressive agents, having a known history of HIV seropositivity, having active bleeding or bleeding diathesis, having severe or uncontrolled medical conditions or infections, currently receiving chemotherapy, immunotherapy, or radiotherapy, having a corrected QT interval (QTc) greater than 480 milliseconds, having a history of certain cardiovascular conditions within the past 12 months, having poorly controlled hypertension, having a history of cerebrovascular accident, pulmonary embolism, or untreated deep venous thrombosis within the past 6 months, having undergone major surgery or trauma within 28 days prior to the start of the trial, having evidence of active bleeding or bleeding susceptibility, and having known endobronchial lesions or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage.\n\nThe specific drug being studied in this trial is pazopanib. The sample does not provide any additional information about the study design, outcomes, or other details of the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"atopic dermatitis\". The corresponding ICD-10 codes for this disease are \"L20.89\" and \"L20.9\". The trial involves two drugs, namely \"aqx-1125\" and \"placebo\". The eligibility criteria for participants in this trial include being between 18 and 65 years old, having a confirmed clinical diagnosis of active atopic dermatitis according to the Hanifin and Rajka criteria, having a history of atopic dermatitis for at least 6 months, having at least 1% of the body surface area covered with atopic dermatitis, having mild or moderate atopic dermatitis with an IGA score of 2 or 3, having a TLSS (Total Lesion Severity Score) of 5 or more on Day 0, and using a non-medicated emollient daily for at least 7 days prior to Day 0 and throughout the study. The exclusion criteria include being a pregnant or breastfeeding female and having unstable or clinically infected atopic dermatitis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is esophageal squamous cell carcinoma. The ICDCodes associated with this disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drugs being used in the trial are fluorouracil and cisplatin. \n\nThe eligibility criteria for this trial include:\n- R0 resection for primary esophageal squamous cell carcinoma with two-incision esophagectomy (Ivor Lewis approach) or three-incision (right thoracotomy, midline laparotomy, and left cervical incisions) esophagectomy with cervical esophagogastric anastomosis.\n- Absence of previous thoracic radiotherapy.\n- Cervical and/or thoracic postoperative recurrence (biopsy proven or positron emission tomography/computed tomography (PET/CT) proven or follow-up computed tomography (CT) showed progression of disease).\n- Absence of distant metastasis at recurrence.\n- Eastern Cooperative Oncology Group (ECOG) performance status (PS) \u2264 2.\n\nThe exclusion criteria for this trial include:\n- Age younger than 18 or older than 70 years.\n- Eastern Cooperative Oncology Group (ECOG) performance status of 3 or above.\n- History of other cancers.\n- Serious cardiac, liver, or pulmonary disease.\n- Previous history of radiotherapy.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is dry eye syndrome. The ICDCodes associated with this disease are H04.121, H04.122, H04.123, and H04.129. The drugs being tested in this trial are cis-uca ophthalmic solution 1.0%, cis-uca ophthalmic solution 2.5%, and a placebo ophthalmic solution. \n\nThe eligibility criteria for this trial are listed under \"Key Inclusion Criteria\" and \"Key Exclusion Criteria\". The inclusion criteria include being at least 18 years old, providing written informed consent, having a reported history of dry eye, and having a history of using or desiring to use eye drops. The exclusion criteria include having clinically significant eye findings that require therapeutic treatment, wearing contact lenses within 7 days of Visit 1 or planning to use them during the study, having had LASIK surgery in the last 12 months, using Restasis\u00ae within 30 days of Visit 1, having any planned ocular and/or lid surgeries during the study period, being pregnant, nursing, or planning a pregnancy, having allergies or sensitivities to the study drug or its components, having a condition or situation that may put the subject at significant risk or interfere with the study, being currently enrolled in another investigational drug or device study or having used one within 30 days of Visit 1, and being unable or unwilling to follow instructions and participate in all study assessments and visits.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of attention deficit hyperactivity disorder (ADHD). The associated ICD-10 codes for ADHD are ['F90.2', 'F90.8', 'F90.9', 'F90.0', 'F90.1']. The drugs being studied are vortioxetine 10 mg tablet and vortioxetine 20 mg tablet. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The patient must be willing and able to attend study appointments within specified time windows.\n- The patient must be an outpatient.\n- The patient must have a primary diagnosis of ADHD according to the DSM-5 classification.\n- The patient must have an AISRS total score of at least 24.\n- The patient must have a CGI-S rating of 4 or higher (moderately ill or worse).\n\nExclusion Criteria:\n- The patient must not have been previously treated with vortioxetine.\n- The patient must not have any current psychiatric disorder other than ADHD, as assessed using the Mini International Neuropsychiatric Interview (MINI).\n- The patient must not have a first-degree relative with bipolar disorder.\n- The patient must not have intellectual disability, as evaluated by the Wechsler Abbreviated Scale of Intelligence (WASI) II vocabulary and matrix.\n- The patient must not have organic mental disorders or mental disorders due to a general medical condition according to DSM-5 criteria.\n- The patient must not report current use of or test positive for drugs of abuse (opiates, methadone, cocaine, amphetamines, barbiturates, benzodiazepines, and cannabinoids). Exceptions are made for incidental use of codeine-containing medication and ADHD current treatment with amphetamines, provided certain conditions are met.\n- The patient must not have a history of two prior failed adequate trials of ADHD treatment.\n- The patient must not have any other disorder that takes priority over ADHD treatment or is likely to interfere with study treatment or impair treatment compliance.\n- The patient must not have a history of moderate or severe head trauma, other neurological disorders, or systemic medical diseases that are likely to affect central nervous system functioning.\n- The patient must not have attempted suicide within the last 6 months or be at significant risk of suicide, as determined by the investigator or specific criteria on the Columbia-Suicide Rating Scale (C-SSRS).\n\nThe sample also mentions that there are other protocol-defined inclusion and exclusion criteria that apply.",
    "The sample is from a clinical trial in phase 2, focusing on the treatment of irritable bowel syndrome (IBS). The trial is investigating the effectiveness of fecal microbiota transplantation capsules compared to placebo capsules. The eligibility criteria for participants include being between the ages of 19 and 65, having a confirmed diagnosis of IBS-D according to the Rome III Criteria, experiencing moderate to severe disease activity, having persistent symptoms despite conventional therapy, and having a normal colonoscopy with biopsies in the past. Exclusion criteria include pregnancy, nursing, cognitive impairment, severe neuropsychiatric comorbidities, severe immunocompromised or immunosuppressed conditions, recent antibiotic use, presence of underlying organic diseases, previous fecal microbiota transplantation, severe food allergies, inability to comply with protocol requirements, ASA Physical Status classification IV and V, acute illness or fever on the day of planned transplantation, recent antidepressant use or dose changes, elevated ESR or CRP within the past 3 months, baseline laboratory abnormalities, and a pain score above 75 on the IBS-Symptom Severity Score.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the treatment of heart failure. The trial includes patients who have been diagnosed with heart failure and have been taking oral furosemide for at least 30 days prior to the trial. The patients must also have a NT-proBNP level greater than 300 pg/mL or a BNP level greater than 100 pg/mL. The inclusion criteria also specify that the patients must meet certain age, weight, and BMI requirements, and must not be pregnant or lactating. They must also agree to abstain from alcohol, caffeine, and tobacco/nicotine during the trial. The patients must be able to understand and comply with the study procedures. \n\nThe exclusion criteria include patients who have had acute decompensated heart failure or have been hospitalized for heart failure in the last 4 weeks. Patients with worsening signs or symptoms of heart failure, low systolic blood pressure, high temperature, or active infection are also excluded. Other exclusion criteria include abnormal levels of sodium or potassium, significant cardiac abnormalities, current or planned treatment with certain medications or therapies, diabetes requiring insulin therapy, urinary tract abnormalities, impaired renal function, hepatic dysfunctions, recent administration of radiographic contrast agent or surgery, participation in other trials, positive tests for hepatitis B, hepatitis C, or HIV, positive urine drug screen, concomitant use of drugs that interact with furosemide, history of alcohol abuse, severe allergic reactions to furosemide, and recent blood or plasma donation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"hematologic neoplasms\" and its corresponding ICDCodes are ['E70.338', 'E70.339', 'P09.3', 'O28.0', 'P61.8', 'P61.9', 'T45.8X1A']. The drugs being tested in this trial are 'ibrutinib' and 'nivolumab'. The eligibility criteria for this trial include specific requirements for Eastern Cooperative Oncology Group (ECOG) performance status, bone marrow, liver, and renal function, as well as histologically confirmed B-cell non-Hodgkin lymphoma (B-NHL), Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), and relapsed refractory disease. There are also specific criteria for different cohorts within the trial, such as B-cell follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and Richter syndrome. The exclusion criteria include prior therapy or surgery, previous use of certain inhibitors or antibodies, cardiovascular diseases, history of stroke or intracranial hemorrhage, and certain medical conditions like HIV, Hepatitis B, or Hepatitis C.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease gout. The ICD-10 codes associated with gout are provided. The drugs being studied are bucillamine and colchicine. The sample also includes the eligibility criteria for participants in the trial, including the requirement of a confirmed diagnosis of gout, a history of gouty arthritic attacks, and specific pain intensity levels. There are also criteria related to contraindications for using certain medications and the ability to provide informed consent. The sample also lists exclusion criteria, such as the presence of other types of arthritis, a history of certain medical conditions, and the use of certain medications.",
    "The sample from the table is for a phase 2 trial. The disease being studied is \"type 2 diabetes mellitus and microalbuminuria\". The corresponding ICD-10 codes for the disease are \"E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65\". The drugs being tested in the trial are \"tak-272, tak-272 placebo, candesartan cilexetil, candesartan cilexetil placebo\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include factors such as age, type 2 diabetes mellitus with early-stage nephropathy, stability of blood glucose, blood pressure, and lipid levels, and absence of certain medical conditions. The sample also includes specific criteria for male and female participants regarding contraception. The exclusion criteria include factors such as previous exposure to TAK-272, hypersensitivity or allergies to certain medications, certain medical conditions, and recent participation in other clinical studies. The sample also includes criteria specific to different time points in the trial, such as Week -8 and Week -4. The sample provides detailed information about the participant's medical history, medication use, and various health parameters.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating various types of leukemia and myelodysplastic syndromes. The diseases included in this sample are acute lymphoblastic leukemias (ALL), acute myeloid leukemias (AML), myelodysplastic syndromes (MDS), and juvenile myelomonocytic leukemias (JMML). The trial is investigating the use of the drug treosulfan. \n\nThe eligibility criteria for this trial include having a hematological malignant disease (ALL, AML, MDS, or JMML) that requires an allogeneic hematopoietic stem cell transplant (allo-HSCT). Patients must be in their first or second allo-HSCT due to disease relapse, graft failure, or secondary malignancy after a previous HSCT. They must have a matched sibling donor, matched family donor, or matched unrelated donor. Patients with ALL or AML must be in complete morphologic remission, while patients with MDS or JMML must have blast counts below a certain threshold. The trial is open to patients aged 28 days to less than 18 years, with a performance score of at least 70%. Written informed consent is required from parents/legal guardians and assent/consent from the patient. \n\nThere are also exclusion criteria, such as having undergone a third or later allo-HSCT, receiving HSCT from a haploidentical or umbilical cord blood donor, or having symptomatic involvement of the central nervous system at the start of the study. Other exclusion criteria include recent treatment with cytotoxic drugs, obesity, certain solid tumors, specific genetic disorders, impaired liver or renal function, impaired cardiac function, requirement for continuous oxygen, severe active infection, HIV positivity, known pregnancy or breastfeeding, and known hypersensitivity to treosulfan and/or fludarabine.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on breast cancer, specifically invasive breast cancer. The ICD-10 codes associated with the diseases are provided as well. The trial involves the use of two drugs, chloroquine and placebo. The eligibility criteria for participants are listed, including requirements such as being newly diagnosed with primary invasive breast cancer, having a tumor size of at least 1.5 cm, having a certain performance status, and providing written informed consent. The exclusion criteria are also listed, which include factors such as having metastatic breast cancer, having certain pre-existing eye or liver conditions, currently using or having recently used certain drugs, having a history of certain medical conditions, and being unable to comply with the study protocol. Additionally, being pregnant or nursing, having allergies to certain medications, and being unable to provide consent are also listed as exclusion criteria.",
    "The sample is a phase 2 trial for asthma. The eligibility criteria for participants include being between 18-40 years old, having a BMI of 18-40 kg/m2, not currently using corticosteroids, not being pregnant or lactating, having had asthma for at least 3 months, being a non-smoker or having quit smoking for over a year, having a methacholine PC20 of less than 16mg/mL, having normal laboratory values, being in good health based on medical history and assessments, being able to communicate effectively and comply with the study protocol. Exclusion criteria include having any clinically significant abnormality or abnormal laboratory test results, requiring inhaled \u03b22-agonist medication more than 4 times a week, currently being treated with any asthma medication other than inhaled \u03b22-agonist, having frequent emergency room visits, having certain diseases or therapies that could jeopardize well-being, having unstable cardiovascular disease, having any reason that would prevent participation, having clinically significant ECG or vital sign abnormalities, having a history of panic disorder or other anxiety disorders, currently receiving or having received treatment with MAO inhibitors or investigational drugs within a certain timeframe, having received biologic therapy within a certain timeframe, having evidence of alcohol abuse, testing positive on a urine drug screen or cotinine test, being breastfeeding or testing positive on a pregnancy test, and being mentally or emotionally unsuitable or unable/unwilling to comply with study assessments.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of pain. The associated ICD-10 codes for the disease are 'N50.82', 'R07.2', 'R07.82', 'R10.13', 'R10.33', 'R14.1', and 'R52'. The drugs being studied are 'trv130', 'morphine', and 'placebo'. The eligibility criteria for participants are listed, including age requirements, specific surgical procedure plans, ability to understand and comply with study requirements, and providing informed consent. There are also exclusion criteria, such as certain physical status classifications, surgical complications, significant medical conditions, and previous participation in another TRV130 clinical study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. The ICDCodes associated with these diseases are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drugs being used in the trial are cisplatin, 5-fu, and capecitabine.\n\nThe eligibility criteria for this sample include different inclusion and exclusion criteria for different cohorts. Cohort 1 requires participants to have received and progressed on at least two prior chemotherapy regimens, including cisplatin and a fluoropyridine. Cohort 2 or 3 requires participants to be HER2/neu negative and not have received prior systemic anti-cancer therapy for their advanced carcinoma. All participants must have histologically or cytologically confirmed recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma that is considered incurable by local therapies. They must also be willing to provide tissue for PD-L1 biomarker analysis and have measurable disease based on RECIST 1.1 criteria. Other criteria include Eastern Cooperative Oncology Group (ECOG) performance status, life expectancy, contraception requirements, and adequate organ function.\n\nExclusion criteria for all participants include current participation in another study, active autoimmune disease, immunodeficiency or recent immunosuppressive therapy, significant weight loss, clinical evidence of ascites, recent monoclonal antibody therapy, recent chemotherapy or radiation therapy, additional progressing malignancies, active central nervous system metastases, non-infectious pneumonitis, active infection, psychiatric or substance abuse disorders, pregnancy or breastfeeding, prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, HIV, hepatitis B or C, and recent live vaccination.\n\nThis sample provides a comprehensive overview of the trial phase, diseases being studied, drugs used, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease HIV. The ICD-10 codes associated with HIV are listed as \"B20\", \"Z71.7\", \"O98.72\", \"Z21\", \"O98.73\", \"R75\", and \"Z11.4\". The drugs being studied in the trial are \"combination antiretroviral therapy (cart)\", \"raltegravir\", and \"vorinostat\". \n\nThe eligibility criteria for participants in the trial are listed under \"Inclusion criteria\" and \"Exclusion criteria\". Inclusion criteria include being between the ages of 18 and 60, giving informed consent, being diagnosed with primary HIV-1 infection within the past 4 weeks, meeting specific criteria for HIV diagnosis, having adequate hemoglobin levels, weighing at least 50kg, being willing to be treated with combination antiretroviral therapy (preferably including raltegravir), and being able to comply with the visit schedule and provide blood samples.\n\nExclusion criteria include being a woman of childbearing potential, having plans for egg donation or fathering a child in the near future, having co-infection with hepatitis B or hepatitis C, having a history of malignancy or other significant comorbidities, having contraindications to receiving recommended antiretrovirals, having HIV-2 infection or HTLV-1 co-infection, having prior immunization with experimental HIV vaccines, currently or planning to undergo systemic immunosuppressive therapy, having a history of thromboembolism or bleeding diathesis, having contraindications to vorinostat or a history of intolerance to the vaccine or HDACi components, having uncontrolled diabetes or prolonged QTc interval, participating in other clinical trials or non-interventional studies with additional blood draws, having allergies or adverse reactions to vaccines, planning to receive other vaccines within 2 weeks of the trial vaccination, having abnormal blood test results at screening, having evidence of organ dysfunction or clinically significant deviations from normal in physical examination and vital signs, having active alcohol or substance use that may affect adherence to the study requirements, or having insufficient venous access for scheduled blood draws.\n\nThe sample also includes specific details about abnormal blood test results and estimation of blood volume for female participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of hepatitis C. The trial includes participants who are 18 years of age or older and have been diagnosed with chronic HCV infection for more than 6 months. The participants must have a plasma HCV RNA level of at least 1000 IU/ml at the screening. The trial accepts participants with HCV genotypes 1-6 and recent injecting drug use within the previous 6 months. Participants with compensated liver disease and specific liver condition criteria are also eligible. Female participants of childbearing potential must have a negative pregnancy test at baseline, and both fertile males and females must use effective contraception during treatment and for 30 days after treatment ends.\n\nThere are also exclusion criteria for the trial. Participants with clinically significant illnesses or major medical disorders, clinical hepatic decompensation, solid organ transplant, or malignancy within the past 5 years (except for certain cured cancers) are excluded. Participants with significant drug allergies or abnormal lab parameters at screening are also excluded. Pregnant or nursing females, individuals with HIV or HBV infection, and those using prohibited concomitant medications or immunosuppressive agents are not eligible. Previous therapy with specific drugs, ongoing severe psychiatric disease, frequent injecting drug use, and inability or unwillingness to provide informed consent or abide by study requirements are also exclusion criteria.",
    "The sample is for a phase 2 clinical trial. The disease being studied is asthma. The ICD-10 codes associated with the disease are 'J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', and 'J45.40'. The drugs being tested are 'qge031' and 'placebo'. The eligibility criteria for participants include having a diagnosis of allergic asthma that is uncontrolled on current medication, a history of at least 2 asthma exacerbations in the last year, and a Forced Expiratory Volume in one second (FEV1) between 40% and 80% of the predicted normal value with reversibility following administration of a bronchodilator. Exclusion criteria include recent tobacco use within the previous 6 months and recent asthma attack, exacerbation, or respiratory infection.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is multiple myeloma. The ICD-10 codes associated with the disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are selinexor and dexamethasone. The eligibility criteria for participants include having measurable multiple myeloma based on specific guidelines, having received at least three previous anti-MM regimens including certain medications, and having MM that is refractory to previous treatment with glucocorticoids, parenteral PI, IMiD, and the anti-CD38 mAb daratumumab. There are also exclusion criteria, such as having active smoldering MM, active plasma cell leukemia, documented systemic amyloid light chain amyloidosis, or active CNS MM.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on ulcerative colitis. The ICD-10 codes associated with the disease are ['K51.80', 'K51.813', 'K51.814', 'K51.90', 'K51.913', 'K51.914', 'K51.811']. The drugs being studied are 'glpg1205' and 'placebo'. The sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being between 18 and 75 years old, having a documented history of UC, and having active UC for at least 14 days with specific severity scores. Exclusion criteria include allergies to the study drug, any significant medical conditions that may affect participation, recent infections, history of malignancy, and certain types of colitis. Additionally, pregnant or lactating individuals are excluded from the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on Parkinson's disease. The table includes columns for the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being used, and eligibility criteria for participants.\n\nIn this specific sample, the phase of the trial is phase 2/phase 3, and the disease being studied is Parkinson's disease. The corresponding ICD-10 code for Parkinson's disease is \"G20\". The drugs being used in the trial are \"tvp-1012 1mg\", \"tvp-1012 0.5mg\", and \"placebo\". \n\nThe eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include factors such as the participant's ability to understand and comply with the study requirements, having a diagnosis of Parkinson's disease according to specific criteria, and having certain stages of the disease. Other criteria include the participant's medication history and stability, age, and willingness to use contraception if applicable.\n\nExclusion criteria include factors such as recent use of investigational medication, previous use of TVP-1012, being a study site employee or having a dependent relationship with a study site employee, recent blood donation, unstable systemic disease, severe dyskinesia, and certain psychiatric or neurological conditions. Other exclusion criteria include hypersensitivity or allergies to TVP-1012 or selegiline, history of drug abuse or alcohol dependence, recent neurosurgical interventions or transcranial magnetic stimulation, and recent use of specific medications.\n\nThe sample also includes additional exclusion criteria related to pregnancy, certain medical conditions, recent surgeries or hospitalizations, history of cancer, and certain infectious diseases. Laboratory data exceeding certain thresholds for creatinine, bilirubin, ALT, AST, or ALP are also listed as exclusion criteria.\n\nOverall, this sample provides a detailed description of the phase, diseases, drugs, and eligibility criteria for participants in a clinical trial focused on Parkinson's disease.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is Alzheimer's disease. The ICD-10 codes associated with the disease are G30.8, G30.9, G30.0, and G30.1. The drugs being tested in the trial are placebo, placebo, bi 409306, and donepezil. The eligibility criteria for the trial are listed under inclusion and exclusion criteria. Inclusion criteria include patients with early signs of dementia of Alzheimer's type, male and female patients aged at least 55 years, previous use of Alzheimer's disease medications allowed within 3 months prior to screening, patients with at least 6 years of formal education and fluency in the test language, and patients with a reliable study partner. Exclusion criteria include cognitive impairment or dementia with any etiology other than Alzheimer's disease, substantial concomitant cerebrovascular disease, medical history or diagnosis of certain conditions, other psychiatric disorders, previous participation in certain drug studies, and clinically significant uncompensated hearing loss.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is colorectal carcinoma. The ICDCodes associated with this disease are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drugs being used in the trial are oxaliplatin (oxa), levofolinate calcium (l-lv), 5-fu, and panitumumab. The eligibility criteria for enrollment are listed, including requirements such as having unresectable adenocarcinoma originating in the large intestine, measurable lesions according to RECIST ver. 1.1, not having received chemotherapy for colorectal cancer, being aged 20 or older, being classified as KRAS wild-type, and meeting certain criteria for major organ function. There are also inclusion and exclusion criteria for randomization. Exclusion criteria include factors such as having received radiotherapy, having known brain metastasis, having synchronous or metachronous cancers within a certain time period, and having certain medical conditions or infections.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on metastatic breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being studied in the trial are Aslan001, Lapatinib, and Capecitabine. The sample also includes the eligibility criteria for the trial, including inclusion and exclusion criteria. Inclusion criteria include patients with confirmed histological breast cancer with HER 2 overexpression or gene amplification, patients who have failed on prior first-line treatment with trastuzumab, and patients with measurable disease. Exclusion criteria include recent radiation treatment or major surgery, gastrointestinal disorders, uncontrolled illnesses, history of other malignancies, central nervous system metastasis, pregnancy or breastfeeding, previous treatment with ASLAN001 or lapatinib, and previous use of investigational drugs or antineoplastic monoclonal antibodies.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on three diseases: inflammation, coagulation, and HIV infection. The corresponding ICD-10 codes for these diseases are provided as well. The trial involves two drugs, namely edoxaban 30mg daily and a matching placebo. The eligibility criteria for participants are listed, including requirements such as being HIV positive, receiving continuous antiretroviral therapy for at least 2 years, having a certain HIV RNA level, and meeting certain laboratory and medical history criteria. There are also exclusion criteria, such as pregnancy, contraindications to taking edoxaban, and various medical conditions or treatments that would make a participant ineligible. The sample provides a comprehensive description of the trial's phase, diseases, drugs, and eligibility criteria.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"atopic dermatitis.\" The ICD-10 codes associated with this disease are \"L20.89\" and \"L20.9.\" The drugs being studied in this trial are \"lebrikizumab,\" \"placebo,\" and \"tcs cream.\" The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The inclusion criteria include having a diagnosis of atopic dermatitis, moderate to severe symptoms, a history of inadequate response to previous treatments, specific scores for EASI (Eczema Area and Severity Index) and IGA (Investigator Global Assessment), a certain percentage of body surface area affected by the disease, and a minimum pruritus WAS (Visual Analog Scale) score. The exclusion criteria include previous use of certain therapies, recent use of investigational agents, history of severe allergic reactions, use of certain medications, presence of other skin conditions or infections, certain medical conditions, use of specific topical medications, abnormal screening test results, current or recent malignancy, and history of malignancy within a certain timeframe.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is chronic lymphocytic leukemia (CLL). The ICD-10 codes associated with CLL are C91.11, C91.12, and C91.10. The drug being tested is buparlisib. The eligibility criteria for the trial include having previously documented CLL that is recurrent or relapsed after previous therapy, being at least 18 years old, having an ECOG Performance Status score of 0, 1, or 2, and having a life expectancy of at least 12 weeks. Other criteria include having a lymphocyte count of at least 10 x 10^9/L or at least one pathologically enlarged lymph node, having received at least 1 prior systemic treatment regimen, and having recovered from all reversible toxicity related to prior therapy. There are also criteria related to various blood counts, liver function, kidney function, and glucose levels. Exclusion criteria include progression to high-grade lymphoma or myelodysplasia, known hypersensitivity to buparlisib, pregnancy or lactation, and serious illnesses or medical conditions that would prevent the patient from being managed according to the protocol. Other exclusion criteria include uncontrolled or significant cardiovascular disease, certain mood disorders, prior treatment with buparlisib, gastrointestinal function or disease that may affect the absorption of buparlisib, and the use of certain medications. Patients with a history of other malignancies, except those that have been curatively treated and require no ongoing therapy, are also excluded.",
    "The sample from the table represents a phase 2 clinical trial for rectal cancer. The trial aims to assess the effectiveness of a combination of drugs including aflibercept, 5-fluoruracil, oxaliplatin, and leucovorin. The eligibility criteria for participants include being between 18 and 70 years old, having high-risk MRI-defined operable rectal cancer, and having histologically confirmed adenocarcinoma of the rectum. Other criteria include having a good performance status, adequate hematological and renal function, and no prior treatment with aflibercept. Exclusion criteria include a history of metastasis, uncontrolled hypercalcemia or hypertension, and previous treatment with other investigational drugs. Pregnant or breastfeeding women are also excluded. The sample provides detailed inclusion and exclusion criteria for potential participants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"influenza A\". The ICD-10 codes associated with this disease are \"J09.X1\", \"J09.X3\", \"J09.X9\", \"J09.X2\", \"A41.3\", \"A49.2\", and \"B96.3\". The trial involves testing several drugs, including \"vx-787 300 mg\", \"vx-787 600 mg\", \"oseltamivir 75 mg\", and a placebo. The eligibility criteria for the trial are provided, including inclusion and exclusion criteria. The inclusion criteria for Part A include being willing and able to comply with the NP swab procedure, signing an informed consent form, and presenting with symptoms suggestive of acute influenza. The inclusion criteria for Part B include meeting additional requirements such as documented oral temperature, respiratory and systemic symptoms, and a positive Rapid Influenza Diagnostic Test. The exclusion criteria for Part B include having certain medical conditions, abnormal ECG, pregnancy or nursing, and recent blood donation or use of specific medications.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on three diseases: osteoarthritis, rheumatoid arthritis, and avascular necrosis. The corresponding ICD-10 codes for these diseases are also listed. The trial involves two drugs, placebo and lacosamide. The eligibility criteria for participants are outlined, including age range, physical status, and the need for primary total hip arthroplasty. The sample also includes exclusion criteria, such as refusal to participate, certain medical conditions, and medication restrictions.",
    "The sample is a phase 2 trial for the treatment of cystic fibrosis. The trial is looking for male or female participants who are 12 years of age or older and have been diagnosed with cystic fibrosis according to the 1997 CF Consensus criteria. Participants must be non-smokers and have a FEV1 (forced expiratory volume in one second) between 40% and 90% at the screening visit. They should also have been on a stable regimen of CF medications and chest physiotherapy for the 28 days prior to screening, but must be willing to discontinue the use of hypertonic saline for the duration of the study.\n\nOther inclusion criteria include being clinically stable for at least 2 weeks and females of child-bearing potential must have a negative serum pregnancy test and agree to practice effective contraception throughout the study and for 28 days after the last dose of study medication.\n\nExclusion criteria include a history of organ transplantation or any significant disease or disorder, use of diuretics or certain antihypertensive drugs in the 28 days prior to screening, significant intolerance to inhaled hypertonic saline, known hypersensitivity to the study drug or amiloride, and clinically significant laboratory abnormalities. Pregnant or lactating females are also excluded, as well as those with a history of certain bacterial infections, previous participation in an investigational trial within 28 days prior to screening, or current treatment with any ivacaftor containing regimen.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is hematologic malignancies. The ICD-10 codes associated with the disease are E70.338, E70.339, P09.3, O28.0, P61.8, P61.9, and T45.8X1A. The drug being tested is ceritinib. The eligibility criteria for participants in the trial are listed, including age, performance status, disease status, blood counts, liver function, kidney function, and other factors. There are also exclusion criteria listed, such as recent treatments, medical conditions, and medications that would disqualify a participant from the trial. The sample also mentions that women of reproductive potential must use effective birth control during the study and for 3 months after receiving the study drug. Pregnant or nursing women are not eligible to participate.",
    "The sample provided is for a phase 2 clinical trial. The trial is focused on patients with metastatic breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being studied in this trial are everolimus (afinitor), letrozole, and leuprolide (lorelin depot). \n\nThe eligibility criteria for this trial include being at least 20 years old, having histologically or cytologically confirmed HER-2 negative breast cancer with recurrent or metastatic disease, not having HER2 overexpressing breast cancer, being premenopausal, and being ER and/or PR positive. Other criteria include having progressive disease on tamoxifen treatment or sequential or combined treatment of tamoxifen and GnRH agonist, with a minimum duration of tamoxifen treatment of 3 months or more. Patients should not have received prior treatment with an aromatase inhibitor or inactivator or fulvestrant, or mTOR inhibitors. One line of chemotherapy in the metastatic setting is permitted. Patients should have an ECOG performance status of 0, 1, or 2, and at least one measurable lesion or mainly lytic bone lesions in the absence of measurable disease. Adequate hematologic, liver, and kidney function is also required.\n\nExclusion criteria for this trial include being pregnant or lactating, having received more than one line of prior chemotherapy for metastatic breast cancer, receiving GnRH agonist with tamoxifen treatment within 2 weeks, having active malignancy other than breast cancer, in situ carcinoma of the cervix, controlled resected thyroid well differentiated carcinoma, or non-melanomatous skin cancer in the past 5 years. Patients with active cardiovascular disease such as angina, ventricular tachycardia, or uncontrolled hypertension, active uncontrolled infection, symptomatic brain metastases, lymphangitic carcinomatosis involving more than 50% of the lungs, or evidence of metastases involving more than one third of the liver on sonogram or CT are also excluded. Patients who are not able or unwilling to give informed consent are not eligible for the trial.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The phase column indicates the phase of the trial, which can be phase I, phase II, or phase III. The diseases column contains a list of disease names, while the icdcodes column contains a list of corresponding ICD-10 codes for the diseases. The drugs column contains a list of drug names. The criteria column provides the eligibility criteria for the trial.\n\nIn the sample, the phase is listed as phase 1/phase 2. The diseases listed include adenocarcinoma of the esophagus, adenocarcinoma of the gastroesophageal junction, diffuse adenocarcinoma of the stomach, gastrointestinal cancer, intestinal adenocarcinoma of the stomach, mixed adenocarcinoma of the stomach, stage iiia esophageal cancer, stage iiia gastric cancer, stage iiib esophageal cancer, stage iiib gastric cancer, stage iiic esophageal cancer, stage iiic gastric cancer, stage iv esophageal cancer, and stage iv gastric cancer. The corresponding ICDCodes are provided for each disease.\n\nThe drugs listed in the sample are c-met inhibitor amg 337, oxaliplatin, leucovorin calcium, and fluorouracil. The eligibility criteria are also provided, including requirements such as a minimum life expectancy of 12 weeks, specific performance status, and various medical conditions that would exclude a patient from participating in the trial.\n\nAdditionally, the sample includes specific criteria for phase I and phase II of the trial, such as the requirement for measurable disease, histologically or cytologically confirmed adenocarcinoma, and specific disease status. It also mentions the availability of paraffin-embedded tumor specimens for central determination of MET expression status.\n\nOverall, the sample provides detailed information about the trial phases, diseases, drugs, and eligibility criteria for the clinical trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is essential hypertension. The ICDCodes associated with this disease are I10, O10.02, O10.03, O10.011, O10.012, O10.013, and O10.019. The drugs mentioned in this sample are cs-3150, placebo, and eplerenone. The eligibility criteria for this trial include specific age requirements, blood pressure ranges, and exclusion criteria such as secondary hypertension, diabetes mellitus with albuminuria, low or high serum potassium levels, reversed day-night life cycle, and low eGFR (estimated glomerular filtration rate).",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"diabetic nephropathy\". The ICD-10 codes associated with this disease are ['E10.21', 'E11.21', 'E13.21', 'E08.21', 'E09.21']. The drugs being studied in this trial are 'cs-3150' and 'placebo'. The sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include having type 2 diabetes mellitus, being 20 years or older, having a specific urinary albumin to creatine ratio, and a certain estimated glomerular filtration rate. Exclusion criteria include having type 1 diabetes, a high HbA1c level, secondary glucose intolerance, non-diabetic nephropathy, nephrotic syndrome, secondary hypertension or malignant hypertension, and specific serum potassium levels based on eGFRcreat.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"idiopathic pulmonary fibrosis\" (IPF). The ICD-10 code for IPF is \"J84.112\". The trial involves two drugs, \"sar156597\" and \"placebo\". The eligibility criteria for participants are listed, including requirements such as being an adult, having a documented diagnosis of IPF, and providing written informed consent. There are also exclusion criteria, such as being under 40 years old, having a diagnosis of IPF for more than 5 years, and having certain lung function measurements below specified thresholds. Other exclusion criteria include having certain respiratory disorders, pulmonary artery hypertension, or a history of vasculitis or connective tissue disorders. Participants with active tuberculosis or certain viral infections are also excluded. The use of certain medications, including cytotoxic/immunosuppressive agents and cytokine modulators, within specific timeframes prior to screening is also listed as an exclusion criterion. The provided information is not exhaustive and may not include all relevant considerations for potential participants in the clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on studying the effects of a drug called \"nrd135s.e1\" on diabetic peripheral neuropathic pain. The trial is specifically looking for participants who meet certain eligibility criteria.\n\nThe eligibility criteria for this trial include:\n1. Male participants must agree to use condoms throughout the treatment and follow-up periods. Female participants must meet specific criteria to prove they are not of childbearing potential.\n2. Participants must have stable diabetes mellitus for the last 3 months, with no changes in oral hypoglycemic medications allowed and a maximum insulin change of \u00b1 20%.\n3. Participants must have evidence of peripheral neuropathy associated with diabetes mellitus diagnosed by DN4 criteria.\n4. Participants must have ongoing pain due to diabetic peripheral neuropathy for at least 3 months.\n5. Participants must have a mean diabetic peripheral neuropathy pain intensity rating of 4 to 9 on the NPS (Numeric Pain Scale) at screening.\n6. Participants must have an HbA1c level of \u2264 9% of total hemoglobin at screening.\n7. Participants must be willing to stop pain medications for diabetic peripheral neuropathy, except for limited use of paracetamol.\n8. Participants must have signed a written informed consent form and be willing and able to comply with the study requirements.\n\nThe exclusion criteria for this trial include:\n1. Female participants of childbearing potential.\n2. Participants with neurologic disorders unrelated to diabetic peripheral neuropathy that may interfere with the assessment of diabetic peripheral neuropathy.\n3. Participants with a known allergy or intolerance to paracetamol.\n4. Participants with evidence of non-diabetic peripheral neuropathy.\n5. Participants with severe pain associated with conditions other than diabetic peripheral neuropathy that could confound the self-evaluation of pain due to diabetic peripheral neuropathy.\n6. Participants currently on any anti-epileptic or anti-depressive treatment, except for amitriptyline (Elatrol/Elatrolet) or duloxetine (Cymbalta) at screening.\n7. Participants who are constantly using non-steroidal anti-inflammatory drugs or opiates that cannot be withdrawn during the washout period and the entire study duration.\n8. Participants who have participated in another clinical trial in the last 3 months.\n9. Participants with poor compliance with prescribed medication or a history of alcohol or drug abuse within 2 years before screening.\n10. Participants with hypersensitivity to paracetamol or any inactive ingredients in the NRD135S.E1 capsules.\n11. Participants with any serious medical condition or laboratory abnormalities that would put them at an unacceptable risk or confound the interpretation of data from the study.\n12. Participants with any hematological disorder.\n13. Prisoners or subjects who are involuntarily incarcerated.\n14. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.\n15. Patients whose judgment has been impaired by their physical or mental condition.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is castration-resistant prostate cancer. The ICDCodes associated with this disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs being used in the trial are enzalutamide and flutamide. The eligibility criteria for participants include having a testosterone level of less than 50 ng/dL, disease progression or relapse of PSA, relapse after CAB with bicalutamide, ECOG performance status of 0 or 1, age of 20 years or older, and providing written informed consent. The exclusion criteria include prior treatment with enzalutamide, flutamide, abiraterone, or chemotherapy (except for neoadjuvant therapy), active double cancer, prior treatment with bicalutamide within 6 weeks, prior systemic biological therapy or treatment with other antitumor agents for prostate cancer, serious complications, history of hypersensitivity to enzalutamide or flutamide-containing agents, liver dysfunction, and being considered inadequate by the investigator.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being studied is zoledronate. The eligibility criteria for the trial are listed, including requirements such as a confirmed diagnosis of non-metastatic operable primary invasive TN breast cancer, specific receptor status, age, performance status, and availability of tumor tissue for evaluation. There are also exclusion criteria, such as the presence of metastatic disease, previous treatment for the diagnosed breast cancer, and certain medical conditions that may make a patient unsuitable for the study.",
    "The sample provided is for a phase 2 clinical trial. The trial is focused on treating two diseases: adult brain glioblastoma and recurrent adult brain neoplasm. The diseases are identified using ICD-10 codes, which in this case are \"C71.7\", \"C71.9\", \"C79.31\", \"D33.0\", \"D33.1\", \"D33.2\", and \"D49.6\". The drug being tested in the trial is carmustine. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Participants must have histologically confirmed GBM.\n- They must have experienced progressive disease after receiving temozolomide and radiation therapy (in \"first relapse\").\n- At least 28 days must have passed since their last chemotherapy or radiation treatment.\n- Participants must have a Karnofsky performance score of at least 70%.\n- Platelet count must be equal to or greater than 130/mm^3.\n- Absolute neutrophil count must be equal to or greater than 1500/mm^3.\n- Calculated creatinine clearance must be greater than 45 mg/dl using the Cockcroft-Gault formula.\n- Aspartate aminotransferase (AST) must be less than 2 times the upper limit of normal.\n- Bilirubin must be less than 1.5 times the upper limit of normal.\n- Subjects with child-bearing potential must agree to use effective means of contraception.\n\nThe exclusion criteria for participants in the trial are as follows:\n- Participants must not have received prior systemically administered nitrosoureas or vascular endothelial growth factor (VEGF) targeted therapy.\n- Chemotherapy for glioma other than temozolomide or Gliadel wafers is not allowed (steroids are allowed).\n- Participants must not be pregnant or breastfeeding.\n- Active inflammatory bowel disease is not allowed.\n- Participants must not have had an abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within the past 6 months.\n- Hypertension with systolic blood pressure (SBP) greater than 150 or diastolic blood pressure (DBP) greater than 100 mm mercury (Hg) despite antihypertensive medications is not allowed.\n- New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), myocardial infraction, or unstable angina within the past 6 months is not allowed.\n- Participants with a history of thrombosis are not eligible.\n- Symptomatic peripheral vascular disease, stroke, or transient ischemic attack within the past 6 months is not allowed.\n- Participants with bleeding risks, such as being on therapeutic anticoagulation, having coagulopathy, or experiencing any grade III or greater hemorrhage, major surgical procedure, or significant trauma within the past 28 days, are not eligible.\n- Activated partial thromboplastin time (APTT) must not exceed 32.5 seconds, and international normalized ratio (INR) must not exceed 1.30.\n- Participants with serious, non-healing wounds, ulcers, or bone fractures are not eligible.\n- Active implanted medical devices, skull defects, shunts, bullet fragments, or known sensitivity to conductive hydrogels are not allowed.\n- Participants who are HIV positive, have proteinuria at screening, have had prior organ transplantation, have known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, or are taking aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), clopidogrel, or any other drug that inhibits platelet function are not eligible.\n- Participants must be able to give signed informed consent.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being studied is bicalutamide. The eligibility criteria for participants in this trial include being female and over 18 years old, having histologically proven unresectable or metastatic breast cancer, and having undergone at least one chemotherapy regimen for metastatic disease. Other criteria include being positive for the androgen receptor (AR) and triple-negative for estrogen receptor (ER), progestogen receptor (PR), and human epithelial receptor-2 (HER2). Patients must also have at least one measurable disease according to the response evaluation criteria in solid tumor (RECIST 1.1), a performance status no higher than 2, and adequate hematologic, hepatic, and renal function. The sample also includes exclusion criteria such as being pregnant or lactating, not using adequate contraceptive protection, recent use of investigational products or chemotherapy, and having certain medical conditions or infections.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2. The diseases mentioned include age-related macular degeneration (AMD), macular degeneration, exudative age-related macular degeneration, and others. The ICDCodes associated with these diseases are also provided. The drugs mentioned are x-82, anti-VEGF, and placebo. The eligibility criteria for participants are listed, including requirements for the duration of treatment, prior injections, reduction in macular fluid, and visual acuity. Exclusion criteria are also mentioned, such as previous vitrectomy, other causes of choroidal neovascularization, and proliferative diabetic retinopathy.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the disease systemic scleroderma. The ICD-10 codes associated with this disease are 'L94.1' and 'L94.0'. The trial involves two drugs, namely 'c-82 topical gel, 1%' and 'c-82 topical gel, placebo'. The eligibility criteria for participants are listed, including meeting the American College of Rheumatology criteria for systemic sclerosis with diffuse cutaneous involvement, having a disease duration of less than 36 months, having a local skin score over the bilateral forearm of at least 2, and having a modified Rodnan Skin Score (MRSS) of at least 12. Participants must also be on a stable dose of any immunosuppressive medication (except cyclophosphamide or high dose steroids) for at least one month and agree to use effective contraception. There are also exclusion criteria, such as recent participation in another clinical trial, ongoing use of high dose steroids, recent use of topical creams or gels on the forearm area, and recent UV light therapy. Other exclusion criteria include recent treatment with cyclophosphamide, active infections, history of malignancy within the past 2 years, moderate to severe hepatic impairment, pregnancy or nursing, gastrointestinal involvement requiring total parenteral nutrition or recent hospitalization for pseudo-obstruction, moderately severe pulmonary disease, moderately severe cardiac disease, elevated AST or ALT levels, and elevated total bilirubin levels. Participants with Gilbert's Disease may be included if their total bilirubin is within a certain range. The sample also mentions that participants with significant medical or psychosocial problems may be excluded.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"lupus erythematosus, systemic\". The ICD-10 codes associated with this disease are \"M32.9\", \"M32.0\", \"M32.11\", \"M32.12\", \"M32.13\", \"M32.14\", and \"M32.8\". The drugs being studied in this trial are \"ustekinumab iv\", \"placebo infusion\", \"placebo sc\", and \"ustekinumab sc\". The eligibility criteria for participants in this trial are listed, including requirements for medical history, positive autoantibody tests, BILAG scores, and SLEDAI-2K scores. There are also exclusion criteria, such as having other inflammatory diseases, being pregnant or planning a pregnancy, recent use of certain medications, previous use of specific B cell targeting therapies, previous use of ustekinumab, and a history of malignancy within the past 5 years.",
    "The sample from the table is for a phase 2 clinical trial. The diseases being studied are acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The corresponding ICD-10 codes for ALL are C91.01, C91.02, and C91.00, and for AML are C92.A1, C92.A2, C92.61, C92.62, C92.A0, and C92.60. The drugs being used in the trial are clofarabine, cyclophosphamide, and etoposide. \n\nThe inclusion criteria for the trial are as follows:\n- Patients must have a diagnosis of ALL or AML with less than 5% blasts in the bone marrow.\n- Flow cytometric evidence of minimal residual disease (MRD) or molecular/cytogenetic evidence of disease within 7 days.\n- Patients must have an available donor and intend to proceed to allogeneic hematopoietic cell transplantation (HCT) after completing 1 cycle of bridging therapy.\n- Age must be between 0 and 39 years.\n- Karnofsky Performance Status must be at least 50% for patients 16 years and older, and Lansky Play Score must be at least 50 for patients under 16 years of age.\n- Patients must have a life expectancy of at least 8 weeks.\n- Patients must have acceptable organ function, including renal, hepatic, and cardiac function.\n- Patients must have fully recovered from prior chemotherapy, immunotherapy, or radiotherapy.\n- At least 7 days must have elapsed since the completion of therapy with a growth factor.\n- Sexually active females of childbearing potential must use adequate contraception during treatment and for 2 months after the last dose of chemotherapy. Sexually active men must use barrier contraception during treatment and for 2 months after the last dose of chemotherapy.\n- Patients must provide voluntary written consent.\n\nThe exclusion criteria for the trial are as follows:\n- Acute Promyelocytic Leukemia (APL).\n- Active extramedullary disease or presence of chloromatous disease.\n- Receiving concomitant chemotherapy, radiation therapy, immunotherapy, or other anti-cancer therapy not specified in the protocol.\n- Systemic fungal, bacterial, viral, or other uncontrolled infection.\n- Pregnant or lactating.\n- Known allergy to any of the agents or their ingredients used in the study.\n- Participating in a concomitant Phase 1 or 2 study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of prostate cancer. The trial includes patients who meet certain eligibility criteria. The diseases column specifies the disease being studied, and the icdcodes column provides the corresponding ICD-10 codes for the disease. The drugs column lists the drugs being used in the trial, which in this case are \"bhr-200 (0.36% transdermal 17\u03b2-estradiol gel)\" and \"placebo\". The criteria column provides the inclusion and exclusion criteria for the trial, which determine whether a patient is eligible to participate. In this sample, the inclusion criteria include factors such as age, body mass index, clinical indication of prostate cancer, and specific treatment history. The exclusion criteria include factors such as allergies, certain medical conditions, and use of certain medications.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is diabetic retinopathy, which is indicated by the presence of clinically significant diabetic macular edema. The ICD-10 codes associated with this disease are H35.23, H35.20, H35.21, H35.22, E10.3553, E11.3553, and E13.3553. The drug being tested is squalamine lactate ophthalmic solution 0.2%. \n\nThe inclusion criteria for this trial include having clinically significant diabetic macular edema of at least 300 microns with central involvement, a best corrected visual acuity of 20/32 to 20/320 in the study eye, and being an adult aged 18 or older with type 1 or type 2 diabetes mellitus and diabetic macular edema. \n\nThe exclusion criteria include a history of vitreoretinal surgery in the study eye, panretinal laser photocoagulation or macular laser photocoagulation in the study eye within 3 months of screening, previous use of intraocular or periocular corticosteroids in the study eye within 6 months of screening, previous treatment with anti-angiogenic drugs in either eye within 3 months of screening, uncontrolled diabetes mellitus with HbA1c levels greater than 12, and ocular disorders in the study eye, other than diabetic macular edema, that may confound the interpretation of study results.",
    "The sample is a phase 2 trial for the treatment of hepatitis C virus infection. The trial is focused on patients who are currently on the liver transplantation waitlist. The eligibility criteria include having a quantifiable virus infection, having chronic genotype 1 or 4 HCV infection for at least 6 months, and having a negative serum pregnancy test for females. The sample also includes key exclusion criteria such as previous solid organ transplant, serious or active medical or psychiatric illness, HIV infection, and prior exposure to an HCV non-structural protein (NS)5A inhibitor. Other criteria, as defined by the protocol, may also apply.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of heart failure. The trial includes patients who have been on oral furosemide or a therapeutic equivalent for at least 90 days before the study. The inclusion criteria specify that participants must have a history of chronic heart failure with moderate symptoms of chronic fluid overload. The exclusion criteria include recent acute decompensated heart failure, contraindication to furosemide, low blood pressure, high temperature or infection, abnormal levels of sodium or potassium, current or planned treatment with certain medications or therapies, history of gastric or intestinal surgery, need for urinary catheterization, current or planned ultrafiltration, hemofiltration, or dialysis, impaired renal function, recent administration of radiographic contrast agent, recent major surgery, recent participation in another trial or use of investigational drugs or devices, inability to follow instructions or comply with procedures, and any other surgical or medical condition that may interfere with participation or affect the study outcome.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"epilepsy.\" The associated ICD-10 codes for epilepsy are listed as \"G40.803,\" \"G40.804,\" \"G40.911,\" \"G40.919,\" \"G40.B11,\" \"G40.B19,\" and \"G40.801.\" The drugs being studied in this trial include \"staccato\u00ae alprazolam, 0.5 mg,\" \"staccato\u00ae alprazolam, 1 mg,\" \"staccato\u00ae alprazolam, 2 mg,\" \"staccato\u00ae placebo (a),\" and \"staccato\u00ae placebo (b).\" \n\nThe eligibility criteria for participants in this trial include being between the ages of 18 to 60, having a BMI between 18 and 35 kg/m2, being able to speak, read, and understand English, and providing written informed consent. Participants must have a diagnosis and history of a photoparoxysmal response on EEG, with or without a diagnosis of epilepsy, and be on 0-2 concomitant antiepileptic drugs. At least 3 EEGs performed during the screening visit must show a reproducible IPS-induced photoparoxysmal response (PPR) on EEG. Participants must also be in good general health as determined by various medical tests.\n\nExclusion criteria for participants include a history of non-epileptic seizures, seizure worsening in response to narrow spectrum drugs, active CNS infections or diseases that may confound the study results, use of more than 2 concomitant AEDs for epilepsy treatment, and use of certain medications that interact with CYP3A. Other exclusion criteria include allergies to alprazolam or other benzodiazepines, recent use of investigational drugs, history of drug or alcohol dependence or abuse, positive urine screen for drugs of abuse, history of HIV-positivity, pregnancy or breastfeeding, certain medical conditions such as glaucoma, Parkinson's disease, and significant head trauma, and respiratory conditions such as asthma or COPD. Additional exclusion criteria include certain ECG abnormalities, abnormal blood pressure, significant diseases affecting various body systems, and any other condition that may pose undue risk or confound the study results.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of recurrent small cell lung carcinoma using a drug called selinexor. The eligibility criteria for the trial include having a confirmed diagnosis of relapsed small cell lung cancer, measurable disease, and evidence of disease progression. Patients must have received no more than 2 prior chemotherapy regimens and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Other criteria include specific blood counts, liver function, kidney function, and other medical parameters. Female patients of childbearing potential must agree to use contraception, and both male and female patients must use contraception throughout the study and for three months after the last dose. The exclusion criteria include primary refractory disease, pregnancy or lactation, recent treatment with selinexor, major surgery within 3 weeks, unstable cardiovascular function, uncontrolled infection, HIV or hepatitis infection, and other serious medical conditions. The sample also mentions the requirement for available archival tumor tissue or willingness to undergo a repeat biopsy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease mentioned is \"metastatic urothelial carcinoma.\" The ICDCodes associated with this disease are \"C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31.\" The drugs being used in this trial are \"pembrolizumab\" and \"acp-196 in combination with pembrolizumab.\" \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Men and women aged 18 years or older\n- Histologically or cytologically confirmed urothelial carcinoma of the bladder or mixed histology bladder cancer\n- Metastatic bladder cancer with disease progression on or after platinum-based chemotherapy\n- Any primary site of urothelial carcinoma including upper tract, renal pelvis, bladder, and ureters\n- Prior therapy with at least one systemic chemotherapy regimen for urothelial carcinoma\n- Presence of radiographically measurable disease (defined as the presence of at least one lesion measuring at least 10 mm, or at least 15 mm for lymph nodes)\n- ECOG performance status of 0 or 1\n\nExclusion Criteria:\n- Prior malignancy (other than bladder cancer), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease-free for at least 2 years and will not limit survival to less than 2 years.\n- Known central nervous system metastases and/or carcinomatous meningitis\n- Malabsorption syndrome or disease significantly affecting gastrointestinal function\n- Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infraction within 6 months of screening.",
    "The sample from the table represents a clinical trial in phase 2/phase 3 for the treatment of Alzheimer's disease and related symptoms. The diseases being studied include Alzheimer's disease, agitation, weight loss, pain, and oxidative stress. The corresponding ICD-10 codes for these diseases are provided. The drugs being tested are nabilone and a placebo. \n\nThe eligibility criteria for participants include being males or females aged 55 years or older, meeting the diagnostic criteria for Major Neurocognitive Disorder due to Alzheimer's disease, being in the moderate-to-severe stage of dementia, having clinically significant agitation, and having stable dosages of cognitive-enhancing medications for at least 3 months. \n\nExclusion criteria include recent changes in psychotropic medications, contraindications to nabilone, significant cardiovascular disease, presence or history of other psychiatric disorders or neurological conditions, and previous or current abuse of/dependence on marijuana.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is metastatic pancreatic cancer. The ICDCodes associated with this disease are C25.3. The drugs being used in the trial are folfirinox, lv5fu2, folfiri.3, and gemcitabine. The eligibility criteria for inclusion in the trial include having metastatic disease, at least one measurable lesion according to RECIST V1.1 criteria, no prior chemotherapy (except if there is at least one lesion outside the irradiation area), age over 18 years (with a favorable advice from an onco geriatrician required for patients older than 75), performance status (WHO) of 0-1, polynuclear count \u2265 1500/mm3, bilirubin \u2264 1.5 times the LSN, creatinine < 120\u03bcmol / L, and a signed informed consent form. The exclusion criteria include having another type of pancreas tumor (such as endocrine tumor or with acinous cells), ampulloma, cerebral or meningeal metastasis, Gilbert disease, neuropathy grade 1 or higher, contraindication to study treatments, uncontrolled diarrhea or inflammatory disease of the colon or rectum, bowel obstruction or sub-obstruction not resolved with specific treatment, serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease that prevents the patient from receiving study treatment, significant previous cardiac and respiratory disease, being included in another therapeutic study with experimental treatment, pregnancy or breastfeeding, being deprived of freedom or under guardianship, and having psychological, familial, sociological, or geographical conditions that could potentially hinder compliance with the study protocol and follow-up schedule.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is non-small cell lung cancer (NSCLC). The ICD-10 codes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being tested in this trial are medi4736 (durvalumab), vinorelbine, gemcitabine, erlotinib, medi4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), and tremelimumab (anti-CTLA4). The eligibility criteria for participants in this trial include being at least 18 years old, having documented evidence of NSCLC (Stage IIIB/IV disease), disease progression or recurrence after previous treatments, having a World Health Organization (WHO) Performance Status of 0 or 1, and an estimated life expectancy of more than 12 weeks. There are also exclusion criteria, such as prior exposure to certain antibodies, presence of brain metastases or spinal cord compression, active autoimmune disease, severe or uncontrolled systemic disease, unresolved toxicity from previous therapy, known EGFR TK activating mutations or ALK rearrangements, prior Grade \u22653 immune-related adverse events, and active or prior documented inflammatory bowel disease.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is ovarian cancer, and the associated ICDCodes are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are niraparib and bevacizumab. \n\nThe eligibility criteria for this trial include:\n1. Recurrent platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.\n2. High-grade serious or high-grade endometrioid histology.\n3. Patient consents to perform HRD test.\n4. Prior line of therapy with platinum-containing therapy for primary disease.\n5. Age 18+.\n6. Histological confirmed ovarian, fallopian tube, or peritoneal cancers.\n7. Patients must give informed consent.\n8. ECOG performance status 0-2.\n9. Adequate organ function.\n10. Able to take oral medications.\n11. Life expectancy of at least 12 weeks.\n12. Women of childbearing potential must use adequate birth control for the duration of the study participation.\n\nThe exclusion criteria for this trial include:\n1. Ovarian sarcomas, small cell carcinoma with neuroendocrine differentiation, non-epithelial cancers, and cancer types not mentioned in the inclusion criteria.\n2. Concurrent cancer therapy.\n3. Concurrent treatment with an investigational agent or participation in another clinical trial.\n4. Major injuries or surgery within the past 21 days prior to the start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period.\n5. Previous malignant disease detected within 2 years prior to randomization.\n6. Active infections or other serious underlying significant medical illness, abnormal laboratory finding, or psychiatric illness/social situation that would make the patient inappropriate for this study.\n7. Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug.\n8. History of bowel obstruction, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess.\n9. Known contraindications to PARP inhibitors or VEGF directed therapy.\n10. Known uncontrolled hypersensitivity to the investigational drugs.\n11. History of major thromboembolic event within the past 3 months.\n12. History of cerebral vascular accident, transient ischemic attack, or subarachnoid hemorrhage within the past 3 months.\n13. History of clinically significant hemorrhage in the past 3 months.\n14. Uncontrolled and/or symptomatic CNS metastasis or leptomeningeal carcinomatosis.\n15. Significant cardiovascular diseases, including uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina, or myocardial infraction within 6 months prior to randomization.\n16. Pregnancy or breastfeeding.\n17. Radiographic evidence of cavitation or necrotic tumors with invasion of adjacent major blood vessels.\n18. Active or chronic hepatitis C and/or B infection.\n19. Persistence of clinically relevant therapy-related toxicity from previous chemotherapy.\n20. Proteinuria.\n21. Known history of MDS.\n22. Known persistent hematological toxicity from prior cancer therapy.\n23. Known Grade 3 thrombocytopenia or anemia with the last chemotherapy regimen.",
    "The sample is a phase 2 trial for ovarian neoplasms or ovarian cancer. The trial is focused on the drug niraparib. The eligibility criteria for the trial include undergoing tumor HRD testing and blood gBRCAmut status testing, having a negative pregnancy test, having a histologically diagnosed high-grade serous cancer with recurrent disease, having completed 3 or 4 previous chemotherapy regimens, having measurable disease, and having tumor samples available for analysis. The exclusion criteria include not having any persistent \u2265Grade 3 hematologic toxicity or fatigue, not having received pelvic radiotherapy within the past year, not having symptomatic uncontrolled brain or leptomeningeal metastases, not being considered a poor medical risk due to a serious medical disorder or active infection, not having received a transfusion within the past 4 weeks, and not having a history or current diagnosis of myelodysplastic syndrome or acute myeloid leukemia.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is focused on the treatment of metastatic melanoma, a type of skin cancer that has spread to other parts of the body. The trial is in phase 1/phase 2, which means it is still in the early stages of testing. The diseases column specifies the disease being studied, which in this case is metastatic melanoma. The icdcodes column contains a list of ICD-10 codes associated with the disease. The drugs column lists the names of the drugs being used in the trial, including vemurafenib, lymphodepleting chemotherapy, til infusion, and interleukin-2. The criteria column provides the eligibility criteria for participants in the trial. This includes requirements such as having confirmed unresectable stage III or stage IV metastatic melanoma, having a certain type of genetic mutation (BRAF mutation), and having a certain performance status. There are also exclusion criteria, which specify conditions or factors that would disqualify someone from participating in the trial. These include having other malignancies, having cerebral metastasis, and having certain medical or psychiatric comorbidities. The sample also includes additional details about the trial, such as the need for informed consent and the timeline for prior treatments.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"cystic fibrosis\". The ICD-10 codes associated with this disease are \"E84.9\", \"Z14.1\", \"E84.0\", \"E84.11\", \"E84.8\", \"E84.19\", and \"P09.4\". The drugs being studied in this trial are \"gallium nitrate\" and \"normal saline\". The eligibility criteria for participants in this trial include being 18 years or older, having chronic colonization with P. aeruginosa, having a documented CF diagnosis, having a certain level of lung function (FEV1), being able to expectorate sputum, and meeting various laboratory test requirements. There are also criteria related to pregnancy and contraception for female participants and contraception for male participants. The sample also includes exclusion criteria, such as recent use of antibiotics or bisphosphonates, lactating, and known sensitivity to gallium.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the diseases being studied are non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia. The ICDCodes associated with these diseases are Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, and K70.0. The drugs being tested in this phase are placebo, omega-3 carboxylic acid, and fenofibrate 200mg. The eligibility criteria for participants include age between 40 and 75, suitable veins for cannulation or venepuncture, specific serum triglyceride and liver fat content levels, and a body mass index (BMI) between 25 and 40 kg/m2. There are also exclusion criteria, such as having clinically significant diseases or disorders, certain abnormal liver function markers, type 2 diabetes, recent history of drug or alcohol abuse, and other abnormalities in laboratory test results.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 2 and focuses on the disease \"exudative age-related macular degeneration.\" The trial is associated with specific ICD-10 codes related to this disease. The drugs being studied in this trial are \"lha510 ophthalmic suspension,\" \"lha510 vehicle,\" and \"ranibizumab ophthalmic solution.\" \n\nThe record also includes the eligibility criteria for participants in the trial. The inclusion criteria state that participants must provide written informed consent, have wet AMD, have received IVT anti-VEGF therapy for at least 6 months and a maximum of 7 years since the 3rd loading dose, have a BCVA (best-corrected visual acuity) of 50 letters or better in the study eye, be able to administer eye drops, demonstrate a high need for frequent anti-VEGF therapy, and meet other criteria specified in the protocol.\n\nThe exclusion criteria state that participants should not have any active ocular or periocular infection or intraocular inflammation, should not have current or history of macular or retinal disease other than wet AMD in the study eye, should not have current clinically significant vitreous hemorrhage or history of retinal detachment affecting the macula, should not have a history of hypersensitivity to the study drugs or relevant sensitivity to fluorescein dye or povidone iodine, should not be women of child-bearing potential, should not have a medical condition that would interfere with the study, and should not meet other specified exclusion criteria in the protocol.",
    "The sample is a phase 2 clinical trial for the treatment of diabetes mellitus and its complications, specifically gastroparesis. The trial involves the use of the drugs relamorelin and placebo. The eligibility criteria for participants include having type 1 or type 2 diabetes with stable glycemic control, experiencing symptoms of gastroparesis for at least 3 months, having a certain score on the Gastroparesis Cardinal Symptom Index Daily Diary, and meeting specific criteria for delayed gastric emptying. Participants must also have stable concomitant medications, not be using certain gastrointestinal motility agents or anti-emetics, have a body mass index above 18 kg/m2, and meet certain requirements for female participants. The trial also has additional inclusion criteria for randomization after a 2-week single-blind placebo run-in period. Exclusion criteria include certain medical conditions, surgeries, medication use, allergies, and other factors that may confound the study or pose risks to participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on two diseases: chronic kidney disease and type 2 diabetes. The corresponding ICD-10 codes for these diseases are also listed. The trial involves two drugs, namely asp8232 and placebo. The eligibility criteria for participants are then described in detail, including requirements for estimated glomerular filtration rate, documented diagnosis of T2DM, glycated hemoglobin levels, stable therapy with ACE inhibitors or ARBs, stable therapy with other medications, stable dietary interventions, and specific urinary albumin-to-creatinine ratio values. The exclusion criteria are also listed, which include factors such as renal replacement therapy, renal impairment not related to diabetic kidney disease, autoimmune disorders, urinary tract infections, and abnormal blood pressure levels.",
    "The sample is a phase 2 trial for epilepsy. The trial is specifically targeting patients with certain epilepsy syndromes such as PCDH19, CDKL5, Dravet Syndrome, Lennox Gastaut Syndrome (LGS), and Continuous Spikes and Waves during Sleep (CSWS). The inclusion criteria include having a parent or legal guardian available to give consent, being between 2 and 18 years old, having uncontrolled cluster seizures and/or non-clustered seizures, being on a stable regimen of anti-epileptic medication, and being generally in good health. The trial also requires the parent or guardian to maintain a daily written seizure calendar and the subjects to take the study medication with food two or three times daily. The exclusion criteria include previous exposure to ganaxolone, known sensitivity or allergy to any component in the study drug, progesterone, or other related steroid compounds, recent exposure to any investigational drug or device, concurrent use of certain medications, presence of clinically significant medical conditions, active suicidal thoughts or attempts, and abnormal liver function test results.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"pre-diabetes.\" The ICD-10 codes associated with this disease are ['O24.32', 'O24.82', 'O24.02', 'O24.12', 'O24.33', 'O24.83', 'O24.03']. The drugs being studied are \"bti320\" and \"bti320 matching placebo.\" \n\nThe eligibility criteria for this trial are as follows:\n1. The subject must be an adult between the ages of 18 and 70.\n2. The subject must be of Chinese ethnicity.\n3. The subject must be at high risk for pre-diabetes, meeting at least 2 of the following criteria:\n   a. Fasting plasma glucose (FPG) levels between 5.6-6.9 mmol/l and/or 2-hour postprandial glucose (PG) levels between 7.8-11.0 mmol/l during a 75 gram oral glucose tolerance test (OGTT).\n   b. HbA1c levels between 5.7-6.4%.\n   c. Presence of at least one of the following risk factors:\n      - History of gestational diabetes.\n      - Family history of diabetes in a first-degree relative.\n      - Presence of 2 or more components of the metabolic syndrome (triglyceride levels \u2265 1.7 mmol/L, blood pressure \u2265 130/80 mmHg, low high-density lipoprotein (HDL) cholesterol levels <1.3 mmol/L in women or <1.1 mmol/L in men, and waist circumference \u2265 80 cm in women or \u2265 90 cm in men). Patients already on antihypertensive or lipid-lowering medication will be considered to have one component of the metabolic syndrome.\n4. The subject must be capable of giving informed consent.\n5. Female subjects of childbearing potential who are sexually active with a non-sterilized male partner must agree to use adequate contraception during the study and up to 30 days after the final visit.\n6. The subject must be able and willing to consistently record a food diary for continuous glucose monitoring system (CGMS) evaluation.\n\nThe exclusion criteria for this trial are as follows:\n1. The subject must not have received any anti-diabetic agents within 6 weeks prior to the screening visit.\n2. The subject must not be on a dietary supplement known to affect glucose or galactose metabolism.\n3. The subject must not have a history of acute cardiovascular disease, such as myocardial infraction, acute coronary syndrome, or stroke, requiring hospitalization in the last 12 months.\n4. The subject must not have significant renal impairment with an estimated glomerular filtration rate (eGFR) less than 60ml/min/1.73m2.\n5. The subject must not have known lactose or galactose intolerance.\n6. The subject must not have a history of an eating disorder.\n7. Pregnant or lactating female subjects are excluded from the trial.\n8. Subjects with gastrointestinal diseases that may interfere with the absorption of the investigational product are excluded.\n9. The subject must not have received any investigational product within 30 days of the randomization visit.\n10. The subject must not have a reduced life expectancy or any condition considered unsuitable for enrollment, as determined by the investigator.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being studied is metformin. The eligibility criteria for the trial are listed, including requirements such as patients being treated at Lyndon B. Johnson General Hospital, being between 18 and 75 years old, scheduled to undergo paclitaxel chemotherapy, having adequate renal and hepatic function, and being able to speak English and/or Spanish. There are also exclusion criteria, such as patients with a history of diabetes, certain medication usage, enrollment in another trial, nerve pathology or neuropathy, and various other conditions that may preclude the use of the study medication.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of treatment-resistant depression. The associated ICD-10 codes for the disease are ['F32.A', 'F53.0', 'P91.4', 'Z13.31', 'Z13.32']. The drugs being studied in this trial are ketamine and midazolam. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being a male or female veteran aged 18 to 75 years, having a telephone in their home and being able to hear telephone conversations, meeting the DSM-IV criteria for major depressive disorder (MDD) without psychotic features, having a severity score of 32 on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30), and having a current major depressive episode resistant to treatment. The exclusion criteria include not being able to speak English, not being able or willing to provide written informed consent, having moderate/severe cognitive impairment, having certain psychiatric disorders or medical conditions, having a history of substance abuse, having clinically unstable medical illness, currently using barbiturates or monoamine oxidase inhibitors (MAOi), being pregnant or using hormonal treatments, and being at imminent risk of suicidal/homicidal ideation or behavior.\n\nOverall, this sample provides specific details about the phase, diseases, drugs, and eligibility criteria for participants in a clinical trial focused on treatment-resistant depression.",
    "The sample provided is for a phase 2 clinical trial. The trial is focused on treating metastatic breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being tested is icotinib. \n\nThe eligibility criteria for this trial include being 18 years or older, having an ECOG score of 0 or 1, having a confirmed triple negative primary or metastatic tumor, having measurable disease according to RECIST version 1.1, having normal organ function (including bone marrow, renal, liver, and cardiac function), having received two or more prior chemotherapy treatments, having signed an informed consent form, and having a life expectancy of at least 12 weeks.\n\nThe exclusion criteria for this trial include being pregnant or breastfeeding, having an ECOG score of 2 or higher, having uncontrolled medical problems, having hepatic, renal, or bone marrow dysfunction, having a concurrent malignancy or a history of other malignancy within the last five years (with some exceptions), and being unable or unwilling to comply with program requirements.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on heart failure, cardiomyopathy, and ventricular dysfunction. The diseases are represented by their respective ICD-10 codes. The only drug mentioned in this sample is a control solution. The eligibility criteria for participants are listed under inclusion and exclusion criteria. Inclusion criteria include being 18 years or older, providing informed consent, and being a suitable candidate for implantation of an FDA-approved or Health Canada-approved implantable LVAD (left ventricular assist device). Exclusion criteria include planned percutaneous LVAD implantation, requirement for biventricular mechanical support, recent cardiothoracic surgery, and various other factors.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is \"diabetic macular edema.\" The ICDCodes associated with this disease are \"E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513.\" The drugs being used in the trial are \"ranibizumab 0.3 mg\" and \"aflibercept 2.0 mg.\" The eligibility criteria for this trial include factors such as providing written informed consent, being over 21 years old, having a confirmed diagnosis of diabetic macular edema, having a visual acuity of 20/400 or better, and not having a history of post-injection pain or inflammation. There are also exclusion criteria listed, such as a history of endophthalmitis or current inflammation in the eyes, uncontrolled or symptomatic dry eye syndrome, recent intravitreal injection, history of uveitis, recent thromboembolic event, pregnancy or lactation, and premenopausal women not using adequate contraception.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of epilepsy and focal seizures. The diseases column lists the names of the diseases being studied, while the icdcodes column contains the corresponding ICD-10 codes for those diseases. The drugs column includes the names of the drugs being tested, which in this case are \"gwp42006\" and a placebo control. The criteria column provides the eligibility criteria for patients to participate in the trial.\n\nThe eligibility criteria state that patients must be between 18 and 65 years old and have a well-documented history of focal epilepsy. They should also have a compatible electroencephalogram and clinical history, as well as a computerized tomography or magnetic resonance imaging that shows no progressive neurologic abnormality. Patients must have focal seizures despite prior treatment with at least two antiepileptic drugs (AEDs) and currently be treated with one to three AEDs. All medications or interventions for epilepsy must have been stable for one month prior to screening, and the patient must be willing to maintain a stable regimen throughout the study. The patient should also be willing to keep any factors that may affect seizures stable, such as alcohol consumption and smoking.\n\nThere are also exclusion criteria listed, which state that patients cannot enter the study if their focal epilepsy treatment started less than two years prior to enrollment, if they have seizures that are not of focal onset, or if they only have focal seizures without impairment of consciousness or awareness and without an observable motor component. Other exclusion criteria include a history of status epilepticus, pseudo-seizures, recent implantation or activation of epilepsy neurostimulation devices, recent epilepsy surgery, clinically significant unstable medical conditions, recent illness that may affect seizure frequency, impaired hepatic function, active suicidal plan/intent, recent use of cannabis or cannabinoid-based medications, recent use of St John's Wort, recent consumption of grapefruit or grapefruit juice, known or suspected hypersensitivity to cannabinoids or other substances, and recent use of an investigational medicinal product.\n\nOverall, this sample provides specific information about the phase, diseases, icd codes, drugs, and eligibility criteria for patients participating in the clinical trial.",
    "The sample from the table is for a phase 2 trial. The disease being studied is postherpetic neuralgia. The corresponding ICD-10 code for this disease is B02.22. The drugs being tested are tv-45070 and placebo. The eligibility criteria for this trial include having chronic postherpetic neuralgia for more than 6 months and less than 10 years, being between 18 and 34 years old with a BMI within the specified range, not being pregnant (for women) and using contraception if fertile, signing the informed consent form, being medically healthy (except for postherpetic neuralgia), and being able to participate in the study. There are also exclusion criteria, such as having severe pain that may interfere with assessing or evaluating pain due to postherpetic neuralgia, having postherpetic neuralgia affecting the face, having a history of inadequate response to multiple treatments for neuropathic pain, currently taking oral analgesics or receiving topical therapy for pain and being unwilling or unable to discontinue them, having been treated with topical capsaicin in the past 6 months for neuropathic pain, and having a history of fibromyalgia.",
    "The sample provided is for a phase 2 clinical trial for Crohn's disease. The trial is testing the effectiveness of a drug called abt-494 compared to a placebo. The eligibility criteria for participants include having a diagnosis of Crohn's disease for at least 90 days, having a Crohn's Disease Activity Index (CDAI) score between 220 and 450, and having inadequate response or intolerance to previous treatments with immunomodulators and/or anti-TNF agents. Exclusion criteria include having ulcerative colitis, recent bowel resections or plans for resection, having an ostomy or ileoanal pouch, having symptomatic bowel stricture or abdominal or peri-anal abscess, having short bowel syndrome, and having recurring infections or active tuberculosis.",
    "The sample provided is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 2. The disease being studied is \"pulmonary disease, chronic obstructive\" and its corresponding ICD-10 codes are \"J44.9\", \"J44.1\", and \"J44.0\". The drugs being tested in this trial are \"placebo\" and \"pf-03715455\". \n\nThe eligibility criteria for this trial are as follows:\n- Female subjects must be of non-childbearing potential, and male subjects must be between the ages of 40 and 80 years.\n- Subjects must have a diagnosis of moderate to severe COPD for at least 6 months and meet the criteria for Stage II-III disease.\n- Subjects must have a smoking history of at least 10 pack-years.\n\nThe exclusion criteria for this trial are as follows:\n- Subjects should not have any clinically significant disease (other than COPD) or abnormality within the previous 6 months that would put them at risk or compromise the quality of the study data.\n- Subjects should not have had a COPD exacerbation requiring treatment with oral steroids or hospitalization for COPD treatment within 3 months of screening.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease asthma. The ICD-10 codes associated with asthma are provided. The drugs being studied in the trial are vapendavir and placebo. The eligibility criteria for participants in the trial are listed, including age requirements, a history of asthma exacerbation, current medication usage, and documented airway obstruction. The criteria for presumptive rhinovirus infection are also outlined. The exclusion criteria include severe asthma exacerbation, other respiratory conditions, pregnancy or breastfeeding for female participants, and the use of certain medications that may interfere with the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial is Phase 2.\n- Diseases: The trial is focused on triple negative breast cancer.\n- ICD Codes: The ICD-10 codes associated with the disease are ['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60'].\n- Drugs: The drug being tested in the trial is 'gtx-024'.\n- Criteria: The eligibility criteria for participants in the trial are listed in the record. These include factors such as age, previous chemotherapy regimens, confirmation of specific markers in the tumor, availability of tumor tissue, performance status, organ function, and other medical conditions.\n\nThe record also includes exclusion criteria, which specify conditions that would prevent someone from participating in the trial. These include factors such as life expectancy, uncontrolled central nervous system metastases, recent radiotherapy, concurrent illnesses or conditions that may interfere with the study, and previous treatments or medications.\n\nOverall, this record provides specific information about the phase, disease, drugs, and eligibility criteria for a clinical trial focused on triple negative breast cancer.",
    "The sample is from a table that contains information about clinical trials. It provides details about a specific trial in phase 2. The trial focuses on colon and rectal adenocarcinoma, as well as stage III and IV colorectal cancer. The trial involves the use of drugs such as clobetasol propionate and regorafenib. The eligibility criteria for participants are listed, including requirements for disease documentation, previous treatment history, performance status, blood counts, liver function, and other factors. The sample also includes exclusion criteria, such as prior treatment with regorafenib, certain medical conditions, and pregnancy.",
    "The sample from the table is for a clinical trial that is in phase 2/phase 3. The trial is focused on chronic hepatitis C. The ICD-10 codes associated with the disease are 'B18.2', 'B18.0', 'B18.1', 'B18.8', 'B18.9', 'K71.3', and 'K71.4'. The drugs being studied in the trial are ravidasvir hydrochloride, sofosbuvir, and ribavirin. \n\nThe eligibility criteria for the trial include being male or female between the ages of 18 and 65, having a positive HCV antibody test with serum HCV RNA levels of at least 10,000 IU/mL, having a confirmed HCV genotype-4 infection, having a body mass index (BMI) between 18 and 35 kg/m2, and agreeing to practice a method of birth control if of childbearing potential. \n\nThere are different criteria for different groups within the trial. Group 1 consists of treatment-na\u00efve patients, meaning they have never received any antiviral treatment for their HCV infection. Group 2 and Group 3 consist of patients who have previously failed treatment with an interferon-based therapy. Group 2 patients must be non-cirrhotic, while Group 3 patients must have underlying cirrhosis. \n\nOther exclusion criteria include having mixed genotype or non-typable HCV genotype infection, testing positive for HBsAg or HIV antibody, having a history of schistosomiasis or testing positive for schistosoma surface antigen, having a serum alpha-fetoprotein (AFP) level above 100ng/ml, having a medical condition other than HCV contributing to liver disease, having a history of hepatic decompensation or portal hypertension, having uncontrolled diabetes mellitus, having abnormal blood counts or liver function tests, having a history of poorly controlled asthma or recent malignancy, having a history of alcohol or drug abuse, being pregnant or intending to become pregnant, having a history of major surgery or recent participation in another clinical trial, and having a history of certain medication use or cardiac conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is multiple myeloma, and the corresponding ICDCodes are C90.01, C90.02, and C90.00. The drug being used in the trial is vlx1570 and dexamethasone. \n\nThe eligibility criteria for this trial include:\n1. Diagnosis of relapsed or relapsed and refractory multiple myeloma following at least 2 prior therapies, including an immunomodulatory drug and a proteasome inhibitor.\n2. Measurable disease as defined by specific criteria related to serum and urine protein levels.\n3. Adequate kidney function.\n4. Age of 18 years or older.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n6. Females of child-bearing potential must have a negative pregnancy test, and both males and females of child-bearing potential must be willing to use effective contraception during chemotherapy treatment and for at least 6 months afterward.\n7. Adequate blood counts and liver function.\n8. Patient must have or be willing to have a central venous catheter for drug administration.\n\nThe exclusion criteria for this trial include:\n1. Any concurrent treatment that would compromise the study, ongoing corticosteroid use exceeding a certain dose, or persisting effects of previous or ongoing treatment that may interfere with study treatment or assessment of adverse events.\n2. Any cytotoxic or biologic therapy within 2 weeks prior to starting therapy.\n3. Pregnant or breastfeeding females.\n4. Uncontrolled hypertension or diabetes.\n5. Known active hepatitis B or C infection or HIV infection.\n6. Significant cardiovascular disease or history of certain cardiac conditions.\n7. QTc interval exceeding certain thresholds or history of risk factors for torsade de points.\n8. Use of concomitant medications that prolong the QT/QTc interval.\n9. Uncontrolled intercurrent illness or psychiatric illness/social situations that may compromise compliance or put the patient at risk.\n10. Active infection requiring systemic treatment within one week prior to the first dose.\n11. Major surgery within 1 month prior to enrollment.\n12. Use of any investigational agent within the last 28 days.\n13. History of other malignancy, except for certain exceptions.\n14. Known intolerance to steroids or H1/H2-antagonists.\n15. Serum calcium level above the upper limit of normal range.\n16. Diagnosed with plasma cell leukemia, POEMS syndrome, or amyloidosis.\n17. History of central nervous system (CNS) myeloma or other CNS malignancy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are melanoma and brain metastases. The ICDCodes associated with these diseases are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4. The drugs being used in the trial are nivolumab and ipilimumab. The eligibility criteria for this sample include being at least 18 years old, having written informed consent, having stage IV melanoma or unknown primary melanoma with at least one radiologically confirmed brain metastasis, and meeting various other medical and health requirements. The sample also includes exclusion criteria, such as having certain pre-existing medical conditions, being pregnant or breastfeeding, or having received certain prior treatments. Additionally, the sample includes information about different cohorts within the trial and their specific eligibility criteria.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease cholangiocarcinoma. The ICD-10 codes associated with this disease are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']. The drug being studied is ldk378. The eligibility criteria for participants in this trial include having a confirmed diagnosis of intrahepatic or hilar cholangiocarcinoma with ALK and/or ROS1 over-expression, being locally advanced with inoperable or metastatic disease, having an ECOG performance status of 0-2, and meeting certain laboratory criteria. There are also exclusion criteria, such as known hypersensitivity to the drug, presence of symptomatic CNS metastases, prior therapy with ldk378, and certain medical conditions or medications that may interfere with the study. Additionally, there are criteria related to pregnancy and contraception for female participants, as well as requirements for sexually active male participants.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 2. The disease being studied is an infection. The ICD-10 codes associated with this disease are 'K94.02', 'K94.12', 'K94.22', 'K94.32', 'N99.511', 'A02.9', and 'A31.0'. The drug being tested is vancomycin. The eligibility criteria for participants in this trial include being able to sign an informed consent form, being at least 18 years old, and undergoing cardiac surgery with complete sternotomy. Exclusion criteria include having evidence of an active infection, undergoing organ transplantation, having a known hypersensitivity to vancomycin, being pregnant or nursing, and having mental impairment or other conditions that may hinder understanding of the study.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is colorectal cancer. The ICDCodes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are pembrolizumab and mfolfox6. The eligibility criteria for participants include factors such as providing informed consent, being at least 18 years old, having a performance status of 0 or 1, having confirmed metastatic colorectal adenocarcinoma, having measurable disease, and meeting certain requirements for female subjects of childbearing potential. There are also exclusion criteria listed, such as having resectable colon cancer liver metastases, participating in other investigational studies, having certain medical conditions or history, and having psychiatric or substance abuse disorders that may interfere with the trial.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The disease being studied is seasonal allergic rhinitis. The corresponding ICD-10 code for this disease is J30.2. The drugs being tested in the trial are nasapaque nasal solution and placebo saline nasal solution. The eligibility criteria for participants include being 18 years of age or older, having a history of allergic rhinitis, and having a positive response to the Allergen BioCube. The exclusion criteria include not having a significant illness such as moderate to severe allergic asthmatic reactions, not having compromised lung function, not using any disallowed medications, and not having participated in an investigational study in the last 30 days.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of metastatic prostate cancer. The diseases column specifies the disease being studied, which in this case is \"prostate cancer metastatic\". The icdcodes column provides the ICD-10 codes associated with the disease, which are \"C61\", \"D29.1\", \"D40.0\", \"Z15.03\", \"Z80.42\", \"Z85.46\", and \"Z12.5\".\n\nThe drugs column lists the drugs being used in the trial, which are \"osteodex\" and \"placebo\". The criteria column contains the eligibility criteria for participants in the trial. The inclusion criteria include factors such as age, confirmed diagnosis of adenocarcinoma of the prostate, failure or intolerance to previous therapies, evidence of metastatic disease, PSA progression, castrate level of serum testosterone, performance status, and various laboratory requirements. The exclusion criteria include factors such as concurrent use of other anti-cancer agents, recent treatments involving chemotherapy or major surgery, participation in other studies involving investigational drugs, certain medical conditions or abnormalities, high plasma glucose level, presence of brain metastases, recent dental surgery or trauma, and recent treatment with bisphosphonates.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"hepatitis C virus infection.\" The associated ICD-10 codes for this disease are \"B00.81,\" \"B25.1,\" \"B26.81,\" \"B58.1,\" \"K75.4,\" \"A51.45,\" and \"B17.2.\" The drugs being studied in this trial are \"vox,\" \"sof/vel,\" and \"rbv.\" The eligibility criteria for participants in this trial include having chronic HCV infection, HCV RNA levels of at least 10^4 IU/mL at screening, HCV genotype 1, cirrhosis determination (which may require a liver biopsy), specific screening laboratory values, and the use of two contraception methods for sexually active females of childbearing potential or males. The exclusion criteria include being pregnant or nursing, having a current or prior history of hepatic decompensation, hepatocellular carcinoma (HCC) or other clinically significant malignancy, infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV), and having a history of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment, or compliance with the protocol. It is also noted that there may be additional inclusion/exclusion criteria defined by the protocol.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is Hepatitis C Virus Infection. The ICDCodes associated with this disease are B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, and B17.2. The drugs being used in the trial are Vox and Sof/Vel. The sample also includes the eligibility criteria for the trial, including requirements such as having chronic HCV infection, HCV RNA levels above a certain threshold, specific HCV genotypes, cirrhosis determination, and certain screening laboratory values. It also lists exclusion criteria, such as being pregnant or nursing, having a history of hepatic decompensation or hepatocellular carcinoma, and having infections with HBV or HIV.",
    "The sample is a phase 2 trial for the treatment of rheumatoid arthritis. The trial is evaluating the effectiveness of a drug called namilumab, along with methotrexate and folic/folinic acid, compared to a placebo. The eligibility criteria for participants include being 18 years or older, having adult onset rheumatoid arthritis for at least 6 months, having moderately active disease, and experiencing pain. Participants must also be currently receiving treatment with methotrexate and meet certain dosage requirements. Other criteria include having certain laboratory values within normal ranges, not having certain medical conditions or infections, and not being pregnant or planning to become pregnant during the study. The sample also includes exclusion criteria, such as having certain medical conditions, a history of drug or alcohol abuse, or being unable to comply with study procedures.",
    "The sample from the table represents a clinical trial for the treatment of metastatic melanoma. The trial is a combination of phase 1 and phase 2. The disease being studied is metastatic melanoma, and the corresponding ICD-10 codes for the disease are provided. The drugs being tested in the trial include cyclophosphamide, fludarabine, interleukin-2, and peginterferon alfa-2b. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Participants must have histologically confirmed unresectable stage III or stage IV metastatic melanoma with available metastasis for surgical resection and residual measurable disease after resection.\n- Participants must have an ECOG performance status of 0-1.\n- Participants must have a life expectancy of at least 3 months.\n- Participants must not have significant toxicity from prior treatments.\n- Participants must have adequate renal, hepatic, and hematologic function.\n- Women of childbearing potential and men in a sexual relationship with a woman of childbearing potential must use effective contraception during treatment and for at least 6 months after treatment.\n- Participants must be able to comprehend the information given and willing to sign informed consent.\n\nThe exclusion criteria for the trial are as follows:\n- Participants with other malignancies, unless followed for at least 5 years with no sign of disease, except for squamous cell carcinoma or adequately treated carcinoma in situ colli uteri.\n- Participants with cerebral metastasis, unless surgically removed or treated with stereotactic radiosurgery and stable for at least 28 days after treatment.\n- Participants with ocular melanoma.\n- Participants with severe allergies, history of anaphylaxis, or known allergies to the administered drugs.\n- Participants with serious medical or psychiatric comorbidity.\n- Participants with creatinine clearance less than 70 ml/min.\n- Participants with acute or chronic infection with conditions such as HIV, hepatitis, or tuberculosis.\n- Participants with severe and active autoimmune disease.\n- Pregnant and nursing women.\n- Participants in need of immunosuppressive treatment, such as corticosteroids or methotrexate.\n- Participants receiving concomitant treatment with other experimental drugs.\n- Participants with uncontrolled hypercalcemia.\n- Participants who have received systemic antineoplastic treatment within the past four weeks at the time of treatment.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial is focused on breast cancer, specifically HER-2 negative breast cancer that is either stage III disease not amenable to curative therapy or stage IV. The trial includes patients with measurable disease of at least 2 cm by conventional measurement or at least 1 cm on spiral CT. Prior chemotherapy for metastatic disease is allowed, with no limitations on the number of prior chemotherapies. Prior taxanes (except Nab-Paclitaxel) are allowed if it has been at least 6 months since the last taxane treatment. Patients should have received at least one line of chemotherapy in either the advanced or adjuvant setting and hormonal therapy if appropriate. The trial also requires patients to have an ECOG Performance status of at least 2 and be able to swallow and retain oral medicines. Various laboratory values need to be within specified ranges, including absolute neutrophil count, platelets, hemoglobin, bilirubin, AST/ALT, serum creatinine, INR, fasting plasma glucose, HBA1c, and potassium, calcium, and magnesium levels. Bisphosphonates and denosumab for bony metastatic disease are allowed, and radiation to bony metastases is allowed at least 14 days before starting study treatment. Patients with previously treated brain metastases who are free of CNS symptoms and more than 3 months from treatment are eligible. Women of childbearing potential and their partners must use contraception prior to study entry and for 90 days after treatment. Exclusion criteria include other medical or psychiatric disorders placing the subject at undue risk for treatment complications, pregnancy or nursing, previous treatment with Nab-Paclitaxel (except in the adjuvant or neoadjuvant setting), inflammatory breast cancer, known hypersensitivity to Nab-Paclitaxel or BYL719, concurrent malignancy or malignancy within 3 years (except for specified exceptions), diabetes mellitus or steroid-induced diabetes mellitus, impaired gastrointestinal function or disease altering the absorption of study drugs, classification into Child-Pugh class C, known history of HIV infection, active and uncontrolled infection, symptomatic/untreated CNS disease, Grade 2 or higher peripheral neuropathy, active or history of cardiac disease, and various cardiac abnormalities. Other exclusion criteria include a QTcF > 480 msec on the screening ECG, recent major surgery or not having recovered from major side effects, recent use of systemic corticosteroids or not having fully recovered from side effects, use of drugs known to be inhibitors or inducers of CYP3A, use of warfarin or other coumarin-derived anticoagulant, previous treatment with a PI3K inhibitor (with exceptions), and participation in a clinical trial within 30 days prior to enrollment.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of metastatic prostate cancer. The diseases column specifies the disease being studied, which in this case is \"prostate cancer metastatic\". The icdcodes column contains a list of ICD-10 codes associated with the disease. In this sample, the icdcodes are [\"C61\", \"D29.1\", \"D40.0\", \"Z15.03\", \"Z80.42\", \"Z85.46\", \"Z12.5\"].\n\nThe drugs column lists the drugs being used in the trial, which include \"cabazitaxel xrp6258\", \"ezalutamide\", \"abiraterone acetate\", and \"prednisone\". The criteria column provides the eligibility criteria for participants in the trial. It includes both inclusion and exclusion criteria.\n\nThe inclusion criteria state that participants must have a confirmed diagnosis of prostate adenocarcinoma, metastatic disease, and progressive disease while receiving AR targeted therapy with abiraterone acetate or enzalutamide within the past 12 months. Other criteria include specific measurements of disease progression, a minimum PSA value, effective castration, and prior AR targeted therapy cessation.\n\nThe exclusion criteria list various conditions and circumstances that would disqualify a participant from the trial. These include prior chemotherapy for prostate cancer (with some exceptions), recent treatments or adverse events, certain medical conditions, participation in other clinical trials, and reproductive potential without agreed contraception.\n\nOverall, this sample provides a snapshot of the phase 2 clinical trial, including the specific disease being studied, the drugs being used, and the eligibility criteria for participants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the disease \"atopic dermatitis\". The corresponding ICD-10 codes for this disease are \"L20.89\" and \"L20.9\". The drug being tested is \"am1030-cream or placebo\". The eligibility criteria for participants include being between 18 and 65 years old, having a body mass index between 18.0 and 35.0 kg/m2, having atopic dermatitis with mild to severe disease activity, and having AD lesions on the trunk and/or limbs that can be treated topically. The exclusion criteria include having scars, moles, tattoos, sunburn, or other blemishes in the test areas, recent systemic or topical treatment with certain medications, and recent treatment with antihistamines or SSRIs. Participants who have received phototherapy within the past 4 weeks are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"non-small cell lung cancer,\" and the corresponding ICDCodes are provided as well. The drugs being tested in this trial are \"carboplatin,\" \"nab-paclitaxel,\" \"mk-3475 (phase i),\" and \"mk-3475 (phase ii).\" The eligibility criteria for this trial include various factors such as age, stage of cancer, performance status, measurable disease, availability of archival tissue, and willingness to undergo certain tests. There are also exclusion criteria listed, which include factors such as the presence of symptomatic CNS metastases, history of certain treatments, and certain medical conditions. Additionally, there are criteria related to pregnancy and contraception for female participants.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is metastatic pancreatic adenocarcinoma. The ICD-10 codes associated with this disease are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drugs being used in the trial are regorafenib and gemcitabine hydrochloride. The eligibility criteria for the trial include having confirmed metastatic pancreatic adenocarcinoma, measurable disease, prior chemotherapy for metastatic pancreatic cancer, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and a life expectancy of at least 12 weeks. There are also specific criteria related to various laboratory values and medical conditions. The exclusion criteria include recent chemotherapy or radiotherapy, use of other investigational agents, uncontrolled hypertension, significant cardiac disease, bleeding disorders, recent bleeding events, thrombotic or embolic events, presence of other untreated or concurrent cancers, certain medical conditions, and substance abuse or other conditions that may interfere with participation in the study.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is type 1 diabetes mellitus. The ICD-10 codes associated with this disease are E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, and E10.44. The drugs being tested in the trial are sotagliflozin and placebo. \n\nThe eligibility criteria for participants include being young adults between the ages of 18 and 30, with a confirmed diagnosis of type 1 diabetes mellitus at least 1 year prior to giving informed consent. Participants must be currently receiving insulin treatment through continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI). At the screening stage, participants must have an A1C level of 9.0% or higher. They must also be willing and able to perform self-monitored blood glucose (SMBG) and complete a study diary. Female participants of childbearing potential must use contraception and have a negative pregnancy test.\n\nThe exclusion criteria include any prior use of LX4211/sotagliflozin, use of antidiabetic agents other than insulin or insulin analogues at the time of screening, use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to the placebo Run-in Period, chronic systemic corticosteroid use, type 2 diabetes, severely uncontrolled diabetes mellitus, history of diabetic ketoacidosis (DKA) or nonketotic hyperosmolar state within 6 months prior to the screening visit, and history of severe hypoglycemic event within 1 month prior to the screening visit.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"prostate carcinoma metastatic to the bone\" and \"castration resistant prostate cancer\". The ICDCodes associated with these diseases are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']. The drug being tested in this trial is \"enzalutamide\". The eligibility criteria for this trial include specific requirements related to the histology of the prostate cancer, presence of bone metastatic disease, ongoing androgen deprivation therapy, testosterone levels, progressive disease on androgen deprivation therapy, and screening PSA levels. The exclusion criteria include restrictions on prior treatments, hormonal therapy, biologic therapy, investigational agents, radiation therapy, opiate analgesics, bone scintigraphy results, presence of visceral metastatic disease, brain metastasis or leptomeningeal disease, and history of seizures or conditions that may predispose to seizures.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 trial phase. The trial focuses on melanoma, a type of skin cancer. The trial includes participants with stage IIA through IV melanoma, including those with cutaneous, uveal, mucosal, or unknown primary melanoma. The participants must be eligible for treatment with the drug ipilimumab based on clinician judgment within the standard of care.\n\nThe trial has three cohorts: advanced patients with unresectable stage III or IV melanoma, neoadjuvant therapy for primary melanoma with lymph node involvement or recurrence amenable to complete resection, and adjuvant therapy for resected stage IIA to IV melanoma.\n\nParticipants must have radiologically evident disease, confirmed by chest, abdominal, and pelvic CT scans, and a head CT scan or MRI PET/CT fusion scan. Biopsies of melanoma lesions are required before treatment and on day 22.\n\nParticipants with brain metastases are eligible if they have been treated and there has been no growth of the metastases. The most recent surgical resections or gamma-knife therapy for malignant melanoma must have been completed at least 1 week prior to registration.\n\nOther eligibility criteria include an ECOG performance status of 0 or 1, ability and willingness to give informed consent, adequate lab function tests, age 18 years or older, and at least two intact axillary and/or inguinal lymph node basins.\n\nExclusion criteria include recent use of certain medications or treatments, HIV positivity or active Hepatitis C virus, recent nitrosoureas therapy, current or recent use of checkpoint molecule blockade therapy, known allergies to the vaccine components, previous vaccination with the synthetic peptides included in the protocol, pregnancy or breastfeeding, medical contraindications or potential problems in complying with the protocol, Class III or IV heart disease, uncontrolled diabetes, prior autoimmune disorders requiring cytotoxic or immunosuppressive therapy, and other cancer diagnoses except for specific allowed cases.\n\nParticipants with known addiction to alcohol or drugs or recent illicit IV drug use are also excluded, as well as those with body weight less than 110 pounds due to the frequency of blood draws in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are non-small cell lung cancer, NSCLC, adenocarcinoma, and heregulin. The corresponding ICDCodes for these diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31.\n\nThe drugs being investigated in this trial are mm-121 and docetaxel. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Patients must have a diagnosis of cytologically or histologically documented adenocarcinoma of the lung with either metastatic disease (stage IV), Stage IIIB, or Stage IIIC disease not amenable to surgery with curative intent.\n- Patients must not have received more than 2 prior systemic therapies, one of which must have been a platinum-based regimen, for primary or recurrent disease.\n- Tissue must have been submitted for HRG-biomarker testing.\n- Patients must have an ECOG performance status (PS) of 0 or 1.\n\nExclusion Criteria:\n- Patients with a known ALK mutation.\n- Patients with the presence of exon 19 deletion or exon 21 (L858R) substitution of the EGFR gene.\n- Patients who have received more than 2 prior systemic anti-cancer drug regimens for locally advanced disease.\n- Patients who have received prior treatment with an anti-ErbB3 antibody.\n- Patients with CTCAE grade 3 or higher peripheral neuropathy.\n- Patients with symptomatic CNS metastases or CNS metastases requiring steroids.\n- Patients with any other active malignancy requiring systemic therapy.\n- Patients with clinically significant cardiac disease.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of respiratory syncytial virus infections. The trial is evaluating the effectiveness of two drugs, placebo and jnj-53718678. The eligibility criteria for participants are listed, including requirements for female participants to be postmenopausal or surgically sterile, and to have a negative pregnancy test. Participants must also be sero-suitable for respiratory syncytial virus and non-smokers. The exclusion criteria include a history of heart arrhythmias, substance abuse, and current infections such as HIV or hepatitis. Additionally, participants with an active acute respiratory infection at the time of admission are excluded from the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of psoriasis vulgaris, a skin condition. The trial uses a drug called LEO 90100. \n\nThe sample includes eligibility criteria for participants in the trial. There are different sets of inclusion criteria depending on whether the subjects will be performing HPA axis assessment or not. Inclusion criteria include specific requirements for the extent and severity of psoriasis vulgaris on the trunk, limbs, and scalp, as well as the presence of certain scores and serum calcium levels.\n\nThere are also exclusion criteria for all subjects, which include a history of hypersensitivity to LEO 90100 or other treatments, recent use of certain systemic treatments or therapies that may affect psoriasis, and recent use of PUVA or UVB therapy.\n\nAdditionally, there are specific exclusion criteria for subjects performing HPA axis assessment, such as a history of serious allergies or hypersensitivity to certain components, recent use of corticosteroids or medications that affect cortisol levels, and recent use of estrogen therapy.\n\nOverall, the sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for participants in the clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and is focused on non-small cell lung cancer. The ICD-10 codes associated with the disease are ['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']. The drugs being studied are anlotinib and placebo. The sample also includes the eligibility criteria for the trial, including requirements for signed informed consent, diagnosis of advanced NSCLC, previous chemotherapy treatments, normal organ function, and specific exclusion criteria such as previous use of anlotinib, presence of other types of lung cancer, and participation in other clinical trials.",
    "The sample is a phase 2 clinical trial for breast cancer. The eligibility criteria for patients to participate in the trial include being 18 years or older, having a histological confirmation of breast carcinoma with a clinical diagnosis of inflammatory breast cancer (IBC), having confirmed distant metastasis with or without local recurrence, and having negative HER2 expression. Other criteria include having an estimated life expectancy of at least 3 months, having an ECOG performance status score of 0-2, having received prior treatment for local recurrence or metastatic disease and relapsed, and providing written informed consent.\n\nExclusion criteria include having an active infection, impaired cardiac function or clinically significant cardiac diseases, recent cardiovascular events, uncontrolled hypertension, gastrointestinal disorders that may interfere with drug absorption, concurrent diseases or conditions that would make participation inappropriate, and locally or regionally confined disease without evidence of metastatic disease. Other exclusion criteria include prior treatment with BIBF 1120 or any other VEGFR inhibitor, known hypersensitivity to the trial drugs, recent chemotherapy, hormonal therapy, radiotherapy, or immunotherapy, active brain metastases, and various other medical conditions or factors that may interfere with the study or patient safety.\n\nAdditionally, patients must be able to swallow and retain oral medication, and they must meet certain laboratory and clinical parameters related to cardiac, renal, hepatic, and hematologic function. Patients with certain other malignancies within the past 5 years, active or chronic hepatitis C and/or B infection, serious illnesses or non-oncological diseases, and active alcohol or drug abuse are also excluded. Patients who are sexually active must use medically acceptable contraception during the trial and for at least three months after the end of active therapy. Patients with childbearing potential must have a negative pregnancy test prior to treatment. Psychological, familial, sociological, or geographical factors that may hamper compliance with the study protocol and follow-up schedule are also considered exclusion criteria, as well as significant weight loss within the past 6 months and active alcohol or drug abuse.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of myocardial reperfusion injury. The trial is focused on patients presenting with acute myocardial infraction (STEMI) and undergoing primary percutaneous coronary intervention (PPCI). The inclusion criteria include being above 18 years of age, presenting within 6 hours of the onset of chest pain and ST segment elevation, and having a major coronary artery with a diameter of at least 3mm that is proximally occluded at the time of admission coronary angiography. \n\nThe exclusion criteria include patients with immunological dysfunction, clinically unstable patients, patients with evidence of coronary collaterals to the infarct area, patients with an open culprit coronary artery at the time of angiography, previous myocardial infraction or thrombolytic therapy, known hypersensitivity to ciclosporin or certain proteins, known renal or liver insufficiency, uncontrolled hypertension, patients treated with specific compounds, female patients currently pregnant or not using contraception, contraindication to cardiac MRI, patients unable to undergo cardiac MRI due to frailty, claustrophobia, or breathlessness, use of other investigational study drugs within 30 days prior to trial entry, lack of capacity to give initial verbal consent, and life expectancy less than 1 year due to non-cardiac illness.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are various stages of esophageal adenocarcinoma. The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial include paclitaxel, carboplatin, oxaliplatin, leucovorin calcium, and fluorouracil. The eligibility criteria for participants in this trial are listed, including requirements such as specific disease stage, prior treatment history, performance status, and various laboratory values. The sample also includes exclusion criteria, such as patients with metastatic disease or a history of allergic reactions to certain compounds.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied include stage III intrahepatic cholangiocarcinoma, stage IIIB gallbladder cancer, stage IVA gallbladder cancer, and others. The ICDCodes associated with these diseases are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drugs being used in the trial are cisplatin, gemcitabine hydrochloride, and nab-paclitaxel. The eligibility criteria for participants include having a confirmed diagnosis of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer, having metastatic or unresectable disease, not having received prior chemotherapy (or at least 6 months since prior adjuvant therapy), having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and meeting various laboratory and organ function criteria. There are also exclusion criteria, such as having grade 2 or greater peripheral neuropathy, having severe or uncontrolled medical conditions, being pregnant or lactating, and having known central nervous system disease (except for treated brain metastasis).",
    "The sample is a phase 2 trial for the treatment of acute graft-versus-host disease. The trial is focused on patients who are 18 years or older and have undergone allogeneic transplantation. The patients must have grade III or IV acute GVHD and should not have any psychiatric contra-indications. They must also provide informed consent. The trial excludes patients with a history of psychosis, asthma, or known allergy to cannabis constituents. The drugs being tested in this trial are cannabidiol, methylprednisolone, and a calcineurin inhibitor.",
    "The sample from the table is for a clinical trial study. The phase of the trial is Phase 1/Phase 2. The disease being studied is non-small cell lung cancer. The ICD-10 codes associated with the disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being investigated are docetaxel and tak-117. The eligibility criteria for participants include having a confirmed diagnosis of NSCLC, locally advanced or metastatic disease, failure of at least 1 prior chemotherapy regimen, adequate organ function, Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, and adherence to contraception methods for female participants. There are also exclusion criteria such as previous treatment with a PI3K or AKT inhibitor, recent cancer therapy, poorly controlled diabetes mellitus, and various other medical and psychiatric conditions.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has the following columns: phase, diseases, icdcodes, drugs, and criteria.\n\nIn the sample, the phase column indicates that the trial is a combination of phase 1 and phase 2. The diseases column lists various types of adenocarcinoma, including colon adenocarcinoma, rectal adenocarcinoma, recurrent colon carcinoma, recurrent rectal carcinoma, stage iva colon cancer, stage iva rectal cancer, stage ivb colon cancer, and stage ivb rectal cancer. The icdcodes column provides the corresponding ICD-10 codes for each disease.\n\nThe drugs column includes two drugs, capecitabine and nintedanib, that are being used in the trial. The criteria column contains the eligibility criteria for participants in the trial. The inclusion criteria include specific health conditions, such as Eastern Cooperative Oncology Group (ECOG) performance status, hemoglobin levels, neutrophil count, platelet count, creatinine levels, bilirubin levels, liver function, coagulation parameters, measurable disease, and prior treatment history. The exclusion criteria include factors such as prior treatment with nintedanib or regorafenib, recent major injuries or surgeries, uncontrolled hypertension, history of hemorrhagic or thrombotic events, unstable angina or heart failure, history of cerebrovascular or myocardial ischemia, known inherited predisposition to bleeding or thrombosis, active hepatitis B or C or HIV, untreated brain metastases, recent second primary malignancy, pregnancy or nursing, inability to follow protocol requirements, and other conditions that may make a participant unsuitable for the study.\n\nOverall, the sample provides information about the trial phase, specific diseases being studied, corresponding ICD-10 codes, drugs used, and the eligibility criteria for participants.",
    "The sample is a phase 2 trial for the treatment of major depressive disorder. The trial includes patients who meet the criteria for MDD without psychotic features, as defined by the DSM-IV-TR and confirmed by the MINI. The patients must be outpatients aged 20-65 years and willing to sign informed consent. Female patients of child-bearing potential must test negative for pregnancy and use appropriate birth control during the study. The trial also requires patients to have a 17-item HAM-D total score of at least 20 and a CGI total score of at least 4.\n\nThere are exclusion criteria as well. Patients with current or previous major psychiatric disorders, including obsessive-compulsive disorder, posttraumatic stress disorder, bipolar I or II, manic or hypomanic episode, schizophrenia, major Axis II disorders, major depression with psychotic symptoms, or mental retardation, are excluded. Patients who have used any treatment for MDD in the last 2 weeks (4 weeks for fluoxetine) or psychoactive drugs within the last 2 weeks, unless for insomnia, are also excluded. Patients who have been non-responsive to two or more courses of antidepressant medications, have a history of electroconvulsive therapy, transcranial magnetic stimulation, or psychosurgery within the last year, or have a history of any seizure disorder are excluded as well. Other exclusion criteria include clinically significant abnormal vital signs, ECG, or laboratory values, any organic disorder that cannot be well-controlled, high suicidal risk, history of substance abuse within the past 6 months, or severe allergies to multiple classes of medication or multiple adverse drug reactions.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is HIV-1 infection. The ICD-10 codes associated with the disease are B20, Z71.7, O98.72, Z21, O98.73, R75, and Z11.4. The drugs being tested in the trial are bic, f/taf, dtg, bic placebo, dtg placebo, and b/f/taf. The eligibility criteria for participants in the trial include being antiretroviral naive, having a certain level of HIV-1 RNA in the blood, having a genotype report showing sensitivity to certain drugs, having adequate renal function, and having a certain CD4+ cell count. There are also exclusion criteria, such as having a new AIDS-defining condition, prior use of antiretrovirals for pre-exposure or post-exposure prophylaxis, chronic hepatitis B virus infection, and active serious infections. Participation in other clinical trials without prior approval is also prohibited.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of malignant pleural mesothelioma. The associated ICD-10 codes for this disease are C45.9, C45.0, C45.1, C45.2, and C45.7. The drugs being used in the trial are pemetrexed and either cisplatin or carboplatin. \n\nThe eligibility criteria for participants in the trial are as follows:\n1. Pathological or histological evidence of mesothelioma\n2. Age of 18 years or older\n3. Not eligible for curative treatment such as surgery or radiotherapy\n4. At least 4 weeks since major surgery\n5. Presence of at least one measurable or evaluable lesion according to modified RECIST Criteria\n6. ECOG Performance Status of 0-1\n7. Life expectancy of at least 3 months\n8. Participants of childbearing age must use effective contraception as indicated by the investigator\n9. All subjects must sign written informed consent\n10. Able to operate the NovoTTF-100L System independently or with the help of a caregiver\n\nThe exclusion criteria for participants in the trial are as follows:\n1. Patients who are candidates for surgery or radiotherapy with curative intent\n2. Previous chemotherapy or radiation treatment\n3. Prior malignancy requiring anti-tumor treatment, except for certain specific cases\n4. Significant co-morbidities within 4 weeks prior to enrollment, resulting in specific laboratory findings\n5. Significant comorbidity that is expected to affect the patient's prognosis or ability to receive the combined therapy\n6. Untreated brain metastases, unless asymptomatic and pretreated without requiring steroids\n7. Presence of implanted pacemaker, defibrillator, or other electrical medical devices\n8. Known allergies to medical adhesives or hydrogel\n9. Pregnant or breastfeeding, unless using effective contraception throughout the study period based on the recommendation of the investigator or a gynecologist.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of diffuse large B-cell lymphoma (DLBCL). The trial includes eligibility criteria for patients to participate. Some of the criteria include being over 18 years old, having a confirmed diagnosis of DLBCL, providing tumor tissue for review, having relapsed or refractory disease, and having received previous treatments for DLBCL. The trial also specifies certain laboratory criteria that patients must meet, such as specific blood counts and liver function. There are additional criteria related to pregnancy prevention for female patients and contraception for male patients. The sample also includes exclusion criteria, such as having a different type of lymphoma, a history of certain genetic factors, recent treatments or surgeries, and certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 2 and focuses on pancreatic cancer. The associated ICD-10 code for pancreatic cancer is C25.3. The trial involves the use of drugs such as mm-141, placebo, gemcitabine, and nab-paclitaxel. \n\nThe eligibility criteria for this trial include having metastatic adenocarcinoma of the pancreas (excluding islet cell neoplasms), not having received any prior treatment for metastatic disease (including radiotherapy, surgery, chemotherapy, or investigational therapy), and having a blood sample sent for free IGF-1 testing. Additionally, patients must have an ECOG performance status (PS) of 0 or 1.\n\nOn the other hand, the exclusion criteria for this trial include patients who only have localized disease, patients with CNS malignancies (primary or metastatic), and patients with clinically significant cardiac disease.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on studying the effects of a drug called nintedanib on patients with certain types of neuroendocrine tumors. The diseases included in this sample are carcinoid tumor, metastatic carcinoid tumor, and neuroendocrine neoplasm. The corresponding ICD-10 codes for these diseases are also provided. \n\nThe eligibility criteria for participants in this trial are listed, including requirements such as having a confirmed diagnosis of a well or moderately differentiated neuroendocrine tumor, having measurable disease determined by imaging, and having a certain performance status and life expectancy. Other criteria include specific blood count and liver function requirements, as well as the ability to swallow and retain oral medication. Participants must also agree to use adequate contraceptive methods if of child-bearing potential. \n\nThe exclusion criteria outline conditions that would make a participant ineligible for the trial, such as uncontrolled hypertension, presence of brain metastases, recent surgical procedures, and certain medical conditions. Pregnant or nursing females are also excluded. \n\nOverall, this sample provides a snapshot of the phase 2 trial, including the diseases being studied, the drug being tested, and the eligibility and exclusion criteria for participants.",
    "The sample from the table is for a phase 2 clinical trial for ovarian cancer. The eligibility criteria for the trial include having histologically confirmed epithelial, primary fallopian, or primary peritoneal cancer, prior treatment with at least two different cytostatic regimens including platinum, progression on previous treatment, and measurable disease by RECIST 1.1 or evaluable by GCIG CA-125 criteria. Other criteria include being at least 18 years old, having a performance stage of 0-2, and having adequate bone marrow, liver, and renal function. Exclusion criteria include having other malignant diseases within 5 years prior to inclusion, undergoing other experimental therapy or participating in another clinical trial within 28 days prior to treatment initiation, and having underlying medical diseases not adequately treated. Other exclusion criteria include uncontrolled hypertension, recent surgery or non-healing wounds/fractures, recent cerebral vascular attack or subarachnoidal hemorrhage, clinically significant cardiovascular disease, allergy to the active substance or any auxiliary agents, bleeding tumor, and being pregnant or breastfeeding. Fertile women must have a negative pregnancy test at screening and agree to use effective contraception during treatment and for 6 months after the end of treatment.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is smoking cessation. The ICD-10 codes associated with this disease are Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, and Y36.891A. The drugs being used in the trial are simvastatin and placebo. The eligibility criteria for participants are as follows:\n\nInclusion Criteria:\n- Age between 18 and 70 years\n- Smoking more than 10 cigarettes per day for at least 1 year\n- Motivated to quit smoking\n- Without legal tutors or subordination\n- Affiliated to a health insurance system as required by the French law on biomedical research\n- Written informed consent for participation in the study\n\nExclusion Criteria:\n- Age less than 18 or greater than 70 years\n- Contraindication to simvastatin use\n- Presence of depression, psychosis, cognitive disorder, mental retardation, or chronic use of medications for these disorders\n- Substance use disorder other than smoking\n- More than 3 months of abstinence from cigarette smoking in the previous year\n- Use of nicotine replacement therapy, bupropion, or varenicline in the last 3 months\n- Use of clonidine or nortriptyline in the last 3 months\n- Undergoing cognitive-behavioral therapy for smoking cessation in the last 3 months\n- Premenopausal women without contraception.",
    "The sample provided is for a phase 2 clinical trial for the treatment of Waldenstrom's macroglobulinemia. The trial is evaluating the effectiveness of the drugs ixazomib, dexamethasone, and rituximab. The eligibility criteria for participants include being 18 years or older, providing voluntary written consent, and meeting certain requirements for contraception for female patients. Patients must have a clinicopathological diagnosis of Waldenstrom's macroglobulinemia and measurable disease. They must also have an Eastern Cooperative Oncology Group performance status of 0, 1, or 2, and meet specific laboratory criteria. Exclusion criteria include pregnancy, recent major surgery, central nervous system involvement, uncontrolled cardiovascular conditions, and certain medication use. Patients with certain medical or psychiatric illnesses, allergies to study medications, gastrointestinal issues, or recent or residual malignancies are also excluded. Participation in other clinical trials within 30 days of the start of this trial is not allowed.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this particular sample, the phase of the trial is phase 2. The diseases being studied are neuroendocrine tumors and pancreatic neoplasms. The corresponding ICD-10 codes for these diseases are \"C7A.1\", \"C7A.8\", \"C7B.8\", \"D3A.8\" for neuroendocrine tumors and \"C25.3\" for pancreatic neoplasms. The drug being tested is a combination of th-302 and sunitinib. \n\nThe eligibility criteria for this trial include being 18 years of age or older, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, having a histologically proven diagnosis of pancreatic neuroendocrine tumors with a Ki67 assessment of \u2264 20%, having evidence of unresectable or metastatic disease, and having documented disease progression within the past 12 months. Other criteria include having measurable disease, being able to swallow the medication, having a life expectancy greater than 12 weeks, and meeting certain organ function requirements.\n\nThe exclusion criteria for this trial include previous treatments with certain types of chemotherapy or targeted therapies, prior treatment with another hypoxia-activated prodrug under clinical trial, recent major surgery or radiation therapy, and certain medical conditions or laboratory abnormalities that would make the patient inappropriate for the trial.\n\nOverall, this sample provides specific details about the phase, diseases, drugs, and eligibility criteria for a clinical trial focused on neuroendocrine tumors and pancreatic neoplasms.",
    "The sample provided is a record from a table that contains information about a clinical trial. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which includes the eligibility criteria for participants in the trial.\n\nIn this specific sample, the phase of the trial is listed as \"phase 2/phase 3\". The disease being studied is \"complex regional pain syndrome, type i\". The corresponding ICD-10 codes for this disease are listed as \"['G90.50', 'G90.511', 'G90.512', 'G90.513', 'G90.519', 'G90.521', 'G90.522']\". The drugs being tested are \"placebo\" and \"neridronic acid 62.5 mg\". The eligibility criteria for participants are then listed, including requirements such as informed consent, specific age range, diagnosis of complex regional pain syndrome type I, baseline pain intensity score, stable treatment for at least 1 month, recent dental examination, negative pregnancy test for women of child-bearing potential, ability to communicate and answer questionnaires, and compliance with the use of an electronic diary.\n\nThe exclusion criteria are also provided, which include exclusion based on diagnosis of complex regional pain syndrome type II, history of peripheral neuropathy or other chronic pain conditions, certain body weight or renal impairment, abnormal serum calcium or magnesium levels, certain medical conditions or treatments, history of allergic reactions, recent dental procedures or radiation therapy, use of certain medications or treatments, history of alcohol or drug abuse, severe medical conditions or mood disorders, engagement in litigation related to disability, pregnancy or breastfeeding, liver disease, and recent participation in other drug trials.\n\nOverall, this sample provides specific details about the phase, diseases, drugs, and eligibility criteria for participants in a clinical trial focused on complex regional pain syndrome type I.",
    "The sample is a phase 2 clinical trial for the treatment of relapsed multiple myeloma. The trial is evaluating the effectiveness of the drug dexamethasone. The eligibility criteria for participants include having relapsed multiple myeloma with measurable disease parameters, having received at least 2 prior regimens for multiple myeloma, being at least 18 years old, having a Karnofsky Performance Status score of at least 70, and being able to adhere to the study visit schedule and other protocol requirements. Exclusion criteria include having received radiotherapy or systemic therapy within a certain timeframe, having had a peripheral autologous stem cell transplant within 12 weeks, having an active systemic infection requiring treatment, having an active malignancy (with some exceptions), having known or suspected HIV or hepatitis B or C infection, and having certain medical conditions that could interfere with the study or pose a medical hazard. The sample also mentions specific exclusion criteria related to cardiovascular, neurological, endocrine, gastrointestinal, respiratory, or inflammatory illnesses. Additionally, it states that participants should not have a history of adverse reaction to dexamethasone or other corticosteroids, and should not have a history of allergic reaction to certain required prophylactic medications. The sample also mentions that participants should be able to monitor glucose at home if necessary and should not have known or suspected AL Amyloidosis. Finally, participants should not be currently receiving an investigational agent for any reason.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on breast cancer. The associated ICD-10 codes for the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being studied is selinexor. The eligibility criteria for participants in the trial are listed, including requirements such as confirmed triple negative breast cancer, written informed consent, certain body surface area and age requirements, and a life expectancy of more than 3 months. Other criteria include the disease being either locally recurrent or metastatic, measurable disease, documented disease progression, previous chemotherapy regimens, specific performance status, and adequate hematological, hepatic, and renal function. Additional criteria involve contraception for women of child-bearing potential, prior anthracycline and taxane therapy, and exclusion criteria such as significant medical illness, pregnancy or lactation, recent radiation or chemotherapy, major surgery, unstable cardiovascular function, uncontrolled infection, HIV or hepatitis infection, conditions interfering with medication absorption, peripheral neuropathy, recent participation in another anti-cancer study, coagulation problems or active bleeding, active central nervous system malignancy, and not having recovered from previous adverse effects.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are non-small cell lung cancer, breast cancer (HER2 positive or triple negative), and pancreatic cancer (adenocarcinoma). The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs being investigated in this trial are ibrutinib and durvalumab. The eligibility criteria for participants in this trial include having a confirmed diagnosis of one of the specified cancers, being in a relapsed or refractory stage of the disease, having measurable lesions according to RECIST 1.1 criteria, and meeting certain hematologic, hepatic, and renal function requirements.\n\nThere are also exclusion criteria listed, such as having mixed small cell and non-small cell lung cancer histology, a history of central nervous system involvement (with some exceptions), recent anti-tumor therapy, prior treatment with specific drugs (except for certain antibodies), a history of allogeneic organ transplant, and treatment with a strong cytochrome P450 (CYP) 3A inhibitor.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 2 and focuses on the disease melanoma. The corresponding ICD-10 codes for melanoma are ['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']. The drugs being studied in this trial are vesanoid and ipilimumab. The eligibility criteria for this trial are listed under inclusion and exclusion criteria. Inclusion criteria include being over 18 years old, diagnosed with advanced melanoma, considered a candidate for ipilimumab therapy, willing to sign informed consent documents, and willing to have regular blood draws. Exclusion criteria include being under 18 years old, having stage I or II melanoma and not being a candidate for ipilimumab, receiving systemic treatments within four weeks prior to the trial, being pregnant or nursing, taking immunosuppressive medications, having active autoimmune disease, having known sensitivity to retinoic acid derivatives, and having elevated levels of AST, ALT, or bilirubin.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes information about the diseases being studied, the associated ICD-10 codes, the drugs being used, and the eligibility criteria for participants.\n\nIn this particular trial, the diseases being studied are hepatitis C and HIV infection. The ICD-10 codes associated with hepatitis C are 'B18.2', 'B17.10', 'B17.11', 'B19.20', 'B19.21', 'B15.0', and 'B15.9'. The ICD-10 code associated with HIV infection is 'Z21'. The drugs being used in the trial are sofosbuvir, ribavirin, and ledipasvir.\n\nThe eligibility criteria for participants include being at least 18 years old, having confirmed genotype 1, 2, or 4 hepatitis C virus (HCV) infection, having a plasma HCV-RNA level of at least 1000 IU/mL, and having no history of previous HCV treatment. Participants must also be willing to use a birth control method and meet certain weight requirements.\n\nFor participants infected with HIV, additional criteria include having confirmed HIV-1 infection, being on stable HIV treatment for at least 8 weeks with specific antiretroviral drugs, having a current CD4+ lymphocyte count of at least 100/mm3, and having a current plasma HIV-1 RNA level of less than 200 copies/mL.\n\nThere are also exclusion criteria, which include having cirrhosis classified as Child-Pugh B or C, co-infection with the Hepatitis B virus, being pregnant or breastfeeding, having a history of organ or tissue transplantation, having progressive cancer or hepatocellular carcinoma, having epilepsy or sickle cell disease, having a history of myocardial infraction or severe heart disease, having excessive alcohol consumption or drug use, currently participating in another clinical trial, having contraindications to the drug Sofosbuvir, and having certain laboratory abnormalities.\n\nFor participants infected with HIV, additional exclusion criteria include having severe opportunistic infections in the last 6 months, poor adherence to antiretroviral treatment history, and using antiretroviral drugs other than those permitted in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is diabetes mellitus, type 2. The corresponding ICD-10 codes for this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are ttp399 400 mg, ttp399 800 mg, sitagliptin 100 mg, and a placebo. \n\nThe eligibility criteria for participants in this trial are as follows:\n- Participants must have a historical diagnosis of Type 2 Diabetes according to the American Diabetes Association guidelines, with a diagnosis at least 6 months prior to screening.\n- Participants must be on a stable regimen of metformin monotherapy equivalent to at least 1000 mg once daily for the last 3 months prior to screening.\n- Both males and females of childbearing potential (with a negative pregnancy test and willingness to comply with protocol contraception) and females of non-childbearing potential are eligible.\n- Participants must be between the ages of 18 and 75 at the time of screening.\n- HbA1c levels must be between 7.0% and 9.5%.\n- Participants must have generally stable health without active infection, major surgery, or significant injuries within the last year.\n\nThe exclusion criteria for this trial are as follows:\n- Participants with a diagnosis of Type 1 diabetes mellitus, maturity-onset diabetes of the young, insulin-requiring Type 2 Diabetes, other unusual or rare forms of diabetes mellitus, or a history of diabetic ketoacidosis are not eligible.\n- Participants with clinically significant abnormal lab values, including eGFR <50ml/min/1.73m2, ALT, bilirubin or AST >1.5 X ULN, hypokalemia, or other clinically significant electrolyte abnormality are not eligible.\n- Participants with a history of myocardial infraction, unstable angina, coronary revascularization, stroke, or transient ischemic attack within 2 years of screening are not eligible.\n- Participants with symptomatic congestive heart failure are not eligible.\n- Participants with a history of cardiac arrhythmias requiring treatment or prophylaxis with drugs or devices during the last 2 years, or any history of atrial fibrillation or flutter beyond a single short-term episode, are not eligible.\n- Participants with a history or presence of a 2nd degree or greater atrioventricular block in the absence of a pacemaker are not eligible.\n- Participants with a 12-lead ECG from screening or baseline demonstrating QTcF interval >450 msec for males or >47 msec for females are not eligible.\n- Participants with a family or personal history of long QT syndrome are not eligible.\n- Participants with a history of pancreatitis are not eligible.\n- Participants with persistent, uncontrolled hypertension are not eligible.\n- Participants with chronic active hepatitis (hepatitis B, hepatitis C, nonalcoholic steatohepatitis [NASH]), and/or known liver cirrhosis are not eligible.\n- Participants who have participated in any formal weight loss program, experienced fluctuation of >5% in body weight, or received medications approved for weight loss within 3 months prior to screening are not eligible.\n- Participants with a positive pre-study drug screen are not eligible.\n- Participants who have participated in a clinical trial and received an investigational product within 30 days are not eligible.\n- Participants with a history of drug abuse within 2 years of screening or a positive pre-screen drug screen are not eligible.\n- Participants with a history of hypoglycemic episode requiring glucose, glucagon, or orange juice administered by someone other than the patient within 6 months prior to screening are not eligible.\n- Participants with a history of excessive alcohol consumption within the last 2 years prior to screening are not eligible.\n- Participants with mental or legal incapacitation are not eligible.\n- Participants who have donated approximately 1 pint (500 mL) of blood within 8 weeks are not eligible.\n- Participants with a history of MEN-2 or a family history of medullary thyroid cancer are not eligible.\n- Participants with a history of cancer, other than non-melanoma skin cancer, that required therapy in the 5 years prior to the study start are not eligible.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 2. The disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drug being used in the trial is carfilzomib/lenalidomide/dexamethasone. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Patients must be diagnosed with multiple myeloma based on the new International Myeloma Working Group.\n- Subjects must have symptomatic myeloma with at least one CRAB criteria.\n- Subjects must not have been previously treated with any systemic therapy for multiple myeloma.\n\nExclusion Criteria:\n- Pregnant or lactating females.\n- Evidence of mucosal or internal bleeding and/or platelet refractory.\n- Acute active infection requiring treatment.\n- Treatment by localized radiotherapy if the interval between the end of radiotherapy and initiation of protocol therapy is lower than 2 weeks.\n- Treatment by corticosteroids if it exceeds the equivalent of 160 mg of dexamethasone in a 2-week period before initiation therapy.\n- Subjects who are not eligible for high dose therapy.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The trial is testing the effectiveness of the drugs andecaliximab and placebo. The eligibility criteria for participants include having a documented diagnosis of Crohn's disease with involvement of the ileum and/or colon, having moderately to severely active Crohn's disease, and demonstrating an inadequate response or intolerance to certain medications within the past 5 years. Participants may also be receiving certain other drugs for Crohn's disease. Exclusion criteria include having certain medical conditions, current use of high-dose oral corticosteroids, and recent participation in another clinical study.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 2.\n- Diseases: The trial is focused on Alzheimer's disease.\n- ICD Codes: The ICD-10 codes associated with the disease are 'G30.8', 'G30.9', 'G30.0', and 'G30.1'.\n- Drugs: The drugs being tested in the trial are 'jnj-54861911, 10 mg', 'jnj-54861911, 25 mg', 'placebo', and 'jnj-54861911, 5 mg'.\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include requirements such as participants being in the early Alzheimer's disease spectrum, completing a previous JNJ-54861911 clinical study, signing an informed consent form, having a reliable informant, and not having certain medical conditions or taking specific medications.\n\nOverall, this sample provides information about a Phase 2 clinical trial for Alzheimer's disease, including the specific drugs being tested and the eligibility criteria for participants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of metastatic prostate cancer. The trial involves the use of three drugs: ly3023414, enzalutamide, and placebo. The eligibility criteria for participants are listed, including requirements such as confirmed adenocarcinoma of the prostate, documented metastatic disease, prior abiraterone treatment, castration status, performance status, and various medical parameters. The sample also includes exclusion criteria, such as prior chemotherapy or specific treatments, certain medical conditions, and active infections.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is atopic dermatitis. The ICD-10 codes associated with the disease are 'L20.89' and 'L20.9'. The drug being tested is dupilumab. The eligibility criteria for the trial are listed, including age requirements, disease severity, and exclusion criteria such as recent treatment with certain medications, history of infections or malignancy, elevated transaminases, presence of severe concomitant illnesses or skin comorbidities, and pregnancy or breastfeeding for female patients. Female patients of reproductive potential who are sexually active must be willing to use adequate contraception.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of type 1 diabetes mellitus. The trial includes the use of the drug liraglutide, as well as a placebo and a mixed meal tolerance test with paracetamol. The eligibility criteria for participants include having a diagnosis of type 1 diabetes mellitus, being between the ages of 18 and 64, having a body mass index (BMI) between 20.0 and 25.0 kg/m2, and having a stable insulin dose. Exclusion criteria include hypersensitivity to the trial product or related products, recent use of liraglutide or exenatide, severe hypoglycemia, and certain abnormal laboratory test results. Other exclusion criteria include a history of medullary thyroid carcinoma, pancreatitis, and various other medical conditions. Female participants of child-bearing potential must be using adequate contraceptive methods. Severe acute and/or chronic diseases are also excluded.",
    "The sample is a record from a table that contains information about clinical trials. It is for a phase 2 trial and focuses on non-small cell lung cancer. The trial uses the drug nivolumab. The eligibility criteria for participants include having a certain ECOG status, having a documented diagnosis of squamous non-small cell lung cancer, experiencing disease progression or recurrence after a previous chemotherapy regimen, having evaluable disease according to specific criteria, and having treated or asymptomatic CNS metastases. There are also exclusion criteria, such as having untreated symptomatic CNS metastases, having carcinomatous meningitis, having active autoimmune disease, and having received certain prior therapies.",
    "The sample is a phase 2 trial that focuses on two diseases: iron deficiency and fibromyalgia. The trial includes eligibility criteria for participants, such as being 18 years or older, having a diagnosis of fibromyalgia based on specific criteria, and having a baseline score of at least 60 on the FIQR (Fibromyalgia Impact Questionnaire Revised). Participants must also have stable doses of current medications for fibromyalgia and negative pregnancy tests if at risk for pregnancy.\n\nExclusion criteria include recent use of parenteral iron, a history of multiple blood transfusions, hypersensitivity to the drug Injectafer\u00ae (Ferric Carboxymaltose), current or chronic infections (except for viral upper respiratory tract infections), malignancy (except for certain types of skin cancer), active inflammatory arthritis, pregnancy or lactation, severe peripheral vascular disease, seizure disorder being treated with medication, and various abnormal laboratory results or medical conditions that may put the participant at risk.\n\nOverall, the sample provides specific details about the phase 2 trial, the diseases being studied, the drugs involved, and the eligibility and exclusion criteria for potential participants.",
    "The sample is a record from a table that contains information about clinical trials. It provides details about a specific trial, including the phase of the trial (phase 2), the disease being studied (multiple sclerosis, relapsing-remitting), the corresponding ICD-10 codes for the disease, the drug being tested (dimethyl fumarate), and the eligibility criteria for participants.\n\nThe eligibility criteria are divided into key inclusion criteria and key exclusion criteria. The key inclusion criteria state that parents or legal guardians must be able to understand the purpose and risks of the study and provide informed consent. The subject must have a body weight of at least 30 kg and a diagnosis of relapsing-remitting multiple sclerosis according to specific criteria.\n\nThe key exclusion criteria state that subjects with progressive forms of multiple sclerosis (primary progressive, secondary progressive, or progressive relapsing) are not eligible. Other disorders that mimic multiple sclerosis, severe allergic reactions or hypersensitivity to the drug being tested are also exclusion criteria.\n\nIt is important to note that there may be additional inclusion/exclusion criteria defined in the protocol for this trial.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of malignant melanoma. The trial is focused on patients with either unresectable Stage IIIc or metastatic Stage IV melanoma who have tested positive for the BRAF V600E/K mutation. The trial involves the use of the drugs dabrafenib and trametinib.\n\nThe eligibility criteria for the trial include being at least 18 years old, having a confirmed diagnosis of cutaneous melanoma, having a measurable lesion for biopsy, and having not received prior treatment with BRAF or MEK inhibitors (for Cohort A). For Cohort B, patients must have shown a partial or complete response to previous selective BRAF/MEK combination treatment that was discontinued due to tumor progression and have received subsequent alternative treatment.\n\nOther criteria include having a performance status of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG), having adequate organ function, and having a left ventricular ejection fraction (LVEF) within the institutional lower limit of normal.\n\nExclusion criteria include recent major surgery, radiotherapy, chemotherapy, or immunotherapy, current use of prohibited medications, history of other malignancies (with exceptions), serious pre-existing medical conditions or psychiatric disorders, known HIV, active Hepatitis B or C, glucose-6-phosphate dehydrogenase (G6PD) deficiency, brain metastases (unless specific criteria are met), cardiovascular risk factors, history of retinal vein occlusion or central serous retinopathy, hypersensitivity to study treatments or related drugs, interstitial lung disease or pneumonitis, and pregnancy or breastfeeding.\n\nThese criteria help to define the specific patient population that will be included or excluded from the trial.",
    "The sample from the table is for a phase 2 trial. The disease being studied is refractory chronic cough. The associated ICD-10 codes for this disease are D46.4, D46.1, D46.A, D46.0, D46.20, D46.21, and D46.22. The drugs being tested in the trial are pa101 and placebo. The eligibility criteria for participants include a diagnosis of Idiopathic Pulmonary Fibrosis or Chronic Idiopathic Cough, refractory chronic cough for at least 8 weeks, specific cough severity and count measurements, and willingness to provide informed consent. There are also exclusion criteria, such as recent respiratory tract infection, history of certain medical conditions or substance abuse, and recent participation in other drug studies. Pregnant or breastfeeding females or those unwilling to practice birth control during the study are also excluded.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are HIV-1 infection and tuberculosis. The ICDCodes associated with these diseases are provided as well. The drug being used in the trial is depot medroxyprogesterone acetate. The eligibility criteria for participants include having HIV-1 infection, current tuberculosis infection, stable on EFV-based cART for at least 28 days, receiving RIF and Isoniazid-based TB therapy, being a premenopausal female with normal ovarian function, and meeting certain laboratory values. There are also exclusion criteria listed, such as recent use of certain contraceptives, weight restrictions, previous breast cancer diagnosis, and history of deep venous thrombosis or pulmonary emboli.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is diabetes. The ICDCodes associated with diabetes are ['E23.2', 'N25.1', 'P70.2', 'O24.92', 'Z83.3', 'Z86.32', 'E10.65']. The drugs being tested in this trial are sodium nitrite and placebo. The eligibility criteria for this trial include specific requirements for inclusion and exclusion. Inclusion criteria include being a post-menopausal female, having a diagnosis of diabetes with an HbA1c level above 6.0, experiencing diabetic peripheral neuropathy pain in the feet, having ongoing diabetic neuropathic pain for at least 3 months, having a pain score of 4 or higher on the Numerical Pain Rating Scale, and being able to provide written informed consent. Exclusion criteria include having fibromyalgia or regional pain caused by lumbar or cervical compression, a history or diagnosis of significant neurological disease, clinically significant psychiatric diseases, serious liver disease, poorly controlled diabetes, hypersensitivity to sodium nitrite or related compounds, a life expectancy of less than 6 months, a chronic illness that may increase the risks associated with the study, active malignancy requiring active anti-neoplastic therapy, being pregnant or nursing, current diagnosis of alcohol or substance abuse, current use of sildenafil or other phosphodiesterase Type 5 Inhibitors, a history of methemoglobinemia (met-Hb \u2265 15%), being involved in litigation or receiving worker's compensation, and inability to speak English.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating triple-negative breast cancer. The associated ICD-10 codes for the disease are ['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']. The drugs being used in the trial are paclitaxel, carboplatin, doxorubicin, cyclophosphamide, and docetaxel. The eligibility criteria for participants in the trial are listed, including requirements such as having newly diagnosed stage I, II, or III triple-negative breast cancer, not having received prior chemotherapy or radiation therapy, and meeting certain organ and marrow function criteria. There are also exclusion criteria, such as not being pregnant or nursing, not having received previous treatment for breast cancer, and not having certain medical conditions.",
    "The sample provided is for a clinical trial in phase 2. The trial is focused on the disease called non-alcoholic steatohepatitis. The corresponding ICD-10 code for this disease is K75.81. The drugs being tested in this trial are bms-986036 and placebo. The eligibility criteria for participants include being between 21 and 75 years old, having a body mass index (BMI) of 25 or more. The exclusion criteria include having chronic liver disease other than NASH, uncontrolled diabetes, recent major surgery, inability to self-administer under the skin injections, and any recent bone trauma or surgery. For more information about participating in this clinical trial, interested individuals can visit www.BMSStudyConnect.com.",
    "The sample from the table represents a phase 2 clinical trial. The diseases being studied are lymphoma, specifically mantle-cell lymphoma, large B-cell diffuse lymphoma, and follicular lymphoma. The corresponding ICD-10 codes for these diseases are provided. The drug being tested in the trial is daratumumab. The eligibility criteria for participants include having a confirmed diagnosis and prior treatment for each subtype of non-Hodgkin's lymphoma, having at least one measurable site of disease, and having available tumor tissue for CD38 assay. Other criteria include having an ECOG performance status score of 0 or 1, practicing effective birth control methods for women of childbearing potential, and using barrier methods of birth control for sexually active men. The exclusion criteria include having central nervous system lymphoma, prior anti-tumor therapy within specific timeframes, previous use of daratumumab or other anti-CD38 therapies, history of malignancy (except for specific exceptions), and certain respiratory conditions such as severe COPD or uncontrolled asthma.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is metastatic colorectal cancer. The ICD-10 codes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are capecitabine, temozolomide, irinotecan, fluorouracil, and leucovorin. The eligibility criteria for participants include having a confirmed diagnosis of adenocarcinoma of the colon and/or rectum with MGMT promoter methylation and RAS mutation, having progressive disease after receiving a first-line oxaliplatin-containing chemotherapy regimen for metastatic colorectal cancer, and meeting certain age, performance status, and laboratory result requirements. There are also exclusion criteria, such as prior treatment with irinotecan and temozolomide, recent major surgical procedures or radiotherapy, and certain medical conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and is focused on treating glioblastoma multiforme and anaplastic astrocytoma. The diseases are identified by their respective ICD-10 codes. The drugs being used in the trial are toca fc, lomustine, and temozolomide. The sample also includes the eligibility criteria for participants in the trial, including age restrictions, previous treatments received, disease confirmation requirements, and various laboratory values that must be met. There are also exclusion criteria listed, such as previous recurrences of the diseases, certain types of brain tumors, active infections, and allergies or intolerances to specific medications.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 designation. The trial focuses on autism spectrum disorder (ASD) and includes the following information: \n\n- The ICD-10 code for ASD is \"Z16.12\".\n- The drugs being tested are \"8iu intranasal oxytocin\", \"24iu intranasal oxytocin\", and a placebo.\n- The eligibility criteria for inclusion in the trial are:\n  - Male subjects between the ages of 18 and 35 with a confirmed diagnosis of ASD.\n  - Subjects must be in good general health and have no clinically significant abnormalities in their physical examination, vital signs, and electrocardiogram.\n  - Subjects must be able to communicate well with the investigator, understand and comply with the study requirements, and understand the provided patient information.\n  - Subjects must provide signed, written informed consent.\n- The exclusion criteria for the trial are:\n  - Subjects with major septal deviation or significantly altered nasal epithelium.\n  - Subjects with evidence of previous nasal disease, surgery, or dependence on inhaled drugs.\n  - Subjects with current significant nasal congestion due to common colds.\n  - Subjects with a clinically relevant history of significant hepatic, renal, endocrine, cardiac, nervous, pulmonary, hematological, or metabolic disorder.\n  - Subjects with psychiatric co-morbidity that requires intervention or systemic illness requiring treatment within 2 weeks prior to the study.\n  - Subjects with a history of significant drug or alcohol abuse.\n  - Subjects with abnormal laboratory values deemed clinically significant by the investigator.\n  - Subjects with a full-scale IQ less than 75.\n  - Subjects with known allergic reactions or hypersensitivity to any component of the study medication in the nasal spray.\n  - Subjects who have participated in any other clinical trial with an investigational medicinal product or medical device within 3 months prior to randomization.\n  - Subjects who are deemed unsuitable for enrollment for unspecified reasons by the investigator or sponsor.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is \"smoldering multiple myeloma.\" The associated ICD-10 codes for this disease are listed as \"['G35', 'M15.3', 'M67.49', 'M89.09', 'M89.59', 'M94.29', 'Q78.6'].\" The drugs being used in the trial are \"carfilzomib,\" \"lenalidomide,\" \"dexamethasone,\" and \"melphalan.\" The eligibility criteria for this trial are listed, including age requirements, diagnosis criteria for smoldering multiple myeloma, performance status, attendance ability, and pregnancy testing requirements for women of childbearing potential. The exclusion criteria are also listed, which include previous treatment for smoldering multiple myeloma, pregnancy or breastfeeding, presence of certain medical conditions, laboratory abnormalities, history of neoplasm, recent surgery, active infections, and various other medical conditions or contraindications.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is \"infection, human immunodeficiency virus\". The corresponding ICD-10 code for this disease is \"Z21\". The drugs being tested in this trial are \"bms-955176\", \"efv\", and \"tdf/ftc\". The eligibility criteria for participants in this trial include being at least 18 years old, being antiretroviral treatment-na\u00efve, having a plasma HIV-1 RNA level of at least 1000 copies/mL, and having a CD4 T-cell count of more than 200 cells/mm3. The exclusion criteria include having resistance or partial resistance to any of the study drugs, having certain resistance mutations to EFV, TDF, FTC, or Protease Inhibitors, having chronic hepatitis B virus (HBV) or hepatitis C virus (HCV), having normal liver function, and having low hemoglobin or platelet levels. For more information about participating in this clinical trial, individuals are directed to visit www.BMSStudyConnect.com.",
    "The sample provided is a record from a table that contains information about a clinical trial. The table has several columns, including \"phase\" which indicates the phase of the trial (in this case, phase 2), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which provides the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being used in the trial, and \"criteria\" which includes the eligibility criteria for participants.\n\nIn this particular sample, the phase of the trial is phase 2. The diseases being studied are \"aggressive systemic mastocytosis,\" \"mast cell leukemia,\" and \"systemic mastocytosis.\" The corresponding ICD-10 codes for these diseases are \"C96.21,\" \"C94.31,\" \"C94.32,\" \"C94.30,\" \"D47.02,\" and \"C96.21.\" The drug being used in the trial is \"ibrutinib.\" The eligibility criteria for participants are listed under \"criteria\" and include various medical conditions, laboratory values, and other factors that determine whether a person can participate in the trial or not.\n\nIt's important to note that this is just a sample from the table and there may be more records with different phases, diseases, drugs, and criteria in the actual table.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is colorectal cancer. The ICD-10 codes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested in this trial is a combination of capecitabine and oxaliplatin. The eligibility criteria for participants in this trial include having a performance status (ECOG) of 0-2, a histologically confirmed diagnosis of colon cancer, no prior treatment, CT-defined T4 or lymph node-positive colon cancer, specific blood count and liver function levels, a life expectancy of at least 3 months, and providing signed written informed consent. The exclusion criteria include being in the final stage with cancer cachexia, having an allergy to capecitabine or oxaliplatin, having evidence of extrahepatic metastases and/or primary tumor recurrence, and having severe organ failures or diseases such as coronary disease, cardiovascular disorder, myocardial infraction, severe psychiatric illness, severe infection, or DIC.",
    "The sample from the table represents a phase 2 clinical trial. The trial focuses on patients with stage IV non-small cell lung cancer (NSCLC) who are not suitable for or declining palliative chemotherapy. The trial also includes patients who have completed 1st or 2nd-line palliative chemotherapy. The eligibility criteria for the trial include adults with a likely prognosis of at least 3 months, cachexia (weight loss or low BMI), systemic inflammation (elevated C-reactive protein), and adequate renal and liver function. The trial requires participants to suspend the use of certain statins and substitute the use of domperidone for an alternative anti-emetic if necessary. Exclusion criteria include poor performance status, significant weight loss, known hypersensitivity to clarithromycin, cardiac issues, untreated electrolyte imbalances, active infections, certain medical conditions, brain metastases, use of certain medications, pregnancy, and breastfeeding.",
    "The sample provided is for a phase 2 clinical trial. The trial is focused on patients with metastatic breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being tested in the trial is nov120101 (poziotinib). \n\nThe eligibility criteria for inclusion in the trial are as follows:\n1. Patients who agree to provide a tumor tissue specimen for biomarker research.\n2. Patients with an ECOG performance status of 2 or lower.\n3. Patients who have received Taxane-based chemotherapy and at least two HER2-targeted therapies, including lapatinib, T-DM1 (trastuzumab emtansine), and pertuzumab.\n4. Patients with adequate hematological, hepatic, and renal functions.\n\nThe exclusion criteria for the trial are as follows:\n1. Patients who have previously received NOV120101.\n2. Patients expected to have hypersensitivity to IP or its components.\n3. Patients receiving any other concurrent chemotherapies.\n4. Patients who have received radiotherapy within 4 weeks before the study, except for those who have completed and recovered from all treatment-related toxicities after radiotherapy in a limited area as palliative therapy.\n5. Patients with a history of symptomatic or unstable angina, congestive heart failure, arrhythmia requiring medications, clinically significant myocardial infraction, or other cardiac diseases within 6 months before the study.\n6. Patients with a left ventricle ejection fraction (LVEF) below the institutional lower limit of normal, unless no lower limit of normal is defined at the site, in which case the lower limit of normal is 50%.\n7. Patients with concurrent active hepatic or biliary disease, except for Gilbert's syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver diseases.\n8. Patients with a history or concurrent ongoing/active infection or uncontrolled diseases, including psychiatric illness/social situations that may limit compliance with study procedures.\n9. Patients who have received chemo-, immuno-, or surgical therapy within 3 weeks, or hormone therapy within 1 week before IP administration.\n10. Patients with a history of primary malignancies other than breast cancer.\n11. Patients with central nervous system (CNS) metastases.\n12. Patients receiving or expected to receive bisphosphonate for prophylactic use without any bone-related diseases during the trial, except for the treatment of bone metastases or osteoporosis initiated prior to IP administration.\n13. Patients with clinically significant or recent acute gastrointestinal disorders with diarrhea as a major symptom.\n14. Patients who are unstable or have unresolved severe adverse events.\n15. Patients who are pregnant or breastfeeding.\n16. Women of childbearing potential or men who are unwilling to use adequate contraception or be abstinent during the trial and for at least 2 months after the end of treatment.",
    "The sample is a phase 2 trial for the treatment of neovascular age-related macular degeneration. The trial is evaluating the effectiveness of two drugs, \"regn2176-3\" and \"intravitreal aflibercept injection (iai)\". The eligibility criteria for participants include being 50 years or older, having active subfoveal choroidal neovascularization (CNV) secondary to AMD, and having a BCVA ETDRS letter score between 73 and 24 in the study eye. Participants must not have received prior anti-VEGF treatment or treatment with PDGF or PDGFR inhibitors in the study eye. Other exclusion criteria include the presence of dense fibrotic scar or atrophy in the study eye involving the center of the fovea, retinal pigment epithelial tears or rips involving the macula, prior vitrectomy in the study eye, history of macular hole of stage 2 and above in the study eye, recent intraocular or periocular surgery, history of corneal transplant in the study eye, evidence of diabetic retinopathy or diabetic macular edema in either eye, and a positive pregnancy test.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on leukemia, specifically precursor-B acute lymphoblastic leukemia and lymphoblastic lymphoma. The diseases are associated with certain ICD-10 codes. The trial involves the use of various drugs such as cytarabine, daunorubicin, vincristine, and others. The eligibility criteria for participants include having the specified diseases, being untreated or having had only one prior chemotherapy regimen, being between the ages of 12 and 30, and having certain laboratory values within specified ranges. The sample also includes exclusion criteria, such as being pregnant, having certain genetic abnormalities, or having active infectious hepatitis.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of various types of leukemia. The diseases included in the trial are mixed lineage acute leukemia, acute myeloid leukemia, and acute lymphoid leukemia. The corresponding ICD-10 codes for these diseases are provided as well. The trial involves the use of multiple drugs, including bortezomib, vorinostat, mitoxantrone, cytarabine, methotrexate, hydrocortisone, peg-l-asparaginase, erwinia l-asparaginase, dexamethasone, mercaptopurine, and doxorubicin. The eligibility criteria for the trial are also listed, including age restrictions, specific diagnosis requirements, performance level, prior therapy history, and organ function requirements. The exclusion criteria outline factors that would disqualify a patient from participating in the trial, such as certain medications, pregnancy or breastfeeding, uncontrolled infections, HIV infection, and other concurrent diseases or disorders.",
    "The sample from the table represents a phase 2 clinical trial for prostate cancer. The trial is specifically targeting patients who have undergone surgery, radiation, or a combination of both for prostate cancer that has spread to regional lymph nodes. These patients must have a rising PSA value after their initial treatment and no visible metastatic disease on imaging studies.\n\nThe eligibility criteria for the trial include specific requirements for PSA values, such as a minimum value after surgery or radiation and a rising trajectory. The PSA must also be less than 50 ng/mL at the start of the study, and the PSA doubling time must be greater than 4 months. Other criteria include baseline imaging showing no metastatic disease, estimated life expectancy of at least 6 months, and a performance status of 2 or lower according to the Eastern Cooperative Oncology Group (ECOG) scale.\n\nAdditional criteria include certain blood count and renal function requirements, as well as normal levels of bilirubin and transaminases. Patients must also have a serum total testosterone level of at least 150 ng/dL and sign informed consent.\n\nExclusion criteria for the trial include serious systemic disorders that could compromise patient safety or ability to complete the study, prior androgen deprivation therapy within the past 3 months, and certain medical conditions or medications that may interact with the study drugs (aspirin and metformin).\n\nOverall, the sample provides detailed information about the phase 2 trial, including the targeted diseases, eligibility criteria, and exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is leukemia. The ICDCodes associated with the disease are C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, and C91.01. The drugs being used in the trial are rituximab and urelumab. \n\nThe eligibility criteria for this trial include:\n1. Patients must have a diagnosis of CLL or SLL and meet one or more criteria for active disease as defined by the International Working Group for CLL (IWCLL). They should also be relapsed and/or refractory after at least one prior therapy.\n2. Patients must be 18 years or older.\n3. Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or lower.\n4. Patients must have adequate renal and hepatic function.\n5. Females of childbearing potential must have a negative pregnancy test and agree to use contraception during the study and for 12 months after the last dose of the study drugs. Males with partners of childbearing potential must also agree to use contraception.\n6. Patients or their legally authorized representative must provide written informed consent.\n\nThe exclusion criteria for this trial include:\n1. Prior malignancy active within the previous 2 years, except for certain curable cancers.\n2. Any major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, or experimental therapy within 4 weeks prior to the first dose of the study drugs.\n3. Significant cardiovascular disease, history of stroke or cerebral hemorrhage within 2 months, or uncontrolled hypertension.\n4. Known evidence of active cerebral/meningeal CLL or active autoimmune hemolytic anemia or immune thrombocytopenia requiring steroid therapy.\n5. Patients with autoimmune diseases, previous allogeneic stem cell transplant within 6 months, or organ allografts are excluded.\n6. History of any hepatitis, high-dose steroid use, uncontrolled active infection, current or chronic hepatitis B or C infection, or known seropositivity for HIV.\n7. Patient is pregnant or breastfeeding.\n8. Concurrent use of investigational therapeutic agent.\n9. Patients may not receive other concurrent chemotherapy, radiotherapy, or immunotherapy.\n10. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or interfere with the interpretation of study results.\n11. Patients with Richter's transformation are not allowed in the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"nonalcoholic steatohepatitis\". The disease is identified by the ICD-10 code \"K75.81\". The trial involves two drugs, \"gr-md-02\" and \"placebo\". The eligibility criteria for participants are listed, including requirements such as having a liver biopsy demonstrating NASH with Brunt Stage 3 fibrosis within the past year, being between 18 and 75 years old, and providing written informed consent. There are also exclusion criteria, such as a history of hepatic decompensation, other forms of chronic liver disease, certain laboratory values outside of normal ranges, and various medical conditions that would make participation risky.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"her2 positive metastatic breast cancer.\" The ICDCodes associated with this disease are \"C79.81,\" \"D24.1,\" \"D24.2,\" \"D24.9,\" \"D49.3,\" \"C44.501,\" and \"D48.60.\" The drugs being studied in this trial are \"pyrotinib,\" \"lapatinib,\" and \"capecitabine.\"\n\nThe eligibility criteria for this trial include being aged between 18 and 70 years, having an ECOG performance status of 0 to 1, having a life expectancy of more than 12 weeks, having at least one measurable lesion according to RECIST 1.1, having histologically or cytologically confirmed HER2 positive advanced breast cancer that has failed prior therapies, and meeting certain laboratory value requirements.\n\nThe laboratory value requirements include ANC (Absolute Neutrophil Count) of at least 1.5 x 10^9/L, platelet count of at least 100 x 10^9/L, hemoglobin level of at least 9.0 g/dL, total bilirubin level less than or equal to 1.5 times the upper limit of normal (ULN), ALT (Alanine Aminotransferase) and AST (Aspartate Aminotransferase) levels less than or equal to 1.5 times the ULN, BUN (Blood Urea Nitrogen) and creatine clearance rate of at least 50 mL/min, left ventricular ejection fraction (LVEF) of at least 50%, and QTcF (corrected QT interval) less than 470 ms for females and less than 450 ms for males.\n\nThe exclusion criteria for this trial include having received previous therapy with lapatinib, neratinib, pyrotinib, or any other HER2 directed tyrosine kinase inhibitor, and having received previous therapy with capecitabine within the last 3 months.\n\nOverall, this sample provides specific details about the phase, disease, ICDCodes, drugs, and eligibility criteria for a clinical trial related to her2 positive metastatic breast cancer.",
    "The sample from the table is a clinical trial for patients with advanced non-small-cell lung carcinoma. The trial is in phase 1/phase 2. The diseases column specifies the disease as \"carcinoma, non-small-cell lung\". The icdcodes column contains the ICD-10 codes for the disease, which are ['D02.20', 'D02.21', 'D02.22']. The drugs column lists the drugs being used in the trial, which are 'mk-3475' and 'gemcitabine'. The criteria column provides the eligibility criteria for the trial, including requirements such as histologically proven NSCLC, a certain number of prior systemic therapies, specific performance status, negative pregnancy test for women of childbearing potential, ability to give informed consent, anticipated survival of at least 3 months, completion of prior investigational therapy, normal organ and marrow function, availability of archived tumor tissue, measurable disease, and specific timing requirements for radiation and brain metastases. The exclusion criteria include prior therapy with certain antibodies and gemcitabine, complications from radiation, active autoimmune disease (except vitiligo or stable hypothyroidism), ongoing steroid use (except for certain treatments), active other malignancy (except controlled basal cell skin carcinoma), and positive HIV or Hepatitis B or C. Additionally, any other medical or psychiatric conditions that may preclude safe participation in the trial are also listed as exclusion criteria.",
    "The sample is a phase 2 trial for Alzheimer's disease and mild cognitive impairment. The trial is testing a drug called vx-745. The inclusion criteria for participants include being willing and able to provide informed consent, having a diagnosis of mild cognitive impairment or mild Alzheimer's disease, having a MMSE score between 20 and 28, showing evidence of amyloid pathology through an amyloid PET scan, and being proficient in Dutch with adequate visual and auditory abilities. Participants may also be taking medications for Alzheimer's disease as long as the dose has been stable for at least 3 months. The exclusion criteria include having evidence of a neurodegenerative disease other than Alzheimer's disease, being unable to undergo PET and fMRI scans, having a psychiatric disorder that would compromise compliance with the study requirements, having significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, metabolic/endocrine disorders, or any other disease that would prevent treatment with the p38 MAP kinase inhibitor or assessment of drug safety and efficacy. Other exclusion criteria include recent changes to Alzheimer's medications, participation in another investigational drug study within the past 6 months or 5 half-lives of the investigational drug, male subjects with a female partner of child-bearing potential who are unwilling or unable to adhere to contraception requirements, female subjects who have not reached menopause or have not had a hysterectomy or bilateral oophorectomy/salpingoophorectomy, positive pregnancy test or plans to become pregnant during the trial, and any other factor that the investigator deems likely to interfere with the study conduction.",
    "The sample is a phase 2 trial for Alzheimer's disease. The eligibility criteria for participants include being between the ages of 60 and 85, able to provide informed consent, and having clinical symptoms consistent with mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's disease. Additional criteria include a gradual decline in memory function over a period of more than 6 months, amnestic presentation on neuropsychological testing, a Clinical Dementia Rating (CDR) Sum of Box (SOB) score of 0.5 or higher, and a Mini-Mental State Examination (MMSE) score ranging from 20 to 30. Participants must also have brain hypometabolism as indicated by 18F-2-fluoro-2-deoxyglucose (FDG)-PET. They may be taking stable doses of medications for Alzheimer's disease. Exclusion criteria include evidence of any neurodegenerative disease other than Alzheimer's, inability to undergo MRI scans, psychiatric disorders that would hinder compliance with study requirements, recent history of cancer (except for certain types), significant cardiovascular, pulmonary, renal, liver, infectious, immune, metabolic/endocrine disorders, recent changes to Alzheimer's medications, recent use of psychotropic or anticoagulant drugs, recent participation in another investigational drug study, male subjects with female partners of child-bearing potential who are not willing to adhere to contraception requirements, female subjects who have not reached menopause or had certain surgeries, positive pregnancy test or plans to become pregnant during the trial, donation of a large amount of blood or blood products within the past 2 months, history of alcohol or illicit drug abuse within the past 6 months, infection with hepatitis A, B, or C or HIV, and any other factors that the investigator deems likely to interfere with the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of squamous cell lung cancer. The trial includes patients with stage IIIB or stage IV disease, or recurrent non-small cell lung cancer (NSCLC) that cannot be treated with radio-chemotherapy or surgery. The patients must have at least one measurable lesion or lytic/mixed bone lesions. They should also be willing to donate archival diagnostic tissue for research purposes.\n\nThe eligibility criteria include having a histological or cytological diagnosis of squamous NSCLC, excluding patients with adenosquamous or mixed histology. The patients should have specific hematologic and biochemical indices within certain ranges. They should also have an ECOG performance status of 0-2 and be non-childbearing. The trial excludes patients with symptomatic CNS involvement, previous systemic treatment for lung cancer (except for immunotherapy without chemotherapy or adjuvant chemotherapy finished at least 1 year prior), known tumor EGFR mutation or ALK rearrangements (unless contraindicated or therapy not available), significant cardiovascular disease, active second malignancy (except non-melanomatous skin cancer), concurrent treatment with other experimental drugs or participation in another clinical trial, and any other condition that contraindicates the use of an investigational drug or interferes with obtaining informed consent.\n\nOverall, this sample provides specific details about the phase, diseases, icd-10 codes, drugs, and eligibility criteria for a clinical trial focused on squamous cell lung cancer.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on metastatic breast cancer. The trial includes patients with histologically confirmed breast cancer that has spread to other parts of the body or has recurred locally. Patients must have at least one measurable lesion that can be accurately measured at baseline, or lytic or mixed bone lesions in the absence of measurable disease. The trial is specifically for patients with triple-negative breast cancer.\n\nInclusion criteria for the trial include written informed consent, being a woman over 18 years old, having radiological or clinical evidence of recurrence or progression, and having a formalin-fixed paraffin-embedded tumor sample available for testing. Patients must also have the ability to swallow and retain oral medication, meet certain hematologic and biochemical indices, have an ECOG performance status of 0-2, and be non-childbearing or use adequate contraception. Exclusion criteria include having brain metastases, prior chemotherapy for metastatic breast cancer, recent radiotherapy, prior treatment with certain inhibitors, pre-existing sensory or motor polyneuropathy, and various other medical conditions or factors that may interfere with the trial or increase risk.\n\nOverall, the sample provides specific details about the phase, diseases, icd-10 codes, drugs, and eligibility criteria for the clinical trial.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of aggressive T-cell Non-Hodgkin's lymphoma. The trial is open to individuals between the ages of 18 and 75 who have been diagnosed with this type of lymphoma and have relapsed or refractory cases after previous treatments. The eligibility criteria include having a performance status of 2 or lower, having measurable lesions of a certain size, and meeting certain requirements for cardiac, renal, liver, and bone marrow function. Women of childbearing potential must have a negative pregnancy test before starting treatment. There are also exclusion criteria, such as having certain types of lymphoma, previous treatment with specific drugs, and other serious medical conditions.",
    "The sample is a phase 2 trial for atopic dermatitis. The trial is looking for males and females aged 18-65 with a documented history or diagnosis of atopic dermatitis for at least 12 months. The trial requires participants to have an Eczema Area and Severity Index (EASI) score of \u226512 and <48, an Investigator's Global Assessment (IGA) score \u2265 3 at both screening and day 0, and a mean pruritus score of \u2265 5 on a 0-10 scale over the 7-day run-in period. Participants must also have atopic dermatitis affecting \u226510% of their body surface area. \n\nExclusion criteria include having atopic dermatitis of such severity (EASI >48) that the subject could not comply with the demands of the study or is not a suitable candidate for a placebo-controlled study. Participants with concurrent skin diseases that could interfere with the study evaluation or skin comorbidities that may interfere with study assessments are also excluded. Additionally, participants with active skin infections or any other clinically apparent infections, hypersensitivity to mometasone or any other ingredients in the topical corticosteroid product used as rescue medication, or who have received phototherapy or systemic therapy known or suspected to have an effect on atopic dermatitis within 4 weeks of the start of the run-in period are excluded. Participants who have received systemic corticosteroids within 4 weeks of the start of the run-in period are also excluded, except for those on a stable maintenance dose of inhaled or intranasal corticosteroids. Finally, participants who have been treated with oral antihistamines, topical calcineurin inhibitors, or topical steroids within 7 days of starting the run-in period are excluded, except for intranasal antihistamines for the treatment of allergic rhinitis.",
    "The sample from the table represents a clinical trial with a phase 1/phase 2 trial phase. The trial focuses on the treatment of melanoma, a type of skin cancer. The trial includes patients with stage IIB, IIC, III, or IV melanoma, as well as high-risk stage IIA melanoma. Participants must have confirmed diagnosis of melanoma through cytological or histological examination. The trial also requires participants to have accessible metastases of melanoma for biopsy.\n\nThe inclusion criteria include specific radiological studies to rule out radiologically evident disease, such as chest, abdominal, pelvic, and head CT scans. Participants with brain metastases may be eligible if certain conditions are met. Other criteria include ECOG performance status of 0 or 1, ability and willingness to give informed consent, and specific laboratory parameters within normal ranges.\n\nExclusion criteria include recent use of certain medications or treatments, such as chemotherapy, interferon, radiation therapy, and high doses of systemic corticosteroids. Participants currently receiving or recently treated with nitrosoureas or checkpoint molecule blockade therapy are also excluded. Other exclusion criteria include known allergies to any component of the vaccine, previous vaccination with the synthetic peptides included in the trial, pregnancy or breastfeeding, medical contraindications or potential compliance issues, certain heart diseases, uncontrolled diabetes, prior autoimmune disorders requiring cytotoxic or immunosuppressive therapy, and certain other cancer diagnoses. Participants with addiction to alcohol or drugs or recent illicit IV drug use are also excluded. Additionally, participants with body weight less than 110 pounds at registration are not eligible for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of hepatocellular carcinoma (HCC), a type of liver cancer. The trial is focused on patients with unresectable HCC categorized as stage C according to the Barcelona Clinic Liver Cancer (BCLC) staging system. The inclusion criteria for the trial include having a confirmed diagnosis of HCC, being within a certain age range, having a specific performance status, and meeting certain liver, bone marrow, and renal function requirements. Patients with HBV-related HCC must also have controlled HBV replication. The trial requires written informed consent and the ability to comply with the protocol. The exclusion criteria include significant liver function impairment, specific imaging findings for HCC, uncontrolled active infection, presence of active malignancy (except for HCC), pregnancy or lactation in females, and any other medical condition that would prevent participation in the study. Major surgery within 4 weeks prior to enrollment is also an exclusion criterion.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on colorectal neoplasms, adenocarcinoma of the colon, and adenocarcinoma of the rectum. The diseases are associated with specific ICD-10 codes. The trial involves the drug regorafenib. The eligibility criteria for participants are listed, including age, stage of colorectal cancer, previous treatment, performance status, and various laboratory requirements. There are also exclusion criteria, such as previous treatment in this study, uncontrolled hypertension, remaining tumor, abnormal organ function, and various other medical conditions. The sample provides detailed information about the inclusion and exclusion criteria for potential participants in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of chronic constipation. The associated disease is chronic constipation, which is identified by the ICD-10 code \"K59.04\". The drugs being studied are \"asp0456\" and a placebo. \n\nThe eligibility criteria for participants in this trial are as follows:\n- Patients must have experienced spontaneous bowel movements (SBM) less than 3 times per week for at least six months prior to provisional registration. SBM refers to defecation without the use of laxatives, suppositories, enemas, or stool extraction on the day or preceding day of defecation.\n- Patients must have experienced one or more of the following symptoms for at least 25% of their defecations for more than six months prior to provisional registration: straining during defecation, lumpy or hard stools, or a sensation of incomplete evacuation.\n- Patients must not have had loose stools without the use of laxatives for more than six months prior to provisional registration.\n- Patients must have undergone pancolonoscopy or contrast enema (or sigmoidoscopy) after the onset of chronic constipation symptoms and showed no organic changes.\n\nExclusion criteria for participants in this trial include:\n- Patients who meet the diagnostic criteria for IBS-C (Irritable Bowel Syndrome with Constipation) according to Rome III for more than six months prior to provisional registration. This includes patients who have recurrent abdominal pain or discomfort associated with certain symptoms such as improvement with defecation, changes in stool frequency, or changes in stool appearance.\n- Patients with a history of surgical resection of the stomach, gallbladder, small intestine, or large intestine (excluding appendectomy and resection of benign polyps).\n- Patients with a history or current evidence of inflammatory bowel disease (Crohn's disease or ulcerative colitis), ischemic colitis, infectious enteritis, hyperthyroidism, hypothyroidism, mechanical obstruction, mega colon or mega rectum, constipation due to anorectal dysfunction, drug-induced constipation, constipation due to other organic diseases, active peptic ulcer, endometriosis or uterine adenomyosis in females, high depression or anxiety, history of drug or alcohol abuse within the past year, or current abuse.\n- Patients who have used or will use drugs, therapies, or tests prohibited within 3 days before the start of the bowel habit observation period or thereafter, unless specified in the protocol.\n- Patients with a history or current evidence of malignant tumors.\n- Patients currently affected by serious cardiovascular disease, respiratory disease, kidney disease, hepatic disease, gastrointestinal disease (excluding chronic constipation), hemorrhagic disease, or neural/mental disease.\n- Patients with a history of drug allergy.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 2. The diseases being studied are acute graft versus host disease and intestinal graft versus host disease. The icd-10 codes associated with these diseases are 'D89.810' and 'D89.812'. The drugs being used in the trial are budesonide and methylprednisolone sodium succinate. The eligibility criteria for participants include a diagnosis of acute GvHD of the GIT (excluding isolated \"upper\" GIT disease), the recommendation of biopsies, and the allowance of any diagnosis, donor, or source of hematopoietic stem cells. Prior or ongoing therapy is also considered, with specific guidelines for glucocorticoid therapy and acute GvHD prophylaxis. Exclusion criteria include significant risk factors for IASA therapy, the use of other drugs for GvHD treatment or investigational agents, uncontrolled severe infective processes, relapsed or persistent malignancy requiring immunosuppressive withdrawal or modulation, and pregnancy.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is Phase 2.\n- Diseases: The specific disease being targeted in the trial, which is \"pancreatic ductal adenocarcinoma.\"\n- ICD Codes: The ICD-10 codes associated with the disease, which are \"C22.0\", \"C22.1\", \"C4A.9\", \"C7B.1\", \"D09.9\", \"C4A.0\", and \"C4A.31\".\n- Drugs: The drugs being used in the trial, which are \"nab-paclitaxel\" and \"gemcitabine.\"\n- Criteria: The eligibility criteria for participants in the trial, including both inclusion and exclusion criteria.\n\nThe inclusion criteria state that participants must have histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma, be at least 18 years old, have an ECOG performance status of 0-1, have at least one measurable lesion according to RECIST v1.1, and have not received prior palliative chemotherapy for metastatic pancreatic cancer. Other criteria include adequate bone marrow, liver, and renal function, as well as specific requirements for albumin level and absence of jaundice. Female participants of childbearing potential must commit to contraception, have a negative pregnancy test, and male participants must practice abstinence or use condoms during sexual contact with pregnant females or females of childbearing potential.\n\nThe exclusion criteria state that participants with symptomatic brain metastases, a history of malignancy in the last 5 years, breastfeeding or pregnancy, plastic biliary stents, active uncontrolled infections, known infections with HIV, hepatitis B, or hepatitis C, recent major surgery, recent myocardial infraction or other cardiovascular conditions, allergies or hypersensitivity to the study drugs, history of connective tissue disorders or interstitial lung disease, and other significant medical conditions or psychiatric illnesses are not eligible for the trial. Additionally, participants currently enrolled in other clinical protocols or trials, those unwilling or unable to comply with study procedures, and those with any medical condition or psychiatric illness that would prevent participation are also excluded.\n\nOverall, this sample provides specific information about the phase, disease, drugs, and eligibility criteria for a clinical trial targeting pancreatic ductal adenocarcinoma.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 2, and the disease is \"bacterial infections\". The ICDCodes associated with this disease are \"A49.9\", \"A04.9\", \"A04.8\", and \"A49.8\". The drugs being tested in this trial are \"debio 1450 iv\", \"debio 1450 oral\", \"linezolid\", \"debio 1450 oral placebo\", \"linezolid placebo\", and \"vancomycin iv\". The eligibility criteria for this trial include having a clinically documented skin infection caused by a staphylococcal pathogen, meeting other specified criteria, being willing to stay in the study unit for the entire duration of each treatment period, and providing informed consent. Exclusion criteria include a history or current use of certain medications or substances outside the specified parameters, and any condition that may compromise the safety or well-being of the participant or the analysis of results.",
    "The sample is a phase 2 trial for asthma. The diseases column indicates that the trial is focused on asthma. The icdcodes column provides a list of ICD-10 codes associated with asthma. The drugs column lists the drugs being used in the trial, including \"rpl554\", \"salbutamol\", and \"placebo\". The criteria column contains the eligibility criteria for participants in the trial, including requirements such as providing written informed consent, being a non-smoker or ex-smoker for at least 6 months, having a diagnosed asthma for at least 6 months, and meeting certain measurements for FEV1, blood pressure, and heart rate. The exclusion criteria include factors such as recent asthma exacerbation, prior life-threatening episodes of asthma, clinically significant diseases or disorders, abnormal ECG results, and recent treatment with systemic glucocorticosteroids.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is anxiety. The ICD-10 codes associated with the disease are F41.1, F41.9, F40.8, F40.9, F41.3, F41.8, and F43.22. The drugs being tested are MDMA and a placebo. The eligibility criteria for participants include being diagnosed with a life-threatening cancer or non-dementing neurological illness, having a prognosis of at least nine months life expectancy, experiencing anxiety due to their illness, being at least 18 years old, willing to refrain from taking any psychiatric medications during the study, committing to medication dosing and follow-up sessions, staying overnight at the study site after each experimental session, signing a medical release for communication with their therapist and doctors, selecting up to three observers, having a negative pregnancy test (if able to bear children) and agreeing to use effective birth control, being proficient in speaking and reading English, and agreeing to have all psychotherapy sessions recorded. The exclusion criteria include being pregnant or nursing (or not practicing effective birth control), weighing less than 48 kg, abusing illegal drugs, being unable to give informed consent, currently taking medication that is exclusionary, and having a current or past diagnosis that would be considered a risk to participation in the study.",
    "The sample from the table is for a clinical trial that is in phase 2/phase 3. The trial is focused on attention deficit hyperactivity disorder (ADHD). The trial includes a list of diseases, which in this case is only ADHD. The icd-10 codes for ADHD are also provided. The trial involves the use of drugs, specifically dasotraline and a placebo comparator. The eligibility criteria for participants are listed, including age requirements, diagnosis of ADHD based on DSM 5 criteria, specific scores on ADHD assessments, and general good health. There are also exclusion criteria, such as having certain medical conditions, history of certain disorders, and use of certain medications. The sample also includes criteria related to pregnancy and contraception for female participants.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The diseases being studied are pancreatic cancer and adenocarcinoma. The corresponding ICD-10 codes for these diseases are C25.3 and C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31 respectively. The drugs being tested in this trial are gsk2256098 and trametinib. The eligibility criteria for participants in this trial include being 18 years or older, having pancreatic adenocarcinoma that is not responsive to standard therapies or for which there is no approved or curative therapy, having clinical, radiographic, or serologic progression after one prior line of chemotherapy for advanced disease, having a performance status score of 0 or 1, having measurable disease by RECIST version 1.1, being able to swallow and retain oral medication, having malignant disease that is amenable to biopsy and agreeing to collection of mandatory tumor biopsy samples, agreeing to use contraception, not being pregnant, and having adequate organ system function. The exclusion criteria include recent use of chemotherapy, radiotherapy, immunotherapy, or other anti-cancer therapy, current use of prohibited medication, unresolved toxicity from previous anticancer therapy, presence of certain gastrointestinal conditions or bleeding, anticoagulation with warfarin, recent major surgery, malignancies related to HIV or HBV/HCV, active infection requiring treatment, leptomeningeal disease, brain metastases, prolonged QTcF interval, history of certain cardiac conditions, intra-cardiac defibrillators or cardiac metastases, presence of severe or uncontrolled systemic diseases, pregnancy or lactation, history of retinal vein occlusion, and history of interstitial lung disease or pneumonitis.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The trial is open to participants who have been diagnosed with AML or MDS and have relapsed or are refractory to chemotherapy, or have relapsed after hematopoietic stem cell transplantation (HSCT). The eligibility criteria include having a certain percentage of leukemic blasts in the bone marrow, being under 21 years of age, having adequate organ function, and having an available HPC-A donor. The sample also includes criteria for the HPC-A cell donor, such as being at least 18 years old and a first-degree relative of the participant.",
    "The sample from the table is for a phase 2 clinical trial for asthma. The diseases column indicates that the trial is focused on asthma. The icdcodes column provides a list of ICD-10 codes associated with asthma. The drugs column lists the drugs being used in the trial, including glycopyrronium mdi, serevent diskus 50 \u03bcg, and placebo. The criteria column contains the eligibility criteria for participants in the trial, including requirements such as giving written informed consent, being between the ages of 18 and 70, having a diagnosis of intermittent or mild to moderate persistent asthma, and meeting certain pulmonary function and asthma maintenance therapy criteria. The exclusion criteria include factors such as having life-threatening asthma, recent worsening of asthma, concurrent respiratory diseases, concurrent conditions or diseases that could put the participant's safety at risk, smoking history, recent use of inhaled anticholinergics, pregnancy or nursing, recent respiratory tract infection, uncontrolled hypertension, abnormal liver function, renal conditions, glaucoma, recent cancer, drug allergies, substance abuse history, and recent cardiac conditions or diseases.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on studying the effects of certain drugs on patients with specific diseases. The diseases mentioned in this sample are \"pain\" and \"cerebral palsy, spastic\". The corresponding ICD-10 codes for these diseases are provided as well. The drugs being studied are \"dysport\u00ae\" and \"normal saline\". The sample also includes the eligibility criteria for participants in the trial, including age requirements, specific conditions (spastic cerebral palsy and chronic pain related to spastic muscle), and exclusion criteria such as allergies to the drugs, pregnancy, recent treatment with botulinum toxin-A, and certain medical conditions.",
    "The sample from the table represents a clinical trial in phase 2/phase 3. The trial focuses on two diseases, namely \"hypertension, pulmonary\" and \"diseases of mitral valve\". The corresponding ICD-10 codes for these diseases are ['I27.0', 'I27.20', 'I27.21', 'I27.24', 'I27.29', 'P29.30', 'I27.22']. The trial involves the use of two drugs, namely \"sildenafil\" and \"placebo\". The eligibility criteria for participants in the trial are as follows:\n\nInclusion Criteria:\n- New York Heart Association Functional class (NYHA Fc) \u2265 2 dyspnea which was sustained till one year after the previous mitral valve surgery (repair or replacement)\n- TR Vmax \u2265 3.5m/s by echocardiography\n- Normal left ventricle ejection fraction (EF \u2265 50%)\n- Pulmonary vascular resistance \u2265 3 Wood Unit or diastolic pressure gradient \u2265 7mmHg by cardiac catheterization\n\nExclusion Criteria:\n- Other valve disease more than moderate degree (ex. aortic stenosis, aortic regurgitation)\n- Liver cirrhosis\n- Chronic renal failure with serum creatinine \u2265 1.7mg/dL\n- Lung disease (ex. chronic obstructive pulmonary disease, Asthma)\n- Thyroid dysfunction\n- Other causes which can lead to pulmonary hypertension",
    "The sample from the table is for a phase 2 clinical trial focused on temporomandibular disorders. The trial is investigating the effectiveness of the drugs propranolol er and placebo in treating these disorders. The eligibility criteria for participants include having a diagnosis of TMD, experiencing facial pain for at least 3 months, and having a pain intensity rating of at least 30 on a numeric scale. Participants must also agree to certain terms regarding pain medication usage, alcohol consumption, and contraception if applicable. There are several exclusion criteria, such as having certain cardiac conditions, taking specific medications, or undergoing certain treatments. The sample also specifies that pregnant or breastfeeding individuals are not eligible for the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"clostridium difficile\". The ICD-10 codes associated with this disease are \"A04.71\" and \"A04.72\". The drugs being studied in this trial are \"ser-109\" and \"placebo\". The eligibility criteria for participants are listed, including requirements such as signed informed consent, being 18 years or older, and having had at least 3 episodes of CDI within the previous 9 months. There are also exclusion criteria, such as being pregnant or having certain medical conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is phase 2/phase 3. The diseases being studied are recurrent non-small cell lung carcinoma and stage IV non-small cell lung cancer. The corresponding ICD-10 codes for these diseases are ['D02.20', 'D02.21', 'D02.22'] and ['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2'] respectively. The drug being tested in the trial is afatinib dimaleate. The eligibility criteria for the trial include specific requirements for patients' cancer stage, presence of certain genetic mutations, availability of tissue samples, previous treatments received, and various health parameters. The sample also includes additional information about the trial protocol and patient enrollment process.",
    "The sample provided is for a phase 2 clinical trial for the treatment of Waldenstrom's Macroglobulinemia. The trial is evaluating the drug gs-1101. The eligibility criteria for participants include having a clinicopathological diagnosis of Waldenstrom's Macroglobulinemia, measurable disease, having received at least one prior therapy for WM, being at least 18 years old, having an ECOG performance status of less than 2, and meeting certain organ and marrow function requirements. Participants should not be on any active therapy for other malignancies, except for topical therapies for skin cancers. Females of childbearing potential must agree to use two reliable forms of contraception or practice abstinence during the study and for at least 28 days after discontinuation. Participants must be able to adhere to the study visit schedule and other protocol requirements, and must understand and be willing to sign an informed consent document. The exclusion criteria include having any serious medical condition, concurrent use of other anti-cancer agents or treatments, prior exposure to idelalisib, and various other medical conditions that could affect patient safety or the assessment of study results.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on muscular dystrophy, specifically Duchenne muscular dystrophy.\n- ICD Codes: The ICD-10 code associated with the disease is \"G71.01\".\n- Drugs: The trial involves the drugs \"edasalonexent\" and \"placebo\".\n- Criteria: The eligibility criteria for the trial are listed, including requirements for written consent, diagnosis of DMD, ability to walk independently, and adequate immunization. There are also exclusion criteria, such as recent use of corticosteroids or participation in other clinical trials. Additionally, there are specific criteria for patients who have already participated in a previous part of the trial.\n\nIt is mentioned that there are no entry criteria for Part C, and patients who complete Part B will automatically continue in Part C.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease is acute leukemia. The ICDCodes associated with the disease are C91.01, C91.02, C92.01, C92.02, C92.41, C92.42, and C92.51. The drug mentioned is micafungin. The eligibility criteria for this trial include specific requirements for patients with newly diagnosed acute myeloid leukemia or acute lymphoid leukemia who are undergoing induction chemotherapy with certain drug combinations. Other criteria include Eastern Cooperative Oncology Group performance status, absence of fungal infection, no hypersensitivity to echinocandin, no previous malignancy within 5 years, no previous treatment history with chemotherapy, radiation therapy, or immunosuppressive therapy, not being pregnant or breastfeeding, absence of immunodeficiency or uncontrolled seizure or psychiatric disorder, no clinically significant heart disorder, no interstitial lung disease, no previous organ transplantation history, no galactose intolerance, and not having participated in the study before.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on pancreatic ductal adenocarcinoma. The trial is specifically for patients with metastatic or locally advanced stage pancreatic ductal adenocarcinoma who have not responded to or have progressed after receiving Gemcitabine-based first-line chemotherapy. \n\nThe eligibility criteria for this trial include being between the ages of 19 and 75, having a life expectancy of more than 3 months, and having an ECOG performance status of 2 or lower. Patients must also have measurable lesions in imaging studies and adequate bone marrow, liver, renal, and cardiopulmonary function.\n\nThere are also exclusion criteria, such as not having any other type of pancreatic cancer except ductal adenocarcinoma, no evidence of metastatic adenocarcinoma originating from other organs, and no evidence of CNS metastasis. Other exclusion criteria include having an active infection, uncontrolled serious medical or psychiatric illness, and participation in any other investigational drug study within the past month. Patients must also provide signed informed consent to participate in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 2 and phase 3. The disease being studied is hepatitis C, and the corresponding ICDCodes are B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, and B15.9. The drugs being used in the trial are abt-493 and abt-530. The eligibility criteria for participants include being 18 years or older, having received at least one dose of an ABT-493 and/or ABT-530 regimen in a previous AbbVie hepatitis C virus study, and meeting certain time intervals between previous treatments. The sample also includes both inclusion and exclusion criteria for participants.",
    "The sample is a record from a table that contains information about clinical trials. It is for a phase 2 trial and focuses on breast cancer. The diseases mentioned include breast cancer, hormone receptor positive tumor, and early-stage breast carcinoma. The icd-10 codes associated with these diseases are also provided. The drugs being studied in this trial are abemaciclib, loperamide, and anastrozole. The eligibility criteria for participants are listed, including requirements such as postmenopausal status, specific characteristics of the breast tumor, and adequate organ function. There are also exclusion criteria, such as having bilateral or metastatic breast cancer, prior therapy for breast cancer, and prior anti-estrogen therapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested is azd9291. \n\nThe eligibility criteria for this trial include being at least 18 years old and from the Asia Pacific region, having locally advanced or metastatic NSCLC that is not amenable to curative surgery or radiotherapy, and having radiological documentation of disease progression on the last treatment administered prior to enrolling in the study. Patients must also have a documented EGFR mutation associated with EGFR TKI sensitivity and central confirmation of tumour T790M mutation positive status. They should have a World Health Organisation (WHO) performance status of 0-1, a minimum life expectancy of 12 weeks, and at least one measurable lesion that can be accurately measured. Females of child-bearing potential must be using contraception and have a negative pregnancy test.\n\nThe exclusion criteria for this trial include recent treatment with EGFR-TKIs, cytotoxic chemotherapy, investigational agents, or other anticancer drugs, previous treatment with AZD9291 or a 3rd generation EGFR TKIs, major surgery or radiotherapy treatment within a certain timeframe, and currently receiving treatment with certain inhibitors or inducers. Other exclusion criteria include unresolved toxicities from prior therapy, unstable spinal cord compression or brain metastases, severe or uncontrolled systemic diseases, refractory nausea and vomiting, cardiac disease, past medical history of interstitial lung disease, inadequate bone marrow reserve, or organ function.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"nonalcoholic steatohepatitis\" (NASH). The ICD-10 code for NASH is \"K75.81\". The drugs being tested in this trial are \"jkb-121: 5 mg twice daily\", \"jkb-121: 10 mg twice daily\", and a placebo. \n\nThe eligibility criteria for participants in this trial are as follows:\n\nInclusion Criteria:\n1. Age \u2265 18 years\n2. Provision of written informed consent\n3. Biopsy-proven NASH within 12 months or at screening\n4. ALT > 40 U/L for women and > 60 U/L for men at screening and at least once in the previous 12 months.\n5. HBA1C of \u2264 9.0\n\nExclusion Criteria:\n1. Any chronic liver disease other than NASH\n2. Cirrhosis, as assessed clinically or histologically\n3. Presence of vascular liver disease\n4. BMI \u2264 25 kg/m2\n5. Excessive alcohol use (> 20 g/day) within the past 2 years\n6. AST or ALT > 250 U/L.\n7. Type 1 diabetes mellitus\n8. Bariatric surgery in the past 5 years.\n9. Weight gain of > 5% in past 6 months or > 10% change in past 12 months.\n10. Contraindication to MRI\n11. Inadequate venous access\n12. HIV antibody positive, hepatitis B surface antigen positive (HBsAg), or Hepatitis C virus (HCV) RNA positive.\n13. Receiving an elemental diet or parenteral nutrition\n14. Chronic pancreatitis or pancreatic insufficiency\n15. Any history of complications of cirrhosis\n16. Concurrent conditions:\n   - Inflammatory bowel disease\n   - Significant cardiac disease\n   - Chronic infection or immune-mediated disease\n   - Any malignant disease\n   - Prior solid organ transplant\n   - Any other concurrent condition which, in the opinion of the investigator, could impact adversely on the subject participating or the interpretation of the study data.\n17. Concurrent medications which may treat NASH\n18. HbA1C > 9.0%\n19. Pregnancy or breastfeeding.\n\nThis information provides details about the phase, disease, ICD-10 code, drugs, and eligibility criteria for participants in the clinical trial.",
    "The sample is a phase 2 trial for diabetes, specifically type 1 diabetes mellitus (T1DM). The trial is for individuals aged 18-45 who have been diagnosed with T1DM within the past 20 weeks. The trial aims to evaluate the effectiveness of the drugs \"nnc0114-0006\", \"liraglutide\", and a placebo. \n\nThe inclusion criteria for the trial include obtaining informed consent, having a non-fasting peak C-peptide level of 0.2 nmol/l or higher, having a body mass index (BMI) of 18.5 kg/m^2 or higher, and having one or more islet specific auto antibodies (GAD, IA2, or ZnT8). Participants must also be insulin-dependent, unless in temporary spontaneous remission.\n\nThe exclusion criteria for the trial include using more than 1 U/kg per day of insulin or continuous subcutaneous insulin infusion (CSII), having a history of recurrent or chronic infections, having a history of severe systemic fungal infection within the past 12 months, receiving vaccination within 4 weeks before randomization, and using any other medications or herbal products that can influence the immune system within 90 days prior to screening. Other exclusion criteria include a history of pancreatitis, family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary Thyroid Carcinoma (MTC), any past or current diagnosis of malignant neoplasms, and known impairment of the immune system, except for T1DM, coeliac disease, alopecia, autoimmune antibodies not considered clinically important, and vitiligo.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer that has spread to other parts of the body. The trial is testing the effectiveness of two drugs, ly3023414 and necitumumab. The eligibility criteria for participants include having confirmed squamous advanced NSCLC, having progressed on one prior line of platinum-based chemotherapy, having measurable disease, and having an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. Participants must also be able to swallow the study drugs whole and have adequate organ function. Women of childbearing potential must have a negative pregnancy test and use effective birth control measures during treatment and for 3 months after. The exclusion criteria include having received more than one prior line of chemotherapy, prior treatment with certain inhibitors, history of brain metastases, serious pre-existing medical conditions, insulin-dependent diabetes, pregnancy or breastfeeding, significant electrolyte imbalance, current treatment with warfarin sodium, recent treatment with bisphosphonates or certain targeted agents, concurrent serious infection, second primary malignancy that may affect the interpretation of results, active fungal, bacterial, or viral infection, and history of arterial or venous embolism within the past 3 months.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. The trial is evaluating the effectiveness of the drug ramucirumab. The eligibility criteria for participants include having a confirmed diagnosis of gastric or gastroesophageal junction cancer, documented disease progression after previous chemotherapy, and adequate organ function. Participants must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of 12 weeks. Exclusion criteria include having squamous cell or undifferentiated gastric cancer, receiving certain medications within 7 days prior to randomization, and having certain medical conditions such as brain metastases or uncontrolled hypertension. The sample provides detailed inclusion and exclusion criteria to ensure that eligible participants are selected for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is \"surgical site infection.\" The ICDCodes associated with this disease are \"O86.09, O86.01, O86.02, T81.49XS, O86.03, T81.41XS, T81.42XS.\" The drug being used in the trial is \"cefuroxime 4 hourly bolus.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include undergoing colorectal surgery, being over 18 years old, having an expected surgery duration of more than 2 hours, having a creatinine clearance of more than 40 ml/min, and being capable of giving informed consent. Patients undergoing colorectal surgery with additional surgeries are also included. \n\nExclusion criteria include being unable to consent, being pregnant, having an expected surgery duration of less than 2 hours, having a creatinine clearance of less than 40 ml/min, having specific microbiological advice for non-cefuroxime based prophylaxis, having a cephalosporin or penicillin allergy, being on coumarin treatment, having an active blood-borne virus infection, having a seizure history, using probenecid concurrently, participating in another research project aimed at reducing surgical site infections, receiving antibiotics for a systemic Gram-negative infection within 2 hours of surgery initiation (with some exceptions), and having a current diagnosis of a surgical site infection at the time of study entry.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in phase 2/phase 3, indicating that it is in an advanced stage of testing.\n- Diseases: The trial is focused on studying chronic hepatitis C and hepatitis C virus (HCV) infections.\n- ICD Codes: The ICD-10 codes associated with the diseases are provided.\n- Drugs: The drugs being tested in the trial are abt-493, abt-530, and ribavirin (rbv).\n- Criteria: The eligibility criteria for participants in the trial are listed, including age restrictions, previous treatment history, and specific genotype infections. The inclusion and exclusion criteria are also mentioned, such as restrictions for pregnant or breastfeeding individuals, history of drug or alcohol abuse, and co-infection with multiple HCV genotypes.\n\nOverall, this sample record provides information about a clinical trial focused on treating chronic hepatitis C and HCV infections using specific drugs, with eligibility criteria outlined for potential participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the treatment of osteoarthritis in the knee and hip. The diseases mentioned are \"osteoarthritis, knee\" and \"osteoarthritis, hip\", with corresponding ICD-10 codes. The drugs being studied are \"regn475\" and \"placebo\". \n\nThe eligibility criteria for participants in this trial include having a body mass index (BMI) of 39 or lower, a clinical diagnosis of osteoarthritis in the knee or hip, a history of inadequate pain relief or intolerance to analgesics used for osteoarthritis, moderate to severe pain in the affected joint, a history of regular use of analgesic medications for osteoarthritis pain, and a willingness to discontinue current non-steroidal anti-inflammatory drugs (NSAIDs) and opioid pain medications.\n\nExclusion criteria for participants include having other diseases that may involve the knee or hip joint, such as inflammatory joint diseases, crystalline disease (gout or pseudogout), endocrinopathies, metabolic joint disease, lupus erythematosus, rheumatoid arthritis, joint infections, neuropathic disorders, avascular necrosis, Paget's disease, renal osteodystrophy, or tumors. Other exclusion criteria include a history of osteonecrosis, destructive arthropathy, hip dislocation, pathologic fractures, neuropathic joint arthropathy, knee dislocation, or hip dislocation, recent trauma to the affected joint, active fibromyalgia or other moderate to severe pain that may confound assessments, prior recommendation or scheduled joint replacement surgery, presence of subchondral insufficiency fracture, recent intra-articular injection of hyaluronic acid, recent systemic or intra-articular corticosteroid use, history of autonomic neuropathy or clinically relevant peripheral neuropathy, positive pregnancy test or unknown pregnancy status, and being pregnant or breastfeeding.\n\nThis information provides an overview of the trial phase, diseases being studied, drugs involved, and the criteria for participant eligibility and exclusion.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is ulcerative colitis. The icd-10 codes associated with this disease are K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, and K51.811. The drugs being studied in this trial are etrasimod and placebo. The eligibility criteria for inclusion and exclusion are also provided in the sample.",
    "The sample from the table is for a phase 2 trial. The disease being studied is gastric adenocarcinoma. The ICD-10 codes associated with this disease are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drug being tested is a combination of docetaxel and selumetinib. The eligibility criteria for the trial include providing informed consent, being at least 20 years old, having advanced gastric adenocarcinoma that has progressed after first-line therapy, having a previous adjuvant/neoadjuvant chemotherapy completed more than 6 months prior to starting the first-line therapy, providing a tumor sample, having MEK signature, RAS mutation, or amplification through the VIKTORY trial, being willing and able to comply with the study protocol, having an ECOG performance status of 0-1, having a life expectancy of at least 3 months, having acceptable bone marrow, liver, and renal function, having at least one measurable lesion, having a negative pregnancy test for women of childbearing potential, and providing consent for a mandatory biopsy at progression. The exclusion criteria include having more than one prior chemotherapy regimen (except for adjuvant/neoadjuvant chemotherapy with a more than 6-month washout period), previous treatment with MEK, RAS, or RAF inhibitors, previous treatment with docetaxel, having a second primary cancer (except for certain cases), being HER2 positive, being unable to swallow orally administered medication, recent treatment with investigational products, recent systemic chemotherapy or radiotherapy, concomitant use of certain CYP3A4 inhibitors, ongoing toxicities caused by previous cancer therapy, intestinal obstruction or upper GI bleeding, abnormal resting ECG or family history of long QT syndrome, certain cardiac problems, certain ophthalmological conditions, being pregnant or not using effective contraception, and having severe or uncontrolled systemic disease, active infection, active bleeding diatheses, or renal transplant, including hepatitis B, hepatitis C, or HIV.",
    "The sample is a phase 2 trial for metastatic colorectal cancer. The eligibility criteria include being 18 years or older, having progressed after receiving 2-3 prior standard of care treatments, having a life expectancy of more than 3 months, and having a weight between 40 kg and 180 kg. Other criteria include having a confirmed diagnosis of CRC, having metastatic CRC that is not amenable to surgical resection, and having known KRAS and NRAS mutation status. The sample also includes criteria related to measurable lesions, performance status, hematological function, renal function, liver function, venous access, and contraception for both male and female subjects. The exclusion criteria include central nervous system metastases, prior malignancies within the past 3 years (with some exceptions), prior treatment with panitumumab, residual adverse events from previous treatment, and various other medical conditions and factors that may impede participation in the study.",
    "The sample is from a table that contains information about clinical trials. In this specific sample, the trial is in phase 2 and focuses on chronic obstructive pulmonary disease (COPD). The ICD-10 codes associated with COPD are provided. The trial involves two drugs, namely \"qbw251\" and \"placebo\". The eligibility criteria for participants are also listed, including requirements such as having a diagnosis of GOLD II-III COPD, a clinical diagnosis of chronic bronchitis, and a smoking history. There are also exclusion criteria, such as not receiving chronic, daily, systemic steroids and not having severe emphysema. Other specific inclusion/exclusion criteria may also apply.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in phase 2/phase 3.\n- Diseases: The trial is focused on soft tissue sarcoma.\n- ICD Codes: The ICD-10 code for soft tissue sarcoma is C46.1.\n- Drugs: The trial involves the drugs anlotinib and placebo.\n- Criteria: The eligibility criteria for participants in the trial are listed.\n\nThe inclusion criteria include:\n- Signed and dated informed consent.\n- Histological documentation of soft tissue sarcoma, with specific subtypes mentioned.\n- Previous failure of chemotherapy regimens within the past 6 months (except for alveolar soft part sarcoma).\n- Age between 18 and 70 years, with an ECOG performance status of 0-1 and a life expectancy of more than 3 months.\n- Normal function of main organs.\n- Female patients of childbearing age must agree to use contraceptive methods during the trial and for 6 months after it. They should not be lactating and should have a negative pregnancy test. Male patients must also agree to use contraceptive methods during the trial and for 6 months after it.\n\nThe exclusion criteria include:\n- Prior treatment with anlotinib.\n- Presence of pleural effusion or ascites causing respiratory syndrome.\n- Previous treatment with vascular endothelial growth inhibitor class targeted drugs.\n- Planned systemic anti-tumor therapy within 4 weeks before or during the trial, including cytotoxic therapy, signal transduction inhibitors, and immunotherapy. Patients who have used mitomycin C within 6 weeks before the experimental drug treatment are also excluded. Patients who have undergone extended field radiotherapy (EF-RT) within 4 weeks before the trial or limited field radiotherapy with proposed assessment of the nidus within 2 weeks before the trial are also excluded.\n- Uncontrolled symptoms of brain metastases for less than 2 months.\n- Presence of severe and uncontrolled diseases.\n- Occurrence of venous thromboembolic events within 6 months.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of advanced gastric adenocarcinoma. The trial includes patients who have progressed during or after first-line therapy, which must have included a doublet 5-fluoropyrimidine and platinum-based regimen. Patients who have relapsed within 6 months of completing adjuvant/neoadjuvant chemotherapy with the same regimen can also be considered for the trial. \n\nThe eligibility criteria for the trial include providing informed consent, being at least 20 years old, having a tumor sample available, having a negative biomarker status, and having an Eastern Cooperative Oncology Group performance status of 0-1. Patients must also have a life expectancy of at least 3 months and meet certain criteria for bone marrow, liver, and renal function. Additionally, patients must have at least one measurable lesion that can be assessed, and they must have a negative pregnancy test.\n\nThe exclusion criteria for the trial include having received more than one prior chemotherapy regimen for advanced gastric cancer, previous treatment with specific inhibitors or agents, previous treatment with paclitaxel, having certain types of second primary cancer, being HER2 positive, being unable to swallow oral medication, and having received any investigational drug within a certain timeframe. Other exclusion criteria include recent major surgery, exposure to certain inhibitors or inducers, ongoing toxicities from previous cancer therapy, intestinal obstruction or upper GI bleeding, certain cardiac problems, active or untreated brain metastases or spinal cord compression, being pregnant or breastfeeding, and having severe or uncontrolled systemic disease or infections.\n\nIt is also noted that patients with proteinuria (3+ on dipstick analysis) are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with stage IV non-small cell lung cancer. The trial is testing the effectiveness of the drugs abemaciclib and docetaxel. The eligibility criteria for inclusion in the trial include having a confirmed diagnosis of stage IV NSCLC, having progressed during or after platinum-based chemotherapy, not having received prior treatment with docetaxel, having availability of adequate tumor material, having adequate organ function, having a good performance score, having measurable disease, and agreeing to use a reliable method of birth control. The exclusion criteria include having received prior treatment with any CDK 4 and 6 inhibitor, currently participating in another clinical trial with an investigational product or non-approved use of a drug or device, having unstable central nervous system metastasis, and having had major surgery within 28 days of the initial dose of the study drug.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is non-small-cell lung cancer. The ICD-10 codes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested is ldk378. \n\nThe eligibility criteria for this trial include having a confirmed diagnosis of Stage IIIb or IV NSCLC with an ALK rearrangement, progression of the disease at the time of enrollment, previous treatment with alectinib or a combination of alectinib and crizotinib, being chemotherapy-na\u00efve or having received only one line of prior cytotoxic chemotherapy, and being 18 years or older.\n\nThe exclusion criteria include hypersensitivity to any excipients of ldk378, prior therapy with other ALK inhibitor investigational agents except crizotinib and alectinib, prior systemic anti-cancer therapy aside from alectinib, crizotinib, and one regimen of previous cytotoxic chemotherapy, symptomatic central nervous system metastases with neurological instability or increasing doses of steroids within the 2 weeks prior to study entry, history of interstitial lung disease or interstitial pneumonitis, history of carcinomatous meningitis, concurrent malignancy or history of a malignant disease other than NSCLC within the past 3 years, and clinically significant, uncontrolled heart disease and/or recent cardiac event within the past 6 months.",
    "The sample is a phase 2/phase 3 trial that focuses on the treatment of pain and postoperative depression. The trial involves the use of the drug ketamine. The eligibility criteria for participants include being adults between the ages of 18 and 65 who are undergoing gastric bypass or sleeve gastrectomy. They should not be pregnant or breastfeeding, and should be in good medical condition. Exclusion criteria include being under 18 or over 65 years old, having cognitive impairment or altered mental status, a history of misuse or abuse of ketamine, chest pain in the PACU, recent use of medication that interferes with ketamine metabolism, a diagnosis of schizophrenia or chronic antipsychotic medication use, history of head trauma, intracranial mass or hemorrhage, stroke, cardiac arrhythmia, contraindications to ketamine, or unwillingness to give informed consent.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on several diseases, including lung non-squamous non-small cell carcinoma, radiation-induced pneumonitis, and various stages of lung non-small cell cancer. The diseases are associated with specific ICD-10 codes. The trial involves the use of the drug nintedanib. \n\nThe eligibility criteria for the trial are listed, including requirements such as histologically or cytologically-proven non-squamous cell NSCLC, a complete or partial response to radiation therapy, and specific blood count and liver function requirements. The criteria also include exclusions, such as recent whole-brain radiotherapy, squamous cell NSCLC, and active untreated brain or leptomeningeal metastases.\n\nOverall, the sample provides information about the phase, diseases, ICD-10 codes, drug, and eligibility criteria for a specific clinical trial.",
    "The sample is a phase 2 trial for patients with heart failure. The trial is specifically targeting clinically stable patients with left-ventricular dysfunction (LVEF \u2264 45%) after a myocardial infraction that occurred 6 or more months before randomization. The patients should be in New York Heart Association (NYHA) class I-II and have a left-ventricular ejection fraction \u2264 45%, confirmed by any imaging technique within the last 3 months prior to the screening visit.\n\nThe patients should also be on evidence-based therapy for left-ventricular dysfunction post myocardial infraction for at least 4 weeks prior to the screening visit, including an Angiotensin-converting enzyme (ACE) inhibitor or an Angiotensin receptor blockers (ARB). Other medications such as beta-blockers, diuretics, mineralocorticoid receptor antagonist (MRAs), antiplatelet therapy, statins, and aspirin should also be used if indicated. The patients should not have any planned changes to their post myocardial infraction drug therapy during the active treatment phase of the study.\n\nThe inclusion criteria also specify that the participants should be men or confirmed postmenopausal women or women without childbearing potential. Men of reproductive potential should agree to use two reliable and acceptable methods of contraception simultaneously when sexually active and not act as sperm donors.\n\nThe age range for the participants is 40 to 79 years, and they should be of Caucasian race.\n\nThe exclusion criteria include patients with non-ischemic causes for cardiomyopathy, hospitalization for decompensated heart failure within the last 3 months, recent coronary revascularization or anticipated need for revascularization during the study, clinically relevant cardiac ischemia in a stress test within 3 months before screening, and patients carrying certain implantable devices that had significant clinical events requiring treatment or changes to background medical therapy.\n\nOther exclusion criteria include primary and uncorrected valvular disease with a foreseen requirement of valve repair within the next 6 months, recent stroke or acute coronary syndrome, clinically relevant hepatic dysfunction, and systolic blood pressure below 100 or above 160 mm Hg at the screening visit.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of prostatic neoplasms (prostate cancer). The trial includes patients with metastatic disease who have shown progressive disease while receiving hormonal therapy or after surgical castration. The eligibility criteria for the trial are listed, including the requirement of histologically- or cytologically-confirmed prostate adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status of less than 2, and the ability to fill out a quality of life questionnaire. The sample also includes exclusion criteria, such as prior chemotherapy for prostate cancer (except estramustine), prior treatment with abiraterone acetate and/or enzalutamide, and inadequate organ and bone marrow function. The sample provides detailed information about the inclusion and exclusion criteria for the trial, as well as other important information for potential participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on studying the effects of certain drugs on patients with metabolism and nutrition disorders and obesity. The diseases are described using both their names and their corresponding ICD-10 codes. The drugs being tested in this trial are semaglutide, liraglutide, and a placebo. \n\nThe eligibility criteria for participants in this trial are as follows: \n- Participants must provide informed consent before any trial-related activities.\n- Both males and females who are 18 years or older at the time of signing the informed consent are eligible.\n- Participants must have a body mass index (BMI) equal to or above 30.0 kg/m^2 at the screening visit.\n- Participants must have had at least one unsuccessful weight loss attempt, as determined by the investigator.\n\nThere are also exclusion criteria for this trial, which include:\n- Participants with a HbA1c (glycosylated hemoglobin) equal to or above 6.5% at screening or diagnosed with type 1 or type 2 diabetes mellitus.\n- Participants who have been treated with glucose lowering agents within 90 days before screening.\n- Participants with a screening calcitonin equal to or above 50 ng/L (pg/mL).\n- Participants with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.\n- Participants with a history of pancreatitis (acute or chronic).\n- Participants with obesity induced by endocrine disorders (e.g. Cushing Syndrome).\n- Participants who have been treated with any medication within 90 days before screening that, according to the investigator's judgement, may cause significant weight change.\n- Participants who have undergone previous surgical treatment for obesity, except for liposuction and/or abdominoplasty performed 1 year before screening.\n- Participants with a history of major depressive disorder within 2 years before randomization.\n- Participants with any lifetime history of a suicidal attempt.\n- Female participants who are pregnant, breastfeeding, intend to become pregnant, or are of childbearing potential and not using an adequate contraceptive method as required by local regulation or practice.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is lymphoma, specifically mantle-cell lymphoma. The ICDCodes associated with this disease are \"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", and \"S33.131S\". The drug being used in the trial is copanlisib (bay80-6946). \n\nThe eligibility criteria for this trial include the following:\n- Patients must have histologically confirmed mantle-cell lymphoma.\n- Patients must have previously received treatment with ibrutinib, either completing at least 1 cycle of treatment with evidence of disease progression or refractoriness, or discontinuing ibrutinib due to toxicity.\n- Measurable disease according to the Lugano Classification is required.\n- There must be a minimum of 28 days or 5 half-lives from the completion of previous anti-cancer treatment to the start of study treatment, excluding ibrutinib where the window may be less and at minimum 3 days.\n- Fresh tumor tissue must be available at screening.\n- Patients must be 18 years or older.\n- ECOG performance status must be \u2264 2.\n- Left ventricular ejection fraction (LVEF) must be \u2265 the lower limit of normal (LLN) for the Institution.\n- Adequate bone marrow, liver, and renal function are required.\n\nThe exclusion criteria for this trial include the following:\n- Palpable lymph nodes not visible on imaging studies, skin lesions, or bone marrow involvement as the only site(s) of disease.\n- Current central nervous system (CNS) involvement by lymphoma.\n- New York Heart Association (NYHA) class III or IV heart disease.\n- Unstable angina or myocardial infraction within the last 6 months.\n- Uncontrolled arterial hypertension despite optimal medical management.\n- Type I or II diabetes mellitus with HbA1c > 8.5% at screening.\n- Arterial or venous thrombotic or embolic events within 3 months before the start of study treatment, unless the patient has recovered to ECOG performance status of \u2264 2.\n- Ongoing or active infection of Common Terminology Criteria for Adverse Events (CTCAE) Grade \u2265 3.\n- Known history of HIV infection.\n- Acute or chronic hepatitis B (HBV) or hepatitis C (HCV) infection requiring concomitant treatment prohibited by this protocol.\n- History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function.\n- Prior treatment with PI3K inhibitor(s).\n- Cytomegalovirus (CMV) PCR positive at baseline.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on two diseases, namely \"ocular pain\" and \"dry eye syndrome\". The corresponding ICD-10 codes for these diseases are \"H57.13\", \"H57.10\", \"H57.11\", \"H57.12\" for ocular pain, and \"H04.121\", \"H04.122\", \"H04.123\", \"H04.129\" for dry eye syndrome. The drugs being tested in this trial are \"syl1001\" and \"placebo\". \n\nThe inclusion criteria for participants in this trial include giving written informed consent, experiencing persistent, daily, mild to moderate dry eye for more than three months (measured using the OSDI scale between 13-70 and WAS scale between 2-7), and specific eye test results such as corneal fluorescein staining (Oxford scale > 0), tear break-up time < 10 seconds, and Schirmer's test with anesthesia < 10 mm/5min.\n\nOn the other hand, the exclusion criteria for participants include being pregnant or breastfeeding, having certain diseases or conditions (respiratory, cardiovascular, endocrine, neurological, hematological, kidney, oncological, liver, gastrointestinal dysfunction, hypertension, or active acute infectious processes), having previous chronic or recurrent conditions that may affect the study, using other medications with analgesic activity, recent changes in eye or systemic medication, changes in the administration schedule of artificial tears, recent initiation or changes in cyclosporine treatment, history of hypersensitivity to drugs, use of contact lenses during treatment, history of drug abuse or dependence, clinically significant laboratory abnormalities, previous refractive surgery, participation in another clinical trial within the past 2 months, and having another significant eye disease according to the investigator's opinion.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 2 and is focused on the disease called cholangiocarcinoma. The ICD-10 codes associated with this disease are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']. The drug being tested in this trial is folfirinox. \n\nThe eligibility criteria for this trial include a histological or cytological diagnosis of cholangiocarcinoma, metastatic disease or irresectable locally advanced cholangiocarcinoma, measurable disease according to RECIST criteria version 1.1, age between 18 and 75 years, WHO/ECOG performance status of 0-2, previous treatment with at least 3 cycles of gemcitabine/cisplatin in the first line, adequate hematological, hepatic, and renal function, absence of cardiac insufficiency or recent myocardial infraction, and signed informed consent.\n\nThe exclusion criteria for this trial include concurrent secondary malignancies within the past 3 years (with exceptions), presence of cerebral or meningeal metastases, contraindication to the planned treatment, history of chronic diarrhea or colorectal inflammatory conditions, active infection or other serious underlying conditions, presence of cardiac insufficiency or other cardiac conditions, inclusion in another investigational clinical trial, pregnancy or breastfeeding, age younger than 18 or older than 76 years, and individuals under correctional supervision or guardianship.",
    "The sample is a phase 2 trial for major depressive disorder (MDD). The trial is testing the effectiveness of the drug CERC-301 compared to a placebo. The eligibility criteria for participants include a diagnosis of MDD without psychotic features, a history of at least two major depressive episodes, and a failure to respond to previous antidepressant treatments. Exclusion criteria include a duration of the current depressive episode of two years or more, use of certain medications within 30 days of screening, and a history of certain psychiatric disorders. The sample also includes various medical and health-related exclusion criteria, such as excessive alcohol use, substance use disorders, and certain comorbid diseases.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of type 1 diabetes mellitus. The trial includes participants who have been diagnosed with type 1 diabetes mellitus at least 1 year prior to giving their informed consent. These participants are currently being treated with insulin or insulin analog delivered via continuous subcutaneous insulin infusion (CSII) or multiple daily injection (MDI). The inclusion criteria also specify that the participants' A1C levels should be between 7.0% and 10.0% at the screening visit. Female participants of childbearing potential need to use adequate contraception and have a negative pregnancy test. \n\nOn the other hand, the exclusion criteria state that participants should not be using any antidiabetic agent other than insulin or insulin analog at the time of screening. They should not have used sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to screening, and they should not be on chronic systemic corticosteroid use. Additionally, participants with type 2 diabetes mellitus (T2DM) or severely uncontrolled T1D, as determined by the Investigator, are excluded from the trial.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is chronic graft versus host disease. The ICD-10 codes associated with this disease are D89.811 and D89.812. The drug being tested is ponesimod. \n\nThe sample also includes the eligibility criteria for the trial. The inclusion criteria state that patients must have signed informed consent, be symptomatic with moderate or severe chronic GVHD and in need of a change in systemic immunosuppressant therapy. Women of childbearing potential must have a negative pregnancy test and use reliable contraception.\n\nThe exclusion criteria state that patients with clinically significant medical conditions, such as active or uncontrolled infections, new or recurrent malignancy, serious cardiac, pulmonary, or renal disease, and uncontrolled diabetes, are not eligible. Patients with a Karnofsky Performance Score less than 60 are also excluded. Other exclusion criteria include the use of immunosuppressant therapies other than allowed background therapy, anti-arrhythmic and heart rate lowering drugs, and any other circumstances or conditions that may affect full participation in the study or compliance with the protocol.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on diabetes. The diseases associated with the trial are \"diabetes\" and \"diabetes mellitus, type 2\". The corresponding ICD-10 codes for these diseases are provided as well. The drugs being studied in the trial are \"semaglutide\", \"liraglutide\", and a placebo. The eligibility criteria for the trial are listed, including age requirements, stable diabetes treatment, specific HbA1c and BMI ranges, and exclusion criteria such as simultaneous participation in other trials, pregnancy or intent to become pregnant, certain medical conditions, and recent cardiovascular events.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on pancreatic cancer. The ICD-10 code for pancreatic cancer is C25.3. The drug being used in the trial is gemcitabine. The eligibility criteria for participants in the trial are listed, including age requirements, confirmation of pancreatic adenocarcinoma, negative margins from surgery, specific lab test results, good heart and lung function, negative pregnancy test for females of child-bearing potential, and ability to adhere to the study requirements. The exclusion criteria are also listed, which include positive resections, other types of pancreatic cancer, severe complications, severe bone marrow suppression, history of severe lung or liver diseases, severe heart diseases, long-term steroid use, early recurrence of pancreatic cancer, diarrhea and infection, recent enrollment in another clinical study, pregnancy or nursing, presence of other malignancies, significant medical conditions or psychiatric illness, and any condition that may confound the interpretation of data from the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of schizophrenia and schizoaffective disorder. The diseases are represented by their names and corresponding ICD-10 codes. The trial involves the use of several antipsychotic drugs, including aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone.\n\nThe eligibility criteria for participants are listed, including a diagnosis of schizophrenia or schizoaffective disorder based on the DSM-5, recent medication treatment modification, and current use of specific antipsychotic medications. The criteria also mention the absence of significant suicidal behavior or ideation, overall good health, and stable medical conditions.\n\nOn the other hand, the exclusion criteria state that participants who have been attending the outpatient psychiatric clinic for more than 12 months since their last psychiatric hospitalization, those with active alcohol or substance use disorder, and those with clinically significant medical illnesses unrelated to the indication for antipsychotic therapy are not eligible. Participants receiving clozapine or who have recently donated blood or had substantial blood loss are also excluded.\n\nOverall, this sample provides specific details about the phase, diseases, ICDCodes, drugs, and eligibility criteria for participants in a clinical trial focused on schizophrenia and schizoaffective disorder.",
    "The sample is a phase 2 trial for patients with cirrhosis presumably due to nonalcoholic steatohepatitis (NASH). The trial aims to evaluate the effectiveness of the drug GR-MD-02 compared to a placebo. The eligibility criteria for participants include having a HVPG measurement of at least 6 mm Hg, a liver biopsy showing cirrhosis due to NASH, being between 18 and 75 years old, and not having hepatocellular carcinoma. Other criteria include providing written informed consent, not being pregnant or lactating, using effective contraception, and having stable doses of certain medications. Exclusion criteria include a history of hepatic decompensation, presence of medium or large varices or varices with red signs, prior transjugular porto systemic shunt procedure, and evidence of other forms of chronic liver disease. Other exclusion criteria include abnormal laboratory values, high MELD score or Child Turcotte Pugh Class B or C, low creatinine clearance, inability to undergo HVPG or liver biopsy, HIV infection, recent major surgery or trauma, history of solid organ transplant, recent use of nonselective \u03b2 adrenergic inhibitors, planned variceal ligation therapy, recent weight reduction surgery, significant alcohol consumption, positive urine screen for certain substances, uncontrolled cardiovascular disease, history of significant medical or psychiatric conditions, and known allergies to the drug. The sample also excludes individuals who have previously received GR-MD-02 within 6 months or have a relationship with the investigator or study center personnel.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of type 1 diabetes mellitus. The trial includes patients between the ages of 8 and 17 who were diagnosed with type 1 diabetes within the previous 100 days. The trial requires informed consent from the patients and their parents or legal guardians. The inclusion criteria also include specific fasting C-peptide levels, positive GADA (glutamic acid decarboxylase autoantibodies) but less than 50,000 Units, immunity against Varicella, and adherence to the Swedish vaccination program.\n\nFemale participants must agree to avoid pregnancy and have a negative urine pregnancy test. Patients of childbearing potential must use adequate contraception until 1 year after the last administration of GAD-alum and etanercept. Adequate contraception methods for females include oral contraceptives (except low-dose gestagen), intrauterine devices, and intrauterine systems. For males of childbearing potential, condoms are considered adequate contraception.\n\nThe exclusion criteria for the trial include previous or current treatment with immunosuppressant therapy, continuous treatment with anti-inflammatory drugs, treatment with any oral or injected anti-diabetic medications other than insulin, treatment with Vitamin D, a history of hypercalcemia or abnormal hematological results, and various other medical conditions and history that may make the patient ineligible for the study.\n\nOverall, the sample provides information about the phase, diseases being studied, ICDCodes, drugs being used, and the eligibility criteria for the clinical trial.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is insomnia, and the corresponding ICD-10 codes for insomnia are ['F51.01', 'F51.02', 'F51.03', 'F51.04', 'G47.00', 'G47.09', 'A81.83']. The drugs being tested in the trial are 'jnj-42847922' and 'placebo'. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Participants must be healthy males and females between the ages of 18 and 65.\n- Participants must have a body mass index (BMI) between 18 and 30 kg/m^2.\n- Participants must have an Insomnia Severity Index (ISI) score of 15 or higher at screening.\n- Participants must report difficulties with both sleep onset and sleep maintenance.\n- Objective confirmation of insomnia will be established through polysomnography (PSG) recorded over 3 consecutive nights. Participants will sleep in a sleep center for 3 nights, and the data from the second and third nights will be used to determine eligibility criteria.\n- Participants must meet specific objective inclusion criteria based on PSG data, including a mean latency to persistent sleep (LPS) of 30 minutes or more, total sleep time (TST) of 6 hours or less, and wake after sleep onset (WASO) of more than 30 minutes.\n- Participants must be medically stable based on clinical laboratory tests, medical history, vital signs, and electrocardiogram (ECG) results.\n\nThe exclusion criteria for participants in the trial are as follows:\n- Participants with current signs/symptoms of liver or renal insufficiency, hypothyroidism or hyperthyroidism, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, or metabolic disturbances. However, participants with non-insulin dependent diabetes mellitus who are adequately controlled may still participate.\n- Participants with a history of epilepsy, fits, or unexplained blackouts.\n- Participants with clinically significant abnormal values for hematology, clinical chemistry, or urinalysis.\n- Participants with clinically significant abnormal physical and neurological examination, vital signs, or ECG results.\n- Participants who smoke 10 or more cigarettes per day.\n- Participants with insomnia related to restless leg syndrome, sleep breathing disorder, narcolepsy, obstructive sleep apnea/hypopnea, central sleep apnea, sleep-related hypoventilation, circadian rhythm sleep-wake disorders, substance/medication-induced sleep disorder, or parasomnias.\n- Participants who work night shifts or have significantly shifted diurnal activity patterns.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is \"diffuse cutaneous systemic sclerosis\". The corresponding ICD-10 codes for this disease are ['A06.7', 'A22.0', 'A26.0', 'A32.0', 'A36.3', 'A43.1', 'B38.3']. The drugs being tested in this trial are 'jbt-101', 'placebo', and 'part b open-label extension'. The eligibility criteria for this trial include specific requirements related to the disease, disease duration, previous treatment, and laboratory test results. There are also exclusion criteria that specify conditions or factors that would disqualify a subject from participating in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of cystic fibrosis. The trial is testing a drug called jbt-101 (lenabasum). The eligibility criteria for participants include having a documented diagnosis of cystic fibrosis, with specific clinical features and genetic mutations. Participants must also have a forced expiratory volume in one second (FEV1) of at least 40% predicted corrected and have stable CF treatment for 14 days prior to the trial. \n\nExclusion criteria include having severe or unstable CF, recent intravenous antibiotic or corticosteroid treatment, and certain abnormal laboratory test results. These include low hemoglobin, neutrophils, and platelets, as well as impaired kidney function, elevated liver enzymes, and high bilirubin levels. Additionally, any other clinically significant condition that may pose a safety risk or interfere with the study assessments may exclude a participant from the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on colorectal neoplasms. The ICD-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being studied is regorafenib, also known as Stivarga or Bay73-4506. The record includes the eligibility criteria for participants, including age, confirmation of adenocarcinoma, previous treatment history, measurable disease, performance status, and adequate organ function. It also lists the exclusion criteria, such as prior treatment with an antiangiogenic agent, heart conditions, hypertension, infections, and other medical conditions. The record specifies that participants must not have a history of brain metastases, other concurrent cancers, or certain medical conditions. It also states that participants must not be pregnant or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"systemic lupus erythematosus\". The associated ICD-10 codes for this disease are ['M32.9', 'M32.0', 'M32.11', 'M32.12', 'M32.13', 'M32.14', 'M32.8']. The trial involves two drugs, \"hril-2 active\" and \"hril-2 placebo\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include meeting the American College of Rheumatology criteria for SLE diagnosis, being under standard treatment for at least 2 months, having failed background treatment, and exhibiting specific manifestations and laboratory test results. Exclusion criteria include severe chronic organ dysfunction, serious infections, recent cancer history, high-dose steroid therapy, previous administration of rituximab or other biologics, positive tuberculin test, mental disorders or chronic illnesses that may interfere with the trial, and inability to comply with IL-2 treatment regimen.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"leiomyoma,\" which is a type of uterine fibroid. The ICD-10 codes associated with this disease are \"D25.0,\" \"D25.1,\" \"D25.2,\" and \"D25.9.\" The drugs being studied in this trial are \"vilaprisan (bay1002670)\" and \"ulipristal.\" \n\nThe eligibility criteria for participants in this trial include being women between the ages of 18 and 50, having a diagnosis of uterine fibroids with at least one fibroid measuring 3.0 cm or larger, experiencing heavy menstrual bleeding (HMB) of more than 80 mL, being in good general health, having a normal or clinically insignificant cervical smear, and having a normal endometrial biopsy. Participants must also use an acceptable nonhormonal method of contraception during the study.\n\nExclusion criteria for this trial include pregnancy or lactation, having a uterine fibroid with a diameter larger than 10.0 cm, hypersensitivity to any of the study drugs, low hemoglobin levels, any conditions that could affect the absorption or metabolism of the study drug, any conditions that could interfere with the study or interpretation of results, substance abuse, use of other treatments that could interfere with the study, and undiagnosed abnormal genital bleeding.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which includes the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is listed as \"phase 1/phase 2\". The diseases being studied are \"clinical efficacy\" and \"safety\". The corresponding ICD-10 codes for these diseases are listed as \"['Z71.85', 'Y38.4X1S', 'Y38.9X1S', 'Y38.4X1A', 'Y38.4X1D', 'Y38.5X1S', 'Y38.6X1S']\". The drug being tested is \"adcetris-levact\". The eligibility criteria for the trial are then listed, including specific requirements for patients with advanced classical Hodgkin Lymphoma, age range, previous treatment history, organ function, contraception, informed consent, and affiliation with a health insurance system. The exclusion criteria are also provided, which include age restrictions, previous or concurrent malignancies, specific medical conditions, recent surgeries or infections, hypersensitivity, psychiatric conditions, and cardiovascular conditions.\n\nOverall, this sample provides a detailed description of the phase, diseases, drugs, and eligibility/exclusion criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"influenza\". The ICD-10 codes associated with this disease are \"J11.81\", \"J11.82\", \"J10.01\", \"J10.81\", \"J10.82\", \"J11.08\", and \"J11.2\". The drugs being studied in this trial are \"vis410\" and \"placebo\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being a male or female between the ages of 18-45, with specific requirements for women of childbearing potential. Women must either be post-menopausal, surgically sterile, using adequate contraception, or sexually inactive by abstinence. Women of childbearing potential must also have a negative pregnancy test. Non-vasectomized males must use effective birth control. Participants must also be seronegative for the challenge virus.\n\nExclusion criteria include known or suspected intolerance or hypersensitivity to the study drug or virus, presence of medical conditions that would render the study drug unsafe or interfere with evaluation, use of medications that affect the immune system, and history of certain respiratory conditions. Other exclusion criteria include recent vaccinations, confirmed diagnosis of influenza A, abnormal nasal structure, lung disease, history of alcohol or drug abuse, positive HIV or hepatitis screening, recent cancer treatment, immunosuppression, and other factors that the investigator deems unfit for the study.\n\nOverall, this sample provides a snapshot of the phase 2 trial focusing on influenza, including the diseases, drugs, and eligibility criteria involved.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is dry eye. The ICDCodes associated with this disease are H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, and H35.3121. The drug being used in the trial is dexamethasone. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- The participant must have a known history of dry eye disease.\n- The participant must have a minimal Corneal Fluorescein Staining Score and OSDI score in each eye.\n\nExclusion Criteria:\n- The participant must not have a history of intraocular inflammation in either eye.\n- The participant must not be using anti-inflammatory or immunomodulating agents, either ocular or systemic, for the duration of the study.\n- The participant must not have uncontrolled glaucoma or be on medications to treat glaucoma.\n- The participant must not have a history of IOP spikes in either eye.\n- The participant must not have active epiphora.",
    "The sample from the table represents a phase 2 trial for the treatment of virus diseases. The diseases are specified using ICD-10 codes. The drugs being tested in the trial include \"gsk1325756 (danirixin)\", \"placebo to match gsk1325756\", \"oseltamivir phosphate\", and \"placebo to match oseltamivir phosphate\". The eligibility criteria for participants include being between 18 and 64 years old, having onset of influenza-like illness symptoms within 48 hours prior to enrollment, having a positive influenza rapid antigen test, and meeting certain weight and BMI requirements. There are also specific criteria for male and female participants regarding contraception. The exclusion criteria include being at high risk of complications from influenza infection, having certain chronic diseases or conditions, requiring in-hospital care, having low pulse oximetry levels, having complications of respiratory tract infection, being pregnant or breastfeeding, having liver disease or abnormalities, having certain cardiac conditions, and using certain medications.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are non-small cell lung cancer, lung cancer, metastatic lung cancer, and NSCLC. The corresponding ICDCodes for these diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being used in the trial is nivolumab and ablation. \n\nThe eligibility criteria for this trial include the following:\n- Pathologically or cytologically confirmed NSCLC\n- Stage IIIB or stage IV\n- Progression after at least 1 line of systemic treatment for metastatic or locally advanced disease, or patients progressing within 6 months of completion of neoadjuvant or adjuvant chemotherapy\n- Ablation for advanced lung cancer is being considered by the treating physician for treatment or prevention of symptoms\n- At least 1 site of measurable disease that will not be treated with ablation\n- At least 3 weeks since prior chemotherapy and radiation therapy\n- No brain metastases, except for patients whose metastases have been removed or treated with stereotactic radiation or gamma knife\n- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n- Life expectancy of at least 12 weeks\n- Required entry laboratory parameters within 14 days of study entry\n- Age > 18 years\n- Men and women of childbearing potential must agree to use adequate barrier birth control measures\n- Written informed consent\n\nThe exclusion criteria for this trial include:\n- Patients with a history of clinically significant chronic autoimmune disease\n- Prior therapy with antibodies that modulate T-cell function\n- Conditions currently requiring immunosuppressive medications\n- Known history of HIV or hepatitis B or C\n- Bleeding diathesis or coagulopathy that would prevent ablation from being safely performed\n- Patients with unstable angina or recent myocardial infraction\n- History of organ allograft\n- Pregnant or breastfeeding.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on diabetes, specifically type 2 diabetes mellitus. The ICD-10 codes associated with the diseases are provided. The trial involves the use of drugs such as insulin 338 (gipet i), insulin glargine, and a placebo. The eligibility criteria for participants are also listed, including age, body mass index, duration of diabetes diagnosis, and previous insulin treatment. The exclusion criteria mention hypersensitivity to trial products, any disorder that may jeopardize safety or compliance, and gastrointestinal disorders that could affect drug absorption.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is Alzheimer's Disease, which is represented by the disease name and its corresponding ICD-10 codes. The drugs being used in the trial are \"orm-12741\" and \"placebo\". The sample also includes the eligibility criteria for participants in the trial, including age range, diagnosis of probable Alzheimer's Disease, brain imaging consistent with the disease, and specific scores on cognitive and agitation assessments. It also lists exclusion criteria, such as certain medication usage, cardiac conditions, history of malignancy, and abnormal test results. Additionally, it states that participants should not reside in a skilled nursing facility.",
    "The sample provided is for a phase 2 clinical trial. The trial is focused on studying the effects of a drug called ads-5102 on patients with walking impairment due to multiple sclerosis. The eligibility criteria for participants include being between 18 and 70 years old, having a confirmed diagnosis of multiple sclerosis according to the 2010 Revised McDonald criteria, being on a stable regimen of medications for at least 30 days prior to screening, having a maximum EDSS score of 6.5, and having sufficient ambulatory ability to complete the Timed 25 Foot Walk (T25FW) test. The inclusion criteria also specify certain time ranges for completing the T25FW test and stable doses of other medications. The exclusion criteria include a history of seizures or clinically significant MS relapse within 30 days prior to screening, presence of vertigo or vestibular dysfunction, recent physical therapy or systemic steroid use, recent use of specific medications for fatigue or walking improvement, recent use of botulinum toxin, history of hallucinations or certain mental health conditions, cognitive impairment, history of stroke or cancer within specific time frames, untreated angle closure glaucoma, pregnancy or lactation in females, and recent participation in other clinical trials or planned elective surgery during the study.",
    "The sample is a phase 2 clinical trial for the treatment of mantle cell lymphoma. The trial is evaluating the effectiveness of two drugs, abt-199 and ibrutinib. The eligibility criteria for participants include being at least 18 years old, having a confirmed diagnosis of mantle cell lymphoma, having received prior systemic therapy for the disease, and having radiographically assessable disease. Other criteria include having a performance score of 2 or lower, adequate bone marrow function, adequate coagulation, renal, and hepatic function, and the ability to swallow whole tablets. Female participants of childbearing potential and non-sterile male participants must use contraception during the study. Exclusion criteria include recent stem cell transplant, active autoimmune cytopenias, central nervous system involvement by MCL, previous participation in an ibrutinib clinical trial, recent monoclonal antibody therapy, recent anti-cancer therapy or investigational therapy, ongoing therapy with certain medications, recent consumption of certain fruits, clinically significant cardiovascular disease, life-threatening illness or medical condition, history of other active malignancies, history of HIV or active hepatitis infection, recent live, attenuated vaccines, and recent major surgery.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of analgesia. The trial involves the use of drugs called htx-011 and placebo. The eligibility criteria for participants are listed, including age requirements, physical health status, and contraception requirements for female participants. Exclusion criteria are also listed, which include allergies to certain medications, abnormal laboratory test results, certain medical conditions, and substance abuse history. The sample also mentions specific requirements regarding medication usage and previous participation in clinical trials or bunionectomy procedures. Additionally, it states that any significant medical events during surgery prior to the administration of the investigational product may disqualify a participant from the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is thyroid cancer. The ICDCodes associated with this disease are 'C73', 'D34', 'D44.0', and 'Z85.850'. The drug mentioned is a combination of gemcitabine and oxaliplatin. The eligibility criteria for this trial include having histologically confirmed differentiated or poorly differentiated thyroid cancer that is metastatic or unresectable, being refractory to radio iodine, having radiologic evidence of clinically relevant disease progression, having measurable disease, having an ECOG performance status of \u2264 1, having adequate hematologic, renal, and liver function, having a negative serum pregnancy test in premenopausal women, and having signed informed consent. The non-inclusion criteria include having other histological subtypes of thyroid tumors (such as anaplastic, medullary, lymphoma, or sarcoma), having active CNS metastases, having prior chemotherapy (except for patients previously treated with molecular targeted therapies), and having severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities that would make the patient inappropriate for entry into the study.",
    "The sample is a record from a table that contains information about clinical trials. It is for a phase 2 trial and focuses on breast cancer and breast tumors. The ICD-10 codes associated with these diseases are provided. The trial involves the drugs metformin and doxorubicin. The eligibility criteria for participants are listed, including requirements for breast cancer treatment, organ function, performance status, and age. There are also exclusion criteria, such as having diabetes, cardiac issues, or hypersensitivity to metformin. Additionally, factors that increase the risk of metformin-associated lactic acidosis and pregnancy or breastfeeding are also listed as exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 2.\n- Diseases: The trial is focused on the disease \"homozygous familial hypercholesterolemia.\"\n- ICD Codes: The ICD-10 codes associated with the disease are \"E78.01,\" \"E78.00,\" and \"Z83.42.\"\n- Drugs: The trial involves the use of the drug \"mbx-8025\" in different dosages during different periods of the trial.\n- Criteria: The record includes both inclusion and exclusion criteria for participants in the trial. The inclusion criteria specify requirements such as written informed consent, confirmation of HoFH through genotype testing, age of 18 or older, stable lipid-lowering therapies, and specific LDL-C levels. The exclusion criteria list conditions that would disqualify a participant from the trial, such as recent treatment with certain medications, heart failure, uncontrolled cardiac arrhythmia, recent cardiovascular events, uncontrolled hypertension, abnormal liver or muscle enzyme levels, pregnancy or breastfeeding, and any other conditions that may compromise patient safety or the quality of the study.\n\nOverall, this record provides information about the phase, diseases, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is systemic lupus erythematosus. The ICDCodes associated with this disease are M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, and M32.8. The drugs being tested in this trial are a matching placebo and cenerimod. The eligibility criteria for participants include being between the ages of 18 and 65, having established SLE, having an active SLEDAI-2K score of at least 2 points for musculoskeletal or mucocutaneous manifestations, and having a history or presence of positive ANA or anti-dsDNA antibodies. Participants must also be receiving background SLE medications. Exclusion criteria include having significant medical conditions or therapies for such conditions, being lactating or pregnant, having severe SLE disease, or having other medical or surgical conditions that would put the participant at risk.",
    "The sample from the table is for a phase 2 clinical trial. The diseases being studied are rectal neoplasms, adenocarcinoma, and carcinoma. The corresponding ICD-10 codes for these diseases are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drugs being tested in the trial are capecitabine, metformin, and a placebo. \n\nThe eligibility criteria for the trial include being 18 years or older, having biopsy-proven poorly differentiated carcinoma or adenocarcinoma of the rectum, having lesions located within 12 cm of the anal verge, being able to tolerate oral treatment, having a locally advanced tumor with positive regional lymph nodes or primary tumor invasion beyond the serosa, being eligible for curative surgery, having a performance status (PS) of Eastern Cooperative Oncology Group (ECOG) 0-2, and having adequate hematologic, renal, and hepatic functions.\n\nThe exclusion criteria for the trial include known hypersensitivity to metformin or its excipients, having squamous carcinomas of the rectum or anal canal, chronic treatment with corticosteroids or other immunosuppressive agents, treatment with oral antidiabetic products, distant metastasis at diagnosis or tumor invasion of pelvic bone structures, chronic or acute infections, use of drugs under study up to four weeks prior to randomization, being pregnant or nursing, prior radiotherapy to the pelvic region, myocardial infraction up to six months prior to randomization, or uncontrolled ischemic heart disease, and congestive heart insufficiency New York Heart Association (NYHA) III-IV.",
    "The sample from the table is for a phase 2 trial. The disease being studied is depressive disorder, major. The corresponding ICD-10 codes for this disease are F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, and F33.40. The drugs being tested in the trial are sirukumab 50 mg and placebo. The eligibility criteria for participants include having a primary DSM-5 diagnosis of MDD, having a HDRS total score greater than or equal to 18 at screening and predose at Day 1, being medically stable based on physical examination, medical history, vital signs, clinical laboratory tests, and 12-lead ECG performed at screening, and meeting certain requirements for participants with hypothyroidism. The exclusion criteria include having any other current Axis one psychiatric condition, a history of alcohol or substance use disorder within 6 months prior to screening, a current or recent history of clinically significant suicidal ideation or any suicidal behavior within the past year, having more than 3 failed antidepressant treatments in the current episode of depression, and having a length of current major depressive episode longer than 60 months.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is \"mitochondrial diseases\". The corresponding ICD-10 codes for the disease are \"E88.40\", \"E88.49\", and \"G71.3\". The drug being used in the trial is \"cysteamine bitartrate\". The eligibility criteria for the trial are listed, including requirements such as completing previous visits in a related study, having a body weight of at least 5 kg, and being willing to abstain from certain medications and supplements. There are also specific criteria for female subjects of childbearing potential, including the use of contraception. The exclusion criteria are also listed, which include factors such as concurrent inborn errors of metabolism, abnormal blood test results, liver insufficiency, and various medical conditions that would prevent the completion of the study.",
    "The sample from the table is for a clinical trial that is in phase 2/phase 3. The trial is focused on treating acute myeloid leukemia and hematopoietic stem cell transplantation. The diseases are identified using icd-10 codes, with the codes being ['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']. The drug being tested in the trial is sorafenib. The eligibility criteria for the trial include being FLT3-ITD positive AML and being an allo-HSCT recipient. The exclusion criteria include having cardiac dysfunction, hepatic abnormalities, renal dysfunction, abnormal vital signs, or any other conditions that are not suitable for the trial as determined by the investigators.",
    "The sample is a phase 2 trial for psoriatic arthritis. The trial is looking for patients with a documented clinical diagnosis of mild to moderate psoriatic arthritis for at least 3 months. The patients must have active psoriatic arthritis with at least 2 tender and 2 swollen joints. They must also be in good general health, have no serious toxic side effects from methotrexate (if using), and be willing to comply with study procedures. Female patients of childbearing age must be surgically sterile or use a highly effective contraceptive method. \n\nExclusion criteria include being pregnant or breastfeeding, planning to become pregnant during the trial, having known allergies to the products being tested, having immunosuppressive diseases, having a history of certain infections or inflammatory diseases, having pustular forms of psoriasis or other non-psoriatic arthropathy, having other serious or progressive diseases, using certain biological Disease Modifying Antirheumatic Drugs (bDMARDs) or corticosteroid injections within a certain timeframe, and having certain stomach, intestinal, liver, kidney, or blood abnormalities. Patients who have participated in another clinical trial within the last 2 months or a trial with another psoriatic arthritis treatment within the last 6 months are also excluded.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of pruritus and atopic dermatitis. The diseases are listed as \"pruritus\" and \"atopic dermatitis,\" and their corresponding ICD-10 codes are provided. The drugs being studied are \"asimadoline\" and \"placebo.\" \n\nThe eligibility criteria for participants are also included in the sample. The main inclusion criteria state that participants must provide informed consent, be 18 years or older, have a clinical diagnosis of atopic dermatitis for at least 6 months, have a certain level of itching based on a visual analog scale, and agree to use contraception if applicable. \n\nThe main exclusion criteria state that participants who are pregnant, attempting to conceive, or nursing are not eligible. Additionally, participants who have received certain treatments or medications within specific timeframes, are currently participating in other clinical studies, have pruritus due to conditions other than atopic dermatitis, have certain medical conditions, have a history of certain diseases or substance abuse, or have used certain medications within a certain timeframe are also excluded. \n\nFinally, participants with allergies to asimadoline or its components are not eligible for the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on HIV infections. The trial uses the drug ruxolitinib. The eligibility criteria for participants include having HIV-1 infection, a CD4+ T cell count greater than 350 cells/mm^3, virologic suppression, and a negative tuberculosis screening. Participants must also be on continuous antiretroviral therapy (ART) for at least 730 days prior to study entry. Various laboratory values must be within certain ranges, and females of reproductive potential must have a negative pregnancy test and agree to use contraception. Exclusion criteria include a history of progressive multifocal leukoencephalopathy, breastfeeding or pregnancy, use of certain medications, allergies to study drugs, active drug or alcohol use, recent illness or infection, recent vaccinations or use of immunomodulators or chemotherapy, and certain cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, neuropsychiatric, or psychiatric conditions. Participants must not have changed their ART regimen within 12 weeks prior to study entry or have untreated latent tuberculosis infection.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of metastatic colorectal cancer. The trial is focused on patients with RAS wild-type status and unresectable colorectal cancer who have not previously received standard chemotherapy for advanced or metastatic disease. The trial aims to evaluate the effectiveness of various drugs, including 5-fluorouracil, leucovorin, panitumumab, and oxaliplatin, in treating the disease.\n\nThe eligibility criteria for the trial include being at least 18 years old, having an ECOG Performance Status of 0-1, and a life expectancy of at least 12 weeks. Patients must have histologically or cytologically confirmed adenocarcinoma of the colon or rectum and measurable or non-measurable metastatic lesions. They must also meet certain laboratory requirements, such as specific blood cell counts, liver function, and kidney function.\n\nExclusion criteria for the trial include having other active malignancies, brain or leptomeningeal metastasis, active infection, certain medical conditions, uncontrolled diabetes, recent myocardial infraction or severe heart failure, gastrointestinal hemorrhage, and certain viral infections. Patients who have received specific types of chemotherapy in the past or have potentially resectable disease are also excluded.\n\nThe sample also includes information on the timing of previous surgeries, anticancer therapies, and radiation treatments that would exclude patients from participating in the trial. It also mentions the exclusion of patients with unresolved toxicities from previous treatments.\n\nAdditionally, the sample specifies that pregnant or lactating females, as well as those planning to become pregnant during or shortly after the treatment period, are excluded from the trial. Women of child-bearing potential must have a negative pregnancy test or be willing to use contraception during the study and for at least 2 months after the end of treatment with panitumumab. Postmenopausal women are considered of non-child bearing potential if they have been amenorrheic for at least 12 months.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease schizophrenia. The ICD-10 codes associated with schizophrenia are listed as ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drugs being studied are 'tak-063 20 mg' and 'placebo'. The eligibility criteria for participants are listed, including requirements such as understanding and complying with the protocol, having a confirmed diagnosis of schizophrenia, being between the ages of 18 and 65, having certain scores on symptom scales, and having a reliable caregiver. There are also exclusion criteria, such as recent use of investigational compounds, certain medical conditions, history of certain disorders or diseases, and use of specific medications. The sample also includes information about laboratory values that are considered clinically significant.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is multiple myeloma, and the associated ICDCodes are C90.01, C90.02, and C90.00. The drugs being used in the trial are mln9708, dexamethasone, bendamustine (multiple dose levels), and bendamustine (mtd). \n\nThe eligibility criteria for this trial include being 18 years or older, providing voluntary written consent, and meeting certain requirements for contraception for female patients. Male patients must also agree to contraception or abstinence. Patients must have confirmed symptomatic multiple myeloma that is non-responsive to or ineligible for autologous stem cell transplant, and have progressed after prior exposure to certain drugs. They must also meet specific parameters for measurable disease or lytic bone disease. Other criteria include performance status, previous transplantation, recovery from prior treatments, and meeting certain laboratory criteria.\n\nExclusion criteria include lactating or pregnant female patients, not fully recovering from prior chemotherapy, recent major surgery or radiotherapy, central nervous system involvement, active infections or cardiovascular conditions, ongoing use of certain medications, certain medical or psychiatric illnesses, allergies to study medications, gastrointestinal issues, poor prognosis for another malignancy, peripheral neuropathy, participation in other clinical trials, previous treatment with the study drug, and severe chronic obstructive pulmonary disease.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on studying the efficacy and safety of a drug called AZD7594 in treating asthma. The diseases listed in the record are asthma, efficacy, and safety. The corresponding ICD-10 codes for these diseases are also provided. The drugs being tested in the trial include different doses of AZD7594, a placebo, and salbutamol. \n\nThe eligibility criteria for participants in the trial are also listed. Inclusion criteria include having a body mass index within a specific range, being between 18 and 75 years old, having a clinical diagnosis of asthma for at least 6 months, and being on specific asthma medications. Other criteria include having specific lung function measurements, demonstrating the ability to use the study inhalation device properly, and meeting certain criteria for women of childbearing potential. Male participants are also required to use contraception during the study period. \n\nExclusion criteria include known hypersensitivity to the drugs or their components, recent systemic steroid use, presence of any active disease other than asthma, and use of certain medications within a specific timeframe. Other exclusion criteria include non-compliance with the study requirements, recent use of certain biological drugs, and any other clinically relevant disease or safety concerns. \n\nOverall, the sample provides a snapshot of the trial phase, diseases being studied, drugs being tested, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on breast cancer. The associated ICD-10 codes for the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being studied is eribulin mesylate. \n\nThe eligibility criteria for participants in this trial include having histological or cytological adenocarcinoma of the breast, being female and at least 18 years old, being HER2-negative, having received 2 to 5 prior chemotherapy regimens for metastatic breast cancer, having at least one measurable lesion of a certain size, having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or less, having a life expectancy of at least 3 months, having neuropathy of Grade 2 or lower, having adequate renal and bone marrow function, and having adequate liver function. Participants must also be willing and able to comply with the treatment protocol and provide written informed consent.\n\nThe exclusion criteria for this trial include previous treatment with eribulin, hypersensitivity or intolerance to eribulin or its components, current enrollment in another clinical study or use of any investigational drug or device within the past 28 days, previous treatment with chemotherapy, radiation, biological, or targeted therapy within the last 2 weeks or 5 times the half-life, being pregnant or breastfeeding, not using a highly effective method of contraception, having certain medical conditions or diseases such as CNS disease or HIV, having existing toxicities of Grade 2 or higher from previous anticancer therapy (excluding alopecia), having a prior malignancy other than carcinoma in situ of the cervix or nonmelanoma skin cancer within the past 5 years, having clinically significant cardiovascular impairment or ECG abnormalities, having pulmonary lymphangitic involvement requiring active treatment, having concomitant medical conditions that would compromise the participant's ability to complete the study safely, or being deemed medically unfit or unsuitable by the investigator.\n\nOverall, this sample provides specific details about the phase, diseases, ICDCodes, drugs, and eligibility criteria for participants in a clinical trial focused on breast cancer and the drug eribulin mesylate.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is allergic rhinoconjunctivitis. The ICD-10 codes associated with the disease are D69.0, L50.0, B44.81, J30.89, J30.9, L20.84, and H10.45. The drugs being used in the trial are sq tree slit-tablet and placebo. The eligibility criteria for participants are listed, including requirements such as written informed consent, age between 18 and 65, negative pregnancy test for female subjects, history of moderate-to-severe rhinoconjunctivitis induced by birch pollens, positive skin prick test response to Betula verrucosa, positive specific IgE against Bet v1, and willingness to comply with the trial protocol. There are also exclusion criteria listed, such as symptoms induced by other allergens, uncontrolled asthma, reduced lung function, ongoing immunotherapy treatment, and various other medical conditions or medications that could interfere with the trial. Immediate family members of the investigator or trial staff are also excluded from participation.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the treatment of external genital warts. The trial includes a list of diseases, which in this case is only external genital warts. The corresponding ICD-10 codes for these diseases are also provided. The trial involves the use of two drugs, namely \"investigational treatment\" and \"aldara\". The eligibility criteria for participants are listed, including requirements such as signed informed consent, being a circumcised male between 18-60 years old, having a clinical diagnosis of external genital warts, and agreeing to remain abstinent or use condoms during intercourse for the duration of the study. The criteria also include exclusion factors, such as recent treatment of genital warts, HPV vaccination, presence of large warts, genital herpes, history of Bowenoid papulosis, significant illness, use of other investigational drugs, known hypersensitivity to study drugs, history of ECG abnormalities or significant heart conditions, impaired renal or liver function, history of immunodeficiency disease, drug or alcohol abuse, immunosuppressive therapies, malignancies in the past 5 years, and hypertrophic scarring.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the disease HIV. The ICD-10 codes associated with HIV are ['B20', 'Z71.7', 'O98.72', 'Z21', 'O98.73', 'R75', 'Z11.4']. The drugs being studied are 'pro 140', 'placebo', and 'optimized background regimen'. The eligibility criteria for participants include being at least 18 years old, having a history of at least 3 months on a current antiretroviral regimen, and having documented resistance to at least one ART drug within three drug classes or two drug classes with limited treatment options. Other criteria include specific laboratory values, normal ECG results, and agreement to use contraception. There are also exclusion criteria, such as having a CXCR4-tropic virus, having no viable treatment options, and having certain medical conditions or taking specific medications.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"acute coronary syndromes.\" The corresponding ICD-10 code for this disease is \"I24.0.\" The trial involves two drugs, \"cer-001\" and \"placebo.\" The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being male or female over 18 years old, having acute coronary syndrome, and having angiographic evidence of coronary artery disease suitable for IVUS evaluation. Exclusion criteria include being a female of child-bearing potential, having >50% stenosis of the left main artery, uncontrolled diabetes, hypertriglyceridemia, congestive heart failure, ejection fraction <35%, uncontrolled hypertension, and known major hematologic, renal, hepatic, metabolic, gastrointestinal, or endocrine dysfunction.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of major depression. The trial focuses on subjects who meet specific eligibility criteria. Inclusion criteria include being between 18 and 65 years old, having a sufficient level of understanding to consent to the study, fulfilling the diagnostic criteria for major depressive disorder (MDD), and having a history of inadequate response to at least one antidepressant trial. Exclusion criteria include having psychotic features, a diagnosis of schizophrenia or any other psychotic disorder, a history of drug or alcohol dependency or abuse, head injury resulting in loss of consciousness, certain personality disorders, pregnancy or nursing, serious unstable illnesses, hyperthyroidism or hypothyroidism, unexplained seizures, abnormal laboratory tests, recent treatment with certain medications or therapies, a history of deep brain stimulation, current serious suicidal or homicidal risk, positive HIV test, contraindications to magnetic resonance spectroscopy (MRS), and inability or unwillingness to stop psychotherapy during the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease mentioned is \"choroidal neovascularization.\" The ICDCodes associated with this disease are \"H44.2A1, H44.2A2, H44.2A3, H44.2A9, H35.3231, H35.3232, H35.3211.\" The drugs involved in this trial are \"faricimab, ranibizumab, sham procedure.\" The eligibility criteria for this trial include specific inclusion and exclusion criteria. Inclusion criteria include being treatment-naive with CNV secondary to AMD, having active CNV, and having subfoveal CNV or juxtafoveal CNV with a subfoveal component related to the CNV activity by FFA or SD-OCT. Exclusion criteria include having CNV due to causes other than AMD, having subretinal hemorrhage, fibrosis, or atrophy involving the fovea or more than 50% of the total lesion area, having recent cataract surgery or any other previous intraocular surgery, having a major illness or surgery within 1 month prior to screening, having a glycosylated hemoglobin (HbA1c) above 7.5%, and having uncontrolled blood pressure.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is macular edema. The ICDCodes associated with this disease are ['H59.033', 'H34.8130', 'H59.031', 'H59.032', 'H59.039', 'H34.8110', 'H34.8120']. The drug mentioned is dexamethasone phosphate ophthalmic. The eligibility criteria for this trial include being between the ages of 18 and 90, having a diagnosis of macular edema secondary to specific conditions, having a mean CST (central subfield thickness) of at least 300\u00b5m on SD-OCT images taken at the baseline visit, having a history of previous positive response to steroid treatment, and being able to comply with study-related instructions. The exclusion criteria are not mentioned in the provided sample.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 2, and the diseases being studied are adenocarcinoma of the gastroesophageal junction, gastric adenocarcinoma, and gastric cancer. The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are 5-fu, capecitabine, docetaxel, and irinotecan. The eligibility criteria for this trial include specific disease documentation, eligibility for surgical resection, FDG avid malignancy, no prior history of congestive heart failure or neuropathy, no known hypersensitivity to certain drugs, not being pregnant or nursing, age 18 or older, ECOG Performance Status 0 or 1, and specific laboratory values within certain ranges. Additionally, there are registration eligibility criteria for treatment arms A or B, which include disease progression, restrictions on concomitant medications, and previous chemotherapy regimens. The sample also includes a timeframe for pre-registration chemotherapy.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of cancer of the stomach. The trial is specifically targeting patients with adenocarcinoma of the low esophagus or stomach. The eligibility criteria for the trial include factors such as signed informed consent, confirmation of localized and operable disease, HER2 negative tumors, and no prior therapy for localized disease. Other criteria include age, performance status, hematological status, renal function, liver function, and baseline evaluations. The sample also includes exclusion criteria such as metastatic disease, non-operable primary tumor, and certain medical conditions or treatments that may interfere with the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"adenocarcinoma\" of the pancreas. The trial is specifically for patients with borderline resectable disease who have not received any previous therapy. The trial involves the use of three drugs: pegph20, gemcitabine, and nab-paclitaxel. \n\nThe eligibility criteria for this trial include being 18 years or older, having histologically confirmed pancreatic adenocarcinoma, having a performance status of 0-1 according to the Eastern Cooperative Oncology Group (ECOG), and having evaluable disease either through RECIST-defined measurable disease or an elevated serum CA19-9 level above 100 u/ml. \n\nOther criteria include having adequate organ function, such as bone marrow, hepatic, and renal function, and having peripheral neuropathy below grade 2. There are also exclusion criteria, such as being younger than 18 years old, having locally advanced or metastatic disease, having known allergies to hyaluronidase, and having contraindications to prophylactic dose low molecular weight heparin (LMWH). \n\nThe exclusion criteria also include various medical conditions and situations that may interfere with the study or pose risks to the participants, such as recent bleeding events, contraindications to heparin, presence of metal biliary stents, uncontrolled HIV or Hepatitis B infection, active infection or recent antibiotic use, presence of other active malignancies, serious medical comorbidities, and various other conditions that may affect informed consent, follow-up, and compliance for the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"amyotrophic lateral sclerosis\" (ALSO). The ICD-10 code associated with ALSO is \"G12.21\". The trial involves the drugs \"odm-109\" and a placebo for odm-109. The eligibility criteria for participants are listed, including requirements such as written informed consent, being at least 18 years old, having a diagnosis of ALSO supported by laboratory tests, being able to swallow capsules, and having specific measurements within certain ranges. There are also exclusion criteria, which include having other neuromuscular weaknesses, having a diagnosis of another neurodegenerative disease, requiring assisted ventilation or gastrostomy, having major psychiatric or cognitive impairments, recent major surgery, abnormal levels of potassium or creatinine, low blood hemoglobin, significant hepatic impairment, not using contraception for women of reproductive age, hypersensitivity to levosimendan, recent administration of levosimendan, history of botulinum toxin treatment, history of HIV infection, history of significant arrhythmias or cardiac events, and other significant medical conditions that could interfere with the study or pose a health risk to participants. The sample also mentions restrictions on blood donation or significant blood loss prior to screening, previous participation in other clinical trials or the present study, and any other conditions that could interfere with the study or pose a health risk.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on HIV-1 infection. The ICD-10 codes associated with the disease are ['B20', 'Z71.7', 'O98.72', 'Z21', 'O98.73', 'R75', 'Z11.4']. The drugs being studied are 'vm-1500', 'efavirenz', and 'antiretroviral therapy (art)'. The eligibility criteria for participants are listed, including requirements such as being at least 18 years old, having confirmed HIV-1 infection, being clinically stable, and meeting certain laboratory parameters. There are also exclusion criteria, such as having primary HIV-1 resistance to antiretroviral therapy, a history of previous ART, or certain infections or medical conditions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of papillary renal cell carcinoma. The trial includes eligibility criteria for participants, such as age, confirmation of the disease through histological review, no prior systemic treatment for metastatic renal cancer, and specific health requirements. The trial also has exclusion criteria, which include prior TKI treatment, significant cardiovascular disease, presence of brain metastases, recent major surgical procedures, and other medical conditions that may affect the evaluation of the patient or their ability to complete the study. Additionally, the sample includes information about the drugs being used in the trial, which in this case is axitinib.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of neuropathic pain, specifically neuralgia and complex regional pain syndromes. The diseases are associated with specific ICD-10 codes. The drugs being studied are cetuximab and a placebo. The eligibility criteria for participants are listed, including requirements such as signed informed consent, specific pain criteria, duration of neuropathic pain, and previous treatment attempts. There are also exclusion criteria, such as certain medical conditions, pregnancy or breastfeeding, and recent participation in other clinical trials.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"chronic graft versus host disease\" (GVHD). The associated ICD-10 codes for this disease are \"D89.811\" and \"D89.812\". The drug being studied in this trial is \"carfilzomib\". \n\nThe record also includes eligibility criteria for participants. Inclusion criteria include a diagnosis of chronic GVHD according to National Institutes of Health (NIH) Consensus Criteria, failure of at least one prior line of systemic immune suppressive therapy for managing chronic GVHD, and undergoing transplantation at least 3 months prior to enrollment. Other criteria include specific health parameters such as liver function, blood counts, and kidney function, as well as requirements for informed consent and contraception for female participants.\n\nExclusion criteria are also listed, which include factors such as recurrent or progressive underlying malignant disease, pregnancy or lactation, recent surgery, uncontrolled infection, HIV infection, active hepatitis B or C infection, and certain cardiovascular conditions. Other exclusions include uncontrolled hypertension or diabetes, recent non-hematologic malignancy, significant neuropathy, allergy to a specific substance, and other medical or psychological conditions that may interfere with protocol adherence or informed consent.\n\nAdditionally, the record mentions that the addition of a new systemic immune suppressive agent for the treatment of chronic GVHD within 2 weeks prior to enrollment and treatment with a non-FDA approved drug in the previous 4 weeks are also exclusion criteria.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of type II diabetes mellitus. The trial includes a list of diseases, which in this case is only type II diabetes mellitus. The table also includes a list of ICD-10 codes associated with the diseases, with the codes provided being E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, and E10.65.\n\nThe trial involves the use of several drugs, including mk-8521, placebo, liraglutide, and metformin. The eligibility criteria for participants are also provided, including requirements such as having type II diabetes in accordance with American Diabetes Association guidelines, being on metformin monotherapy or dual therapy, having a specific body mass index range, and meeting certain reproductive criteria for female participants.\n\nThe exclusion criteria are also listed, which include factors such as having a history of type 1 diabetes or diabetic ketoacidosis, being treated with certain medications within the last 6 months, having certain medical conditions or diseases, having a family history of specific conditions, and having a positive urine pregnancy test, among others.\n\nOverall, this sample provides a snapshot of the phase 2 clinical trial, including the diseases being studied, the drugs being used, and the eligibility and exclusion criteria for participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"colitis, ulcerative.\" The corresponding ICD-10 codes for this disease are \"K51.80,\" \"K51.813,\" \"K51.814,\" \"K51.90,\" \"K51.913,\" \"K51.914,\" and \"K51.811.\" The trial involves the use of three drugs: \"high dose,\" \"low dose,\" and \"placebo.\" The eligibility criteria for participants are listed, including age requirements, duration of suffering from ulcerative colitis, and specific diagnostic criteria. There are also exclusion criteria, such as the presence of other types of colitis, pregnancy or breastfeeding, and certain medical conditions.",
    "The sample is a record from a table that contains information about clinical trials. It is for a phase 2 trial and the diseases being studied are chronic hepatitis C and hepatitis C genotype 1a. The ICD-10 codes associated with these diseases are provided. The drugs being used in the trial are ombitasvir/abt-450/ritonavir, dasabuvir, and ribavirin (rbv). The eligibility criteria for the trial are listed, including requirements for HCV genotype 1 infection, non-cirrhotic status, and ability to adhere to the study schedule. There are also exclusion criteria, such as pregnancy, positive test results for hepatitis B or HIV, and previous use of certain HCV treatments. The sample also mentions that a history of solid organ transplant and abnormal screening laboratory results are exclusion criteria.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of plaque psoriasis. The diseases column specifies the disease being studied, and the icdcodes column provides the corresponding ICD-10 codes for the disease. The drugs column lists the names of the drugs being tested, which in this case are \"prurisol\" and \"placebo\". The criteria column contains the eligibility criteria for participants in the trial, including inclusion and exclusion criteria. The inclusion criteria specify that participants must be adults aged 18 years or older with a clinical diagnosis of stable plaque psoriasis. The extent of psoriasis must meet certain criteria, including a specific body surface area affected, severity score, and target lesion assessment. Female participants of reproductive potential must not be pregnant and must agree to use contraception. The exclusion criteria include factors such as uncontrolled systemic diseases, unstable forms of psoriasis, recent use of certain treatments, and history of allergic reactions to specific drugs.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is prostate cancer. The ICDCodes associated with this disease are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']. The drugs being used in the trial are degarelix, doxorubicin, ketoconazole, docetaxel, and estramustine. \n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- Pathologic proof of prostatic adenocarcinoma without evidence of regional and/or distant metastasis, with specific clinical stage requirements.\n- Recent negative bone scan and CT of the chest and abdomen.\n- Appropriate surgical candidate for radical prostatectomy with a performance status of less than 2.\n- Adequate bone marrow, hepatic, and renal function.\n- Normal coagulation profile and no history of substantial non-iatrogenic bleeding diatheses.\n- Age of 18 years or older.\n- Written informed consent to participate in the study.\n\nThe exclusion criteria for this trial include:\n- Prostatic adenocarcinoma with neuroendocrine differentiation or small cell features.\n- Recent surgical resection or major surgery, or stereotactic biopsy.\n- Previous or current hormonal treatment, chemotherapy, radiation therapy, immunotherapy, or investigational study drug.\n- Inability to tolerate multiparametric MRI or contraindication to it.\n- Inappropriate surgical candidate for radical prostatectomy based on medical evaluation.\n- Uncontrolled cardiac, hepatic, renal, or neurologic/psychiatric disorders.\n- Severe gastrointestinal bleeding within 12 weeks of treatment.\n- HIV positive or chronic hepatitis B or C infections.\n- Congestive heart failure NYHA class 3 or 4, or history of it, unless specific cardiac tests show a normal left ventricular ejection fraction.\n- Sensory neuropathy grade greater than 1.\n- History of another malignancy within the previous 5 years, except for non-melanoma skin cancer.\n- Use of certain herbal products or systemic corticosteroids within 4 weeks of enrollment.\n- Any other condition that, in the opinion of the investigator, could compromise patient safety and/or compliance with study requirements.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is focused on the treatment of non-small-cell lung cancer. The phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are specified as non-small-cell lung cancer. The corresponding ICD-10 codes for the diseases are provided. The drugs being tested in the trial are gilteritinib and erlotinib. The eligibility criteria for participants are listed, including requirements such as having a confirmed diagnosis of metastatic or locally advanced non-small-cell lung cancer, having specific EGFR activating mutations, and having received prior treatment with an EGFR tyrosine kinase inhibitor. Additional criteria are specified for participants in phase 1b and phase 2. Exclusion criteria are also listed, which include factors such as ongoing toxicity from prior treatment, recent use of certain medications, active infections, uncontrolled hypertension, and various other medical conditions.",
    "The sample is a phase 2 trial for the treatment of irritable bowel syndrome with constipation (IBS-C). The trial is testing the effectiveness of three drugs: syn-010 21 mg, syn-010 42 mg, and a placebo. The eligibility criteria for participants include having a positive breath CH4 test result, meeting the modified Rome III criteria for IBS-C, experiencing abdominal pain with a score of 3 or higher, having fewer than 3 complete spontaneous bowel movements per week, and agreeing not to make any lifestyle changes that may affect IBS-C symptoms during the study. Exclusion criteria include previous use of IBS treatments, proton pump inhibitors, laxatives, or antibiotics, having any structural abnormalities or conditions that can affect gastrointestinal motility, having a family history of certain types of colorectal cancer, and reporting loose or watery stools.",
    "The sample from the table is for a phase 2 trial. The disease being studied is highly drug-resistant focal epilepsy. The ICD-10 codes associated with this disease are G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, and G40.801. The drugs being used in the trial are ucb0942 and placebo. The eligibility criteria for participants include being an adult (18 years or older), having a diagnosis of focal epilepsy that meets the ILAE (1989) criteria, having failed to achieve seizure control with at least 4 different antiepileptic drug regimens, and currently being treated with a stable dose of at least 1 antiepileptic drug for the 4 weeks prior to the screening visit. Female participants must either be of nonchildbearing potential or use medically accepted contraceptive methods. Male participants must use a barrier contraceptive when having sexual intercourse with a woman of childbearing potential. Exclusion criteria include recent participation in another study, known hypersensitivity to the study drug or similar drugs, current or past psychiatric conditions that could compromise safety or participation, use of certain medications that interact with the study drug, clinically significant heart abnormalities, history of hypersensitivity reactions or autoimmune disease, and pregnancy or breastfeeding in female participants.",
    "The sample from the table is for a phase 2 trial. The disease being studied is diabetes type 2. The corresponding ICD-10 codes for the disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested are ormd-0801 and a placebo comparator. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- HbA1c levels must be at least 7.5% if the patient is new to antidiabetic therapy, or between 6.5% and 10% if the patient is on metformin at a dose of at least 1,500 mg daily. If the patient is on monotherapy with a different antidiabetic drug or on metformin and one other antidiabetic drug, the HbA1c levels must be between 6.5% and 9.5%. If the patient is on metformin at a dose of less than 1,500 mg daily, the HbA1c levels must be at least 7.0%.\n- At the time of randomization, patients must be treated for their diabetes with diet, exercise, and metformin at a dose of at least 1,500 mg daily. They must have been on a stable regimen of metformin for at least two weeks prior to the placebo run-in period.\n- Other antidiabetic agents should not be used for two weeks prior to the placebo run-in period.\n- Patients who can tolerate a maximum dose of metformin of 1,000 mg are allowed to enter the study.\n- At Day -7 (Visit 3), all patients must have HbA1c levels between 6.5% and 10%.\n- Patients must have a body mass index (BMI) between 25 and 40 kg/m2.\n- Fasting blood glucose levels must be at least 126 mg/dL (8.3 mmol/L) prior to randomization at Day -7 (Visit 3). If the fasting blood glucose levels are between 115 mg/dL and 126 mg/dL and the HbA1c levels are between 7% and 10%, a minimum of 5 daily self-monitored fasting blood glucose checks can be averaged to determine eligibility.\n- Females of childbearing potential must have a negative urine pregnancy test result at screening. They must also have negative urine pregnancy tests at Visit 2 and Visit 4 (prior to randomization). Both males and females of childbearing potential must use two methods of contraception, one of which must be an acceptable barrier method, from screening to the last study visit.\n- Patients must have at least 80% compliance with placebo during the run-in period prior to randomization.\n- Patients must have at least 80% of the glucose readings on at least two 24-hour periods (6AM - 6AM) during the seven-day continuous glucose monitoring (CGM) period.\n- Patients must have performed at least 10 out of 14 self-monitored glucose level measurements during the placebo run-in period prior to randomization.\n\nThe exclusion criteria for the trial are as follows:\n- Patients with any clinically significant endocrine disease, except euthyroid patients on replacement therapy with stable thyroxine dosage for at least six weeks prior to screening, are not eligible.\n- Patients with a clinical diagnosis of Type 1 diabetes are not eligible.\n- Patients with fasting blood glucose levels greater than 260 mg/dL at the end of Day -7/Visit 3 are not eligible. If the fasting blood glucose levels are between 260 mg/dL and 300 mg/dL and the HbA1c levels are between 7% and 10%, a minimum of 5 self-monitored fasting blood glucose checks can be averaged to determine eligibility.\n- Patients with a history of cancer within the past five years, except for adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer, are not eligible.\n- Patients with laboratory abnormalities at screening, such as C-peptide levels less than 1.0 ng/mL, positive pregnancy test in females of childbearing potential, abnormal serum thyrotropin (TSH) levels more than 1.5 times the upper limit of normal, positive tests for hepatitis B surface antigen and/or hepatitis C antibody, positive test for HIV, serum creatinine levels greater than 1.4mg/dL in males or greater than 1.3mg/dL in females, or any other relevant abnormality that may interfere with the efficacy or safety assessments during study drug administration, are not eligible.\n- Patients who have used insulin for more than one week in the last six months, or any use of insulin in the last six weeks prior to randomization, are not eligible. Patients who have used anti-diabetic drugs other than metformin within four weeks prior to randomization, or thyroid preparations or thyroxine within six weeks prior to screening, are also not eligible.\n- Patients who have received systemic long-acting corticosteroids within two months, or prolonged use (more than one week) of other systemic corticosteroids or inhaled corticosteroids within 30 days prior to screening, are not eligible.\n- Patients using medications known to modify glucose metabolism or decrease the ability to recover from hypoglycemia, such as oral, parenteral, and inhaled steroids, beta blockers (except for beta blocker ophthalmic solutions for glaucoma or ocular hypertension), and immunosuppressive or immunomodulating agents, are not eligible.\n- Patients with a history of tobacco or nicotine use in excess of two packs/day within ten weeks prior to screening are not eligible.\n- Patients who are on a weight loss program and are not in the maintenance phase, or patients who have started any approved or non-approved weight loss medication within eight weeks prior to screening, are not eligible.\n- Pregnant or breastfeeding patients are not eligible.\n- Patients with a screening visit systolic blood pressure of 160 mm Hg or higher, or diastolic blood pressure of 100 mm Hg or higher, are not eligible. Patients who have been on stable blood pressure medication for at least four weeks prior to the screening visit are allowed to continue taking the medication.\n- Patients who are users of recreational or illicit drugs at the time of signing informed consent, or have had a recent history (within the last year) of drug or alcohol abuse or dependence, are not eligible.\n- Patients with elevated liver enzymes (alanine transaminase (ALT), alanine aminotransferase (AST), alkaline phosphatase) greater than two times the upper limit of normal at screening, or very high triglyceride levels (>500 mg/dL) at screening, are not eligible.\n- Patients with any clinically significant electrocardiogram (ECG) abnormality at screening, or with a history of stroke, transient ischemic attack, or myocardial infraction within six months prior to screening, or with a history of or currently have New York Heart Associate Class II-IV heart failure prior to screening, or with uncontrolled hypertension defined as blood pressure of 160 mmHg (systolic) or 100 mmHg (diastolic) at screening, are not eligible.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of malignant pleural mesothelioma. The trial is investigating the use of the drug nivolumab. The eligibility criteria for the trial include patients with histological or cytological diagnosed malignant pleural mesothelioma who are over 18 years old and have progressive disease after at least one course of chemotherapy. Patients must also be medically suitable for limited surgical intervention and not considered candidates for trimodality treatment. They should have measurable or evaluable disease and a WHO performance status of 0 or 1. Adequate organ function is required, as evidenced by specific peripheral blood counts and serum chemistries. Women of childbearing potential must use contraception during treatment and for a certain period after the last dose of the investigational drug. Men who are sexually active with women of childbearing potential must also use contraception. There are various exclusion criteria, including active uncontrolled infection, severe cardiac dysfunction, and uncorrectable bleeding tendency. Patients with certain conditions or prior treatments are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"atrophy.\" The associated ICD-10 codes for this disease are ['H21.29', 'H31.23', 'H47.20', 'H47.22', 'N50.0', 'N64.2', 'N90.5']. The trial involves the drugs \"oxytocin\" and \"placebo.\" The eligibility criteria for participants are listed, including age requirements, menopausal status, vaginal smear cytology, estradiol and FSH levels, symptoms of vaginal atrophy, BMI, general health evaluation, endometrial thickness, and restrictions on sexual activity and vaginal douching. The exclusion criteria specify conditions that would disqualify a participant, such as ongoing medical conditions, history of certain diseases, contraindications to oxytocin therapy, drug and alcohol abuse, recent use of medications or hormonal devices, and participation in other clinical trials.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"gout\". The ICD-10 codes associated with this disease are \"M10.9\", \"M10.08\", \"M10.00\", \"M10.011\", \"M10.012\", \"M10.019\", and \"M10.021\". The drugs being studied are \"rdea3170 2.5 mg\" and \"allopurinol 300 mg\". \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The subject must be able to understand the study procedures and risks and provide written informed consent.\n- The subject must meet one or more criteria for the diagnosis of gout according to the American Rheumatism Association Criteria.\n- The subject must have a body weight of at least 50 kg and a body mass index between 18 and 45 kg/m2.\n- The subject must have a screening serum urate level of at least 8 mg/dL.\n- The subject must be free of any clinically significant disease or medical condition, as determined by the investigator.\n\nExclusion Criteria:\n- The subject must be unable to take colchicine for gout flare prophylaxis.\n- The subject must have a history or suspicion of kidney stones.\n- The subject must have any gastrointestinal disorder that affects motility and/or absorption.\n- The subject must have had unstable angina, New York Heart Association class III or IV heart failure, ischemic heart disease, stroke, or deep venous thrombosis within the past 12 months, or currently be receiving anticoagulants.\n- The subject must have screening laboratory parameters outside the normal limits and considered clinically significant by the investigator.\n- The subject must have an estimated creatinine clearance less than 60 mL/min calculated by the Cockcroft-Gault formula using ideal body weight during the screening period.\n- The subject must be taking losartan, fenofibrate, guaifenesin, or sodium-glucose linked transporter-2 inhibitors, with chronic and stable doses permitted if stable for at least 14 days prior to study medication dosing.\n- The subject must be unable or unwilling to comply with the study requirements or have a situation or condition that may interfere with participation, as determined by the investigator.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is squamous cell carcinoma of the head and neck (SCCHN). The ICD-10 codes associated with this disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drugs being used in the trial are palbociclib, cetuximab, and placebo. The eligibility criteria for participants in the trial include having histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx that is not amenable to salvage surgery or radiotherapy. Other criteria include having measurable disease, being HPV-negative, having documented progressive disease, and having a tumor tissue specimen available for biomarker analysis. There are also exclusion criteria, such as having prior nasopharyngeal cancer, salivary gland or sinus tumors, or more than one chemotherapeutic regimen given for R/M disease.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has several columns including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for patients participating in the trial.\n\nThe sample data in the table includes information for two different phases of the trial: phase 2 and peripheral T-cell lymphomas. For phase 2, the disease being studied is \"lymphatic diseases\" and the corresponding ICD-10 codes are \"I89.9\" and \"I89.8\". The drugs being used in this phase are \"brentuximab vedotin\" and \"bendamustine\". The eligibility criteria for patients with classical Hodgkin's lymphoma include specific requirements such as having primary refractory disease or relapse after one previous line of therapy, histologically-confirmed CD30+ disease, age between 18 and 60 years, presence of measurable disease as documented by PET and CT scans, and specific laboratory values within normal ranges.\n\nFor peripheral T-cell lymphomas, the eligibility criteria include having refractory or relapsed PTCL, histologically confirmed diagnosis of PTCL, CD30+ PTCL, specific performance status score, presence of measurable disease, and specific laboratory values within normal ranges. The exclusion criteria for both phases include previous treatment with bendamustine or brentuximab vedotin, certain cardiovascular conditions, history of other primary malignancies within a certain time frame, and various other medical conditions or infections.\n\nOverall, the sample provides detailed information about the phases, diseases, drugs, and eligibility criteria for patients participating in the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is small cell lung cancer, and the corresponding ICDCodes for this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being tested in this trial are carboplatin, placebo, trilaciclib, and etoposide. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being male or female aged 18 years or older, having a confirmed diagnosis of small cell lung cancer, having at least one unirradiated and measurable target lesion, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and having adequate organ function. Exclusion criteria include having received prior chemotherapy for extensive-stage small cell lung cancer, having symptomatic brain metastases requiring immediate treatment, having uncontrolled ischemic heart disease or congestive heart failure, having a history of stroke or cerebrovascular accident within the past 6 months, having other uncontrolled serious chronic diseases or conditions that could affect compliance or follow-up, having concurrent radiotherapy or recent radiotherapy to the target lesion sites, and having received any investigational medication within the past 4 weeks.",
    "The sample is a record from a table that contains information about a clinical trial. It includes details about the phase of the trial (phase 2), the diseases being studied (metastatic melanoma, stage iiib cutaneous melanoma ajcc v7, stage iiic cutaneous melanoma ajcc v7, stage iv cutaneous melanoma ajcc v6 and v7), the corresponding ICD-10 codes for the diseases, the drugs being used (cyclophosphamide, fludarabine phosphate), and the eligibility criteria for participants.\n\nThe eligibility criteria are divided into two sections: Turnstile I - Screening and Turnstile II - Treatment. The criteria include requirements such as having specific types of melanoma, having a lesion amenable to resection, receiving brain imaging, having a certain performance status, being previously treated or treatment naive, and having a negative pregnancy test for women of childbearing potential.\n\nThere are also exclusion criteria listed, which include factors such as active infections, immunodeficiency, pregnancy or nursing, significant psychiatric disease, participation in other studies, recent chemotherapy or radiation therapy, and active autoimmune diseases.\n\nOverall, the sample provides a snapshot of the information stored in the table, including the phase, diseases, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of two diseases: scleroderma, diffuse and diffuse cutaneous systemic sclerosis. The diseases are identified by their corresponding ICD-10 codes. The trial involves two drugs, iva337 and placebo. The eligibility criteria for participants are listed, including requirements such as informed consent, specific diagnostic criteria for systemic sclerosis, and being within a certain age range. The criteria also mention that patients on certain stable treatments may be included in the study. The exclusion criteria are also provided, which include factors such as recent use of certain medications, specific medical conditions, and abnormal laboratory results. The sample also mentions a wash-out period for certain biologic medications.",
    "The sample from the table is for a phase 2 clinical trial. The diseases being studied are lung cancer and targeted therapy. The corresponding ICD-10 codes for the diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested is azd9291. \n\nThe eligibility criteria for the trial include: \n1. Signed and dated, written informed consent.\n2. Age over 18 years.\n3. Locally advanced or metastatic NSCLC (non-small cell lung cancer) that cannot be treated with surgery or radiotherapy.\n4. Disease progression after previous treatment with an EGFR TKI (tyrosine kinase inhibitor).\n5. Documented EGFR mutation associated with EGFR TKI sensitivity, including T790M.\n6. ECOG status 0-2 (performance status) and a minimum life expectancy of 12 weeks.\n7. Presence of at least one measurable lesion that has not been previously irradiated or chosen for biopsy during the study screening period.\n8. Females should be using adequate contraceptive measures, not breastfeeding, and have a negative pregnancy test if of child-bearing potential. Post-menopausal women or those with irreversible surgical sterilization are also eligible.\n9. Male subjects must be willing to use barrier contraception.\n\nThe exclusion criteria for the trial include:\n1. Recent treatment with an EGFR-TKI or other anticancer drugs.\n2. Previous treatment with AZD9291 or another EGFR TKI with a similar profile.\n3. Major surgery or radiotherapy to a large area within a certain timeframe.\n4. Use of potent inhibitors or inducers of CYP3A4.\n5. Unresolved toxicities from prior therapy greater than CTCAE grade 1 (with the exception of alopecia grade 2).\n6. Spinal cord compression or brain metastases, unless asymptomatic and on stable steroid dosage.\n7. Severe or uncontrolled systemic diseases or active infections.\n8. Gastrointestinal conditions that affect swallowing or absorption of AZD9291.\n9. Certain cardiac criteria, such as prolonged QT interval or other abnormalities in resting ECG.\n10. Current or previous significant interstitial lung disease or radiation pneumonitis.\n11. Abnormal blood counts or liver function tests.\n12. History of hypersensitivity to AZD9291 or similar drugs.\n13. Pregnancy or breastfeeding.\n14. Inability or unwillingness to comply with study procedures, restrictions, and requirements.\n\nThis sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for the clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2, and the diseases being studied are gastrointestinal problems and autism spectrum disorders. The corresponding ICD-10 codes for these diseases are ['A21.3', 'A22.2', 'B46.2', 'K92.2', 'K92.81', 'K91.0', 'P54.3'] and ['Z16.12'], respectively. The drugs being tested in the trial are oral vancomycin, moviprep, and prilosec. \n\nThe eligibility criteria for participants in the trial are as follows:\nInclusion Criteria:\n1. Children ages 7-17 years\n2. Diagnosis of autism per Autism Diagnostic Interview-Revised (ADI-R)\n3. Moderate or Severe GI problems (on the GSRS, a single score of 4 (severe) on any item, or a score of 3 (moderate) on two items, or a score of 2 (mild) or more on any 4 items)\n4. No changes in medications, supplements, diet, therapies, or education in the last 3 months, and no intention to change them during the clinical trial\n5. General good physical health aside from gastrointestinal problems\n6. Cognitive ability to provide informed assent\n\nExclusion Criteria:\n1. Antibiotics in the last 6 months\n2. Probiotics in the last 3 months\n3. Single-gene disorder (Fragile X, etc.)\n4. Major brain malformation\n5. Tube feeding\n6. Severe gastrointestinal problems that require immediate treatment (life-threatening)\n7. Ulcerative Colitis, Crohn's Disease, diagnosed Celiac Disease, Eosinophilic Gastroenteritis, or similar conditions\n8. Severely underweight/malnourished\n9. Recent or scheduled surgeries\n10. Current participation in other clinical trials",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"arthritis, rheumatoid.\" The ICD-10 codes associated with this disease are \"M06.9,\" \"M05.9,\" \"M06.08,\" \"M06.00,\" \"M06.011,\" \"M06.012,\" and \"M06.019.\" The drugs being studied in this trial are \"gsk3196165,\" \"mtx,\" \"folic acid,\" and \"placebo.\" \n\nThe eligibility criteria for participants in this trial include being at least 18 years old, meeting the ACR/EULAR 2010 RA Classification Criteria with a disease duration of at least 12 weeks, having a certain number of swollen and tender joints, having a specific DAS28(CRP) score and CRP level, and having previously received MTX for a certain duration. Other criteria include meeting contraceptive requirements, having certain lung function measurements, and not having active or latent tuberculosis infection.\n\nExclusion criteria for this trial include being pregnant or lactating, having other inflammatory rheumatological or autoimmune disorders (except Sj\u00f6gren's syndrome secondary to RA), having certain respiratory diseases, having significant cough or dyspnea, having unstable or uncontrolled acute or chronic diseases, having a history of malignancy, having immunodeficiency disorders, and having current or previous infections with HBV, HCV, or HIV.",
    "The sample is a record from a table that contains information about clinical trials. It includes the following fields: phase, diseases, icdcodes, drugs, and criteria. In this particular sample, the phase is \"phase 2\", the diseases are \"renal cancer\" and \"birt-hogg-dube syndrome\", the icdcodes are \"['C65.1', 'C65.2', 'C65.9', 'D30.10', 'D30.11', 'D30.12', 'C64.1']\" and \"['D68.61', 'D69.41', 'D81.4', 'E24.1', 'E26.01', 'E26.81', 'E34.0']\", the drug is \"everolimus\", and the criteria include various eligibility requirements for patients to participate in the trial. These criteria include having a clinical diagnosis of Birt-Hogg-Dub Syndrome, measurable disease, specific age and performance status, normal organ and marrow function, and no history of certain medical conditions or prior therapy with an mTOR-pathway inhibitor. The sample also includes exclusion criteria, such as receiving anticancer therapies, known intolerance to everolimus, and uncontrolled intercurrent illnesses. Additionally, it specifies criteria related to diabetes, severe medical conditions, and prior use of certain medications. The sample also includes criteria related to pregnancy and contraception for women of child-bearing potential, as well as criteria related to prior invasive malignancy and certain infections. Finally, it mentions the exclusion of patients currently using or having recently used certain inhibitors or inducers of Cytochrome P450 3A4 or P-glycoprotein.",
    "The sample provided is for a phase 2 clinical trial for the treatment of Hodgkin lymphoma. The trial is specifically for previously untreated stage IA, IB, or IIA classical Hodgkin Lymphoma patients with non-bulky disease (less than 10 cm in diameter). The trial aims to evaluate the effectiveness of the drugs brentuximab vedotin, adriamycin, and dacarbazine.\n\nThe inclusion criteria for participants include being at least 18 years old, having an ECOG performance status of 0-2, and having certain organ and marrow function parameters within specified ranges. Participants must also have measurable disease of at least 1.5 cm and must be willing to use two effective forms of birth control during the trial and for 6 months following treatment. Additionally, participants must have a normal LVEF (left ventricular ejection fraction) as determined by echocardiogram or MUGA.\n\nExclusion criteria for the trial include having received prior chemotherapy or radiotherapy specifically for Hodgkin lymphoma, currently receiving any other investigational agents, having known central nervous system involvement of lymphoma, and having a history of allergic reactions to the drugs being used in the trial. Other exclusion criteria include pre-existing grade 2 or greater neuropathy, uncontrolled intercurrent illnesses, pregnancy or breastfeeding, history of a different malignancy (unless disease-free for 1 year and considered at low risk for relapse), and known HIV positivity.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2. The disease being studied is \"prostatic neoplasms\" (prostate cancer). The icd-10 codes associated with this disease are \"B38.81\", \"N42.31\", \"Z87.430\", \"N40.0\", and \"N40.1\". The drug being used in the trial is \"ipilimumab\". The eligibility criteria for participants in this trial include having histologically confirmed adenocarcinoma of the prostate without previous therapy, being eligible for radical prostatectomy within a 3-month timeframe, having adequate organ function, not having certain medical conditions or prior treatments, and meeting other specified requirements.",
    "The sample is a phase 2 clinical trial for patients with metastatic colon or rectal cancer. The trial is investigating the effectiveness of a combination treatment involving the drugs fluorouracil, irinotecan hydrochloride, and leucovorin calcium. The eligibility criteria for participants include having a confirmed diagnosis of colon or rectal cancer with metastasis, having previously responded to anti-EGFR therapy, and having certain laboratory values within normal ranges. There are also exclusion criteria, such as a history of severe toxicity to anti-EGFR therapy, intolerance to irinotecan or 5-FU, and the use of certain medications that may interfere with the study. The sample provides detailed inclusion and exclusion criteria to ensure that eligible participants are selected for the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the disease \"septic shock.\" The ICD-10 codes associated with this disease are \"T81.12XS,\" \"R65.20,\" \"R65.21,\" \"T81.12XA,\" and \"T81.12XD.\" The drugs being studied in the trial are \"selepressin\" and \"placebo.\" \n\nThe eligibility criteria for participants in the trial are as follows:\nInclusion Criteria:\n- Participants must be 18 years of age or older.\n- They must have a proven or suspected infection.\n- They must have septic shock, which is defined as hypotension requiring vasopressor treatment despite adequate fluid resuscitation.\n- Informed consent must be obtained in accordance with local regulations.\n\nExclusion Criteria:\n- Participants cannot initiate trial drug treatment more than 12 hours after the onset of vasopressor treatment for septic shock.\n- The primary cause of hypotension should not be due to sepsis.\n- Participants who have had severe sepsis with intensive care unit admission within the current hospital stay are excluded.\n- Those with known or suspected acute mesenteric ischaemia are excluded.\n- Participants with suspicion of concomitant acute coronary syndrome based on clinical symptoms and/or ECG during this episode of septic shock are excluded.\n- Individuals who are on chronic mechanical ventilation for any reason or have severe chronic obstructive pulmonary disease (COPD) requiring continuous daily oxygen use or mechanical ventilation in the preceding 30 days are excluded.\n- Participants who have received a bone marrow transplant in the preceding 6 months or chemotherapy in the preceding 30 days for lymphoma or leukemia are excluded.\n- Pregnant individuals are excluded.\n- Participants who have made a decision to limit full care before obtaining informed consent are excluded.\n- Those who have used vasopressin in the past 12 hours prior to the start of trial drug treatment or terlipressin within 7 days prior to the start of trial drug treatment are excluded.\n- Individuals who have previously enrolled in the trial are excluded.\n- Participants who have used an investigational medicinal product within the last month or are planned or concurrently participating in a clinical trial for any investigational drug or investigational device are excluded.",
    "The sample is a phase 2 trial for the treatment of nonalcoholic steatohepatitis (NASH) using the drug solithromycin. The eligibility criteria for participants include having histologic evidence of NASH based on a liver biopsy obtained within the last 180 days, a NAS (NAFLD Activity Score) of 5 or higher, and the ability to swallow capsules intact. The exclusion criteria include having symptoms of acute liver disease, cirrhosis on liver biopsy, positive HIV or Hepatitis tests, primary biliary cirrhosis, poorly controlled diabetes with HgA1C greater than 8.5%, ALT (alanine aminotransferase) levels greater than 4-fold the upper limit of normal, QTcF (corrected QT interval) greater than 450 msec, and a creatinine clearance (CrCl) less than 40 mL/min.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on macular degeneration. The ICD-10 codes associated with the disease are ['H35.30', 'H35.353', 'H35.351', 'H35.352', 'H35.359', 'H35.3130', 'H35.3230']. The drug being studied is ranibizumab. The sample also includes the eligibility criteria for participants. Inclusion criteria include being newly diagnosed with wet AMD within 9 months, having received at least 2 prior ITV anti-VEGF injections (with the most recent being ranibizumab at least 7 days prior to screening), demonstrating response to prior treatment, and having a Best Corrected Visual Acuity (BCVA) of 20/20-20/200 Snellen equivalent. Exclusion criteria include recent treatment with other ITV anti-VEGF agents, history of certain eye surgeries or interventions, prior participation in a clinical trial involving anti-angiogenic drugs other than ranibizumab, certain eye conditions, uncontrolled ocular hypertension or glaucoma, uncontrolled blood pressure, recent history of myocardial infraction or stroke, and other contraindications or high-risk conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on small cell lung cancer (SCLC). The ICD-10 codes associated with SCLC are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being studied in the trial are trilaciclib, placebos, and topotecan. The sample also includes the eligibility criteria for the trial, including age, confirmed diagnosis of SCLC, progression after prior chemotherapy, presence of measurable target lesions, performance status, and adequate organ function. The exclusion criteria include symptomatic brain metastases, uncontrolled heart disease, recent stroke, other serious chronic diseases, concurrent or recent radiotherapy, recent use of investigational medication, and previous topotecan treatment for SCLC.",
    "The sample is from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is phase 2. The disease being studied is \"patients with resistant hypertension\". The corresponding ICD-10 codes for this disease are \"I15.0\", \"I97.3\", \"K76.6\", \"P29.2\", \"G93.2\", \"H40.053\", and \"I10\". The drugs being tested are \"lhw090\" and \"placebo\". The eligibility criteria for the trial include age requirements (40 to 85 years), uncontrolled hypertension despite treatment with specific medications, weight and BMI requirements, and exclusion criteria such as certain medical conditions and recent medical events. Pregnant or nursing women and women of child-bearing potential are also excluded from the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the disease muscular dystrophy (DMD). The ICD-10 codes associated with this disease are 'H35.51', 'L60.3', 'G71.00', 'G71.02', 'G71.11', 'H35.52', and 'H18.513'. The drugs being studied are ro7239361 and placebo. The sample also includes the eligibility criteria for participants. Inclusion criteria include being diagnosed with DMD, being able to walk without assistance, being able to walk up 4 stairs in 8 seconds or less, weighing at least 15 kg, and taking corticosteroids for DMD. Exclusion criteria include having an ejection fraction less than 55% on an echocardiogram, having any behavior or mental issues that would affect the ability to complete study procedures, previously or currently taking medications like androgens or human growth hormone, using a ventilator during the day, being unable to have blood samples collected or receive an injection under the skin, receiving exon skipping therapies within 6 months prior to the study start, and receiving ataluren or any investigational drug within 5 half-lives prior to the study start.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is \"geographic atrophy,\" and its corresponding ICDCodes is \"K14.1.\" The drugs being used in the trial are \"clg561,\" \"lfg316,\" and \"sham injection.\" The eligibility criteria for this trial include signing a written informed consent form, having geographic atrophy in both eyes, and meeting any other specified inclusion criteria. The exclusion criteria include being pregnant or lactating, having any medical condition that may interfere with the study, having contraindications or hypersensitivities to the drugs being used, having contraindications to intravitreal injections, having recent ocular surgery, having uncontrolled ocular hypertension or glaucoma in the study eye, and meeting any other specified exclusion criteria.",
    "The sample from the table represents a phase 2 clinical trial for various diseases, including acute lymphoblastic leukemia, non-Hodgkin's lymphoma, T-cell leukemia, and B-cell leukemia. The trial is focused on evaluating the effectiveness of multiple drugs, such as dexamethasone, panobinostat, liposomal vincristine, and others, in treating these diseases. The eligibility criteria for participants include being \u2264 21 years old, having relapsed or refractory disease, and meeting certain performance score and renal function requirements. The sample also includes exclusion criteria, such as prior use of specific medications, impaired cardiac or gastrointestinal function, and concurrent medical conditions that could pose safety risks. Participants must provide written informed consent to participate in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease osteoarthritis. The ICD-10 codes associated with this disease are ['M15.4', 'M15.0', 'M16.9', 'M17.9', 'M19.011', 'M19.012', 'M19.019']. The trial involves testing several drugs, including 'cr845 0.25 mg', 'cr845 0.50 mg', 'cr845 1 mg', and 'cr845 5 mg'. The eligibility criteria for participants are listed, including age, BMI, diagnosis of osteoarthritis, pain intensity level, and willingness to discontinue current pain medications. Additional criteria are specified for female and male participants. The exclusion criteria are also provided, which include factors such as joint replacement, recent medication changes, substance dependence, and certain medical conditions or abnormalities.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 2, the disease is Duchenne muscular dystrophy, the icd-10 code is G71.01, the drug is ht-100, and the eligibility criteria are provided in a list format. The inclusion criteria include completing two previous studies, providing written informed consent, and being able to understand and follow instructions for the entire duration of the study. The exclusion criteria include having a major disease unrelated to DMD that could affect safety or protocol adherence, a history of severe allergic or anaphylactic reactions, and recent drug or alcohol abuse.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of non-small cell lung cancer. The trial is investigating the effectiveness of a combination of drugs, including mpdl3280a, carboplatin, and paclitaxel. The eligibility criteria for the trial include being at least 18 years old, having histologically confirmed non-small cell lung cancer that is considered non-metastatic and unresectable, and having adequate hematologic and end organ function. Patients must also have measurable disease and a performance status of 0, 1, or 2 according to the Eastern Cooperative Oncology Group (ECOG) scale. Exclusion criteria include having any distant metastasis, recent use of anticancer therapy, significant liver disease, certain types of leukemia or lymphoma, pregnancy or breastfeeding, and known hypersensitivity to certain antibodies. The sample also includes additional exclusion criteria related to autoimmune diseases, infections, surgical procedures, and medication use.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is Type 2 Diabetes Mellitus. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being used in the trial are Met DR, Met IR, and Placebo. \n\nThe eligibility criteria for this trial include being at least 25 years old, having a body mass index (BMI) between 20.0 and 45.0 kg/m\u00b2, having no clinically significant abnormalities in a physical examination, having Type 2 Diabetes Mellitus with an HbA1c level between 7.5% and 10.5%, having an estimated glomerular filtration rate (eGFR) of \u226560 mL/min/1.73 m\u00b2, and being on a stable treatment regimen with certain medications for at least 3 months prior to the trial. \n\nThe exclusion criteria include having certain medical conditions that could affect study participation or well-being, a history of diabetic ketoacidosis or hyperosmolar non-ketotic hyperglycemia within the past year, recent major surgery or significant weight change, clinically significant laboratory abnormalities, certain liver function test results, unsuitability for the study based on physical, psychological, or historical findings, and being treated or expected to be treated with certain excluded medications. \n\nAdditionally, the sample includes criteria related to drug and alcohol abuse, blood transfusions or significant blood loss, allergies or hypersensitivity to study treatment components, employment by Elcelyx Therapeutics, Inc., and specific fasting plasma glucose values.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is HIV-1 infection. The ICD-10 codes associated with the disease are ['B20', 'Z71.7', 'O98.72', 'Z21', 'O98.73', 'R75', 'Z11.4']. The drugs being used in the trial are 'dolutegravir (tivicay\u00ae) - phase 1', 'lamivudine (epivir\u00ae) - phase 2', and 'dolutegravir (tivicay\u00ae) - phase 2'. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- The patient must be HIV-1 infected.\n- The patient must be at least 18 years old.\n- The patient's CD4 cell count nadir must be greater than 200/mm3.\n- The patient's genotype on pre-HAART must not have major mutations on protease or RT, and no mutations on integrase if the genotype is available.\n- The patient must be on first-line treatment with suppressive triple HAART.\n- The patient's plasma HIV RNA must be \u2264 50 copies/mL for \u2265 2 years with at least 2 viral load determinations per year.\n- The patient must test negative for Hepatitis Bs Antigen.\n- Women of childbearing potential must be using effective contraception.\n- The patient must have signed an informed consent form.\n- The patient must be enrolled in or a beneficiary of a Social Security program.\n\nThe exclusion criteria for the trial are as follows:\n- The patient must not have HIV-2 infection.\n- The patient must not have positive HBc Ac isolated.\n- The patient must not be co-infected with Hepatitis B Virus (HBV).\n- The patient must not be currently treated for or needing therapy for chronic hepatitis C in the next 12 months.\n- The patient must not have a history of HIV-associated neurocognitive disorders.\n- The patient must not be currently pregnant or breastfeeding.\n- Women of childbearing potential must not have effective contraception.\n- The patient must not have previous treatment with chemotherapy or immunotherapy, except for bleomycin on Kaposi disease's treatment.\n- The patient must not have grade > 2 abnormality for usual biological parameters.\n- The patient must not have certain liver abnormalities or diseases.\n- The patient must not have known biliary abnormalities, except for Gilbert's syndrome or asymptomatic gallstones.\n- The patient's creatininemia clearance must be above 50 mL/min.\n- The patient must not have a history or presence of allergy to the trial drugs or their components.\n- The patient must not have severe hepatic insufficiency.\n- The patient must not be participating in another clinical trial with an exclusion period that is still in force during the screening phase.\n- The patient must not be under \"sauvegarde de justice\" or under legal guardianship.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the disease \"familial partial lipodystrophy\". The corresponding ICD-10 code for this disease is \"E88.1\". The drugs being studied in the trial are \"volanesorsen\" and \"placebo\". The eligibility criteria for participants include giving written informed consent, having a clinical diagnosis of familial partial lipodystrophy with type 2 diabetes mellitus, hypertriglyceridemia, and fatty liver. The diagnosis of familial partial lipodystrophy is based on physical examination and specific measurements, as well as genetic diagnosis or family history. Participants must also have poorly controlled diabetes and high triglyceride levels. The presence of fatty liver is confirmed through a screening MRI. There are also exclusion criteria, such as not having generalized or acquired lipodystrophy, recent acute pancreatitis or unstable cardiac condition, high LDL-C levels, low platelet count, or recent treatment with metreleptin.",
    "The sample is a record from a table that contains information about clinical trials. It includes the following details:\n- Phase: The phase of the trial, which in this case is phase 2.\n- Diseases: The specific disease being studied, which in this case is \"type 1 diabetes mellitus\".\n- ICD codes: The ICD-10 codes associated with the disease, which are \"E10.65\", \"E10.9\", \"E10.21\", \"E10.36\", \"E10.41\", \"E10.42\", and \"E10.44\".\n- Drugs: The drugs being used in the trial, which are \"placebo\" and \"asp1941\".\n- Criteria: The eligibility criteria for participants in the trial, including inclusion and exclusion criteria.\n\nThe inclusion criteria state that the subject must be diagnosed with type 1 diabetes mellitus and have been treated with insulin therapy for at least 52 weeks. They must also be able to be admitted to the site as scheduled and record in a patient's diary. Other criteria include specific HbA1c values, insulin therapy doses, fasting serum C-peptide levels, BMI values, and the absence of certain complications or diseases.\n\nThe exclusion criteria state that subjects with type 2 diabetes mellitus or those who have participated in other clinical studies within the past 12 weeks are not eligible. Other exclusion criteria include specific medical conditions, such as proliferative retinopathy, hypoglycemia unawareness, diabetic ketoacidosis, chronic diseases requiring corticosteroids or immunosuppressants, and various other conditions related to renal, hepatic, urinary, cardiovascular, gastrointestinal, and psychiatric health. Additionally, subjects with drug addiction or alcohol abuse, drug allergies, or those unable to adhere to study requirements are also excluded.\n\nOverall, this sample provides information about the phase, disease, drugs, and eligibility criteria for a specific clinical trial related to type 1 diabetes mellitus.",
    "The sample provided is for a phase 2 clinical trial for gastric cancer. The trial is focused on patients with unresectable gastric cancer who are unable to undergo radical excision due to local metastasis or other conditions. The inclusion criteria include being definitively diagnosed with gastric cancer before the operation, being untreated with any previous therapies, having a negative HER-2 status, having an ECOG score of 0-2, and being between the ages of 18 and 75. The patient's hemodynamic indices and cardiac function should be normal, and they should not have any other uncontrollable benign diseases or be participating in other clinical trials. The patient must also sign an informed consent form.\n\nThe exclusion criteria include not meeting the inclusion conditions, having distal metastasis to the lung, brain, or bone, having previously undergone stomach surgery, being intolerant to surgery due to other systemic diseases, having been administered other drugs before the trial, having allergies to the drugs used in the trial, being pregnant or lactating, or being a woman of childbearing age with a desire to become pregnant during the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on breast neoplasms. The ICD-10 codes associated with the diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being studied in the trial are trastuzumab, pertuzumab, palbociclib, and fulvestrant. The eligibility criteria for the trial are listed, including requirements for age, tumor size, HER2 status, estrogen receptor and progesterone receptor levels, Ki67 value, availability of tumor tissue, performance status, and informed consent. The exclusion criteria are also provided, which include factors such as bilateral invasive breast cancer, pregnancy or lactation, previous treatments, hypersensitivity reactions, and various medical conditions. The sample also mentions baseline measurements for left ventricular ejection fraction, corrected QT interval, and various blood values.",
    "The sample from the table describes a clinical trial for patients with leukemia, specifically acute myeloid leukemia (AML). The trial is divided into different phases, such as phase I and phase II. The diseases column lists the specific diseases being studied, which in this case are leukemia and acute myeloid leukemia. The icdcodes column contains the corresponding ICD-10 codes for these diseases.\n\nThe drugs column lists the drugs being used in the trial, which are selinexor and sorafenib. The criteria column provides the eligibility criteria for patients to participate in the trial. These criteria include having specific genetic mutations, previous treatment history, age, performance status, and various health parameters such as liver and kidney function.\n\nThe inclusion criteria specify the requirements for patients to be eligible for each phase of the trial. The exclusion criteria list the conditions or situations that would disqualify a patient from participating in the trial. These include allergies to the drugs, concurrent medical conditions, recent surgeries, receiving other treatments for AML, and unstable cardiovascular function, among others.\n\nOverall, the sample provides detailed information about the phase, diseases, icd codes, drugs, and eligibility criteria for patients participating in the clinical trial for leukemia.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on Crohn's disease. The ICD-10 codes associated with Crohn's disease are provided. The drug being tested in this trial is called rpc1063. The eligibility criteria for this trial include confirmation of Crohn's disease through endoscopy and histology, active disease as evaluated by specific scores, and inadequate response to previous treatments. The exclusion criteria include a diagnosis of ulcerative colitis or indeterminate colitis, presence of strictures or stenosis leading to obstruction symptoms, current stoma or need for ileostomy or colostomy, relevant cardiovascular conditions or other diseases that could impact the trial, history of uveitis or known macular edema, and history of colonic dysplasia.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of diffuse large B-cell lymphoma. The trial includes the use of several drugs such as metformin, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, and pegfilgrastim. The eligibility criteria for participants include having a diagnosis of diffuse large B-cell lymphoma, no prior therapy for the disease, measurable lymphadenopathy or extranodal lymphoid malignancy, a performance score of 0-2, a life expectancy of at least 6 months, and no history of medication-dependent diabetes mellitus. The sample also includes exclusion criteria such as being on any class of anti-diabetic medication, having certain types of lymphomas or other malignancies, having certain infections or liver conditions, being HIV positive, having inflammatory bowel disease or ongoing alcohol/drug addiction, being pregnant, or having a history of prior bone marrow or organ transplantation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is cystic fibrosis, and the corresponding ICDCodes associated with this disease are E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, and P09.4. The drugs being tested in this trial are qr-010 and placebo. The eligibility criteria for participants are listed under inclusion and exclusion criteria, which include factors such as confirmed diagnosis of CF, specific CFTR gene mutations, body mass index, non-smoking status, lung function, and hepatic and renal function. Exclusion criteria include factors such as pregnancy, use of specific drugs, history of lung transplantation, and hemoptysis.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is respiratory syncytial virus (RSV). The ICD-10 code for this disease is Z29.11. The drugs being used in the trial are presatovir and placebo. The eligibility criteria for participants in the trial are listed, including age requirements, confirmation of RSV infection, respiratory symptoms, negative pregnancy test for females, and agreement to use contraception. There are also exclusion criteria related to previous medication use, transplant history, medical conditions, and laboratory values. It is noted that there may be additional inclusion/exclusion criteria defined in the protocol.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as a combination of phase 1 and phase 2. The diseases being studied in this trial are \"condylomata acuminata,\" \"papillomavirus infections,\" and \"sexually transmitted diseases.\" The corresponding ICD-10 codes for these diseases are \"A64\" and \"A63.8.\" The drugs being investigated in the trial are \"ranpirnase\" and \"vehicle.\" \n\nThe eligibility criteria for participants in this trial are as follows:\n- Participants must have a diagnosis of external genital/perianal warts with at least 2 warts and no more than 30 lesions.\n- Participants must agree to follow study instructions and provide their informed consent.\n- Participants must abstain from sexual intercourse for 6 hours after applying the study product during the trial.\n\nThe exclusion criteria for participants in this trial are as follows:\n- Participants who have undergone any topical and/or destructive treatments for external genital warts within 4 weeks (or within 12 months for imiquimod and within 12 weeks for sinecatechins) prior to enrollment are not eligible.\n- Pregnant women are not eligible, and women of reproductive age must undergo a pregnancy test and use double barrier contraceptives.\n- Participants with known allergies to the study product, internal warts requiring or undergoing treatment, dermatological diseases or skin conditions that may interfere with evaluation, or who are using certain medications or undergoing certain procedures are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is urothelial carcinoma. The ICDCodes associated with this disease are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']. The drug being tested in this trial is tipifarnib. \n\nThe eligibility criteria for this trial include:\n1. The subject must be at least 20 years of age.\n2. The subject must have a confirmed diagnosis of urothelial carcinoma arising from the urinary bladder or upper urinary tract.\n3. The subject must have been treated with platinum-based chemotherapy for advanced disease and have refractory or progressive disease with no further curative therapy available.\n4. The subject must have a tumor that carries a missense HRAS mutation according to a standard methodology.\n5. The subject must consent to provide at least 10 unstained tumor slides for retrospective testing of HRAS gene tumor status.\n6. The subject must have a life expectancy of 3 months or more.\n7. The subject must have measurable disease according to RECIST v1.1 and have relapsed or be refractory to prior therapy.\n8. The subject must have completed their last systemic therapy regimen at least 2 weeks prior to enrollment and have recovered from any acute toxicities.\n9. The subject must have completed their last radiotherapy at least 2 weeks prior to enrollment, unless there is documentation of disease progression at the irradiated site.\n10. The subject must have an ECOG performance status of 0 or 1.\n11. The subject must have acceptable liver function and acceptable renal function.\n12. The subject must have acceptable hematologic status.\n13. Female subjects must meet certain criteria related to pregnancy and contraception.\n14. The subject must provide written and voluntary informed consent.\n\nThe exclusion criteria for this trial include:\n1. Ongoing treatment with an anticancer agent not included in the protocol.\n2. Prior treatment with an FTase inhibitor.\n3. History of clinically relevant coronary artery disease, myocardial infraction, congestive heart failure, cerebrovascular attack, or serious cardiac arrhythmia.\n4. Known uncontrolled brain, leptomeningeal, or epidural metastases.\n5. Non-tolerable > Grade 2 neuropathy or unstable neurological symptoms.\n6. Major surgery within 4 weeks prior to enrollment without complete recovery.\n7. Double primary cancer of other sites, except for cured ones at the discretion of the investigator.\n8. Active, uncontrolled bacterial, viral, or fungal infections, HIV infection, or active hepatitis B or C infection.\n9. Allergic reactions to tipifarnib or similar compounds.\n10. Concomitant disease or condition that could interfere with the study or pose an unacceptable risk to the subject.\n11. Legal incapacity or limited legal capacity.\n12. Dementia or significantly altered mental status that would limit understanding or compliance with the study protocol.\n13. QTcF interval \u2265 470 msecs.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is \"hepatitis c virus infection\". The ICDCodes associated with this disease are ['B00.81', 'B25.1', 'B26.81', 'B58.1', 'K75.4', 'A51.45', 'B17.2']. The drugs mentioned in this sample are 'sof/vel/vox' and 'rbv'. The eligibility criteria for this trial include specific requirements such as being treatment experienced with a direct acting antiviral-containing regimen without achieving sustained viral response, absence of cirrhosis or presence of compensated cirrhosis, specific screening laboratory values, and the use of specific contraceptive methods for females of childbearing potential or sexually active males. There are also exclusion criteria mentioned, such as co-infection with HIV or hepatitis B virus, current or prior history of clinical hepatic decompensation, chronic use of systemic immunosuppressive agents, history of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment, or compliance with the protocol. Pregnant or nursing females are also excluded. It is noted that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is ulcerative colitis. The ICDCodes associated with this disease are K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, and K51.811. The drugs being tested in this trial are etrasimod and placebo. The eligibility criteria state that patients who completed the APD334-003 study are included, while those who did not complete the study are excluded.",
    "The sample from the table represents a clinical trial with a phase 1/phase 2 trial phase. The trial focuses on the disease \"functional constipation\" and includes a list of associated ICD-10 codes. The trial involves testing various drugs, including \"yh12852 ir\" at different dosages, \"yh12852 dr1\" at different dosages, \"yh12852 dr2 8mg\", \"prucalopride 2mg\", and a placebo. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Subjects must be willing and able to provide written informed consent.\n- BMI (Body Mass Index) must be within the range of 18 to 25 kg/m2.\n\nExclusion criteria for participants are as follows:\n- History of positive serologic evidence for infectious diseases such as HBsAg, anti-HCV, anti-HIV.\n- Clinically significant lab/ECG abnormalities as determined by the investigator.\n- Women of childbearing potential (WOCBP) who are unwilling or unable to use an adequate contraceptive method to avoid pregnancy for the entire study. Acceptable contraceptive methods include intrauterine devices, physical barrier methods with chemical barrier methods, sterile partner, or practicing abstinence.\n- WOCBP who are willing to use hormonal methods or hormone-releasing devices for the entire study.\n- WOCBP who are pregnant or breastfeeding.\n- WOCBP with a positive pregnancy test prior to randomization.\n- Males who have not received a vasectomy must agree to use contraceptive methods and refrain from donating sperm throughout the study.\n- Presence of uncontrolled or severe medical illness.\n- Presence of a disease that requires surgery at any time during the study.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on various diseases, including head and neck squamous cell carcinoma, recurrent nasal cavity and paranasal sinus squamous cell carcinoma, recurrent nasopharynx carcinoma, recurrent salivary gland carcinoma, squamous cell carcinoma metastatic in the neck with occult primary, stage III major salivary gland carcinoma, stage III nasal cavity and paranasal sinus squamous cell carcinoma, stage III nasopharyngeal carcinoma, stage IV nasopharyngeal carcinoma, stage IVA major salivary gland carcinoma, stage IVA nasal cavity and paranasal sinus squamous cell carcinoma, stage IVB major salivary gland carcinoma, stage IVB nasal cavity and paranasal sinus squamous cell carcinoma, stage IVC major salivary gland carcinoma, and stage IVC nasal cavity and paranasal sinus squamous cell carcinoma.\n\nThe diseases are associated with specific ICD-10 codes. The trial involves the use of the drug vorinostat. The eligibility criteria for the trial include various factors such as disease progression, prior systemic therapy, organ function, performance status, and pregnancy status. There are also exclusion criteria, including participation in other studies, immunodeficiency, prior treatments, active infections, and certain medical conditions.\n\nOverall, the sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease mentioned is leukemia, specifically myeloid leukemia. The ICDCodes associated with this disease are C92.Z1, C92.Z2, C92.91, C92.92, C92.Z0, C92.90, and C92.11. The drug mentioned in this record is lenalidomide. The eligibility criteria for participants in this trial include age restrictions, understanding and voluntary consent, relapsed or refractory acute myeloid leukemia, adherence to the study schedule, specific scores for physical condition, recovery from prior treatments, time elapsed from radiation therapy and stem cell infusion, adequate renal and liver function, reproductive education and contraception requirements for females, and abstinence or condom use for males. The exclusion criteria include Down syndrome, specific types of leukemia, isolated central nervous system involvement or extramedullary relapse, recent treatment with chemotherapy or biologic antineoplastic agents, prior treatment with lenalidomide, pregnancy or lactation, uncontrolled infections, HIV positivity, prior history of malignancies, significant medical conditions or abnormalities, cardiac disorders, history of veno-occlusive disease, and other organ dysfunctions.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. The trial includes the use of drugs such as ramucirumab, placebo, s-1, oxaliplatin, and paclitaxel. The eligibility criteria for participants include having a confirmed diagnosis of the specified cancers, not having received prior first-line systemic therapy, having measurable or evaluable disease, having a performance status of 0 or 1, and having adequate organ function. Participants must also have an estimated life expectancy of at least 12 weeks and agree to use contraception during the study period. Exclusion criteria include having HER2-positive status, recent radiation therapy, brain metastases or spinal cord compression, recent major surgery, participation in other clinical trials, pregnancy or breastfeeding, prior malignancies, and any condition that may hinder compliance with the study procedures.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is acute pain. The ICDCodes associated with this disease are 'G89.12', 'G89.18', 'G89.11', and 'G89.3'. The drugs being tested in this trial are wafermine, oxycodone, and placebo. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being scheduled for a bunionectomy (with no additional procedures), being a healthy and ambulatory subject who can understand and comply with study procedures, having a BMI between 19 and 33 kg/m2, not being pregnant or lactating, and having acceptable contraception or being surgically sterile. Additionally, participants must be able to read and understand English and swallow oral capsules whole.\n\nExclusion criteria include having allergies, intolerances, or contraindications to specific medications, having a clinically significant medical condition, a history of illicit drug use or alcohol abuse, testing positive for HIV, HBV, or HCV, having clinically significant 12 lead ECG abnormalities, and being a smoker unwilling to abstain during the inpatient stay.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of penile squamous cell carcinoma (PSCC). The trial involves the drug \"gilotrif\". The eligibility criteria for participants are listed, including requirements such as confirmed PSCC, progressive disease after prior chemotherapy, measurable disease, specific organ function levels, and the ability to provide informed consent. The sample also includes exclusion criteria, such as recent major surgery, cardiovascular abnormalities, and active infections.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is oral mucositis. The corresponding ICD-10 codes for this disease are K12.30, K12.39, K12.33, K12.31, and K12.32. The drugs being tested in this trial are cobiprostone, placebo, and standard care - chemotherapy. \n\nThe eligibility criteria for this trial include being recently diagnosed with non-metastatic squamous cell carcinoma of the oral cavity and/or oropharynx, which can be treated with radiotherapy and concurrent chemotherapy. The treatment plan should involve a minimum radiation dose of 50 Gy administered through external beam irradiation using intensity-modulated radiation therapy (IMRT) and/or image-guided radiation therapy (IGRT). The chemotherapy regimen should include cisplatin or carboplatin given either conventionally or on a weekly/tri-weekly basis.\n\nThe exclusion criteria for this trial include having received prior radiation to the head and neck region, having any other invasive malignancy unless disease-free for at least 3 years, having metastatic disease (Stage IV-C), having mucosal ulceration or oral mucositis at screening or before randomization, and using a pre-existing feeding tube for nutritional support at the start of the study.",
    "The sample is a phase 2 trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of several drugs, including salbutamol, ipratropium, and rpl554, along with their respective placebos. The eligibility criteria for participants include providing informed consent, being of a certain age and gender, having specific ECG readings, being able to use the study nebulizer correctly, having a specific BMI range, having a COPD diagnosis for at least 1 year, demonstrating reversibility to bronchodilators, having a normal chest X-ray, meeting medication restrictions, having a smoking history of at least 10 pack years, and being able to withdraw from certain bronchodilators. Exclusion criteria include a history of life-threatening COPD, recent COPD exacerbation or hospitalizations, recent respiratory tract infection, cor pulmonale or pulmonary hypertension, other respiratory disorders, previous lung surgery, recent oral therapies for COPD, drug or alcohol abuse, recent experimental drug exposure, previous exposure to RPL554, chronic uncontrolled disease, recent cardiovascular disease, recent major surgery, history of malignancy (except for localized skin cancers), abnormal safety laboratory test results, history of non-compliance in previous studies, requirement for oxygen therapy, inability to perform whole body plethysmography, and any other reason the investigator deems unsuitability for participation. Additionally, patients with known hypersensitivity to certain medications are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is \"healthy,\" which seems to be a control group or a reference point. The icd-10 codes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drug being used in this phase is a placebo. \n\nThe eligibility criteria for participants in this phase are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being in stable health, meeting specific laboratory criteria, being able to attend all scheduled visits and comply with study procedures, having a body mass index (BMI) of less than or equal to 35 kg/m^2, and having a negative urine pregnancy test for women of childbearing potential. \n\nExclusion criteria include being pregnant, breastfeeding, or planning to become pregnant within 3 months after study vaccine administration for women, or planning to father a child within 3 months after study vaccine administration for men. Other exclusion criteria include having an acute illness, acute infection, or fever, having a serious chronic disorder, a history of neoplastic disease or hematological malignancy, known or suspected immunodeficiency, recent immunosuppressive therapy, or chronic active hepatitis B or hepatitis C infection.\n\nOverall, this sample provides information about the phase, disease, icd-10 codes, drug, and eligibility criteria for participants in a Phase 2 clinical trial.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is non-small cell lung cancer. The trial is specifically looking at participants with squamous or non-squamous NSCLC who have stage IIIB or IV disease and have been pretreated with only 1 prior systemic platinum-based chemotherapy. The participants need to provide a tumor tissue sample for testing the PD-L1 status. They should also have radiographically-documented measurable disease and an Eastern Cancer Oncology Group (ECOG) performance status of 0 to 1. The participants' organ functions and bone marrow function should be adequate. Female participants of childbearing potential need to have negative pregnancy tests and agree to use two effective methods of contraception. Male participants need to practice true abstinence or use a condom during sexual contact with a pregnant female or a female of childbearing potential. The participants should be willing to adhere to the study visit schedule and other protocol requirements. They need to understand and sign an informed consent document. There are also exclusion criteria, such as participants with known sensitizing EGFR and/or ALK mutations, participants who have received more than one line of therapy for stage IIIB or IV disease, participants who have received prior therapy with anti-PD-1, PD-L1, or PD-L2 agents, and participants with active infections or certain medical conditions.",
    "The sample from the table is for a phase 2 clinical trial. The trial is focused on attention-deficit hyperactivity disorder (ADHD). The ICD-10 codes associated with ADHD are ['F90.2', 'F90.8', 'F90.9', 'F90.0', 'F90.1']. The drugs being tested in the trial are ctn sr and placebo. The eligibility criteria for participants include being between 18 and 60 years old, meeting the DSM-5 criteria for a primary diagnosis of ADHD, having a baseline score above 28 using the ADHD-RS-IV, and having a minimum score of 4 on the CGI-S at baseline. There are also exclusion criteria, such as having comorbid psychiatric disorders, being a suicide risk, having certain medical conditions, and having a history of substance abuse or dependence disorder. Female participants are required to have negative pregnancy tests and use contraception during the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and is focused on patients with type 2 diabetes mellitus, chronic kidney disease (CKD), and albuminuria. The trial is investigating the effects of the drugs dapagliflozin 10 mg and saxagliptin 2.5 mg, as well as a placebo. \n\nThe eligibility criteria for participants include providing informed consent, being at least 18 years old, having a history of type 2 diabetes for more than 12 months, having an HbA1c level between 7.0% and 11.0%, and having stable antidiabetic treatment for the past 12 weeks. Other criteria include having an estimated glomerular filtration rate (eGFR) between 25-75 mL/minute/1.73m2, having micro or macroalbuminuria (UACR 30-3500 mg/g), and being on treatment with an ACE inhibitor or an ARB for at least 3 months prior to screening. The body mass index should be between 20 and 45 kg/m2.\n\nExclusion criteria include recent cardiovascular or vascular diseases, significant hepatic disease, elevated levels of AST or ALT, high total bilirubin levels, history of acute kidney injury requiring renal replacement therapy, ongoing treatment with certain medications, and any condition that may interfere with the patient's ability to complete the study or pose a significant risk to the patient's health.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is type 2 diabetes mellitus. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are medi0382 and placebo. The eligibility criteria for participants include a diagnosis of T2DM, written informed consent, a body mass index (BMI) between 27 and 40 kg/m^2, suitable venous access, normal vital signs, non-lactating and non-childbearing potential for females, and the practice of two effective contraceptive measures for sexually active males. The exclusion criteria include any concurrent condition that may interfere with the evaluation of the investigational product, history or presence of gastrointestinal, renal, or hepatic disease, history of cancer within the last 10 years (excluding non-melanoma skin cancer), recent illness, medical/surgical procedure, or trauma, fasting glucose level of 200 mg/dL or higher, positive tests for Hepatitis B, Hepatitis C, or HIV, previous use of a glucagon-like peptide 1 receptor agonist, recent use of systemic corticosteroids, prohibition of weight or appetite control medications, known or suspected history of alcohol or drug abuse within the past 3 years, and positive drug screen.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in phase 2/phase 3.\n- Diseases: The trial is focused on the disease \"secondary hyperparathyroidism\".\n- ICD Codes: The ICD-10 codes associated with the disease are \"E21.1\" and \"N25.81\".\n- Drugs: The drugs being studied are \"khk7580\" and \"krn1493\".\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". \n\nThe \"Inclusion Criteria\" include requirements such as providing written consent, having stable chronic renal disease treated with hemodialysis for at least 12 weeks, and having a mean intact PTH level of > 240 pg/ml. \n\nThe \"Exclusion Criteria\" include factors such as recent treatment with cinacalcet hydrochloride, changes in dosage of certain drugs, recent parathyroidectomy or intervention, severe heart disease or hepatic dysfunction, uncontrolled hypertension or diabetes, recent participation in other clinical studies, primary hyperparathyroidism, and other conditions deemed unfit for participation by the investigator or subinvestigator.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is ulcerative colitis. The ICDCodes associated with this disease are K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, and K51.811. The drug being tested is budesonide. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- The participant must have signed informed consent.\n- Men or women aged 18 to 75 years are eligible.\n- The participant must have active ulcerative colitis, confirmed by endoscopy and histology, except for proctitis limited to 15 cm ab ano.\n- The participant must have established disease.\n\nExclusion Criteria:\n- Participants with Crohn's disease, indeterminate colitis, ischaemic colitis, radiation colitis, microscopic colitis, diverticular disease associated colitis, toxic megacolon, or fulminant colitis are not eligible.\n- Participants who have undergone colon resection are not eligible.\n- Evidence of infectious colitis, malabsorption syndromes, celiac disease, bleeding hemorrhoids, active peptic ulcer disease, or other inflammatory or bleeding disorders of the colon and intestine, or diseases that may cause diarrhea or gastrointestinal bleeding will exclude participants from the trial.\n- Participants with hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease, glaucoma, cataract, or infection will only be eligible if careful medical monitoring is ensured.\n- Participants with severe infectious diseases (e.g., tuberculosis, AIDS) or severe co-morbidity that substantially reduces life expectancy are not eligible.\n- Participants with a history of colorectal cancer or any other cancer (except for basal cell carcinoma) in the last 5 years are not eligible.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease called lupus nephritis. The International Classification of Diseases (ICD-10) codes associated with this disease are ['B26.83', 'A51.44', 'N11.8', 'N11.9', 'N12']. The drugs being studied in this trial are mycophenolate mofetil/mycophenolic acid, obinutuzumab, methylprednisolone, and prednisone. The eligibility criteria for participants in this trial include a diagnosis of Systemic Lupus Erythematosus (SLE) according to the American College of Rheumatology (ACR) criteria, a diagnosis of International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV LN as confirmed by a recent renal biopsy, proteinuria (urine protein to creatinine ratio) greater than 1.0, and specific contraceptive requirements for women and men. The exclusion criteria include certain medical conditions, previous treatments, and known intolerances to specific medications.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The diseases being studied in this trial are \"basal cell nevus syndrome,\" \"skin neoplasm,\" and \"nodular basal cell carcinoma of skin.\" The corresponding ICD-10 codes for these diseases are \"D68.61,\" \"D69.41,\" \"D81.4,\" \"E24.1,\" \"E26.01,\" \"E26.81,\" and \"E34.0.\" The drug being tested in this trial is \"5-fu.\" The eligibility criteria for this trial include specific inclusion and exclusion criteria, such as having low-risk nodular basal cell carcinoma, willingness to undergo injection therapy followed by surgery, and not having known or suspected metastatic disease. Other criteria include not being pregnant or lactating, not having clinically active or uncontrolled skin disease, not being immunocompromised or receiving immunomodulating agents, and not having received psoralen plus Ultraviolet A or Ultraviolet B light therapy within the past 6 months. Additionally, participants should not have any serious or active medical or psychiatric illness, engage in recreational or therapeutic drug or alcohol use, or have taken any investigational product within 1 month of the first dose of ASN-002.",
    "The sample in the table is for a phase 2 clinical trial related to contraception. The disease being studied is contraception, and the corresponding ICD-10 codes are 'Z92.0', 'Z30.012', and 'Z30.09'. The drug being tested is a gestodene/ee patch (bay86-5016). \n\nThe sample includes both inclusion and exclusion criteria for the trial. Inclusion criteria are conditions that participants must meet to be eligible for the trial, while exclusion criteria are conditions that would disqualify participants from participating. \n\nIn this sample, the inclusion criteria include being a healthy female requesting contraception, aged 18 to 35 years (smokers must not be older than 30 years), having a normal or clinically insignificant cervical smear, a history of regular menstrual periods, willingness to use nonhormonal contraception methods during the study, and proven ovulation after the pretreatment cycle.\n\nThe exclusion criteria in this sample include being pregnant or lactating, having a body mass index (BMI) greater than 30.0 kg/m2 (indicating obesity), having a significant skin reaction to transdermal preparations or sensitivity to surgical/medical tape, having any disease or condition that may worsen under hormonal treatment, and using hormonal contraception other than the study medication during the trial.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is small cell lung cancer, and the corresponding ICD-10 codes for this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are pembrolizumab and paclitaxel. The eligibility criteria for participants include being willing and able to provide informed consent, being at least 20 years old, having measurable lesions based on RECIST 1.1, providing tissue samples for analysis, having a performance status of 0 or 1 on the ECOG Performance Scale, and demonstrating adequate organ function. There are also specific criteria for females of childbearing potential and male subjects regarding contraception. The exclusion criteria include current participation in another investigational study, immunodeficiency or recent immunosuppressive therapy, recent use of anti-cancer monoclonal antibodies or chemotherapy, presence of progressing or actively treated additional malignancies, active central nervous system metastases, active autoimmune disease requiring systemic treatment, interstitial lung disease or active pneumonitis, active infection requiring systemic therapy, and various other conditions or disorders that may interfere with the trial or the subject's ability to participate. Additionally, pregnant or breastfeeding individuals, those with a history of certain prior therapies or infections, and those with known hypersensitivity to the study drug or its components are also excluded from the trial.",
    "The sample is a record from a table that contains information about clinical trials. In this particular record, the trial is in phase 2 and is focused on Alzheimer's disease. The ICD-10 codes associated with the disease are G30.8, G30.9, G30.0, and G30.1. The drug being tested in this trial is a placebo. The record also includes eligibility criteria for participants. Inclusion criteria include a diagnosis of mild Alzheimer's disease, Mini-Mental State Examination (MMSE) scores between 20 and 26, clinical dementia rating (CDR) scores of 0.5 or 1, and other criteria that are not specified. Exclusion criteria include the presence of clinically significant neurological diseases other than Alzheimer's disease, major psychiatric disorders, severe systemic diseases, serious adverse reactions to any vaccine, and other criteria that are not specified.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 2. The disease mentioned is \"end-stage renal disease (esrd)\". The ICDCodes associated with this disease are \"N25.0\", \"Q61.4\", \"N23\", \"N26.9\", \"P96.0\", \"Q60.0\", and \"Q60.1\". The drugs being tested in this trial are \"isis 416858\" and \"placebo\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria state that patients must have end-stage renal disease and be maintained on outpatient hemodialysis at a healthcare center for more than 3 months. They should also be receiving hemodialysis using heparin (unfractionated heparin or low-molecular weight heparin) three times per week for a minimum of 3 hours per dialysis session, and plan to continue this throughout the study.\n\nExclusion criteria include having had a thrombotic event (acute coronary syndrome, stroke, or transient ischemic attack, venous thromboembolic event) in the past 3 months, active bleeding within the past 3 months, or a bleeding disorder. Certain screening values such as platelet count, INR, and aPTT should also be within specific ranges. Abnormal liver function at screening, concomitant medication restrictions, uncontrolled hypertension, and planned major surgery in the next 6 months are also listed as exclusion criteria.",
    "The sample from the table represents a clinical trial that is in phase 2/phase 3. The trial focuses on major depressive disorder, overweight, and inflammation as the targeted diseases. The corresponding ICD-10 codes for these diseases are provided. The trial involves the use of three different drugs: epa 1 g/day, epa 2 g/day, and epa 4 g/day. The eligibility criteria for participants are listed, including age range, specific diagnostic criteria for major depressive disorder, BMI requirements, and other medical and psychiatric conditions that would exclude individuals from participating. The criteria also include restrictions on medication use, pregnancy or breastfeeding status, and other factors that could affect the study results.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is Type 2 Diabetes Mellitus. The ICD-10 codes associated with the disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in the trial are pf-06291874 and placebo. The eligibility criteria for the trial include age between 18 and 70, stable dose of metformin, specific HbA1c levels, and exclusion criteria such as certain medical conditions, blood pressure levels, and history of alcohol consumption.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The phase column indicates the phase of the trial, which can be phase I, phase II, or phase III. The diseases column lists the names of the diseases being studied, while the icdcodes column contains the corresponding ICD-10 codes for those diseases. The drugs column lists the names of the drugs being tested in the trial. The criteria column provides the eligibility criteria for participants in the trial.\n\nThe sample data in the table includes information for a trial involving psoriasis. The phase is listed as \"phase 1/phase 2\". The disease is specified as \"psoriasis\", and the corresponding ICDCodes are provided as \"['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']\". The drugs being tested in this trial are \"vtp-43742\", \"placebo 1\", and \"placebo 2\". The eligibility criteria are then listed for both healthy volunteers and psoriasis patients, including age requirements, body weight and mass index ranges, medical health conditions, contraception requirements for women of child-bearing potential, and consent to participate in the trial.\n\nAdditionally, the exclusion criteria are provided for both healthy volunteers and psoriasis patients, which include factors such as history of significant diseases, organ dysfunction, recent surgeries, positive test results for certain infections, history of alcoholism or drug abuse, hypersensitivity to drugs, gastrointestinal conditions, recent blood donations or transfusions, and pregnancy for women of child-bearing potential. The criteria also state that prisoners or subjects who are involuntarily incarcerated for treatment of psychiatric or physical diseases should not be enrolled in the study. Any other medical, psychiatric, or social reasons for exclusion are determined by the investigator.",
    "The sample from the table represents a phase 2 clinical trial. The trial focuses on the diseases gout and hyperuricemia. The corresponding ICD-10 codes for gout are 'M10.9', 'M10.08', 'M10.00', 'M10.011', 'M10.012', 'M10.019', and 'M10.021', while the ICD-10 code for hyperuricemia is 'E79.0'. The drugs being tested in this trial are 'urc102' and 'placebo'. The eligibility criteria for inclusion in the trial include being diagnosed with gout, while the exclusion criteria state that participants should not have participated in any other clinical study within the past 12 weeks and should not have received any investigational product, including placebo, during that time.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is \"irritable bowel syndrome with constipation.\" The corresponding ICDCodes for this disease are \"K58.1.\" The drugs being used in the trial are \"linaclotide\" and a \"matching placebo.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having completed a colonoscopy according to the American Gastroenterological Association (AGA) criteria with no significant findings, no clinically significant findings on physical examination and laboratory tests, meeting the protocol criteria for diagnosis of IBS-C, demonstrating continued IBS-C through the Pretreatment Period, and maintaining a minimum level of compliance with a daily diary.\n\nExclusion criteria include having a history of loose or watery stools, symptoms or diagnosis of a medical condition that may contribute to abdominal pain, a structural abnormality of the gastrointestinal (GI) tract or a disease/condition that can affect GI motility, and any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments.",
    "The sample is a phase 2 trial that focuses on two diseases: thalassemia major and osteoporosis. The diseases are identified by their respective ICD-10 codes. The trial involves the use of two drugs, denosumab and placebo. The eligibility criteria for participants are listed, including age requirements, specific disease conditions, and low bone mineral density in certain areas of the body. The sample also includes exclusion criteria, such as previous use of denosumab, participation in other clinical trials, and certain medical conditions. Additionally, it mentions criteria related to pregnancy, contraception, and concurrent illnesses. The sample provides detailed information about the inclusion and exclusion criteria for potential participants in the trial.",
    "The sample from the table is for a phase 2 clinical trial for the treatment of acute myeloid leukemia. The trial is testing the effectiveness of a combination of drugs including alisertib, cytarabine, idarubicin, and daunorubicin. The eligibility criteria for participants include being newly diagnosed with high-risk acute myeloid leukemia, being at least 18 years old, having a certain performance status and left ventricular ejection fraction, and not having received certain types of therapy within 14 days prior to enrollment. There are also criteria related to renal function, liver function, contraception, ability to take oral medication, and understanding and willingness to participate in the study. The exclusion criteria include certain cytogenetic results, specific types of leukemia, recent chemotherapy or radiotherapy, use of other investigational agents, certain medical conditions or treatments, history of certain infections, certain cardiac conditions, hypersensitivity to the trial drugs, certain GI diseases or procedures, pregnancy or breastfeeding, and certain drug-drug interactions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2. The disease being studied is urinary bladder neoplasms. The icd-10 codes associated with this disease are D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, and D41.4. The drugs being used in the trial are gemcitabine, paclitaxel, and cisplatin. The eligibility criteria for this trial include histologic demonstration of metastatic or locally unresectable transitional cell carcinoma of the urothelium, measurable or evaluable disease, adequate physiologic reserves, no previous systemic chemotherapy for bladder cancer, negative pregnancy test for women of childbearing potential, absence of active or likely to become active second malignancy, and exclusion of patients with uncontrolled CNS metastasis, history of peripheral neuropathy greater than grade 1, and pregnant women.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is \"prostatic neoplasms.\" The ICDCodes associated with this disease are ['B38.81', 'N42.31', 'Z87.430', 'N40.0', 'N40.1']. The drugs being used in the trial are 'doxorubicin', 'ketoconazole', 'docetaxel', 'estramustine', and 'degarelix'. \n\nThe eligibility criteria for this trial include various inclusion and exclusion criteria. Inclusion criteria state that patients must have pathologic proof of adenocarcinoma of the prostate and belong to specific subsets based on prior local therapy, nodal involvement, bone disease, or metastatic disease at presentation. Patients may have started ADT (Androgen Deprivation Therapy) within 3 months of study entry. Previous cytotoxic therapy is not allowed, except for limited radiation therapy to one metastatic site. Patients must be free of serious comorbidity, have a life expectancy of at least 3 years, and meet certain physiological requirements such as ECOG status, bone marrow function, renal function, and liver function. There should be no evidence of active ischemia on ECG, and the ejection fraction should be at least 50%.\n\nExclusion criteria state that patients should not have a second malignancy unless previous curative therapy has been successful. Patients with recent history of transient ischemic attack (TIA), requiring regular antianginal therapy, or having claudication sufficient to limit activity are not eligible. Patients with a previous history of deep venous thrombosis or pulmonary embolism within the last 12 months are also not eligible. Additionally, patients should not have a serious intercurrent medical or psychiatric illness, including serious active infection, and should not have sensory neuropathy greater than grade 1.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include anaplastic large cell lymphoma (ALK-negative and ALK-positive), hepatosplenic T-cell lymphoma, peripheral T-cell lymphoma (not otherwise specified), and various stages of angioimmunoblastic T-cell lymphoma and enteropathy-associated T-cell lymphoma. The ICDCodes associated with these diseases are also provided.\n\nThe drugs being used in the trial include cyclophosphamide, doxorubicin hydrochloride, etoposide, lenalidomide, prednisone, and vincristine sulfate.\n\nThe eligibility criteria for participants in the trial are listed, including requirements such as a confirmed diagnosis of specific types and stages of peripheral T-cell non-Hodgkin's lymphoma, pathology material for review, no prior therapy except for radiation or prednisone, expected survival duration of more than 3 months, certain blood counts and liver function within normal limits, and other specific medical conditions and requirements.\n\nThere are also exclusion criteria listed, such as pregnancy or breastfeeding, certain viral infections, recent major surgery, prior malignancies within the past 3 years (with some exceptions), contraindications to required drugs or treatments, and other medical conditions that may interfere with the study or a participant's ability to give informed consent.\n\nOverall, this sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for a clinical trial.",
    "The sample from the table represents a clinical trial in phase 2/phase 3. The trial focuses on patients with vascular diseases, cardiovascular diseases, and acute myocardial infraction. The corresponding ICD-10 codes for these diseases are provided. The only drug being tested in this trial is doxycycline. \n\nThe eligibility criteria for participants include being between the ages of 18 and 75, having ST-elevation Q wave myocardial infraction, being admitted to an intensive care unit within the first 24 hours of onset, and undergoing reperfusion of the infarct-related coronary artery within 24 hours of the initial onset of acute transmural myocardial infraction. Participants must also provide written informed consent to participate in the research.\n\nOn the other hand, there are exclusion criteria for participants, such as having permanent atrial fibrillation, valvular heart disease, severe comorbidity, acute heart failure according to the Killip classification IV FC, a history of chronic heart failure (NYHA III-IV), poor image quality for echocardiography, sinus bradycardia with a heart rate under 50 beats per minute, interventricular conduction delay (QRS > 0.11 s), and atrioventricular block II-III degree.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on studying the effects of two drugs, syn-004 and placebo, on patients with certain diseases. The diseases mentioned in this sample are \"clostridium difficile\" and \"clostridium infections\". The corresponding ICD-10 codes for these diseases are \"A04.71\", \"A04.72\", \"A05.2\", and \"B96.7\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include an expected minimum hospital stay of 5 days, a minimum 5-day course of intravenous ceftriaxone (alone or with a macrolide), and a clinical diagnosis of moderate to severe lower respiratory tract infection with a specific Pneumonia Severity Index (PSI/PORT) score. Exclusion criteria include recent presence of a diarrheal illness, ongoing treatment for CDAD or active CDI, a certain number of previous CDAD episodes within a specific timeframe, and recent use of antibiotics.\n\nOverall, this sample provides a snapshot of the trial's phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of psoriasis. The diseases column lists the disease names, with 'psoriasis' being the disease for this particular record. The icdcodes column contains the ICD-10 codes associated with the diseases, with the codes for psoriasis being ['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']. The drugs column lists the names of the drugs being used in the trial, including 'gsk2894512 1% cream', 'gsk2894512 0.5% cream', and 'vehicle cream'. The criteria column provides the eligibility criteria for participants in the trial, including inclusion and exclusion criteria. The inclusion criteria specify requirements such as age, duration and severity of psoriasis, and specific characteristics of the target plaque. The exclusion criteria list conditions or factors that would disqualify a participant from the trial, such as infections, serious illnesses, allergies, liver disease, certain medications, recent exposure to UV light therapy, and previous participation in a study involving the same investigational product.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which includes the eligibility criteria for participants in the trial.\n\nIn this specific sample, the phase of the trial is phase 2. The disease being studied is \"dermatitis, atopic\" and its corresponding ICD-10 codes are \"L20.89\" and \"L20.9\". The drugs being tested are \"gsk2894512 1% cream\", \"gsk2894512 0.5% cream\", and \"vehicle cream\". The eligibility criteria for participants are listed under \"criteria\" and include age requirements, specific diagnostic criteria for atopic dermatitis, body surface area involvement, and the presence of target lesions. There are also criteria related to the reproductive potential of female participants and the exclusion of individuals with certain medical conditions or history of specific treatments.\n\nOverall, this sample provides specific details about the phase, diseases, drugs, and eligibility criteria for a clinical trial focused on atopic dermatitis.",
    "The sample provided is a record from a table that contains information about a clinical trial. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which includes the eligibility criteria for participants.\n\nIn this particular sample, the phase of the trial is listed as \"phase 2/phase 3\". The disease being studied is \"binge eating disorder\" and its corresponding ICD-10 code is \"F50.81\". The drugs being tested are \"dasotraline\" and \"placebo\". The eligibility criteria for participants are then listed, including age requirements, specific diagnostic criteria for binge eating disorder, confirmation of diagnosis through various assessments, and exclusion criteria such as certain medical conditions, medication usage, and participation in other clinical trials.\n\nOverall, this sample provides a detailed description of the phase, diseases, drugs, and eligibility criteria for participants in a clinical trial focused on binge eating disorder.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 2, and the disease is rheumatoid arthritis. The icd-10 codes associated with the disease are M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, and M06.019. The drug mentioned is adalimumab pfs and pen. The eligibility criteria for this sample include being aged 18-55 years, having a diagnosis of rheumatoid arthritis for at least 6 months, being considered a suitable candidate for self-administering adalimumab treatment, and providing informed consent. The exclusion criteria include previous treatment with biologic agents, hypersensitivity to human immunoglobulin proteins or other components of SB5, current diagnosis of active tuberculosis, recent exposure to active tuberculosis, history of serious infections or recent antibiotic treatment, history of chronic or recurrent infections, and various other medical conditions that may put the subject at risk if enrolled in the trial.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is pulmonary disease, chronic obstructive. The ICD-10 codes associated with this disease are J44.9, J44.1, and J44.0. The drugs being tested in the trial are gsk2269557 dpi and placebo dpi. The eligibility criteria for participants include being between 18 and 70 years old, having a documented history of bronchial asthma, not currently using corticosteroid controllers, having a certain level of lung function, and meeting certain contraceptive requirements for male and female participants. The exclusion criteria include a history of life-threatening asthma, recent severe asthma exacerbations, respiratory infections, concurrent respiratory diseases, certain liver abnormalities, prolonged QTc interval, other significant medical conditions, use of prohibited medications, smoking history, excessive alcohol consumption, allergies to study medications, and certain blood-related restrictions. Additionally, individuals affiliated with the investigator site are not eligible to participate in the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating Hodgkin disease. The trial includes patients who have not received previous treatment for Hodgkin disease and are at least 16 years old. The eligibility criteria include specific stages of Hodgkin disease, certain medical conditions, and measurable disease. The trial requires written informed consent and the ability to comply with the protocol. There are also exclusion criteria, such as having certain types of lymphoma, peripheral neuropathy, and other medical conditions. The sample also includes information about the drug being used in the trial, which is brentuximab vedotin.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The disease mentioned in this sample is \"non-hodgkin lymphoma\". The corresponding ICD-10 codes for this disease are \"['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']\". The drugs being tested in this trial are \"entospletinib\" and \"vincristine\". The eligibility criteria for participants in this trial include having measurable disease, a confirmed diagnosis of relapsed or refractory B-Cell NHL, and having received prior treatment for lymphoid malignancy. Other criteria include performance status, organ function, discontinuation of prior therapy, and willingness to comply with study procedures. There are also exclusion criteria, such as having certain medical conditions, ongoing infections, or prior treatment with a spleen tyrosine kinase (SYK) inhibitor.",
    "The sample from the table represents a clinical trial in phase 2/phase 3 for the treatment of early-stage breast carcinoma and her-2 positive breast cancer. The diseases are identified by their respective ICD-10 codes. The drugs being tested in the trial are docetaxel + trastuzumab sc + pertuzumab and trastuzumab emtansin. \n\nThe eligibility criteria for the trial include written informed consent, confirmation of breast cancer through histology and immunohistochemistry, availability of tumor and blood samples, age 18 years or older, primary breast cancer larger than 20mm or with verified lymph node metastases, adequate bone marrow, renal, hepatic, and cardiac functions, no uncontrolled medical or psychiatric disorders, left ventricular ejection fraction (LVEF) of at least 55%, and an ECOG performance status of 0-1. Additionally, patients must have at most 2 well-defined distant metastases accessible for stereotactic radiotherapy.\n\nThe exclusion criteria for the trial include distant metastases in the contralateral thoracic region or mediastinum, any other malignancy diagnosed within the last five years (except for treated basal or squamous cell carcinoma of the skin or CIS of the cervix), patients of child-bearing age without adequate contraception, pregnancy or lactation, and uncontrolled hypertension, heart, liver, kidney-related, or other medical or psychiatric disorders.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of various types of ovarian and fallopian tube carcinomas. The diseases included in the trial are malignant ovarian endometrioid tumor, malignant ovarian serous tumor, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, and recurrent primary peritoneal carcinoma. The corresponding ICD-10 codes for these diseases are also provided. The drugs being tested in the trial are topotecan hydrochloride and acetylcysteine. \n\nThe eligibility criteria for the trial include having a histologically confirmed high-grade endometrioid or serous ovarian, primary peritoneal, or fallopian tube carcinoma. Patients must have measurable disease that can be accurately measured and at least one target lesion to assess response. Patients must also have a GOG performance status of 0, 1, or 2 and be free of active infections. Prior hormonal therapy and other tumor-directed therapies must be discontinued before starting the trial. Patients must have had at least one prior platinum/taxane combination chemotherapy regimen and be platinum resistant. Adequate bone marrow, renal, hepatic, coagulation, and neurologic function are required. Patients must have signed informed consent and meet pre-entry requirements. Pregnancy and nursing women or women of childbearing potential must be using effective contraception. Patients must be 18 years of age or older and not receiving any other investigational agent. Patients must also be able to swallow whole pills.\n\nThe exclusion criteria for the trial include previous treatment with topotecan, more than 4 prior chemotherapy regimens, radiation to more than 25% of marrow-bearing areas, and a history of other invasive malignancies within the last 3 years. Patients who have received prior chemotherapy for abdominal or pelvic tumors other than ovarian carcinoma within the last 3 years are also excluded, unless they have received prior chemotherapy for localized breast cancer more than three years prior and remain free of recurrent or metastatic disease. Pregnant or nursing women or women of childbearing potential who are not using effective contraception are also excluded.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is chronic obstructive pulmonary disease (COPD). The ICD-10 codes associated with the disease are J44.9, J44.1, and J44.0. The drugs being tested in the trial are batefenterol, umeclidinium/vilanterol, and a placebo. The eligibility criteria for participants include being an outpatient, providing written informed consent, being 40 years of age or older, and meeting certain gender requirements. Other criteria include having an established clinical history of COPD, being a current or former smoker with a history of at least 10 pack-years, and having specific lung function measurements. There are also exclusion criteria, such as having asthma, other respiratory disorders, certain diseases or abnormalities, hepatitis, liver disease, cancer, and certain medication use. The sample also includes additional criteria related to chest X-rays, drug allergies, COPD exacerbations, pneumonia, lung resection, ECG results, screening labs, medication use prior to spirometry, and various other factors that may affect eligibility.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 1/phase 2. The disease being studied is Hodgkin lymphoma. The ICD-10 codes associated with this disease are 'S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', and 'S33.131S'. The drugs being tested in this trial are brentuximab vedotin and nivolumab. The eligibility criteria for participants include having relapsed or refractory Hodgkin lymphoma after standard frontline chemotherapy, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and not having been previously treated with brentuximab vedotin, immune-oncology agents, or received a stem cell transplant. Exclusion criteria include a history of cerebral vascular event, another invasive malignancy that has not been in remission for at least 3 years, and a history of progressive multifocal leukoencephalopathy (PML).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial include induction with car-cy-dex and conditioning with carfilzomib and high-dose melphalan, carfilzomib/dexamethasone maintenance, and observation without carfilzomib/dexamethasone maintenance. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having a myeloma diagnosis according to IMWG criteria, experiencing a first treatment demanding relapse after HDT according to IMWG criteria, having more than 2.0 x 10m CD34+ stem cells/kg body weight in the freezer for stem cell support, providing signed informed consent, and being over 18 years of age. \n\nExclusion criteria include having allogeneic transplantation scheduled as part of the treatment, experiencing a treatment demanding relapse less than one year after HDT, receiving myeloma treatment after the first HDT (except for specific treatments), not having received HDT as first-line treatment, previous treatment with carfilzomib, expected survival of less than six months, and having a performance status (WHO) of 3 or higher. \n\nAdditional exclusion criteria include specific laboratory abnormalities such as low ANC, hemoglobin, platelet count, elevated ALT or AST, and low creatinine clearance. Concurrent conditions that make treatment with certain drugs unsuitable, significant neuropathy, recent major surgery, acute active infection, known or suspected hypersensitivity or intolerance to certain medications, uncontrolled or severe cardiovascular disease, LVEF below 40%, pleural effusions or ascites, serious hepatic disorder, other serious medical or psychiatric illness likely to interfere with participation, and recent use of investigational agents or experimental medical devices are also listed as exclusion criteria. \n\nLastly, there are ethical and other criteria such as being pregnant or lactating, females of childbearing potential agreeing to ongoing pregnancy testing and contraception, and male subjects agreeing to practice contraception.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the diseases being studied are \"human immunodeficiency virus\" and \"dolutegravir monotherapy treatment efficacy.\" The ICDCodes associated with these diseases are \"B20,\" \"Z71.7,\" \"O98.72,\" \"Z21,\" \"O98.73,\" \"R75,\" and \"Z11.4.\" The drug being tested is \"dolutegravir.\" The eligibility criteria for this trial include being HIV-1 positive, being a patient included in the Swiss HIV Cohort Study, being at least 18 years old, having been virologically suppressed for at least 24 months on first-line triple ART, having no history of previous failure on ART, having no documented antiretroviral drug resistance, not having co-infection with Hepatitis B or C virus, using effective contraception in women, being willing to provide CSF and semen samples, and providing written informed consent. The exclusion criteria include having HIV-2 infection, having renal dysfunction, having elevated levels of aspartate transaminase or alanine aminotransferase, using certain medications, having previous AIDS defining conditions or active malignancy in the past five years, having a positive HIV viral load in CSF at baseline, being known or suspected of non-compliance, and being pregnant or breastfeeding for women.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial includes patients who are 40 years of age or older and have a confirmed diagnosis of COPD. The eligibility criteria include being an outpatient, capable of giving informed consent, and meeting certain age and gender requirements. Female participants must not be pregnant or lactating, and they must meet specific criteria related to reproductive potential.\n\nThe trial also specifies the inclusion criteria for COPD disease severity, smoking history, and pack years. Exclusion criteria include a current diagnosis of asthma, other respiratory disorders, and various other diseases or abnormalities that could affect the safety or efficacy of the study. Poorly controlled COPD, history of COPD exacerbation, and recent pneumonia or lower respiratory tract infection are also exclusionary.\n\nThe sample further outlines exclusion criteria related to medication use, liver disease, abnormal laboratory findings, and abnormal electrocardiogram (ECG) results. It also includes restrictions on certain medications prior to spirometry testing and throughout the study. Drug or alcohol abuse, contraindications to study participation, recent participation in other clinical trials, and affiliation with the investigator site are additional exclusion criteria.\n\nFinally, the sample mentions criteria related to the subject's ability to read and understand the study procedures, as well as their compliance with the scheduled visits.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are clarithromycin, placebo, and vcd induction therapy. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The patient must have a diagnosis of myeloma according to IMWG criteria.\n- The disease must require treatment.\n- High-dose melphalan with stem cell support is scheduled as part of the treatment.\n- The patient must have given signed informed consent prior to any study-related activities.\n- The patient must be over 18 years of age.\n\nExclusion Criteria:\n- Allogeneic transplantation is scheduled as part of the treatment.\n- The patient has received myeloma treatment prior to entry in the study, except for radiotherapy, bisphosphonates/denosumab, or corticosteroids for symptom control.\n- The patient has a concurrent disease that makes clarithromycin treatment unsuitable.\n- For women with childbearing potential, a positive pregnancy test is an exclusion criterion.\n- The patient has a known or suspected hypersensitivity or intolerance to clarithromycin.\n- The patient has a prolonged QT corrected (QTc) interval (> 500 msec on screening ECG).\n- The patient is concurrently receiving treatment with cabergoline, fluconazole, ketoconazole, pimozide, quetiapine, sirolimus, verapamil, tacrolimus, ergot alkaloid, simvastatin, or other statins.\n- The patient has uncontrolled or severe cardiovascular disease, including myocardial infraction within 6 months of enrollment, uncontrolled angina, or known cardiac amyloidosis.\n- The patient has severe renal dysfunction (estimated creatinine clearance <10 mL/min).\n- The patient has a serious medical or psychiatric illness that, in the judgment of the investigator, would make them inappropriate for entry into the study.",
    "The sample from the table is for a phase 2 trial. The disease being studied is non-small-cell lung carcinoma. The ICD-10 codes associated with the disease are D02.20, D02.21, and D02.22. The drugs being used in the trial are mk-3475 and docetaxel. The eligibility criteria for the trial include signed written informed consent, locally advanced NSCLC of squamous cell and non-squamous cell histology, performance status of Eastern Cooperative Oncology Group (ECOG) \u2264 1, measurable disease according to RECIST 1.1 criteria, and various laboratory requirements. There are also exclusion criteria, such as currently participating in another investigational study, diagnosis of immunodeficiency or receiving immunosuppressive therapy, prior monoclonal antibody treatment within 4 weeks, prior chemotherapy or radiation therapy within 2 weeks, and various other conditions that may interfere with the trial or the subject's participation.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The trial is testing the effectiveness of a drug called brazikumab, which can be administered either through intravenous infusion or subcutaneous injection. A placebo is also being used as a control. The trial is looking for participants who have been diagnosed with ileal, ileo-colonic, or colonic Crohn's disease for at least 3 months prior to screening. The participants should be between the ages of 18 and 80 and have moderate to severely active Crohn's disease, as determined by the Crohn's Disease Activity Index (CDAI) and endoscopic evidence of inflammation. They should also have a stable dose of medications for Crohn's disease and have previously failed or been intolerant to at least one Anti-Tumor Necrosis Factor-Alpha Therapy (anti-TNF \u03b1) agent. Participants must use effective contraception during the trial and for 36 weeks after the last dose of the investigational product. Exclusion criteria include severe underlying immunosuppression, severe gastrointestinal complications, recent infections, recent treatment with biologic therapy for Crohn's disease, recent or planned live attenuated vaccine, history of cancer (except for certain types), pregnancy or breastfeeding, and drug abuse.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is Alzheimer's disease. The ICD-10 codes associated with this disease are G30.8, G30.9, G30.0, and G30.1. The drugs being tested in this trial are cnp520 and placebo. The eligibility criteria for participants include being in a healthy status, having a body weight of at least 45kg, and having a BMI between 18 and 34 kg/m2. The exclusion criteria include having a history or presence of any clinically significant disease, being a heavy smoker, having a history or presence of clinically significant neurological or psychiatric disorders, having any medical condition that may lead to cognitive deficits, and having severely impaired renal function.",
    "The sample from the table is for a phase 2 clinical trial for the treatment of psoriasis. The eligibility criteria for participants include being between 6 and 17 years old, having a diagnosis of chronic plaque psoriasis for at least 6 months, and having moderate to severe psoriasis as determined by specific criteria such as Psoriasis Area and Severity Index (PASI) score, Body Surface Area (BSA), and Static Physician Global Assessment (sPGA). Participants must also have psoriasis that is inadequately controlled by or inappropriate for topical therapy and be a candidate for systemic or phototherapy. They should not have been exposed to more than one systemic agent for psoriasis. Additionally, there are specific laboratory value ranges that participants must fall within, and certain contraceptive measures must be followed for both male and female participants of childbearing potential. The exclusion criteria include various medical conditions, infections, allergies, and prior treatments that would prevent participation in the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 2. The disease being studied is atopic dermatitis. The corresponding icd-10 codes for atopic dermatitis are \"L20.89\" and \"L20.9\". The drugs being used in the trial are baricitinib, placebo, and triamcinolone (optional). \n\nThe eligibility criteria for participants in this trial are as follows:\n\nInclusion Criteria:\n- Participants must have moderate-to-severe atopic dermatitis, as determined by the following:\n  1. EASI (Eczema Area and Severity Index) score of 12 or more.\n  2. Greater than or equal to 10% of body surface area involvement.\n  3. Must have been diagnosed with atopic dermatitis at least 2 years prior.\n- Participants must have a history of inadequate clinical response to other eczema treatments.\n\nExclusion Criteria:\n- Females who are pregnant or nursing.\n- Participants who do not agree to use adequate contraception.\n- Participants who currently have or have a history of certain skin conditions such as psoriasis or lupus erythematosus, skin disease requiring frequent hospitalizations or intravenous treatment, or compromised immunity.\n- Participants with serious illnesses that could interfere with study participation or have clinically important deviations in physical examination, vital sign measurements, electrocardiograms, or abnormalities on laboratory tests.\n- Participants who currently have or have a history of active or latent tuberculosis, specific immunity disorders and infections, malignancy or lymphoproliferative diseases in the last 5 years (or cervical, basal or squamous skin cancer re-occurrence in the last 3 years), human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or chronic liver disease.\n- Participants who have received certain types of vaccinations.\n\nThis information provides details about the phase, disease, icd-10 codes, drugs, and eligibility criteria for participants in this specific clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on Parkinson's disease. The disease is identified by the ICD-10 code \"G20\". The drug being studied is called nd0612, which is a solution containing levodopa/carbidopa. \n\nThe eligibility criteria for participants in this trial include being male or female, aged between 30 and 80 years, and having a confirmed diagnosis of Parkinson's disease according to the UK Brain Bank Criteria. Participants should have a Modified Hoehn & Yahr scale score of stage \u22643 in the \"ON\" state. They should also be taking at least 4 doses per day of levodopa (or at least 3 doses per day of Rytary) and have tried at least 2 other classes of anti-PD medications for at least 30 consecutive days each. \n\nAdditionally, participants must have been stable on their anti-PD medications for at least 30 days before the start of the trial. They should not have received SC apomorphine injections/infusion for at least 4 weeks prior to the screening visit, and treatment with apomorphine is not allowed during the trial. Participants should experience a minimum of 2.5 hours of \"OFF\" time per day, with predictable early morning \"OFF\" periods. They should also have a good response to levodopa for treating the early morning \"OFF\" periods, as determined by the investigator. \n\nOther criteria include having a Mini Mental State Examination (MMSE) score greater than 26, no clinically significant medical, psychiatric, or laboratory abnormalities that would be unsafe or non-compliant for the study, and meeting certain requirements for contraception for female participants. Participants must also be willing and able to comply with the study requirements. \n\nExclusion criteria for the trial include having atypical or secondary parkinsonism, experiencing acute psychosis or hallucinations within the past 6 months, having any medical, surgical, or psychiatric condition, laboratory value, or concomitant medication that would make the participant unsuitable for the study or potentially unable to complete all aspects of it. Prior neurosurgical procedures for Parkinson's disease or duodopa treatment are also exclusion criteria. Additionally, participants with a history of drug abuse or alcoholism within the past 12 months, clinically significant ECG rhythm abnormalities, or renal or liver dysfunction that may alter drug metabolism are not eligible for the trial. Finally, participants must be willing to operate the pump system used in the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is multiple myeloma. The ICD-10 codes associated with the disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are ixazomib, pomalidomide, and dexamethasone. The eligibility criteria for the trial are listed, including age requirements, consent, contraception requirements for female patients, and performance status. Other criteria include having a diagnosis of relapsed and/or refractory multiple myeloma, having received prior therapy, and having a life expectancy of at least 3 months. The record also includes exclusion criteria, such as lactating or pregnant female patients, recent major surgery or radiotherapy, central nervous system involvement, and ongoing infections. Other exclusion criteria include uncontrolled cardiovascular conditions, active hepatitis B or C, and any serious medical or psychiatric illness that could interfere with treatment. The record concludes with additional criteria related to allergies, gastrointestinal issues, previous or concurrent malignancies, peripheral neuropathy, and participation in other clinical trials.",
    "The sample from the table represents a clinical trial for the treatment of congestive heart failure. The trial is in phase 2/phase 3, indicating that it is in an advanced stage of testing. The disease being studied is congestive heart failure, and the corresponding ICD-10 codes associated with the disease are provided. The drugs being tested in the trial are furosemide injection solution (scp-101) and furosemide injection solution, usp.\n\nThe eligibility criteria for participants in the trial are as follows:\n- Participants must be over 18 years of age.\n- They must have a history of at least 3 months of treated heart failure (NYHA class II/III/IV) or recent hospitalization for heart failure.\n- Participants should be presenting with decompensated heart failure symptoms, including elevated jugular venous pressure, dyspnea, and peripheral edema, where the decision is made to administer IV diuretics.\n- Participants must be able to understand the requirements of the study and willing to comply with all study procedures.\n\nThere are also exclusion criteria for participants, including:\n- Presenting with symptoms that may require hospitalization, such as ischemia, uncontrolled arrhythmia, infection, hemodynamic instability, respiratory compromise, or electrolyte abnormalities.\n- Currently on experimental medication or participating in another cardiovascular research study.\n- Presence or need for urinary catheterization, urinary tract abnormality, or disorder interfering with urination.\n- Any surgical or medical condition that may interfere with participation in the study or affect the study's outcome.\n- Inability to comply with study requirements.\n\nOverall, this sample provides information about the phase, diseases, drugs, and eligibility criteria for a clinical trial focused on congestive heart failure.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on Alzheimer's disease. The table includes columns for the phase, diseases, icd-10 codes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase is phase 2, and the disease is Alzheimer's disease. The icd-10 code for Alzheimer's disease is provided as ['G30.8', 'G30.9', 'G30.0', 'G30.1']. The drug being used in this trial is a placebo. \n\nThe eligibility criteria for this trial are listed under the \"criteria\" column. The inclusion criteria include a diagnosis of probable Alzheimer's disease according to specific criteria, a Mini Mental State Examination (MMSE) score between 20 and 26, a brain MRI finding consistent with Alzheimer's disease, medial temporal lobe atrophy or a positive AD biomarker profile, at least 6 years of formal elementary education, age between 50 and 85 years, fluency in the local language, sufficient auditory and visual capacities for testing, ability to read and understand the informed consent, stable therapy with an acetylcholinesterase inhibitor or memantine for at least 3 months prior to screening, a Hachinski Ischemia Scale score of 4 or less, availability of a caregiver, and specific requirements for female and male patients regarding contraception or sterilization. \n\nThe exclusion criteria include recent participation in another clinical study, pregnancy or breastfeeding, inability to complete the study, allergy to vaccine components, contraindication for MRI imaging, specific brain MRI findings, recent or scheduled surgery under general anesthesia, history or current presence of autoimmune disease or immunosuppressive treatment, recent history of cancer, recent myocardial infraction, presence of certain infectious diseases or immunodeficiency, presence of clinically important systemic illnesses, hypothyroidism, significant psychiatric illnesses, current or recent depressive episodes, metabolic or toxic encephalopathy or dementia due to a general medical condition, history of alcohol or drug abuse, Wernicke's encephalopathy, history or evidence of any CNS disorder other than Alzheimer's disease, cerebrovascular disease or vascular dementia, epilepsy, recent treatment with experimental immunotherapeutics or disease-modifying therapies for AD, current or past treatment with active vaccines for AD, treatment with immunosuppressive drugs, recent changes in medication doses, and vitamin B12 deficiency.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"chronic hepatitis B.\" The associated ICD-10 codes for this disease are \"B18.0,\" \"B18.1,\" \"B18.2,\" \"B18.8,\" and \"B18.9.\" The trial involves the drugs \"tdf,\" \"vesatolimod,\" and a placebo. The eligibility criteria for participants include being adult males or females between the ages of 18-65, having chronic hepatitis B virus (HBV) infection with HBV DNA levels of at least 2000 IU/mL at screening. There are also exclusion criteria, such as having extensive bridging fibrosis or cirrhosis, recent use of oral antiviral treatment for HBV or immune-modulators/biologics, co-infection with other viruses (HCV, HIV, HDV), having chronic liver disease other than HBV, being lactating or pregnant, or planning to become pregnant during the study. It is important to note that there may be additional inclusion/exclusion criteria defined in the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is biliary tract cancer. The ICDCodes associated with this disease are C24.9 and C24.8. The drug being used in the trial is lenvatinib. The eligibility criteria for participants in this trial include having a confirmed diagnosis of adenocarcinoma of biliary tract cancer, being unresectable, having received one prior gemcitabine-based doublet chemotherapy, having measurable disease, having an ECOG Performance Status of 0-1, having a survival expectation of 3 months or longer, and meeting certain organ function and blood coagulation requirements. There are also exclusion criteria listed, such as recent anti-cancer treatment, major surgery, certain medical conditions, and pregnancy or breastfeeding for females.",
    "The sample provided is a record from a table that contains information about clinical trials. The record corresponds to a phase 2 trial for metastatic renal cell cancer. The eligibility criteria for this trial include having histologically confirmed, locally recurrent or metastatic clear cell renal cell carcinoma, having received one prior systemic therapy regimen for metastatic renal cell carcinoma directed against PD-1 and/or PD-L1, and having evidence of measurable disease per RECIST 1.1. Other criteria include a Karnofsky performance status of at least 70%, adequate organ function, and signed informed consent. The exclusion criteria include having non-clear cell renal cell carcinoma, having undergone major surgery or radiation therapy within a certain timeframe, and having certain medical conditions or abnormalities that may increase the risk associated with the study or interfere with the interpretation of the results. The record also specifies that concurrent treatment on another clinical trial is not allowed, and pregnancy or breastfeeding is an exclusion criterion for female subjects unless they meet certain conditions. Additionally, the presence of uncontrolled central nervous system metastases is an exclusion criterion, unless the patient has completed local therapy and is off steroids with clinical and radiographic stability for a certain period of time.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on two diseases: eosinophilic esophagitis and milk allergy. The diseases are associated with specific ICD-10 codes. The trial involves the use of two drugs: \"viaskin milk 500 mcg\" and \"viaskin placebo\". The eligibility criteria for participants are listed, including requirements related to medical history, biopsy results, pregnancy status, contraception, consent, diet, and medication. The exclusion criteria are also listed, which include factors such as severe anaphylaxis, active IgE-mediated milk allergy, pregnancy or lactation, other eosinophilic gastrointestinal disorders, certain medications, asthma conditions, and various other medical conditions or circumstances.",
    "The sample provided is for a clinical trial study. The trial is in phase 1/phase 2 and focuses on the disease osteoarthritis. The associated ICD-10 codes for osteoarthritis are ['M15.4', 'M15.0', 'M16.9', 'M17.9', 'M19.011', 'M19.012', 'M19.019']. The drug being studied is hyaluronic acid. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- Patients must have symptomatic knee osteoarthritis, with Kellgren and Lawrence grade I, II, or III on plain radiographs.\n- Patients must also have chondromalacia patella grade I-III on knee MRI, with or without a meniscal tear.\n- The knee must be stable and have a normal clinical examination.\n- Patients must provide written informed consent.\n\nThe exclusion criteria for the trial are as follows:\n- Patients with bilateral symptomatic knee osteoarthritis are not eligible.\n- Patients with local or systemic infection are excluded.\n- Patients with active neoplasia or an immunosuppressive state are not eligible.\n- Pregnant or breastfeeding individuals are excluded.\n- Patients with a body mass index (BMI) of 30 or higher are not eligible.\n- Patients with a pacemaker or lower extremity metal implant are excluded.\n- Patients on anticoagulant treatment, other than aspirin, are not eligible.\n- Recent use of oral (within the previous month) or intra-articular (within the previous 3 months) corticosteroids excludes patients.\n- Patients with concomitant inflammatory joint disease (such as crystal or connective tissue disease) are not eligible.\n- Patients with a valgus (>10\u00b0) or varus (>5\u00b0) deformity of the involved extremity are excluded.\n- Patients with condylar or tibial plateau generalized bone marrow edema on MRI are not eligible.\n- Patients with significant symptomatic hip or spine disease are excluded.\n- Patients with significant abnormalities in baseline lab tests are not eligible.",
    "The sample is a phase 2 clinical trial for the treatment of oral leukoplakia and erythroplakia, which are conditions associated with the oral cavity. The trial is testing the effectiveness of metformin hydrochloride, a drug commonly used to treat diabetes, in reducing the severity of these conditions. \n\nThe inclusion criteria for participants in the trial include having oral leukoplakia or erythroplakia with mild, moderate, or severe histologic dysplasia, or hyperplasia not caused by mechanical factors such as ill-fitted dentures. Participants must also have measurable disease with a minimum lesion size of 8 x 3 mm before the initial biopsy. Other criteria include a Karnofsky performance status of at least 70%, certain blood cell counts within normal ranges, and normal liver and kidney function. Participants must also have a life expectancy of at least 3 months, be willing to use contraception during the study, be able to take oral medication, and provide informed consent.\n\nExclusion criteria for the trial include patients with diabetes who are taking insulin or oral agents, a history of diabetic ketoacidosis, and recent use of other investigational agents. Other exclusion criteria include a history of allergic reactions to compounds similar to metformin, oral carcinoma in situ, chronic alcohol use or abuse, high glycated hemoglobin levels, pregnancy or nursing, liver or renal disease, a history of prior head and neck squamous cell carcinoma unless treated for at least 1 year, and recent chemotherapy or radiation for any malignancy (excluding non-melanoma skin cancer and certain organ-confined cancers).\n\nOverall, the trial aims to evaluate the potential of metformin hydrochloride as a treatment option for oral leukoplakia and erythroplakia, and the sample provides the specific eligibility criteria for participants in the trial.",
    "The sample from the table represents a phase 2 clinical trial for patients with metastatic breast cancer and brain metastases. The trial is evaluating the effectiveness of the drug eribulin mesylate in treating these conditions. The eligibility criteria for the trial include being a female with histologically confirmed breast cancer, having evidence of metastatic disease, and radiologically confirmed brain metastases. Patients must also be neurologically stable and have stable doses of steroids and anticonvulsants. They should not have uncontrolled systemic disease or tumor-related complications that would limit their life expectancy to less than 3 months. Patients should not be on any cytotoxic chemotherapy or hormonal treatment for breast cancer during the trial, except for trastuzumab in HER2 positive patients. Other criteria include having a Karnofsky performance status of at least 60, no brain radiation therapy for more than 4 weeks, and no chemotherapy for more than 3 weeks before starting the trial. Adequate bone marrow, renal, and hepatic function is required, as well as a negative pregnancy test for females of child-bearing potential. Patients should be able to undergo MRI evaluation with and without gadolinium contrast. The exclusion criteria include the presence of an active infection, abscess, or fistula, known leptomeningeal disease or CNS midline shifts, severe or uncontrolled systemic disease, significant QTc prolongation, grade 3/4 peripheral neuropathy, and the use of pacemakers or ICD devices. Previous treatment with eribulin mesylate is also an exclusion criterion.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on Tourette Syndrome. The ICD-10 code for Tourette Syndrome is \"F95.2\". The drugs being studied are \"nbi-98854\" and \"placebo\". The eligibility criteria for participants are listed, including having a clinical diagnosis of Tourette Syndrome, moderate tic severity, impaired school, occupational, and/or social function due to TS symptoms, being on stable doses of medication if already taking any for TS or related diagnoses, being in good general health, passing a urine drug screen, and agreeing to use contraception if of childbearing potential. The exclusion criteria are also listed, which include having unstable medical conditions, a history of certain cardiac conditions or neuroleptic malignant syndrome, recent cancer diagnosis, allergy or intolerance to VMAT2 inhibitors, history of substance dependence or abuse, significant risk of suicidal or violent behavior, being pregnant or breastfeeding, starting Comprehensive Behavioral Intervention for Tics (CBIT) during the study, recent use of investigational drugs, and recent blood loss or blood donation.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of metastatic melanoma and recurrent cutaneous melanoma. The trial is specifically focused on patients with stage IV disease who have not responded to previous treatments, including BRAF inhibitors and PD1/PD-L1 inhibitors. The trial is evaluating the effectiveness of the drug ibrutinib.\n\nThe eligibility criteria for the trial include having histologically confirmed melanoma, measurable disease, and documented refractory disease to previous treatments. Other criteria include specific laboratory values, performance status, and life expectancy. Patients with brain metastases are allowed if certain conditions are met. The use of corticosteroids and the availability of archival tumor tissue are also considered.\n\nExclusion criteria include certain types of melanoma, recent chemotherapy or radiotherapy, and the use of other biologic or investigational agents. Patients with certain medical conditions or illnesses, such as uncontrolled cardiovascular disease or active hepatitis B or C infection, are excluded. Other exclusions include prior exposure to ibrutinib, certain malignancies within the past 2 years, and the use of certain medications.\n\nOverall, the sample provides detailed information about the phase 2 clinical trial, including the specific diseases being targeted, the drugs being tested, and the eligibility criteria for participation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2, and the disease being studied is type 2 diabetes. The icd-10 codes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are \"isis-gcgrrx- dose level 1\", \"isis-gcgrrx- dose level 2\", and \"placebo\". The eligibility criteria for participants in this trial include being male or female between the ages of 18 and 75, having a BMI of 25.0 kg/m2 or higher, having an HbA1c level between 8.0% and 10.5%, having type 2 diabetes and being on a stable dose of Metformin, and agreeing to conduct home-based (fasted) blood glucose testing as directed. There are also exclusion criteria listed, which include having clinically significant abnormalities in medical history or physical exam, showing evidence of uncorrected hypothyroidism or hyperthyroidism hormone results, having a history of solid organ transplant or renal dialysis, having a history of liver disease, having a history of severe hypoglycemia episodes, being treated with any other antidiabetic drugs other than metformin within 3 months of screening, having a history of diabetic ketoacidosis, having any other significant illness or condition that may interfere with participation in the study, and having an inability or unwillingness to comply with the study's protocol or procedures.",
    "The sample provided is for a phase 2 clinical trial for breast cancer. The trial is specifically targeting postmenopausal women with histologically proven breast cancer that is progesterone and/or estrogen receptor positive, and HER2 negative. The patients must be taking hormone therapy and have already been treated with at least one line of anti-aromatase non-steroidal hormone therapy and one line of chemotherapy. They must also be starting a second or third line of chemotherapy and have one or more measurable or assessable metastatic lesions. If the lesions are isolated bone lesions, they must be non-irradiated with an osteolytic component and have an elevation of the CA15-3 marker. Other inclusion criteria include being over 50 years old, having an ECOG performance status of 0, 1, or 2, and having adequate biological function (neutrophil count, platelet count, creatinine clearance, total bilirubin, alkaline phosphatase, ALT, and AST within specified ranges). The patients must have a life expectancy of greater than 3 months, sign informed consent, and be affiliated with a social security scheme. Exclusion criteria include patients with localized or single metastatic tumor relapse that is accessible to surgical treatment, patients who have already received more than 2 lines of chemotherapy for metastatic or advanced disease, patients who have already received treatment with Navelbine\u00ae, patients requiring immediate localized radiotherapy for analgesic action, patients with non-irradiated cerebral or symptomatic metastasis or symptomatic pulmonary carcinomatosis lymphangitis, patients receiving simultaneous administration of another chemotherapy, hormone therapy, or anti-tumoral drug, patients who have received another treatment within 30 days before the screening visit, patients with known positive HIV serology, patients with a previous cancer within 5 years (except for certain types), patients with any serious concomitant pathology or uncontrolled condition that could compromise participation in the study, patients with disorders of gastrointestinal function or pathology that could interfere with the absorption of the drugs, patients with known hypersensitivity to the drugs or any other component, patients with certain rare hereditary diseases, patients with a history of poor compliance with medical treatment, patients who cannot be regularly monitored for various reasons, and patients with altered mental status that would prevent them from understanding the study or giving informed consent.",
    "The sample from the table represents a clinical trial for the treatment of medullary thyroid carcinoma. The trial is in phase 2/phase 3. The diseases column specifies the disease being targeted, which in this case is medullary thyroid carcinoma. The icdcodes column provides a list of ICD-10 codes associated with the disease. The drugs column lists the drugs being used in the trial, which are anlotinib and placebo. The criteria column contains the eligibility criteria for participants in the trial, including inclusion and exclusion criteria. The inclusion criteria include signed informed consent, histological documentation of medullary thyroid carcinoma, no ability to undergo surgery, presence of measurable disease, ECOG performance status of 0-1, and normal organ function. The exclusion criteria include prior treatment with anlotinib or VEGFR-targeted therapies, recent radiotherapy or plans for anti-cancer treatment, presence of other malignancies, certain toxicities from previous treatments, factors affecting oral medication, pleural effusion or ascites causing respiratory syndrome, and recent major surgical treatment or injury.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on autism spectrum disorders. The ICD-10 code associated with the disease is \"Z16.12\". The drug being studied is \"tideglusib\". \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being an outpatient between the ages of 12 and 17, meeting the DSM-5 criteria for ASD, having a moderate level of illness according to the CGI-S score, and having stable concomitant medications and non-pharmacological interventions for a certain period of time. Participants must also have normal physical examination and laboratory results and be able to provide informed consent or assent.\n\nExclusion criteria include having a primary psychiatric diagnosis other than ASD, being pregnant or sexually active without adequate birth control, having known PTEN mutations, having a serious medical condition that could interfere with the study, having unstable epilepsy or not being on stable antiepileptic medications, having hypersensitivity to tideglusib, being unable to tolerate blood sampling, being actively enrolled in another intervention study, having elevated liver enzymes or abnormal serum creatinine levels, taking certain medications, and being unable to speak and understand English sufficiently for study assessments.\n\nOverall, this sample provides specific details about the phase, disease, drug, and eligibility criteria for participants in a clinical trial for autism spectrum disorders.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the treatment of bronchiolitis in children. The diseases column lists the names of the diseases being studied, which in this case is \"bronchiolitis\". The icdcodes column contains the corresponding ICD-10 codes for the diseases, such as \"J21.9\" and \"J21.1\". The drugs column lists the names of the drugs being used in the trial, including \"0.9% saline solution\" and \"oral betamethasone\". The criteria column provides the eligibility criteria for participants in the trial, including age requirements, specific symptoms, and exclusion criteria such as pre-existing conditions or recent medication use.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer. The trial is evaluating the effectiveness of the drug pemetrexed in treating refractory or progressive colorectal cancer for which there is no further curative therapy available. The eligibility criteria for participants include being at least 20 years old, providing informed consent, having an ECOG performance status of 0-2, having at least one measurable lesion, having a life expectancy of 3 months or more, and demonstrating adequate organ function. Exclusion criteria include having an ECOG performance status of 3 or higher, a history of malignancy in the last 5 years, known infection with HIV, hepatitis B, or hepatitis C, being pregnant or breastfeeding, inability to take Folic acid or Vitamin B12, recent treatment with pemetrexed, inability to swallow oral medication, recent systemic chemotherapy or radiation therapy, experiencing significant toxicity from previous cancer treatment, upper gastrointestinal bleeding or bowel obstruction, and having certain cardiovascular conditions or seizure disorder in the past year. Participants who meet the inclusion and exclusion criteria will be required to provide fresh tissue for biomarker analysis.",
    "The sample from the table represents a clinical trial for the treatment of lymphoma. The trial is in phase 1/phase 2. The diseases being studied are lymphoma. The icd-10 codes associated with the diseases are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drugs being tested in the trial are lenalidomide, vorinostat, gemcitabine, busulfan, melphalan, rituximab, dexamethasone, caphosol, glutamine, pyridoxine, enoxaparin, and palifermin. The eligibility criteria for the trial include age between 15-65, patients with ABC DLBCL with primary refractory disease, relapse <12 months after initial therapy, secondary International Prognostic Index (IPI) >1, less than partial response to salvage treatment or exposure to >3 salvage regimens, adequate renal function, adequate hepatic function, adequate pulmonary function, adequate cardiac function, ECOG performance status <2, negative Beta HCG in women with child-bearing potential, registration into the mandatory Revlimid REMS program, and adherence to the scheduled pregnancy testing for females of reproductive potential. The exclusion criteria include grade >/= 3 non-hematologic toxicity from previous therapy, prior whole brain irradiation, active hepatitis B or hepatitis C, active infection requiring parenteral antibiotics, HIV infection without effective antiretroviral therapy, recent radiation therapy, history of arterial or venous thromboembolic events, and history of hypersensitivity to lenalidomide or thalidomide.",
    "The sample is a phase 2 trial for the treatment of cystic fibrosis. The trial involves the drugs cavosonstat and placebo. The eligibility criteria for inclusion in the trial include being treated with lumacaftor/ivacaftor for at least 8 weeks prior to the start of dosing, having a history of Sweat Chloride (SC) \u2265 60 mEq/L, having a body weight of at least 40 kg, having a ppFEV1 (forced expiratory volume in 1 second) between 40-85% predicted at screening, and having an oxygen saturation of at least 90% breathing ambient air at screening. Exclusion criteria include having an acute infection requiring treatment or hospitalization within 2 weeks of the start of the trial, colonization with certain organisms associated with rapid decline in pulmonary status, recent changes in chronic therapies for CF lung disease, being pregnant, having low blood hemoglobin or serum albumin levels, abnormal liver or renal function, history of certain cardiac conditions, history of solid organ or hematological transplantation, history of alcohol or drug abuse, ongoing participation in another therapeutic clinical trial, and use of continuous or nocturnal supplemental oxygen.",
    "The sample is a phase 2 trial for the treatment of ulcerative colitis. The trial is testing the drugs mirikizumab and placebo. The eligibility criteria for participants include having moderate to severe active ulcerative colitis, evidence of the disease extending beyond the rectum, and up-to-date colorectal cancer surveillance. Participants must either be new to biologic therapy or have a history of failure to respond to or tolerate previous biologic treatments. Exclusion criteria include having indeterminate colitis, proctitis, or Crohn's Disease, having had surgery for UC or likely to require surgery during the study, and recent use of certain medications for UC treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is \"clostridium difficile infection\". The ICDCodes associated with this disease are \"A05.2\", \"A04.71\", \"A04.72\", and \"B96.7\". The drug being used in the trial is \"standard of care antibiotics\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being at least 18 years old, having a medical record documenting recurrent CDI with a positive C. difficile test within 60 days prior to enrollment, and having either at least two recurrences after a primary episode with completed rounds of standard-of-care oral antibiotic therapy or at least two episodes of severe CDI resulting in hospitalization. It also requires a positive stool test for C. difficile within 60 days prior to enrollment.\n\nExclusion criteria include having a known history of continued CDI diarrhea despite being on antibiotics prescribed for CDI treatment, requiring continuous antibiotic therapy for a condition other than CDI, having a previous successful or unsuccessful fecal transplant for recurrent CDI within the last 6 months, previous treatment with RBX2660, diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS), history of chronic diarrhea or celiac disease, disease symptoms caused by a confirmed intestinal pathogen other than C. difficile, having a colostomy, planned surgery requiring perioperative antibiotics within 3 months of study enrollment, having a life expectancy of less than 12 months, or having a compromised immune system.",
    "The sample from the table represents a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is evaluating the effectiveness of the drugs carboplatin and nab-paclitaxel. The eligibility criteria for the trial include being over 70 years old, having a life expectancy of at least 12 weeks, and having an ECOG performance status of 0-2. Patients must also have normal organ and marrow function, as well as a comprehensive geriatric assessment and chemotherapy toxicity assessment score between 7-17. The sample also includes exclusion criteria, such as having received palliative chemotherapy within the past 12 months, having known EGFR or ALK mutated disease, and having preexisting peripheral neuropathy of grade 2 or higher.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease amyloidosis. The ICD-10 codes associated with this disease are ['E85.89', 'E85.9', 'E85.1', 'E85.2', 'E85.3', 'E85.4', 'E85.0']. The drug being studied is idelalisib. The eligibility criteria for participants are listed, including requirements such as the presence of IgM paraprotein or a lymphoplasmacytic population, biopsy-proven relapsed or refractory AL amyloidosis, age 18 or older, and a performance status below 2. Exclusion criteria are also provided, such as previous treatment with idelalisib, certain medical conditions, ongoing alcohol or drug addiction, and inability to comply with the protocol.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase,\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases,\" which lists the names of the diseases being studied, \"icdcodes,\" which contains the corresponding ICD-10 codes for the diseases, \"drugs,\" which lists the names of the drugs being tested, and \"criteria,\" which includes the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is phase 2. The disease being studied is non-small cell lung cancer. The corresponding ICD-10 codes for this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being tested are fruquintinib and placebo.\n\nThe eligibility criteria for this trial are listed under \"criteria.\" The inclusion criteria include understanding and voluntarily signing the informed consent form, being diagnosed with locally advanced and/or metastatic stage IIIB/IV non-squamous NSCLC, having previously failed two chemotherapy regimens, having a positive EGFR mutation (if treated with EGFR-TKI previously), being between the ages of 18 and 75, having a body weight of at least 40 kg, having measurable lesions, having an ECOG Performance Status of 0-1, and having an expected survival of more than 12 weeks.\n\nThe exclusion criteria include being involved in another clinical trial or receiving systemic anti-tumor chemotherapy, radiotherapy, or biotherapy within the past 3 weeks, previous therapy with VEGF/VEGFR inhibitors, not fully recovering from previous anti-cancer treatment or surgery, having active brain metastasis, having other malignancies (except basal cell carcinoma or cervical carcinoma in situ) within the past 5 years, having uncontrolled clinical active infection or known drug malabsorption, having certain gastrointestinal diseases or conditions, having a history of thrombosis or bleeding tendency, having had a stroke or transient ischemic attack within the past 12 months, and having certain organ function abnormalities or uncontrolled hypertension.\n\nThere are additional exclusion criteria related to heart function, myocardial infraction, skin wounds or fractures, pregnancy or lactation, contraception, clinical or laboratory abnormalities, psychological or psychiatric disorders, and allergies to the trial drugs.\n\nOverall, this sample provides information about a phase 2 clinical trial for non-small cell lung cancer, including the diseases being studied, the drugs being tested, and the eligibility criteria for participation in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on non-small cell lung cancer. The associated ICD-10 codes for the disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are mk-3475, carboplatin, paclitaxel, and pemetrexed. \n\nThe eligibility criteria for the trial are as follows:\n- Participants must be at least 18 years old.\n- Participants must have a life expectancy of at least 3 months.\n- Participants must have a confirmed diagnosis of stage IV NSCLC.\n- Participants must have a performance status of 0 or 1 on the ECOG scale.\n- Participants must have measurable disease based on RECIST 1.1.\n- Participants must have provided tissue from a tumor sample.\n- For patients with non-squamous non-small cell lung cancer, the EGFR mutation status or ALK translocation status must be documented.\n- Participants must have adequate organ function.\n- Female participants of childbearing potential must have a negative pregnancy test and agree to use two methods of birth control or be surgically sterile.\n- Male participants must agree to use an adequate method of contraception.\n\nThe exclusion criteria for the trial are as follows:\n- Participants who have received prior treatment with chemotherapy or biologic therapy for stage IV NSCLC.\n- Participants who are currently participating in or have participated in a study of an investigational agent or using an investigational device.\n- Participants with immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy.\n- Participants who have received a prior monoclonal antibody within 4 weeks prior to the study or have not recovered from adverse events due to agents administered more than 4 weeks earlier.\n- Participants who have had prior chemotherapy or radiation.\n- Participants with a known additional malignancy that is progressing or requires active treatment.\n- Participants with known active CNS metastases and/or carcinomatous meningitis.\n- Participants with an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.\n- Participants with evidence of interstitial lung disease or active, non-infectious pneumonitis.\n- Participants with an active infection requiring systemic therapy.\n- Participants with a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial.\n- Participants with known psychiatric or substance abuse disorders.\n- Participants who are pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial.\n- Participants who have received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA-4 antibody.\n- Participants with a known history of HIV.\n- Participants with known active Hepatitis B or Hepatitis C.\n- Participants who have received a live vaccine within 30 days prior to the planned first dose of study therapy.\n- Participants with a known history of active TB.\n- Participants with hypersensitivity to pembrolizumab or any of its excipients.",
    "The sample provided is for a phase 2 clinical trial. The diseases being studied in this trial are \"hepatitis c viral infection,\" \"chronic hepatitis c,\" \"hepatitis c (hcv),\" and \"hepatitis c genotype 4.\" The corresponding ICD-10 codes for these diseases are \"B18.2,\" \"B18.0,\" \"B18.1,\" \"B18.8,\" \"B18.9,\" \"K71.3,\" \"K71.4,\" \"B00.81,\" \"B25.1,\" \"B26.81,\" \"B58.1,\" \"K75.4,\" \"A51.45,\" and \"B17.2.\" The drugs being tested in this trial are \"faldaprevir,\" \"td-6450,\" and \"ribavirin.\" \n\nThe eligibility criteria for this trial include being diagnosed with chronic genotype 4 hepatitis C infection and having a HCV RNA level of at least 10^4 IU/mL at screening. Participants must also be treatment-naive for hepatitis C virus, meaning they have never received a direct-acting antiviral (DATA) and have received no more than 8 weeks of interferon at least 6 months prior to screening. Additionally, participants must not have cirrhosis, which can be determined through a liver biopsy, transient elastography (FibroScan\u00ae), or specific blood tests (FibroSure\u00ae score and AST:platelet ratio). \n\nThe exclusion criteria for this trial include having an infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV-1 or HIV-2).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"end stage renal disease,\" and the corresponding ICDCodes are ['N18.6', 'I12.0', 'I13.11', 'I13.2']. The drug mentioned is \"triferic.\" \n\nThe eligibility criteria for this trial include:\n1. The parents or legal guardians of the patient must understand the study requirements and have given consent for their child to participate.\n2. The patient must be under 18 years of age at the screening.\n3. The patient must have chronic kidney disease and receive in-center hemodialysis at least twice weekly for at least 1 month prior to screening.\n4. The patient must be receiving adequate hemodialysis, as assessed by a single pool Kt/V measurement >1.2.\n5. The patient must have a suitable vascular access for hemodialysis treatment (tunneled catheter, AV fistula, or AV graft).\n6. The patient must have a body mass of at least 11 lbs (5 kg).\n7. The patient must have sufficient iron levels, indicated by a TSAT >20% and a ferritin >100 micrograms/L at screening.\n8. The patient must have a whole blood Hgb concentration of 10.0 g/dL at screening.\n9. If the patient is receiving ESA (erythropoiesis-stimulating agents), the dose must have been stable for at least 3 weeks prior to baseline admission.\n10. The patient must have appropriate laboratory values for their disease state, as determined by the investigator.\n11. The patient must not have any significant abnormal findings on physical examination that would prevent participation in the study.\n12. If the patient is female, she must be pre-pubertal, have undergone surgical sterilization, or be practicing adequate birth control. Female patients aged 9 years and older, as well as those who have reached menarche before age 9 years, must have a negative serum pregnancy test during screening. The investigator is responsible for determining whether the patient has adequate birth control for study participation.\n\nThe exclusion criteria for this trial include:\n1. The patient is positive for human immunodeficiency virus (HIV) or hepatitis B based on their medical history.\n2. The patient has had an acute illness within 1 week of baseline admission (they may be screened again 2 weeks after the illness has resolved).\n3. The patient is currently receiving intravenous or oral antibiotics or antifungals for any infectious process, except for regular prophylactic antibiotics.\n4. The patient has evidence of an ongoing active inflammatory process, such as systemic lupus erythematosus or acute/chronic active hepatitis.\n5. The patient has participated in an investigational drug study within the 30 days prior to baseline admission.\n6. The patient has received IV or oral iron supplements within 2 weeks prior to baseline admission.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on gastric cancer. The ICD-10 codes associated with the disease are provided. The trial involves the use of two drugs, apatinib and docetaxel. The eligibility criteria for participants are listed, including age, diagnosis of advanced gastric cancer with measurable metastases, failure of prior therapy, Eastern Cooperative Oncology Group Performance Status, and various organ function requirements. Other criteria include expected survival, pregnancy test for women of childbearing age, and voluntary participation. The exclusion criteria are also listed, which include allergies to apatinib, uncontrolled hypertension, gastrointestinal bleeding risk, CNS metastases, pregnancy or lactation, history of other malignant tumors, and other conditions that may pose a risk or prevent completion of the study.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial is looking at the effectiveness of the drug propanolol in patients with stage I-III breast cancer who are planning to undergo surgery. The inclusion criteria for the trial include being between the ages of 18-65, having a confirmed diagnosis of breast cancer through a core biopsy, and having normal blood pressure and EKG results. The exclusion criteria include pregnancy, uncontrolled diabetes or hypertension, cardiac diseases, asthma or bronchospastic disease, and allergies to certain medications. Patients taking specific medications are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are carfilzomib, cyclophosphamide, and dexamethasone. The eligibility criteria for participants in this trial include having relapsed symptomatic multiple myeloma, measurable disease, prior treatment with one to three regimens for multiple myeloma, documented relapse or progressive disease, achieved response to at least one prior regimen, age 18 or older, life expectancy of at least 3 months, ECOG performance status of 0-2, and meeting specific laboratory requirements. There are also exclusion criteria listed, such as being refractory to any proteasome inhibitor therapy, prior carfilzomib treatment, certain medical conditions, and ongoing graft-versus-host disease, among others.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 2.\n- Diseases: The trial is focused on three diseases - atherosclerotic cardiovascular disease, familial hypercholesterolemia, and diabetes.\n- ICD Codes: The ICD-10 codes associated with the diseases are provided.\n- Drugs: The trial involves the use of two drugs - \"aln-pcssc\" and \"normal saline\".\n- Criteria: The eligibility criteria for participants are listed, including inclusion and exclusion criteria. The inclusion criteria specify requirements such as age, medical history, LDL-C levels, and kidney function. The exclusion criteria outline conditions or circumstances that would prevent participation in the trial, such as uncontrolled diseases, heart failure, certain medical conditions, and pregnancy.\n\nOverall, this sample provides information about the phase, diseases, ICD codes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on studying the effects of certain drugs on various diseases. The diseases being studied in this sample are postherpetic neuralgia, diabetic polyneuropathy, and peripheral neuropathy. The corresponding ICD-10 codes for these diseases are B02.22 and G90.09. The drugs being used in the trial are lidocaine hcl and normal saline. The eligibility criteria for participants in this trial include having a NRS score greater than 4, being on stable oral medication during the trial period, and providing informed consent. There are also exclusion criteria listed, such as pregnancy, hypersensitivity to lidocaine or other local anesthetics, and having important diseases that may interfere with the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and is focused on the treatment of dry eye syndrome. The trial involves the use of the drugs \"rgn-259\" and \"placebo\". The eligibility criteria for participants include being at least 18 years old, having a history of dry eye for at least 6 months, and having certain test scores related to dry eye symptoms. There are also exclusion criteria, such as having certain eye conditions or infections, recent eye surgeries, or using certain medications. The sample provides specific details about the inclusion and exclusion criteria for potential participants in the trial.",
    "The sample provided is for a phase 2 clinical trial. The trial is focused on breast cancer, specifically estrogen receptor negative neoplasm and HER-2 positive breast cancer. The trial is testing the drugs nab-paclitaxel and trastuzumab. \n\nThe eligibility criteria for participants include having histologically confirmed invasive breast cancer with a tumor size of 3cm or less and no spread to nearby lymph nodes (N0). Participants must also have hormone receptors identified as negative and HER2 positive confirmed by specific tests. Other criteria include having a left ventricular ejection fraction (LVEF) greater than 50% as measured by echocardiogram or MUGA, adequate EKG results, no prior treatment for breast cancer, and a performance status (PS) of 0-1. \n\nBaseline laboratory data must show certain values within normal ranges, including white blood cell count (WBC) greater than 4,000/mm3, neutrophil count (Neut) greater than 2,000/mm3, platelet count (PLT) greater than 100,000/mm3, hemoglobin (Hb) greater than 9.0g/dl, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels less than 2.5 times the upper limit of normal (ULN), total bilirubin (T-Bil) less than 1.5mg/dl, and serum creatinine less than 1.5mg/dl. \n\nExclusion criteria include a history of hypersensitivity reaction to any important drug in the study, a history of invasive breast cancer, bilateral invasive breast cancer, and medical conditions that make participants intolerant to primary chemotherapy and related treatment. Other exclusion criteria include being positive for HBs antigen or HCV antibody, having a history of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infraction, poorly controlled hypertension, severe edema, severe peripheral neuropathy, severe psychiatric disorder, being pregnant or nursing, and being deemed unsuitable for the study by a physician.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of glucose transporter type 1 deficiency syndrome. The trial uses a drug called ux007. The eligibility criteria for participants include having a confirmed diagnosis of Glut 1 DS, being at least 1 year old, and having completed a previous study related to UX007. Participants must also provide informed consent and be willing to comply with the study requirements. Females of childbearing potential must have a negative pregnancy test and agree to use contraception during the study. The sample also includes exclusion criteria, such as hypersensitivity to triheptanoin, history of suicidal ideation, and current pregnancy or breastfeeding. Participants must discontinue the use of certain medications and cannot have used any other investigational products within 30 days prior to the study. The sample also mentions that participants with severe conditions or concurrent diseases may not be eligible for the trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2, and the disease being studied is hepatitis C. The icd-10 codes associated with this disease are B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, and B15.9. The drugs being used in the trial are grazoprevir, elbasvir, ribavirin, and sofosbuvir. The eligibility criteria for participants in this trial include having HCV RNA (>= 10,000 IU/mL in peripheral blood) at screening, having documented HCV GT3, having compensated cirrhosis of the liver, having liver imaging within 6 months of Day 1 with no evidence of hepatocellular carcinoma (HCC), being either HCV TN or TE, being otherwise healthy as determined by medical history, physical examination, ECG, and clinical laboratory measurements, and meeting other specific requirements. There are also exclusion criteria listed, such as having previously received one or more doses of a direct-acting antiviral (DATA), having evidence of decompensated liver disease, being coinfected with hepatitis B, having a recent history of malignancy or under evaluation for HCC or other suspected malignancy, and other conditions that may affect the study or pose additional risks.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is essential hypertension. The ICDCodes associated with this disease are \"I10\", \"O10.02\", \"O10.03\", \"O10.011\", \"O10.012\", \"O10.013\", and \"O10.019\". The drugs being tested in this trial include \"aprocitentan 5 mg\", \"aprocitentan 10 mg\", \"aprocitentan 25 mg\", \"aprocitentan 50 mg\", \"lisinopril 20 mg\", and \"placebo\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include signed informed consent, no contra-indication to stop anti-hypertensive treatment, and having mild-to-moderate essential hypertension. Exclusion criteria include severe hypertension, secondary hypertension, certain medical conditions, and use of specific medications.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is described as \"phase 1/phase 2\". The disease being studied in this trial is \"influenza\". The corresponding ICD-10 codes for this disease are \"J11.81\", \"J11.82\", \"J10.01\", \"J10.81\", \"J10.82\", \"J11.08\", and \"J11.2\". The drugs being tested in this trial are \"oseltamivir\", \"medi8852\", and \"placebo\". \n\nThe eligibility criteria for participants in this trial are as follows:\n- Age between 18 and 65 years at the time of screening.\n- Presence of symptomatic presumptive Influenza A infection with symptoms appearing within the last 5 days before MEDI8852 administration. Symptoms include fever of 38.0 degrees Celsius (100.4 degrees Fahrenheit) or higher, at least one moderate systemic symptom (such as headache, malaise, myalgia, sweats and/or chills, or fatigue), and at least one moderate respiratory symptom (such as cough, sore throat, or nasal symptoms).\n- Confirmation of Influenza A infection through a positive rapid antigen test.\n- Ability to complete the follow-up period through Day 101 as required by the protocol, including telephone follow-up from Days 11 to 101.\n- Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception for at least 2 days prior to the first dose of the investigational product and continue using such precautions until Day 101 of the study.\n\nThe exclusion criteria for participants in this trial are as follows:\n- Hospitalized subjects.\n- Receipt of influenza antiviral therapy within the preceding 14 days.\n- Receipt of immunoglobulin or blood products within 6 months prior to screening.\n- Known immunodeficiency due to illness, including HIV, or due to drugs, including glucocorticoid therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months prior to screening.\n- Current clinical evidence of pneumonia.\n- Active bacterial infection requiring treatment with oral or parenteral antibiotics.\n- History of malignancy other than treated non-melanoma skin cancers or locally-treated cervical cancer in the previous 3 years.\n- Any planned surgical procedure before completion of Day 101.",
    "The sample provided is a phase 2 clinical trial for the treatment of Waldenstrom's Macroglobulinemia. The trial is evaluating the drug ibrutinib. The eligibility criteria for participants include having a clinicopathological diagnosis of Waldenstrom's Macroglobulinemia, measurable disease, age 18 or older, ECOG performance status of 2 or lower, and normal organ and marrow function. Participants must not be on any active therapy for other malignancies, and females of childbearing potential must agree to use contraception. The sample also includes exclusion criteria such as prior systemic therapy for WM, serious medical conditions, concurrent use of other anti-cancer treatments or investigational agents, and certain medical conditions that could interfere with the absorption or metabolism of ibrutinib.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of postpartum hemorrhage. The trial is investigating the use of tranexamic acid and ethamsylate as drugs. The eligibility criteria for participants include being women undergoing elective caesarean section, having one or more risk factors for postpartum hemorrhage, being at least 18 years old, and having a gestational age of at least 35 weeks. Informed oral consent from the patient is also required. The exclusion criteria include a history of venous or arterial thrombosis, epilepsy or seizure history, any known cardiovascular, renal, or liver disease, autoimmune diseases, sickle cell disease, severe hemorrhagic disease, placenta previa, morbidly adherent placenta, abruptio placenta, eclampsia, hemolysis, elevated liver enzymes, and low platelet count syndrome, and administration of low molecular weight heparin or antiplatelets the week before delivery.",
    "The sample is a phase 2 trial with two diseases, HIV-1 infection and hepatitis C. The diseases are represented by their respective ICD-10 codes. The trial involves two drugs, ledipasvir/sofosbuvir and ribavirin. The eligibility criteria for the trial include providing written informed consent, having documentation of non-cirrhotic or cirrhotic status, being HIV-1 positive, meeting specific HIV antiretroviral treatment status and CD4+ T-cell count requirements, having HCV GT-1 within the past 12 months, and having prior virologic treatment failure with certain SOF-containing regimens. Other criteria include meeting certain laboratory values, having specific hemoglobin, AST, and ALT levels, having a negative pregnancy test for female participants, agreeing to use contraception, and intending to comply with the dosing instructions and study schedule. The exclusion criteria include recent exposure to investigational drugs or devices, prior exposure to a DATA other than SOF and SIM, having chronic liver disease of a non-HCV etiology, having certain infections or conditions, having a history of certain diseases or disorders, having difficulty with blood collection, having active drug or alcohol use or dependence, using prohibited concomitant medications, having known hypersensitivity to certain drugs, currently receiving specific medications, having acute HIV infection or hepatocellular carcinoma, being pregnant or breastfeeding, and having a male participant with a pregnant female partner.",
    "The sample is a phase 2 clinical trial for bladder cancer. The eligibility criteria for the trial are as follows:\n\nInclusion Criteria:\n1. Patients must have histologically confirmed non-muscle invasive bladder cancer (NMIBC) and have undergone their transurethral resection of bladder tumor (TURBT).\n2. Only patients with \"Intermediate\" or \"High risk\" bladder cancer, as per the European Association of Urology (EAU) guidelines, will be enrolled. For patients with \"high risk\" bladder cancer, only those who undergo BCG therapy following their TURBT will be eligible.\n3. Patients who receive BCG instillations post-operatively will be eligible.\n4. Patients whose tumors are androgen receptor positive (AR(+)) as well as androgen receptor negative (AR(-)) will be included, but the inclusion of AR(-) subjects will be limited to represent no more than 1/3 of the total study population or any single cohort.\n5. Subjects of child-bearing potential must agree to use two acceptable forms of birth control.\n\nExclusion Criteria:\n1. Patients with \"low risk\" bladder cancer, as defined by the EAU guidelines, will be ineligible.\n2. Patients with \"high risk\" bladder cancer who do not undergo BCG therapy following their TURBT will be ineligible.\n3. Patients who have had a recurrence of bladder cancer despite prior use of BCG therapy will be ineligible.\n4. Patients who receive an immediate post-TURBT single instillation of intravesical chemotherapy will be ineligible.\n5. Patients who receive a post-operative induction course of intravesical chemotherapy (more than just a single immediate post-operative dose) will be ineligible.\n6. Patients who undergo blue-light/fluorescence cystoscopy will be ineligible.\n7. Patients with a history of heart attack within the previous 12 months or unstable cardiovascular status will be ineligible.\n8. Patients with uncontrolled hypertension (systolic blood pressure > 160 on 2 occasions despite appropriate medical therapy) will be ineligible.\n9. Patients with a history of venous thrombo-embolism (DVT/PE) within the past 3 years will be ineligible.\n10. Patients with a history of seizure disorders, stroke, or transient ischemic attacks (TIA) within the previous 12 months will be ineligible.\n11. Patients with a history of liver disease with elevated hepatic enzymes, alkaline phosphatase, or bilirubin greater than twice the upper limit of normal will be ineligible.\n12. Patients with kidney disease and an estimated glomerular filtration rate (eGFR) less than 30 will be ineligible.\n13. Patients with neutropenia will be ineligible.\n14. Patients with clinical hypogonadism, those on androgen replacement therapy, or those with prostate cancer or other diseases treated with hormonal therapy (excluding 5-alpha reductase inhibitors) will be ineligible.\n15. Patients who have undergone therapy for any malignancy within the past 5 years, except for basal and squamous cell carcinomas of the skin, will be ineligible.\n16. Patients with prior histories of prostate cancer treated by definitive local therapy more than 5 years ago will only be eligible if they have had no clinical or biochemical evidence of recurrent prostate cancer.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is gastrointestinal stromal tumors. The ICD-10 codes associated with this disease are C49.A0, C49.A1, C49.A2, C49.A5, C49.A3, C49.A4, and C49.A9. The drug being tested is paclitaxel. The eligibility criteria for participants in this trial include being 20 years or older, having confirmed metastatic and/or advanced GIST with specific genetic markers, having failed prior treatments for GIST, having a certain performance status, having resolved toxic effects from previous treatments, having measurable lesions, and having adequate organ functions. There are also exclusion criteria, such as pregnancy or breastfeeding, certain cardiac diseases, uncontrolled infections, diabetes with peripheral vascular disease, liver disease, gastrointestinal toxicities, and other medical or psychiatric conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease mentioned is \"stage IIIA non-small cell lung cancer.\" The ICDCodes associated with this disease are \"C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2.\" The drugs being used in this trial are \"cisplatin, docetaxel, gemcitabine hydrochloride, pemetrexed disodium.\" The eligibility criteria for this trial include various medical conditions and requirements such as specific cancer stage, performance status, blood cell counts, liver function, kidney function, previous treatments, and other health conditions. Additionally, there are specific criteria for patients who will receive pemetrexed/cisplatin therapy. It is also mentioned that patients should have no contraindications for FDG-PET/CT.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is hypercholesterolemia. The ICDCodes associated with this disease are E78.01, E78.00, and Z83.42. The drugs being used in the trial are cat-2054, placebo, and atorvastatin. The eligibility criteria for participants include being between 18 and 74 years old, having hypercholesterolemia with LDL-C levels between 70 mg/dL and 190 mg/dL, and being on a stable dose of statin for at least 4 weeks prior to screening. There are additional criteria related to contraception for female patients of childbearing potential and the use of acceptable contraceptive methods for male patients. The sample also includes exclusion criteria such as a history of major cardiovascular events, type I diabetes mellitus or insulin use, and active peptic ulcer disease or a history of muscle disease or myopathy.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is asthma, and the corresponding ICD-10 codes for asthma are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drug being tested is called crd007. The eligibility criteria for participants include providing written informed consent, being between the ages of 18 and 50, and having a diagnosis of asthma. The exclusion criteria include having clinically significant comorbidities, having had a lower respiratory tract infection within the past 6 weeks prior to Visit 1, and any other criteria specified in the protocol.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease called mesothelioma. The ICD-10 codes associated with this disease are C45.9, C45.0, C45.1, C45.2, and C45.7. The drugs being studied in this trial are anetumab ravtansine (bay94-9343) and vinorelbine. The eligibility criteria for participants include having histological documentation of malignant pleural mesothelioma that overexpresses mesothelin, having unresectable locally advanced or metastatic mesothelioma after progression on first-line treatment with platinum and pemetrexed, having measurable disease, having an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1, having a life expectancy of at least 3 months, having adequate bone marrow, liver, and renal function, and having a left ventricular ejection fraction (LVEF) of at least 50% or within the normal range. The exclusion criteria include having received more than one previous systemic anti-cancer therapy line, having corneal epitheliopathy or any eye disorder that may increase the risk of this condition, having brain metastases, meningeal tumors, or other metastases in the central nervous system, having a history of bleeding diathesis, having an ongoing or active infection of grade higher than 2 according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03, and having pre-existing cardiac conditions.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for participants in the trial.\n\nIn this particular sample, the phase of the trial is phase 2. The disease being studied is \"acute kidney injury\" and its corresponding ICD-10 codes are listed as \"N26.2\", \"Q63.0\", \"Q63.2\", \"Z52.4\", \"I75.81\", \"N19\", and \"N20.0\". The drugs being tested are \"qpi-1002\" and \"placebo\". The eligibility criteria for participants are then listed, including requirements such as the ability to understand and provide informed consent, being at least 45 years old, having stable renal function, and being scheduled for non-emergent open chest cavity cardiovascular surgeries. There are also specific AKI (acute kidney injury) risk factors listed as inclusion criteria. Exclusion criteria are also provided, such as having an eGFR (estimated glomerular filtration rate) below a certain level, having a history of organ or cellular transplant, or having certain medical conditions or infections.\n\nOverall, this sample provides a snapshot of a clinical trial focusing on acute kidney injury, its corresponding ICD-10 codes, the drugs being tested, and the eligibility criteria for participants.",
    "The sample provided is for a phase 2 clinical trial for the treatment of primary Sj\u00f6gren's syndrome. The trial is investigating the effectiveness of the drugs \"ucb5857\" and \"placebo\". The eligibility criteria for participants include being between 18 and 75 years old, meeting the 2002 AECG criteria for primary Sj\u00f6gren's syndrome, and having a positive serum test for anti-SSA/Ro or anti-SSB/La autoantibodies. \n\nExclusion criteria include having any other autoimmune disease, sicca syndrome, significant fibromyalgia syndrome or depression, oral candidiasis, being pregnant or breastfeeding, having an immunosuppressive state, a history of chronic infections, recent serious or life-threatening infection, receiving intranasal influenza vaccine within the past 8 weeks, significant hematologic abnormalities, or a history of cancer. \n\nParticipants must also have completed any prior anti-infective therapy before starting the study drug, except for specific cases such as acne or urinary tract infections. Additionally, participants at a particularly high risk of infection due to lifestyle or occupation are excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the ICD-10 codes associated with the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for participants in the trial.\n\nIn this specific sample, the phase of the trial is phase 2. The diseases being studied are \"osteoarthritis of the knee\" and \"chronic lower back pain\". The associated ICD-10 codes for these diseases are [\"M15.4\", \"M15.0\", \"M16.9\", \"M17.9\", \"M19.011\", \"M19.012\", \"M19.019\"]. The drugs being tested are \"asp7962\", \"naproxen\", and \"placebo\". The eligibility criteria for participants are listed in a detailed format, including requirements related to the diagnosis of osteoarthritis, radiographic evidence, pain levels, medication use, and various medical history and health factors.\n\nOverall, this sample provides a snapshot of a specific clinical trial, including the phase, diseases being studied, drugs being tested, and the criteria that participants must meet to be eligible for the trial.",
    "The sample from the table is for a phase 2 clinical trial. The diseases being studied are urinary bladder neoplasms, ureteral neoplasms, and urethral neoplasms. The corresponding ICD-10 codes for these diseases are provided. The drug being tested in the trial is crizotinib. The eligibility criteria for the trial include having histologically confirmed stage IV urothelial carcinoma of the bladder, upper urinary tract, or urethra, prior treatment for metastatic disease with at least one cisplatin or carboplatin-based multi-agent chemotherapeutic regimen, and measurable disease per RECIST 1.1. There are also criteria related to tissue pre-screening, age, performance status, liver function, bone marrow function, renal function, ability to understand and sign informed consent, and ability to swallow oral medication. The exclusion criteria include currently receiving any other investigational agents or a prior c-MET inhibitor or crizotinib, being pregnant or breastfeeding, having uncontrolled and current illness, having certain cardiovascular conditions, having a history of active malignancy other than urothelial carcinoma, having certain cardiac conditions, having a pulmonary disorder requiring supplemental oxygen or a history of pulmonary fibrosis, and receiving medications or substances that are strong inhibitors or inducers of CYP3A. There are also criteria related to medications that are CYP3A substrates with a narrow therapeutic range and specific timeframes for major surgery, prior systemic therapy, prior non-palliative radiotherapy, completion of palliative radiotherapy, and recovery of adverse events from prior therapies. Additionally, the presence of untreated brain metastases or recent treatment for brain metastases, active neurologic symptoms, or the use of prohibited medications in subjects with a history of brain metastases are also exclusion criteria.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is cancer. The ICDCodes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested is snx-5422. \n\nThe eligibility criteria for this trial include:\n- The patient must have confirmed solid or hematological TP53 null type cancer.\n- The patient must have had no more than 4 prior lines of systemic anti-cancer therapy.\n- The patient must be male or a non-pregnant, non-breastfeeding female who is 18 years of age or older.\n- The patient must have a Karnofsky performance score of 60.\n- The patient must have a life expectancy of at least 3 months.\n- The patient must have adequate baseline laboratory assessments.\n- The patient must have recovered from toxicities of previous anticancer therapy to CTCAE Grade \u2264 1, except for alopecia.\n\nThe exclusion criteria for this trial include:\n- The patient must not have received treatment with an investigational agent within 30 days prior to the first dose of SNX-5422 or planning to receive an investigational agent during the study.\n- The patient must not have received treatment with other anticancer drugs within 28 days or 5 half-lives of anticancer therapy (whichever is shorter) from 30 days prior to the first dose of SNX-5422 and throughout the study.\n- The patient must not have received radiation treatment within 2 weeks.\n- The patient must not need treatment with medications metabolized by the cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of SNX-5422.\n- The patient must not have an appropriately corrected screening ECG QTc interval of 470 msec for females or 450 msec for males.\n- The patient must not be currently receiving medications known to cause QT prolongation and have a corrected QTc of 450 msec for females or 430 msec for males.\n- The patient must not have chronic diarrhea of grade 2 or greater despite maximal medical management.\n- The patient must not have gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.\n- The patient must not have gastrointestinal diseases that could alter the assessment of safety, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.\n- The patient must not have a history of documented adrenal dysfunction not due to malignancy.\n- The patient must not be seropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).\n- The patient must not have a history of chronic liver disease.\n- The patient must not have active hepatitis A or B.\n- The patient must not have current alcohol dependence or drug abuse.\n- The patient must not have clinically significant glaucoma, retinitis pigmentosa, or macular degeneration.\n- The patient must not have any other serious concurrent illness or medical condition.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of refractory chronic cough. The diseases column specifies the disease being studied, while the icdcodes column provides the corresponding ICD-10 codes for the disease. The drugs column lists the drugs being tested in the trial, including gefapixant and a placebo for gefapixant. The criteria column outlines the eligibility criteria for participants in the trial, including age range, having refractory chronic cough, using birth control for women of child-bearing potential, and providing informed consent. It also lists exclusion criteria such as being a current smoker, having certain respiratory conditions, recent opioid use, abnormal blood pressure or ECG, abnormal laboratory tests, pregnancy or breastfeeding, and other medical or psychiatric conditions that may interfere with the trial or its results.",
    "The sample from the table is a clinical trial for colorectal cancer patients in phase 1/phase 2. The eligibility criteria for participants include being aged between 20 and 75 years, having unresectable adenocarcinoma originating in the large intestine, having lesions that can be evaluated according to specific criteria, and being refractory to or failing previous chemotherapies for metastatic colorectal cancer. Participants must also be classified as KRAS/NRAS wild-type, able to take medications orally, and have satisfactory organ function. Other criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy of at least 3 months. Exclusion criteria include previous treatment with certain drugs, recent radiotherapy or chemotherapy, brain metastasis, synchronous or metachronous cancers with a disease-free period of 5 years or more, and various other medical conditions. Participants who do not meet the eligibility criteria or are deemed ineligible by the investigator or subinvestigator are excluded from enrollment in the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of dry eye syndromes. The ICD-10 codes associated with this disease are 'H04.121', 'H04.122', 'H04.123', and 'H04.129'. The drugs being studied are cyclosporine a and a placebo. The eligibility criteria for participants are listed, including requirements such as signing an informed consent form, having a patient-reported history of dry eye in both eyes, and currently using eye drops for dry eye symptoms. There are also exclusion criteria, such as being pregnant or nursing, having certain eye conditions or infections, and having a known allergy or sensitivity to the study drug or its components.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of cluster headaches, both episodic and chronic. The diseases column specifies the disease name, while the icdcodes column provides the corresponding ICD-10 codes for the diseases. The drugs column lists the names of the drugs being used in the trial, which in this case are \"som230\" and \"placebo\". The criteria column contains the eligibility criteria for participants in the trial, including both inclusion and exclusion criteria. The inclusion criteria include factors such as age, diagnosis of cluster headaches, ability to communicate with the investigator, and ability to self-inject medication. The exclusion criteria include factors such as a history of more than 6 cluster headache attacks per day, pregnancy or lactation, history of drug or alcohol abuse, and certain medical conditions or abnormalities.",
    "The sample from the table represents a clinical trial in phase 2/phase 3. The trial focuses on the treatment of primary open angle glaucoma and ocular hypertension. The diseases are identified by their corresponding ICD-10 codes. The drugs being tested in the trial include a placebo ophthalmic solution, de-117 ophthalmic solution (low and high doses), and latanoprost ophthalmic solution 0.005%. \n\nThe eligibility criteria for the trial are as follows:\n- Inclusion Criteria: Patients with primary open angle glaucoma or ocular hypertension.\n- Exclusion Criteria: Patients at risk of progression of visual field loss, patients with severe visual field defect, and patients with any diseases that would prevent their participation in the study for safety reasons.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the disease \"appendicitis\". The ICD-10 codes associated with the disease are ['K36', 'K37', 'K35.80', 'K35.20', 'K35.21', 'K35.890', 'K35.891']. The drugs being studied are \"ropivacaine\" and \"normal saline\". \n\nThe eligibility criteria for participants are as follows:\n- Children and adolescents aged 7-18 years old\n- ASA Score I or II (American Society of Anesthesiologists classification) indicating a normal healthy patient or a patient with mild systemic disease\n- Patients scheduled for laparoscopic appendectomy surgery\n- Uncomplicated appendicitis, with no evidence of appendiceal perforation based on preoperative clinical and imaging assessment, and diagnosed as simple acute appendicitis by intraoperative laparoscopy\n- Patients who have provided a written informed assent, and caregivers who have provided a written informed consent\n\nThe exclusion criteria for participants are as follows:\n- ASA Score III, IV, or V indicating severe systemic disease or a moribund patient\n- Hemodynamically unstable patient\n- Evidence of appendiceal perforation based on preoperative clinical and imaging assessment, or diagnosed with perforated or gangrenous appendicitis during laparoscopic surgery\n- Postoperative admission in an intensive care unit with sedation or ventilatory assistance\n- Cognitive impairment or mental retardation\n- Progressive degenerative diseases of the CNS\n- Seizures or chronic therapy with antiepileptic drugs\n- Severe hepatic or renal impairment\n- Allergy to one of the specific drugs under study\n- Alcohol or drug addiction\n- Failure to successfully undergo a laparoscopic appendectomy\n- A significant communication problem including language barrier, precluding phone follow-up\n- Participation in a concomitant research study\n- Inability to assure complete follow-up\n- Failure to acquire informed consent and assent",
    "The sample from the table is for a phase 2 clinical trial for the treatment of multiple myeloma. The diseases column specifies that the trial is focused on multiple myeloma. The icdcodes column provides the ICD-10 codes associated with the disease, which are \"C90.01\", \"C90.02\", and \"C90.00\". The drugs column lists the drugs being used in the trial, which are \"daratumumab\" and \"dexamethasone\". The criteria column outlines the eligibility criteria for participants in the trial. These criteria include being able to understand and sign an informed consent form, adhering to the study visit schedule, being at least 18 years old, having a life expectancy of more than 6 months, and having relapsed myeloma that is resistant or refractory to previous treatments. The criteria also specify the required levels of certain biomarkers, the Eastern Cooperative Oncology Group (ECOG) performance status score, and adequate organ function. There are also exclusion criteria, such as having certain medical conditions, prior or concurrent invasive malignancies, uncontrolled cardiovascular or pulmonary disease, and positive HIV or active hepatitis B or C. The sample also includes criteria related to pregnancy and contraception for women of childbearing potential, as well as other physical and laboratory test findings that would exclude participants from the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on Alzheimer's disease. The ICD-10 codes associated with the disease are G30.8, G30.9, G30.0, and G30.1. The trial involves testing different drugs, including s47445 5mg, s47445 15mg, s47445 50mg, and a placebo. The eligibility criteria for participants are listed, including being an out-patient, able to perform neuropsychological tests, having a responsible informant, meeting the DSM-IV-TR criteria for Alzheimer's disease, having a Mini Mental State Examination (MMSE) score between 15 and 24, meeting the National Institute of Mental Health (NIMH) provisional criteria for depression in Alzheimer's disease (NIMH-dAD), having a Cornell Scale for Depression in Dementia total score of 8 or higher, not having been previously treated with Alzheimer's disease treatments or having stopped treatment, and either not currently being treated with an antidepressant or being treated with an antidepressant at the recommended dose for at least 8 weeks without clinical efficacy. The exclusion criteria are also listed, including not being able to read or write, having participated in a study testing disease modifying therapy for Alzheimer's disease or another study with an investigational drug or device within the previous 3 months, having depressive symptoms clearly due to a medical condition other than Alzheimer's disease or non-mood related dementia symptoms, having a history of epilepsy or solitary seizure, having a medical history of Major Depressive Disorder more than 3 years before the onset of the disease and being treated with antidepressive drugs or electroconvulsive therapy, having a severe or unstable disease that could interfere with safety and efficacy assessments, having a history of alcohol or drug abuse or addiction (excluding nicotine), having clinically relevant lactose intolerance, not having stopped antidepressant treatment for at least 3 weeks before inclusion, having a significant worsening of depressive symptoms or a high suicidal risk according to the investigator's judgment, and having medically unstable Chronic Obstructive Pulmonary Disease and asthma or a known hypersensitivity to donepezil hydrochloride or piperidine derivatives for the optional extension phase of the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is renal cell carcinoma. The corresponding ICD-10 codes for this disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drug being tested in this trial is sunitinib malate. The eligibility criteria for participants in this trial include having advanced renal cell carcinoma with histology confirmation, experiencing Grade III/IV adverse events during the first cycle of sunitinib treatment, having an ECOG performance status of 0 or 1, and having appropriate vital organ functions. The exclusion criteria include having received prior systemic treatment for metastatic renal cell carcinoma, undergoing neoadjuvant or adjuvant systemic therapy, having undergone major surgery within the past 4 weeks or radiation therapy within the past 2 weeks prior to starting the study treatment (except for palliative radiotherapy to non-irradiated measurable lesions), being pregnant, and having a history of allergy to sunitinib.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial is Phase 2.\n- Diseases: The trial is focused on uveal melanoma, a type of eye cancer.\n- ICD Codes: The ICD-10 codes associated with the disease are ['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4'].\n- Drugs: The drugs being used in the trial are ipilimumab and nivolumab.\n- Criteria: The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include providing written informed consent, having a histological diagnosis of uveal melanoma, having progressive metastatic disease, being over 18 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and having measurable disease according to RECIST 1.1 criteria. Exclusion criteria include prior systemic treatment for metastatic uveal melanoma, active malignancy within the previous 3 years (with some exceptions), autoimmune diseases, certain medical or psychiatric conditions, prior treatment with specific antibodies or drugs targeting T-cell costimulation or immune checkpoint pathways, concomitant therapy with certain immunotherapy regimens or chronic use of systemic corticosteroids, active brain metastases or leptomeningeal metastases, and women of childbearing potential who are unwilling or unable to use contraception or are pregnant or breastfeeding.\n\nThis record provides specific information about a Phase 2 clinical trial focused on uveal melanoma, the associated ICD-10 codes, the drugs being used, and the eligibility criteria for participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"leukemia, chronic myeloid\" and \"myelodysplastic syndromes\" along with \"leukemia, myeloid, chronic, atypical, bcr-abl negative\". The corresponding ICDCodes for these diseases are \"D46.9\", \"D46.C\", and \"D46.Z\". \n\nThe drugs being used in this trial are \"busulfan\", \"fludarabine monophosphate\", \"tacrolimus\", \"mycophenolate mofetil\", \"cyclophosphamide\", and \"thymoglobulin\". \n\nThe eligibility criteria for this trial include having an indication for allogeneic hematopoietic stem cell transplantation, a specific diagnosis, signed informed consent, availability of a 10/10 HLA-matched unrelated donor, peripheral blood stem cells as the graft source, no second tumors, no prior history of Thymoglobulin exposure or anaphylactic shock after Thymoglobulin administration, and no severe concurrent illness. \n\nThe exclusion criteria include moderate or severe cardiac dysfunction, moderate or severe decrease in pulmonary function, respiratory distress, severe organ dysfunction, low creatinine clearance, uncontrolled bacterial or fungal infection, requirement for vasopressor support, low Karnofsky index, pregnancy, and somatic or psychiatric disorders that would prevent the patient from signing informed consent.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is rheumatoid arthritis. The ICDCodes associated with this disease are ['M06.9', 'M05.9', 'M06.08', 'M06.00', 'M06.011', 'M06.012', 'M06.019']. The drugs being used in the trial are 'ly3337641' and 'placebo'. The eligibility criteria for participants include being a female of childbearing potential who tests negative for pregnancy, agreeing not to breastfeed, using a reliable method of birth control, having a diagnosis of rheumatoid arthritis based on specific criteria, having at least one of the specified indicators of active RA, and having had an inadequate response or intolerance to previous treatments. The exclusion criteria include having received certain specific treatments, having certain medical conditions or infections, being at high risk of infection, having had certain types of cancer within the past 5 years, and having received a live vaccine recently or planning to receive one during the study.",
    "The sample is a phase 2 trial for patients with chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of the drug solithromycin compared to a placebo. The inclusion criteria for the trial include a history of cigarette smoking, specific lung function measurements, and willingness to comply with study visits and procedures. Exclusion criteria include recent exacerbation of COPD, certain medical conditions that could affect drug absorption, and use of certain medications. The sample also includes criteria related to pregnancy and contraception for female participants. Overall, the sample provides detailed information about the eligibility criteria for the trial.",
    "The sample from the table is for a phase 2 clinical trial. The trial is focused on gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. The diseases are identified by their ICD-10 codes. The drugs being studied are ramucirumab and paclitaxel. The eligibility criteria for the trial include having confirmed gastric carcinoma, metastatic or locally recurrent disease, measurable or evaluable disease, disease progression after first-line therapy, and not being a candidate for curative resection. Other criteria include age, performance status, hepatic and renal function, hematologic function, coagulation function, and absence of certain medical conditions. Exclusion criteria include brain or leptomeningeal metastases, recent GI bleeding or arterial thromboembolic events, certain medical conditions, ongoing psychiatric illness or social limitations, uncontrolled hypertension, recent surgery or therapy, and allergies or sensitivities to the treatment components. The patient must not have received more than 1 prior therapy in the metastatic setting.",
    "The sample is a phase 2 trial for HIV-1 infection. The table includes information about the phase, diseases, icd-10 codes, drugs, and eligibility criteria for the trial. In this specific sample, the phase is phase 2, the disease is HIV-1 infection, and the icd-10 codes associated with the disease are B20, Z71.7, O98.72, Z21, O98.73, R75, and Z11.4. The drugs being used in the trial are doravirine, tenofovir, and lamivudine. The eligibility criteria include being HIV-1 positive, being na\u00efve to antiretroviral therapy, having specific NNRTI mutations, being clinically stable, and not being likely to become pregnant or impregnate a partner. The exclusion criteria include a history of drug or alcohol abuse, previous treatment for viral infections other than HIV-1, resistance to study drugs, recent participation in other studies, medical conditions requiring immunosuppressant drugs, and contraindications to the study drugs. Additionally, being pregnant, breastfeeding, or planning to conceive or donate eggs/sperm during the study are also exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is oral mucositis, and the corresponding ICDCodes are K12.30, K12.39, K12.33, K12.31, and K12.32. The drugs being tested are melatonin oral gel 3% and placebo oral gel. The eligibility criteria for this trial include requirements such as patients being 18 years or older, providing written informed consent, having a life expectancy of at least 3 months, and being willing to comply with treatment and follow-up. Other criteria include specific histological diagnoses, treatment plans, performance status, and baseline organ function. The exclusion criteria list various conditions and circumstances that would make a patient ineligible for participation in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of proliferative diabetic retinopathy. The trial is focused on evaluating the effectiveness of the drug aflibercept. The eligibility criteria for participants include having active proliferative diabetic retinopathy with high-risk characteristics, being 18 years or older with a history of diabetes mellitus, and having a certain level of visual acuity. The inclusion criteria specify the specific characteristics of the retinopathy that make a patient eligible, while the exclusion criteria list various conditions and treatments that would disqualify a patient from participating in the trial. Additionally, there are criteria related to ocular disorders, previous surgeries, and other medical conditions that would affect the interpretation of the study results. The sample also mentions the need for adequate contraception for sexually active participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are solid tumors, soft-tissue sarcoma, and breast cancer. The ICDCodes associated with these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial include cyclophosphamide and jx-594 dose escalation, cyclophosphamide and jx-594, cyclophosphamide, and avelumab and jx-594 and cyclophosphamide. The eligibility criteria for the trial include specific histology requirements, metastatic or unresectable locally advanced disease, age over 18 years, specific ECOG scores, life expectancy of more than 3 months, measurable disease according to RECIST v1.1 criteria, a certain time since last treatment, adequate organ functions, negative pregnancy test for women of childbearing potential, agreement to use contraception, awareness of drug interactions, and signed informed consent. The exclusion criteria include previous treatment with JX-594 or other vaccina vector-based treatment, certain concomitant diseases/conditions, active central nervous system metastasis, recent participation in another study, inability to comply with study procedures, known hypersensitivity to study drugs, use of certain medications, previous malignancies, active cardiovascular disease, inability to suspend anti-hypertensive medication, certain cardiac conditions, severe systemic reaction to previous smallpox vaccination, cardiac disease, urinary tract obstruction, household contact exclusions, and recent vaccination.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is migraine. The ICD-10 codes associated with the disease are G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, and G43.419. The drugs being tested are placebo and erenumab. The eligibility criteria for the trial include having a history of migraine for at least 12 months, having a migraine frequency of 4 to 15 migraine days per month, and a headache frequency of less than 15 headache days per month. Other criteria include compliance with an electronic diary, exclusion of certain medications, devices, or procedures, absence of certain medical conditions, and not being pregnant or breastfeeding. There are also exclusion criteria specific to a Clinical Home Use (CHU) Substudy.",
    "The sample from the table is for a phase 2 clinical trial for breast cancer. The eligibility criteria for the trial include being a premenopausal or postmenopausal woman aged 18 or older with histologically confirmed adenocarcinoma of the breast, ER positive and HER2 negative status. Patients must have progressed during or within 12 months of completion of adjuvant endocrine therapy or during prior endocrine therapy for advanced/metastatic disease. One line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy. Patients must have evidence of disease, but measurable disease is not mandatory. For those with measurable disease, specific criteria for size apply. Patients must have an ECOG performance status of 0-2 and adequate organ and bone marrow function. Tumor tissue from the most recent pathological specimen must be provided. Patients must be able to complete quality of life questionnaires and provide informed consent. Patients must be accessible for treatment and follow-up. There are also exclusion criteria, such as patients with advanced, symptomatic, visceral spread or symptomatic CNS involvement, prior treatment with certain inhibitors, active second malignancy, and concurrent medical conditions that may interfere with the study. Participation in a prior anti-cancer investigational study within 30 days prior to enrollment is also an exclusion criterion.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the treatment of lymphoma, specifically follicular lymphoma. The trial involves the use of drugs such as atezolizumab (mpdl3280a) [tecentriq], lenalidomide, and obinutuzumab. The eligibility criteria for participants include having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2, having relapsed or refractory follicular lymphoma after previous treatment, and having a histologically documented CD20-positive lymphoma. Other criteria include having measurable lesions, availability of a tumor specimen for confirmation, and compliance with contraception requirements. Exclusion criteria include having grade 3b follicular lymphoma, a history of transformation to diffuse large B-cell lymphoma, and known CD20-negative status. Other exclusion criteria include prior stem-cell transplantation, previous resistance to lenalidomide, and certain medical conditions or infections. The sample also mentions criteria related to pregnancy and lactation.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease called AL amyloidosis. The ICD-10 code for this disease is E85.81. The trial involves two drugs, neod001 and placebo. The eligibility criteria for participants include being at least 18 years old, having a confirmed diagnosis of systemic AL amyloidosis, having received prior therapy for plasma cell dyscrasia with a partial hematologic response, having cardiac involvement, and having an NT-proBNP level of at least 650. The exclusion criteria include not having AL amyloidosis, meeting the definition of multiple myeloma according to the International Myeloma Working Group, having an NT-proBNP level higher than 5000, having received plasma cell directed chemotherapy within the past 6 months, and having received an autologous stem cell transplant within the past 12 months.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of head and neck neoplasms. The trial involves the use of drugs such as patritumab, cetuximab, cisplatin, carboplatin, and a placebo. The eligibility criteria for participants include having histologically confirmed recurrent or metastatic SCCHN tumor, providing tumor tissue for testing, having measurable disease, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and meeting certain hematological, renal, and hepatic function requirements. Participants must also agree to use effective contraception during the study and provide written informed consent. Exclusion criteria include having a left ventricular ejection fraction (LVEF) below 50%, prior use of epidermal growth factor receptor (EGFR) targeted regimen or anti-human epidermal growth factor receptor 3 (anti-HER3) therapy, prior chemotherapy for recurrent/metastatic disease, and recent anti-cancer therapy. Other exclusion criteria include a history of certain malignancies, brain metastases, uncontrolled hypertension, significant electrocardiograph (ECG) findings, recent myocardial infraction or heart-related conditions, recent platinum-containing drug therapy with radiotherapy, and recent therapeutic or palliative radiation therapy or major surgery.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is nonalcoholic steatohepatitis (NASH). The ICD-10 code for NASH is K75.81. The drugs being tested in the trial are obeticholic acid, atorvastatin, and a placebo. The eligibility criteria for participants include being at least 18 years old, having histologic evidence of NASH with a score of at least 4 according to NASH Clinical Research Network criteria, having fibrosis stage 1 to stage 4 without hepatic decompensation, and meeting certain requirements for diabetes medication and contraception. There are also exclusion criteria, such as a history of significant alcohol consumption, intolerance to atorvastatin or other HMG Coenzyme A reductase inhibitors, and certain medication restrictions. Other exclusion criteria include the presence of other chronic liver diseases, liver transplant or placement on a transplant list, hepatic decompensation, and certain abnormal laboratory values. The sample also includes additional criteria related to cardiovascular disease, concomitant diseases or conditions, substance abuse, pregnancy or breastfeeding, previous participation in clinical research studies, and hypersensitivity to the drug being tested. Any other conditions that may impede compliance or hinder completion of the study are also considered exclusion criteria.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease mentioned is \"osteoarthritis of the knee\" and its corresponding ICDCodes are ['M15.4', 'M15.0', 'M16.9', 'M17.9', 'M19.011', 'M19.012', 'M19.019']. The drugs being studied are 'fx006 32 mg' and 'tca ir 40'. The eligibility criteria for this trial include written consent to participate, willingness to comply with study procedures, symptoms of knee osteoarthritis for at least 6 months, meeting the American College of Rheumatology criteria for OA, experiencing knee pain for more than 15 days in the last month, having a BMI of 40 kg/m2 or less, and being in good general health. The exclusion criteria include having certain other diseases or conditions, recent infections or surgeries in the knee, recent use of corticosteroids or other investigational drugs, prior use of FX006, and being a pregnant or nursing woman without effective contraception.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease mentioned is gastroesophageal reflux disease (GERD), and its corresponding ICDCodes are K21.9, K21.00, and K21.01. The drugs involved in the trial are iw-3718, matching placebo, and PPI (proton pump inhibitor). \n\nThe eligibility criteria for this sample include being an ambulatory, community-dwelling male or nonpregnant female who is at least 18 years old. Lactating females must agree not to breastfeed. The patient must have a diagnosis of GERD and report experiencing GERD symptoms (heartburn or regurgitation) on at least 4 days per week during the 8 weeks before the Screening Visit while taking standard QD PPI therapy.\n\nThere are also exclusion criteria, such as not meeting any of the excluded conditions specified in the protocol, having alarm symptoms like GI bleeding, anemia, vomiting, dysphagia, or unexpected weight loss during the Screening or Pretreatment Periods, and having a history of clinically significant hypersensitivity or allergies to any of the excipients contained in the study medication (active or placebo).\n\nIt is important to note that additional inclusion/exclusion criteria may apply, but they are not specified in this sample.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is a combination of phase 2 and phase 3. The disease being studied is \"nocturia,\" which is associated with the ICD-10 code \"R35.1.\" The drugs being tested are \"fedovapagon 2 mg\" and a placebo. The eligibility criteria for participants include being adult males aged 18 years or older, having benign prostatic hyperplasia, experiencing persistent nocturia despite previous lifestyle modifications, having serum sodium levels within the normal range, providing informed consent, and being able to comply with the study requirements. The exclusion criteria are not specified in the sample.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 2, and the diseases listed include colorectal adenocarcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, hepatocellular adenocarcinoma, gastric adenocarcinoma, and esophageal adenocarcinoma. The ICDCodes associated with these diseases are also provided. The drug mentioned in this sample is ceritinib. The eligibility criteria for this trial include specific requirements related to the diagnosis, age, previous treatments, organ function, laboratory values, contraception, and ability to provide informed consent. The exclusion criteria outline conditions or medications that would disqualify a patient from participating in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The disease being studied in this particular record is pruritus. The ICD-10 codes associated with this disease are L29.0, L29.1, L29.2, L29.8, L29.9, and L29.3. The drugs being used in the trial are botox and saline. \n\nThe eligibility criteria for participants in this trial are as follows:\n\nInclusion Criteria:\n1. Healthy volunteers between 18 and 50 years of age.\n2. Must be in general good health with no disease or physical conditions that would impair evaluation of itch and pain perception.\n3. No history of chronic itch or pain.\n4. Must abstain from the use of any systemic or topical anti-histamine, steroid, or pain relief medications from the week prior to the study till the completion of the study.\n5. Must abstain from the use of moisturizers on the arm.\n\nExclusion Criteria:\n1. Individuals under 18 or over 50 years of age.\n2. Inability to complete the required measures.\n3. The presence of an itchy skin disease.\n4. Diagnosis of diseased that would affect itch or pain perception (e.g. neuropathies).\n5. Currently enrolled in any investigational study in which the subject is receiving any type of drug, biological, or non-drug therapy.\n6. Use of oral, topical analgesics, or other medications known to interfere with itch or pain perception in the week prior to the study and throughout the study (e.g. antihistamines, anesthetics, opioids, neuroleptics, etc.).\n7. Use of emollients on the arms a week prior to the study and throughout the study.\n8. Use of anti-depressants, anti-psychotics, and illicit drugs.\n9. Known history of neuropathy, uremia, uncontrolled thyroid disease, and diabetes mellitus.\n10. Use of Botulinum toxin in the last year.\n11. Known allergies to Botox.\n12. Pregnant women. (Women of childbearing potential will undergo a human chorionic gonadotrophin (hCG) pregnancy test before Botox application).\n13. Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.\n14. Infection at the injection site.\n15. Cardiovascular disease.\n16. Neuromuscular disorder (e.g., amyotrophic lateral sclerosis, myasthenia gravis, or Lambert-Eaton syndrome).\n17. Compromised respiratory function.\n18. Dysphagia.\n19. History of urinary tract infection.\n20. History of urinary retention.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 2 and phase 3. The disease being studied is fibromyalgia, and its corresponding ICD-10 code is M79.7. The drug being tested is pregabalin. The sample also includes the eligibility criteria for participants. Inclusion criteria include meeting the ACR 2010 criteria for fibromyalgia diagnosis, being literate, and having a mean WAS (Visual Analog Scale) for pain higher than 6 in the last 3 months. Exclusion criteria include pregnancy or inadequate use of contraception, contraindications for Transcranial Magnetic Stimulation, alcohol or drug abuse in the last 6 months, any severe neurological, neurosurgical, cardiac, endocrinological, or oncological disease (current or past), decompensated chronic systemic disease, and previous use of pregabalin.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 2, and the disease mentioned is \"hemoglobin sc disease\". The icd-10 codes associated with this disease are \"D56.5\", \"D56.4\", \"D58.2\", \"D59.5\", \"D59.6\", and \"R82.3\". The drug mentioned is \"hydroxyurea\". The eligibility criteria for this trial include a diagnosis of HbSC disease, a score of 80 or lower on the AdultQLTM 3.0 Sickle Cell Disease Module, or any disease-related complications such as pain events, retinopathy, avascular necrosis, cholelithiasis, or thrombotic events. Exclusion criteria include failure to meet the inclusion criteria, recent usage of hydroxyurea, chronic RBC transfusion therapy, recent packed red blood cell transfusion, pregnancy or refusal to use birth control, and current phlebotomy therapy.",
    "The sample is a phase 2 trial that focuses on the disease of smoking. The trial involves the use of the drugs cerc-501 and placebo. The eligibility criteria for participants include providing informed consent, being between the ages of 21 and 60, having a body mass index (BMI) between 18.5 and 40, being a heavy smoker, not currently seeking smoking cessation therapy, being in good general health, and being able to read, write, and speak in English. Female participants must either be post-menopausal or meet specific criteria for contraception. Male participants must agree to use a condom if their partner is of childbearing potential. Exclusion criteria include having any substance use disorder other than nicotine or caffeine, current neurological or psychiatric conditions that interfere with the study, a history of certain mental disorders, gastric diseases, comorbid diseases that may limit participation, clinically significant laboratory test results, elevated AST or ALT levels, positive HIV or hepatitis serology, severe allergies or adverse drug reactions, hypersensitivity to CERC-501, current use of certain medications without permission, and recent use of investigational medications.",
    "The sample provided is a record from a table that contains information about a clinical trial. The table has several columns, including \"phase\" which indicates the phase of the trial (in this case, phase 2), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for participating in the trial.\n\nIn this particular sample, the phase of the trial is phase 2. The diseases being studied are \"kras gene mutation\", \"recurrent lung non-small cell carcinoma\", and \"stage iv lung non-small cell cancer ajcc v7\". The corresponding ICD-10 codes for these diseases are \"C96.20\", \"C96.29\", and \"D47.09\". The drugs being used in the trial are \"docetaxel\" and \"trametinib\". The eligibility criteria for participating in the trial are listed in detail, including disease-related criteria, prior/concurrent therapy criteria, clinical/laboratory criteria, and regulatory criteria. These criteria cover various aspects such as disease confirmation, disease stage, prior treatment history, laboratory results, medical conditions, and consent requirements.\n\nOverall, this sample provides a snapshot of the information stored in the table, giving details about the phase, diseases, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample from the table represents a clinical trial for the treatment of acute myeloid leukemia (AML). The trial is divided into different phases, including phase I, phase II, and phase III. The diseases targeted in the trial include recurrent childhood AML, secondary AML, and therapy-related AML. The diseases are identified by their corresponding ICD-10 codes. The drugs being tested in the trial include cytarabine, fludarabine phosphate, and liposome-encapsulated daunorubicin-cytarabine. \n\nThe eligibility criteria for the trial are listed, including requirements for histologic verification of AML, specific disease characteristics, previous treatment history, performance status, recovery from prior treatments, and various medical parameters such as kidney and liver function. \n\nThere are also exclusion criteria, which include previous exposure to certain doses of daunorubicin equivalents, current use of other investigational drugs, specific medical conditions such as acute promyelocytic leukemia (APL) and Down syndrome, active infections, and allergies to daunorubicin and/or cytarabine. \n\nFemale patients who are pregnant or lactating, as well as sexually active patients of reproductive potential, must use effective contraception during the trial. \n\nOverall, the sample provides detailed information about the phase, diseases, drugs, eligibility criteria, and exclusion criteria for the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is phase 2.\n- Diseases: A list of disease names related to the trial, including \"painful diabetic neuropathy,\" \"diabetic neuropathy,\" and \"neuropathy.\"\n- ICD Codes: A list of ICD-10 codes associated with the diseases mentioned above.\n- Drugs: A list of drug names being tested in the trial, such as \"clonidine hydrochloride topical gel, 0.1%\" and \"clonidine hydrochloride gel comparator.\"\n- Criteria: The eligibility criteria for participants in the trial, including both inclusion and exclusion criteria.\n\nThe inclusion criteria specify requirements for subjects to be eligible for the trial, such as being fluent in English, having diabetes mellitus, experiencing chronic pain due to neuropathy, and meeting certain pain score thresholds.\n\nThe exclusion criteria outline conditions or circumstances that would disqualify a subject from participating in the trial, such as having neuropathy from non-diabetic causes, significant neurological disorders, or unstable medical or psychiatric conditions.\n\nOverall, this sample provides a snapshot of a phase 2 clinical trial focusing on painful diabetic neuropathy, including the diseases being studied, the drugs being tested, and the criteria for participant eligibility.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease called \"cardiorenal syndrome.\" The ICD-10 codes associated with this disease are \"Q93.81,\" \"B33.4,\" \"A36.81,\" \"A50.54,\" \"A52.00,\" \"A52.09,\" and \"B33.24.\" The drugs being studied in this trial are \"milrinone\" and \"dobutamine.\" \n\nThe eligibility criteria for participants in this trial are as follows:\n\nInclusion Criteria:\n1. Age greater than 18 years.\n2. Admitted to the hospital with a primary diagnosis of Decompensated Heart Failure.\n3. Onset of cardio-renal syndrome (increasing creatinine > 0.3mg/dl) after or before hospitalization. After hospitalization within 7 days from the time of admission after receiving intravenous diuretics and heart failure medication optimization. Before hospitalization in the setting of escalating doses of outpatient loop diuretics and heart failure medication optimization.\n4. Persistent volume overload - For patients with a pulmonary artery catheter, persistent volume overload will include: Pulmonary capillary wedge pressure > 22mm Hg and one of the following clinical signs: 2+ peripheral edema and/or pulmonary edema or pleural effusion on chest X-ray. For patients without a pulmonary artery catheter, persistent volume overload will include at least 2 of the following: 2+ peripheral edema, jugular venous pressure > 10 mm Hg, and pulmonary edema or pleural effusion on chest X-ray.\n5. BNP > 400.\n6. Cr-1.2-3.0.\n\nExclusion Criteria:\n1. Intravascular volume depletion.\n2. Acute coronary syndrome within 4 weeks.\n3. Indication for hemodialysis.\n4. Systolic Blood pressure < 90mm Hg or MAP < 60mm Hg at the time of enrollment.\n5. Alternate explanation for worsening renal function, such as obstructive nephropathy, contrast-induced nephropathy, ATN.\n6. Clinical instability likely to require the addition of intravenous vasoactive drugs including vasodilators and/or inotropic drugs.\n7. The use of iodinated radio-contrast material in the past 72 hours or anticipated use of intravenous contrast during the current hospitalization.\n8. Underlying rhythm disorder.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease called spinal muscular atrophy. The ICD-10 codes associated with this disease are 'G12.9', 'G12.1', and 'G12.0'. The drugs being studied in this trial are placebo, reldesemtiv 150 mg, and reldesemtiv 450 mg. The eligibility criteria for participants in this trial are listed, including age requirements, ambulatory status, specific scores and measurements, laboratory findings, ability to swallow an oral suspension, and requirements for contraception. There are also exclusion criteria listed, such as hypersensitivity to drugs or substances, recent hospitalization, certain medical conditions, and participation in other clinical trials.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on the disease of obesity, with the associated ICD-10 codes being E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, and O99.211. The drugs being studied are liraglutide and a placebo. \n\nThe inclusion criteria for the trial include being overweight or obese (with a body mass index of \u226530 kg/m^2 or \u226527 kg/m^2 with an obesity-related co-morbidity), residing within 125 miles of Mayo Clinic in Rochester, Minnesota, being healthy with no unstable psychiatric disease or current treatment for various disorders, women of childbearing potential using effective contraception and having negative pregnancy tests, and having the ability to provide informed consent.\n\nThe exclusion criteria for the trial include weight exceeding 137 kilograms, previous abdominal surgery other than appendectomy, Caesarean section, or tubal ligation, positive history of chronic gastrointestinal diseases or use of medications that may affect gastrointestinal motility, personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia-type 2, personal history of pancreatitis, significant untreated psychiatric dysfunction, intake of certain medications within 7 days of the study (with some exceptions), and hypersensitivity to the study medication, liraglutide.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is esophageal squamous cell carcinoma. The ICD-10 codes associated with this disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drugs being tested in the trial are anlotinib and placebo. The eligibility criteria for the trial include having histological documentation of esophageal squamous cell carcinoma, advanced stage with distant metastasis, failure of previous chemotherapy treatment, age between 18-75 years, ECOG performance status of 0-2, normal organ function, and willingness to use contraception. The exclusion criteria include active bleeding in the primary lesion, failure of previous anti-tumor angiogenesis drug treatment, presence of factors affecting oral medication, brain metastases with symptoms, severe or uncontrolled diseases, non-healing wounds or fractures, recent bleeding events, recent thromboembolic events, drug abuse or mental disorders, tumors involving important blood vessels, participation in other anticancer drug trials, history of immunodeficiency, and concomitant diseases that could endanger safety or affect completion of the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on patients with metastatic colorectal cancer. The trial is testing the drugs regorafenib and perindopril. The eligibility criteria for the trial are listed, including requirements such as age, histological documentation of adenocarcinoma, previous treatment history, disease progression, and various laboratory assessments. The sample also includes exclusion criteria, such as certain medical conditions, previous treatment with regorafenib or VEGFR-targeting kinase inhibitors, and concurrent cancer requiring treatment that is different from colorectal cancer. The sample provides detailed information about the inclusion and exclusion criteria for the trial.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is Phase 2. The diseases being studied are atopic dermatitis, eczema, and chronic pruritus. The corresponding ICD-10 codes for these diseases are provided. The drugs being tested in the trial are tradipitant and placebo. The sample also includes the eligibility criteria for the trial, including inclusion and exclusion criteria. Inclusion criteria include being a male or non-pregnant, non-lactating female aged 18-65 years, diagnosed with atopic dermatitis, and suffering from chronic pruritus. Exclusion criteria include having chronic pruritus due to a condition other than atopic dermatitis, previous participation in a tradipitant trial, affiliation with the site or sponsor, and any other medical reason determined by the investigator that may interfere with study compliance or confound results.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is Type 2 diabetes mellitus. The corresponding ICD-10 codes for this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are ttp273 and placebo. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The subject must have a 6-month diagnosis of Type 2 diabetes mellitus prior to screening and meet the American Diabetes Association (ADA) guidelines for Type 2 diabetes mellitus.\n- The subject must be on a stable regimen of metformin monotherapy equivalent to at least 1000 mg/day for the last 3 months prior to screening.\n- Only males and females of non-childbearing potential are eligible.\n- The subject must be in generally stable health without a history of major surgery or significant injuries within the last year and without an active infection.\n\nExclusion Criteria:\n- The subject must not have a diagnosis of Type 1 diabetes mellitus, maturity-onset diabetes of the young, insulin-requiring Type 2 Diabetes, other unusual or rare forms of diabetes mellitus, or a history of diabetic ketoacidosis.\n- The subject must not have participated in a clinical trial and received an investigational product within the last 30 days.\n- The subject must not have participated in any formal weight loss program, experienced a fluctuation of > 5% in body weight, or received medications approved for weight loss within the last 3 months prior to screening or contemplate such therapy during the trial.\n- The subject must not have undergone previous surgical treatment of obesity.\n- The subject must not have a history of hypoglycemic episode requiring glucose, glucagon, or orange juice administered by someone other than the patient within the last 6 months prior to screening.\n- The subject must not have used other diabetic agents except metformin within the last 3 months prior to screening.\n- The subject must not have a history of pancreatitis.\n- The subject must not have donated blood of approximately 1 pint (500 mL) within the last 8 weeks prior to screening.\n- The subject must not have a history of hemolytic anemia, chronic transfusion requirement, or any other condition rendering HbA1c results unreliable.\n- The subject must not have a history of MEN-2 or a family history of medullary thyroid cancer.\n- The subject must not have a history or presence of clinically significant disease other than Type 2 diabetes mellitus.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is multiple myeloma. The ICD-10 codes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are elotuzumab, pomalidomide, and dexamethasone. The record also includes eligibility criteria for participants, such as having at least 2 prior lines of therapy, being refractory or relapsed and refractory to multiple myeloma, and having measurable disease at screening. There are also exclusion criteria listed, such as having active plasma cell leukemia, prior treatment with pomalidomide, and being unable to tolerate thromboembolic prophylaxis.",
    "The sample from the table is for a phase 2 trial. The diseases being studied are epidermolysis bullosa and pruritus. The corresponding ICD-10 codes for epidermolysis bullosa are Q81.0, Q81.1, Q81.2, Q81.8, Q81.9, L12.30, and L12.35. The corresponding ICD-10 codes for pruritus are L29.0, L29.1, L29.2, L29.8, L29.9, and L29.3. The drug being tested is vpd-737. The inclusion criteria for the trial are a clinical diagnosis of epidermolysis bullosa and pruritus. The exclusion criteria are chronic liver or renal disease.",
    "The sample from the table is for a phase 2 clinical trial. The trial is focused on the treatment of epilepsy and Lennox Gastaut syndrome. The diseases are represented by their names and corresponding ICD-10 codes. The drug being tested is fenfluramine. The eligibility criteria for participants include having an electro-clinical epilepsy syndrome compatible with Lennox Gastaut syndrome, experiencing at least 4 documented seizures in the last 4 weeks, being on at least 2 anti-epileptic drugs (including VNS) for the 4 weeks prior to inclusion, and being between the ages of 3 and 18. Female participants must not be pregnant or breastfeeding and must have a negative pregnancy test. They must also be willing to use medically acceptable forms of birth control during the study and for 90 days after the last dose of the study drug. The exclusion criteria include having known clinical cardiovascular abnormalities, cardiac ultrasound/ECG abnormalities at baseline, weight below the 3rd percentile for age, receiving concomitant therapy with certain medications, and unwillingness to refrain from consuming large or daily servings of grapefruits and/or Seville oranges and their juices throughout the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is prostate cancer. The ICDCodes associated with this disease are \"C61\", \"D29.1\", \"D40.0\", \"Z15.03\", \"Z80.42\", \"Z85.46\", and \"Z12.5\". The drug being used in the trial is abiraterone acetate. \n\nThe eligibility criteria for this trial include:\n1. The patient must have a written diagnosis of prostate cancer.\n2. The patient must be an adult with a histological or cytological diagnosis of adenocarcinoma of the prostate.\n3. Men with castration-resistant metastatic decline maintained for at least 3 weeks are eligible.\n4. The patient must have a confirmed biochemical response to prior abiraterone acetate treatment.\n5. Progressive disease according to PCWG2 criteria during prior therapy with standard dose of abiraterone acetate or soft-tissue or bone progression is required for eligibility.\n6. Documented progression of disease by PSA, soft tissue, or bone scan criteria is necessary.\n7. Patients may have received treatment with docetaxel, enzalutamide, or radium-223.\n8. The patient's PSA level must be \u226510ug/l.\n9. The patient's ECOG performance status must be between 0 and 2.\n10. At least 3 months (90 days) must have passed since the patient stopped prior abiraterone acetate treatment.\n\nThe exclusion criteria for this trial include:\n1. Major surgery within 28 days prior to the start of treatment.\n2. Prior treatment with cabazitaxel or the CYP-17 inhibitor TAK-700/orteronel.\n3. Any concurrent or prior treatment with an investigational drug within 28 days prior to the start of treatment.\n4. Known brain or leptomeningeal disease.\n5. Concurrent use of steroids other than prednisone >10mg/d.\n6. Inadequate bone marrow and organ function as evidenced by specific criteria.\n7. Uncontrolled hypertension or cardiac failure or LVEF <50%.\n\nThe calculation of creatinine clearance is to be done using the Cockcroft-Gault formula as described in appendix 4 of the protocol.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is acute optic neuritis. The ICDCodes associated with this disease are A17.83, A39.82, H46.13, H46.8, H46.9, H46.10, and H46.11. The drugs mentioned are placebo and biib033 100mg/kg. The eligibility criteria include key inclusion and exclusion criteria, such as previous participation in a specific study, kidney function, pregnancy status, and other protocol-defined criteria.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating certain diseases. The diseases listed in this sample include estrogen receptor positive, postmenopausal, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma, and recurrent uterine corpus carcinoma. The corresponding ICD-10 codes for these diseases are also provided. The drugs being used in the trial are letrozole and ribociclib. The eligibility criteria for participants are listed, including requirements such as being post-menopausal, having specific types of cancer, and meeting certain medical conditions. There are also exclusion criteria, which specify conditions or circumstances that would disqualify a patient from participating in the trial.",
    "The sample from the table represents a clinical trial for breast cancer, specifically metastatic breast cancer. The trial is in phase 1/phase 2. The diseases being studied are breast cancer and metastatic breast cancer. The corresponding ICD-10 codes for these diseases are provided. The drugs being investigated in the trial are vinorelbine and trastuzumab emtansine. \n\nThe eligibility criteria for the trial are as follows:\n1. The patient must have histologically or cytologically documented breast cancer.\n2. The patient must have metastatic or unresectable locally advanced/recurrent breast cancer.\n3. The patient must have HER2-positive disease, as determined by positive results from immunohistochemistry (IHC) testing, fluorescence in situ hybridization (FISH) assay(s), or gene copy number analysis.\n4. The patient must have documented disease progression on the last regimen by radiographic measurement.\n5. The patient must have documented disease progression after at least one regimen of HER2-directed therapy in the metastatic or unresectable locally advanced/recurrent setting.\n6. For patients with hormone receptor-positive disease, there must be disease progression or recurrence on prior hormonal therapy, with or without HER2-directed therapy.\n7. The patient must have measurable or bone-only disease.\n8. The patient must have received prior treatment with a taxane.\n9. The patient must have received a minimum of 6 weeks of prior trastuzumab for the treatment of metastatic or unresectable locally advanced/recurrent disease.\n10. Prior use of Pertuzumab or Lapatinib is permitted but not required.\n11. The patient must be at least 18 years old and have a life expectancy of at least 3 months.\n12. The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n13. The patient must have normal organ and marrow function.\n14. The patient's international normalized ratio (INR) must be less than 1.5 times the upper limit of normal (ULN).\n15. The patient's left ventricular ejection fraction (LVEF) must be at least 50%.\n16. Premenopausal women of reproductive capacity and women < 12 months after menopause must have negative results of a serum pregnancy test. Both men and women of childbearing potential must agree to use two effective non-hormonal forms of barrier contraception throughout the treatment on the study.\n17. The patient must be able to understand and willing to sign a written informed consent and HIPAA document.\n\nThe exclusion criteria for the trial are as follows:\n1. The patient must not have received chemotherapy within 21 days prior to the first dose of study treatment.\n2. The patient must not have received trastuzumab within a specific time frame based on the dose received.\n3. The patient must not have received Lapatinib within 14 days prior to the first dose of study treatment.\n4. The patient must not have received Pertuzumab within 21 days prior to the first dose of study treatment.\n5. The patient must not have received hormone therapy within 7 days prior to the first dose of study treatment.\n6. The patient must not have received investigational therapy or any other experimental therapy within 28 days prior to the first dose of study treatment.\n7. The patient must not have received prior treatment with trastuzumab emtansine.\n8. The patient must not have prior use of vinorelbine in any setting.\n9. The patient must not have received previous radiotherapy for the treatment of unresectable, locally advanced, recurrent, or metastatic breast cancer within a specific time frame or if more than 25% of marrow-bearing bone has been irradiated.\n10. The patient must not have untreated or symptomatic brain metastases or require any radiation, surgery, or continued steroid therapy to control symptoms from brain metastases within 14 days of study enrollment.\n11. The patient must not have a history of intolerance or hypersensitivity to trastuzumab or murine proteins.\n12. The patient must not have a history of exposure to specific cumulative doses of anthracyclines.\n13. The patient must not have current peripheral neuropathy of Grade \u22653.\n14. The patient must have recovered from any other acute toxicity prior to study enrollment.\n15. The patient must not have a history of other malignancy within the last 3 years, except for certain exceptions.\n16. The patient must not meet specific cardiopulmonary function criteria or have certain severe, uncontrolled systemic diseases.\n17. The patient must not have any uncontrolled, intercurrent illness or any other serious medical or psychiatric illness/condition that is likely to interfere or limit compliance with study requirements/treatment.",
    "The sample is a phase 2 clinical trial for patients with degenerative arthritis and knee osteoarthritis. The trial aims to study the effectiveness of a saline solution drug in treating the condition. The inclusion criteria for participants include being 18 years or older, having a diagnosis of osteoarthritis of the knee according to ACR criteria, having a radiographic diagnosis of Kellgren and Lawrence grade 2-4, experiencing pain of at least grade 4 on a 0-10 scale for at least 12 weeks, meeting ACR global functional criteria for osteoarthritis, and agreeing to contraception. \n\nThe exclusion criteria include being pregnant or lactating, having a BMI greater than 35, having other diseases such as septic arthritis, rheumatoid or inflammatory joint disease, gout or pseudogout, Paget disease, articular fractures, and various other conditions. Patients with serious internal medicine diseases, positive HIV, hepatitis B or C, syphilis, behavioral or cognitive disorders, significant neurologic or psychiatric disorders, alcohol or drug abuse history, recent participation in other clinical trials, recent intra-articular drug injection, previous knee joint cartilage and stem cell therapy, and those considered inappropriate by the principal investigator are also excluded from the trial. Patients with penicillin hypersensitivity reactions are also excluded.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on patients with schizophrenia or schizoaffective disorder. The trial is specifically testing the effectiveness of a drug called \"risperidone implant\". The eligibility criteria for participants include being an outpatient, having a PANSS Total Score of 80 or less at screening, and meeting certain criteria for PANSS items such as conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content. Participants must also be between 18 and 60 years old and have a diagnosis of schizophrenia or schizoaffective disorder according to DSM-V criteria. \n\nThere are also exclusion criteria, which include being hospitalized or requiring acute crisis intervention in the 60 days prior to admission, having a history of suicide attempt or being at imminent risk of suicide, having a current or recent diagnosis of moderate or severe substance use disorder, having impaired hepatic or renal function, having a hypersensitivity to risperidone, having a history of neuromalignant syndrome, having undergone electroconvulsive therapy within 6 months, and requiring current use of certain agents that affect cytochrome P450 2D6.",
    "The sample provided is for a phase 2 clinical trial for the treatment of stress urinary incontinence. The trial is specifically targeting females between the ages of 18 and 80 who have been clinically confirmed as postmenopausal. The inclusion criteria include having SUI symptoms for at least 6 months, a 24-hour pad weight of more than 3 grams at baseline, and a minimum of 1 SUI episode per day. The sample also includes various medical criteria such as normal liver function, negative history of certain medical conditions, and not taking certain medications that affect lower urinary tract function. The exclusion criteria include a history of certain medical procedures, significant urological findings, neurogenic urinary incontinence, morbid obesity, chronic hepatitis, and other medical conditions that may increase subject risk.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"hyperlipidemia\". The corresponding ICD-10 codes for this disease are \"E78.2\", \"E78.49\", and \"E78.5\". The drugs being studied in this trial are \"etc-1002\", \"atorvastatin\", and \"placebo\". The eligibility criteria for participants in this trial include taking stable statin doses for at least 4 weeks prior to the screening visit, having specific LDL-C levels depending on the type of statin being taken, and being willing to discontinue other lipid-regulating therapies during the study. The exclusion criteria include a history of acute significant cardiovascular disease, current clinically significant cardiovascular disease, and a history of intolerance to any statin due to muscle-related pain or weakness.",
    "The sample from the table is for a phase 2 clinical trial for the treatment of binge eating disorder. The eligibility criteria for participants include being between the ages of 18-65, meeting the DSM-5 criteria for a diagnosis of BED, and being obese or overweight with at least one weight-related comorbidity. The sample excludes individuals with current bulimia nervosa or anorexia nervosa, pregnant or lactating women without adequate contraceptive measures, and those displaying clinically significant suicidality. Other exclusion criteria include receiving psychological or weight loss interventions for BED or weight management within the past 3 months, a history of substance-related or addictive disorders, and certain psychiatric or medical conditions. Participants must also not have a history of certain cardiac, seizure, or thyroid disorders, and should not be taking medications that may interact with the study medication.",
    "The sample provided is for a phase 2 clinical trial for the treatment of osteoarthritis. The trial is specifically focused on patients with osteoarthritis of the knee. The eligibility criteria for participants include being between the ages of 40 and 80, having a body mass index (BMI) between 18.0 and 38.0 kg/m2, and a total body weight between 50 and 150 kg. Participants must also have symptoms of osteoarthritis in the knee for at least 6 months, including knee joint pain. Radiographic evidence of at least one tibiofemoral osteophyte in the knee within the past year is also required.\n\nThere are exclusion criteria as well, such as a history of certain types of arthritis, malignancy (except for specific cases), cardiac dysrhythmias, abnormal laboratory results, and infections with HIV or hepatitis B or C viruses. Other exclusion criteria include having other serious medical or psychiatric illnesses, recent participation in another investigational study, history of drug or alcohol dependence, and current use of opioids for pain relief.\n\nThe sample also includes additional criteria related to analgesic treatment, intra-articular injections, previous surgeries, hip pain, knee infection, use of a handicap assistance device, recent physical therapy or exercise programs, and lab abnormalities at the screening visit.\n\nOverall, the sample provides a detailed description of the eligibility and exclusion criteria for participants in the phase 2 clinical trial for osteoarthritis treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 2. The diseases being studied are \"prolymphocytic leukemia,\" \"recurrent chronic lymphocytic leukemia,\" \"recurrent non-hodgkin lymphoma,\" and \"recurrent small lymphocytic lymphoma.\" The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial are \"ibrutinib\" and \"idelalisib.\" The eligibility criteria for participants are listed, including requirements such as specific diagnoses, certain timeframes for relapse or progression, ability to give informed consent, and various medical parameters such as blood counts and liver function. The sample also includes exclusion criteria, which outline conditions or circumstances that would disqualify a participant from the trial, such as pregnancy, certain medical conditions, or concurrent use of other anti-cancer treatments.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is chronic obstructive pulmonary disease (COPD). The ICDCodes associated with this disease are G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, and N13.8. The drugs being tested in this trial are reldesemtiv and placebo. The eligibility criteria for participants in this trial include having a body mass index (BMI) between 18-35 kg/m2, a clinical diagnosis of moderate to severe COPD, stable health with no recent medication changes or exacerbations, a smoking history of at least 10 pack years, and specific respiratory and physical performance capabilities. There are also criteria related to pregnancy and contraception for female participants, as well as exclusion criteria such as previous enrollment in a study of CK-2127107, abnormal test results, certain medical conditions, and recent use of specific medications.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of pulmonary arterial hypertension (PAH). The trial is specifically targeting patients with WHO Group 1 PAH, which is characterized by certain criteria related to pulmonary pressure, heart function, and pulmonary vascular resistance. The trial also requires participants to have a WHO/NYHA-FC of II or III and be on a stable dose of PAH-specific therapies. Other eligibility criteria include a specific range for the 6-minute walk distance and the absence of thromboembolic disease.\n\nThe sample also includes exclusion criteria, which are conditions that would disqualify a participant from the trial. These include uncontrolled hypertension, left-sided heart disease, acute decompensated heart failure, and certain pulmonary diseases. Other exclusion criteria are related to various medical conditions, such as chronic infections, liver disease, active infection, and certain medical treatments. Laboratory values, such as renal function, liver enzymes, and blood counts, are also considered in the exclusion criteria.\n\nOverall, the sample provides detailed information about the phase 2 trial for the treatment of pulmonary arterial hypertension, including the specific eligibility and exclusion criteria that potential participants must meet.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of chronic B-cell leukemia. The trial includes patients who meet certain eligibility criteria. The diseases being targeted in this trial are chronic B-cell leukemia. The trial also includes a list of ICDCodes, which are specific codes used to classify diseases. The drugs being tested in this trial include ga101, ibrutinib, cyclophosphamide, and fludarabine. The eligibility criteria for this trial include factors such as patient age, confirmation of B-CLL, disease stage, prior treatment history, performance status, and various hematological and biochemical values. There are also exclusion criteria that specify conditions or factors that would prevent a patient from participating in the trial. These criteria include factors such as certain disease conditions, co-morbidities, allergies, and pregnancy or breastfeeding. Additionally, there are specific exclusion criteria for the treatment with ibrutinib, which include factors such as recent surgery, central nervous system lymphoma, cardiovascular disease, and certain infections.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is Phase 2.\n- Diseases: The specific disease being studied, which in this case is basal cell carcinoma.\n- ICD codes: The ICD-10 codes associated with the disease, which are listed as ['C44.510', 'C44.91', 'C44.01', 'C44.311', 'C44.511', 'C44.81', 'C44.41'].\n- Drugs: The drug being used in the trial, which is erivedge.\n- Criteria: The eligibility criteria for participating in the trial.\n\nThe eligibility criteria include various conditions that patients must meet in order to be included in the study. These conditions include having a certain stage of basal cell carcinoma, being at least 18 years old, having a specific performance status, and having adequate organ function. There are also criteria related to pregnancy and contraception for female participants, as well as requirements for male participants regarding contraception and semen/blood donation. The sample also includes exclusion criteria, such as patients with BCC outside of the head or neck area, pregnancy or lactation, and concurrent non-protocol-specified anti-tumor therapy.\n\nOverall, this sample provides information about a Phase 2 clinical trial for basal cell carcinoma, including the specific disease, drug, and eligibility criteria for participants.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of dementia with Lewy bodies (DLB). The trial includes patients who have a probable diagnosis of DLB and have a Mini Mental State Examination (MMSE) score between 14 and 26. Patients must be able to comply with cognitive and other testing procedures and have a reliable caregiver who can report on their status throughout the study. Patients currently receiving therapy for DLB are also eligible for enrollment. \n\nExclusion criteria include patients with atypical clinical features or a clinical course that suggests an alternate dementia diagnosis. Patients with any clinically relevant concomitant disease that would make them unsuitable for inclusion in the study, as determined by the investigator, are also excluded.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of primary central nervous system lymphoma. The trial is looking at the drug pqr309. The eligibility criteria for participants are listed, including age requirements, confirmation of the disease, presence of measurable disease, prior treatment history, performance score, and various health factors. There are also exclusion criteria listed, such as previous treatments, certain medications, and medical conditions that could interfere with the study. The sample also includes information about pregnancy and contraception requirements.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is multiple myeloma. The ICD-10 codes associated with this disease are C90.01, C90.02, and C90.00. The drug being used in the trial is melphalan hcl for injection (propylene glycol free). \n\nThe record also includes eligibility criteria for the trial. Inclusion criteria include patients with symptomatic multiple myeloma requiring treatment, patients who qualify for ASCT therapy and have received pretransplant therapy, adult patients meeting certain criteria for a total melphalan dose, patients with an adequate autologous graft, and patients with adequate organ function. Exclusion criteria include patients with systemic AL amyloidosis, patients with an ECOG performance status of 2 or higher, patients with uncontrolled hypertension, patients with serious active infections, patients with prior malignancies (except for certain cases), pregnant or breastfeeding female patients, female patients of childbearing potential who are unwilling to use contraception, patients seropositive for HIV, patients unwilling to provide informed consent, patients receiving other concurrent anticancer therapy, patients concurrently participating in any other clinical study, and patients who are hypersensitive or intolerant to any component of the study drug formulation.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on several diseases, including breast cancer, heart disease, cardiotoxicity, and myocardial dysfunction. The diseases are associated with specific ICD-10 codes. The trial involves the use of two drugs, atorvastatin and placebo. The eligibility criteria for the trial are listed, including requirements for female patients with newly diagnosed stage 1-3 breast cancer, specific HER2, ER, and PR status, and recommended trastuzumab treatment. There are also exclusion criteria, such as prior use of statin medication, certain medical conditions, and contraindications for MRI testing. The sample provides detailed information about the inclusion and exclusion criteria for potential participants in the trial.",
    "The sample is a phase 2 clinical trial for hormone receptor positive breast cancer and her-2 positive breast cancer. The trial is testing the effectiveness of the drugs abemaciclib, trastuzumab, fulvestrant, and standard of care single agent chemotherapy. The eligibility criteria for participants include having a diagnosis of HR+, HER2+ breast cancer, having unresectable locally advanced recurrent or metastatic breast cancer, and having received at least 2 HER2-directed therapies and trastuzumab emtansine (T-DM1) in any disease setting. Other criteria include having received a taxane in any disease setting, being postmenopausal, having a performance status of 0 to 1, and having adequate organ function. There are also exclusion criteria, such as having untreated or symptomatic central nervous system metastases, recent major surgery, or a history of certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is phase 2. The disease being studied is \"neuroendocrine tumors\". The corresponding ICD-10 codes for these tumors are \"C7A.1\", \"C7A.8\", \"C7B.8\", and \"D3A.8\". The drug being tested is \"lenvatinib\". The eligibility criteria for this trial include having a confirmed diagnosis of advanced/metastatic neuroendocrine tumors, evidence of measurable disease, evidence of disease progression within the past 12 months, and meeting specific inclusion criteria based on the primary tumor site. There are also additional criteria related to performance status, previous treatments, blood pressure, renal function, liver function, and reproductive potential for both males and females.\n\nThe exclusion criteria for this trial include specific types of neuroendocrine tumors, prior lines of targeted therapy, previous treatment with lenvatinib, recent anti-cancer treatments or investigational agents, major surgery within the past 3 weeks, certain medical conditions or impairments, and pregnancy or breastfeeding in females.\n\nOverall, this sample provides detailed information about the phase, diseases, icdcodes, drugs, and eligibility criteria for a specific clinical trial related to neuroendocrine tumors and the drug lenvatinib.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is \"acute coronary syndrome,\" and its corresponding ICDCodes is \"I24.0.\" The drugs being tested are \"mdco-216\" and \"placebo.\" The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The criteria include specific requirements related to recent ACS events, qualifying myocardial infraction, baseline coronary angiogram, IVUS interrogation, and various medical conditions or factors that may exclude individuals from participating in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on Tourette Syndrome. The ICD-10 code for Tourette Syndrome is \"F95.2\". The drugs being studied are \"nbi-98854\" and \"placebo\". The record also includes the eligibility criteria for participants in the trial. Inclusion criteria include having a clinical diagnosis of Tourette Syndrome, moderate tic severity, impaired school, occupational, and/or social function due to TS symptoms, being on stable doses of medication if already using them, being in good general health, and meeting certain requirements for adolescent subjects and subjects of childbearing potential. Exclusion criteria include having an unstable medical condition, a history of long QT syndrome or cardiac arrhythmia, neuroleptic malignant syndrome, recent cancer diagnosis, allergy or intolerance to VMAT2 inhibitors, recent blood loss or blood donation, history of substance dependence or abuse, significant risk of suicidal or violent behavior, initiation of Comprehensive Behavioral Intervention for Tics (CBIT) during the screening period or study, and recent use or planned use of investigational drugs other than NBI-98854.",
    "The sample is a phase 2 clinical trial for the treatment of various diseases including non-alcoholic steatohepatitis, hypertriglyceridemia, non-alcoholic fatty liver disease, and hypercholesterolemia. The trial is testing a drug called mn-001. The eligibility criteria for participants include being at least 18 years old, having a confirmed diagnosis of NASH or NAFLD, having a fasting serum triglyceride level above 150 mg/dL, and having stable liver function and other laboratory values. Participants must also meet certain criteria regarding alcohol consumption, contraception, physical health, and willingness to comply with the study protocol. There are also exclusion criteria, such as having other known liver diseases, severe liver disease, uncontrolled diabetes, history of bariatric surgery, and various other medical conditions. The sample provides a detailed list of both inclusion and exclusion criteria for potential participants in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being studied is eribulin. The eligibility criteria for participants in the trial are listed, including requirements such as written informed consent, age over 18, confirmation of ER+ve metastatic breast cancer, Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, progression after previous hormonal and chemotherapy treatments, measurable disease, and adequate organ function. There are also exclusion criteria, such as being triple negative or HER2 positive, hypersensitivity to the drug, history of another primary malignancy within 5 years, uncontrolled active infection, severe hepatic impairment, and concurrent use of other investigational agents. The sample also includes additional details about the trial, such as the need for effective non-hormonal contraception for reproductive patients and the exclusion of those who have previously received eribulin therapy.",
    "The sample from the table represents a phase 2 trial for the treatment of diabetic retinopathy, posterior vitreous detachment, and disease progression. The trial involves the use of drugs such as ocriplasmin 0.0625mg, ocriplasmin 0.125mg, and sham injection. The eligibility criteria for participants include being 18 years or older, having a best-corrected visual acuity of 65 letters or greater, and having moderate to very severe non-proliferative diabetic retinopathy. Other criteria include specific measurements of central subfield thickness and the absence of certain ocular conditions. Participants must provide written informed consent before undergoing screening procedures.",
    "The sample from the table represents a phase 2 trial. The trial focuses on two diseases, namely \"cigarette smoking\" and \"obesity\". The corresponding ICD-10 codes for these diseases are provided as well. The trial involves the use of the drug \"varenicline\". The eligibility criteria for participants are listed, including inclusion criteria such as being a smoker with a scheduled surgery 5-10 weeks in advance, and exclusion criteria such as contraindication for varenicline use, evidence of psychiatric instability, unwillingness or inability to adhere to the study schedule, refusal to provide study access to medical records, and being deemed inappropriate for study participation by the study team.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease osteoarthritis. The ICD-10 codes associated with this disease are ['M15.4', 'M15.0', 'M16.9', 'M17.9', 'M19.011', 'M19.012', 'M19.019']. The trial involves two drugs, gsk3196165 and placebo. The eligibility criteria for participants include being at least 18 years old, meeting the American College of Rheumatology classification for osteoarthritis, having active disease with specific joint symptoms, showing signs of inflammation in an MRI scan, experiencing a certain level of hand pain, and meeting certain weight and lung function requirements. There are also exclusion criteria, such as being pregnant or lactating, having other inflammatory diseases, or having a history of certain medical conditions or infections.",
    "The sample is a phase 2 trial that focuses on nonalcoholic fatty liver disease (NAFLD) and HIV. The eligibility criteria for participants include being at least 18 years old, having risk factors for more severe liver disease, having lipodystrophy confirmed through clinical and radiologic assessment, and having a history of HIV documented by a positive HIV Elisa or PCR. Participants must also have a stable antiretroviral regimen for at least 12 weeks prior to study inclusion and provide written informed consent.\n\nExclusion criteria include having evidence of another form of liver disease, liver cirrhosis, excessive alcohol ingestion, contraindications to MRI, history of gastrointestinal bypass surgery or ingestion of drugs known to produce hepatic steatosis, recent use of medications to treat hepatic steatosis, use of Aramchol or similar agents, recent use of insulin for diabetes management, uncontrolled diabetes, significant systemic or major illnesses, active substance abuse, pregnancy or inability to practice adequate contraception in women of childbearing potential, evidence of hepatocellular carcinoma, specific HIV-related exclusions, symptoms of uncontrolled gastrointestinal disorders, hypersensitivity to Aramchol or its excipients, and any other condition that may impede competence, compliance, or hinder completion of the study.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is colonic neoplasms. The ICD-10 codes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested in the trial is imatinib. The eligibility criteria for participants include being male or female aged 18 years or older, having histologically proven adenocarcinoma of the colon, completing cancer staging with CT scans, being eligible for surgery with curative intent as determined by a multidisciplinary board review, having a specific gene expression profile indicative of the mesenchymal phenotype, having pre-treatment biopsies available for analysis, having a WHO performance status of 0 or 1, and meeting certain criteria for organ function and laboratory values. Participants must also be willing and able to comply with the study requirements and provide written informed consent. Exclusion criteria include the presence of synchronous distant metastases, the need for neoadjuvant therapy, concurrent participation in another clinical trial, pregnancy or plans to become pregnant, HIV or Hepatitis B/C infection, symptomatic congestive heart failure, and the need for concomitant treatment with certain drugs that may interact with imatinib.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is breast cancer, specifically unilateral or bilateral primary carcinoma of the breast. The trial includes patients with triple negative disease, meaning they have tested negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2). The eligibility criteria include having measurable tumor lesions in the breast or nodes, being in stages cT1b - cT4a-d, and having a confirmed Ki-67 value. Other criteria include being at least 18 years old, having an ECOG performance status of 0-1, and having normal cardiac function. The sample also includes exclusion criteria such as prior chemotherapy or radiation therapy for breast cancer, pregnancy or lactation, inadequate general condition for the treatment, and previous malignant disease within the last 5 years. There are additional exclusion criteria related to heart conditions, immunodeficiency, inflammatory bowel disease, and other medical conditions. The sample does not include male patients.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is type 2 diabetes mellitus. The corresponding ICD-10 codes for this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are ds-8500a 25 mg, ds-8500a 75 mg, and a placebo. The eligibility criteria for inclusion in the trial are as follows: the patient must be Japanese and have type 2 diabetes, be at least 20 years old, have been treated with sitagliptin 50 mg monotherapy for type 2 diabetes, and have an HbA1c level between 7.0% and 9.0%. The exclusion criteria include patients with type 1 diabetes, a history of diabetic coma or ketoacidosis, those receiving or requiring insulin treatment, patients with a BMI below 18.5 kg/m2 or above 35.0 kg/m2, patients with renal impairment or significant renal disease, and patients with fasting plasma glucose levels of 240 mg/dL or higher.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease of cardiac arrest. The ICD-10 codes associated with this disease are ['I97.120', 'I97.710', 'I46.9', 'P29.81', 'I46.2', 'I97.121', 'I97.711']. The drugs being studied in this trial are iloprost and saline. The eligibility criteria for participants are listed, including age, type of cardiac arrest, level of consciousness, and other factors. There are also exclusion criteria, such as certain medical conditions, limitations in therapy, and known allergies.",
    "The sample is a phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH), fibrosis, and liver diseases. The trial is testing the effectiveness of the drug emricasan at two different doses (5 mg and 50 mg) compared to a placebo. The eligibility criteria for participants include being 18 years or older, providing written informed consent, having histological evidence of definite NASH, having a NAFLD Activity Score (NAS) of 4 or greater, and having fibrosis stage 1, 2, or 3. Other criteria include willingness to use contraception, not having significant alcohol consumption, not using certain drugs with hepatotoxic effects, not having uncontrolled diabetes, not having cirrhosis, and not having certain other liver diseases. The sample also includes exclusion criteria such as abnormal liver function tests, certain medical conditions, and previous treatment with emricasan or other investigational medications.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is Parkinson's disease, which is identified by the ICD-10 code \"G20\". The drugs being tested in this trial include a placebo and various doses of a drug called pf-06649751. The eligibility criteria for participants in this trial include being a non-childbearing female or a male between the ages of 40 and 85, having a clinical diagnosis of Parkinson's disease, and being able to refrain from taking any Parkinson's disease medication not allowed by the trial protocol. Exclusion criteria include being a female of childbearing potential, having a history or presence of atypical Parkinsonian syndrome, having undergone surgical intervention for Parkinson's disease, having severe medical or psychiatric conditions or laboratory abnormalities, having any condition that may affect drug absorption, and having participated in other studies involving investigational drugs or being treated with any investigational drug within the past 30 days.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of analgesia. The trial involves the use of various drugs, including htx-011b, placebo, htx-011a, htx-002, and bupivacaine hcl. The eligibility criteria for participants are listed, including requirements such as being scheduled for abdominoplasty surgery, having a certain physical classification, being 18 years or older, having normal laboratory values, and having a body mass index of 30 kg/m2 or less. There are also specific criteria for female participants regarding pregnancy, lactation, and contraception. Male participants must either be surgically sterile or commit to using reliable birth control during the study. Exclusion criteria are also listed, such as contraindications or allergies to trial medications, presence of other painful conditions, history of certain medical conditions or medication use, and evidence of alcohol or drug abuse. The sample also includes additional criteria and restrictions for participation in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"diabetes mellitus, type 2\". The ICD-10 codes associated with this disease are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\". The drugs being studied in this trial are \"evogliptin\", \"sitagliptin\", \"placebo evogliptin\", and \"placebo sitagliptin\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being between 20 and 75 years old, having a diagnosis of type 2 diabetes according to the American Diabetes Association criteria, not having received treatment with oral hypoglycemic agents or insulin within the past 12 weeks, having glycated hemoglobin levels between 7.5% and 10.5% after 12 weeks of appropriate diet and exercise, having a body mass index between 20 kg/m2 and 40 kg/m2, and signing the Informed Consent Form.\n\nExclusion criteria include having fasting blood glucose values over 300 mg/dL with severe clinical manifestations, currently participating in weight loss programs, having heart failure functional class III or IV, having symptomatic liver or gall bladder disease, having a history of myocardial infraction, transient ischemic attack, or coronary angioplasty within the past 6 months, having a history of gastrointestinal resection, having estimated creatinine clearance less than 60 mL/min, having serum ALT and/or AST levels greater than or equal to 2.5 times the upper normal limit, having serum CPK levels greater than or equal to 3 times the upper normal limit, having fasting triglycerides over 400 mg/dL, having a history of major skin allergy, using corticosteroids within the past 3 months, receiving concomitant treatment with certain medications, having a history of untreated or uncontrolled thyroid disorder, having a history of drugs of abuse or moderate/heavy alcohol consumption within the past 2 months, having severe or uncontrolled diseases, being pregnant or breastfeeding, not using a proven effective contraceptive method for women of childbearing potential, participating in another clinical trial within the past 12 months unless there is a direct benefit, and having any condition that may render the patient inadequate for study participation.\n\nOverall, this sample provides detailed information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of various diseases such as pain, thermal injury, burns, and hyperalgesia. The diseases are associated with specific ICD-10 codes. The trial involves the use of drugs, specifically voriconazole (topical) and a topical sterile water placebo group. The eligibility criteria for participants are listed, including age requirements, specific burn wound size, and the need for excision and grafting. The criteria also include exclusion factors such as critical illnesses, inability to communicate pain, and contraindications for voriconazole.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on three diseases: chemotherapy-induced neutropenia, myelosuppression, and breast cancer. The diseases are associated with specific ICD-10 codes. The trial involves two drugs, myelo001 and placebo. The eligibility criteria for participants are listed, including requirements such as being a female patient over 18 years old, having confirmed invasive breast cancer, and being scheduled for neoadjuvant or adjuvant chemotherapy. Other criteria include specific laboratory thresholds, performance status, and the ability to read and sign an informed consent form. The exclusion criteria are also listed, which include factors such as allergies to the drug, prior chemotherapy or radiotherapy, and certain medical conditions or diseases. Additionally, pregnant or breastfeeding individuals and those not using effective birth control methods are excluded from the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of major depressive disorder. The trial includes a list of diseases, which in this case is only major depressive disorder. The diseases are also associated with specific ICD-10 codes. The trial involves the use of different drugs, including \"80 milligrams nsi-189\", \"placebo\", and \"40 milligrams nsi-189\". The eligibility criteria for participants are also provided, including age requirements, diagnosis confirmation, specific depression scale scores, and certain medical health conditions. The sample also includes exclusion criteria, such as the presence of other major diseases, history of certain disorders, and inability to comply with the study requirements.",
    "The sample is a phase 2 trial that focuses on the treatment of prediabetic state and obesity. The trial includes two drugs, dapagliflozin and metformin. The eligibility criteria for participants include having an HbA1c level between 5.7% and 6.4%, being between the ages of 30 and 70, and having a BMI of 25 or higher. There are also exclusion criteria, such as having uncontrolled medical issues, being on certain medications, having undergone bariatric surgery in the past 2 years, and having impaired renal function. Other exclusion criteria include being pregnant or lactating, having allergies to the study medications, and being unable to understand the informed consent and study procedures.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is metastatic colorectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested in this trial is regorafenib. The eligibility criteria for this trial include having a signed informed consent, being diagnosed with metastatic colorectal cancer, having previously been treated with or not considered a candidate for available therapies, having an ECOG performance status of 0 or 1, being 18 years or older, having a life expectancy of at least 3 months, and meeting certain requirements for renal, bone marrow, liver, and pancreatic functions. The sample also includes exclusion criteria such as psychological, familial, sociological, or geographical conditions that may hamper compliance with the study protocol, pregnancy or breastfeeding, congestive heart failure, unstable angina, and various other medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is diabetic macular edema. The ICD-10 codes associated with this disease are E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, and E10.3513. The drugs being tested in this trial are faricimab and ranibizumab. The eligibility criteria for participants in this trial include having macular edema associated with diabetic retinopathy, decreased visual acuity due to diabetic macular edema, and a diagnosis of diabetes mellitus. Exclusion criteria include having high-risk proliferative diabetic retinopathy, recent cataract surgery or other intraocular surgery, uncontrolled glaucoma, any other ocular disease in the study eye, major illness or surgical procedure within the past month, uncontrolled blood pressure, a glycosylated hemoglobin (HbA1c) level greater than 12% at screening, and untreated diabetes or recent initiation of oral anti-diabetic medication or insulin.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"carcinoma, renal cell\" and \"clear cell renal cell carcinoma\". The corresponding ICDCodes for these diseases are \"C22.0\", \"C4A.9\", \"C7B.1\", \"C4A.0\", \"C4A.31\", \"C4A.51\", and \"C4A.8\". The drug being used in the trial is \"axitinib\". \n\nThe eligibility criteria for this trial include histologic confirmation of renal cell carcinoma with a clear cell component, measurable disease, previous treatment with sunitinib or pazopanib, favorable prognosis according to IMDC criteria, availability of tumor tissue for submission, meeting various laboratory parameters, and providing written informed consent. \n\nThe exclusion criteria state that patients with underlying medical conditions that may make the administration of the study drug hazardous or obscure the interpretation of adverse events should not participate. Additionally, patients with a history of uncompensated diseases, metabolic dysfunction, physical examination findings, or clinical laboratory findings that contraindicate the use of an investigational drug or may affect the interpretation of study results or pose a high risk of treatment complications should also be excluded.",
    "The sample from the table is for a phase 2 trial. The disease being studied is pulmonary disease, specifically chronic obstructive pulmonary disease (COPD). The ICD-10 codes associated with this disease are J44.9, J44.1, and J44.0. The drugs being tested in the trial are bct197 and a placebo. The eligibility criteria for inclusion in the trial include being a male or female adult, having an active exacerbation of COPD requiring hospitalization, having a documented diagnosis of COPD C or D, being a current or former smoker, having a history of at least one moderate or severe COPD exacerbation in the past year, and currently receiving regular treatment for COPD. The exclusion criteria include being less than 40 years old, having a current diagnosis of asthma, having already completed treatment for the current COPD exacerbation, requiring intensive care unit (ICU) or mechanical ventilation, and having received a course of PDE4, p38, or PDE3/4 inhibitors within their respective washout periods.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and is focused on the disease \"dry eye\". The ICD-10 codes associated with this disease are \"H04.121\", \"H04.122\", \"H04.123\", \"H04.129\", \"H35.3111\", \"H35.3112\", and \"H35.3121\". The drugs being studied are \"pregabalin\" and \"placebo\". The eligibility criteria for participants are listed, including age requirements, undergoing LASIK surgery, stable medication regimen, and negative pregnancy test for females of child-bearing age. There are also exclusion criteria, such as being pregnant or lactating, using certain medications, having a history of allergic reactions to pregabalin or gabapentin, and having certain systemic co-morbidities. Additionally, individuals unable to consent, minors, and prisoners are excluded from the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"diabetes mellitus, type 1.\" The trial uses icd-10 codes to identify the specific types of diabetes. The drugs being tested in the trial are \"empagliflozin medium dose,\" \"empagliflozin low dose,\" \"empagliflozin high dose,\" and a placebo. \n\nThe eligibility criteria for participants in the trial are listed under \"Inclusion criteria\" and \"Exclusion criteria.\" Inclusion criteria include factors such as having a signed informed consent, being a Japanese male or female patient with a documented diagnosis of type 1 diabetes for at least 1 year, having specific C-peptide and HbA1c levels, and demonstrating a good understanding of the disease and ability to manage it. Exclusion criteria include factors such as having a history of type 2 diabetes or other specific conditions, recent occurrences of severe hypoglycemia or DKA, certain medical conditions or disorders, and various other factors that may affect patient safety or the study outcome.\n\nOverall, this sample provides a snapshot of the phase 2 trial, the specific disease being studied, the drugs being tested, and the eligibility criteria for participants.",
    "The sample is a record from a table that contains information about clinical trials. In this particular record, the trial is in phase 2 and is focused on the disease of acute pain. The associated ICD-10 codes for this disease are G89.12, G89.18, G89.11, and G89.3. The drugs being studied in this trial are bupivacaine and tramadol. The eligibility criteria for participants in this trial include having undergone a lower abdominal operation. Some exclusion criteria include having a systemic disease that compromises the immune system, severe coagulation disorder, true allergy to local anesthetics, major malformations of the lower spine or meninges, any cutaneous or subcutaneous lesion at the injection site, unplanned reoperation or reoperation within three months, and having diabetes mellitus.",
    "The sample is from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which includes the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is phase 2. The disease being studied is osteoarthritis of the knee. The ICD-10 codes associated with this disease are M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, and M17.30. The drugs being tested are miv-711 and placebo. The eligibility criteria for the trial include having current average knee pain with a severity score of 4 or higher but less than 10 on a 0-10 Numeric Rating Scale, being between 40 and 80 years old, and having a diagnosis of primary knee osteoarthritis. The exclusion criteria include having any inflammatory arthritis, any generalized pain condition that may interfere with evaluating knee pain, any severe or significant uncontrolled concurrent illness, and any known or suspected intolerance or hypersensitivity to the investigational product or its ingredients.",
    "The sample from the table represents a phase 2 clinical trial. The diseases being studied include fgfr gene amplification, fgfr1 gene amplification, fgfr2 gene amplification, fgfr2 gene mutation, fgfr3 gene mutation, head and neck squamous cell carcinoma, human papillomavirus infection, recurrent head and neck carcinoma, recurrent nasopharynx carcinoma, and recurrent oropharyngeal squamous cell carcinoma. The corresponding ICD-10 codes for these diseases are provided. The drug being tested in the trial is bgj398. The eligibility criteria for the trial include having a histologically documented diagnosis of squamous cell carcinoma of the head/neck, having progressed on prior platinum-based therapy, and having known FGFR genetic alterations. Other criteria include Eastern Cooperative Oncology Group (ECOG) performance status of 1 or lower, providing written informed consent, being 18 years or older, and being able to comply with scheduled visits and treatment plan. The sample also includes exclusion criteria such as having a history of another primary malignancy, having metastatic central nervous system tumors, and receiving certain anti-cancer therapies prior to the study. Additional criteria related to bone marrow function, hepatic and renal function, calcium-phosphate homeostasis, and cardiac disease are also listed. Pregnant or nursing women, individuals with certain infections, and sexually active males without contraception are excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is systemic lupus erythematosus. The ICDCodes associated with this disease are M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, and M32.8. The drugs being tested in this trial are baricitinib and placebo. \n\nThe eligibility criteria for participants in this trial include having a diagnosis of SLE at least 24 weeks prior to screening, meeting specific diagnostic criteria, having a positive antinuclear antibody (ANA) or positive anti-double-stranded deoxyribonucleic acid (dsDNA) test, having a SLEDAI-2K score of at least 4 based on clinical symptoms, and having active arthritis and/or active rash. \n\nExclusion criteria for this trial include having active severe lupus nephritis or central nervous system (CNS) lupus, having a history or presence of certain medical disorders or serious illnesses that could pose a risk or interfere with the interpretation of data, having a current or recent serious infection, currently receiving high doses of oral corticosteroids or recently adjusted the dose, recently started or adjusted the dose of nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarials, or immunosuppressants, and having received cyclophosphamide or any other cytotoxic agent within 12 weeks prior to screening.",
    "The sample is a phase 2 trial that focuses on three diseases: dementia with Lewy bodies, REM sleep behavior disorder, and Parkinson's disease dementia. The corresponding ICD-10 codes for these diseases are G31.83, G20, and G31.83 respectively. The trial involves the use of two drugs, nelotanserin and placebo. The eligibility criteria for participants include being at least 50 years old, having a diagnosis of DLB or PDD and RBD based on DSM-5 criteria, having frequent REM sleep behavior episodes, and having a Mini Mental State Examination score of 18 or higher. Exclusion criteria include having significant psychotic disorders, RBD symptoms caused by another medical condition or substance abuse, and having serious or unstable medical disorders in various systems.",
    "The sample from the table is a clinical trial for breast cancer patients in phase 1/phase 2. The trial is testing the effectiveness of the drugs entinostat, atezolizumab, and placebo. The eligibility criteria for participants include having confirmed triple negative breast carcinoma that is either metastatic or locally recurrent and not amenable to local curative treatment. Participants must also have received 1-2 prior lines of systemic therapy for locally recurrent and/or metastatic disease. Other criteria include having a performance status of 0 or 1, acceptable laboratory parameters, and being willing to use birth control methods. Exclusion criteria include having immunodeficiency, receiving systemic steroid therapy, or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. Participants must not have a history of certain conditions or diseases, such as active autoimmune disease, previous treatment with certain antibodies or inhibitors, or certain cardiovascular or metabolic conditions. Other exclusion criteria include contraindications to oral agents, recent vaccination, recent treatment with certain agents, and certain medical conditions or allergies.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"cystic fibrosis.\" The associated ICD-10 codes for this disease are \"E84.9,\" \"Z14.1,\" \"E84.0,\" \"E84.11,\" \"E84.8,\" \"E84.19,\" and \"P09.4.\" The drugs being studied in this trial are \"vx-371,\" \"saline,\" \"placebo,\" and \"orkambi.\" \n\nThe eligibility criteria for this trial are as follows:\n- Participants must be willing and able to use the delivery device as instructed in the study manual.\n- They must have a confirmed diagnosis of cystic fibrosis, which is defined as a sweat chloride value of 60 mmol/L or higher.\n- Participants must be homozygous for the F508del CFTR mutation, and if the CFTR screening genotype result is not available, a previous CFTR genotype lab report can be used for eligibility.\n- The percent predicted FEV1 (forced expiratory volume in 1 second) must be between 40 and 90 percentage points adjusted for age, sex, and height according to the Global Lung Initiative (GLI) at the screening visit.\n- Participants must be willing to discontinue physician-prescribed saline use.\n- Female subjects of childbearing potential must have a negative serum pregnancy test at the screening visit.\n\nThe exclusion criteria for this trial are as follows:\n- Participants with any comorbidity that could confound the study results or pose additional risks in administering the study drug.\n- Clinically significant laboratory abnormalities at the screening visit that would interfere with the study assessments or pose undue risk to the participant.\n- Recent respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before the first dose of the study drug.\n- An electrocardiogram (ECG) showing QTcF (corrected QT interval) greater than 450 msec at the screening visit.\n- History of solid organ or hematological transplantation.\n- Use of diuretics or certain antihypertensive drugs in the 28 days prior to screening or anticipated need for these medications during the study.\n- Ongoing or recent participation in another investigational drug study within 30 days of the screening visit.\n- Inability to withhold bronchodilator use for a specified period before clinic visits.\n- History of significant intolerance to inhaled saline or intolerance to a single dose of saline at screening.\n- Known hypersensitivity or intolerance to Orkambi.\n- Pregnant or nursing females.\n- Participants who have previously participated in another study conducted by Parion Sciences (Study NCT02343445).",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 2 trial for the treatment of diabetic macular edema. \n\nThe phase of the trial is specified as phase 2. The disease being studied is diabetic macular edema. The corresponding ICD-10 codes for this disease are ['E10.311', 'E10.319', 'E11.311', 'E11.319', 'E13.311', 'E13.319', 'E10.3513']. \n\nThe drugs being tested in this trial are 'regn910-3' and 'intravitreal aflibercept injection (iai)'. \n\nThe eligibility criteria for participants in this trial include being men or women aged 18 or older with type 1 or type 2 diabetes mellitus and clinically significant DME with central involvement in the study eye. The BCVA ETDRS letter score in the study eye should be between 73 and 24 (Snellen equivalent of 20/40 to 20/320). Participants should be willing and able to comply with clinic visits and study-related procedures, and provide signed informed consent. \n\nThere are also exclusion criteria, such as having macular edema due to any cause other than diabetes mellitus in either eye, receiving IVT anti-VEGF treatment in the study eye within 12 weeks of the screening visit, or undergoing panretinal laser photocoagulation or macular laser photocoagulation in the study eye within 3 months of screening. \n\nIt is important to note that there may be additional inclusion and exclusion criteria that apply to this trial, but they are not specified in the provided sample.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease asthma. The ICD-10 codes associated with asthma are provided. The drugs being studied in the trial include fluticasone furoate (ff) (100 mcg), vilanterol (vi) (25 mcg), and a placebo. The eligibility criteria for participants in the trial are listed, including age requirements, a doctor's diagnosis of asthma for at least 6 months, specific lung function measurements, current and previous medication use, non-smoking status, and specific criteria for females. The exclusion criteria are also listed, which include a history of life-threatening asthma, other significant pulmonary diseases, recent respiratory infections or asthma exacerbations, certain medications and dietary restrictions, tobacco use, previous participation in similar trials, and various other concurrent diseases or abnormalities. The sample also mentions that pregnant and lactating females, as well as individuals with specific allergies, are excluded from the trial.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 2 and focuses on pain and osteoarthritis of the knee. The associated ICD-10 codes for these diseases are provided. The trial involves the use of drugs such as neo6860, neo6860 placebo, naproxen, and naproxen placebo. The eligibility criteria for participants are listed, including requirements for body mass index, specific diagnosis criteria for osteoarthritis, Kellgren-Lawrence classification, WOMAC pain subscale score, and the outcome value of the Focused Analgesia Selection Task. There are also exclusion criteria, such as patients with clinically significant disorders, recent treatment with certain medications, and contraindications for the use of Naproxen or acetaminophen.",
    "The sample is a record from a table that contains information about clinical trials. In this particular record, the trial is in phase 2 and is focused on the disease called neovascular age-related macular degeneration. The ICD-10 codes associated with this disease are H35.3211, H35.3212, H35.3221, H35.3222, H35.3231, H35.3232, and H35.3291. The drugs being studied in this trial are regn910-3 and intravitreal aflibercept injection (iai). The eligibility criteria for participants in this trial include being 50 years or older, having active subfoveal choroidal neovascularization (CNV) secondary to AMD, and having a certain level of visual acuity in the study eye. There are also exclusion criteria, such as not having CNV due to any cause other than AMD, not having received prior intravitreal anti-VEGF treatment in the study eye, and not having certain conditions like diabetic macular edema or diabetic retinopathy.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is Rett syndrome. The corresponding ICD-10 code for Rett syndrome is F84.2. The drugs being tested in this trial are nnz-2566 and placebo. The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include a diagnosis of classic/typical Rett syndrome with a documented mutation of the MeCP2 gene, age between 5 and 15 years, weight between 15.0 kg and 100.0 kg, and the ability to swallow the study medication or receive it via a gastrostomy tube. Exclusion criteria include actively undergoing neurological regression, abnormal QT interval or significant cardiovascular history, current treatment with insulin, use of anti-convulsants with liver enzyme inducing effects, unstable seizure profile, excluded concomitant medications, current clinically significant cardiovascular, renal, hepatic, or respiratory disease, gastrointestinal disease that may interfere with the absorption, distribution, metabolism, or excretion of the study medication, history of or current cerebrovascular disease or brain trauma, history of or current clinically significant endocrine disorder, history of or current malignancy, significant hearing and/or visual impairments that may affect the ability to complete the test procedures, and allergy to strawberry.",
    "The sample is a phase 2 trial for the treatment of psoriasis vulgaris. The eligibility criteria for participants include being diagnosed with psoriasis vulgaris according to the classification criteria, being between the ages of 18 and 70, having a PASI grade of at least 7 points, and not having received treatment with topical corticosteroids, immunosuppression, biological agents, tretinoin cream, or phototherapy in the month prior to enrollment. Additional criteria include having normal levels of total bilirubin, AST/ALT, and creatinine clearance, understanding and voluntarily participating in the study, and signing the informed consent form. Exclusion criteria include being pregnant, planning to become pregnant, or lactating, having serious heart, lung, kidney, or endocrine system conditions, having abnormal liver function or being a carrier of hepatitis B, having chronic diarrhea or peptic ulcer for the past year, having a malignant tumor, having acute or chronic infectious diseases, having mental disorders or a history of alcohol or substance abuse, and any other cases that the researchers deem ineligible for enrollment.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is mesothelioma, and the corresponding ICD-10 codes for the disease are C45.9, C45.0, C45.1, C45.2, and C45.7. The drugs being tested in the trial are nivolumab and nivolumab + ipilimumab. The eligibility criteria for the trial include having a histologically proved diagnosis of unresectable malignant pleural mesothelioma, availability of pathological samples for PD-L1 expression assessment, being at least 18 years old, having an ECOG performance status of 0-1, having a weight loss of less than 10% in the last 3 months, having a life expectancy of more than 12 weeks, having documented progression of the disease, having measurable disease, having received previous treatment with 1 or 2 systemic chemotherapy lines (including at least one line with pemetrexed in combination with a platinum agent), providing written informed consent, and having adequate organ function. The exclusion criteria include having primitive peritoneal, pericardial, testis, or tunica vaginalis mesothelioma, having a recent history of other malignancies (except adequately treated non-melanoma skin cancer and curatively treated in-situ cancer), having brain metastasis (unless surgically resected or treated with stereotaxic radiotherapy with no evolution within the last 3 months), having a history of primary immunodeficiency or organ transplant requiring immunosuppression, having a condition requiring systemic treatment with corticosteroids or other immunosuppressive medications, having received live attenuated vaccination within the last 30 days, having a known history of interstitial lung disease or CT-scan signs of interstitial lung disease, having an active or suspected autoimmune disease (except for type I diabetes mellitus, hypothyroidism requiring hormone replacement, or skin disorders not requiring systemic treatment), having active or history of inflammatory bowel disease or other serious gastrointestinal chronic conditions associated with diarrhea, having active or uncontrolled infections or serious illnesses or medical conditions that would not permit the patient to be managed according to the protocol, having prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, and having received the last dose of prior chemotherapy or radiation therapy (excluding palliative radiotherapy) less than 3 weeks prior to randomization.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"non small cell lung cancer\". The corresponding ICD-10 codes for this disease are \"C78.00\", \"C78.01\", \"C78.02\", \"D14.30\", \"D14.31\", \"D14.32\", and \"C34.2\". The trial involves the drugs \"afatinib\" and \"cetuximab\". The eligibility criteria for this trial include specific conditions such as stage III or IV NSCLC, non-squamous NSCLC confirmation, no previous treatment for NSCLC, presence of certain EGFR mutations, measurable lesions, and a performance status of 0 or 1. The exclusion criteria include conditions such as symptomatic brain metastasis, T790M mutation or exon 20 insertion, recent radiotherapy, and interstitial pneumopathy.",
    "The sample is a phase 2 clinical trial for the treatment of esophageal cancer using the drug S-1 in combination with radiotherapy. The eligibility criteria for participants include having a confirmed diagnosis of esophageal carcinoma, a performance status of 0-1 according to the ECOG scale, no prior treatments, and at least one measurable lesion. Participants should also have normal heart, lung, liver, kidney, and bone marrow functions, as well as meet certain blood exam qualifications. Informed consent is required.\n\nExclusion criteria include prior chemotherapy or irradiation treatments, poor bone marrow, liver or kidney functions that would make chemotherapy intolerable, contraindications for irradiation, participation in other clinical trials, and the presence of clinically significant and uncontrolled major medical conditions. The sample also excludes individuals with certain active malignancies within the past five years, except for specific exceptions.\n\nOverall, the sample represents a phase 2 trial investigating the efficacy and safety of S-1 in combination with radiotherapy for the treatment of esophageal cancer, with specific eligibility and exclusion criteria outlined.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"carcinoma, hepatocellular\" and \"secondary.\" The ICDCodes associated with these diseases are \"C22.0,\" \"C4A.9,\" \"C7B.1,\" \"C4A.0,\" \"C4A.31,\" \"C4A.51,\" and \"C4A.8.\" The drugs being used in the trial are \"sorafenib,\" \"capecitabine,\" and \"oxaliplatin.\" \n\nThe eligibility criteria for this trial include:\n- Advanced or metastatic hepatocellular carcinoma (HCC) that is not suitable for surgery or other loco-regional therapies.\n- Diagnosis of HCC confirmed either by cyto-histological confirmation or by non-invasive criteria according to the European Association for Study of Liver disease (EASL) criteria.\n- Child-Pugh A or B7 cirrhosis.\n- Eastern Co-Operative Group (ECOG) performance status \u2264 2.\n- Life expectancy of at least 12 weeks.\n- Adequate organ function (blood transfusion or use of biologic response modifiers is not permitted).\n- Measurable disease with at least one lesion that is at least 1 cm in one dimension on computed tomography (CT) or magnetic resonance imaging (MRI).\n- Able and willing to meet all protocol-required treatments, investigations, and visits.\n- Signed written informed consent form.\n\nThe exclusion criteria for this trial include:\n- Prior systemic therapy for advanced HCC.\n- Central nervous system (CNS) metastasis.\n- History of liver transplantation.\n- Peripheral sensory neuropathy with functional impairment before the first cycle of treatment.\n- History of cardiac disease.\n- Uncontrolled hypertension.\n- Women who are pregnant or breastfeeding, or women of child-bearing potential who are unable or unwilling to practice a highly effective means of contraception.\n- Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of study results.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on chronic lymphocytic leukemia (CLL). The ICD-10 codes associated with CLL are ['C91.11', 'C91.12', 'C91.10']. The drug being studied is acp-196 (acalabrutinib). \n\nThe eligibility criteria for this trial are as follows:\n- Participants must be men and women aged 18 or older.\n- They must have a prior diagnosis of CLL and have received at least one prior therapy for CLL.\n- Participants must be intolerant of ibrutinib and have documented disease progression after stopping ibrutinib therapy, as defined by the IWCLL 2008 criteria.\n- They must be willing and able to participate in all required evaluations and procedures, including swallowing capsules without difficulty.\n- Participants must have an ECOG performance status of 2 or lower.\n\nThere are also exclusion criteria, which include:\n- Ongoing adverse events attributed to ibrutinib therapy.\n- Prohibition of treatment with systemic anticancer therapy for CLL between discontinuation of ibrutinib and enrollment in this trial.\n- Prior exposure to a BCL-2 inhibitor (e.g., venetoclax/ABT-199).\n- Prior malignancy (other than CLL), except for adequately treated basal cell or squamous cell skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 2 years.\n- Significant cardiovascular disease, such as uncontrolled or symptomatic untreated arrhythmias, congestive heart failure, or myocardial infraction within 6 months of screening.\n- Malabsorption syndrome, gastrointestinal diseases, or gastric restrictions and bariatric surgery.\n- Evidence of active Richter's transformation or disease progression on ibrutinib therapy or any BTK inhibitor.\n- CNS involvement by CLL or related Richter's transformation.\n- Known history of HIV, active hepatitis B or C infection, or any uncontrolled active systemic infection.\n- Uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP).\n- History of stroke or intracranial hemorrhage within 2 months before the first dose of the study drug.\n- History of bleeding diathesis.\n- Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening.\n- Major surgical procedure within 28 days of the first dose of the study drug.\n- Requires treatment with a strong CYP3A inhibitor.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the disease cystic fibrosis. The ICD-10 codes associated with this disease are ['E84.9', 'Z14.1', 'E84.0', 'E84.11', 'E84.8', 'E84.19', 'P09.4']. The drugs being studied are pti-428 and placebo. The sample also includes the eligibility criteria for participants. Inclusion criteria include a confirmed diagnosis of CF, a forced expiratory volume in 1 second (FEV1) of 40-90% predicted, and being a non-smoker and non-tobacco user for at least 30 days prior to screening. Exclusion criteria include recent participation in another clinical trial or treatment with an investigational agent, a history of cancer within the past five years (excluding certain cases), a history of organ transplantation, recent sinopulmonary infection or CF exacerbation, history of alcohol or drug abuse or dependence, and being pregnant or nursing.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on the treatment of acute otitis media (AOM) with tympanostomy tubes (AOMT). The trial includes patients aged 6 months to 17 years, both male and female. The trial requires the caregiver of the patient to comply with the protocol and attend all study visits.\n\nThe sample also includes exclusion criteria, which are conditions that would disqualify a patient from participating in the trial. These criteria include a history of sensorineural hearing loss, tympanic membrane perforation other than the surgical tympanostomy tube perforation, and a history of known immunodeficiency disease.\n\nThe sample provides information about the diseases being studied, the corresponding ICD-10 codes, the drugs being used in the trial, and the eligibility criteria for participants.",
    "The sample is a phase 2 trial for the treatment of psoriatic arthritis. The trial is evaluating the effectiveness of the drug risankizumab compared to a placebo. The eligibility criteria for participants include having psoriatic arthritis symptoms for at least 6 months, meeting the classification criteria for psoriatic arthritis, having a certain number of tender and swollen joints, and having at least one psoriasis lesion or a documented history of psoriasis. Participants must also have active psoriatic arthritis that has not been adequately controlled by standard treatments. There are also exclusion criteria, such as having other chronic inflammatory or connective tissue diseases, prior use of certain medications, and certain medical conditions or surgeries. The sample provides detailed inclusion and exclusion criteria for potential participants.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is multiple myeloma. The ICD-10 codes associated with the disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are revlimid, velcade, dexamethasone, and farydak. The eligibility criteria for participants in the trial are listed, including requirements such as a diagnosis of multiple myeloma, specific biomarkers of malignancy, measurable disease, eligibility for stem cell transplantation, and certain age and performance status criteria. The exclusion criteria are also listed, which include factors such as concomitant anti-cancer therapy, unresolved diarrhea, intolerance to certain drugs, peripheral neuropathy, recent treatments, and certain medical conditions. The sample also mentions the need for written informed consent and excludes pregnant or nursing women from participating in the trial.",
    "The sample is a record from a table that contains information about clinical trials. It is for a trial that is in phase 2/phase 3 and focuses on rheumatoid arthritis. The trial includes patients who have been diagnosed with rheumatoid arthritis for at least 3 months and meet the classification criteria for rheumatoid arthritis set by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) in 2010. The patients must have been receiving conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy for at least 3 months and on a stable dose for at least 4 weeks prior to the trial. They should have at least 6 swollen joints and 6 tender joints at the screening and baseline visits. Patients who have had limited exposure to a biological disease-modifying anti-rheumatic drug (bDMARD) or had to discontinue bDMARD therapy due to intolerability may also be enrolled. However, patients with prior exposure to any Janus kinase (JAK) inhibitor or those who are considered inadequate responders to bDMARD therapy are excluded. Additionally, patients with a history of arthritis before the age of 17 or a current diagnosis of inflammatory joint disease other than rheumatoid arthritis are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are schizophrenia, major depressive disorder, and bipolar I disorder. The corresponding ICDCodes for these diseases are provided as well. The drug being tested is a combination of aripiprazole and an ingestible event marker (IEM). \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having a primary diagnosis of schizophrenia, major depressive disorder, or bipolar I disorder according to the DSM-5, being able to swallow tablets, currently taking a stable daily dose of oral aripiprazole, having the capacity to utilize the technology, and having skin free of any skin disorders or dermatological problems in the area of patch application. \n\nExclusion criteria include subjects using long-acting injectable antipsychotic medications, subjects likely to be incapable of using the Digital Medicine System even with assistance, subjects who present a serious risk of suicide, a history of epilepsy or seizures, hypersensitivity to antipsychotic agents or any component of the sensor skin patch or ingestible event marker, current history of substance use disorder meeting DSM-5 criteria, and subjects with unstable mood, acute psychosis, or exhibiting symptoms requiring hospitalization.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is metastatic colorectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are pemetrexed and erlotinib. \n\nThe eligibility criteria for this trial include being male or female aged 19 years or older, having a confirmed diagnosis of colorectal carcinoma with metastatic (Stage IV) disease, having a confirmed KRAS (codon 12 or 13) status, and having received prior chemotherapy for metastatic disease that includes fluoropyrimidine, oxaliplatin, and irinotecan. Other criteria include having an Eastern Cooperative Oncology Group performance status of 2 or lower, being able to swallow oral medication, having a life expectancy of greater than 3 months, and meeting certain organ and marrow function requirements.\n\nFemale participants of childbearing potential and male participants whose partner is of childbearing potential must be willing to use effective contraception during the study and for 6 months afterward. The effects of the drugs on the developing human fetus are unknown. Participants must also be willing and able to give informed consent for participation in the study.\n\nExclusion criteria for this trial include previous treatment with pemetrexed and erlotinib, a history of allergic reactions to similar compounds, inability to allow the administration of folic acid or vitamin B12, a history of neoplasm other than colorectal carcinoma within the past 5 years, recent systemic chemotherapy or major surgical operation, and active brain metastases. Other exclusion criteria include uncontrolled intercurrent illness, breastfeeding or pregnancy in females, and certain medical conditions that would limit compliance with study requirements.",
    "The sample is a phase 2 trial for the treatment of cystic fibrosis. The trial is testing the drugs cavosonstat and placebo. The eligibility criteria for participants include having a confirmed diagnosis of cystic fibrosis and being heterozygous for the F508del-CFTR mutation and a gating mutation approved for treatment with ivacaftor. Participants must have been treated with ivacaftor twice daily for at least 6 months prior to screening and currently be receiving commercially available ivacaftor. Other criteria include a negative pregnancy test, a weight of at least 40 kg, and an oxygen saturation level of at least 90% breathing ambient air. Exclusion criteria include recent acute infections, recent infection with certain organisms associated with decline in pulmonary status, recent changes in CF lung disease therapies, abnormal blood hemoglobin and serum albumin levels, abnormal liver or renal function, history of ventricular tachycardia or other significant ventricular arrhythmias, history of prolonged QT interval, history of solid organ or hematological transplantation, history of alcohol or drug abuse in the past year, and use of continuous or nocturnal supplemental oxygen.",
    "The sample from the table represents a phase 2 clinical trial for gastric cancer and gastroesophageal junction cancer. The diseases column lists the names of the diseases being studied, while the icdcodes column contains the corresponding ICD-10 codes for each disease. The drugs column lists the names of the drugs being used in the trial. The criteria column provides the eligibility criteria for patients to participate in the trial.\n\nIn this sample, patients must have a confirmed diagnosis of gastric or GEJ adenocarcinoma. They must have stage IV disease with HER2 overexpression and/or amplification. The HER2 status can be determined through various testing methods. Patients must have disease that can be evaluated radiographically, and they may not have received prior chemotherapy for stage IV disease. Other criteria include age of 18 years or older, ECOG performance status 0-1, and peripheral neuropathy \u2264 grade 1.\n\nPatients must also meet certain requirements for hepatic, hematologic, renal, and coagulation function. They must have adequate hepatic function, hematologic function, and renal function. Their urinary protein should be \u22642+ on routine urinalysis. Coagulation function should be within specified limits. Female patients of childbearing potential must have a negative pregnancy test.\n\nThere are also exclusion criteria, such as uncontrolled hypertension, concurrent anticancer therapy, certain cardiac diseases, bleeding diathesis or coagulopathy, and prior trastuzumab treatment. Patients with active brain or central nervous system metastases, those who are pregnant or breastfeeding, and those with recent major surgery or radiation are also excluded.\n\nOverall, the sample provides detailed information about the phase 2 clinical trial, including the diseases being studied, the drugs being used, and the eligibility criteria for patient participation.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is dementia, specifically Alzheimer's disease. The trial is looking at the effectiveness of a drug called xanamem\u2122 compared to a placebo. The eligibility criteria for participants include being 50 years or older, having a diagnosis of mild dementia due to Alzheimer's disease, and meeting certain cognitive and functional ability requirements. Participants must also be in good health, have a study partner who can provide accurate information about their cognitive abilities, and be willing to comply with the study requirements. There are also exclusion criteria, such as having significant abnormalities in vital signs or laboratory values, having other neurological diseases or psychiatric disorders, and recent stroke or significant head trauma. The sample also includes specific instructions for the study, such as avoiding certain medications and foods before starting the study.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 study design. The trial focuses on patients with lymphoma, specifically diffuse large B-cell lymphoma, mantle cell lymphoma, transformed lymphoma, follicular lymphoma, small lymphocytic lymphoma, marginal zone lymphoma, or Hodgkin lymphoma, who have had at least 2 lines of therapy without a curative treatment option. The drug being studied is tak228. \n\nThe eligibility criteria for the trial include patients being 18 years or older, providing voluntary written consent, and meeting certain requirements for contraception for female patients and barrier contraception for male patients. Patients must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower and adequate organ function. Measurable disease is also required for inclusion.\n\nExclusion criteria for the trial include patients who are eligible for therapy with a high likelihood of a curative result, lactating or breastfeeding female patients, and patients with serious medical or psychiatric illnesses that could interfere with treatment. Patients with concurrent malignancies, recent treatment with investigational products, or who have not recovered from the reversible effects of prior anticancer therapies are also excluded. Other exclusion criteria include manifestations of malabsorption, poorly controlled diabetes mellitus, and a history of certain cardiovascular or pulmonary diseases.\n\nThe sample also includes additional exclusion criteria related to cardiovascular or pulmonary diseases, treatment with certain medications, and the presence of certain medical conditions. Patients with central nervous system lymphoma, human immunodeficiency virus infection, or hepatitis B or C infection are also excluded. Patients who have been diagnosed or treated for another malignancy within the past 2 years or who have daily or chronic use of a proton pump inhibitor are also excluded from the trial.",
    "The sample is a clinical trial for multiple sclerosis, in phase 2/phase 3. The trial is testing the effectiveness of three drugs: bcd-033 (interferon beta 1a), rebif (interferon beta 1a), and a placebo. The eligibility criteria for participants include being between the ages of 18-55, having a diagnosis of multiple sclerosis based on the McDonald criteria 2010, no relapses in the 28 days prior to randomization, and an Expanded Disability Status Scale score between 0-5.5. Exclusion criteria include having primary or secondary progression of multiple sclerosis, an Expanded Disability Status Scale score higher than 5.5, severe depression or suicidal thoughts/attempts, and the use of systemic corticosteroids within 30 days before randomization.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is \"hepatitis c virus infection.\" The ICDCodes associated with this disease are \"B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2.\" The drug mentioned is \"sof/vel.\" The eligibility criteria for this trial include being HCV-infected, male or non-pregnant/non-lactating females, and undergoing liver transplantation. The key exclusion criteria are receiving an HCV-infected liver and being co-infected with HIV or hepatitis B virus (HBV).",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is cystic fibrosis. The ICD-10 codes associated with this disease are E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, and P09.4. The drugs being tested in this trial are tezacaftor/ivacaftor, ivacaftor, and placebos. \n\nThe eligibility criteria for this trial include being homozygous for the F508del CFTR mutation, having a confirmed diagnosis of CF, having a percent predicted forced expiratory volume (ppFEV1) of at least 70% of predicted normal for age, sex, and height during screening, and having stable CF disease as determined by the investigator. \n\nThe exclusion criteria include having any comorbidity that could confound the study results or pose an additional risk, having had a respiratory infection or pulmonary exacerbation within 28 days before the start of the study, being pregnant or nursing, not being willing to follow contraception requirements if sexually active and of reproductive potential, and having any contraindication to undergoing chest imaging according to the site's guidelines.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is acute ischemic stroke. The ICD-10 codes associated with this disease are 'I25.5', 'H47.013', 'H93.013', 'G45.9', 'H47.011', 'H47.012', and 'H47.019'. The drugs being tested in the trial are natalizumab and placebo. The eligibility criteria for participants include having a clinical diagnosis of supratentorial acute ischemic stroke within 24 hours prior to the study, specific scores on the NIHSS (National Institutes of Health Stroke Scale), being able to perform basic activities of daily living without assistance, and having certain imaging findings. There are also exclusion criteria, such as having certain types of stroke, presence of acute intracranial hemorrhage, severe stroke based on imaging criteria, history of certain treatments or infections, and others.",
    "The sample is a phase 2 trial for the treatment of various diseases including leukemia, myelofibrosis, anemia, and splenomegaly. The trial is testing the drug rigosertib. The eligibility criteria for participants include being at least 18 years old, having a diagnosis of primary myelofibrosis or post-polycythemia vera or post-essential thrombocythemia myelofibrosis, having anemia or RBC-transfusion dependence, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and being willing to adhere to the study's prohibitions and restrictions. Exclusion criteria include ongoing clinically significant anemia due to certain factors, serum ferritin levels below 50 ng/mL, any active malignancy within the past year (except for certain types), uncontrolled intercurrent illness, active infection not responding to therapy, and various other medical conditions. Female patients who are pregnant or lactating, or of childbearing potential who are unwilling to follow strict contraception requirements, are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2. The disease being studied is thyroid cancer. The icd-10 codes associated with the disease are C73, D34, D44.0, and Z85.850. The drugs being used in the trial are apatinib. The eligibility criteria for participants in this trial include having locally advanced or metastatic differentiated thyroid cancer, with at least one measurable lesion. The participants must have experienced disease progression within 14 months before inclusion and must be 131I-refractory/resistant. Other criteria include normal organ function, an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2, an expected survival of at least 3 months, and negative pregnancy test results for women of childbearing age. The sample also includes exclusion criteria such as having other thyroid cancer histological subtypes, recent VEGFR inhibitor treatment, poorly controlled arterial hypertension, and factors that could affect oral medication.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is breast cancer. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are ribociclib, everolimus, and exemestane. \n\nThe eligibility criteria for this trial include being an adult man or woman, having a confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer, having HER2-negative breast cancer, having either measurable disease or bone lesions, having an ECOG Performance Status of 0-1, having disease refractory to AI, tamoxifen, or fulvestrant, having been previously treated with any CDK 4/6 inhibitor, and having adequate bone marrow and organ function.\n\nThe exclusion criteria for this trial include having symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy, having received more than one line of chemotherapy for advanced disease, having previous treatment with mTOR inhibitors or exemestane for advanced disease, having progressed on more than one CDK 4/6 inhibitor, having CNS involvement unless at least 4 weeks have passed since prior therapy completion, and having clinically significant, uncontrolled heart disease and/or recent cardiac events.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is macular edema. The ICD-10 codes associated with the disease are H59.033, H34.8130, H59.031, H59.032, H59.039, H34.8110, and H34.8120. The drugs being tested are bi 1026706 and placebo. The eligibility criteria for the trial are listed, including age requirements, specific diagnosis of diabetes mellitus type 1 or type 2, retinal thickening due to diabetic macular edema, specific measurements of retinal thickness and visual acuity, and other exclusion criteria.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2. The diseases being studied are candidemia, mycoses, fungal infection, fungemia, and invasive candidiasis. The corresponding ICDCodes for these diseases are provided as well. The drugs being tested in the trial are cd101, caspofungin, fluconazole, intravenous placebo, and oral placebo. The eligibility criteria for participants are listed, including requirements such as having a mycological diagnosis of candidemia and/or invasive candidiasis, willingness to receive medical treatment, and agreement to use contraception methods. There are also exclusion criteria, such as having certain forms of IC, neutropenia, or known hypersensitivity to the drugs being tested.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on two diseases: nasopharyngeal neoplasms and stomatitis. The diseases are associated with specific ICD-10 codes. The trial involves the use of two drugs: oral ulcer gargle (forrad\u00ae) and a quadruple mixture composed of dexamethasone, gentamicin, vitamin B12, and procaine. The eligibility criteria for participants are listed, including requirements such as confirmed and untreated nasopharyngeal carcinoma, age between 18 and 65, a Karnofsky performance status score of at least 70, and planned radiotherapy or concurrent chemoradiotherapy with intensity-modulated radiation therapy. Adequate bone marrow function and a life expectancy of at least 3 months are also required. The exclusion criteria include known allergies to the drugs used in the trial and any other conditions deemed inappropriate for enrollment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is HIV infection. The corresponding ICDCodes for this disease are ['Z21']. The drugs being tested in this trial are 'abx464' and 'placebo'. The eligibility criteria for this trial include various conditions such as being infected with HIV, having a specific viral load, being on specific medications, having a certain CD4+ T cell count, and falling within a specific age range. There are also exclusion criteria listed, such as having specific HIV protease inhibitor resistance mutations, a history of certain illnesses, or concurrent AIDS-related opportunistic infections.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on prostate cancer. The ICD-10 codes associated with the disease are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']. The drugs being studied are 'zytiga\u00ae (abiraterone acetate)' and 'solumatrix\u2122 (abiraterone acetate)'. The eligibility criteria for participants are listed, including requirements such as written informed consent, confirmed adenocarcinoma of the prostate, ongoing therapy with a GnRH agonist or antagonist, and meeting disease progression criteria. There are also exclusion criteria, such as a history of impaired pituitary or adrenal gland function, prior therapy with certain medications, and various other medical conditions or treatments that would make a participant ineligible.",
    "The sample provided is for a phase 2 clinical trial for non-small cell lung cancer. The trial is evaluating the effectiveness of the paclitaxel and carboplatin regimen in treating this type of cancer. The eligibility criteria for participants include being between the ages of 18 and 75, having confirmed advanced non-small cell lung cancer through pathology, having indications for paclitaxel/carboplatin chemotherapy, having at least one measurable tumor lesion, having an ECOG PS score of 0 to 2, having a life expectancy of more than 3 months, having good bone marrow and organ function, and being willing to comply with the study requirements. Exclusion criteria include having an ECOG Performance Score greater than 2, having organic diseases or active infections that would prevent completion of the chemotherapy cycles, having any other tumor history within the past 3 years, having ineligible bone marrow or organ function for chemotherapy, and currently receiving standard anti-diabetes treatment.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is categorized as either phase I, phase II, or phase III. The specific disease being studied is \"diabetic foot infections,\" and it is associated with a list of ICD-10 codes. The trial involves the use of two drugs, \"bisphosphocin nu-3\" and \"placebo.\" The eligibility criteria for participants are listed, including age requirements, consent, specific diabetes type, and characteristics of the diabetic foot ulcer. Additional criteria for female participants are also mentioned. The exclusion criteria are also provided, which outline conditions that would disqualify a participant from the trial.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on patients with type 2 diabetes mellitus. The ICD-10 codes associated with the disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The trial involves the use of two drugs, tesofensine/metoprolol and placebo. The eligibility criteria for inclusion in the trial include being male or female, having a confirmed diagnosis of type 2 diabetes mellitus, being between 18 and 70 years old, and having an HbA1c level of 7.0% or higher. The exclusion criteria include hypersensitivity to tesofensine/metoprolol, heart failure class II or greater, recent history of myocardial infraction or stroke, recent history of coronary revascularization or angioplasty, recent angina, treatment with insulin or other injectable anti-diabetic medications, and any clinically significant cardiac arrhythmia.",
    "The sample provided is for a clinical trial in phase 2, focusing on the disease of multiple sclerosis. The corresponding ICD-10 codes for multiple sclerosis are 'G35' and 'C81.18'. The trial is using a placebo as the drug being tested. The eligibility criteria for participants include having a diagnosis of relapsed multiple sclerosis, having active disease, and experiencing more than one relapse in the past two years. The exclusion criteria include recent treatment with anti-CD20 monoclonal antibody or alemtuzumab within the last 12 months, as well as being pregnant or nursing.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"idiopathic pulmonary fibrosis\" (IPF). The corresponding ICD-10 code for IPF is \"J84.112\". The trial involves two drugs, \"glpg1690 600 mg qd\" and \"placebo qd\". The eligibility criteria for participants are listed, including requirements such as signing the Informed Consent Form, being aged 40 years or older, having a recent chest HRCT scan, being diagnosed with IPF by a multidisciplinary team, meeting certain lung function criteria, being on stable supportive care, and being in a stable condition. The exclusion criteria are also provided, which include hypersensitivity to the study drug ingredients, immunosuppressive conditions, recent history of malignancy, clinically significant abnormalities on ECG, recent IPF exacerbation or respiratory tract infection, smoking within the past 3 months, presence of interstitial lung disease, history of lung volume reduction surgery or lung transplant, unstable cardiac or pulmonary disease other than IPF, abnormal liver or renal function.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on type 1 diabetes mellitus.\n- ICD Codes: The ICD-10 codes associated with the disease are ['E10.65', 'E10.9', 'E10.21', 'E10.36', 'E10.41', 'E10.42', 'E10.44'].\n- Drugs: The trial involves the use of three drugs: 'biochaperone human insulin (hinsbet\u00ae)', 'insulin lispro (humalog\u00ae)', and 'regular human insulin (huminsulin\u00ae normal)'.\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include age, duration of type 1 diabetes, insulin treatment, BMI, HbA1c levels, and fasting C-peptide levels. The exclusion criteria include hypersensitivity to certain products, presence of type 2 diabetes, previous participation in the trial, recent participation in other clinical trials, abnormal screening test results, gastrointestinal symptoms, gastric emptying issues, special diet requirements, and pregnancy or lack of effective contraception for females of childbearing potential.",
    "The sample provided is a record from a table that contains information about clinical trials. The record belongs to a trial in phase 2 and focuses on the disease \"duchenne muscular dystrophy\". The corresponding ICD-10 code for this disease is \"G71.01\". The trial involves two drugs, namely \"ns-065/ncnp-01\" and \"placebo\". The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being a male between 4 and 10 years old, having a confirmed DMD mutation amenable to skipping exon 53, being able to walk independently, and having a stable dose of glucocorticoid for at least 3 months. Exclusion criteria include recent acute illness, symptomatic cardiomyopathy, severe allergies or hypersensitivity to medications, severe behavioral or cognitive problems, previous participation in the study or any other study involving NS-065/NCNP-01, and other medical conditions that could affect safety or study results.",
    "The sample is a phase 2 trial for heart failure. The eligibility criteria include being at least 40 years old, experiencing symptoms of dyspnea without a non-cardiac or ischemic explanation, having an ejection fraction (EF) of at least 50%, and meeting one of the following conditions: previous hospitalization for heart failure with radiographic evidence of pulmonary congestion, elevated filling pressures documented through catheterization, elevated levels of NT-proBNP or BNP, or evidence of diastolic dysfunction/elevated filling pressures on echocardiogram. The primary factor limiting activity should be heart failure-related. Other criteria include having a peak VO2 of no more than 75% predicted, not being on chronic nitrate therapy or using intermittent sublingual nitroglycerin, not using daily phosphodiesterase 5 inhibitors or soluble guanylyl cyclase activators, being ambulatory, being able to wear the accelerometer belt comfortably, and being willing to provide informed consent. Exclusion criteria include recent hospitalization for heart failure, ongoing requirement for certain medications, low hemoglobin or GFR levels, low blood pressure or high resting heart rate, previous adverse reaction to the study drug, significant chronic obstructive pulmonary disease or ischemia contributing to dyspnea, certain cardiac conditions, severe liver disease, terminal illness with less than 1 year expected survival, regular swimming or water aerobics, enrollment in another therapeutic clinical trial in the next 3 months, inability to comply with study procedures, and pregnancy or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is metastatic colorectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being tested in this trial are trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab. \n\nThe eligibility criteria for this trial include obtaining written informed consent, having an ECOG performance status of 0, 1, or 2, having a confirmed diagnosis of adenocarcinoma of the colon or rectum, determining the RAS status (mutant or wild), having at least one measurable metastatic lesion, not having received previous systemic anticancer therapy for unresectable metastatic colorectal cancer, allowing previous adjuvant or neoadjuvant chemotherapy if completed more than 6 months before the start of the study treatment, not being a candidate for combination chemotherapy with irinotecan or oxaliplatin or curative resection of metastatic lesions, being able to take medication orally, having adequate organ function, having coagulation parameters within normal limits, testing negative in a serum pregnancy test for women of childbearing potential, and agreeing to use a highly effective method of birth control for women and male participants with partners of childbearing potential.\n\nThe exclusion criteria for this trial include being a pregnant or lactating female, having certain serious illnesses or medical conditions as described in the protocol, having had certain other recent treatments such as major surgery, field radiation, or receiving investigational agents within specified time frames prior to randomization, having previously received Trifluridine/tipiracil or having a history of allergic reactions to compounds of similar composition, having rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, and having a contraindication to bevacizumab or capecitabine.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are ocular hypertension and open-angle glaucoma. The ICDCodes associated with these diseases are provided as well. The drugs being tested are \"mgv354 ophthalmic suspension\" and \"mgv354 placebo\". \n\nThe eligibility criteria for participants in this trial include having documented informed consent, being within a certain age range, being able to communicate well with the investigator, having a specific body mass index (BMI), and meeting certain vital sign requirements. Other criteria include being in good health for healthy volunteers or being diagnosed with open-angle glaucoma or ocular hypertension for patients. \n\nThere are also exclusion criteria, such as a history of hypersensitivity to the study drugs, certain medical conditions, exposure to certain medications, and pregnancy or lactation for women. Additional exclusion criteria may apply as specified in the protocol.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of acute lymphoblastic leukemia. The trial involves the use of two drugs, dasatinib and blinatumomab. The eligibility criteria for participants include being newly diagnosed with adult B-precursor Ph+ ALL, being at least 18 years old, having a good performance status, and meeting certain renal, hepatic, and pancreatic function requirements. Other criteria include having normal cardiac function, testing negative for HIV, HBV, and HCV, and having a negative pregnancy test for women of childbearing potential. The sample also includes exclusion criteria, such as having a history of CNS pathology, impaired cardiac function, gastrointestinal disorders, autoimmune disease, recent cancer chemotherapy, and other concurrent medical conditions that may interfere with the study. Additionally, it states that nursing women or women of childbearing potential must use effective contraception during the study and for at least three months afterward.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is Phase 2.\n- Diseases: The specific disease being studied, which in this case is \"endometrial cancer.\"\n- ICD Codes: The ICD-10 codes associated with the disease, which are \"N85.00\", \"N85.01\", \"N85.02\", and \"N99.85\".\n- Drugs: The drugs being used in the trial, which are \"carboplatin auc\" and \"abraxane.\"\n- Criteria: The eligibility criteria for participating in the trial, which are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\"\n\nThe inclusion criteria specify the requirements for patients to be eligible for the trial, such as having high-risk resected stage I disease, not having received prior cytotoxic chemotherapy, and having a GOG performance status of 0, 1, or 2. The exclusion criteria list factors that would make a patient ineligible for the trial, such as having other prior malignancies within 3 years, being pregnant or breastfeeding, and having certain cardiac conditions.\n\nOverall, this sample provides information about a Phase 2 clinical trial for endometrial cancer, including the specific disease, drugs being used, and the criteria for patient eligibility.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is constipation. The ICDCodes associated with this disease are \"K59.00\", \"K59.09\", \"K59.01\", \"K59.02\", \"K59.03\", \"K59.04\", and \"K58.1\". The drug being tested is naloxegol.\n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Adults who are 18 years old or older.\n- Eastern Cooperative Oncology Group (ECOG) score of 3 or lower.\n- Glomerular filtration rate (GFR) of 30 ml/min/1.73m2 or higher by Modification of Diet in Renal Disease (MDRD).\n- Corrected serum calcium level of 10.5 mg/dL or lower.\n- Estimated life expectancy of 6 months or longer.\n- Negative pregnancy test required for females of childbearing potential.\n\nExclusion Criteria:\n- Patients who have taken opioid antagonists, mixed antagonists, strong CYP3A4 and/or P-glycoprotein (P-gp) inhibitors, moderate CYP3A4 and/or P-gp inhibitors, or strong CYP3A4 inducers within 3 days of Study Day 1 or planned to receive them throughout the study period.\n- Patients receiving total parenteral nutrition or using metoclopramide.\n- Patients at high risk for bowel perforation.\n- Constipation not primarily caused by opioids according to the investigator's medical opinion.\n- Conditions that may have affected the permeability of the blood-brain barrier, such as known brain metastases, meningeal metastases, brain injury, multiple sclerosis, recent brain injury, uncontrolled epilepsy.\n- Clinically active diverticular disease.\n- Past medical history of irritable bowel syndrome, signs of active gastrointestinal (GI) bleeding, acute surgical abdomen, bowel stents, indwelling peritoneal catheter, mechanical GI obstruction, fecal impaction, or fecal ostomy.\n- Patients with motility/neurologic disorders including autonomic failure (spinal cord lesions, tumor invasion of nerves) and/or poorly controlled endocrine/metabolic disorders (hypercalcemia, hypokalemia, diabetes, hypothyroidism), as determined by the investigator.\n- Uncontrolled cancer pain despite analgesic therapy.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which includes the eligibility criteria for the trial.\n\nIn this particular sample, the phase of the trial is listed as \"phase 2/phase 3\". The disease being studied is \"acute migraine\" and its corresponding ICD-10 codes are provided as \"['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']\". The drugs being tested are \"zp-zolmitriptan\" and \"placebo\". The eligibility criteria for the trial are then listed, including inclusion criteria such as having a history of episodic, acute migraine for more than 1 year, complying with the diagnostic criteria of the International Headache Society, and experiencing certain characteristics during migraine attacks. Exclusion criteria are also listed, such as contraindications to triptans, history of certain types of migraines, and participation in other clinical trials.\n\nTo be eligible for treatment, subjects must continue to meet certain criteria observed during the run-in period, including having an average of at least two qualifying migraines per 28-day period, no more than 10 headache days in the last 28 days prior to randomization, and demonstrating the ability to properly use the electronic diary and apply the demo study drug patch. The subject must also be in good general health or have a stable non-serious disease that will not put them at risk, as determined by the investigator.",
    "The sample provided is for a phase 2 clinical trial. The trial is focused on esophageal cancer and the drug being tested is endostatin, along with oxaliplatin. The eligibility criteria for participants include having a confirmed diagnosis of esophageal carcinoma, being between the ages of 18 and 80, having an ECOG performance status of 0-1, and not having received any prior treatments. Participants must also have at least one measurable lesion on CT, MRI, or esophageal barium exam, and normal functions of the heart, lung, liver, kidney, and bone marrow. Blood exams must qualify for chemotherapy, with specific requirements for hemoglobin, neutrophil count, platelet count, and creatinine levels. Informed consent is also required. Exclusion criteria include prior treatments of chemotherapy or irradiation, poor bone marrow, liver, or kidney functions that would make chemotherapy intolerable, contraindications for irradiation, participation in other clinical trials, pregnancy, breastfeeding, or not using birth control. Participants with certain medical conditions, such as active uncontrolled infection, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements, are also excluded. Additionally, participants who have had another active malignancy within the past five years, except for specific exceptions, are not eligible for the trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial is testing the effectiveness of the drugs abemaciclib, tamoxifen, and prophylactic loperamide. The eligibility criteria for participants include having a diagnosis of HR+, HER2- breast cancer, relapsing or progressing after endocrine therapy, and having received at least 2 chemotherapy regimens, with 1 or 2 administered in the metastatic setting. Participants must also have measurable disease, a performance status \u22641, and have discontinued previous cancer therapies for a certain period of time. They must have adequate organ function, a negative pregnancy test, and be able to swallow oral medication. Exclusion criteria include having central nervous system metastasis, certain cardiac conditions, active infections, prior treatment with a cyclin-dependent kinase (CDK4) and CDK 6 inhibitor, chronic diarrhea, and a history of other cancers unless in complete remission for at least 3 years.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific record, the phase is Phase 2, and the disease mentioned is pancreatic adenocarcinoma. The ICDCodes associated with this disease are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drug mentioned is \"preoperative modified folfirinox and postoperative gemcitabine.\" The eligibility criteria for this trial include various conditions such as age, confirmation of adenocarcinoma, meeting specific criteria for borderline resectable disease, no previous chemotherapy or radiotherapy, specific performance status, adequate bone marrow and renal function, adequate hepatic function, absence of other malignant diseases, and written informed consent. The exclusion criteria include factors such as potentially resectable or metastatic disease, locally advanced unresectable disease, adenosquamous carcinoma, medical or psychiatric conditions that affect informed consent or protocol completion, recent radiotherapy, gastrointestinal obstruction or bleeding, significant heart disease, severe or uncontrolled systemic disease, pregnancy or lactation in females, and lack of willingness or ability to use effective contraception.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"esophageal\" cancer. The ICD-10 codes associated with this disease are \"K22.2\", \"K22.81\", \"Q39.4\", \"P78.83\", \"I85.00\", \"I85.01\", and \"I85.10\". The drugs being studied in this trial are \"endostar\", \"liposo\", \"cisplatin\", and \"gimeracil and oteracil potassium (tegafur)\". The eligibility criteria for participants in this trial include having confirmed esophageal cancer, being in the potentially resectable stage, being able to eat more than a liquid diet, having no signs of esophageal perforation or distant metastasis, being between the ages of 18 and 75, having an ECOG performance status of 0-1, having an expected survival period of at least 3 months, having adequate blood function, liver function, and renal function, having a normal ECG, not having received previous anti-tumor drug treatment, having recovered from any previous surgeries, having a negative pregnancy test for female participants, not having a history of severe allergic reactions to biological agents, and meeting certain exclusion criteria such as not having a history of taxol allergy, not being pregnant or nursing, not having serious acute infections or uncontrolled chronic infections, not having serious heart disease, not having uncontrolled nerve or mental illnesses, and not having a bleeding tendency.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are breast cancer, specifically early stage and triple negative breast cancer. The ICDCodes associated with these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being tested is enzalutamide.\n\nThe eligibility criteria for Step 1 of the study population include having Stage 1, 2, or 3 invasive breast cancer that is triple negative. Triple negative breast cancer is defined as having low levels of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). The patient must also be willing and able to provide informed consent, be at least 18 years old, and be a candidate for treatment of their early stage breast cancer.\n\nThe eligibility criteria for Step 2 of the study population include having Stage 1, 2, or 3 invasive breast cancer that is triple negative. In addition to the criteria mentioned for Step 1, Step 2 also requires the patient to have tested positive for androgen receptor (AR) expression, have completed any neoadjuvant or adjuvant chemotherapy regimen, and have a performance status of 0 or 1 according to the ECOG scale. Other criteria include being able to swallow the study drug, being able to comply with study requirements, and using two acceptable methods of birth control for women of childbearing potential.\n\nThe exclusion criteria for participation in the study include having severe concurrent diseases, infections, or comorbid conditions that would interfere with participation, having metastatic or Stage 4 breast cancer, having a history of another invasive cancer within the past 5 years (with exceptions), having abnormal blood counts or liver function, having a history of seizures or conditions that may predispose to seizures, having an active gastrointestinal disorder affecting absorption, and having hypersensitivity reactions to the active pharmaceutical ingredient or any of the capsule components.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The diseases being studied are Hepatitis B and Viral Hepatitis. The ICDCodes associated with these diseases are B18.0, B18.1, B19.10, B19.11, B17.0, B16.0, and B16.1. The drugs being used in the trial are SB 9200, Placebo, and Tenofovir. The eligibility criteria for this sample include requirements such as documented evidence of chronic HBV infection, specific levels of HBV DNA and ALT, absence of hepatocellular carcinoma, and willingness to comply with study requirements. There are also inclusion and exclusion criteria for the extension period of the trial.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is diffuse large b-cell lymphoma. The icd-10 codes associated with this disease are 'S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', and 'S33.131S'. The drugs being used in the trial are azd 2014 and rituximab. The eligibility criteria for the trial include having relapsed or refractory DLBCL, confirming histology within 3 months, providing informed consent, being at least 18 years old, having an ECOG performance status of \u2264 2, and meeting certain contraceptive requirements for females. Other criteria include being able to swallow and retain oral medication, having measurable disease, and testing negative for HIV, hepatitis B, and hepatitis C. The exclusion criteria include recent treatment with other therapies, major surgery, exposure to certain medications, previous treatment with specific inhibitors, CNS involvement, and various other medical conditions. There are additional exclusion criteria specific to the rituximab cohort.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is described as \"phase 2/phase 3\". The disease being studied in this trial is \"type 2 diabetes\". The corresponding ICD-10 codes for this disease are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\". The drugs being tested in the trial are \"yh1 group\" and \"placebo group\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being between 20-75 years old, diagnosed with type 2 diabetes, having a BMI of 23 kg/m2 or higher, and having been treated with at least 3 kinds of oral hypoglycemic agents with persistent high HbA1c levels. Exclusion criteria include having type 1 diabetes, gestational diabetes, or other specific types of diabetes, recent insulin therapy, serious gastrointestinal tract diseases, recent stressful situations or surgeries, hepatic or renal insufficiency, uncontrolled hypertension, mental illness or substance abuse, pregnancy or lactation, hemoglobin disease or chronic anemia, underlying conditions that could affect compliance, history of cerebrovascular disease or myocardial infraction, and recent Chinese medicine treatment.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is \"proliferative diabetic retinopathy.\" The ICD-10 codes associated with this disease are \"H35.23,\" \"H35.20,\" \"H35.21,\" \"H35.22,\" \"E10.3553,\" \"E11.3553,\" and \"E13.3553.\" The drug being tested is \"emixustat hydrochloride.\" \n\nThe sample also includes the eligibility criteria for the trial. The inclusion criteria include being able and willing to provide written informed consent, having a documented diagnosis of type 1 or type 2 diabetes mellitus, meeting specific ocular criteria for the study eye (such as the presence of proliferative diabetic retinopathy with or without diabetic macular edema), and having adequate media clarity, pupillary dilation, and subject cooperation for assessments.\n\nThe exclusion criteria include any condition that would preclude participation in the study (such as unstable medical status or history of myocardial infraction), history of chronic renal failure or prior participation in any clinical study of emixustat, treatment with any investigational study drug within 30 days of screening, known allergy to fluorescein sodium for injection in angiography, treatment with specific prohibited medications or therapy, history of systemic anti-VEGF or pro-VEGF treatment within 4 months prior to randomization, pre-specified laboratory abnormalities at screening, specific ocular characteristics in the study eye, male subjects who are not surgically sterile and not willing to practice birth control, female subjects of childbearing potential who are not willing to practice birth control, and female subjects who are pregnant or lactating.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on gynecologic malignancies. The ICD-10 codes associated with these diseases are Y76.0, Y76.1, Y76.2, Y76.3, Y76.8, Z01.411, and Z01.419. The drugs being used in the trial are paclitaxel and carboplatin. The eligibility criteria for participants include having a confirmed or presumed diagnosis of gynecologic malignancy, a body surface area greater than 2.0, and meeting certain requirements for renal, bone marrow, hepatic, and neurologic function. Participants must also have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2, and must be entered into the trial within 12 weeks of diagnosis. Exclusion criteria include prior radiotherapy or chemotherapy, acute hepatitis or active infection, significant cardiovascular disease, pregnancy or nursing, and known allergy to cremophor or polysorbate 80.",
    "The sample is from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the ICD-10 codes associated with the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is phase 2. The disease being studied is \"irritable bowel syndrome with diarrhea\". The associated ICD-10 codes for this disease are \"K58.0\" and \"K58.9\". The drugs being tested are \"bekinda\" and \"placebo\". The eligibility criteria for this trial include specific requirements such as age (\u226518 years), meeting FDA guidance and Rome III criteria for IBS-D, having a certain frequency and form of stool, and having certain laboratory parameters within specified limits. There are also exclusion criteria listed, which include factors such as having other causes for bowel disease, history of abdominal surgery, and certain medical conditions or medications that may interfere with the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"atopic dermatitis.\" The ICD-10 codes associated with this disease are \"L20.89\" and \"L20.9.\" The drugs being studied are \"pac-14028 cream 0.1%,\" \"pac-14028 cream 0.3%,\" \"pac-14028 cream 1.0%,\" and \"pac-14028 cream vehicle.\" \n\nThe eligibility criteria for this trial are as follows:\n- The patient must be between 19 and 70 years old.\n- The patient must have been diagnosed with atopic dermatitis according to Haniffin and Rajka criteria.\n- The affected body surface area (BSA) must be over 5% and the Investigator's Global Assessment (IGA) score must be 2 (mild) to 3 (moderate).\n- The patient must voluntarily agree to participate in the study and sign an informed consent form.\n\nThere are also exclusion criteria, which include:\n- Having other skin diseases or scars in the affected area that could affect the study.\n- Having a clinically significant medical history or diseases involving the liver, kidney, neurological system, or mental disorders that could affect the study results.\n- Having used systemic steroids, antibiotics, immunosuppressants, or received photochemical therapy within 28 days before the study drug administration.\n- Having used topical steroids, immunosuppressants, or antibiotics to treat atopic dermatitis within 14 days before the study drug administration.\n- Using or expected to use prohibited concomitant medications during the study.\n- Being pregnant, breastfeeding, or having childbearing potential without using available contraceptives.\n- Having taken other study medications within 30 days before screening.\n- Being determined ineligible for study participation by investigators for any other reasons.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2. The disease being studied is prostate cancer. The icd-10 codes associated with this disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs being used in the trial are enzalutamide, abiraterone, and prednisone. The eligibility criteria for this trial include having histologic proof of adenocarcinoma of the prostate with clinical evidence of metastatic disease to the bone, castrate resistant progression of prostate carcinoma, measurable disease within the bone, a life expectancy of at least 12 weeks, an ECOG Performance status of less than 2, adequate bone marrow, hepatic, and renal function, no evidence of coagulopathy, and a serum calcium level between 8 and 11.5 mg/dL. The exclusion criteria include having variant histologies, visceral disease, prior use of certain drugs, concurrent cancer chemotherapy, radiotherapy or surgery, concurrent serious infection, life-threatening illness, uncontrolled hypertension, the need for invasive dental procedures, known or suspected brain metastases (except for treated epidural disease), recent administration of any investigational drug, and being under 18 years of age.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is head and neck cancer. The ICDCodes associated with this disease are C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, and D36.11. The drugs being used in the trial are cisplatinum, docetaxel, and carboplatin. \n\nThe eligibility criteria for this trial include:\n- The patient must have biopsy-proven squamous cell carcinoma of the oropharynx (tonsil, base of tongue, vallecula, soft palate) and supraglottis.\n- The patient must have stages III (T1N1, T2N1, T3N0, T3N1) and stage IVA (T1N2, T2N2, T3N2, very select early T4) disease that has not been previously treated with surgery, radiation, or chemotherapy.\n- There should be no evidence of distant metastatic disease.\n- The patient must be fit for surgery and the primary tumor must be assessed as surgically resectable via a transoral approach.\n- The patient must be over 18 years old.\n- The Karnofsky performance status must be greater than 60% or ECOG less than 2.\n- The ANC (absolute neutrophil count) must be greater than 2,000, platelets must be greater than 100,000, and calculated creatinine clearance must be greater than 50 cc/min.\n- The patient must have signed a study-specific consent form.\n- The protocol must begin within 4 weeks of biopsy and within 3 weeks of the latest medical imaging.\n- The patient must not have any other malignancies except cutaneous basal or squamous cell cancer within the last 5 years.\n- The patient must have measurable disease based on RECIST criteria.\n- Men and women of childbearing potential must agree to use effective contraception while on the study, and women must have a negative pregnancy test and not be lactating.\n\nThe exclusion criteria for this trial include:\n- Patients with advanced T4 cancer judged unresectable by a transoral approach.\n- Patients with N3 disease (Stage IVB).\n- Patients with distant metastatic disease (Stage IVC).\n- Patients with radiologically positive neck nodes with radiological evidence of extracapsular nodal tumor invasion.\n- Patients with anatomy that does not allow transoral access and exposure for surgery, as judged by the surgical PI at the time of biopsy under general anesthesia.\n- Patients with prior head and neck cancer at any time (other than basal or squamous cell cancer of the skin).\n- Patients with a coexistent second malignancy or a history within 5 years of prior malignancy (other than basal or squamous cell cancer of the skin or curatively treated Stage I carcinoma of the cervix) are ineligible.\n- Patients with peripheral neuropathy grade 1 or higher are not eligible for the study.\n- Patients who have had prior Taxanes or Cisplatin.\n- Patients with concurrent infection are not eligible, unless the fever is due to the tumor.\n- Patients with coexisting medical illness of a severity that might interfere with treatment or follow-up, or who do not have the ability to give informed consent.\n- Patients who have received prior radiation therapy, surgery, and chemotherapy for the tumor being treated.\n- Patients must not be receiving any other investigational agent while on the study.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is basal cell nevus syndrome. The ICD-10 codes associated with this disease are D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, and E34.0. The drugs being tested in the trial are patidegib and a vehicle gel. The eligibility criteria for participants include being between 18 and 85 years old, providing written informed consent, meeting diagnostic criteria for BCNS, having a history of at least 10 BCCs, having at least 5 previously untreated SEBs, being willing to have SEBs biopsied and provide plasma samples, abstaining from certain topical medications, having a negative pregnancy test (for females), using effective birth control methods (for males with female partners), contacting the study center after each primary skin care physician visit, and being willing to forego treatment of the treatment targeted baseline SEBs. The exclusion criteria include being a woman of childbearing potential, using certain topical or systemic therapies that may interfere with the study, having a history of hypersensitivity to the study drug formulation, being unable or unwilling to attend follow-up visits, having uncontrolled systemic disease, having a clinically important history of liver disease, having any condition or situation that may put the participant at significant risk or interfere with the study, having a history of invasive cancer within the past 5 years (excluding certain types), participating in another experimental drug study, and having female sexual partners who are unwilling or unable to comply with pregnancy prevention measures.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on two diseases: osteoarthritis of the knee and type 2 diabetes mellitus. The ICD-10 codes associated with these diseases are also provided. The trial involves the use of two drugs: fx006 32 mg and tca ir 40 mg. The eligibility criteria for participants are listed, including age requirements, specific criteria related to diabetes management and symptoms of osteoarthritis, body mass index, and willingness to comply with study procedures. The exclusion criteria are also listed, which include specific medical conditions, recent use of certain medications, and pregnancy or nursing for women of child-bearing potential.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is esophageal cancer. The ICDCodes associated with this disease are \"K22.2\", \"K22.81\", \"Q39.4\", \"P78.83\", \"I85.00\", \"I85.01\", and \"I85.10\". The drug being used in the trial is the nab-paclitaxel group. The eligibility criteria for this trial include having inoperable locally advanced histologically confirmed esophageal cancer, an ECOG performance status scale of 0-1, at least 1 measurable target lesion, specific blood count and liver function requirements, normal cardiac function, and not having a history of esophagectomy, pregnancy or breastfeeding, other past cancers (except for non-melanoma skin cancer or cervical cancer), or concomitant treatment with other anticancer drugs.",
    "The sample from the table is for a clinical trial in phase 2/phase 3. The diseases being studied are recurrent squamous cell lung carcinoma and stage IV squamous cell lung carcinoma. The corresponding ICD-10 codes for these diseases are D02.20, D02.21, and D02.22. The drug being tested is docetaxel. The eligibility criteria for the trial include various requirements such as not having prior exposure to certain immunotherapies, not having received certain medications within a specific timeframe, not having certain autoimmune or inflammatory diseases, not having a history of primary immunodeficiency, and not having certain allergies or reactions to the drug being tested. Other criteria include not having a history of tuberculosis, not having certain infections or diseases, and not having received certain vaccinations within a specific timeframe. The sample also includes additional criteria for patients who have already received 12 months of treatment with the drug and are being considered for re-treatment. Various medical assessments and laboratory tests are required to determine eligibility. Patients must also provide informed consent to participate in the trial.",
    "The sample from the table represents a phase 2 clinical trial for pancreatic cancer. The eligibility criteria for participants include having a confirmed resected ductal pancreatic adenocarcinoma with complete resection, being able to start treatment within 12 weeks post-surgery, having an ECOG/WHO Performance Status of 0-1, and being at least 18 years old. Female participants of child-bearing potential must agree to use two approved contraceptive methods and have a negative pregnancy test. Male participants must practice abstinence or use a condom during sexual contact with a pregnant female or a female of childbearing potential. Participants must also meet certain hematology and liver function parameters. Exclusion criteria include prior treatment for pancreatic adenocarcinoma, presence of metastatic or locally recurrent pancreatic adenocarcinoma, and history of certain serious medical conditions. Participants must also not have any allergies to the investigational agents or any agents used in the trial. Other conditions that may interfere with protocol compliance or pose unacceptable risk are also exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on breast cancer. The trial is specifically for women between the ages of 18 and 75 who are HER2 negative. The eligibility criteria include having an ECOG score of 0-1 and an expected survival time of at least 3 months. The patients must have confirmed breast cancer and have previously been treated with anthracycline- or taxane-based chemotherapies. They must also have at least one measurable lesion according to RECIST 1.1 criteria. The patients' organ function must meet certain requirements, including blood counts, liver function, and renal function. Women of child-bearing age must have a negative pregnancy test and be willing to use contraception during the trial and for 8 weeks after the last administration of the drugs. The patients must be able to swallow oral drugs and have good compliance with the therapy and follow-up. They must also understand the study protocol and sign the Informed Consent Form.\n\nThe exclusion criteria include patients who are pregnant or breastfeeding without effective contraception, patients who have received three or more chemotherapies after recurrence and metastasis, and patients who have participated in other clinical trials within four weeks prior to the start of this study. Patients with factors that affect the oral administration and absorption of drugs are also excluded, as well as those who have previously received anti-VEGF or anti-VEGFR therapies. Patients with rapid progression of viscera invasion, uncontrollable mental illness, serious adverse effects to oral vinorelbine, or allergies to vinorelbine are also excluded. Patients with only bone metastasis without other measurable lesions, severe cardiovascular diseases, severe upper gastrointestinal ulcer or malabsorption syndrome, abnormal bone marrow or renal function, abnormal liver function, uncontrollable brain metastasis, or poor compliance with therapy are also excluded.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, the diseases are lung neoplasms and EGFR gene mutations, the ICDCodes are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2, the drug is osimertinib, and the eligibility criteria are listed in a detailed format. The inclusion criteria include factors such as provision of informed consent, age requirement, specific type of lung cancer, no prior exposure to certain drugs, presence of activating EGFR mutation, performance status, life expectancy, contraceptive measures for females, and compliance with the study protocol. The exclusion criteria include factors such as previous treatment with specific drugs, recent use of certain medications, unresolved toxicities from prior therapy, severe or uncontrolled systemic diseases, symptomatic central nervous system metastases, history of interstitial lung disease, inadequate bone marrow reserve or organ function, certain cardiac criteria, refractory nausea and vomiting, hypersensitivity to the drug, pregnancy or breastfeeding, and non-compliance with study procedures.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is biliary tract cancer. The ICDCodes associated with this disease are C24.9 and C24.8. The drug being used in the trial is a combination of mek162 and capecitabine. \n\nThe eligibility criteria for this trial include:\n- The patient must have histologically or cytologically verified non-resectable, recurrent, or metastatic biliary tract carcinoma, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder carcinoma.\n- The patient must have previously been treated with gemcitabine-based chemotherapy, with up to 2 prior treatment regimens allowed.\n- The patient must have measurable or evaluable disease according to RECIST 1.1 criteria.\n- The patient's Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1.\n- The patient must be at least 20 years old.\n- The patient must have adequate bone marrow function, renal function, and hepatic function.\n- Patients with biliary obstruction can participate if their bilirubin levels correct to the required limit after adequate biliary drainage.\n- Women of childbearing potential must have a negative pregnancy test and both men and women of childbearing potential must be willing to use effective contraception during the trial and for at least 3 months afterward.\n- The patient must be able to understand and sign a written informed consent document.\n\nThe exclusion criteria for this trial include:\n- Evidence of another active cancer that may influence patient outcome, except for certain specified types of cancer.\n- Known brain metastases or primary central nervous system tumors with uncontrolled seizures.\n- Uncontrolled intercurrent illness, including psychiatric illness or social situations that would limit compliance with study requirements.\n- Known HIV positive status.\n- Significant cardiovascular disease, uncontrolled diabetes mellitus, history of myocardial infraction or stroke within 6 months, clinically significant peripheral vascular disease, or major surgical procedure within 4 weeks.\n- Uncontrolled infection, known or suspected allergy to capecitabine, pregnancy, breastfeeding, any condition that impairs the patient's ability to swallow whole pills, malabsorption problem that may limit or inhibit the absorption of MEK162, or history of any organ or bone marrow transplant.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied include breast carcinoma metastatic in the brain, estrogen receptor negative, HER2/neu negative, HER2/neu positive, progesterone receptor negative, recurrent breast carcinoma, and stage IV breast cancer. The corresponding ICDCodes for these diseases are also provided. The drug being tested in this trial is palbociclib. The eligibility criteria for this trial include specific requirements related to the patient's medical history, disease characteristics, previous treatments, and overall health. These criteria include factors such as histological confirmation of HER2-positive metastatic breast cancer, limited prior chemotherapy, measurable brain lesions, stable corticosteroid use, adequate bone marrow, liver, and renal function, and the ability to comply with study requirements. There are also exclusion criteria that specify conditions or situations that would make a patient ineligible for participation in the trial, such as uncontrolled neurological symptoms, impending herniation or significant vasogenic edema, certain medical illnesses or infections, previous treatment with palbociclib, and allergies or hypersensitivity to the drug.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on three diseases: dyslipidemia, menopause, and obesity. The corresponding ICD-10 codes for these diseases are provided as well. The trial involves testing different drugs, including \"carduus marianus 6ch,\" \"carduus marianus 12ch,\" \"carduus marianus 30ch,\" and a placebo. The eligibility criteria for participants are outlined, including age range, specific health conditions (hypertriglyceridemia, hypercholesterolemia, overweight or obesity), and other medical factors. There are also exclusion criteria, such as a history of cardiovascular disease, certain medications, and pregnancy or breastfeeding.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 2. The disease being studied is primary Sj\u00f6gren's syndrome. The corresponding ICD-10 codes for this disease are D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, and E34.0. The drugs being tested in this trial are cdz173 and placebo. The eligibility criteria for participants include a diagnosis of primary Sj\u00f6gren's syndrome and an ESSDAI score of at least 6 at the screening visit. Secondary Sj\u00f6gren's syndrome is listed as an exclusion criterion. Other inclusion and exclusion criteria may also apply, as defined by the protocol.",
    "The sample provided is for a phase 2 clinical trial. The trial is focused on treating head and neck cancer, specifically squamous cell carcinoma. The trial requires patients to meet certain eligibility criteria in order to participate. These criteria include having a confirmed diagnosis of squamous cell carcinoma in the head and neck region, with specific tumor sites specified. The patients must have undergone a complete surgical removal of the tumor, with certain risk factors present in the pathology report. The trial excludes patients with evidence of distant metastasis, prior chemotherapy or radiotherapy to the head and neck region, and other previous cancers except for specific exceptions. Pregnant or breastfeeding females, as well as males and females of childbearing potential not using adequate contraceptive measures, are also excluded. The trial also requires patients to have certain organ functions within normal ranges and to provide signed written informed consent. The sample does not provide information about the specific drug being tested in the trial.",
    "The sample is a phase 2 trial for the treatment of salivary gland tumors and head and neck cancer. The trial is looking for patients who have been diagnosed with a malignant salivary gland tumor of intermediate or high-grade and have undergone surgical resection with curative intent. The patients should have no evidence of gross tumor residual, no distant metastases, and no synchronous or concurrent head and neck primary tumors. They should also have a Karnofsky score over 60 and meet certain criteria for organ function, such as specific blood counts and liver and kidney function. The patients should provide signed written informed consent.\n\nThe exclusion criteria include evidence of distant metastasis, prior chemotherapy or anti-cancer biologic therapy, prior radiotherapy to the head and neck region, and other previous cancers (except for in situ cervical cancer and cutaneous basal cell carcinoma). Pregnant or breastfeeding females, as well as females and males of childbearing potential not taking adequate contraceptive measures, are also excluded. Additionally, patients with uncontrolled concomitant illnesses, such as ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia, are not eligible for the trial.",
    "The sample provided is for a phase 2 clinical trial focused on obesity. The trial is investigating the use of the drug perindopril for weight loss in individuals with a body mass index (BMI) between 30.0 to 40.0 kg/m2. The eligibility criteria for inclusion in the trial include being 18 years or older, providing written informed consent, and having the ability to comply with the study requirements. If a woman of childbearing potential, she must agree to use effective contraceptive methods.\n\nThe exclusion criteria for the trial include being pregnant or breastfeeding, having a known cause for obesity (such as hypothyroidism or Cushing's disease), currently being treated with perindopril or other similar medications, having hypertension, experiencing significant weight variation in the past 3 months, having a history of eating disorders, having a systolic blood pressure below 110 mmHg, having a history of hypersensitivity to perindopril or related compounds, having a history of angioedema associated with previous ACE inhibitor therapy, having a history of idiopathic or hereditary angioedema, being on concomitant medication affecting weight loss, being on concomitant medication that may interfere with the absorption, distribution, metabolism, or elimination of perindopril, being on any investigational drug or device within 1 month prior to the trial, having moderate to severe hepatic impairment or moderate to severe renal impairment, having unstable coronary artery disease, having aortic and mitral valve stenosis or hypertrophic cardiomyopathy, being on hemodialysis or having undergone kidney transplantation, having experienced anaphylactoid reactions during LDL apheresis, having neutropenia, agranulocytosis, thrombocytopenia, or anemia, undergoing major surgery or anesthesia with agents that produce hypotension, having hyperkalemia, or having any other condition or therapy that the study physician deems unsuitable for the trial.",
    "The sample from the table is for a clinical trial that is in phase 2/phase 3. The trial is focused on the treatment of attention deficit disorder with hyperactivity (ADHD). The trial includes subjects who meet certain criteria, such as having a diagnosis of ADHD according to the DSM-5 and a score of at least 28 on the ADHD-RS-5 scale. The subjects also need to have an IQ greater than 79 and have been previously genotyped to have disruptive mutations in genes within the glutamate receptor metabotropic (GRM)-network. The trial excludes subjects with comorbid major psychiatric disorders, those currently taking prohibited medications, and those with a history of illnesses that could confound the results or pose additional risks. Subjects with certain cardiac or neurological conditions are also excluded.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is endometriosis. The ICD-10 codes associated with the disease are N80.8, N80.9, N80.0, N80.1, N80.5, N80.2, and N80.3. The drugs being tested in the trial are placebo and obe2109. The sample also includes the eligibility criteria for the trial, including key inclusion criteria such as having a recent surgical and histological diagnosis of pelvic endometriosis, experiencing moderate to severe endometriosis-associated pain, having regular menstrual cycles, and having a BMI of 18 kg/m2 or higher. Key exclusion criteria include being pregnant or planning a pregnancy during the treatment period, having had interventional surgery for endometriosis within 60 days before screening, not responding to prior treatment with GnRH agonists or antagonists, having a history of osteoporosis or other metabolic bone disease, and having chronic pelvic pain not caused by endometriosis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is \"myelodysplastic syndromes.\" The ICDCodes associated with this disease are \"D46.9,\" \"D46.C,\" and \"D46.Z.\" The drug being tested in this trial is \"tipifarnib.\" \n\nThe eligibility criteria for this trial include being at least 18 years old, having documented pathological evidence of MDS, and having transfusion-dependent anemia. The criteria also specify the required average transfusion requirement, the hemoglobin levels, and the unresponsiveness or refractoriness to erythropoiesis-stimulating agents. Other criteria include risk category, ECOG performance status, absence of known curative treatment, acceptable hematological and liver function, acceptable renal function, and specific requirements for female subjects regarding contraception and pregnancy testing.\n\nThe exclusion criteria include prior progression to acute myeloid leukemia, other myelodysplastic or myeloproliferative syndromes, prior systemic treatments for MDS, prior cytoreductive therapy, recent use of an ESA, participation in other interventional studies, ongoing treatment with anticancer agents not included in the protocol, prior treatment with a farnesyltransferase inhibitor, and various medical conditions or circumstances that could interfere with the study or pose risks to the subjects.\n\nOverall, this sample provides detailed information about the phase, disease, drug, and eligibility criteria for a specific clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"atopic dermatitis\". The ICD-10 codes associated with this disease are \"L20.89\" and \"L20.9\". The drugs being studied in this trial are \"pf-04965842\" and \"placebo\". The eligibility criteria for participants include being between 18 and 75 years old, having a clinical diagnosis of chronic atopic dermatitis for at least 1 year, and having an inadequate response to topical medications. There are also exclusion criteria, such as having HIV or hepatitis, or having received certain treatments within specific timeframes.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 2.\n- Diseases: The trial is focused on heart failure.\n- ICD Codes: The ICD-10 codes associated with heart failure are ['I50.814', 'I09.81', 'I50.82', 'I50.89', 'I50.9', 'T86.22', 'I11.0'].\n- Drugs: The trial involves the drugs 'qgc001' and 'placebo'.\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". \n\nThe \"Inclusion Criteria\" include requirements such as signed informed consent, a clinical diagnosis of heart failure with a specific NYHA class, documented left ventricular ejection fraction (LVEF) below 40%, certain levels of BNP or NT-proBNP, specific eGFR and serum potassium levels, prescribed optimal pharmacologic therapy, and other conditions related to medication and health status.\n\nThe \"Exclusion Criteria\" list factors that would disqualify potential participants, such as high BMI, recent cardiovascular events, certain heart conditions, specific levels of heart rate and blood pressure, lung disease, kidney function, electrolyte levels, history of certain medical conditions, use of certain medications, and other factors that may affect the trial's results or the participant's safety.\n\nOverall, this sample record provides information about a Phase 2 clinical trial focused on heart failure, including the specific diseases, drugs, and eligibility criteria involved.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 2.\n- Diseases: The trial is focused on colorectal neoplasms.\n- ICD Codes: The ICD-10 codes associated with the disease are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2'].\n- Drugs: The drugs being tested in the trial are nintedanib and capecitabine.\n- Criteria: The eligibility criteria for the trial are listed under \"Inclusion criteria\" and \"Exclusion criteria\". The criteria include factors such as confirmed colorectal adenocarcinoma, metastatic or locally advanced disease, performance status, previous treatments, time interval between treatments, liver and kidney function, and various exclusion criteria related to prior treatments, hypersensitivity, other malignancies, medical conditions, cardiovascular diseases, bleeding or thrombotic disorders, gastrointestinal disorders, brain metastases, and more.\n\nThis sample provides a specific example of a trial in Phase 2 focused on colorectal neoplasms, with specific eligibility and exclusion criteria, and the drugs being tested.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is Hepatitis C Virus Infection. The ICDCodes associated with this disease are B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, and B17.2. The drugs mentioned in this sample are Sof/Vel and RBV. The eligibility criteria include key inclusion criteria such as providing written informed consent, having chronic genotype 3 HCV infection with compensated cirrhosis, and having or not having HIV-1 coinfection. The key exclusion criteria include a history of clinically significant illness or any other medical disorder that may interfere with treatment assessment or compliance, co-infection with active hepatitis B virus, laboratory results outside acceptable ranges at screening, being pregnant or nursing, and having chronic liver disease not caused by HCV. It is also noted that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"multiple sclerosis, relapsing-remitting.\" The associated ICD-10 codes for this disease are \"G35,\" \"G93.81,\" \"K74.1,\" \"Q85.1,\" \"G12.21,\" \"G12.23,\" and \"M34.0.\" The trial involves two drugs, \"gnbac1\" and \"placebo.\" The eligibility criteria for participants include having reliable contraception for those with reproductive potential, meeting the 2010 revised McDonald criteria for relapsing-remitting multiple sclerosis, having disease activity such as recent relapse or Gd-enhancing T1 lesion, and having an EDSS score less than 6.0. The main exclusion criteria are patients with secondary progressive MS or primary progressive MS at screening, and pregnant or nursing women.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is \"clostridium difficile infection\". The corresponding ICD-10 codes for this disease are \"A05.2\", \"A04.71\", \"A04.72\", and \"B96.7\". The drugs being tested in this trial are \"ridinilazole\" and \"fidaxomicin\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include informed consent, clinical diagnosis of CDI with a laboratory test, limited antimicrobial treatment, and the use of contraception for female subjects of childbearing potential. Exclusion criteria include life-threatening or fulminant CDI, multiple episodes of CDI in the previous year, pregnancy or breastfeeding, history of inflammatory bowel disease, co-administration of potent P-glycoprotein inhibitors, recent participation in other clinical research studies, and subjects deemed inappropriate by the investigator.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of psoriasis. The table includes columns for the phase, diseases, icd-10 codes, drugs, and eligibility criteria.\n\nIn this particular sample, the phase is phase 2, and the disease being studied is psoriasis. The icd-10 codes associated with psoriasis are ['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']. The drugs being used in the trial are 'idp-118 vehicle lotion', 'idp-118 vehicle cream', 'idp-118 lotion', and 'ultravate cream'.\n\nThe eligibility criteria for participants in this trial include being at least 18 years old, providing informed consent, having an area of plaque psoriasis covering a specific body surface area, being willing to avoid ultraviolet radiation exposure, having a clinical diagnosis of psoriasis with a specific assessment score, and meeting certain requirements for female participants of childbearing potential.\n\nThere are also exclusion criteria, such as having certain types of psoriasis, having concurrent skin conditions that could interfere with the evaluation, being pregnant or planning a pregnancy during the study period, and having received treatment with investigational drugs or devices within a specific timeframe.\n\nOverall, this sample provides specific details about the phase, diseases, icd-10 codes, drugs, and eligibility criteria for a clinical trial focused on psoriasis treatment.",
    "The sample is a phase 2 trial for the treatment of psoriasis. The trial is testing multiple drugs, including \"idp-122 vehicle lotion,\" \"idp-122 vehicle cream,\" \"idp-122 lotion,\" and \"ultravate cream.\" The eligibility criteria for participants include being at least 18 years old, providing informed consent, avoiding prolonged exposure to ultraviolet radiation, and being willing to comply with study instructions and clinic visits. Exclusion criteria include having rapidly improving or deteriorating psoriasis, previous treatment failure with prescription medication, concurrent skin conditions that could interfere with evaluation, pregnancy or nursing, and recent participation in other clinical studies with investigational drugs or devices.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 2. The diseases being studied are recurrent squamous cell lung carcinoma and stage iv squamous cell lung carcinoma. The icd-10 codes associated with these diseases are D02.20, D02.21, and D02.22. The drug being tested is taselisib. The eligibility criteria for this sample include various medical conditions and requirements that patients must meet in order to participate in the trial. These criteria include specific lab test results, absence of certain medical conditions, ability to take oral medications, and not taking certain drugs or supplements. The sample also includes additional criteria for patients who have progressed on a specific treatment and have measurable disease. The sample provides detailed information about the inclusion and exclusion criteria, as well as other requirements for participation in the trial.",
    "The sample from the table represents a clinical trial for a combination therapy involving the drugs docetaxel and palbociclib. The trial is in phase 2/phase 3 and is focused on patients with specific diseases, including ccnd1 gene amplification, ccnd2 gene amplification, ccnd3 gene amplification, cdk4 gene amplification, recurrent squamous cell lung carcinoma, and stage iv squamous cell lung carcinoma ajcc v7. The diseases are identified by their corresponding ICD-10 codes.\n\nThe eligibility criteria for the trial include meeting certain screening and pre-screening criteria, being assigned to a specific sub-study, not taking certain medications, having specific laboratory measurements within a certain timeframe, being able to take oral medications, and not having certain medical conditions or history. The criteria also include requirements for disease assessment, previous treatment history, laboratory measurements, performance status, and other factors.\n\nPatients must provide informed consent and agree to use effective contraception if they are of reproductive potential. The trial also requires the treating institution to have received institutional review board approval.\n\nOverall, the sample provides information about the phase, diseases, drugs, and eligibility criteria for the clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of ischemic stroke. The trial involves the use of three drugs: \"sp-8203 high dose,\" \"sp-8203 low dose,\" and \"placebo.\" The eligibility criteria for the trial are listed, including specific criteria for stage 1 and stage 2 patients. Inclusion criteria include being an adult between the ages of 19 and 80, fulfilling the criteria for rtPA therapy, being available for brain MRI scanning, and providing consent to participate in the trial. Exclusion criteria include having systemic allergic diseases or hypersensitivity to specific drugs, recent acute myocardial infraction or arrhythmia, abnormal ECG findings, severe heart failure, fever or infection signs, pulmonary diseases, abnormal hematological findings, undergoing hemodialysis or treatments for renal failure, having cancer, being pregnant or breastfeeding, not consenting to use double barrier contraception, recent participation in other clinical trials, and having contraindications for the use of rtPA. The contraindications for rtPA include hypersensitivity to gentamycin, high risk of bleeding, history of hemorrhagic diseases or diathesis, use of oral anticoagulants, recent hemorrhage or central nervous system damage, hemorrhagic retinopathy or ophthalmic hemorrhage, recent traumatic events or procedures, uncontrollable severe arterial hypertension, recent major surgery or trauma, bacterial endocarditis or pericarditis, acute pancreatitis, records of gastrointestinal diseases or malformations, severe liver diseases, mild or severe neurologic deficit, seizure at onset of stroke, suspicion of subarachnoid hemorrhage, recent use of heparin, history of stroke or head injury, high blood pressure, and abnormal blood glucose levels.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is \"colorectal adenocarcinoma.\" The ICDCodes associated with this disease are \"C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31.\" The drug mentioned is \"regorafenib 160 mg.\" The eligibility criteria for this trial include various conditions such as having metastatic colorectal cancer with histological proof, measurable disease according to RECIST 1.1, age \u2265 70 years, ECOG \u2264 1, specific biological values within certain ranges, no response to previous chemotherapy or anti-VEGF treatment or anti-EGFR treatment (if RAS wild-type), geriatric questionnaires answered, life expectancy \u2265 3 months, and signed informed consent. The exclusion criteria include conditions such as inability to swallow tablets, previous treatment with regorafenib or other multikinase treatment, presence of other cancers in the last 5 years (except specific cases), recent radiotherapy or major surgery, unresolved toxicity from previous treatment, certain cardiac or medical conditions, recent myocardial infraction or arterial/venous thromboembolism, certain infections or diseases, and various other factors that may interfere with the study participation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is prostate cancer. The ICDCodes associated with the disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs mentioned are durvalumab and tremelimumab. The eligibility criteria include various requirements such as histologically confirmed adenocarcinoma of the prostate, disease progression, testosterone levels, presence of clinically and/or radiologically documented disease, measurable lesions, age, ECOG performance status, prior therapies, laboratory requirements, and more. The sample also includes exclusion criteria, which specify conditions that would make a patient ineligible for the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on Crohn's disease. The diseases column specifies the disease being studied, and the icdcodes column provides the corresponding ICD-10 codes for Crohn's disease. The drugs column lists the drugs being used in the trial, which are \"crown\" and \"crown placebo\". The criteria column outlines the eligibility criteria for participants in the trial.\n\nThe inclusion criteria state that eligible participants must be adults with a confirmed history of symptomatic Crohn's disease, as confirmed by endoscopy or radiology. Their CDAI score (Crohn's Disease Activity Index) should be less than or equal to 350, and they should have active endoscopic disease. Participants should also be on a stable dose of infliximab, adalimumab, or certolizumab therapy for 8 weeks prior to randomization. They should be able to consume oral nutrition, understand the informed consent process, and be willing to follow study instructions. Additionally, they should have access to necessary devices and internet for data collection and be able to undergo required procedures.\n\nThe exclusion criteria state that pregnant or nursing females, or those planning to become pregnant during the study period, are excluded. Subjects with certain conditions such as fistula contributing to diarrhea, recent bowel obstruction, stricturing disease, or anticipated need for gastrointestinal surgical therapy in the next 6 months are also excluded. Other exclusion criteria include current treatment with high-dose systemic corticosteroids, recent changes in antimetabolite therapy, current treatment with specific antibiotics, current ostomy, serious infections or medical conditions that may interfere with participation, history of non-compliance with protocols, active participation in another Crohn's disease trial or recent use of investigational products, diagnosis of celiac disease, known sensitivity to milk or soy protein, and any other condition that the investigator deems unsuitable for study participation or may confound the results.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is type 1 diabetes mellitus. The ICD-10 codes associated with this disease are E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, and E10.44. The drugs being used in the trial are hdv insulin lispro and insulin lispro. The eligibility criteria for participants in this trial include being at least 18 years old, having a clinical diagnosis of type 1 diabetes mellitus for at least 12 months, having a body mass index (BMI) of 35 Kg/m2 or less, using basal insulin such as insulin Glargine or insulin Detemir, using bolus insulin defined as 2 to 4 doses of regular human insulin or rapid-acting analog at meals, having an HbA1c level between 7.0% and 10.5%, having a fasting C-peptide level of 0.5 pmol/mL or less, being willing to adhere to the protocol and perform all required tests, reviewing and signing the Informed Consent Form, using an acceptable form of birth control if of childbearing age, being willing to wear continuous glucose monitoring (CGM) devices and complete diaries. The exclusion criteria include having a total daily insulin dose of 1.5 IU/kg/day or more, having a history of recent blood transfusions, hemoglobinopathies, or any other conditions that affect HbA1c measurements, having evidence of serious complications of diabetes, being unwilling or unable to participate in the MRI evaluation subset, having significant cardiovascular dysfunction or a history of certain cardiovascular conditions, having impaired liver function, having high creatinine levels, being on a low carbohydrate diet, having a history of adrenal supplementation within 3 years, having a history of unawareness or severe recurrent hypoglycemia, being treated with systemic corticosteroids, having triglyceride levels of 500 mg/dL or more, having a history of cancer within the past 5 years (excluding certain types), having epilepsy or other conditions that could result in non-compliance with the study, participating in another clinical trial or using an investigational drug within 30 days prior to the study, being unwilling to discontinue the use of an insulin pump for the duration of the study, being pregnant, nursing, or planning to become pregnant during the study, using NPH as the basal insulin, having a positive history of hepatitis A, hepatitis B, hepatitis C, or HIV, and having a history of drug addiction and/or alcohol abuse within 12 months prior to the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is amyotrophic lateral sclerosis (ALSO). The corresponding ICD-10 code for ALSO is G12.21. The drugs being tested in this trial are np001 and placebo. The eligibility criteria for participants in this trial include a diagnosis of clinically possible, probable, or definite ALSO, a forced vital capacity greater than or equal to 65% of the predicted value for age and height, onset of ALSO-related weakness within the past 3 years, a certain level of plasma high sensitivity C-reactive protein (hs-CRP), and stable use of riluzole if already undergoing treatment with it. Female participants must either not be of childbearing potential or agree to use adequate birth control during the study. The exclusion criteria include a life expectancy of less than 6 months, the use of tracheotomy or ventilatory assistance, active pulmonary disease, gastrostomy, previous stem cell therapy, recent immune modulator therapy or participation in other studies involving different agents within the past 12 weeks, and any unstable medical condition other than ALSO.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is indicated as \"phase 1/phase 2\". The disease mentioned in this sample is \"nasopharyngeal carcinoma\". The corresponding ICD-10 codes for this disease are listed as \"['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']\". The drug mentioned in this sample is \"cisplatin\". \n\nThe eligibility criteria for this trial are then listed. The inclusion criteria include having a confirmed diagnosis of nasopharyngeal carcinoma, completing a specific course of radiation therapy, having a recurrence diagnosed more than 12 months after the initial treatment, being between the ages of 18 and 70, having a Karnofsky Performance Score of at least 70, being willing to use contraception if applicable, understanding the trial's implications, and signing the informed consent form.\n\nThe exclusion criteria include having a local recurrence of nasopharyngeal carcinoma within 12 months of completing previous radiation therapy, having distant metastasis, using a different technology for the initial treatment, being pregnant or lactating, not having recovered from previous therapies, having a diagnosis of another malignancy within the past 5 years (except for certain types), and refusing to participate in the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of acute myelogenous leukemia. The trial includes patients aged 65 to less than 75 years with at least one non-severe comorbidity, or patients aged 75 years or older with or without any comorbidity. The patients must be newly diagnosed and untreated with de novo or secondary AML according to WHO classification. \n\nThere are several exclusion criteria for the trial, including prior or current treatment with chemotherapy or radiotherapy, prior treatment with specific drugs, prior malignancies within the past 5 years (with some exceptions), chronic myelogenous or acute promyelocytic leukemia, known CNS involvement, eligibility for bone marrow or stem cell transplant, high white blood cell count, impaired renal function, abnormal liver function, high serum calcium levels, history of calcium disorders or kidney stones, hypersensitivity to certain drugs, current use of certain medications, use of experimental drugs or therapies within the past 4 weeks, known HIV infection, eligibility for intensive induction therapy, refractory congestive heart failure, active infection, pulmonary disease, liver cirrhosis or acute viral hepatitis, current mental illness or cognitive impairment, and uncontrolled neoplasia.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is systemic lupus erythematosus (SLE). The ICD-10 codes associated with SLE are also provided. The drugs being tested in this trial are placebo and dapirolizumab pegol (dzp). The eligibility criteria for participants in this trial are listed, including the requirement of a clinical diagnosis of SLE confirmed by specific classification criteria, moderate to severe disease activity, and evidence of certain SLE markers. There are also exclusion criteria listed, such as the presence of certain other diseases or conditions, history of thromboembolic events, and use of prohibited medications.",
    "The sample from the table is for a phase 2 trial. The disease being studied is major depressive disorder. The ICD-10 codes associated with this disease are F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, and F33.40. The drugs being tested in the trial are s47445 15mg, s47445 50mg, and a placebo. The eligibility criteria for the trial include being an outpatient, fulfilling DSM-5 criteria for major depressive disorder, being treated with an SSRI antidepressant for at least 6 weeks and no more than 4 months, having a stable dosage for at least 3 weeks, having a HAM-D total score of 20 or higher, having a Clinical Global Impression Severity of illness score between 4 and 6, and having an Antidepressant Treatment Response Questionnaire score of less than 50% for the current SSRI. The exclusion criteria include having a depressive episode of mild intensity, having any type of depressive episode other than those occurring in major depressive disorder, having a depressive episode within 12 months after a stroke, having a suicidal risk, having lactose intolerance or hereditary problems of galactose intolerance, having resistant depression for the current episode, having current panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, acute stress disorder, or past or current psychotic disorder, and having any severe personality features.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of endometriosis. The trial is specifically targeting healthy premenopausal female volunteers between the ages of 18 and 49. The participants must have a body mass index (BMI) between 18 and 32 kg/m2 and weigh at least 110 lbs. They should also have regular menstrual cycles with a length ranging from 21 to 35 days.\n\nIf the participants are sexually active and at risk of pregnancy, they must be willing to use one of the specified methods of contraception throughout the study and for at least 30 days after the last drug administration. These methods include the use of an intra-uterine contraceptive device, diaphragm with spermicide, or having a sterile male partner.\n\nThe participants must refrain from excessive alcohol use during the study and abstain from alcohol for 24 hours prior to any PK blood draw. They should also avoid using prescription medications, over-the-counter medications, and natural health products throughout the study.\n\nThe exclusion criteria include hypersensitivity to certain medications, undiagnosed abnormal vaginal bleeding, known or suspected pregnancy, breastfeeding or having stopped breastfeeding within 2 months prior to the screening visit, and a history of thrombophlebitis, thromboembolic disorders, cerebral apoplexy, or breast carcinoma.\n\nOther exclusion criteria include recent childbirth or abortion, abnormal cervical cytology smear or Bethesda System report, tobacco use within the past 3 months, history of alcohol or drug abuse, clinically significant vital sign abnormalities, and various medical conditions such as liver disease, neurologic disorders, diabetes mellitus requiring insulin, and history of severe respiratory depression.\n\nThe sample also includes additional exclusion criteria related to thyroid disorders, sickle cell anemia, depression, lipid metabolism disturbance, hepatic adenoma or carcinoma, abnormal genital bleeding, endometrial carcinoma or estrogen-dependent neoplasia, sensitivity to certain medications, gastrointestinal or kidney disease, difficulty swallowing medication, food allergies or restrictions, positive test for hepatitis B, hepatitis C, or HIV, recent use of investigational drugs or biologics, abnormal ECG findings, recent use of depot injections or implants, recent use of oral contraceptives or sex steroid hormones, and any clinically significant physical or gynecological abnormalities or abnormal laboratory test results.\n\nFinally, participants must not have a hemoglobin level below 115 g/L or hematocrit below 0.32 L/L, and they should not have used prescription medication or donated plasma or blood within specific timeframes prior to the study. The investigator must also deem the participant capable of complying with the study protocol.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on the treatment of attention deficit disorder with hyperactivity (ADHD) using the drug mazindol. The eligibility criteria for participants include having a primary diagnosis of ADHD based on DSM-5 criteria, meeting certain baseline scores on ADHD assessment tools, being in good physical health, and being fluent in English. Participants must also agree to use contraception if they are women of child-bearing potential. \n\nExclusion criteria include having any other primary DSM-5 Axis I disorder or comorbid disorder that requires treatment, a history of bipolar disorder, current or recent use of certain medications for psychiatric or neurological conditions, significant cardiovascular disease or abnormalities, and other medical conditions that may interfere with the study. Other exclusion criteria include certain ECG abnormalities, high blood pressure, extreme BMI, use of certain medications affecting cognition or attention, positive drug screen (except for current ADHD medication), and concomitant use of certain medications with narrow therapeutic indices. \n\nAdditional exclusion criteria include being pregnant or lactating, recent psychotherapeutic treatment for ADHD, moderate or severe substance use disorder, recent suicidal ideation or behavior, out-of-range laboratory values, known hypersensitivity to mazindol, and any other condition or abnormal findings that may make the participant unsuitable for the study or put them at additional risk. Participants must also not have received any investigational drug within 30 days prior to the study.",
    "The sample is a phase 2 trial for ulcerative colitis. The trial is testing three drugs: ged-0507-34-levo 80 mg, ged-0507-34-levo 160 mg, and a placebo. The eligibility criteria for participants include being 18 years or older, having a diagnosis of ulcerative colitis for at least 3 months, and having a MMS score between 4 and 8. Participants must also have had a colonoscopy within the past 12 months and have relapsed on maintenance therapy with doses of 5-ASA \u2264 2.4 g/day. Exclusion criteria include having other types of colitis, having had surgery for ulcerative colitis or likely to require surgery during the study, having signs of severe colitis or toxic megacolon, having a pathogenic enteric infection, a history of colorectal cancer or dysplasia, prior use of TNF inhibitors or other biologic agents, prior use of certain medications like mycophenolic acid or corticosteroids, and recent use of immunosuppressants.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is acidosis, and its corresponding ICDCodes are E87.2 and P74.0. The drugs being tested are placebo and trc101. The eligibility criteria for this trial include specific ranges for estimated glomerular filtration rate (eGFR) and serum bicarbonate levels. There are also exclusion criteria listed, such as the presence of severe comorbid conditions, chronic obstructive pulmonary disease, and anticipated changes in doses of certain drugs or drug classes. Additionally, there is a list of drugs and drug classes that are excluded from the trial.",
    "The sample from the table is for a phase 2 trial and focuses on autism spectrum disorder. The ICDCodes for this disease are listed as ['Z16.12']. The drugs being studied are clonidine and placebo (for clonidine). The eligibility criteria for participants include being outpatients between 6-14 years old from underserved populations, having a diagnosis of autism spectrum disorder based on DSM-V criteria, and having a mental age of at least 24 months. Participants must also have significant sleep disturbance, as determined by specific criteria such as delayed sleep onset, sleep association problems, nighttime awakenings, or early morning awakenings. Other criteria include having a CGI Severity rating of at least 4 (Moderate) for sleep disruption, having a reliable care provider, and being on stable doses of psychotropic medications and exogenous melatonin. There are also exclusion criteria, such as having a diagnosis of bipolar disorder, not having had an adequate trial of exogenous melatonin, having certain physical illnesses or taking specific medications, and having allergies or prior trials of certain drugs.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of stage III and stage IV skin melanoma. The trial involves the drug imatinib mesylate. The eligibility criteria for participants include having a confirmed diagnosis of melanoma, having a mutation or amplification of the c-KIT gene, providing informed consent, having measurable disease, and meeting certain health requirements such as blood counts, liver function, and kidney function. There are also exclusion criteria, such as not currently participating in another study, not having active tuberculosis, not having hypersensitivity to certain medications, and not having certain medical conditions or infections. The sample also includes information about contraception requirements for female participants and restrictions on prior treatments and vaccinations.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is preeclampsia, and its corresponding ICD-10 codes are ['O14.10', 'O14.12', 'O14.13', 'O14.14', 'O14.90', 'O14.92', 'O14.93']. The drugs being tested are torsemide and placebo. The sample also includes the eligibility criteria for the trial, which includes specific inclusion and exclusion criteria. Inclusion criteria include being a postpartum woman aged 18 or older and having a diagnosis of preeclampsia or preeclampsia with severe features. Exclusion criteria include having chronic hypertension without superimposed preeclampsia, gestational hypertension, low urine output, heart failure or pulmonary edema, hypersensitivity to torsemide or sulfonylureas, hypokalemia, and recent diuretic use.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of diffuse large B-cell lymphoma (DLBCL). The trial is looking at the effectiveness of the drug metformin. The eligibility criteria for participants include being 18 years or older, having a documented diagnosis of DLBCL based on World Health Organization criteria, and having an Eastern Cooperative Oncology Group performance status of 0-2. Other criteria include not having a history of medication-dependent diabetes mellitus, not being on any anti-diabetic medication including metformin, and not having certain medical conditions or infections. The sample also includes exclusion criteria such as not having histological transformation from indolent non-Hodgkin Lymphoma or chronic lymphocytic leukemia to an aggressive form of non-Hodgkin's lymphoma, not having certain types of malignancies or diseases, and not being HIV positive. Additionally, the sample mentions exclusion criteria related to ongoing inflammatory bowel disease, alcohol or drug addiction, pregnancy or breastfeeding, and a history of prior bone marrow or organ transplantation.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is chronic obstructive pulmonary disease (COPD), and the corresponding ICDCodes are J44.9, J44.1, and J44.0. \n\nThe drugs involved in the trial are chf6297 and placebo, with different parts specified for each drug. The eligibility criteria are divided into inclusion and exclusion criteria for different parts of the trial. \n\nFor healthy subjects in parts 1, 2, and 4, the inclusion criteria include being male, aged 18-55 years, non-smokers, having lung function above 80% of predicted normal value, and being deemed healthy based on medical evaluation. In part 4, the ability to produce an adequate induced sputum sample is also required. \n\nFor COPD patients in part 3, the inclusion criteria include being males or females aged 40-75 years, current or past smokers, having stable lung function within a specific range, and the ability to produce both spontaneous and induced sputum samples. \n\nThe exclusion criteria for healthy subjects include having clinically relevant abnormalities or uncontrolled diseases, abnormal laboratory values, recent respiratory tract infection, hypersensitivity to the drug or excipients, positive serology results, and positive cotinine, alcohol, or drug abuse tests. \n\nFor COPD patients in part 3, the exclusion criteria include being females of childbearing potential, having a history of asthma, unstable concomitant diseases, abnormal relevant Holter ECG parameters, recent acute exacerbations of COPD or respiratory tract infection, hypersensitivity to the drug or excipients, and positive serology results.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 1/phase 2. The diseases being studied are Lennox-Gastaut syndrome and Dravet syndrome. The corresponding ICD-10 codes for these diseases are 'G40.813', 'G40.814', 'G40.811', 'G40.812' for Lennox-Gastaut syndrome and 'G40.833', 'G40.834' for Dravet syndrome. The drug being tested in the trial is cannabidiol. The sample also includes the eligibility criteria for the trial, including inclusion criteria such as being diagnosed with Dravet syndrome or Lennox-Gastaut syndrome, planning to obtain medical cannabidiol, or already taking medical cannabidiol and planning to stop taking it. The exclusion criteria state that patients without a diagnosis of Dravet syndrome or Lennox-Gastaut syndrome are not eligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 2 and is focused on the disease called Duchenne Muscular Dystrophy. The corresponding ICD-10 code for this disease is \"G71.01\". The drug being tested in this trial is called Ataluren. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being male, between the ages of 2 and 5, having a body weight of at least 12 kg, and being diagnosed with DMD with a nonsense mutation in at least one allele of the dystrophin gene. Exclusion criteria include not being able to participate in any other drug or device clinical investigation and ongoing use of prohibited concomitant medications.",
    "The sample is a phase 2 trial for the treatment of neuropathic pain. The trial is focused on patients who have primarily chemotherapy-induced neuropathic pain that has been refractory to at least one analgesic compound for at least 3 months. The patients must have a numeric pain scale score of at least 4 for neuropathic pain at the screening visit. The trial is open to patients who are 18 years or older and have a body weight between 50 and 150 kg. Participants must provide written informed consent.\n\nThere are several exclusion criteria for the trial, including participation in other interventional clinical studies within the last 3 months, certain medical conditions such as Parkinson's disease, movement disorders associated with antipsychotics, and severe hypotension. Other exclusion criteria include a prolonged corrected QT interval, known alcohol or drug abuse, concomitant use of certain medications, and pregnancy or lactation.\n\nThe trial does not specify the duration or number of participants.",
    "The sample provided is for a phase 2 clinical trial. The trial is focused on patients with type 2 diabetes. The ICD-10 codes associated with the disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The trial involves two drugs, namely \"isis-gcgrrx\" and \"placebo\". The eligibility criteria for the trial include being between the ages of 18 and 75, having a BMI between 25.0 kg/m2 and 36.0 kg/m2, having an HbA1c level between 7.5% and 10.5%, and being on a stable dose of metformin for at least 3 months prior to screening. Patients on a stable dose of metformin plus a sulfonylurea (SU) or metformin plus a dipeptidyl peptidase-IV (DPPIV) inhibitor may also be allowed. The trial requires patients to conduct home-based (fasted) blood glucose testing as directed. There are also exclusion criteria, such as having clinically significant abnormalities in medical history or physical exam, evidence of uncorrected hypothyroidism or hyperthyroidism, history of liver transplantation or renal dialysis, history of liver disease, history of severe hypoglycemia, treatment with any other antidiabetic drugs within 3 months of screening, history of diabetic ketoacidosis, and any other significant illness or condition that may interfere with the patient's participation or completion of the study. In addition, patients must be willing and able to comply with the protocol and study procedures.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of dry eye disease. The trial is focused on subjects who have a history of predominantly tear-deficient dry eye of mild to moderate severity. The inclusion criteria for the trial include providing written informed consent, being between the ages of 18 and 80, having normal lid anatomy, and remaining on current medications for the duration of the study. The exclusion criteria include having undergone refractive eye surgery or uncomplicated cataract surgery in the past year or three months respectively, previous eyelid surgery (except for external blepharoplasty), recent botulinum toxin injection in the periocular area, having a systemic, multi-organ disease requiring active treatment (except for subjects with SS or GVHD), having punctal plugs, punctal occlusion, history of nasolacrimal duct obstruction, wear scleral lens, or having certain eye conditions such as exposure keratopathy, neurotrophic keratopathy, lagophthalmos, or trichiasis. The trial involves the use of two drugs, namely \"p-321 ophthalmic solution\" and its placebo.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the treatment of metastatic pancreatic cancer. The trial includes eligibility criteria for patients to be included in the study. These criteria include confirmation of pancreatic adenocarcinoma, distant metastatic disease, recent scan results, measurable lesions, a life expectancy of more than 3 months, no previous chemotherapy (except for adjuvant chemotherapy with gemcitabine administered more than 6 months prior), no previous radiotherapy (unless there is at least one measurable target lesion outside the irradiation zone), monitored pain levels, age between 18 and 75, a performance status of WHO < 2, specific blood count and liver function requirements, negative pregnancy test for women of childbearing age, agreement to use contraception during and after treatment, affiliation to the social security scheme, and informed consent. The exclusion criteria include other types of pancreatic tumors, presence of specific metastases, certain medical conditions, history of certain diseases, and participation in other clinical trials. The record also mentions that women who are breastfeeding, persons deprived of liberty or under guardianship, and those unable to submit to medical monitoring for various reasons are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with unresectable, locally advanced, or metastatic biliary tract cancer. The trial is testing the effectiveness of the drug nivolumab. The eligibility criteria include having a documented carcinoma in the biliary system or gall bladder, having failed or being intolerant to one or two prior lines of systemic chemotherapy, being at least 18 years old, having a performance status assessment of 0 or 1, having measurable disease, and having a life expectancy of at least 12 weeks. Other criteria include having resolved toxic effects from prior treatment, having adequate bone marrow, liver, and kidney function, and being willing to comply with study requirements. Exclusion criteria include having active central nervous system metastases, having active autoimmune disease, receiving systemic treatment with corticosteroids or immunosuppressive medications, having prior therapy with certain antibodies, having a history of certain cancers within the past 3 years, having HIV or AIDS, having severe hypersensitivity reactions to monoclonal antibodies, and having certain medical or social conditions that may interfere with participation in the study. The sample also includes a list of excluded therapies and medications for cancer.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of rheumatoid arthritis. The trial includes patients with a diagnosis of adult-onset rheumatoid arthritis who meet specific criteria. These criteria include having a certain number of tender and swollen joints, as well as a high sensitivity C-reactive protein level. The trial also includes participants who have had an inadequate response to methotrexate (MTX) or previous treatment with biologic TNF-alpha inhibitors. The sample also lists the drugs being used in the trial, which include gdc-0853, adalimumab, folic acid, methotrexate (MTX), and a placebo. The sample also provides exclusion criteria, such as having other inflammatory joint diseases or systemic autoimmune disorders, previous treatment with certain medications, and certain medical conditions. Additionally, the sample states that pregnant or nursing women are not eligible to participate in the trial.",
    "The sample from the table is for a phase 2 clinical trial for metastatic colorectal cancer. The trial is testing the drug regorafenib. The eligibility criteria for the trial include having signed informed consent, being 18 years or older, having a life expectancy of at least 3 months, having histological or cytological documentation of adenocarcinoma of the colon or rectum, having measurable metastatic stage IV disease, and having progressed during or within 3 months following the last administration of approved standard therapies. Other criteria include having an ECOG Performance Status of 0 or 1, and meeting certain laboratory requirements for bone marrow, liver, and renal function. Women of childbearing potential and men must agree to use adequate contraception during the trial. The exclusion criteria include prior treatment with regorafenib, recent major surgical procedures or significant traumatic injuries, pregnancy or breastfeeding, certain cardiac conditions, uncontrolled hypertension, recent arterial or venous thromboembolism, and various other medical conditions or medications that may interfere with the subject's participation in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of insomnia disorder. The associated ICD-10 code for this disease is F51.05. The trial involves several drugs, including act-541468 (in different dosages), zolpidem, and two placebos. The eligibility criteria for participants are listed, including requirements such as signed informed consent, age between 18 and 64, negative pregnancy tests for women of childbearing potential, a specific body mass index range, meeting the DSM-5 criteria for insomnia disorder, and having insufficient sleep quantity as measured subjectively and objectively. The sample also includes exclusion criteria, such as having other sleep disorders, excessive daytime napping, high caffeine consumption, recent shift work or travel, abnormal test results, severe renal impairment, and any other medical conditions that may interfere with the study or put the participant at risk.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of insomnia disorder. The associated ICD-10 code for insomnia disorder is \"F51.05\". The drugs being studied are \"act-541468\" and \"placebo\". \n\nThe eligibility criteria for participants in this trial are as follows:\n- Participants must provide signed informed consent before any study-related procedures.\n- Participants must be male or female aged 65 years or older.\n- Participants must have a body mass index (BMI) between 18.5 and 32.0.\n- Participants must meet the criteria for insomnia disorder according to DSM-5.\n- Participants must have a self-reported history of insufficient sleep quantity.\n- Insufficient sleep quantity must be confirmed subjectively through a sleep diary and objectively through polysomnography.\n- Participants must have an Insomnia Severity Index score of 15 or higher.\n\nThe exclusion criteria for participants in this trial are as follows:\n- Participants must not have any current or lifetime history of sleep disorders other than insomnia.\n- Participants must not have a history of related breathing disorders, periodic limb movement disorder, restless legs syndrome, circadian rhythm disorder, rapid eye movement (REM) behavior disorder, or narcolepsy.\n- Participants must not report usual daytime napping of 1 hour or more per day, on at least 3 days per week.\n- Participants must not consume more than 600 mg of caffeine per day.\n- Participants must not have engaged in shift work within 2 weeks prior to the screening visit or have planned shift work during the study.\n- Participants must not have traveled across 3 or more time zones within 1 week prior to the screening visit or have planned travel across 3 or more time zones during the study.\n- Participants must not have hematology or biochemistry test results that deviate from the normal range to a clinically relevant extent, as determined by the investigator.\n- Participants must not have AST and/or ALT levels greater than 2 times the upper limit of normal (ULN) and/or bilirubin levels greater than 1.5 times the ULN, unless they have a known history of Gilbert's syndrome.\n- Participants must not have severe renal impairment, defined as estimated creatinine clearance less than 30 mL/min.\n- Participants must not have a history or clinical evidence of any disease, medical condition, or treatment that may put them at risk or interfere with the study assessments.\n- Participants must not have any circumstances or conditions that, in the opinion of the investigator, may affect their full participation in the study or compliance with the protocol.",
    "The sample is a phase 2 trial for the treatment of metastatic colorectal cancer. The trial includes patients with unresectable and non-pretreated metastases who are considered able to receive 3 lines of chemotherapy. The inclusion criteria include having metastatic colorectal cancer that is histologically proven, being BRAF wild-type, having at least one measurable target lesion, being at least 18 years old, having a WHO performance status of 2 or lower, and meeting certain laboratory test requirements. The exclusion criteria include having potentially resectable colorectal cancer, symptomatic metastases, aggressive disease with a large tumor volume, certain laboratory value abnormalities, certain medical conditions, previous treatment with specific drugs, central nervous system metastasis, previous malignancies within 5 years (except for certain types), and various other conditions. The sample also mentions the need for signed informed consent and the exclusion of pregnant or breastfeeding women.",
    "The sample is a phase 2 clinical trial for the treatment of Sj\u00f6gren's syndrome, a chronic autoimmune disease. The trial is sponsored by Bristol-Myers Squibb. The eligibility criteria for participants include being diagnosed with moderate to severe primary Sj\u00f6gren's syndrome based on specific classification criteria, having a certain level of disease activity, testing positive for specific autoantibodies, and having a minimum level of saliva secretion. Women of childbearing potential must have a negative pregnancy test and use effective contraception during the study. Exclusion criteria include having secondary Sj\u00f6gren's syndrome or other systemic autoimmune diseases, severe complications of Sj\u00f6gren's syndrome, active infections, significant concurrent medical conditions, recent use of certain medications, and high doses of corticosteroids. Additional inclusion/exclusion criteria may also apply.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are hormone-resistant prostate cancer and stage IV prostate adenocarcinoma. The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are cabazitaxel and prednisone. The eligibility criteria for participants in this trial include having histologically confirmed prostate adenocarcinoma, metastatic disease, castration-resistant disease, and a specific Eastern Cooperative Oncology Group (ECOG) performance status. There are also various other criteria related to previous treatments, medical history, and laboratory values. Additionally, there are exclusion criteria listed, such as prior therapy with certain drugs and certain medical conditions that may increase the risk or interfere with the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is bladder cancer, and the associated ICDCodes are D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, and D41.4. The drugs being used in the trial are vinflunine and cisplatin. The eligibility criteria for participants include age between 18 and 75, signed informed consent, confirmed diagnosis of muscle-invasive urothelial cell carcinoma of the bladder, specific imaging assessments, ECOG performance status of 0 or 1, and various requirements for bone marrow, renal, and hepatic functions. The sample also includes exclusion criteria such as prior systemic chemotherapy, contraindications for imaging, presence of metastasis, and various other medical conditions. Additionally, there are criteria related to pregnancy and contraception for female participants and birth control for sexually active fertile men.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease osteoarthritis. The ICD-10 codes associated with this disease are ['M15.4', 'M15.0', 'M16.9', 'M17.9', 'M19.011', 'M19.012', 'M19.019']. The trial involves several drugs, including placebo, gz389988, acetaminophen or paracetamol, fixed combination of paracetamol + codeine, and fixed combination of paracetamol + tramadol hydrochloride. \n\nThe eligibility criteria for this trial include being between 40 and 80 years old, having a diagnosis of primary knee osteoarthritis based on specific criteria, having a certain level of pain in the target knee, and being symptomatic for more than 6 months. Other criteria include being in good general health, providing written informed consent, and using effective contraception for sexually active male participants. \n\nExclusion criteria for the trial include being a woman of childbearing potential, being pregnant or breastfeeding, having uncontrolled chronic conditions or laboratory findings that could increase the patient's risk, and having certain medical conditions or diseases that could interfere with the evaluation of the investigational medicinal product. Other exclusion criteria include having chondrocalcinosis, fibromyalgia, moderate to severe depression or anxiety, a history of drug or alcohol abuse, and being unable to comply with the study requirements. \n\nThere are additional exclusion criteria related to abnormal coagulation parameters, renal impairment, hepatobiliary disease, and certain test results for hepatitis B, hepatitis C, and HIV. Other exclusion criteria include secondary osteoarthritis, history of osteonecrosis or rapidly progressive osteoarthritis, recent intraarticular injection, inability to maintain paracetamol use, recent use of any investigational medicinal product, contraindications for knee magnetic resonance imaging, and a high pain DETECT questionnaire score. \n\nIt is important to note that the provided information may not include all relevant considerations for a patient's potential participation in the clinical trial.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on two diseases, namely idiopathic pulmonary fibrosis and hypoxemia. The icd-10 code for idiopathic pulmonary fibrosis is \"J84.112\". The trial involves two drugs, gbt440 and placebo. The eligibility criteria for the trial are listed under inclusion and exclusion criteria. Inclusion criteria include having a documented diagnosis of IPF, oxygen desaturation with exercise, completion of the baseline 6MWT, weight of at least 50 kg, and being a male or female of childbearing potential willing to use contraception. Exclusion criteria include having FEV1/FVC less than 70%, being on supplemental oxygen therapy at rest, having a history of other interstitial lung diseases, significant polycythemia, being pregnant or breastfeeding, having a current or recent history of malignancy, use of certain medications, recent hospitalization due to IPF exacerbation, plans to begin or have commenced pulmonary rehabilitation, use of corticosteroids, current or recent smoking history, being listed for lung transplant, having unstable or deteriorating cardiac or pulmonary disease, having any condition that may affect drug absorption, recent participation in another clinical trial, or being deemed inappropriate for the study by the investigator.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"sarcoma\" and \"dedifferentiated liposarcoma\". The ICDCodes associated with these diseases are \"['C96.A', 'C46.9', 'C96.22', 'C46.0', 'C46.2', 'C92.31', 'C92.32']\". The drug being tested is \"abemaciclib\". \n\nThe eligibility criteria for this trial include:\n- A confirmed diagnosis of dedifferentiated liposarcoma at MSKCC.\n- Metastatic and/or locally advanced or locally recurrent disease that is not surgically resectable.\n- Measurable disease as defined by RECIST 1.1 and evidence of disease progression within 6 months of the first dose of the study drug.\n- Any number of prior therapies is permitted, with the last dose of systemic therapy given at least 2-4 weeks prior to initiation of therapy.\n- Patients with brain metastasis that have been treated with definitive surgery or radiation and have been clinically stable for 3 months are eligible.\n- Age \u2265 18 years.\n- ECOG performance status 0 or 1.\n- Adequate organ and marrow function as defined by specific criteria.\n- Patients must not have current evidence of another malignancy that requires treatment.\n- Women of child-bearing potential and men must agree to use adequate contraception.\n- Ability to understand and willingness to sign a written informed consent document.\n- Ability to swallow capsules.\n\nThe exclusion criteria for this trial include:\n- Patients who have not recovered from adverse events of prior therapy to \u2264 NCI CTCAEv4.0 Grade 1.\n- Patients receiving any other investigational agents.\n- Patients who have received prior treatment with a selective CDK4 inhibitor.\n- Uncontrolled intercurrent illness, including active infections, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n- Pregnant women and women who are breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 2 and is focused on Parkinson's disease. The ICD-10 code for Parkinson's disease is \"G20\". The drugs being studied are a placebo and a drug called pf-06649751. The eligibility criteria for participants include being diagnosed with Parkinson's disease, being in stages I-III of the Hoehn & Yahr scale, and either being treatment naive or having a history of prior incidental treatment with dopaminergic agents for no more than 28 days. Participants must also be able to refrain from taking any Parkinson's disease medication not allowed by the trial protocol. Exclusion criteria include having an atypical Parkinsonian syndrome, severe medical or psychiatric conditions, cognitive impairment, laboratory abnormalities, or any condition that may affect drug absorption. Participants must not have participated in other studies involving investigational drugs or received any investigational drug within the past 30 days.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"stage iii prostate adenocarcinoma ajcc v7,\" \"stage iii prostate cancer ajcc v7,\" \"stage iv prostate adenocarcinoma ajcc v7,\" and \"stage iv prostate cancer ajcc v7.\" The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial are \"abiraterone acetate,\" \"apalutamide,\" \"degarelix,\" \"indomethacin,\" and \"prednisone.\" The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria,\" which include factors such as performance status, histological confirmation of adenocarcinoma, risk level of prostate cancer, testosterone levels, ability to swallow the study drugs, and various medical conditions or treatments that may affect participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are pancreatic neoplasms and pancreatic adenocarcinoma. The ICDCodes associated with these diseases are C25.3 for pancreatic neoplasms and C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31 for pancreatic adenocarcinoma.\n\nThe drug being used in this trial is gemcitabine. The eligibility criteria for participants in this trial include having a primary diagnosis of pancreatic ductal adenocarcinoma (PDAC) confined to the head of the pancreas with certain high-risk clinical features, intention to undergo open pancreaticoduodenectomy as treatment for PDAC, and being in adequate clinical condition to undergo preoperative and perioperative chemotherapy, among other requirements.\n\nThere are also exclusion criteria, which specify conditions or circumstances that would disqualify a participant from the trial. These include evidence of locoregional or distant metastases, non-curative intent of treatment, high body mass index (BMI), previous history of certain pancreatic resections or other specific tumors, unstable respiratory or cardiac disease, severe hepatic or renal dysfunction, bleeding diathesis or coagulopathy, and being pregnant or nursing.\n\nOverall, this sample provides information about a Phase 2 clinical trial focusing on pancreatic neoplasms and pancreatic adenocarcinoma, with gemcitabine as the drug being studied, and specific eligibility and exclusion criteria for potential participants.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is alcoholic hepatitis (AH). The ICDCodes associated with this disease are G62.1, G72.1, I42.6, K70.0, K29.20, K29.21, and K70.10. The drugs mentioned in this sample are selonsertib, prednisolone, and placebo. The eligibility criteria for this trial include specific inclusion and exclusion criteria. Some of the key inclusion criteria are the ability to provide informed consent, a clinical diagnosis of severe AH, and a Maddrey's Discriminant Function (DF) score of 32 or higher at screening. Some of the key exclusion criteria include being pregnant or lactating, having other causes of liver disease, having certain liver enzyme levels above a certain threshold, and having specific medical conditions such as hepatocellular carcinoma or HIV. It is important to note that there may be additional inclusion and exclusion criteria defined in the protocol.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is nonalcoholic steatohepatitis (NASH). The corresponding ICD-10 code for this disease is K75.81. The drugs being tested in this trial are firsocostat and placebo. The eligibility criteria for participants in this trial include having a clinical diagnosis of nonalcoholic fatty liver disease (NAFLD), a screening MRI-PDFF with at least 8% steatosis, a screening MRE with liver stiffness of at least 2.5 kPa, or a historical liver biopsy consistent with NASH and non-cirrhotic fibrosis. Other criteria include a platelet count of at least 100,000/mm^3 and a creatinine clearance (CLcr) of at least 60 ml/min. Exclusion criteria include being pregnant or lactating, having an alanine aminotransferase (ALT) level greater than 5 times the upper limit of the normal range (ULN), having other causes of liver disease such as autoimmune, viral, or alcoholic liver disease, having cirrhosis of the liver, having a body mass index (BMI) less than 18 kg/m^2, having an international normalized ratio (INR) greater than 1.2 (unless on anticoagulant therapy), and having a total bilirubin level greater than 1 times the ULN (except with a diagnosis of Gilbert's syndrome).",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 2.\n- Diseases: The trial is focused on lymphoma.\n- ICD Codes: The ICD-10 codes associated with the disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S'].\n- Drugs: The drug being tested in the trial is nivolumab.\n- Criteria: The eligibility criteria for participants in the trial are listed, including requirements such as confirmed PCNSL or PTL, measurable disease on scans, tumor tissue for testing, and a Karnofsky performance status of 70-100. There are also exclusion criteria, such as certain diseases, prior malignancy within the previous 3 years, and prior treatment with specific antibodies or drugs. Additionally, there is a specific exclusion criterion related to the use of dexamethasone or equivalent doses.\n\nOverall, this record provides information about a Phase 2 clinical trial focused on lymphoma, using nivolumab as the drug, and outlines the eligibility and exclusion criteria for potential participants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is categorized into different phases, and this particular sample is from phase 2. The trial focuses on the disease called Duchenne muscular dystrophy. The disease is identified using ICD-10 codes, with the specific code being \"G71.01\". The drug being tested in this trial is called \"ezutromid\". The sample also includes eligibility criteria for participants to be included in the trial. These criteria include being able to provide informed consent, being male, having phenotypic evidence of dystrophinopathy, having prior confirmation of the Duchenne muscular dystrophy diagnosis, being able to undergo an MRI examination, and having used stable systemic corticosteroids for at least 6 months. The sample also includes specific inclusion criteria for different cohorts within the trial, as well as exclusion criteria. Exclusion criteria include factors such as having physical exam findings that should be exclusionary, having uncontrolled clinical symptoms of congestive heart failure, having abnormal laboratory values, having a history of major surgical procedure, and having ongoing medical conditions that could affect the safety of the participant.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied include recurrent respiratory papillomatosis, juvenile laryngeal papilloma, laryngeal papilloma (recurrent), respiratory papillomatosis, and human papilloma virus. The corresponding ICDCodes for these diseases are also listed. The drug being tested in this trial is avelumab. The eligibility criteria for participants in this trial are listed under \"criteria\" and include various medical and demographic requirements. These criteria include age, diagnosis confirmation, previous treatments, laboratory values, and the absence of certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The diseases being studied include estrogen receptor status, her2/neu negative, invasive breast carcinoma, postmenopausal, stage iii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, and stage iv breast cancer. The ICDCodes associated with these diseases are also provided. The drugs being used in the trial are alisertib and fulvestrant. The eligibility criteria for participants in this trial are listed, including requirements related to age, menopausal status, previous treatments, disease measurement, medical history, and other factors.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is melanoma. The ICDCodes associated with this disease are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4. The drugs being used in the trial are mrx34 and dexamethasone. The eligibility criteria for participants include being 18 years of age or older, having advanced or metastatic cutaneous, acral, or mucosal melanoma, having tumor lesions accessible for biopsies, having an ECOG score of 1 or lower, and having ANC (Absolute Neutrophil Count) and Plts (Platelets) levels above certain thresholds. The exclusion criteria include having a serious active non-malignant disease and having central nervous system metastasis.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating solid tumors that have been caused by previous radiation exposure. The trial is specifically for patients with metastatic or unresectable tumors that cannot be treated with standard curative or palliative measures. The sample includes the ICD-10 codes associated with the diseases being studied. The drug being used in the trial is nivolumab. The sample also includes the eligibility criteria for participating in the trial, which includes factors such as age, performance status, organ function, and previous treatments. The sample also lists the exclusion criteria, which includes factors such as autoimmune diseases, uncontrolled brain metastases, and pregnancy.",
    "The sample is a phase 2 trial for patients with gastric adenocarcinoma or gastroesophageal junction adenocarcinoma. The trial is testing the drugs andecaliximab and nivolumab. The eligibility criteria include having confirmed inoperable locally advanced or metastatic adenocarcinoma, having progressed on at least one prior systemic therapy, and having an Eastern Cooperative Oncology Group (ECOG) performance score of 1 or less. Other criteria include having measurable disease, accessible tumor sites for biopsies, and adequate archival tumor tissue. There are also exclusion criteria, such as not having received only neoadjuvant or adjuvant therapy, not having undergone radiotherapy within 28 days of randomization, and not having certain concurrent illnesses or infections.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 2 and phase 3. The disease being studied is \"short bowel syndrome.\" The ICDCodes associated with this disease are ['D68.61', 'D69.41', 'D81.4', 'E24.1', 'E26.01', 'E26.81', 'E34.0']. The drugs being tested in this trial are 'ntra-9620' and 'placebo'. The eligibility criteria for this trial include specific requirements for the subject's age, weight, and previous surgical procedures. There are also exclusion criteria listed, which include conditions or factors that would disqualify a subject from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"post-menopausal vasomotor symptoms\" and its corresponding ICDCodes is \"J30.0\". The drugs being tested are \"bay3427080\" and \"placebo (for bay3427080)\". The eligibility criteria for this trial include being a post-menopausal female experiencing frequent moderate to severe hot flashes. Exclusion criteria include having a BMI greater than 35kg/m2, having any active comorbid disease or clinically significant ECG or laboratory results, using prohibited medications, or being unable or unwilling to comply with study procedures or requirements.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is ovarian cancer. The ICDCodes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are apatinib and etoposide. The eligibility criteria for participants include having a confirmed diagnosis of epithelial carcinoma of the ovary, being platinum resistant or refractory, having received at least one line of platinum-based chemotherapy, being female aged 18 to 70 years, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, having measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 version, having a life expectancy of at least 3 months, and meeting certain organ function criteria. The exclusion criteria include prior exposure to apatinib or allergies to any of its excipients, history of myocardial infraction or unstable angina, QT interval prolongation, serious non-healing wound or bowel obstruction, history of abdominal fistula or gastrointestinal perforation, bleeding diathesis or coagulopathy, inadequately controlled hypertension, major surgical procedure within 28 days prior to Day 1, and symptomatic central nervous system (CNS) metastasis.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 2 and focuses on the disease \"acute kidney injury\". The associated ICD-10 codes for this disease are \"N26.2\", \"Q63.0\", \"Q63.2\", \"Z52.4\", \"I75.81\", \"N19\", and \"N20.0\". The drugs being studied in this trial are \"conestat alfa\" and \"sodium chloride 0.9%\". \n\nThe record also includes the eligibility criteria for participants in the trial. The inclusion criteria state that participants must have an estimated glomerular filtration rate (eGFR) of less than 50 ml/min/1.73m2 and at least one of the following risk factors: diabetes mellitus, age at least 75 years, anemia, congestive heart failure class III or IV, or a history of pulmonary edema. \n\nThe exclusion criteria list various conditions and factors that would disqualify someone from participating in the trial, such as contraindications to the class of drugs being studied, allergies to rabbits, current treatment with certain medications, pregnancy or breastfeeding, multiple myeloma, recent acute heart failure or myocardial infraction, dialysis, recent exposure to iodinated contrast media, participation in another study with an investigational drug, previous enrollment in the current study, and enrollment of the investigators and their family members.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is colorectal cancer. The ICD-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being tested in the trial are tremelimumab and durvalumab. The eligibility criteria for participants include having histologically or pathologically confirmed advanced colorectal cancer that is unresectable, having received prior thymidylate synthase inhibitor treatment, having failed irinotecan and oxaliplatin-containing regimens, and having received and failed cetuximab or panitumumab-containing regimens for RAS-wild type colorectal cancer. Other criteria include having measurable or evaluable disease, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, having a life expectancy of at least 12 weeks, being at least 18 years old, and agreeing to use contraception if of childbearing potential. The patient must also consent to provide tissue and blood samples for correlative marker assays and complete quality of life questionnaires. The patient must be accessible for treatment and follow-up, not receiving therapy in another clinical study, and agree not to participate in other clinical studies during their participation in this trial.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on the disease \"acute myeloid leukemia\" and includes patients with specific ICD-10 codes related to this disease. The drugs being studied in this trial are \"cx-01\", \"idarubicin\", and \"cytarabine\". The eligibility criteria for inclusion in the trial include being newly diagnosed with AML, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. The exclusion criteria include having acute promyelocytic leukemia, prior chemotherapy for AML, prior intensive chemotherapy or stem cell transplantation for the treatment of myelodysplastic syndrome, and CNS leukemia.",
    "The sample from the table is for a phase 2 trial. The diseases being studied are recurrent diffuse large B-cell lymphoma and refractory diffuse large B-cell lymphoma. The corresponding ICD-10 codes for these diseases are provided. The drugs being tested in the trial are ibrutinib and pi3k-delta inhibitor tgr-1202. The eligibility criteria for the trial include histologically confirmed diagnosis of diffuse large B-cell lymphoma, previous treatment with at least one systemic therapy, and measurable or evaluable disease. Other criteria include specific laboratory values, performance status, ability to swallow oral medication, and willingness to adhere to the study requirements. There are also exclusion criteria, such as currently receiving cancer therapy, recent major surgery, history of stroke or intracranial hemorrhage, and certain medical conditions that could compromise the patient's safety or participation in the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are lenalidomide, bortezomib, dexamethasone, and daratumumab. \n\nThe eligibility criteria for this trial include being eligible for high-dose chemotherapy and autologous stem cell transplantation based on age, medical history, cardiac and pulmonary status, overall health and condition, co-morbid conditions, physical examination, and laboratory studies. Participants must not have had prior systemic therapy for multiple myeloma, but emergency steroid treatment and radiation therapy are permitted. The Eastern Cooperative Oncology Group (ECOG) performance status score must be 0, 1, or 2. \n\nFor women of childbearing potential, two negative highly sensitive serum tests for beta-human chorionic gonadotropin (b-hCG) are required before starting the study treatment. Women must also agree not to donate eggs for assisted reproduction during the study and for a certain period after discontinuation of lenalidomide or daratumumab.\n\nThe exclusion criteria include having been diagnosed or treated for any malignancy other than multiple myeloma, except for certain cases. Participants should not have clinical signs or a history of meningeal or central nervous system involvement by multiple myeloma. Participants with certain respiratory conditions, such as chronic obstructive pulmonary disease or uncontrolled asthma, are also excluded. Additionally, participants should not be seropositive for HIV, have hepatitis B surface antigen positivity, or have a history of hepatitis C, unless they have completed treatment for hepatitis C and have no detectable circulating hepatitis C virus.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2. The diseases being studied are ocular hypertension and open-angle glaucoma. The corresponding icd-10 codes for these diseases are 'H40.053', 'H40.051', 'H40.052', 'H40.059' and 'H40.10X0', 'H40.10X1', 'H40.10X2', 'H40.10X3', 'H40.10X4', 'H40.1130', 'H40.1131' respectively. The drug being tested is netarsudil ophthalmic solution 0.02%. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n1. The participant must be 18 years of age or older.\n2. They must have ocular hypertension or open-angle glaucoma in both eyes.\n3. The unmedicated intraocular pressure should be greater than 17 mmHg in one or both eyes and less than 30 mmHg in both eyes.\n4. The corrected visual acuity in each eye should be equivalent to 20/200 or better.\n5. The participant must be able and willing to give signed informed consent and follow study instructions.\n\nExclusion Criteria:\n1. Participants with glaucoma with pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles.\n2. Intraocular pressure should be equal to or greater than 30 mmHg.\n3. Use of ocular medications within the last 30 days.\n4. Known hypersensitivity to any component of the test formulations or to medications used routinely during a clinical eye examination.\n5. Previous eye surgery, except for cataract surgery.\n6. Ocular trauma within the last 6 months.\n7. Clinically significant ocular disease that might interfere with the study.\n8. Central corneal thickness greater than 620 \u00b5m.",
    "The sample is a phase 2 clinical trial for patients with non-keratinizing/undifferentiated, EBV-related nasopharyngeal carcinoma that is not amenable to curative intent therapy. The trial is testing the drug avelumab. The inclusion criteria state that patients must have confirmed histology/cytology of the carcinoma, at least one measurable site of disease, and have received at least one prior line of systemic therapy in the recurrent/metastatic setting. Patients must also be willing to undergo a fresh tumor biopsy for correlative analyses. The exclusion criteria include receiving another investigational agent within 4 weeks prior to the trial, receiving chemotherapy or radiotherapy within 4 weeks prior to the trial (except for palliative radiotherapy to non-radiated lesions), and having received prior immunotherapy with inhibitors of the PD-1/PD-L1 axis. Other exclusion criteria include major surgery within 14 days prior to the trial, unresolved immune-related adverse events, known additional progressing malignancy, active central nervous system metastases or carcinomatous meningitis, active autoimmune disease requiring systemic treatment in the past 2 years, immunodeficiency or recent immunosuppressive therapy, active tuberculosis or non-infectious pneumonitis, chronic interstitial lung disease, active infection requiring systemic therapy, pregnancy or breastfeeding, and known active Hepatitis B, Hepatitis C, or HIV infection. Patients who have received a live vaccine within 30 days prior to the trial are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied include acute leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, diffuse large B-cell lymphoma, follicular lymphoma, graft versus host disease, mantle cell lymphoma, marginal zone lymphoma, myelodysplastic syndrome, myelofibrosis, myeloproliferative neoplasm, and small lymphocytic lymphoma. The corresponding ICDCodes for these diseases are also provided. The drugs being used in the trial are bortezomib and tacrolimus. The eligibility criteria for participants include specific disease conditions, cardiac function, renal function, pulmonary function, bilirubin levels, liver function, and certain requirements for female and male subjects. There are also exclusion criteria, such as prior allogeneic transplant, certain performance scores, active infections, and other medical or psychiatric conditions that may interfere with participation in the study.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is respiratory syncytial virus infections. The corresponding ICD-10 codes for this disease are 'R09.2', 'A15.7', 'A15.8', 'A15.9', 'J98.9', 'R06.03', and 'J12.1'. The drugs being tested in this trial are 'medi8897' and 'placebo'. The eligibility criteria for participants in this trial include being a healthy infant born between 29 weeks 0 days and 34 weeks 6 days gestational age, and entering their first full RSV season at the time of screening. Some exclusion criteria include meeting criteria to receive commercial palivizumab, having a fever or lower respiratory illness within 7 days prior to randomization, having an acute illness at the time of randomization, having an active RSV infection or a known prior history of RSV infection, and having received palivizumab or any RSV monoclonal antibody or vaccine.",
    "The sample is from a table that contains information about clinical trials. It provides details about a specific trial with the following characteristics:\n\n- Phase: Phase 2\n- Disease: Rheumatoid arthritis\n- ICD-10 Codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019\n- Drugs: gs-9876, filgotinib, gs-9876 placebo, filgotinib placebo, methotrexate\n- Eligibility Criteria:\n  - Key Inclusion Criteria:\n    - Active RA disease with a tender joint count (TJC) of at least 6 out of 68 and a swollen joint count (SJC) of at least 6 out of 66 at screening and Day 1\n    - Inadequate response to treatment with oral or parenteral methotrexate (MTX) at a dose of 7.5 to 25 mg/week continuously for at least 12 weeks\n    - No evidence of active or latent tuberculosis\n  - Key Exclusion Criteria:\n    - Prior treatment with B-cell depleting agents (e.g., rituximab), unless more than 6 months prior to the first dose of study drug and documented return of CD19+ cells at screening\n    - Prior treatment with any commercially available or investigational spleen tyrosine kinase (SYK) inhibitor\n    - Concurrent treatment with any other conventional synthetic DMARD (csDMARD) other than MTX and/or hydroxychloroquine (HCQ) (prior csDMARD treatment allowed if appropriate washout as defined in the protocol)\n    - Concurrent treatment with any biological disease modifying anti-rheumatic drug (bDMARD) (prior bDMARD treatment allowed if appropriate washout as defined in the protocol). Prior failure to treatment with bDMARDs is not an exclusion criterion.\n\nPlease note that there may be additional inclusion/exclusion criteria defined in the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are acute myeloid leukemia (AML) and relapse. The ICDCodes associated with these diseases are \"C90.02\", \"C90.22\", \"C90.32\", \"C92.32\", \"C95.92\", \"C90.12\", and \"C91.02\". The drug being tested is called \"chidamide plus dcag regimen\". \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Men and women aged between 18 and 59 years old.\n- Patients diagnosed with AML according to the 2008 WHO myeloid malignant disease diagnosis standard.\n- Patients who have relapsed after remission or have not achieved remission after at least two cycles of systemic therapy.\n- ECOG performance status of 0-3.\n- Expected survival time of more than 3 months.\n- Patients without serious heart, lung, liver, or kidney disease.\n- Patients who have not received any treatment (radiotherapy, chemotherapy, targeted therapy, or hematopoietic stem cell transplantation) within 4 weeks prior to enrollment.\n- Patients who are able to understand and willing to sign informed consent.\n\nExclusion Criteria:\n- Patients who are allergic to the study drug or drugs with a similar chemical structure.\n- Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception.\n- Patients with active infections.\n- Patients with a history of drug abuse or long-term alcohol abuse that may affect the evaluation results.\n- Patients with mental disorders or conditions that prevent them from giving informed consent or meeting the study's treatment and procedure requirements.\n- Patients with a history of significant QTc interval prolongation, ventricular heart tachycardia, atrial fibrillation, II degree heart block, myocardial infraction attack within the past year, congestive heart failure, or coronary heart disease with clinical symptoms requiring drug treatment.\n- Patients with a diastolic pericardial fluid dark area width greater than 10mm according to cardiac ultrasound.\n- Patients who have received organ transplantation.\n- Patients with active bleeding.\n- Patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or medical history within the past year.\n- Patients who have undergone major organ surgery within the past 6 weeks.\n- Patients with bone marrow hyperplasia and white blood cell count less than 2.0 * 10^9/L.\n- Patients with abnormal liver function (total bilirubin > 1.5 times the upper limit of normal range, ALT/AST > 2.5 times the upper limit of normal range, or patients with liver involvement whose ALT/AST > 1.5 times the upper limit of normal range) or renal anomalies (serum creatinine > 1.5 times the upper limit of normal value).\n- Patients who are not suitable for the study according to the investigator's assessment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is rectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being used in the trial is mfolfox6. \n\nThe eligibility criteria for this trial include a diagnosis of adenocarcinoma of the rectum, age between 18 and 70 years old, signed informed consent, and the ability to comply with study and follow-up procedures. The stage of the primary tumor can be determined by ultrasound or MRI, and it must be either Stage II (T3-4, N0) or Stage III (T1-4, N1-2). The tumor must be palpable by digital rectal exam or accessible by proctoscope or sigmoidoscope, and its distal border must be located less than 12 cm from the anal verge. The tumor must also be amenable to curative resection.\n\nIn addition to these criteria, the patient must meet certain laboratory requirements within 7 days of starting the study treatment, including specific levels of leukocytes, absolute neutrophil count, platelet count, and hemoglobin. The patient's total bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, amylase, lipase, and serum creatinine levels must also be within certain limits. The patient's calculated creatinine clearance or 24-hour creatinine clearance must be at least 50 mL/min, and they should not have any renal disease that would preclude study treatment or follow-up. The patient's ECOG status should be 0-1.\n\nThere are also exclusion criteria for this trial, including hypersensitivity to fluorouracil, oxaliplatin, or irinotecan, recent participation in any investigational drug study, clear indication of involvement of the pelvic side walls by imaging, presence of distant metastasis, history of invasive rectal malignancy, fertile patients not using effective contraception, uncontrolled hypertension, cardiovascular disease that would preclude study treatment or follow-up, lack of upper gastrointestinal tract integrity or malabsorption syndrome, active upper gastrointestinal tract bleeding, synchronous colon cancer, pregnancy or nursing, other malignancy within the past 5 years (except certain effectively treated cancers), psychiatric or addictive disorders, or any other conditions that, in the opinion of the investigator, would preclude study participation.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of chronic viral hepatitis B with delta-agent. The trial involves the use of drugs such as myrcludex b, peg ifn alfa-2a, and tenofovir. The eligibility criteria for participants are listed, including age requirements, specific hepatitis B and delta-agent status, and certain laboratory test results. There are also exclusion criteria, which outline conditions or factors that would prevent someone from participating in the trial, such as allergies to the study drugs, previous treatments, certain medical conditions, and concurrent medications or diseases.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is psoriasis vulgaris. The corresponding ICD-10 code for psoriasis vulgaris is L40.0. The drugs being tested in this trial are leo 32731 and leo 32731 placebo. The eligibility criteria for participants in this trial include having a clinical diagnosis of psoriasis vulgaris, being between the ages of 18 and 65, and being a male or female of non-childbearing potential. Participants must also have moderate to severe psoriasis vulgaris and be candidates for systemic anti-psoriatic treatment and/or phototherapy. Exclusion criteria include having therapy-resistant psoriasis, previous exposure to apremilast, and systemic treatment with biological therapies or other therapies that may affect psoriasis vulgaris.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of sarcoma. The ICD-10 codes associated with the disease are ['C96.A', 'C46.9', 'C96.22', 'C46.0', 'C46.2', 'C92.31', 'C92.32']. The drug being used in the trial is doxorubicin hydrochloride. The record also includes the eligibility criteria for participants, which include requirements such as providing informed consent, having measurable disease, having a certain performance status, and meeting specific laboratory values. There are also exclusion criteria listed, such as prior treatment with anthracyclines, certain sarcoma subtypes, and active infections.",
    "The sample is a record from a table that contains information about clinical trials. It is for a trial that is in phase 2/phase 3. The trial is focused on the disease \"coronary artery disease\" and the associated ICD-10 codes are \"I25.10\", \"I25.110\", \"I25.119\", \"I25.111\", and \"I25.118\". The drugs being studied in this trial are \"ticagrelor\" and \"clopidogrel\". The eligibility criteria for this trial include having stable coronary artery disease, diabetes, and meeting certain inclusion and exclusion criteria. The inclusion criteria include having stable angina, low-risk unstable angina, variant angina, or being asymptomatic with appropriate therapy. The exclusion criteria include having acute coronary syndrome, planned use of certain medications, low platelet count, low creatinine clearance rate, respiratory or circulatory instability, a history of bleeding tendency, or allergies to ticagrelor or clopidogrel.",
    "The sample is a phase 2 trial for patients with metastatic pancreatic adenocarcinoma, recurrent pancreatic carcinoma, or stage IV pancreatic cancer. The trial aims to evaluate the effectiveness of a combination of drugs including fluorouracil, irinotecan hydrochloride, leucovorin calcium, and veliparib. The eligibility criteria include having histologically or cytologically documented pancreatic adenocarcinoma, measurable metastatic disease, no history of brain metastases, and having completed prior systemic therapy at least 14 days prior to registration. Other criteria include specific laboratory values, performance status, and the ability to undergo a biopsy. Patients must also provide informed consent and be willing to submit tumor and blood samples. The trial is conducted under the Oncology Patient Enrollment Network (OPEN) registration process.",
    "The sample is a phase 2 trial for Crohn's disease. The trial is testing the effectiveness of the drugs mirikizumab and placebo. The eligibility criteria for participants include having active Crohn's disease, inadequate response or intolerance to certain medications, and not having complications or other digestive tract conditions. Participants should not have had recent bowel surgery or any other abdominal surgery. The sample also includes exclusion criteria, such as having complications of Crohn's disease or any condition that may compromise safety or data interpretation.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of ulcerative colitis. The ICD-10 codes associated with this disease are ['K51.80', 'K51.813', 'K51.814', 'K51.90', 'K51.913', 'K51.914', 'K51.811']. The drugs being studied are 'ptg-100' and 'placebo'. The eligibility criteria for participants include being between the ages of 18 and 80, having a diagnosis of UC for at least 2 months, having moderate to severe active UC as defined by the Mayo Score, and having an inadequate response or intolerance to certain medications. There are also criteria related to pregnancy and contraception for female participants. The exclusion criteria include having Crohn's Disease or other specific conditions, as well as various medical disorders or conditions that could confound the study results or pose additional risk to the participant. Other exclusion criteria include pregnancy, recent surgeries, history of certain disorders or dependencies, and inability to attend study visits or comply with procedures. Concurrent participation in other interventional studies is also not allowed.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating mantle cell lymphoma, a type of cancer. The trial includes patients who are between the ages of 18 and 65 and have been diagnosed with mantle cell lymphoma based on specific criteria. The patients must also be eligible for autologous stem cell transplant and have not received any previous treatment for their condition. They should be in stage Ann Arbor II-IV and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. The trial requires patients to have a life expectancy of more than 3 months and provide written informed consent. Patients with severe cardiac disease, impaired liver or kidney function, or other organ function issues that may interfere with treatment are excluded from the trial. Pregnant or nursing mothers, fertile men or women of childbearing potential, and patients with certain medical conditions or infections are also excluded. The sample also includes additional exclusion criteria related to previous medical history and allergies.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"non-small cell lung cancer,\" \"carcinoma,\" and \"nsclc.\" The corresponding ICDCodes for these diseases are provided as well. The drugs being investigated in this trial are \"ensartinib\" and \"durvalumab.\" The eligibility criteria for this trial include various conditions and requirements that potential participants must meet. These criteria include histologic confirmation of metastatic NSCLC, measurable disease according to RECIST 1.1, normal laboratory parameters, Eastern Cooperative Oncology Group Performance Status \u2264 2, age \u2265 18 years, and willingness to comply with the protocol. There are also exclusion criteria listed, which specify conditions or circumstances that would disqualify a potential participant from the trial.",
    "The sample is a phase 2 trial for patients with asthma. The trial is testing the effectiveness of the drugs azd1419 and placebo. The eligibility criteria for participants include being diagnosed with asthma and requiring treatment with ICS (inhaled corticosteroids) and a long-acting beta agonist (LABA). Participants must have been taking ICS plus LABA medication for at least 3 months prior to screening. Other criteria include having a certain level of lung function (forced expiratory volume in 1 second \u226550% predicted), meeting certain requirements for contraception for both male and female participants, having a certain level of blood eosinophils, and having specific scores on the ACQ-5 (Asthma Control Questionnaire-5). Participants must also have documentation of certain lung function tests or variations in peak expiratory flow (PEF) within the past 5 years. Exclusion criteria include having other clinically significant lung diseases, autoimmune diseases, ongoing allergen immunotherapy, low DLco (diffusing capacity of the lungs for carbon monoxide), breastfeeding or pregnancy, and chest X-ray findings suggesting significant parenchymal disease other than asthma.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of extensive-stage small cell lung carcinoma. The trial involves the use of multiple drugs, including carboplatin, cediranib, cediranib maleate, cisplatin, etoposide, and olaparib. The eligibility criteria for participants include having a confirmed diagnosis of extensive-stage small cell lung cancer with no prior systemic treatment, measurable disease, and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower. Other criteria include specific blood count levels, liver and kidney function, ability to swallow oral medication, and the use of effective contraception for sexually active participants. Exclusion criteria include recent major surgery or trauma, radiotherapy, non-healing wounds or ulcers, and uncontrolled intercurrent illnesses. The sample also includes specific criteria related to pregnancy, history of certain medical conditions, and medication use. Participants must have archival tumor tissue available or undergo a fresh tumor tissue biopsy. Adequate blood pressure and thyroid function control are required, and certain gastrointestinal abnormalities and bleeding disorders are excluded. The sample also excludes patients with certain medical conditions, such as recent cerebrovascular accidents, active bleeding diathesis, and active infections. Pregnant women, breastfeeding mothers, and HIV-positive patients on combination antiretroviral therapy are also excluded. Participants receiving cediranib must be willing and able to check and record daily blood pressure readings.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of plaque psoriasis. The ICD-10 codes associated with the disease are ['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']. The drugs being studied in the trial are mirikizumab and placebo. The eligibility criteria for participants are listed, including requirements for the severity and extent of the psoriasis, as well as exclusions for certain medical conditions, recent infections, and previous treatments.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"dermatitis, atopic.\" The corresponding ICD-10 codes for this disease are \"L20.89\" and \"L20.9.\" The trial involves two drugs, \"jaungo\" and \"placebo.\" \n\nThe eligibility criteria for participants are as follows:\n1. The diagnosis of AD (atopic dermatitis) will be made according to the criteria of Hanifin and Rajka.\n2. Participants must be between 5 and 65 years old.\n3. Participants must have an objective SCORAD (Scoring Atopic Dermatitis) score of 40 or less, indicating mild to moderate AD.\n4. Participants must have at least one of the following: exoriation, lichenification, dryness, or a combination of these symptoms.\n5. Participants must be able to express their intention to participate.\n6. Participants must be willing to provide written informed consent.\n\nThe exclusion criteria for participants are as follows:\n1. Participants with oozing in the lesion are excluded.\n2. Participants who have used oral steroids, immunosuppressants, antibiotics, topical steroids, immunosuppressants, antibiotics, or undergone light therapy within specific time periods prior to the trial are excluded.\n3. Participants with severe burns or wide wounds are excluded.\n4. Participants with oozing or ulcers in the lesion are excluded.\n5. Participants with allergic reactions to Angelica gigas, Siebold et Zuccarini, sesame oil, and lard are excluded.\n6. Participants with skin diseases other than atopic dermatitis are excluded.\n7. Participants with severe renal function disease (sCr > 2.0 mg/dL) are excluded.\n8. Participants with severe liver function disease (ALT, AST, ALP \u2265 2.5 \u00d7 normal limits) are excluded.\n9. Participants with uncontrolled chronic diseases are excluded.\n10. Pregnant or lactating individuals are excluded.\n11. Participants who have participated in another clinical trial within one month of enrollment are excluded.\n12. Participants with underlying diseases or a history of severe disease, abnormal state (paralysis, mental retardation, emotional or mental problems, diseases that can affect drug absorption, lack of time to participate in the trial, visual disturbance, hearing impairment, inability to understand written consent, or engage in the study) are excluded.\n13. The potential subject's participation is deemed inappropriate by experts.\n\nThis information provides details about the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for participants in the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"diabetes mellitus, type 2\" and \"hypertension\". The corresponding ICDCodes for these diseases are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44'] for diabetes and ['I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', 'I10'] for hypertension. The drugs being used in the trial are \"matching placebo\" and \"iw-1973\". The eligibility criteria for this trial include various conditions such as being an ambulatory male or female, having a specific body mass index score, negative pregnancy test for women of childbearing potential, stable health condition, diagnosed diabetes and hypertension, specific medication regimens, abnormal endothelial function, and other criteria as per the protocol. There are also exclusion criteria listed, such as having a clinically significant medical condition, being on certain medications, severe end-organ damage, severe renal insufficiency, and other criteria as per the protocol.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"stress urinary incontinence.\" The associated ICD-10 codes for this disease are ['N39.41', 'N39.46', 'N39.490', 'N39.491', 'N39.492', 'R32', 'R39.81']. The trial involves two drugs, \"tas-303\" and \"placebo.\" The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having symptoms of stress urinary incontinence for at least 12 weeks, experiencing at least 1 incontinence episode per day, and meeting specific urinary frequency criteria. Exclusion criteria include having predominant or primary urge incontinence, previous surgical treatment for stress urinary incontinence, being diagnosed with stage II or higher pelvic organ prolapse, having symptoms of urinary tract infection, testing positive on a pregnancy test, and having physical or examination results that, in the investigator's opinion, would exclude the subject from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is Alzheimer's disease, and the corresponding ICDCodes are G30.8, G30.9, G30.0, and G30.1. The drugs being used in the trial are ct1812 and placebo.\n\nThe eligibility criteria for this trial include:\n\n1. The participant must be willing and able to provide written informed consent.\n2. The participant must be between 50-80 years old and have a diagnosis of mild to moderate Alzheimer's disease.\n3. The participant must have experienced a decline in cognition for more than six months.\n4. The participant must have had a neuroimaging (MRI) scan within the previous 6 months or during screening, consistent with the clinical diagnosis of Alzheimer's disease.\n5. The participant's MMSE score must be between 18-26.\n6. The participant must not have active depression and must have a Geriatric Depression Score (GDS) of less than 6.\n7. The participant's Modified Hachinski Ischemia score must be less than or equal to 4.\n8. The participant must have a formal education of eight or more years.\n9. The participant must be living at home or in a community setting without continuous nursing care and must have a reliable caregiver who can oversee the administration of the study drug and participate in all clinic visits and some study procedures.\n10. The participant's concurrent use of acetylcholinesterase inhibitors or memantine must be stable for 90 days prior to screening and not expected to change.\n\nThe exclusion criteria for this trial include:\n\n1. The participant must not have a history of or screening brain MRI scan indicative of significant abnormality.\n2. The participant must not have clinical or laboratory findings consistent with other primary degenerative dementia, other neurodegenerative conditions, seizure disorder, or other infectious, metabolic, or systemic diseases affecting the central nervous system.\n3. The participant must not have a current DSM-V diagnosis of active major depression, schizophrenia, or bipolar disorder.\n4. The participant must not have clinically significant, advanced, or unstable disease that may interfere with outcome measures or put the patient at special risk.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for participants in the trial.\n\nIn this particular sample, the phase of the trial is phase 2. The diseases being studied are psoriasis and plaque psoriasis. The corresponding ICD-10 codes for these diseases are listed as well. The drugs being tested are mp1032 and placebo. The eligibility criteria for participants include being legally competent to give informed consent, being between the ages of 18 and 65 with chronic plaque psoriasis, having a certain PASI score and disease duration, having a specific body mass index, and meeting certain clinical laboratory criteria. There are also exclusion criteria listed, which include factors such as having certain types of psoriasis, having certain medical conditions or illnesses, being pregnant or planning to become pregnant, and having certain allergies or previous medical treatments.",
    "The sample provided is for a phase 2 clinical trial for breast cancer. The trial is specifically targeting patients with histologically confirmed estrogen receptor positive, androgen positive, and HER2 negative breast cancer. The patients must have metastatic or unresectable locally advanced disease and be postmenopausal. They should also have experienced disease progression after treatment with an aromatase inhibitor. The trial is open to patients over 18 years of age with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and a life expectancy of over 3 months. The disease should be measurable according to RECIST version 1.1 or only bone metastasis. Patients should also have adequate hematological and hepatic function. The sample includes both inclusion and exclusion criteria, with exclusion criteria including life-threatening visceral metastasis, uncontrolled concomitant diseases/conditions, history of other primary malignancy, and resistance to steroidal or nonsteroidal aromatase inhibitors.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes the following details:\n\n- Diseases: The trial is focused on Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease dementia.\n- ICD-10 Codes: The corresponding ICD-10 codes for the diseases are G30.8, G30.9, G30.0, G30.1 for Alzheimer's disease, G31.83 for dementia with Lewy bodies, and G20 for Parkinson's disease dementia.\n- Drugs: The trial involves the drugs \"rvt-101 35 mg\" and a placebo.\n- Criteria: The eligibility criteria for the trial include a clinical diagnosis of Alzheimer's disease, dementia with Lewy bodies, or Parkinson's disease dementia. The subjects must have a Mini Mental State Examination score between 14 and 26, gait impairment, and be on stable background acetylcholinesterase inhibitor therapy. The exclusion criteria include having any other CNS disorder that could be interpreted as a cause of dementia and any clinically relevant concomitant disease that would make the subject unsuitable for inclusion in the study.",
    "The sample provided is a record from a clinical trial table. It belongs to phase 2 of the trial and focuses on the disease \"non-alcoholic steatohepatitis\". The corresponding ICD-10 code for this disease is \"K75.81\". The drugs being studied in this phase are \"mgl-3196\" and \"placebo\". The eligibility criteria for participants include being willing to participate and provide informed consent, being an adult with a BMI below 45 kg/m^2, having negative pregnancy tests for female patients of childbearing potential, and using effective birth control methods. Other criteria include having at least 10% liver fat content, biopsy-proven NASH with specific NAS scores, and consistent ALT and AST levels. Exclusion criteria include a history of significant alcohol consumption, recent weight gain or loss, hyperthyroidism, certain medical conditions or treatments, cirrhosis, low platelet count, hepatic decompensation, and participation in other drug trials. Any other condition that may hinder compliance or compromise the well-being of the patient is also considered an exclusion criterion.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is non-alcoholic steatohepatitis (NASH). The corresponding ICD-10 code for NASH is K75.81. The drugs being tested in this trial are lmb763 and a placebo. \n\nThe inclusion criteria for this trial are as follows:\n- Male/female patients who are 18 years or older\n- Patients who have provided written informed consent\n- Patients who have evidence of NASH through liver biopsy and elevated alanine aminotransferase (ALT), or have a phenotypic diagnosis of NASH based on elevated ALT, BMI, and a diagnosis of Type 2 diabetes mellitus\n\nThe exclusion criteria for this trial are as follows:\n- Patients currently using obeticholic acid (OCA)\n- Patients who have initiated GLP-1 agonists such as liraglutide, exenatide, lixisenatide, albiglutide, or dulaglutide within 3 months of screening\n- Pregnant or nursing (lactating) women\n- Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 5 days after stopping study medication\n- Patients with a history of significant alcohol consumption for more than 3 consecutive months within 1 year prior to screening\n- Patients with clinical evidence of hepatic decompensation or severe liver impairment\n- Patients with a previous diagnosis of other forms of chronic liver disease\n- Patients with uncontrolled diabetes mellitus\n- Patients with a history or current diagnosis of ECG abnormalities\n- Patients with contraindications to MRI imaging",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of heart failure. The trial includes patients with a history of chronic heart failure for at least 1 month who have been treated with specific medications. The inclusion criteria also require the patients to have been admitted to the hospital for observation and treatment for up to 72 hours due to heart failure with persistent congestion. The patients should have severe edema and a systolic blood pressure above 90 mmHg. They should also have a history of left ventricular ejection fraction (LVEF) of 40% or less, and elevated levels of NT-proBNP or BNP. The exclusion criteria include recent major surgical procedures, invasive cardiac investigations or treatments, and the use of certain medications or medical procedures. Other exclusion criteria include specific heart conditions, certain heart rhythms, recent placement of a ventricular resynchronization device, and the presence of mechanical assist devices or a history of heart transplant. The sample also includes exclusion criteria related to respiratory and kidney function, as well as liver and blood parameters.",
    "The sample from the table represents a clinical trial for the treatment of epithelial ovarian cancer, peritoneal cancer, and fallopian tube cancer. The trial is in phase 1/phase 2. The diseases are identified by their names and corresponding ICD-10 codes. The drugs being tested in the trial are entinostat, avelumab, and placebo. The eligibility criteria for the trial include confirmation of the specified cancers, evidence of measurable disease, previous treatment with platinum-based therapy, acceptable laboratory requirements, and resolution of toxic effects from prior therapy. There are also exclusion criteria, such as non-epithelial ovarian carcinomas, active autoimmune disease, previous treatment with certain inhibitors or antibodies, and enrollment in another investigational drug study. The sample provides detailed inclusion and exclusion criteria for potential participants in the trial.",
    "The sample provided is a record from a clinical trial database. It pertains to a phase 2 trial involving patients with systemic sclerosis and digital ulcers. The trial is investigating the efficacy of the drugs riociguat and placebo in treating these conditions. The eligibility criteria for participants include being 18 years or older, having a diagnosis of systemic sclerosis according to specific classification criteria, and having at least one visible, active ischemic digital ulcer. Female participants of reproductive potential must have a negative pregnancy test before treatment and undergo monthly tests during treatment. Adequate contraception is required for sexually active participants. Certain medications are allowed if the participant has been on a stable dose for at least 2 weeks prior to the baseline visit. There are also exclusion criteria, such as active digital ulcers related to calcinosis, recent major surgery, history of malignancy within the last 5 years (except for certain types), and specific medical conditions related to hepatic, renal, cardiovascular, and pulmonary function. Laboratory values below certain thresholds are also exclusion criteria. Concomitant use of certain medications, active smoking, pregnancy, breastfeeding, and participation in other clinical studies within 30 days prior to randomization are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 2 and is focused on the treatment of dry eye syndrome. The associated ICD-10 codes for this disease are H04.121, H04.122, H04.123, and H04.129. The drugs being tested in this trial are hu00701, hu007, restasis, and a placebo. \n\nThe eligibility criteria for this trial are as follows:\n- The participant must be over 19 years old.\n- The participant must have a corneal staining score (Oxford grading) greater than 2 or a Schirmer test result less than 10mm/5min. If the Schirmer test result is 0mm/5min, a nasal stimulation Schirmer test result greater than 3mm/5min is required.\n- The participant must be a volunteer who went through menopause more than 1 year ago before screening or has undergone surgical menopause.\n- The participant must have a negative result on a pregnancy test or be using effective contraception.\n\nThe exclusion criteria for this trial are as follows:\n- Current or recent use of medications for dry eye syndrome (topical or systemic) that may affect the trial results.\n- Presence of systemic or ocular disorders that may affect the test results.\n- Currently being treated with systemic steroids.\n- Wearing contact lenses within 3 days of the screening visit.\n- Pregnancy or breastfeeding.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of oral cavity and oropharyngeal neoplasms. The trial aims to evaluate the effectiveness of a specific drug in patients who will undergo surgical, radiotherapy, or chemoradiation treatment. The eligibility criteria include having a newly diagnosed, histologically confirmed stage I-IV squamous cell carcinoma or squamous cell carcinoma in situ of the oral cavity or oropharynx. Patients who are not candidates for localized treatment with curative intent or those with lesions highly suspicious for cancer are also eligible. The trial requires the collection of tumor and adjacent tissue samples for biomarker analysis. The exclusion criteria include previous treatment for cancer, concurrent diabetes treatment with insulin or oral antidiabetic agents, and the use of certain medications. Other criteria include normal organ and marrow function, ability to swallow a tablet whole, and willingness",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on treating non-small-cell lung carcinoma, specifically in patients with advanced stage IIIB or metastatic (stage IV) disease. The trial involves the use of various drugs, including oral vinorelbine, cisplatin, pemetrexed, and maintenance therapy with these drugs. The eligibility criteria for participants include having histologically or cytologically confirmed non-squamous NSCLC, measurable disease, specific levels of thymidylate synthase expression, and normal organ and marrow function. Participants must also have a life expectancy of at least 3 months and an ECOG performance status of 2 or lower. Exclusion criteria include prior chemotherapy or systemic anti-neoplastic therapy, recent participation in another clinical trial, symptomatic brain metastasis or spinal cord compression, and certain allergies or contraindications to the drugs used in the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is Phase 2.\n- Diseases: The specific disease being studied, in this case, \"cystic fibrosis.\"\n- ICD Codes: The ICD-10 codes associated with the disease, which are \"E84.9,\" \"Z14.1,\" \"E84.0,\" \"E84.11,\" \"E84.8,\" \"E84.19,\" and \"P09.4.\"\n- Drugs: The drugs being used in the trial, which are \"rpl554\" and \"placebo.\"\n- Criteria: The eligibility criteria for participants in the trial, which are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\"\n\nThe inclusion criteria include factors such as signing an informed consent document, being of a certain age, having specific ECG readings, being able to comply with study restrictions and procedures, having a specific BMI range, having a genetic diagnosis of cystic fibrosis, and demonstrating a certain level of lung function.\n\nThe exclusion criteria include factors such as having a history of certain medical conditions, recent hospitalization for a cystic fibrosis exacerbation, recent use of antibiotics, having non-CF related respiratory disorders, history of drug or alcohol abuse, recent use of experimental drugs, history of chronic uncontrolled diseases, documented cardiovascular disease, recent major surgery, infection with specific bacteria, use of immune-suppression, history of malignancy, abnormal laboratory test results, history of non-compliance in previous studies, requiring oxygen therapy, pregnancy or lactation, and any other reason that the investigator deems unsuitable for participation.\n\nOverall, this sample record provides information about a Phase 2 clinical trial for cystic fibrosis, including the specific eligibility criteria for participants.",
    "The sample from the table is a clinical trial for the treatment of non-small cell lung cancer. The trial is in phase 1/phase 2. The diseases being studied are non-small cell lung cancer. The corresponding ICD-10 codes for the diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being tested in the trial are gedatolisib, paclitaxel, and carboplatin. The eligibility criteria for participants include being 18 years or older, having advanced-stage unresectable NSCLC, having a performance status score of less than 2, and having a life expectancy of at least 12 weeks. Other criteria include having measurable disease, meeting certain blood count and liver function requirements, and using adequate contraception methods for women of childbearing potential. The exclusion criteria include having uncontrolled cardiac disease, HIV infection, or chronic active Hepatitis B, as well as having recent thrombotic or embolic events, bleeding events, or major surgeries.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the diseases listed include cervical adenocarcinoma, cervical adenosquamous carcinoma, cervical squamous cell carcinoma, recurrent cervical carcinoma, and stage IV cervical cancer. The ICDCodes associated with these diseases are also provided. The drug mentioned in this sample is atezolizumab. The eligibility criteria include various medical conditions and requirements that patients must meet in order to participate in the clinical trial. These criteria include measurable disease, prior chemotherapy treatment, performance status, blood counts, liver function, kidney function, and various other factors. The sample also includes exclusion criteria, such as prior organ transplantation, recent chemotherapy or radiotherapy, and certain medical conditions or medications that may affect eligibility.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial is evaluating the effectiveness of the drugs atezolizumab and trastuzumab emtansine. The eligibility criteria for participants include having archival tumor samples, being able to submit tumor tissue for PD-L1 expression evaluation, having HER-2 positive breast cancer, and having previously received treatment for breast cancer. Other criteria include having measurable disease, a specific performance status, negative pregnancy test, and using contraception. Exclusion criteria include prior treatment with certain drugs, recent radiation therapy, history of certain malignancies, cardiopulmonary dysfunction, severe infection, severe systemic disease, recent major surgery, liver disease, chronic corticosteroid therapy, spinal cord compression, central nervous system disease, autoimmune disease, prior transplantation, active tuberculosis, recent live vaccine, recent immunostimulatory or immunosuppressive treatment, breastfeeding, or planning to become pregnant during the study.",
    "The sample is a phase 2 trial for the treatment of atopic dermatitis. The trial is evaluating the effectiveness of the drug upadacitinib compared to a placebo. The eligibility criteria for participants include having a confirmed diagnosis of atopic dermatitis, with symptoms present for at least 1 year. Participants must also have moderate to severe atopic dermatitis, as determined by specific criteria such as Eczema Area and Severity Index (EASI) score and Investigators Global Assessment (IGA) score. Additionally, participants must have a history of inadequate response to previous treatments and have been using a specific type of emollient for at least 7 days prior to the trial. There are also exclusion criteria, such as prior exposure to certain medications or treatments, including Janus kinase (JAK) inhibitors and other systemic therapies for atopic dermatitis. Participants must not have been enrolled in another clinical study recently.",
    "The sample is a phase 2 trial for the treatment of glioblastoma multiforme, a grade IV brain tumor. The trial is for patients who have experienced a first recurrence of the disease after receiving adjuvant treatment. The eligibility criteria include age \u2265 18, confirmed diagnosis of glioblastoma multiforme, measurable contrast-enhancing lesions on MRI scan, documented disease progression, and adequate bone marrow, liver, and renal function. Other criteria include negative pregnancy test for females of childbearing potential, use of contraception during the study, and good performance status. The sample also lists exclusion criteria such as the use of certain medications, recent radiotherapy, prior treatment with regorafenib or VEGFR-targeting kinase inhibitors, and various medical conditions.",
    "The sample is a phase 2 trial for the treatment of hyperlipidemia and non-alcoholic fatty liver disease (NAFLD). The trial is testing the drug vk2809 compared to a placebo. The eligibility criteria for participants include having at least 10% liver fat as assessed by MRI, having a fasting serum LDL-C level above 130 mg/dL (or above 110 mg/dL while on lipid lowering medications), and meeting at least one of the following conditions: triglycerides above 150 mg/dL (or receiving medication for elevated triglycerides), high blood pressure (systolic above 130 mmHg or diastolic above 85 mmHg, or receiving medication for hypertension), or a waist circumference above 40 inches for men or above 35 inches for women. Participants must also have a body mass index (BMI) between 18.50 and 40.00 kg/m2. Additionally, participants must provide informed consent. Exclusion criteria include being a female of childbearing potential who is unwilling to use barrier birth control, having abnormal ECG results, having had a cardiovascular event requiring hospitalization in the past year, having a history or presence of thyroid disorder, having had malignancy in the past 5 years, having LDL-C levels above 190 mg/dL or familial hypercholesterolemia, and having significant hepatic or renal function test abnormalities.",
    "The sample from the table is for a phase 2 trial. The disease being studied is virus diseases, specifically those with icd-10 codes A83.6, A84.81, A92.0, A92.5, A93.0, A98.3, and A98.4. The drugs being tested are danirixin 15 mg fbe, danirixin 50 mg fbe, placebo, and oseltamivir 75 mg. The eligibility criteria for participants include being 18 years or older, having a fever or history of fever, having low oxygen saturation or requiring supplemental oxygen, having certain respiratory and heart rate measurements, having symptoms of influenza, testing positive for influenza, meeting certain renal and liver function criteria, and meeting certain contraceptive requirements. Exclusion criteria include not likely to survive the next 48 hours, immunosuppression, liver disease, certain liver function test results, prolonged corrected QT interval, diabetes and chronic kidney disease, requiring dialysis or ECMO, pregnancy or breastfeeding, previous treatment for influenza, recent use of immunoglobulins or certain drugs, history of drug abuse, allergies to study medications, low absolute neutrophil count, and recent participation in another clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"stroke\". The ICD-10 codes associated with this disease are \"G46.4\", \"G46.3\", and \"Z82.3\". The trial involves the drugs \"basmisanil\" and \"placebo\". The eligibility criteria for participants are listed, including requirements such as confirmation of an acute middle cerebral artery ischemic stroke, the stroke occurring within the past 3-4 days, and having severe hemiparesis or hemiplegia. There are also exclusion criteria, such as having a NIHSS score greater than 20, severe aphasia, or a history of epilepsy or neurosurgery.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is myelodysplastic syndromes. The ICD-10 codes associated with this disease are 'D46.9', 'D46.C', and 'D46.Z'. The drugs being tested in this trial are eltrombopag/revolade and lenalidomide. The eligibility criteria for participants include being 18 years of age or older, having MDS with low or intermediate-1 IPSS risk and del5q as a single abnormality, not having received prior treatment with immunomodulating agents or TPO-R agonists, being dependent on regular packed RBC transfusions, having a PLT count >25 Gi/L, having ANC \u2265 0.5 GiL, being resistant or refractory to erythropoetic stimulating agents (ESAs) and/or having serum erythropoetin levels > 500 miU/L, being ineligible or relapsed or refractory to receive treatment options of azacitidine and decitabine, having PLT count and RBC and PLT transfusion data available over a period of 8 weeks prior to screening, having a baseline BM examination including cytomorphology, cytogenetics, and histology during the 2 months prior to randomization, having an ECOG Performance Status of 0-3, having certain clinical chemistries within normal ranges, and meeting certain criteria for childbearing potential. The exclusion criteria include having MDS with intermediate-2 or high IPSS risk, having additional cytogenetic abnormalities, having transfusion independence, having ANC < 0.5 Gi/L and/or Platelet counts < 25 Gi/L, having a history of treatment for cancer with systemic chemotherapy and/or radiotherapy within the last 2 years, having a history of treatment with immunomodulatory drugs or other TPO-R agonists, having certain thrombophilia or cardiovascular conditions, having bone marrow fibrosis that prevents marrow aspiration, having leukocytosis or monocytosis above certain levels, being pregnant or nursing, having known hypersensitivity to lenalidomide, having current alcohol or drug abuse, having received an investigational product within a certain timeframe, having active and uncontrolled infections, or being infected with Hepatitis B, C, or HIV.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is categorized as either phase I, phase II, or phase III. The diseases being studied are myelodysplastic syndrome and myelodysplastic syndromes. The corresponding ICD-10 codes for these diseases are D46.9, D46.C, and D46.Z. The drugs being used in the trial are gsk2879552 and azacitidine. The eligibility criteria for participants include being at least 18 years old, having high or very high risk myelodysplastic syndromes according to the World Health Organization classification, and having failed previous hypomethylating treatment. Other criteria include not being a candidate for or having failed allogeneic stem cell transplantation, having an Eastern Cooperative Oncology Group performance status of 0-1, and having a life expectancy of at least 12 weeks. There are also specific criteria related to organ function, prior treatment toxicities, and pregnancy/contraception status. The exclusion criteria include having acute myeloid leukemia, active hepatitis B or hepatitis C treatment, a baseline Montreal Cognitive Assessment score of 22 or lower, and a history of or concurrent malignancy of solid tumors, among others.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"atrial fibrillation.\" The ICD-10 codes associated with this disease are \"I48.0,\" \"I48.21,\" \"I48.91,\" \"I48.11,\" \"I48.19,\" and \"I48.20.\" The drug being studied is \"metformin.\" \n\nThe eligibility criteria for this trial state that individuals diagnosed with atrial fibrillation who choose to undergo a rhythm control strategy at Robert Packer Hospital and have a BMI (Body Mass Index) of 27 or higher are eligible to participate. Additionally, participants must be able to understand and sign a written informed consent document.\n\nThere are also exclusion criteria listed, which state that individuals who are already taking metformin or other antidiabetic medications, have a diagnosis of diabetes, have an allergy or contraindication to taking metformin, have a low eGFR (estimated glomerular filtration rate), have metabolic acidosis, have a history of significant alcohol use, have hepatic dysfunction, have New York Heart Association (NYHA) Class III or IV heart failure, or are pregnant will be excluded from the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease psoriasis. The ICD-10 codes associated with psoriasis are ['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']. The drugs being studied are 'bms-986165' and a placebo for 'bms-986165'. The eligibility criteria for participants are listed, including age requirements, diagnosis of plaque psoriasis for at least 6 months, and certain restrictions for women of childbearing potential and sexually active males. There are also exclusion criteria, such as having certain medical illnesses, recent blood transfusion, inability to tolerate oral medication, and positive tests for hepatitis-B or hepatitis-C. The sample also includes additional exclusion criteria related to tuberculosis, unstable clinical condition, chest X-ray findings, and recent use of specific medications for psoriasis. It is mentioned that there may be other inclusion/exclusion criteria defined by the protocol.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of post-traumatic stress disorder (PTSD). The trial is investigating the effectiveness of a drug called bnc210 compared to a placebo. The eligibility criteria for participants include being between 18 and 70 years old, having a current diagnosis of PTSD, and not currently using any psychiatric medications except for specific exceptions. Participants must also not be currently receiving psychotherapy, except for long-term supportive counseling or intensive regular psychotherapy for at least three months prior to screening. Females of childbearing potential must have a negative pregnancy test and both females and males of childbearing potential must agree to use two effective methods of contraception. The exclusion criteria include ongoing exposure to the trauma that caused the PTSD, having failed more than three trials of antidepressant medication for PTSD, recent use of certain psychiatric medications, history of significant traumatic brain injury, depression, bipolar or psychotic disorders, borderline personality disorder, seizure disorders, increased risk of suicide, recent use of specific medications, clinically significant abnormalities in laboratory tests or vital signs, positive results for HIV or hepatitis, substance use disorder, current military service, and involvement in ongoing insurance or workplace claims that may impact mental health.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 2 and focuses on breast cancer. The associated ICD-10 codes for the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being studied in this trial are neoadjuvant chemotherapy and postoperative chemotherapy. The eligibility criteria for participants are listed, including requirements such as confirmation of invasive breast cancer, negative ER/PgR status, and lack of HER2/neu overexpression or amplification. The criteria also specify age, performance status, cancer stage, and previous treatment history. Adequate hematologic and hepatic function are also required. The exclusion criteria include positive ER/PgR status, reduced ejection fraction, presence of second malignancies, bilateral breast cancer, and allergic constitution.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on two types of dependencies: opioid dependence and cocaine dependence. The corresponding ICD-10 codes for these diseases are provided. The drugs being studied are prednisolone and a placebo for prednisolone. \n\nThe eligibility criteria for participants are listed under \"Inclusion Criteria\" and include requirements such as informed consent, age 18 or older, and specific detoxification conditions for both groups A and B. Group A refers to detoxification of stimulants (cocaine, amphetamine, and/or methamphetamine), while group B refers to opioid dependency and dependency on stimulants. Participants must have been admitted for detoxification to ward U2 of the University Psychiatric Hospital of Basel.\n\nThe \"Exclusion Criteria\" list factors that would disqualify individuals from participating in the study, such as contraindications to the drugs being studied, severe psychiatric disturbances, certain medical conditions, recent glucocorticoid therapy, alcohol abuse, and the use of specific prohibited drugs. Additionally, pregnant or breastfeeding women, those intending to become pregnant during the study, and individuals who are unable to follow study procedures are also excluded. Previous enrollment in the current study or participation in another study with an investigational drug within the past 30 days are also grounds for exclusion. The investigator, their family members, employees, and other dependent persons are also not eligible to participate.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 2 and focuses on Parkinson's disease. The trial is associated with the ICD-10 code \"G20\". The drugs being studied are \"kw-6356\" and \"placebo\". The eligibility criteria for participants are listed, including requirements such as meeting specific diagnostic criteria for Parkinson's disease, being in certain stages of the disease, and having a certain score on the MDS-UPDRS part III assessment. There are also exclusion criteria, such as recent use of certain drugs, previous treatment with levodopa, and certain medical conditions. The record concludes with a note that individuals who are deemed unsuitable for the study by the investigator or sub-investigator will not be included.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"pneumonia, ventilator-associated\" and \"pneumonia, staphylococcal\". The corresponding ICD-10 codes for these diseases are \"J95.851\" and \"G00.3\", \"M00.09\", \"A05.0\", \"M00.08\", \"L00\", \"M00.00\", \"M00.011\" respectively. The drugs being tested in this trial are \"asn100\" and \"placebo\". The sample also includes the eligibility criteria for the trial, including inclusion and exclusion criteria.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The disease being studied is cancer, and the corresponding ICD-10 codes for the specific types of cancer are provided. The drugs being used in the trial are \"nox66\" and \"carboplatin\". The eligibility criteria for participants in the trial are listed, including requirements such as providing informed consent, being at least 18 years old, having locally advanced or metastatic cancer with no standard treatment options, having a certain performance status, and meeting specific medical criteria related to bone marrow, liver, and kidney function. Female participants must have a negative pregnancy test and agree to use contraception during the study. There are also criteria related to the timing of previous treatments and surgeries. The exclusion criteria include being pregnant or breastfeeding, having uncontrolled infection or systemic disease, having certain cardiac conditions, having a prolonged QTc interval on an electrocardiogram, recent major surgeries, recent chemotherapy or immunotherapy, certain infectious diseases, a history of solid organ transplantation, and certain psychiatric or social situations that would prevent participation. Additionally, there is a specific exclusion criterion related to the suitability for treatment with carboplatin based on renal function.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on Parkinson's disease. The record includes the following details:\n\n- Phase: Phase 2\n- Diseases: Parkinson's disease\n- ICD Codes: G20 (ICD-10 code for Parkinson's disease)\n- Drugs: Ambroxol\n- Criteria: The eligibility criteria for participants in the trial\n\nThe inclusion criteria for participants include being male or female, aged between 40 and 80 years, having a confirmed diagnosis of Parkinson's disease according to the Hoehn and Yahr criteria (staged between I - III), being able to provide informed consent, and being capable of complying with all study procedures. Participants should also be willing to self-administer oral ambroxol medication for a specific duration and be able to travel to the study site.\n\nFor female participants, there are additional criteria related to their reproductive status. Non-childbearing potential is defined as having undergone tubal ligation or hysterectomy, or being postmenopausal for at least 12 consecutive months. Women of childbearing potential must use accepted contraceptive methods and have negative pregnancy tests. Both male and female participants of childbearing potential must agree to use double-barrier birth control or practice abstinence during the study and for 2 weeks after the last dose of the study drug.\n\nThe exclusion criteria include current treatment with anticoagulants, current participation in another clinical trial, dysphagia that would prevent self-administration of ambroxol, spinal abnormalities that would preclude lumbar puncture, known sensitivity to the study medication or its components, certain hereditary disorders, history of drug abuse or alcoholism, recent blood donation, pregnancy or breastfeeding, and any clinically significant or unstable medical or surgical conditions.\n\nOverall, this record provides specific details about the phase, diseases, drugs, and eligibility criteria for participants in a phase 2 clinical trial for Parkinson's disease.",
    "The sample provided is for a phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC). The eligibility criteria for participants are listed, including a recent diagnosis of PSC based on cholangiogram, elevated serum alkaline phosphatase levels, stable use of ursodeoxycholic acid (UDCA) or no use of UDCA for at least 12 months, stable doses of biologic treatments or immunosuppressants for at least 3 months, and a screening FibroSURE/FibroTest\u00ae score below a certain threshold. Exclusion criteria are also listed, such as elevated alanine aminotransferase levels, high total bilirubin levels, abnormal international normalized ratio, small-duct PSC, other liver diseases, recent ascending cholangitis, presence of a percutaneous drain or bile duct stent, recent use of fibrates or obeticholic acid, cirrhosis of the liver, and current active inflammatory bowel disease. It is noted that there may be additional inclusion/exclusion criteria defined in the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is \"high risk smoldering multiple myeloma.\" The ICDCodes associated with this disease are \"['G35', 'M15.3', 'M67.49', 'M89.09', 'M89.59', 'M94.29', 'Q78.6'].\" The drug mentioned is \"ibrutinib.\" The eligibility criteria are listed, including disease-related inclusion criteria and exclusion criteria, as well as laboratory and demographic requirements.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 2, and the diseases are anemia and myelodysplastic syndrome. The icd-10 codes associated with these diseases are provided. The drug mentioned is deferasirox. The eligibility criteria for this trial include various factors such as the ability to provide informed consent, specific diagnostic criteria for MDS, certain baseline levels of serum ferritin, hemoglobin, bilirubin, liver enzymes, and kidney function. Additionally, there are requirements for contraceptive precautions for participants with reproductive potential. Exclusion criteria are also listed, including current treatment with certain medications, presence of certain medical conditions, hypersensitivity to deferasirox, and history of certain medical procedures or infections.",
    "The sample is a phase 2 trial for allergic rhinitis. The trial is focused on patients who have moderate to severe allergic rhinitis to birch pollen. The inclusion criteria for the trial include being an adult between 18 to 65 years old, having a positive skin prick test and specific IgE CAP to birch pollen extract. The exclusion criteria include having persistent non-controlled asthma, previous specific immunotherapy to tree pollens, previous SIT to any allergen within 5 years, previous history of severe anaphylactic reaction, perennial allergic rhinitis, any other disorder that could influence the trial outcomes, pregnancy, any severely debilitating disease, and primary or secondary immunodeficiency or treatment with immunosuppressor drugs within one month prior to randomization. The trial will involve the drugs \"allert\" and \"placebo\".",
    "The sample is a phase 2 trial for the treatment of osteoarthritis (OA) in the hip or knee. The trial is testing the effectiveness of a drug called cr845 tablet at different doses (1 mg, 2.5 mg, and 5 mg) compared to a placebo tablet. The eligibility criteria for participants include being at least 25 years old, having a body mass index (BMI) of 40 kg/m2 or less, meeting the American College of Rheumatology (ACR) criteria for OA, reporting an average pain intensity level of 5 or higher in the affected joint, and being either opioid-na\u00efve or opioid-experienced. Participants must be willing to discontinue current pain medications (except for acetaminophen) and practice birth control if of childbearing potential. Exclusion criteria include having had a joint replacement in the affected joint, recent intra-articular injections, certain medication use, substance dependence or abuse, certain medical conditions or abnormalities, and recent use of pain medications other than acetaminophen. Participants must also provide written informed consent and be able to communicate in English or Spanish.",
    "The sample is a phase 2 trial for patients with essential hypertension. The trial is testing the effectiveness of different drugs, including candesartan cilexetil and amlodipine, in treating the condition. The eligibility criteria for inclusion in the trial include being 19 years of age or older, having a diagnosis of essential hypertension or currently taking antihypertensive medication, and voluntarily agreeing to participate. Exclusion criteria include severe hypertension, significant blood pressure differences, secondary hypertension, orthostatic hypotension, severe heart failure, recent acute coronary syndrome or peripheral vascular disease, history of switching antiarrhythmic drugs or receiving cardioversion or ICU treatment, uncontrolled diabetes, haemodynamic disturbance or heart valve disease, recent cerebrovascular or eye disease, autoimmune diseases, chronic inflammatory disease, significant renal or liver impairment, hypokalaemia or hyperkalaemia, gastrointestinal disease or surgery that may affect drug absorption, allergy or hypersensitivity to certain medications, heredity defects, concomitant use of certain drugs, history of malignant tumors or substance abuse, pregnancy or lactation, and use of other investigational products. The final decision on suitability for participation is made by the investigator.",
    "The sample is a phase 2 clinical trial for small cell lung cancer (SCLC). The trial is specifically for patients with extensive stage SCLC who have previously received first-line therapy with EP or CE and second-line therapy with topotecan. The eligibility criteria include having a histologic or cytologic diagnosis of SCLC, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and being between 18 and 75 years old with an expected survival of at least three months. Patients must also have at least one measurable lung tumor lesion and meet certain hematologic and hepatic function requirements. They should be able to take oral medication, understand and sign the informed consent, and be willing to undergo follow-up. \n\nThere are also exclusion criteria, such as a history of cardiovascular disease, serious clinical infection, epilepsy requiring medication, previous allogeneic organ transplantation, bleeding tendency or coagulation disorders, need for renal dialysis, and other tumors within the past 5 years (with some exceptions). Other exclusion criteria include uncontrolled hypertension, recent thrombosis or embolism, pulmonary or organ hemorrhage, severe uncured wounds or fractures, dehydration, factors that may affect safety and compliance, inability to comply with the study protocol, pregnancy or breastfeeding, and the researcher's belief that the patient is not suitable for the study.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is autism, and its corresponding ICD-10 code is Z13.41. The drugs being tested are l1-79 and placebo. The sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being male and not sexually active, being between the ages of 13 and 21, having signed informed consent, having normal clinical laboratory values, having a DSM-5 compliant diagnosis of autism spectrum disorder confirmed by the Autistic Diagnosis Interview Review (ADIR) and the Autism Diagnosis Observation Schedule (ADOS), and not taking more than one concomitant medication for the treatment of autism. Exclusion criteria include having any co-morbidities such as Fragile-X syndrome, epilepsy, Retts syndrome, ADHD, or any other disease or syndrome aside from autism that requires treatment, having any other psychiatric disorder or out-of-range lab values, having a DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or alcohol use disorder, having active medical problems such as unstable seizures, and having concomitant physical illness.",
    "The sample is a phase 2 trial for the treatment of autistic disorder. The trial is focused on children and teenagers between the ages of 5 and 17 who have been diagnosed with typical autism or Asperger syndrome according to the WHO's classification criteria (CIM-10). The patients must have a known etiology and their CARS results must be equal to or greater than 30. The trial requires the parents to provide their consent and the patients must be affiliated or beneficiaries of the French social security.\n\nThere are several inclusion and exclusion criteria for the trial. Inclusion criteria include not being under treatment with an inlet diuretic, not having electrolytic disorders, not having a known hypersensitivity to sulfa drugs, not having hepatic or renal failure, not having uncontrolled epilepsy, not being under treatment with psychotropic drugs (except melatonin), not having an allergy to bumetanide or its excipients, and not being under treatment with specific medications such as lithium, diphemanil, erythromycin IV, halofantrine, pentamidine, sultopride, vincamine, or aminoglycoside. Pregnant and lactating women are also excluded from the trial.\n\nThere are also secondary exclusion criteria, which include QT prolongation noticed on the ECG at Day 0, anomalies on the biological check-up made before including the patient that would contraindicate the prescription of bumetanide, and patients whose CARS results are strictly less than 30.",
    "The sample from the table is for a phase 2 clinical trial for ovarian cancer. The trial is testing the effectiveness of the drugs quisinostat, paclitaxel, and carboplatin. The eligibility criteria for participants include being female, aged 18 or older, having a confirmed diagnosis of serous epithelial ovarian, primarily peritoneal or fallopian tube carcinoma, and having an ECOG status of 0 or 1. Participants must have received only one prior line of platinum and paclitaxel based chemotherapy and must have tumor progression observed within 1 to 6 months after completing the first line chemotherapy. They must also have at least one measurable lesion according to RECIST 1.1 criteria. Other criteria include specific laboratory parameters, expected survival time of at least 6 months, and practicing effective birth control for women of childbearing potential. Exclusion criteria include previous treatment with an HDAC inhibitor, specific toxicities related to prior anti-cancer therapy, presence of cerebral metastases, and various cardiovascular diseases. Other exclusion criteria include pregnancy, drug or alcohol abuse, and inability to comply with the study procedures.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"EGFR activating mutation,\" \"recurrent non-small cell lung carcinoma,\" and \"stage IV non-small cell lung cancer.\" The corresponding ICDCodes for these diseases are \"D68.52, J84.83,\" \"D02.20, D02.21, D02.22,\" and \"C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2\" respectively. The drugs being used in the trial are \"chemotherapy,\" \"targeted molecular therapy,\" and \"tyrosine kinase inhibitor.\"\n\nThe eligibility criteria for this trial include:\n- Patients must have histologically or cytologically confirmed incurable non-small cell lung cancer with specific genetic mutations.\n- Patients must be receiving or planning to start treatment with a tyrosine kinase inhibitor targeting the activated gene.\n- Patients should not be receiving the treatment targeting the activated gene as part of another clinical trial.\n- Patients should have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.\n- Certain laboratory values, such as total bilirubin and AST/ALT levels, must be within specific ranges.\n- Women of child-bearing potential and men must agree to use contraception during the study.\n- Patients must be able to understand and sign an informed consent document.\n\nThe exclusion criteria for this trial include:\n- Patients with an emergent need for palliative radiation.\n- Patients who are receiving other investigational agents for the treatment of non-small cell lung cancer.\n- Patients with uncontrolled intercurrent illnesses or conditions that may limit compliance with study requirements.\n- Pregnant women are excluded, and breastfeeding should be discontinued.\n\nThis sample provides a specific example of a clinical trial record with detailed information about the trial phase, diseases being studied, associated ICDCodes, drugs used, and the eligibility and exclusion criteria for participants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"lupus nephritis.\" The associated ICD-10 codes for this disease are \"B26.83,\" \"A51.44,\" \"N11.8,\" \"N11.9,\" and \"N12.\" The drug being studied is \"voclosporin.\" \n\nThe eligibility criteria for this trial include a diagnosis of systemic lupus erythematosus (SLE) according to the American College of Rheumatology criteria. The participant must have had a kidney biopsy within the past 24 months, which confirmed a histologic diagnosis of lupus nephritis. The trial also requires laboratory evidence of active nephritis, as defined by specific proteinuria levels.\n\nThere are also exclusion criteria, such as having a low estimated glomerular filtration rate (eGFR), requiring renal dialysis, or having a previous or planned kidney transplant during the study period. Other exclusion criteria include recent malignancy, lymphoproliferative disease, severe viral infections, active tuberculosis, and various other medical conditions.\n\nOverall, this sample provides specific details about the phase, disease, associated ICD-10 codes, drug, and eligibility criteria for a clinical trial focused on lupus nephritis.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on breast cancer. The associated ICD-10 codes for the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being studied is zafirlukast. \n\nThe eligibility criteria for this trial include patients who are scheduled to undergo therapeutic or prophylactic mastectomy with immediate placement of tissue expanders and have a strong family history or hereditary cancer. The patients must be at least 18 years old and willing to use adequate contraception if they are of child-bearing potential. They should also be able to understand and sign an informed consent document. Additionally, they should be at least 4 weeks post-completion of chemotherapy and have adequate organ function.\n\nThe exclusion criteria for this trial include any significant medical condition or laboratory abnormalities that would pose an unacceptable risk to the participant. Patients who are currently on a leukotriene inhibitor or have used one within the past 6 months are also excluded. Prior chest wall radiation, pregnancy or breastfeeding, hepatic impairment, and known psychiatric or substance abuse disorders that would interfere with trial requirements are also exclusion criteria.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on bladder cancer. The ICD-10 codes associated with the disease are D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, and D41.4. The drug being studied is atezolizumab. The record also includes the eligibility criteria for participants in the trial. This includes requirements such as having locally advanced or metastatic transitional cell carcinoma of the urothelium, a performance status of 0 or 1, and a life expectancy of at least 12 weeks. There are also specific inclusion criteria for Cohort 1, which includes not having received prior chemotherapy and being ineligible for cisplatin-based chemotherapy due to certain conditions. The record also lists exclusion criteria, such as recent treatment with other anti-cancer therapies, active central nervous system metastases, uncontrolled tumor-related pain, and various other medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are daratumumab, cyclophosphamide, bortezomib, and dexamethasone. \n\nThe eligibility criteria for this trial include having documented multiple myeloma as defined by the International Myeloma Working Group (IMWG) 2015 criteria, having previously untreated myeloma or relapsed myeloma with one prior line of therapy, having an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2, and meeting certain requirements for women of childbearing potential and sexually active men. \n\nThe exclusion criteria for this trial include being refractory to any proteasome inhibitor (PI) or the combination of PI and immunomodulatory drug (IMiD) agents, exhibiting signs of meningeal or central nervous system involvement by multiple myeloma, having certain respiratory conditions, and having certain viral infections.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of multiple myeloma in patients who have relapsed or are refractory to previous therapies. The trial is investigating the use of two drugs, \"jnj-42756493\" and \"dexamethasone\". The eligibility criteria for the trial are listed, including requirements such as a diagnosis of multiple myeloma, previous treatment with proteasome and immunomodulatory agents, confirmation of FGFR3 expression and mutational status, and an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2. The sample also includes exclusion criteria, such as patients who cannot have their FGFR3 expression or mutational status determined, recent chemotherapy or other anti-myeloma therapy, and certain medical conditions or treatments that may contraindicate participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is graft-versus-host disease (GVHD). The ICDCodes associated with this disease are D89.810, D89.811, D89.813, and D89.812. The drugs being used in the trial are ruxolitinib and prednisone or methylprednisolone. \n\nThe eligibility criteria for this trial include having undergone the first allogeneic hematopoietic stem cell transplantation (allo-HSCT) for hematologic malignancies, clinically suspected Grades II to IV acute GVHD, and evidence of myeloid engraftment. Other criteria include not having received more than 1 allo-HSCT or more than 1 systemic treatment in addition to corticosteroids for acute GVHD. Exclusion criteria include the presence of GVHD overlap syndrome, having had a splenectomy, and having an active uncontrolled infection. \n\nThere are additional exclusion criteria related to HIV infection, hepatitis B or C virus infection, serum creatinine levels, relapsed primary disease, unresolved toxicity or complications from previous allo-HSCT, and corticosteroid therapy for indications other than GVHD. Severe organ dysfunction unrelated to GVHD, currently breastfeeding, and previous treatment with Janus kinase inhibitor (JAK) therapy after allo-HSCT are also exclusion criteria. \n\nFinally, the sample includes criteria related to treatment with other investigational agents, devices, or procedures, any condition that would interfere with full participation in the study, and known allergies or intolerances to the study medications or similar compounds.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"cystic fibrosis\". The ICD-10 codes associated with this disease are \"E84.9\", \"Z14.1\", \"E84.0\", \"E84.11\", \"E84.8\", \"E84.19\", and \"P09.4\". The drugs being studied are \"pbi4050\" and \"placebo\". The eligibility criteria for participants are listed, including age, confirmed diagnosis of cystic fibrosis, specific tests performed within the last 12 months, body mass index, consent, ability to self-monitor blood glucose, and contraception requirements for female and male participants. The exclusion criteria are also listed, including recent infection, use of certain medications, liver enzyme levels, history of substance abuse, history of malignancy, unstable chronic heart failure, HIV or active Hepatitis infection, pregnancy or breastfeeding, and other conditions that may interfere with the study. The sample also mentions that the patient should not be under insulin and/or repaglinide treatment at screening/baseline.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 2 and focuses on the disease \"autistic disorder\". The corresponding ICD-10 code for this disease is \"F84.0\". The trial involves the use of three drugs: \"cannabinoids - 99% pure cannabinoids mix\", \"placebo\", and \"cannabinoids - whole plant extract\". The eligibility criteria for participants in this trial include having a diagnosis of ASD according to the DSM-V and having moderate or greater behavioral problems as measured by the CGI-S rating scale. There are also exclusion criteria, such as not being able to make planned changes in existing interventions during the trial, not currently receiving cannabis-based therapy or having received it in the last 3 months, having heart, liver, renal, or hematological disorders, and having a history of psychotic disorder in a first-degree relative.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is \"respiratory syncytial virus infections.\" The icd-10 codes associated with this disease are \"R09.2,\" \"A15.7,\" \"A15.8,\" \"A15.9,\" \"J98.9,\" \"R06.03,\" and \"J12.1.\" The drug mentioned is \"placebo (formulation buffer s9b).\" \n\nThe eligibility criteria for this sample include various inclusion and exclusion criteria. Inclusion criteria state that subjects must be able to comply with the protocol, provide written informed consent, be non-pregnant females between 18 and 45 years old, be healthy, and meet certain conditions for childbearing potential. Exclusion criteria include the use of other investigational or non-registered products, participation in another clinical study, administration of immunosuppressants or immune-modifying drugs, administration of immunoglobulins or blood products, planned administration of certain vaccines, previous experimental vaccination against RSV, history of neurological disorders or seizures, family history of immunodeficiency, autoimmune disease, significant pulmonary, cardiovascular, hepatic or renal abnormalities, lymphoproliferative disorder or malignancy, hypersensitivity to study vaccine components, latex hypersensitivity, medical conditions that make intramuscular injection unsafe, current alcohol or drug abuse, acute disease or fever at enrollment, high body mass index, pregnancy or lactation, planned move to a location that prohibits trial participation, and any other condition that may interfere with the study procedures or findings.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is divided into different phases, and this particular record is from phase 1/phase 2. The diseases being studied in this trial are contraception, liver metabolism, and hemostasis parameter. The corresponding ICD-10 codes for these diseases are ['Z92.0', 'Z30.012', 'Z30.09']. The drugs being tested in the trial are '15 mg e4/3 mg drsp', '30 mcg ee/150 mcg lng', and '20 mcg ee/3 mg drsp'. \n\nThe eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being a healthy adult woman, having a negative pregnancy test, being between the ages of 18-50, having good physical and mental health, having a BMI between 18.0 and 30.0 kg/m\u00b2, and being willing to participate in the study. Exclusion criteria include known hypersensitivity to the investigational product ingredients, smoking if over 35 years old, dyslipoproteinemia or use of antilipidemic agent, known diabetes mellitus, current use of antidiabetic drugs, arterial hypertension, conditions associated with an increased risk of thromboembolism, abnormal uterine/vaginal bleeding, presence of an undiagnosed breast mass, current symptomatic gallbladder disease, history of pregnancy- or COC-related cholestasis, severe hepatic disease, pancreatitis associated with hypertriglyceridemia, porphyria, benign liver tumors, renal impairment, hyperkalemia, hormone-related malignancy, history of non-hormone-related malignancy within 5 years, use of drugs potentially triggering interactions with COCs, history of alcohol or drug abuse within 12 months, thyroid disorders, participation in another investigational drug clinical study within 1 month, and being affiliated with the study's sponsor, CRO, or PI's site personnel. The final exclusion criterion is being judged by the PI to be unsuitable for any reason.",
    "The sample provided is for a phase 2 clinical trial. The diseases being studied are liver neoplasms and hepatocellular cancer. The corresponding ICD-10 codes for these diseases are 'D13.4', 'Z85.05', 'C22.8', 'C78.7', 'C22.9', 'D37.6' for liver neoplasms and 'P59.20', 'P59.29' for hepatocellular cancer. The drug being tested in this trial is doxorubicin. The eligibility criteria for participants include having hepatocellular carcinoma larger than 3 cm and non-resectable, with a diagnosis established either by dynamic imaging or histopathology. Other criteria include specific tumor characteristics, liver volume, cirrhosis stage, performance status, blood test results, and consent to participate. There are also exclusion criteria such as eligibility for other treatments, disease spread, previous treatments, uncontrolled ascites or encephalopathy, and certain medical conditions.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on two diseases, namely \"healthy volunteers\" and \"asthma\". The corresponding ICD-10 codes for the diseases are provided as well. The trial involves the administration of two drugs, \"rp3128\" and \"placebo\". The eligibility criteria for participants include being male or non-childbearing female subjects with mild asthma or healthy subjects. Other criteria include having a specific body mass index (BMI) range, being a non-smoker or ex-smoker, and being willing to adhere to the protocol requirements. Participants should also have negative screenings for drugs of abuse and alcohol. Male subjects should agree not to donate sperm for three months post-dose, and female partners of male subjects should use two methods of highly effective contraception for the same duration. Additional criteria are specified for pre-bronchodilator Forced expiratory volume in 1 sec (FEV1) and steroid-na\u00efve subjects with a history of mild asthma. Exclusion criteria include a history of clinically significant medical history, tuberculosis, use of immunotherapy within three months prior to screening, history of serious adverse reactions or allergies to drugs, abnormal liver function, and positive screenings for hepatitis-B, hepatitis C, or HIV antibodies.",
    "The sample is a phase 2 trial for the treatment of cirrhosis, portal hypertension, and non-alcoholic steatohepatitis (NASH). The trial is testing the drug emricasan compared to a placebo. The eligibility criteria for participants include being 18 years or older, having cirrhosis due to NASH, and having either compensated or decompensated cirrhosis with no more than one prior significant decompensating event. Participants must also have severe portal hypertension, defined as HVPG (hepatic venous pressure gradient) of at least 12 mmHg. They should be on a stable dose of certain medications for at least 3 months prior to the start of the trial and be willing to use effective contraception during the study period. There are various exclusion criteria, including severe decompensation, severe hepatic impairment, abnormal liver function tests, and certain medical conditions or medications. The sample also specifies criteria related to pregnancy, previous treatments, and other medical conditions.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial is evaluating the effectiveness of a drug called E6011 compared to a placebo. The eligibility criteria for participants include being aged 18 to 75, diagnosed with rheumatoid arthritis for at least 12 weeks, and having received methotrexate treatment. Other criteria include specific joint symptoms, certain levels of C-reactive protein or erythrocyte sedimentation rate, and radiographic evidence of erosions. Participants must also meet certain weight requirements and provide written consent. Exclusion criteria include having other inflammatory arthritic disorders, certain medical conditions, recent immunoglobulin or blood product use, and recent live vaccine administration. Other exclusions include certain infections, history of tuberculosis, positive test results for certain diseases, and certain pregnancy or contraception-related factors. Participants must not have certain surgical plans, be enrolled in another clinical study, or have used any investigational drugs or devices recently. The sample also mentions that participants should not have been treated with E6011 or any unapproved biologics for rheumatoid arthritis, and should not be using psychotropic agents for recreational purposes. Any medical conditions that could compromise the participant's ability to safely complete the study are also considered exclusion criteria.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial is looking at the effectiveness of a drug called E6011 compared to a placebo. The eligibility criteria for participants include being aged 18-75, having a diagnosis of rheumatoid arthritis for at least 12 weeks, and having received biologics treatment but discontinued it due to inadequate response. Other criteria include having a certain number of tender and swollen joints, being on a stable dose of methotrexate, and meeting certain laboratory test results. There are also exclusion criteria, such as having other inflammatory arthritic disorders, certain medical conditions, or being pregnant or breastfeeding. The sample also includes information on the diseases, ICDCodes, and drugs associated with the trial.",
    "The sample provided is for a phase 2 clinical trial. The specific disease being studied is homozygous familial hypercholesterolemia. The ICD-10 codes associated with this disease are 'E78.01', 'E78.00', and 'Z83.42'. The drugs being tested in this trial are 'aln-pcssc' and 'standard of care'. \n\nThe eligibility criteria for participants in this trial include being males or females aged 12 years or older with a diagnosis of homozygous familial hypercholesterolemia confirmed through genetic testing or clinical diagnosis. They should have a history of untreated low-density lipoprotein cholesterol (LDL-C) concentration above 500 mg/dL (13 mmol/L) along with either xanthoma before the age of 10 or evidence of heterozygous familial hypercholesterolemia in both parents. Participants should also be stable on a low-fat diet and pre-existing lipid-lowering therapies for at least 4 weeks, with no planned changes in medication or dosage during the study. Additionally, they should have a fasting central lab LDL-C concentration above 130 mg/dL (3.4 mmol/L) and triglyceride concentration below 400 mg/dL (4.5 mmol/L). The minimum body weight required for participation is 40 kilograms.\n\nExclusion criteria for this trial include having undergone LDL or plasma apheresis within 8 weeks prior to the screening visit, with no plans for apheresis during the study due to the difficulty in maintaining stable LDL-C concentrations during apheresis. Participants who have used mipomersen or lomitapide therapy within 5 months of screening or have been previously treated with monoclonal antibodies directed towards PCSK9 within 8 weeks of screening are also excluded.\n\nIt is important to note that the provided information may not include all the relevant considerations for potential participants in the clinical trial.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial is focused on patients with relapsed or refractory solid tumors and non-small cell lung cancer. The diseases are identified by their respective ICD-10 codes. The drugs being studied are lenalidomide and pembrolizumab. \n\nThe eligibility criteria for the trial include having a confirmed metastatic solid tumor malignancy for the phase 1 component, and histologically or cytologically confirmed non-small cell lung carcinoma for the phase 2 component. Patients must have measurable disease according to RECIST criteria v. 1.1 and have completed at least one line of prior therapy for the phase 2 portion, or one or two lines of prior therapy for the phase 1 portion. \n\nOther criteria include age over 18, ECOG performance status of 0 or 1, normal organ and marrow function, ability to understand and sign informed consent, and availability of a core tumor biopsy obtained after progression on the last treatment for the phase 2 portion. Female subjects of childbearing potential must have a negative serum pregnancy test and use contraception during the study. Male subjects of childbearing potential must also use contraception. \n\nExclusion criteria include recent chemotherapy or radiotherapy, ongoing adverse events from previous treatments, active autoimmune disease requiring systemic treatment in the past 2 years, untreated symptomatic brain metastases, interstitial lung disease or active noninfectious pneumonitis, recent live vaccination, uncontrolled intercurrent illness, known hypersensitivity to thalidomide or lenalidomide or pomalidomide, peripheral neuropathy of grade \u22653, and pregnancy or breastfeeding.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The disease being studied is Duchenne muscular dystrophy. The corresponding ICD-10 code for this disease is G71.01. The drug being tested is (+)-epicatechin. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being male, aged between 8 and 17 years, non-ambulatory, weighing less than or equal to 100kg, and having a confirmed diagnosis of Duchenne muscular dystrophy through various tests or having a positive family history. Other criteria include having a cardiac ejection fraction greater than 55% on an echocardiogram, discontinuing the use of certain supplements prior to screening, having stable glucocorticoid and cardiac therapy for a certain period, and having normal hematology and laboratory safety chemistry profiles.\n\nExclusion criteria include the inability to complete certain assessments, current enrollment in another treatment trial, significant concomitant illness or impairment of renal or hepatic function, recent use of medication with antiplatelet effects, and cardiac symptoms suggestive of imminent moderate to severe cardiac events.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is divided into different phases (phase I, phase II, phase III). The sample specifically belongs to a trial in phase 2/phase 3. The diseases being studied in this trial include fgfr1 gene amplification, fgfr1 gene mutation, fgfr2 gene amplification, fgfr2 gene mutation, fgfr3 gene amplification, fgfr3 gene mutation, recurrent squamous cell lung carcinoma, and stage iv squamous cell lung carcinoma ajcc v7. The icd-10 codes associated with these diseases are D02.20, D02.21, and D02.22. The drugs being used in the trial are docetaxel and fgfr inhibitor azd4547. The eligibility criteria for participating in the trial are listed in detail, including requirements related to previous treatments, medical conditions, medications, and various medical tests. The sample also mentions a step 2 re-registration process for patients who have progressed on a specific treatment arm. The sample concludes with additional requirements related to laboratory tests, medical history, contraception, and informed consent.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2, and the disease being studied is myasthenia gravis. The icd-10 codes associated with this disease are \"P94.0\", \"G70.00\", and \"G70.01\". The drug being used in the trial is a placebo. \n\nThe eligibility criteria for this trial include:\n1. The ability to understand the study requirements and provide informed consent.\n2. Being a male or female patient aged 18 years or older.\n3. Having a diagnosis of autoimmune myasthenia gravis with generalized muscle weakness, meeting the clinical criteria defined by the Myasthenia Gravis Foundation of America.\n4. Having a total score of 5 or higher on the MG ADL (Myasthenia Gravis Activities of Daily Living) assessment, with more than 50% of the score attributed to non-ocular items.\n5. Being on a stable dose of MG treatment prior to randomization.\n6. Female participants of childbearing potential must have a negative pregnancy test and agree to use a highly effective method of contraception during the study and for 90 days after discontinuation of the investigational medication.\n7. Sterilized male patients or sexually active non-sterilized male patients must use effective methods of contraception.\n8. Exclusion criteria include pregnancy or lactation, certain MGFA classifications, active or recent serious infections, clinically significant laboratory abnormalities, BMI \u2265 35 kg/m2, recent use of certain medications, and various other medical conditions or history.\n\nThis sample provides a detailed description of the eligibility criteria for the clinical trial, including specific requirements related to the disease, treatment, and patient demographics.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is schizophrenia, and the corresponding ICD-10 codes are provided. The drugs being tested are \"sep-363856\" and \"placebo - cap\". The eligibility criteria for participants include giving written informed consent, being between 18 to 40 years old, meeting DSM-5 criteria for schizophrenia, having certain scores on the PANSS and CGI-S scales, and having an acute exacerbation of psychotic symptoms. There are also criteria related to BMI, pregnancy, contraception, and previous hospitalizations. Exclusion criteria include suicidal ideation, intolerance to venipuncture, recent participation in other studies, previous use of SEP-363856, and various medical conditions or disorders. The randomization criteria involve PANSS and CGI-S scores, suicidal ideation, and scores on the SAS scale.",
    "The sample from the table represents a phase 2 clinical trial for patients with breast neoplasm. The trial aims to evaluate the effectiveness of various drugs, including sfx-01, fulvestrant, tamoxifen, and aromatase inhibitors, in treating estrogen receptor positive (ER+) breast cancer. The eligibility criteria for the trial include being 18 years or older, having histologically confirmed ER+ breast cancer, and having metastatic or locally advanced disease that cannot be surgically removed. Patients must also have at least one measurable lesion and an anticipated life expectancy of at least 12 weeks. Adequate bone marrow, renal, and hepatic function is required, as well as an ECOG performance status of less than 2. Patients must have evidence of progressive disease after previous endocrine therapy and be suitable for continuing endocrine therapy. The trial also has exclusion criteria, such as rapidly progressive visceral disease, current chemotherapy or other combination treatments, recent radiotherapy or major surgery, and certain medical conditions that may interfere with participation or compliance. Pregnant or breastfeeding females are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease called gastroparesis. The ICD-10 code for gastroparesis is K31.84. The drug being studied is vly-686 (tradipitant). The sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being diagnosed with gastroparesis, agreeing to use contraception, providing written informed consent, participating in pharmacogenomics sample collection, and complying with all study requirements and restrictions. Exclusion criteria include having another active disorder or treatment that could explain or contribute to symptoms, being pregnant or nursing, having a history of intolerance or hypersensitivity to medications similar to vly-686, using another NK1 antagonist or palonosetron, being exposed to any investigational medication within 60 days of the baseline visit, and having any other reason determined by the investigator that may lead to unfavorable risk-benefit, interfere with study compliance, or confound study results.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is diabetes mellitus, type 1. The corresponding ICD-10 codes for this disease are E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, and E10.44. The drugs being tested in this trial are insulin lispro, zp4207 (dasiglucagon), and glucagon. The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include having type 1 diabetes for at least 1 year, being 18 years or older, having a stable prescription medication regimen, using an insulin pump for at least 6 months, and being in good health according to medical assessments. The exclusion criteria include previous exposure to ZP4207 or adverse reaction to glucagon, history of liver disease or abnormal liver function tests, renal failure, anemia, history of coronary artery disease or congestive heart failure, history of transient ischemic attack or stroke, seizure disorder, cystic fibrosis or other pancreatic diseases, other endocrine disorders, use of oral anti-diabetic medications, electronically powered implants, hypertension despite treatment, and inadequate venous access.",
    "The sample from the table represents a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD). The trial is investigating the effectiveness of different drugs in treating COPD. The eligibility criteria for participants include being 40 to 80 years old, having a clinical history of COPD for more than 1 year, being a current or former smoker with a history of at least 10 pack-years of cigarette smoking, and meeting certain lung function criteria. Participants must also be willing to change their current COPD therapy as required by the study protocol. Exclusion criteria include having significant diseases other than COPD, being pregnant or lactating, having a current diagnosis of asthma, and having certain pulmonary diseases or conditions. Other exclusion criteria include having certain cardiac, neurological, or renal conditions, and having a history of alcohol or drug abuse. Participants must also be able to cooperate with the study requirements and instructions.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is Type 2 Diabetes. The corresponding ICD-10 codes for this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are dulaglutide and placebo. The eligibility criteria for participants are listed, including having Type 2 Diabetes for at least 6 months, having an HbA1c level between 7.0% and 10.0%, being on stable doses of metformin for at least 3 months, and having a BMI of 25 or higher. The exclusion criteria include having Type 1 Diabetes, using any glucose-lowering medication other than metformin in the past 3 months, having certain cardiovascular conditions, having liver or pancreas diseases, having a low estimated glomerular filtration rate, and having a high serum calcitonin level.",
    "The sample provided is a record from a table that contains information about a clinical trial. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being used in the trial, and \"criteria\" which describes the eligibility criteria for participants.\n\nIn this specific sample, the phase of the trial is phase 2. The diseases being studied are \"bipolar depression\", \"suicidal ideas\", \"suicidal ideation\", and \"suicide, attempted\". The corresponding ICD-10 codes for these diseases are provided. The drugs being used in the trial include \"nrx-101 oral capsule\", \"lurasidone oral capsule\", \"ketamine intravenous infusion\", and \"saline solution intravenous infusion\". The eligibility criteria for participants are listed, including age requirements, diagnosis of bipolar disorder, presence of suicidal ideation or behavior, specific scores on assessment scales, good general health, birth control requirements for females, body mass index range, stability of concurrent psychotherapy and hypnotic therapy, and exclusion criteria such as pregnancy, substance use disorder, certain psychiatric disorders, cognitive disorders, abnormal physical examination findings, recent medical events, and laboratory abnormalities.\n\nOverall, this sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for participants in a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 2 trial for the treatment of pruritus and atopic dermatitis. The trial involves the use of drugs such as serlopitant high dose, placebo oral tablet, and serlopitant low dose. The eligibility criteria for participants include being male or female aged 13 years or older, experiencing pruritus during the screening period, having a diagnosis of atopic dermatitis, and being in good health according to the investigator's opinion. There are also exclusion criteria, such as prior treatment with the study drug or similar drugs, pruritus caused by reasons other than atopic dermatitis, presence of any medical condition or disability that could interfere with the study, history of hypersensitivity to serlopitant or its components, current pregnancy or being a male partner of a pregnant female, and females of childbearing potential who are unable or unwilling to use adequate contraception or who are breastfeeding.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of relapsing-remitting multiple sclerosis. The trial includes eligibility criteria for participants to be included or excluded. The inclusion criteria include having a diagnosis of relapsing multiple sclerosis, being between the ages of 18 and 65, having experienced one or more relapses within the past 2 years, having an Expanded Disability Status Scale score of 0 to 6, and using effective contraception for women of childbearing potential. The exclusion criteria include having progressive MS, having a disease duration of more than 15 years with an EDSS score of 2 or less, using specific medications or treatments, having allergies or contraindications to certain medications, and having certain medical conditions or infections. The sample also includes information about the drugs being used in the trial, such as evobrutinib and placebo, as well as the icd-10 codes associated with the disease.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on three diseases: dry eye, ocular graft vs host disease, and meibomian gland dysfunction. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being studied in the trial are brimonidine 0.15%, brimonidine 0.075%, and a placebo. \n\nThe eligibility criteria for participants are as follows:\n- Participants must be 18 years or older.\n- They must be capable of giving informed consent.\n- They should have a diagnosis of Meibomian Gland Disease.\n- Women must be post-menopausal for at least 1 year or surgically sterilized. If not, they need to provide a negative urine pregnancy test within 7 days of receiving the first dose of the study drug. They must also use contraception during the study.\n- Participants should not be allergic to Brimonidine or any similar products, or their excipients.\n- They should not be currently receiving any Brimonidine preparation for glaucoma management.\n- They should not have received any experimental systemic medication within the past 30 days.\n- Participants should not have an active ocular infection or ocular allergies.\n- They should not have undergone eyelid surgery or ocular surgery within the past 3 months.\n- Participants should not have a corneal epithelial defect larger than 1 mm2 in either eye.\n- They should not have a history of active drug/alcohol dependence or abuse.\n- Vulnerable populations such as neonates, pregnant women, children, prisoners, institutionalized individuals, or others who may be considered vulnerable populations are excluded from the trial.\n\nThis information provides an overview of the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is myocardial infraction. The ICDCodes associated with this disease are \"I25.2\", \"I21.9\", \"I21.A1\", \"I21.A9\", \"I21.4\", \"I22.2\", and \"I23.8\". The drugs being tested in this trial are fulacimstat (bay1142524) and placebo. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Patients with first ST elevation myocardial infraction (STEMI) treated with primary percutaneous intervention (PCI) or thrombolysis within 24 hours after symptom onset.\n- Diagnosis of STEMI requires the presence of typical clinical symptoms such as chest pain and shortness of breath for more than 20 minutes related to the myocardial infraction, new ST elevation indicating myocardial infraction, and significant elevation in troponin T or I with at least one value above the 99th percentile upper reference limit (URL) and/or elevation creatine kinase (CK) and creatine kinase MB (6-10% of total CK).\n- At the screening period, on day 5 to 9 after MI, patients have to have a LVEF \u2264 45% and an infarct size >10% LV mass (as measured by LGE-MRI, central-blinded evaluation).\n\nExclusion Criteria:\n- Contraindication to perform contrast-enhanced cardiac MRI.\n- LVEF < 20%.\n- History of heart failure or LVEF < 50% before occurrence of the first STEMI.\n- Infarct size > 45% (g/g; LV mass) between 5 and 9 days after myocardial infraction.\n- NYHA (New York Heart Association) class IV at randomization.\n- Any planned cardiac intervention after baseline MRI or any other planned operations.\n- Non-ischemic causes for cardiomyopathy.\n- Diagnosis of atrial fibrillation.\n- Systolic blood pressure < 100 mm Hg or > 180 mm Hg; diastolic blood pressure < 50 mm Hg or >110 mm Hg; heart rate < 50 or >100 beat/minute; mean of triplicate values at randomization.\n- Clinically relevant hepatic dysfunction.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 2. The disease being studied is essential tremor. The icd-10 code associated with this disease is G25.0. The drugs being tested in this trial are sage-217 and placebo. The eligibility criteria for participants include having a diagnosis of essential tremor with specific characteristics, such as bilateral postural and kinetic tremor in the hands and forearms that has been present for more than 5 years. There are also exclusion criteria listed, such as the presence of abnormal neurological signs other than tremor, recent exposure to tremorogenic drugs, or evidence of tremor with psychogenic origin.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is hepatocellular carcinoma. The ICDCodes associated with this disease are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']. The drug being used in the trial is the folfox protocol. \n\nThe eligibility criteria for this trial are listed under \"Criteria.\" The inclusion criteria include a diagnosis of HCC based on the diagnostic criteria used by the European Association for the Study of the Liver (EASL), the presence of at least one measurable tumor lesion according to EASL criteria, diagnosis of major or main portal vein invasion (Vp3 or Vp4), KPS\u226570, no previous treatment, absence of cirrhosis or cirrhotic status of Child-Pugh class A only, and not being amendable to surgical resection, local ablative therapy, or any other cured treatment.\n\nThe sample also includes various laboratory parameters that need to be met, such as platelet count, hemoglobin level, total bilirubin level, serum albumin level, ASL and AST levels, serum creatinine level, INR or PT/APTT levels, and absolute neutrophil count (ANC). Additionally, the patient must have the ability to understand the protocol and provide written informed consent.\n\nThe exclusion criteria include evidence of hepatic decompensation, a known history of HIV, history of organ allograft, known or suspected allergy to the investigational agents or any agent given in association with the trial, cardiac ventricular arrhythmias requiring anti-arrhythmic therapy, evidence of bleeding diathesis, recent gastrointestinal bleeding, serious non-healing wound, ulcer, or bone fracture, and known central nervous system tumors including metastatic brain disease.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating metastatic colorectal cancer. The trial includes eligibility criteria for participants, such as having a documented mismatch repair-proficient cancer of the colorectum and having received at least two prior lines of therapy for metastatic disease. Other criteria include measurable disease, age over 18, ECOG Performance Status of 0 to 1, estimated life expectancy of greater than 3 months, and adequate organ function. Participants must also use an acceptable form of birth control during the study and for 120 days after the final dose of the study drug. The sample also includes exclusion criteria, such as having a known additional malignancy that is progressing or requires active treatment, having known central nervous system metastases or carcinomatous meningitis, and having certain study-specified medical conditions. Other exclusion criteria include active infection requiring systemic therapy, history of active TB, infection with HIV or hepatitis B or C, and history of non-infectious pneumonitis that required steroids. The sample also lists criteria related to the patient's ability to comply with study visits and procedures, as well as criteria related to recent medical treatments and surgeries.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 2. The diseases being studied are \"recurrent b acute lymphoblastic leukemia,\" \"recurrent b lymphoblastic lymphoma,\" \"refractory b acute lymphoblastic leukemia,\" and \"refractory b lymphoblastic lymphoma.\" The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial include cyclophosphamide, cytarabine, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, and vincristine. The eligibility criteria for the trial are also listed, including requirements for patients' disease status, previous treatments, recovery from prior therapy, and various medical parameters such as kidney and liver function.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease mentioned is \"leukemia, myeloid, acute.\" The corresponding ICDCodes for this disease are ['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']. The drug being tested in this trial is \"quizartinib.\" \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- AML patients in first relapse or refractory after all prior therapy\n- Presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood\n- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2\n\nExclusion Criteria:\n- Diagnosis of acute promyelocytic leukemia\n- AML secondary to prior chemotherapy for other neoplasms.\n- Persistent, clinically significant > Grade 1 non-hematologic toxicity from prior AML therapy\n- Prior treatment with a FLT3 targeted therapy\n- Active infection not well controlled by antibacterial, antifungal and/or antiviral therapy",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 2, and the disease mentioned is \"progressive supranuclear palsy\". The icd-10 code associated with this disease is \"G23.1\". The drugs mentioned are \"placebo\" and \"abbv-8e12\". The eligibility criteria include being a male or female participant aged 40 years or older, meeting the criteria for possible or probable progressive supranuclear palsy, having PSP symptoms for less than 5 years, being able to walk 5 steps with minimal assistance, and having an identified reliable study partner. The exclusion criteria include weighing less than 44 kg, having a Mini-Mental State Examination (MMSE) score less than 15, having contraindications or inability to tolerate brain magnetic resonance imaging (MRI), residing at a skilled nursing or dementia care facility, having evidence of any clinically significant neurological disorder other than PSP, having a history of or currently having schizophrenia, schizoaffective disorder or bipolar disorder, and having had a significant illness or infection requiring medical intervention in the past 30 days.",
    "The sample provided is for a phase 2 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial aims to evaluate the effectiveness of various drugs in treating COPD. The inclusion criteria for the trial include being a COPD patient, having a history of smoking, and meeting certain lung function criteria. Patients must also have experienced at least one moderate or severe exacerbation in the 12 months prior to the study and have symptoms of COPD. They should also be on daily maintenance therapy with an ICS/LABA (inhaled corticosteroid/long-acting beta-agonist). \n\nThe exclusion criteria for the trial include having a diagnosis of asthma or other respiratory disorders, being on maintenance bronchodilator therapy only, or being on maintenance triple therapy. Patients who have had a moderate or severe COPD exacerbation within 6 weeks prior to the study or during the run-in period are also excluded. Other exclusion criteria include requiring long-term oxygen therapy, having a history of lung cancer or other respiratory disorders, having certain cardiovascular diseases, having abnormal laboratory values, having significant neurological disease, having unstable concurrent diseases, having renal impairment, having abnormal liver function, being severely obese, having a history of alcohol or substance abuse, and having recently participated in another clinical study with an investigational drug.",
    "The sample is a phase 2 clinical trial for patients with estrogen receptor positive breast cancer. The trial aims to evaluate the effectiveness of the drugs tak-228 and tamoxifen in treating this type of breast cancer. The eligibility criteria for the trial include being 18 years or older, having newly diagnosed ER-positive, HER2-negative breast cancer, and being deemed appropriate for neoadjuvant endocrine therapy by the medical oncologist. Other criteria include having a performance status of \u2264 1, meeting certain laboratory values, being able to swallow oral medications, and giving voluntary written consent. Exclusion criteria include having metastatic disease, other significant comorbidities, HIV infection, hepatitis B or C infection, serious medical or psychiatric illness, recent malignancy, breastfeeding or pregnancy, malabsorption issues, recent treatment with investigational products, poorly controlled diabetes, recent cardiovascular events, significant cardiovascular or pulmonary disease, recent treatment with certain medications, and hypersensitivity to mTOR inhibitors or tamoxifen.",
    "The sample from the table is for a phase 2 trial. The disease being studied is influenza, and the corresponding ICD-10 codes for influenza are ['J11.81', 'J11.82', 'J10.01', 'J10.81', 'J10.82', 'J11.08', 'J11.2']. The drugs being tested in the trial are 'vis410 low dose', 'vis410 high dose', and 'placebo'. The eligibility criteria for the trial include age requirements, specific criteria for women, requirements for male subjects with female partners, positive test for influenza A, presence of respiratory or constitutional symptoms, and timing of symptom onset. The exclusion criteria include recent use of certain medications, weight restrictions, history of certain medical conditions, pregnancy or breastfeeding, hypoxemia, worsening of chronic medical conditions, immunocompromised status, presence of certain diseases, recent use of antiviral therapy, enrollment in other studies, inability to take oral medication, history of alcohol or drug abuse, and unstable chronic medication dosing.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is heart failure, and the corresponding ICD-10 codes for heart failure are provided. The drugs being tested in this trial are neladenoson bialanate (bay1067197) and a placebo. The eligibility criteria for participants in this trial include being 18 years or older, having a diagnosis of chronic heart failure (CHF) with a specific classification and certain levels of NT-proBNP, and meeting certain exclusion criteria such as not having acute de-novo heart failure or requiring certain medical treatments.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of hepatitis C virus infection. The trial includes eligibility criteria for participants, such as having a body mass index (BMI) of at least 18 kg/m^2, having chronic HCV infection for at least 6 months, and having quantifiable HCV RNA at screening. The trial also specifies criteria for individuals who have undergone liver transplant or are listed for liver transplant. Other criteria include having a CPT score of 10 to 12, inclusive, liver imaging within 6 months to exclude hepatocellular carcinoma, and completing the most recent HCV treatment at least 8 weeks prior to screening for treatment-experienced individuals. The sample also includes exclusion criteria, such as having significant medical or psychiatric illness, gastrointestinal disorder or post-operative condition that could interfere with drug absorption, and significant pulmonary or cardiac disease. Other exclusion criteria include a history of organ transplant other than liver or kidney, chronic liver disease of a non-HCV etiology, and inability to exclude hepatocellular carcinoma by imaging. The sample also lists other exclusion criteria related to specific medical conditions, laboratory parameters, and prior exposure to certain medications. It is important to note that there may be additional inclusion and exclusion criteria defined by the protocol of the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested is apatinib mesylate tablet. \n\nThe eligibility criteria for this trial include:\n1. Age between 18 and 75 years.\n2. Confirmed diagnosis of small cell lung cancer.\n3. Previous treatment with at least 2 lines of chemotherapy, including a platinum regimen.\n4. No previous treatment with VEGFR-TKI.\n5. Life expectancy of at least 3 months.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n7. Measurable or evaluable disease status as defined by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), with a size larger than 10 mm in diameter by spiral CT scan.\n8. Adequate hepatic, renal, heart, and hematologic functions.\n9. Negative pregnancy test for women of child-bearing age, with appropriate contraception during the study.\n10. Signed informed consent and willingness to comply with study procedures.\n\nThe exclusion criteria for this trial include:\n1. Patients with non-small cell lung cancer.\n2. Imaging results indicating central tumors invading large vessels, pulmonary cavity, or necrotizing tumors.\n3. Clinical symptoms of brain metastases or meningeal metastasis.\n4. Poorly controlled arterial hypertension.\n5. Grade II or above myocardial ischemia or myocardial infraction, uncontrolled arrhythmias, or severe cardiac insufficiency.\n6. Coagulant function abnormality or bleeding tendency.\n7. Urine protein levels indicating abnormality.\n8. Recent major surgical operations, traumatic injuries, bone fractures, or ulcers.\n9. Recent hemoptysis or bleeding symptoms of clinical significance.\n10. Arterial/venous thrombus events within the past 12 months.\n11. Allergy to any ingredients of Apatinib.\n12. Significant medical illness that may increase the risk associated with participation in the study.\n\nThis sample provides a detailed description of the trial phase, disease, ICDCodes, drug, and the criteria for inclusion and exclusion in the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of rheumatoid arthritis. The trial includes patients who meet specific criteria, such as being between the ages of 18 and 75, having a diagnosis of rheumatoid arthritis, and meeting certain classification criteria for the disease. The patients must also have active disease at both the screening and baseline stages, as defined by joint tenderness, joint swelling, and certain blood markers. Additionally, the patients must have been taking oral MTX (methotrexate) for at least 3 months and have had an inadequate response to it. Up to 50% of the patients may have previously received an approved TNF-inhibiting biologic agent that was not effective or not tolerated. \n\nThere are also exclusion criteria, which include having a known immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency. Patients with certain infections or infection history, such as recent infections requiring treatment or hospitalization, infected joint prosthesis, recurrent herpes zoster or disseminated herpes simplex, or positive tests for HIV or hepatitis B or C, are also excluded. Patients with active or latent, untreated or inadequately treated tuberculosis or pre-existing chronic autoimmune disease are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trials. The record belongs to a phase 2 trial and includes information about the diseases being studied, the corresponding ICD-10 codes, the drug being tested, and the eligibility criteria for participants.\n\nIn this particular trial, the diseases being studied are bladder cancer, pancreas cancer, and cholangiocellular carcinoma. The ICD-10 codes associated with these diseases are provided as well. The drug being tested is trastuzumab emtansine.\n\nThe eligibility criteria for participants in this trial include having histologically confirmed HER2-positive tumors, either locally advanced or metastatic. Participants must have exhausted standard treatment options and undergone at least one prior platinum-based treatment for locally advanced or metastatic tumors. The participant's lesion should be measurable according to RECIST V1.1 on diagnostic CT scan/MRI, and at least one biopsy of the primary tumor or metastatic site is required. Other criteria include Eastern Cooperative Oncology Group (ECOG) performance status, cardiac history, organ function, and life expectancy.\n\nExclusion criteria for this trial include previous exposure to HER2-targeted therapies, focal HER2-expression of less than 30% of positively stained tumor cells, brain metastasis as the sole site of metastatic disease, uncontrolled hypertension or angina pectoris, history of congestive heart failure or myocardial infraction, peripheral neuropathy of Grade 3 or higher, dyspnea at rest, severe systemic disease, history of other malignancy within the last 5 years, concurrent serious infections or known infection with HIV/hepatitis B/hepatitis C, severe hypersensitivity to the drug being tested, clinically significant bleeding, recent major surgical procedure or traumatic injury, and concurrent participation in another therapeutic clinical trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 2, and the disease is psoriasis. The icd-10 codes associated with psoriasis are 'L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', and 'L40.50'. The drugs being studied are risankizumab and placebo for risankizumab. The eligibility criteria for this trial include having a diagnosis of chronic plaque psoriasis for at least 6 months, having stable moderate to severe chronic plaque psoriasis, and meeting specific criteria related to body surface area, Psoriasis Area and Severity Index (PASI) score, and Static Physician Global Assessment (sPGA) score. There are also exclusion criteria, such as not having non-plaque forms of psoriasis, not having current drug-induced psoriasis, and not having active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis. Additionally, previous exposure to BI 655066 is an exclusion criterion.",
    "The sample is a phase 2 trial for the treatment of cystic fibrosis. The trial focuses on patients with CF-associated lung disease who have a documented history of chronic infection with Gram-negative organisms. The patients must be established patients of the Principal Investigator's CF Multi Disciplinary Team and be at least 18 years old with a weight of over 40 kg. Their FEV1 (forced expiratory volume in 1 second) must be greater than 30% of predicted within the 6 months prior to the study exacerbation.\n\nThe trial requires patients to be experiencing a new exacerbation of CF-associated lung disease at the baseline visit, which is determined by the presence of at least 4 symptoms based on the Fuchs' criteria and requiring treatment that includes an aminoglycoside antibiotic.\n\nFemale patients of childbearing potential can participate if they are sexually inactive or using highly effective contraceptive methods. These methods include intrauterine devices, surgical sterilization of the partner, hormonal contraception, or bilateral tubal occlusion. They must agree to remain sexually inactive or use the same birth control method for at least 28 days following the last dose.\n\nFemale patients of non-childbearing potential must have undergone sterilization procedures or be postmenopausal with amenorrhea for at least 1 year. Male subjects must use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study medication.\n\nPatients must be willing and able to comply with all protocol requirements and procedures, including induction of sputum if necessary. They must also provide signed and dated informed consent.\n\nExclusion criteria include hypersensitivity to cysteamine or penicillamine, being a transplant recipient, participation in other interventional clinical research studies within 30 days of baseline, pregnancy or planned pregnancy, breastfeeding, and any other significant disease or disorder that may put the patient at risk or influence the study results.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is Major Depression. The ICDCodes associated with this disease are \"F32.A\", \"F53.0\", \"P91.4\", \"Z13.31\", and \"Z13.32\". The drugs being tested in this trial are \"sage-217\" and \"placebo\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include a diagnosis of Major Depressive Disorder as determined by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). Exclusion criteria include a history of suicide attempt, treatment-resistant depression, active psychosis, history of seizures, and a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is Parkinson's Disease. The ICDCodes associated with this disease are 'G20'. The drugs being used in the trial are 'sage-217', 'levodopa', and 'antiparkinsonian agent(s)'. The eligibility criteria for participants are listed under both inclusion and exclusion criteria. Inclusion criteria include having a diagnosis of idiopathic Parkinson's Disease with a duration of less than 7 years, being on a stable dose of an antiparkinsonian agent, and meeting certain Hoehn and Yahr Stage requirements. Exclusion criteria include having early or advanced Parkinson's Disease, presence of certain disorders or syndromes, history of specific medical treatments, and history of suicidal ideation or impulse control disorder.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2, and the disease being studied is rheumatoid arthritis. The icd-10 codes associated with this disease are M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, and M06.019. The drugs being used in the trial are anti-tnf-alpha, methotrexate, placebo, and ro7123520. \n\nThe eligibility criteria for this trial include a diagnosis of adult-onset rheumatoid arthritis as defined by the ACR 2010 criteria, for at least 6 months before screening. The participant must have moderately to severely active rheumatoid arthritis, as defined by at least 4/28 tender joints and at least 4/28 swollen joints, and a DAS28 score greater than or equal to 3.2. For Part 2 of the trial, active synovitis and/or osteitis must be determined by contrast-enhanced magnetic resonance imaging. Participants must be taking a stable dose of anti-TNF-alpha therapies and stable oral glucocorticoids within 6 weeks of planned randomization. They may also be taking non-steroidal anti-inflammatory drugs (NSAIDs) intermittently or regularly. \n\nExclusion criteria for this trial include recent or scheduled administration of parenteral glucocorticoids, recent joint injections with glucocorticoids or hyaluronic acid, active inflammatory diseases of the joints not related to rheumatoid arthritis, systemic autoimmune diseases other than rheumatoid arthritis, juvenile idiopathic arthritis or juvenile rheumatoid arthritis, active fibromyalgia that makes assessment of rheumatoid arthritis disease activity challenging, functional status class IV according to the ACR 1991 criteria, severe chronic or recurrent viral, bacterial, parasitic, or fungal infections, history of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection, any identified confirmed congenital or acquired immunodeficiency, abnormal laboratory values and liver function test, myocardial infraction within the past 6 months, and severe central or peripheral nervous system diseases.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"deep venous thrombosis\". The associated ICD-10 codes for this disease are \"I81\", \"K64.5\", \"I51.3\", \"I67.6\", \"I74.11\", \"I74.5\", and \"I74.8\". The drug being studied in this trial is \"enoxaparin\". \n\nThe record also includes eligibility criteria for participants in the trial. The inclusion criteria are as follows:\n1. The participant must have an untunneled CVC (central venous catheter) inserted in the internal jugular or femoral vein within the past 24 hours.\n2. The child is expected to stay in the pediatric intensive care unit for at least 48 hours.\n3. The CVC is expected to be required for at least 24 hours.\n4. The participant must be between >36 weeks corrected gestational age and <18 years old.\n\nThe exclusion criteria are as follows:\n1. The participant has coagulopathy, indicated by an international normalized ratio >2.0, activated partial thromboplastin time >50 seconds, or platelet count <50,000/mm3.\n2. The participant has a known bleeding disorder.\n3. The participant has clinically relevant bleeding, as defined by the International Society on Thrombosis and Hemostasis, such as a decrease in hemoglobin \u22652 g/dl in 24 hours, requiring medical or surgical intervention to restore hemostasis, or occurring in a critical organ system (e.g., retroperitoneum, pulmonary, intracranial, or central nervous system).\n4. The participant has experienced a clinically relevant bleeding event within the past 60 days.\n5. The participant is within 7 days after trauma or surgery.\n6. The participant is anticipated to undergo surgery within 48 hours after insertion of the CVC.\n7. The participant has renal failure, indicated by a creatinine clearance <30 mL/min.\n8. The participant has an epidural catheter in place.\n9. The participant is currently taking an antithrombotic agent, such as low molecular weight heparin (LMWH), unfractionated heparin (UFH) at therapeutic doses, Coumadin, or aspirin.\n10. The participant has a radiologically documented deep vein thrombosis (DVT) at the site of CVC insertion within the previous 6 weeks.\n11. The participant has a known hypersensitivity to heparin or its components, including pork products.\n12. The participant has a history of heparin-induced thrombocytopenia (HIT), as indicated by a positive serotonin release assay.\n13. The participant is currently pregnant.\n14. The participant is currently lactating.\n15. The participant has previously been enrolled in the study.\n16. The participant has a limitation of care.\n\nThis information provides a detailed description of the sample record in natural language.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is \"lymphoma, large b-cell, diffuse.\" The ICDCodes associated with this disease are \"S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S.\" The drugs being used in the trial are \"durvalumab, rituximab, doxorubicin, vincristine, cyclophosphamide, prednisone, lenalidomide.\" \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n1. The subject must have CD20+Diffuse Large B-Cell Lymphoma.\n2. The subject must have Ann Arbor stage 3 or 4 or stage 2 with bulky disease.\n3. The subject must have high or high-intermediate disease risk.\n4. The subject must not have received any prior anti-lymphoma treatment.\n5. The subject must be willing and able to undergo a biopsy.\n6. The investigator must consider R-CHOP immunochemotherapy appropriate.\n7. The subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n8. The subject must have adequate hematology laboratory results (absolute neutrophil count \u2265 1.5 * 10^9/L, platelet count \u2265 75 * 10^9/L, hemoglobin \u2265 10.0 g/dL).\n9. The subject must have adequate biochemistry laboratory results (AST/SGOT and ALT/SGPT \u2264 3.0 * upper limit of normal; bilirubin \u2264 2.0 mg/dL; creatinine clearance of \u2265 40 mL/min).\n10. The subject must have bi-dimensionally measurable disease (> 2.0 cm).\n11. The subject must be using effective contraception.\n\nExclusion Criteria:\n1. The subject must not have a diagnosis of lymphoma other than Diffuse Large B-Cell Lymphoma.\n2. The subject must not have composite lymphoma or transformed lymphoma.\n3. The subject must not have primary or secondary Central Nervous System involvement by lymphoma.\n4. The subject must not have a seropositive or active viral infection with hepatitis B virus, human immunodeficiency virus, or hepatitis C virus.\n5. The subject must not have a history of other malignancies, unless disease-free for \u2265 5 years.\n6. The subject must not have a left ventricular ejection fraction < 50%.\n7. The subject must not have peripheral neuropathy \u2265 Grade 2.\n8. The subject must not have prior use of lenalidomide or monoclonal antibodies against CTLA-4, PD-1, or PD-L1.\n9. The subject must not be at high risk of developing thromboembolic events and unwilling to take venous thromboembolism prophylaxis.\n10. The subject must not have current or prior documented autoimmune or inflammatory disorders within the past 3 years.\n11. The subject must not have current or prior use of immunosuppressive medication within 28 days before the start of treatment.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on studying the effects of a drug called medi6012 on patients with atherosclerosis and cardiovascular disease. The diseases are represented by their respective ICD-10 codes. The trial involves several different doses of the drug and also includes a placebo. The eligibility criteria for participants are listed, including requirements such as non-childbearing potential, a diagnosis of stable atherosclerotic CVD, and currently receiving a stable dose of Statin. There are also exclusion criteria listed, which include factors such as recent cardiovascular conditions, planned arterial revascularization, abnormal ECG results, and various other medical conditions or history that may affect the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for participants in the trial.\n\nIn this specific sample, the phase of the trial is listed as \"phase 1/phase 2\". The disease being studied is \"psoriasis\" and its corresponding ICD-10 codes are listed as \"['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']\". The drugs being tested are \"gsk2981278 ointment\" and \"vehicle ointment\". The eligibility criteria for participants are then listed, including age requirements, specific criteria related to the severity and location of the psoriasis, contraception requirements for male participants with female partners, and criteria for female participants based on reproductive potential and menopausal status. The exclusion criteria are also provided, which include specific conditions, medical history, and test results that would disqualify a participant from the trial.\n\nOverall, this sample provides a snapshot of a clinical trial focused on psoriasis, including the phase of the trial, the diseases being studied, the drugs being tested, and the eligibility and exclusion criteria for participants.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is \"osteoarthritis of the knee.\" The icd-10 codes associated with this disease are ['M15.4', 'M15.0', 'M16.9', 'M17.9', 'M19.011', 'M19.012', 'M19.019']. The drugs mentioned are 'tlc599 ld group', 'normal saline', and 'tlc599 hd group'. The eligibility criteria are listed under \"Main Inclusion Criteria\" and \"Main Exclusion Criteria.\" The inclusion criteria include factors such as age, documented diagnosis of knee osteoarthritis, severity of OA, and willingness to comply with study procedures. The exclusion criteria include factors such as recent use of corticosteroids, prohibited medications, autoimmune diseases, knee arthritis history, and unstable knee joint, among others.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of metastatic colorectal cancer. The trial involves the use of two drugs, durvalumab and tremelimumab. The eligibility criteria for participants include having an ECOG performance status of 0 or 1, histologic confirmation of colorectal adenocarcinoma, microsatellite stable tumor, evidence of measurable metastatic disease, and accessible metastatic lesion for pretreatment core biopsy. Participants must have also received oxaliplatin and irinotecan as part of standard metastatic chemotherapy regimens. Other criteria include specific blood count levels, adequate hepatic and renal function, and absence of certain cardiac conditions. Exclusion criteria include certain types of cancer, previous therapy with PD-1 or PD-L1 inhibitors, active infections, inflammatory diseases, and autoimmune diseases. Participants must also agree to use contraception if of reproductive potential and not be pregnant or lactating. The sample also includes criteria related to medication use, cardiac conditions, and other medical conditions that may preclude participation.",
    "The sample from the table represents a clinical trial study. The table contains information about the different phases of the trial (phase I, phase II, or phase III), the diseases being studied, the corresponding ICD-10 codes for the diseases, the drugs being tested, and the eligibility criteria for participants.\n\nIn this specific sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include anemia, B-cell prolymphocytic leukemia, various grades of follicular lymphoma, hairy cell leukemia, lymphoplasmacytic lymphoma, mantle cell lymphoma, marginal zone lymphoma, and different types of chronic lymphocytic leukemia. The corresponding ICD-10 codes for these diseases are also provided.\n\nThe drug being tested in this sample is entospletinib. The eligibility criteria for participants include specific diagnostic criteria for each disease, previous treatment regimens, disease progression or lack of response to previous treatments, and meeting certain criteria for requiring treatment based on the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 guidelines.\n\nThe exclusion criteria include prior therapeutic interventions, inadequate recovery from adverse events related to previous therapy, chronic use of corticosteroids, history of certain malignancies, uncontrolled immune hemolysis or thrombocytopenia, history of HIV infection or active hepatitis B or C, major surgery within the past 2 weeks, inability to swallow oral medication, ongoing therapy with proton pump inhibitors, active uncontrolled infection, pregnancy or lactation in women, and fertile men or women of childbearing potential without effective contraception.\n\nOverall, this sample provides information about the phase, diseases, drugs, and eligibility criteria for participants in a clinical trial study.",
    "The sample provided is for a phase 2 clinical trial related to analgesia. The trial is specifically focused on patients who are scheduled to undergo primary bilateral submuscular augmentation mammoplasty with saline or silicone smooth implants. The trial aims to evaluate the effectiveness of different drugs in providing pain relief after the surgery.\n\nThe inclusion criteria for the trial state that the patients must have a scheduled surgery for breast augmentation with specific implant volumes and types. They should also have an American Society of Anesthesiologists Physical Status of I, II, or III. Additionally, the patients must not be pregnant, lactating, planning to become pregnant during the study, sterile, or using acceptable contraceptives.\n\nOn the other hand, the exclusion criteria state that patients with planned concurrent surgical procedures or reconstructive procedures post breast cancer therapy are not eligible. Patients with pre-existing painful physical/restrictive conditions, contraindications or hypersensitivity to the study medication, daily use of opioids, recent use of NSAIDs or bupivacaine, or recent use of local anesthetics are also excluded. Patients who have initiated treatment with certain medications within a month prior to the study, have certain medical conditions, have a history of Hepatitis B, Hepatitis C, or HIV, have uncontrolled anxiety or psychiatric/neurological disorders, have chronic neuromuscular deficits, have chronic conditions that compromise neurological or vascular assessments, have had malignancies in the last year (except for specific cases), have a history of drug or alcohol abuse, have received investigational products or devices in a clinical trial recently, have undergone multiple surgeries in a short period, or have a body mass index (BMI) greater than 35 kg/m2 are also excluded from the trial.\n\nThis description provides an overview of the phase 2 trial, the specific disease being studied (analgesia), the drugs being tested (htx-011, bupivacaine hcl without epinephrine, saline placebo), and the eligibility criteria for participation in the trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is atopic dermatitis. The ICDCodes associated with atopic dermatitis are 'L20.89' and 'L20.9'. The drugs being used in the trial include 'ruxolitinib cream', 'triamcinolone 0.1% cream', and a vehicle cream. The eligibility criteria for this trial include specific requirements for subjects diagnosed with atopic dermatitis, such as having a history of the disease for at least 2 years and meeting certain assessment scores and body surface area involvement. There are also exclusion criteria, such as active infections, recent use of topical treatments, and the presence of other dermatologic or non-dermatologic diseases that could complicate the assessment. Additionally, subjects with certain blood cell counts, liver or kidney impairments, or previous use of Janus kinase inhibitors are excluded from the trial.",
    "The sample from the table represents a phase 2 clinical trial for asthma. The trial is focused on evaluating the efficacy and safety of different drugs in treating asthma. The eligibility criteria for participants include being 18 years or older, having a diagnosis of asthma for at least 6 months, and having a specific score on the Asthma Control Questionnaire. Participants must also be on a specific medication regimen for at least 12 weeks prior to the trial and meet certain lung function criteria.\n\nThe sample also includes exclusion criteria, such as recent pneumonia or severe asthma exacerbation, as well as various medical conditions that could put the participant at risk or affect the study results. Other factors, such as pregnancy, smoking history, and history of alcohol or drug abuse, are also considered in the eligibility criteria.\n\nOverall, the sample provides detailed information about the phase 2 trial, including the diseases being studied, the drugs being tested, and the specific criteria for participant inclusion and exclusion.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is metastatic renal cell carcinoma. The ICD-10 codes associated with this disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drug being tested in the trial is nivolumab. \n\nThe eligibility criteria for the trial include being an adult man or woman over 18 years old, having a histologically confirmed renal cell carcinoma with a clear-cell component, having metastatic renal cell carcinoma with at least one measurable lesion, and having received at least one prior systemic anti-angiogenic treatment. Other criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower, being in the favorable, intermediate, or poor risk group according to the international metastatic renal cell carcinoma database consortium (IMDC) model, and not having certain conditions such as active autoimmune disease, uncontrolled adrenal insufficiency, or positive tests for HIV or hepatitis B/C. \n\nExclusion criteria include having received prior therapy with certain antibodies or drugs targeting T-cell co-stimulation or checkpoint pathways, receiving non-oncology vaccine therapy within 4 weeks of the first dose of study drug, and having other prior malignancy active within the previous 3 years. Other exclusion criteria include having altered hematopoietic or organ function, a history of hypersensitivity to other monoclonal antibodies or the study drug, known drug or alcohol abuse, and certain medical conditions that would make the administration of the study drug hazardous or interfere with compliance.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease is \"analgesia\". The ICDCodes associated with the disease are \"P04.0\". The drugs being studied in this trial are \"htx-011\", \"saline placebo\", \"bupivicaine hcl\", and \"ropivacaine\". The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include factors such as the type of surgery the participant is scheduled for, their physical status, ability to walk unassisted, pregnancy status, previous medication use, medical conditions, and history of drug abuse.",
    "The sample from the table represents a clinical trial for a drug aimed at treating social anxiety disorder and performance anxiety. The trial is in phase 2/phase 3. The eligibility criteria for participants include being between the ages of 18 and 65, meeting the DSM-5 criteria for social anxiety disorder, having a specific score on the LSAS public speaking subscale, and being medically and neurologically healthy. Exclusion criteria include being pregnant or breastfeeding, having a history of substance abuse disorder, having certain dental conditions, and having certain medical conditions or abnormal laboratory test results. Participants must also provide written informed consent.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the adjunctive treatment of major depressive disorder. The associated ICD-10 codes for the diseases are ['F25.1', 'F32.89', 'F33.8', 'F33.0', 'F33.1', 'F33.9', 'F32.0']. The drug being studied is pimavanserin. The eligibility criteria for this trial include being an adult patient aged 18 years and above, having a clinical diagnosis of major depressive disorder, and currently being treated with one of the specified SSRI or SNRI antidepressants as monotherapy. Inadequate response to previous antidepressant treatments is also a requirement. There are exclusion criteria as well, such as having a psychotic disorder other than MDD, having certain serious or unstable medical conditions, and a history or symptoms of long QT syndrome. Patients will be evaluated during screening to ensure they meet all the necessary criteria for study participation.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of chronic hepatitis C. The ICD-10 codes associated with the disease are ['B18.2', 'B18.0', 'B18.1', 'B18.8', 'B18.9', 'K71.3', 'K71.4']. The drugs being tested in the trial are danoprevir, ritonavir, peginterferon alfa-2a, and ribavirin (rbv). The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having chronic HCV infection, positive HCV antibody, specific HCV RNA levels, and not having received prior treatment for HCV. Exclusion criteria include having liver cirrhosis, other chronic liver diseases, a history of liver cell cancer, and certain positive antibody tests.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of chronic hepatitis C. The trial involves the use of drugs such as ravidasvir, danoprevir, ritonavir, and ribavirin. The eligibility criteria for participants include being willing and able to provide written informed consent, having chronic hepatitis C infection for at least 6 months with a certain level of HCV RNA, and never having received prior treatment for HCV with interferon, RBV, or other antivirals. Other criteria include having chronic liver disease consistent with CHC infection without cirrhosis, using effective contraception for male patients with female partners of childbearing potential, and meeting additional criteria specified in the detailed protocol. The exclusion criteria include being pregnant or lactating, having decompensated liver disease, having non-hepatitis C chronic liver disease, testing positive for hepatitis B surface antigen or HIV antibody, having liver cirrhosis, having severe psychiatric or cardiac disease, having a history of active malignancy within the last 5 years (except for localized or in situ carcinoma), having an increased risk for anemia, having pre-existing renal disease (with the exception of nephrolithiasis), and meeting other criteria specified in the detailed protocol.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the treatment of migraine and caffeine withdrawal. The ICD-10 codes associated with these diseases are ['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']. The drug being studied is caffeine. The sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include having a migraine for at least 1 year, experiencing at least 3 migraine attacks per month, not using migraine prophylaxis in the last month, consuming between 300 mg and 800 mg of caffeine per day in the last month, and providing signed consent. Exclusion criteria include suspicion of medication-overuse headache, pregnancy or breastfeeding, serious co-morbidity or conditions requiring medical treatment or caution, working night shift, and use of drugs with moderate or major interactions with caffeine.",
    "The sample from the table is a clinical trial for the treatment of non-small-cell lung carcinoma. The trial is in phase 1/phase 2 and involves the drugs atezolizumab and daratumumab. The eligibility criteria for participants include having a performance status of 0 or 1, having advanced or metastatic non-small cell lung cancer, having measurable disease, and specific tumor cell programmed death-ligand 1 (PD-L1) scores. Women of childbearing potential must have a negative pregnancy test. There are also inclusion and exclusion criteria for participants who are eligible for crossover. The exclusion criteria include previous use of certain prescribed medications or therapies, seropositivity for HIV, prior organ transplant, severe allergic reactions to certain antibodies or fusion proteins, and active hepatitis B or C. The exclusion criteria for crossover include receiving subsequent anti-cancer therapies and recent radiation therapy.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on small cell lung cancer. The ICD-10 codes associated with the disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being studied in the trial are ipilimumab, nivolumab, and rovalpituzumab tesirine. The sample also includes the eligibility criteria for participants. Inclusion criteria include having histologically or cytologically confirmed extensive-stage small cell lung cancer with progressive disease after at least one platinum-based chemotherapeutic regimen and having evaluable or measurable disease. Participants should also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and adequate hematologic, hepatic, and renal function. Exclusion criteria include having active, known, or suspected autoimmune disease and prior exposure to an immuno-oncology or pyrrolobenzodiazepine (PBD)-based drug.",
    "The sample from the table is for a phase 2 trial. The disease being studied is chronic obstructive pulmonary disease (COPD) moderate. The ICD-10 codes associated with this disease are G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, and N13.8. The drugs being tested in the trial are 1.5 mg rpl554 plus tiotropium, 6 mg rpl554 plus tiotropium, and placebo plus tiotropium. \n\nThe eligibility criteria for participants in the trial are as follows:\n1. Participants must sign an informed consent document and be willing to participate in the study.\n2. Participants must be between the ages of 40 and 75.\n3. Male participants must agree to certain restrictions regarding sexual activity.\n4. Female participants must either be post-menopausal or use a highly effective method of contraception.\n5. Participants must meet certain criteria related to their heart health, including specific ECG measurements.\n6. Participants must have a screening Holter report that shows no significant abnormalities.\n7. Participants must be able to comply with all study restrictions and procedures.\n8. Participants must have a BMI between 18 and 33 kg/m2.\n9. Participants must have a diagnosis of COPD and meet certain spirometry criteria.\n10. Participants must have had stable COPD in the 4 weeks prior to screening.\n11. Participants must have a chest X-ray that shows no clinically significant abnormalities unrelated to COPD.\n12. Participants must meet certain medication restrictions.\n13. Participants must have a smoking history of at least 10 pack years.\n14. Participants must be able to withdraw from certain bronchodilators for the duration of the study.\n \nThere are also exclusion criteria that would make a participant ineligible for the trial. These include a history of life-threatening COPD exacerbation, recent hospitalizations for COPD, lactation, pregnancy, hypersensitivity to the drugs being tested, and various other medical conditions or factors that would make a participant unsuitable for the study.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease is urothelial carcinoma. The ICDCodes associated with the disease are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']. The drugs being studied in this trial are moxr0916 and atezolizumab. The eligibility criteria for participants include age over 18, ECOG performance status of 2 or lower, life expectancy of at least 12 weeks, confirmed diagnosis of locally advanced or metastatic urothelial carcinoma, availability of a tumor specimen, no prior systemic therapy for the disease, and ineligibility for cisplatin-based chemotherapy based on specific criteria. The sample also includes exclusion criteria such as significant cardiovascular disease, clinically significant liver disease, recent anti-cancer therapy, prior treatment with certain therapeutic antibodies, untreated or active central nervous system metastases, history of certain diseases or infections, and prior transplantation.",
    "The sample from the table is for a phase 2 trial. The disease being studied is \"stress disorders, post-traumatic\" and it is identified by the ICD-10 codes \"F43.10\", \"F43.11\", and \"F43.12\". The drugs being tested in this trial are \"brexpiprazole (opc-34712)\" and \"sertraline\". The eligibility criteria for inclusion in the trial are being a male or female between the ages of 18-65 with a diagnosis of PTSD. The exclusion criteria include having an index trauma event more than 15 years before screening, having an index trauma event at age younger than 16, and experiencing any traumatic event within 3 months of screening.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on autism and autism spectrum disorder. The associated ICD-10 codes for these diseases are \"Z13.41\" and \"Z16.12\" respectively. The drugs being studied in this trial include different doses of oxytocin and a placebo. \n\nThe eligibility criteria for participants with autism spectrum disorder (ASD) include having a diagnosis based on the Autism Diagnostic Observation Schedule (ADOS) and Autism Diagnostic Interview (ADI) criteria, with an IQ greater than 70, and normal or corrected-to-normal vision. Exclusion criteria for ASD participants include recent seizures, brain damage or head trauma (at the discretion of the principal investigator and sponsor), color blindness, cardiovascular disease, severe medical problems, severe mental retardation, alcoholism or substance abuse, asthma (if infrequent episodes and no active problems at the time of the study), migraine headaches (at the discretion of the nurse practitioner or study physician), claustrophobia (at the discretion of the study physician/designee/PI), and the presence of pacemakers, cochlear implants, surgical clips, or metal fragments.\n\nThe eligibility criteria for healthy age-matched controls include an IQ greater than 70 and normal or corrected-to-normal vision. Exclusion criteria for healthy controls include a history of seizures, neurological disorder, current or previous psychiatric disorder (at the discretion of the principal investigator), current or previous use of psychoactive drugs (at the discretion of the principal investigator), head trauma (at the discretion of the principal investigator), alcoholism or substance abuse, cardiovascular disease, color blindness, asthma (if infrequent episodes and no active problems at the time of the study), migraine headaches (at the discretion of the nurse practitioner or study physician), claustrophobia (at the discretion of the study physician/designee/PI), the presence of a severe medical problem, severe mental retardation, and the presence of pacemakers, cochlear implants, surgical clips, or metal fragments.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of recurrent glioblastoma, a type of brain tumor. The trial uses a combination of drugs, specifically disulfiram/copper and temozolomide (tmz). The eligibility criteria for participants include having a confirmed diagnosis of glioblastoma, completing radiation therapy with concurrent TMZ at least 12 weeks prior to the start of the trial (unless there is evidence of recurrent tumor), experiencing tumor progression within 3 months of the last dose of TMZ, having a Karnofsky performance status of at least 60%, abstaining from alcohol consumption, recovering from prior therapy's toxic effects, meeting specific laboratory criteria, and using an acceptable method of birth control for females of childbearing potential. The exclusion criteria include having certain types of brain tumors, being enrolled in another clinical trial within the past 4 weeks, receiving multiple courses of radiation therapy or a total dose of 75 Gy, having a history of allergic reactions to specific medications, having certain medical conditions or symptoms, and being pregnant or breastfeeding.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and is focused on the treatment of neovascular age-related macular degeneration and wet macular degeneration. The ICD-10 codes associated with these diseases are provided. The drug being studied is dorzolamide-timolol. The sample also includes the eligibility criteria for participants, including requirements such as having active choroidal neovascularization, prior treatment with anti-VEGF agents, specific baseline retinal thickness, and written informed consent. There are also exclusion criteria listed, such as a history of uveitis, certain eye conditions, recent eye surgeries, and allergies to sulfonamide.",
    "The sample from the table is for a phase 2 trial. The disease being studied is hepatitis C virus infection. The corresponding ICD-10 codes for this disease are B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, and B17.2. The drug being tested in this trial is ldv/sof. The eligibility criteria for participants include being chronically infected with HCV genotype 1, 2 (Taiwan only), 4, 5, or 6, being male or nonpregnant/nonlactating females aged 18 years or older, and being on dialysis for end-stage renal disease (ESRD). Additionally, adults with HIV coinfection are eligible if they are suppressed on a stable, protocol-approved antiretroviral (ARV) regimen for at least 8 weeks prior to screening.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is chronic hepatitis C. The ICD-10 codes associated with this disease are B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, and K71.4. The drug being tested is called sof/vel. The eligibility criteria for participants include being chronically infected with HCV, being male or a non-pregnant/non-lactating female aged 18 years or older, and being on dialysis for end-stage renal disease (ESRD). Additionally, adults with HIV co-infection are eligible if they have been on a stable, protocol-approved antiretroviral (ARV) regimen for at least 8 weeks prior to screening.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on the disease \"heterozygous familial hypercholesterolemia\" and the associated ICD-10 codes are \"E78.01\", \"E78.00\", and \"Z83.42\". The drugs being studied are \"mgl-3196\" and \"placebo\". \n\nThe inclusion criteria for the trial include being willing to participate and providing written informed consent, being an adult aged 18 years or older, having a negative pregnancy test for female patients of childbearing potential, using effective birth control methods, having a diagnosis of HeFH by genetic testing or meeting specific diagnostic criteria, having a fasting LDL-C level of at least 2.6 mmol/L, and being on a stable or maximally tolerated dose of an approved statin.\n\nThe exclusion criteria for the trial include having homozygous familial hypercholesterolemia, undergoing LDL or plasma apheresis within the past 2 months, having severe heart failure or a low left ventricular ejection fraction, having uncontrolled cardiac arrhythmia, having had a recent myocardial infraction, unstable angina, or stroke, having type 1 diabetes or poorly controlled type 2 diabetes, having a history of significant alcohol consumption, being on thyroid replacement therapy, having chronic liver disease or hepatitis B or C, having abnormal liver or kidney function, having a history of biliary diversion, being positive for HIV infection, having a history of malignant hypertension, having high blood pressure, having high triglyceride levels, having a serious medical condition with a life expectancy of less than 2 years, having a history of substance abuse, participating in another drug trial within the past 30 days, or having any other condition that may impede compliance or compromise the patient's well-being.\n\nThis description provides an overview of the phase 2 trial, the specific disease being studied, the drugs involved, and the eligibility criteria for participants.",
    "The sample from the table represents a phase 2 clinical trial. The diseases being studied include non-squamous non-small cell lung cancer (NSCLC), adenocarcinoma of the lung, and squamous cell lung cancer. The corresponding ICD-10 codes for these diseases are provided. The drugs being investigated in the trial are docetaxel, nivolumab, gemcitabine, and pemetrexed. The eligibility criteria for participants include factors such as age, performance status, histological confirmation of lung cancer, measurable disease, previous treatment history, organ function, and pregnancy status. There are also exclusion criteria, such as prior treatment with certain chemotherapy agents, autoimmune complications, active infections, pregnancy or breastfeeding, and certain medical conditions.",
    "The sample from the table is for a phase 2 clinical trial for ovarian cancer. The eligibility criteria for participants include being a non-pregnant female adult at least 18 years old, having histologically confirmed serous epithelial ovarian cancer with peritoneal metastases, and having platinum resistant/refractory disease. Participants must also have measurable disease, a performance status of 0 or 1, and adequate hematologic and organ function. Effective contraception is required for women of child-bearing potential. The estimated life expectancy should be at least 6 months, and participants must be willing and able to comply with study procedures. Exclusion criteria include certain types of tumors, central nervous system metastases, significant pleural disease/effusion, and certain medical conditions or history. Participants must not have had previous participation in a clinical study of Kevetrin.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on several diseases, including gastro-enteropancreatic neuroendocrine tumor, pancreatic cancer, neuroendocrine carcinomas of the pancreas, and islet cell carcinoma. The diseases are associated with specific ICD-10 codes. The trial involves the use of two drugs, folfirinox and granulocyte colony-stimulating factor (g-csf). The eligibility criteria for participants are listed, including requirements such as histologically or cytologically confirmed neuroendocrine carcinoma, a Ki-67 index greater than 20%, metastatic disease, measurable disease, and Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. There are also exclusion criteria, such as recent chemotherapy or radiotherapy, untreated brain or meningeal metastases, and uncontrolled intercurrent illnesses. Additionally, participants with childbearing potential must be willing to use adequate contraception precautions during the study and for 3 months after stopping study chemotherapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are small cell lung cancer and extensive-stage small cell lung cancer. The ICDCodes associated with these diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are ipilimumab and nivolumab. \n\nThe eligibility criteria for participants in this trial include having a signed written informed consent, being willing and able to comply with scheduled visits and other study requirements, having small cell lung cancer confirmed by histology or cytology, presenting with extensive-stage disease at initial diagnosis, having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, having received 4-6 cycles of platinum-based first-line chemotherapy with an ongoing response of complete response, partial response, or stable disease, initiating study treatment with thoracic radiation therapy within 8 weeks from the last dose of chemotherapy, and having a tumor tissue sample available for biomarker evaluation.\n\nThere are also exclusion criteria, such as participants with previous brain metastases, participants who have received prior chest radiation that precludes delivery of protocol radiation therapy, participants with carcinomatous meningitis, participants with uncontrollable pleural effusion, and participants with unresolved toxicities from previous anti-cancer therapy. Other exclusion criteria include pregnancy or breastfeeding, active autoimmune disease, systemic treatment with corticosteroids or immunosuppressive medications, prior therapy with certain antibodies or drugs targeting T cell co-stimulation or checkpoint pathways, symptomatic interstitial lung disease, and various other medical conditions that may increase the risk associated with study participation or interfere with safety results.\n\nIt is important to note that additional criteria may apply, but they are not specified in the provided sample.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has several columns including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases, \"icdcodes\" which lists the ICD-10 codes associated with the diseases, \"drugs\" which lists the names of drugs, and \"criteria\" which provides the eligibility criteria for the trial.\n\nThe sample data in the table includes information for a specific trial. The phase of the trial is \"phase 2\" and the disease listed is \"amyloidosis\". The associated ICD-10 codes for amyloidosis are provided. The drug being used in the trial is \"gsk2315698 (cphpc)\". The eligibility criteria for the trial are also listed, including age requirements, contraception requirements for male subjects, and various criteria related to the specific disease being studied.\n\nThe sample also includes inclusion and exclusion criteria for different groups within the trial. For example, there are specific criteria for Group 1, Group 2, and Group 3, each with their own requirements and restrictions. These criteria include factors such as disease confirmation, clinical stability, previous treatments, and various medical conditions that may exclude individuals from participating in the trial.\n\nOverall, the sample provides a comprehensive overview of the schema definition and includes specific information about a trial related to amyloidosis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The diseases being studied include estrogen receptor negative, her2/neu negative, progesterone receptor negative, recurrent breast carcinoma, stage iii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer, and triple-negative breast carcinoma. The ICDCodes associated with these diseases are also provided. The drug being used in the trial is capecitabine. The eligibility criteria for participants in this trial include specific disease characteristics, performance status, life expectancy, laboratory test results, and various other factors. Exclusion criteria are also listed, which outline conditions that would disqualify a patient from participating in the trial.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is cystic fibrosis. The ICD-10 codes associated with the disease are E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, and P09.4. The drugs being tested in the trial are glpg2222 150 mg q.d., glpg2222 300 mg q.d., and a placebo. The eligibility criteria for participants include being at least 18 years old, having a confirmed clinical diagnosis of CF, having specific mutations in the CFTR gene, weighing at least 40 kg, and having a stable concomitant treatment for at least 4 weeks. Exclusion criteria include having unstable or uncontrolled chronic diseases, recent respiratory tract infection, need for supplemental oxygen, history of hepatic cirrhosis, abnormal liver function, and low estimated creatinine clearance.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is appendicitis. The ICD-10 codes associated with the disease are K36, K37, K35.80, K35.20, K35.21, K35.890, and K35.891. The drug being tested is a combination of fosfomycin, metronidazole, and GM-CSF administered intraperitoneally. \n\nThe sample also includes the eligibility criteria for the trial. The inclusion criteria state that men who are 18 years or older and suspected of having acute appendicitis and planned for diagnostic laparoscopy and eventual appendectomy are eligible. They must also provide written informed consent. \n\nThe exclusion criteria list various conditions that would disqualify a participant from the trial, such as not being able to understand, read, or speak Danish, previous allergic reactions to the drugs being tested, perforated appendicitis, normal appendix not requiring appendectomy, other intra-abdominal pathology requiring surgical intervention, known renal or hepatic disease, known autoimmune disease or chronic inflammation, known hematologic disease or cancer, previous abdominal surgery, use of certain medications during the trial period, use of other antimicrobial agents before and after the trial treatment, participation in another drug trial within a month prior to surgery, body mass index \u226535 kg/m2, and weekly intake of alcohol exceeding 14 units.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of malignant pleural mesothelioma. The trial is investigating the use of the drugs nivolumab and ipilimumab. The eligibility criteria for participants include being at least 18 years old, having a confirmed diagnosis of recurrent MPM, having progressive disease after prior treatment, and meeting certain laboratory and organ function requirements. There are also exclusion criteria, such as having certain medical conditions or prior treatments. The sample includes both the inclusion and exclusion criteria in a detailed format.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is hypercholesterolemia. The corresponding ICD-10 codes for this disease are E78.01, E78.00, and Z83.42. The drugs being tested in this trial are bempedoic acid 180mg, ezetimibe 10mg, and atorvastatin 20mg. The eligibility criteria for inclusion in the trial include having a fasting LDL-cholesterol level between 130-189 mg/dL after discontinuing all LDL-C-lowering drugs and nutritional supplements, being a nonpregnant, nonlactating man or woman, and being able to undergo a 12-week washout period for all LDL-C-lowering drugs and nutritional supplements. The exclusion criteria include having fasting blood triglycerides greater than or equal to 400 mg/dL, a body mass index (BMI) greater than 50 kg/m2, a history of clinically significant cardiovascular disease, and a history of type 1 or type 2 diabetes.",
    "The sample is a phase 2 trial for the treatment of depressive disorders, specifically major depressive disorder and treatment-resistant depressive disorder. The trial involves the use of two drugs, rel-1017 and placebo. The eligibility criteria for participants include being between 18 and 65 years old, having a diagnosis of recurrent major depressive disorder, experiencing a current major depressive episode lasting 8 weeks to 36 months, and having an inadequate response to previous antidepressant treatments. Other criteria include specific requirements for dosage and duration of previous antidepressant treatment, certain scores on the Hamilton Depression Rating Scale, and specific BMI and weight ranges. Participants must also meet certain language and contraception requirements and provide written informed consent. Exclusion criteria include various medical conditions, history of certain disorders, use of certain medications, and recent participation in other clinical studies.",
    "The sample from the table is for a phase 2 clinical trial for breast cancer. The eligibility criteria for participants include having histologically or cytologically confirmed Stage IV invasive breast cancer, having at least one evaluable lesion that is not within a previously radiated field, and having HR positive, HER2-negative breast cancer. Participants must have already received or been intolerant to at least two lines of hormonal therapies or be appropriate candidates for chemotherapy. Prior chemotherapy, biologic therapy, hormonal therapy, radiation therapy, and targeted therapy must have been discontinued for a certain period of time before initiation of study therapy. Participants must also meet certain organ and marrow function requirements. Women of child-bearing potential and men must agree to use adequate contraception during the study and for a certain period of time after the last dose of the study drugs. There are also exclusion criteria, such as unresolved chemotherapy-related or radiation-related toxicities, receiving any other investigational agents, previous treatment with eribulin mesylate or any anti-PD-1, PD-L1, or PD-L2 agent, and certain medical conditions or illnesses. The sample also includes information on the effects of the study drugs on the developing human fetus and requirements for pregnancy testing.",
    "The sample from the table represents a phase 2 clinical trial for patients with stage IIIA non-small cell lung cancer. The trial involves the use of pembrolizumab, cisplatin, and paclitaxel as drugs. The eligibility criteria for participants include being 18 years of age or older, having undergone complete resection after neoadjuvant CCRT within the past 6 weeks, and having a performance status of 0 or 1 on the ECOG Performance Scale. Participants must also be willing to provide tissue samples and demonstrate adequate organ function. Female participants of childbearing potential must have a negative pregnancy test and agree to use contraception during the study. Male participants of childbearing potential must also agree to use contraception. Exclusion criteria include current participation in another clinical study with PD-1 or PD-L1 inhibitors, previous treatment with a PD-1 or PD-L1 inhibitor or any anti-cancer therapy after complete resection of lung cancer, and current or prior use of immunosuppressive medication. Other exclusion criteria include certain medical conditions, history of certain diseases, and pregnancy or breastfeeding.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are anemia and non-dialysis dependent chronic kidney disease. The ICD-10 codes associated with these diseases are D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, and D61.9. The drugs being tested in this trial are vadadustat and placebo. The sample also includes the eligibility criteria for the trial, including inclusion and exclusion criteria. Inclusion criteria include being a male or female Japanese subject over 20 years of age, having a diagnosis of CKD with a glomerular filtration rate of 60 mL/min/1.73 m2 or lower, and having a hemoglobin level of 10.5 g/dL or lower. Exclusion criteria include having anemia due to a cause other than CKD, having certain blood disorders or malignancies, recent blood transfusion or iron infusion, and recent use of erythropoiesis-stimulating agents.",
    "The sample is from a table that contains information about clinical trials. In this specific sample, the trial is in phase 2 and focuses on two diseases: anemia and dialysis-dependent chronic kidney disease. The diseases are associated with specific ICD-10 codes. The trial involves two drugs, vadadustat and placebo. The eligibility criteria for participants are listed, including age, the requirement of chronic maintenance hemodialysis, and a specific hemoglobin level. There are also exclusion criteria, such as the presence of other causes of anemia, certain medical conditions, recent blood transfusion, and the expectation of recovering kidney function during the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"dermatitis, atopic.\" The ICD-10 codes associated with this disease are \"L20.89\" and \"L20.9.\" The drugs being studied in this trial are \"mepolizumab 100 mg\" and a placebo that matches mepolizumab. The eligibility criteria for participants in this trial include being between the ages of 18 and 70, having a diagnosis of AD (atopic dermatitis) according to specific criteria, having a certain severity of AD symptoms, having a certain percentage of body surface area affected by AD, and meeting other specific requirements related to blood eosinophil count, previous treatment history, and reproductive status for female participants. The exclusion criteria include having other types of eczema, certain skin disorders or conditions that may interfere with the evaluation of AD, certain medical conditions or infections, abnormal laboratory results, previous treatment with mepolizumab or certain other medications, and various other factors that may impact the subject's ability to complete the study or affect the study results.",
    "The sample is a record from a table that contains information about clinical trials. It is for a phase 2 trial and the diseases being studied are nonalcoholic steatohepatitis, liver cirrhosis, and non-alcoholic fatty liver disease. The corresponding ICD-10 codes for these diseases are K75.81, K74.60, K74.69, P78.81, K71.7, K70.30, K70.31, Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, and K70.0. The drug being tested in this trial is cenicriviroc. The eligibility criteria for inclusion in the trial include successful completion of previous treatment periods, completion of a previous study, and meeting certain liver-related clinical outcomes. The exclusion criteria include prior or planned liver transplantation and other known causes of chronic liver disease.",
    "The sample from the table represents a phase 2 clinical trial for small cell lung cancer. The diseases column includes the specific types of small cell lung cancer being studied, such as limited stage and extensive stage. The icdcodes column contains the corresponding ICD-10 codes for each disease. The drugs column lists the drugs being used in the trial, including atezolizumab, topotecan, carboplatin, and etoposide. The criteria column provides the eligibility criteria for participants in the trial, including requirements such as histologically confirmed small-cell lung cancer, targetable tumor lesions, previous platinum-etoposide treatment, and specific health conditions or factors that would exclude a patient from participating.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as a combination of phase 1 and phase 2. The specific disease being studied is dermatitis, atopic. The corresponding ICD-10 codes for this disease are 'L20.89' and 'L20.9'. The drugs being tested in this trial are 'hat1 topical cream' and 'vehicle cream'. \n\nThe eligibility criteria for participants in this trial are as follows:\n\nInclusion Criteria:\n- Participants must have moderate to severe atopic dermatitis, as determined by the Physician's Global Assessment (PGA > 3).\n- Both males and females between the ages of 12 and 65 are eligible to participate.\n\nExclusion Criteria:\n- Participants who are currently participating or have participated in another interventional clinical study within the past 2 weeks are not eligible.\n- Individuals who have been diagnosed or treated for cancer within the past 5 years are excluded.\n- Participants who require any topical or systemic medications that could affect the course of their atopic dermatitis during the study period (except inhaled steroids and/or stable antihistamines for asthma or allergies) are not eligible.\n- Individuals with a known hypersensitivity to any corticosteroid creams are excluded.\n- Participants with active infections or who have used antibiotics in the past 7 days are not eligible.\n- Individuals with physical attributes or skin conditions that might interfere with clear visual or instrumental assessments (such as cuts, sunburn, birthmarks, tattoos, extensive scarring, excessive hair growth, or acne) are excluded.\n- Participants with immunologic or infectious diseases (e.g., hepatitis, tuberculosis, HIV or AIDS, lupus rheumatoid arthritis) that could place them at risk or interfere with the accuracy of the study results are not eligible.\n- Individuals who have used any immunosuppressant drugs or immunotherapy within the past 30 days or 5 half-lives are excluded.\n- Employees of the sponsor company or clinical testing site are not eligible to participate.\n- Participants who are dependent on oral medication for any skin disease/condition or who, in the opinion of the Investigator, cannot tolerate the restriction of discontinuing the medicine as required in this study are excluded.\n- Individuals who are currently pregnant or lactating or planning to become pregnant in the next 6 months (using double contraception for prevention) are not eligible.\n- Participants with a history of keloid formation following skin injury are excluded.\n- Individuals who are routinely taking anti-coagulant medications (such as Plavix, Coumadin, warfarin, heparin, etc.) are not eligible.\n- Any other condition or factor that the Investigator or their duly assigned representative believes may affect the ability of the subject to complete the study or the interpretation of the results will result in exclusion from the trial.",
    "The sample provided is a record from a clinical trial table. It belongs to phase 2 of the trial and focuses on the disease \"small cell lung cancer.\" The corresponding ICD-10 codes for this disease are ['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']. The drugs being studied are \"anlotinib\" and \"placebo.\" \n\nThe eligibility criteria for this trial are as follows:\n- Patients must have histological documentation of small cell lung cancer.\n- Patients must have advanced small cell lung cancer and have undergone at least two chemotherapy regimens. They should also have at least one measurable lesion according to RECIST1.1.\n- Patients must be between 18 and 75 years old, have an ECOG performance status of 0-2, and a life expectancy of more than 3 months.\n- The main organs of the patients should be functioning normally.\n- Women of childbearing potential must agree to use adequate contraception throughout the treatment and for at least 6 months after the study ends. They should also have a negative pregnancy test and not be lactating. Male participants must also agree to use adequate contraception.\n- Patients must voluntarily participate in the study and sign an informed consent form.\n\nThe exclusion criteria for this trial are as follows:\n- Patients who have previously used anlotinib are excluded.\n- Patients who have previously used targeted drugs, immune targeted drugs, or certain other medications are excluded.\n- Patients who have received cytotoxic therapy, radiation therapy, or surgery within the last 4 weeks are excluded.\n- Patients with active bleeding in the primary lesion within the last 4 months are excluded.\n- Patients with carcinomatous meningitis or known central nervous system involvement are excluded.\n- Patients with conditions that could affect oral medication, such as dysphagia, chronic diarrhea, or intestinal obstruction, are excluded.\n- Patients with severe and/or uncontrolled diseases, including uncontrolled blood pressure, heart conditions, infections, liver diseases, poorly controlled diabetes, and certain kidney conditions, are excluded.\n- Patients with non-healing wounds or fractures are excluded.\n- Patients with recent arterial or venous thromboembolic events, drug abuse history, mental disorders, tumors involving important blood vessels, history of immunodeficiency, or concomitant diseases that could seriously endanger their safety or affect the study completion are excluded.\n\nThis description provides an overview of the phase, disease, ICD-10 codes, drugs, and eligibility criteria for the sample record in the clinical trial table.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the diseases listed are chronic obstructive pulmonary disease (COPD), breathlessness, and exercise intolerance. The ICDCodes associated with these diseases are provided as well. The drugs being studied are cannabis and placebo. The eligibility criteria for this trial include specific requirements for participants, such as having GOLD stage III or IV COPD, a smoking history of at least 10 pack years, and currently taking certain medications. There are also exclusion criteria, which list conditions or factors that would disqualify someone from participating in the trial. These include having certain medical conditions, history of sensitivity to cannabis, use of specific medications, and positive urine tests for cannabinoids or pregnancy. Additionally, participants must be able to arrange for someone to accompany them home after each treatment visit.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is stomach neoplasms. The ICDCodes associated with this disease are D13.1, C16.9, C16.1, C16.2, D37.1, C16.8, and C16.5. The drug being tested is azd2014. \n\nThe eligibility criteria for this trial include the provision of fully informed consent, patients must be at least 20 years old, and have advanced gastric adenocarcinoma that has progressed during or after first-line therapy. Previous adjuvant/neoadjuvant chemotherapy is allowed if completed more than 6 months prior to starting the first-line therapy. Patients must provide a tumor sample, have RICTOR amplification or overexpression through the VIKTORY trial, and be willing and able to comply with the study protocol. Other criteria include ECOG performance status 0-2, a life expectancy of at least 3 months, acceptable bone marrow, liver, and renal function, and at least one measurable lesion that can be assessed. \n\nExclusion criteria for this trial include having received more than one prior chemotherapy regimen for the treatment of gastric cancer in the advanced setting, previous treatment with PIK3CA, AKT, or mTOR inhibitors, having a second primary cancer, inability to swallow orally administered medication, and previous major surgery within 4 weeks prior to enrollment. Other exclusion criteria include exposure to certain inhibitors or inducers of CYP3A4/5 or CYP2C8, ongoing toxicities caused by previous cancer therapy, intestinal obstruction or upper GI bleeding, certain cardiac conditions, active or untreated brain metastases or spinal cord compression, being pregnant or breastfeeding, having severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, and having proteinuria.",
    "The sample is a phase 2 clinical trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The trial is testing the effectiveness of saroglitazar magnesium, with different dosage options, compared to a placebo. \n\nThe eligibility criteria for participants include being 18 to 75 years old with a body mass index (BMI) of 25 kg/m2 or higher. They must have a documented diagnosis of NAFLD, either through imaging or liver biopsy, within the past 24 months. The participants' ALT levels must be at least 50 U/L at two different visits with no more than a 30% variance between the levels. They must also demonstrate understanding of the study requirements and provide written informed consent.\n\nExclusion criteria include excessive alcohol consumption, alternative causes of fatty liver, recent use of certain drugs associated with NAFLD, initiation of high-dose vitamin E or certain other drugs, recent changes in statin or fibrate doses, use of thiazolidinediones, history of bowel surgery or chronic liver disease, cirrhosis, certain medical conditions such as poorly controlled diabetes or unstable cardiovascular disease, history of myopathies or active muscle disease, history of malignancy within the past 5 years, and abnormal laboratory values. \n\nOther exclusion criteria include contraindications to saroglitazar magnesium, known allergy or intolerance to the study drug or placebo, recent participation in other therapeutic clinical studies or NAFLD/NASH trials, history of bladder disease or hematuria, illicit substance abuse within the past year, and pregnancy or lactation for females. \n\nThe sample also includes additional details about contraception requirements for male and female participants, as well as exclusions related to severe illness or conditions that would make a patient unsuitable for the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and is focused on patients with coronary artery disease and poor metabolism of clopidogrel. The ICD-10 codes associated with these diseases are I25.10, I25.110, I25.119, I25.111, and I25.118. The drugs being studied are clopidogrel and ticagrelor. The sample also includes the eligibility criteria for the trial, including inclusion and exclusion criteria. Inclusion criteria involve patients with oral clopidogrel treatment who have been admitted to the hospital within 24 hours or are long-term follow-up outpatients. The platelet aggregation rate (PAgR) must meet certain conditions. Exclusion criteria include planned use of certain medications, low platelet count, low creatinine clearance rate, respiratory or circulatory instability, history of bleeding tendency, allergies to aspirin, ticagrelor, or clopidogrel, and severe liver injury.",
    "The sample is a phase 2 trial for asthma. The diseases being studied are asthma. The icd-10 codes associated with the diseases are J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, and J45.40. The drugs being tested are qvm149 150/50/80 \u03bcg o.d., qvm149 150/50/160 \u03bcg o.d., and salmeterol/fluticasone fdc 50/500 \u03bcg b.i.d. The eligibility criteria for the trial include being a male or female adult patient between 18 and 75 years old, having a documented physician diagnosis of asthma for at least 12 months, using ICS and LABA combinations for at least 3 months at a stable medium or high dose of ICS for at least 1 month, having a pre-bronchodilator FEV1 of less than 80% of the predicted normal value, demonstrating an increase in FEV1 of at least 12% and 200 mL after administration of 400 \u00b5g salbutamol/360 \u00b5g albuterol, and not having certain exclusion criteria such as smoking within the past 6 months, recent asthma attacks or exacerbations, certain medical conditions, and hypersensitivity or intolerance to the study drugs.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is Tourette syndrome, which is identified by the ICD-10 code F95.2. The drug being tested is a combination of dronabinol and palmitoylethanolamide. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being an adult between 18-60 years old, meeting the DSM-5 criteria for Tourette syndrome, having significant tic symptoms, being on a stable psychiatric medication regimen for at least 4 weeks prior to the trial, and having an accepted method of birth control. \n\nExclusion criteria include having comorbid bipolar disorder, psychotic disorder, substance use disorder, developmental disorder, or intellectual disability with an IQ below 70. Other exclusion criteria include recent changes in medications that can affect tic severity, recent changes in behavioral treatment for Tourette syndrome or comorbid conditions, taking medications or supplements that can interact with the test drugs, positive pregnancy or drug screening tests, history of cannabis dependence, significant medical comorbidity, and hypersensitivity to cannabinoids or sesame oil.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is dry eye syndrome. The ICDCodes associated with this disease are H04.121, H04.122, H04.123, and H04.129. The drugs being tested in this trial are brm421 and placebo. The eligibility criteria for participants include being at least 18 years old, providing written informed consent, having a reported history of dry eye for at least 6 months, and having a history of using eye drops. There are also exclusion criteria, such as having certain eye conditions or infections, recent LASIK surgery, or not using acceptable birth control methods for women of childbearing potential.",
    "The sample from the table is a clinical trial entry for a phase 1/phase 2 trial. The trial is focused on breast cancer and breast neoplasm. The ICD-10 codes associated with these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The only drug mentioned in the sample is cyclophosphamide. The eligibility criteria for the trial include having histological confirmation of breast cancer with recurrent and/or metastatic lesions, evidence of persistent, recurrent, or progressive disease with no known treatment available, being 18 years of age or older and female, having an expected survival of at least 4 months, and having an adequate performance status (ECOG 0-2). There are also exclusion criteria listed, such as recent chemotherapy or XRT, hypersensitivity to certain components used in the experimental vaccine, abnormal laboratory values, and certain medical conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the disease \"amyotrophic lateral sclerosis\" (ALSO). The corresponding ICD-10 code for ALSO is \"G12.21\". The drugs being studied in the trial are \"acthar\" and \"placebo\". The sample also includes the eligibility criteria for participants in the trial. The inclusion criteria include being between 18-75 years old, having ALSO symptom onset within 2 years prior to screening, having a forced vital capacity (FVC) no higher than 60% at screening, and being on a stable dose of riluzole for 4 weeks before screening if taking it. The exclusion criteria include having a tracheostomy, diaphragm pacing, or an ongoing need for assisted ventilation, using any medication not allowed per protocol, having a history of Type 1 or Type 2 diabetes mellitus or any clinically significant infection, using edaravone less than 1 week before screening, receiving any stem cell replacement therapy, and using steroids not allowed per protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is \"colorectal adenocarcinoma metastatic to the liver.\" The ICDCodes associated with this disease are \"C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31.\" The drugs being used in the trial are \"floxuridine (fudr), irinotecan (cpt-11), fluorouracil, panitumumab, dexamethasone, leucovorin.\" The eligibility criteria for this trial include various conditions such as a confirmed diagnosis of colorectal adenocarcinoma metastatic to the liver, specific tumor characteristics, prior treatment history, liver resectability, lab values, renal function, hepatic function, and other exclusion criteria.",
    "The sample is a phase 2 trial for colorectal cancer. The eligibility criteria include being tumor-free, having a germline pathologic mutation on one of the MMR genes, being over 25 years old, and meeting certain requirements for contraception or sexual activity. Participants must also provide written informed consent. Exclusion criteria include the presence of non-removable benign neoplasia, certain germline mutations, a history of stage 3 or 4 colorectal cancer, metastatic disease, and regular use of certain medications. Other exclusion criteria include hypersensitivity to 5-ASA, previous colectomy or colorectal surgery, unwillingness to participate, pregnancy or breastfeeding, recent participation in another clinical study, renal insufficiency, severe liver disease, serious psychiatric disorder or substance abuse, and other severe medical conditions that may increase risk or impact study procedures.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes information about the diseases being studied, the associated ICD-10 codes, the drugs being tested, and the eligibility criteria for participants.\n\nIn this particular sample, the phase of the trial is phase 2. The diseases being studied are \"elevated lipoprotein(a)\" and \"cardiovascular disease\". The corresponding ICD-10 codes for these diseases are \"E78.41\", \"Z83.430\", \"A52.00\", \"A52.09\", \"A50.54\", \"Z01.810\", \"Q87.418\", \"Z13.6\", and \"R94.30\". The drugs being tested in this trial are \"isis 681257\" and \"placebo\".\n\nThe eligibility criteria for participants are listed under \"Key Inclusion Criteria\" and \"Key Exclusion Criteria\". Inclusion criteria include having a clinical diagnosis of cardiovascular disease, a plasma level of Lp(a) \u2265 60 mg/dL, and being on standard-of-care preventative therapy for other than elevated Lp(a) cardiovascular disease risk factors. Exclusion criteria include recent acute coronary syndrome, major cardiac surgery, stroke/TIA, arterial revascularization, major non-cardiac surgery, lipoprotein apheresis, and heart failure classified as New York Heart Association (NYHA) class IV.\n\nOverall, this sample provides specific details about the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for a phase 2 clinical trial.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is lymphoma, specifically R/R AITL (relapsed/refractory angioimmunoblastic T-cell lymphoma). The trial is investigating the drug plitidepsin. The eligibility criteria for participants include being at least 18 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower, and a life expectancy of at least 3 months. Other criteria include specific laboratory values for bone marrow, renal, hepatic, and metabolic function, as well as a normal left ventricular ejection fraction (LVEF) by echocardiogram or multiple-gated acquisition (MUGA) scan. Exclusion criteria include prior treatment with plitidepsin, certain cardiac conditions, active infections, myelodysplasia or post-chemotherapy aplasia, and other major illnesses that could increase the risk of participation. Pregnant or breastfeeding women and fertile patients who are not using effective contraception are also excluded. The sample also mentions the exclusion of concomitant medications that may be active against AITL, major upper gastrointestinal bleeding in the past year, and known hypersensitivity to any components of plitidepsin's formulation.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on studying the effects of certain drugs on patients with hyperkalemia and resistant hypertension. The diseases are represented by their names and corresponding ICD-10 codes. The drugs being studied are patiromer, placebo, and spironolactone. The eligibility criteria for participants are listed, including age, medication requirements, blood pressure control, kidney function, and normal blood serum potassium levels. There are also exclusion criteria, such as untreated causes of high blood pressure, inability to measure blood pressure, recent changes in renal function, history of cancer or cardiovascular events, and other medical conditions that may affect participation in the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of acute myeloid leukemia (AML). The trial includes patients with AML that has relapsed or is refractory to chemotherapy, or has relapsed after hematopoietic stem cell transplantation (HSCT). The eligibility criteria include having a certain percentage of leukemic blasts in the bone marrow, adequate organ function, specific age criteria, ability to swallow tablets, and a certain performance status. Patients must also have fully recovered from prior therapy and, if they have received HSCT, must have no evidence of graft-versus-host disease (GVHD) and at least 60 days must have passed since the HSCT. The exclusion criteria include a history of cerebellar toxicity, pregnancy or breastfeeding, certain medical conditions, recent use of investigational agents (except for gemtuzumab ozogamicin), unstable cardiovascular function, uncontrolled infection, HIV infection, malabsorption syndrome, and prior treatment with selinexor.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of mesothelioma, a type of cancer. The trial includes patients with unresectable or medically inoperable malignant pleural mesothelioma who have experienced disease progression after receiving chemotherapy. The trial involves the use of two drugs, tremelimumab and durvalumab. The eligibility criteria for participants include providing informed consent, having measurable disease, being willing to undergo biopsies, having a certain performance status, and meeting certain hematologic, renal, and organ function requirements. There are also criteria related to age, contraception, and ability to understand and comply with the study protocol. The exclusion criteria include previous treatment with certain immune check-point inhibitors, central nervous system metastasis, use of systemic corticosteroids or immunosuppressive drugs, certain autoimmune diseases, interstitial lung disease or pneumonitis, and various other medical conditions. The sample also includes criteria related to previous treatments, immune-related adverse events, investigational agents, and certain illnesses or conditions. Additionally, there are criteria related to QT interval, HIV, hepatitis B and C, pregnancy, and involvement in the study planning or conduct. Subjects who have undergone a pneumonectomy are also excluded from the trial.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of advanced gastric adenocarcinoma. The trial is investigating the effectiveness of a drug called azd2014. The eligibility criteria for the trial include patients who have provided informed consent, are at least 20 years old, and have experienced disease progression during or after first-line therapy. The first-line therapy must have included a combination of 5-fluoropyrimidine and platinum-based regimen. Patients who have relapsed within 6 months of completing adjuvant/neoadjuvant chemotherapy with the same regimen may also be considered for the trial. Previous adjuvant/neoadjuvant chemotherapy is allowed if completed more than 6 months prior to starting the first-line therapy. Patients must also provide a tumor sample for analysis. Additionally, patients with TSC1/2 mutation or null through the VIKTORY trial are eligible. Other criteria include ECOG performance status 0-2, a life expectancy of at least 3 months, and acceptable bone marrow, liver, and renal function. Patients must have at least one measurable lesion that can be assessed, and negative pregnancy test for female patients of child-bearing potential. The exclusion criteria include having received more than one prior chemotherapy regimen for gastric cancer in the advanced setting, previous treatment with specific inhibitors, presence of second primary cancer (except for certain cases), inability to swallow orally administered medication, recent major surgery, ongoing toxicities caused by previous cancer therapy, intestinal obstruction or upper GI bleeding, certain cardiac conditions, active or untreated brain metastases or spinal cord compression, breastfeeding or pregnancy, severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, and proteinuria.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of dry eye syndrome. The diseases column specifies the disease being studied, which in this case is \"dry eye syndrome\". The icdcodes column contains the corresponding ICD-10 codes for the disease, which are \"H04.121\", \"H04.122\", \"H04.123\", and \"H04.129\".\n\nThe drugs column lists the names of the drugs being tested in the trial, which are \"top1630 ophthalmic solution\" and \"placebo to top1630 ophthalmic solution\". The criteria column provides the eligibility criteria for participants in the trial.\n\nThe inclusion criteria include being at least 18 years old, providing written informed consent, having a reported history of dry eye, and a history of using eye drops for dry eye symptoms. Additionally, for Part 2 of the trial, participants should have symptoms and signs of dry eye syndrome, such as ocular discomfort, conjunctival redness, tear film break up time, and Schirmer test score.\n\nThe exclusion criteria include having clinically significant slit lamp findings, an ongoing ocular infection, significant ocular lesions that could interfere with safety or efficacy assessment, planned ocular or lid surgeries during the study period, uncontrolled systemic disease, being pregnant, nursing, or planning a pregnancy, not using acceptable birth control methods for women of childbearing potential, known allergy or sensitivity to the test article or its components, and having a condition or situation that may put the subject at significant risk or interfere with their participation in the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"diabetes mellitus, type 2\" and \"hypertension.\" The corresponding ICDCodes for these diseases are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44'] and ['I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', 'I10'], respectively. The drugs being tested are \"iw-1973\" and \"placebo.\" \n\nThe eligibility criteria for this sample include being an ambulatory male or female, having a body mass index (BMI) score between 20 and 40 kg/m^2, having a negative pregnancy test for women of childbearing potential, having stable health with no significant findings on physical examination, being diagnosed with type 2 diabetes mellitus for more than 6 months and having stable glycemic control, being diagnosed with hypertension for more than 6 months and having blood pressure within the acceptable range, being on a stable regimen for hypertension control that includes an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 28 days, and meeting other inclusion criteria specified in the protocol.\n\nThe exclusion criteria for this sample include having a clinically significant active or unstable medical condition that would prevent trial participation, being on medication(s) that could increase the risk of hypotension when co-administered with a sGC stimulator, having evidence of severe or active end-organ damage, being an active smoker or using nicotine-containing products in the past 6 months, and meeting other exclusion criteria specified in the protocol.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is ulcerative colitis. The ICD-10 codes associated with the disease are K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, and K51.811. The drugs being tested in the trial are abx464 and placebo oral capsule. The eligibility criteria for participants in the trial include a diagnosis of moderate to severe active ulcerative colitis confirmed by endoscopy and histology, specific corticosteroid and medication requirements, and the absence of certain medical conditions or infections.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease called post-herpetic neuralgia. The ICD-10 codes associated with this disease are G50.0, M54.81, B02.22, and M79.2. The drugs being studied in this trial are ema401 and placebo. The eligibility criteria for participants in this trial include having a documented diagnosis of post-herpetic neuralgia, experiencing moderate to severe neuropathic pain, having inadequate response to at least 2 prescribed therapies for post-herpetic neuralgia, and being willing to complete a daily eDiary. The exclusion criteria include having significant risk of safety based on electrocardiogram abnormalities, having a history of major depressive disorder, being a woman of child-bearing potential, having significant renal insufficiency or pre-existing liver condition, having low platelet or neutrophil count, and having high hemoglobin A1c levels for patients with or without a known diagnosis of diabetes.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is heart failure. The corresponding ICD-10 codes for heart failure are I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, and I11.0. The drugs being tested in this trial are neladenoson bialanate (bay1067197) and placebo. The eligibility criteria for participants in this trial include being men or women aged 45 years and older, having a diagnosis of chronic heart failure with NYHA class II-IV, having a left ventricular ejection fraction (LVEF) of at least 45% and elevated NT-proBNP. The exclusion criteria include having experienced acute decompensated heart failure within the past 4 weeks, inability to exercise, and a previous diagnosis of heart failure with reduced ejection fraction (LVEF < 40%).",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the diseases being studied are obesity and overweight. The ICDCodes associated with these diseases are E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211 for obesity and E66.3 for overweight. The drugs being tested are lik066 and placebo. The eligibility criteria for participants include providing informed consent, having a BMI of 30 or higher, or a BMI of 27 or higher with a history of certain cardiovascular diseases, hypertension, dyslipidemia, pre-diabetes, type 2 diabetes mellitus, or sleep-apnea syndrome. Participants must also be willing to comply with lifestyle interventions and treatment for approximately 54 weeks. Exclusion criteria include hypersensitivity to any study medications, pregnancy or lactation, history of malignancies, use of pharmacologically active weight loss products, previous bariatric surgery, ketoacidosis, lactic acidosis, hyperosmolar coma in the 6 months before the screening visit, and HbA1c levels above 10% at the screening visit.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"atopic dermatitis\". The corresponding ICD-10 codes for this disease are \"L20.89\" and \"L20.9\". The drugs being studied in this trial are \"nemolizumab\" and \"placebo\". The eligibility criteria for participants in this trial include being at least 18 years old, having chronic atopic dermatitis for at least 2 years, having specific scores for Eczema Area and Severity Index (EASI) and Investigator Global Assessment (IGA), having a certain percentage of body surface area affected by AD, experiencing severe pruritus, and having a documented history of inadequate response to topical medications. Female participants must also meet certain criteria related to their reproductive potential. There are also exclusion criteria, such as a minimum body weight requirement, a history of poorly controlled asthma, recent infections, and intolerance to certain types of topical corticosteroids.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of essential tremor. The diseases column lists \"essential tremor\" as the disease being studied. The icdcodes column contains the ICD-10 code for essential tremor, which is \"G25.0\". The drugs column includes the names of the drugs being tested, which are \"cx-8998\" and \"placebo\". The criteria column provides the eligibility criteria for participants in the trial, including age requirements, diagnosis criteria, and restrictions on medication use. The inclusion criteria specify that participants must provide informed consent, be able to read and understand English, have a diagnosis of essential tremor, meet certain tremor severity scores, and agree to contraception methods if of reproductive capability. The exclusion criteria list various conditions and factors that would disqualify someone from participating in the trial, such as recent exposure to certain drugs, history of other medical or neurological conditions, prior interventions or treatments, and use of certain medications.",
    "The sample is from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of allergic rhinitis, specifically seasonal rhinitis caused by cedar pollen. The table includes columns for the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being used, and eligibility criteria.\n\nIn this particular sample, the phase is phase 2. The disease being studied is \"rhinitis, allergic, seasonal\" caused by cedar pollen. The corresponding ICD-10 code for this disease is \"J30.2\". The drugs being used in the trial are \"asp4070\" and \"placebo\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". \n\nThe inclusion criteria include having exhibited symptoms of cedar pollinosis, testing positive for the Japanese red cedar (JRC) pollen-specific serum IgE antibody, and having a worsened score compared to baseline after cedar pollen exposure. \n\nThe exclusion criteria include testing positive for serum IgE antibody specific to an antigen other than JRC pollen, having received specific immunotherapy for cedar pollinosis in the past, having received immunotherapy within 5 years prior to screening, having received nasal treatment within 3 years prior to screening, having a history of allergic reactions, testing positive for hepatitis B surface antigen or anti-hepatitis C virus antibody, having nasal disease or autoimmune disease, being diagnosed with immunodeficiency in the past, having complications of other types of rhinitis or cardiovascular, hepatic, renal, or respiratory diseases, having a history of malignant tumor or recent treatment for malignant tumor, being diagnosed with schizophrenia or other mental conditions, having complications that may impact the study results, having received a previous vaccination of Cry j 2-LAMP vaccine, or having participated in a previous clinical study of ASP4070 and received a vaccination of the study drug.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on psoriatic arthritis. The ICDCodes column contains the ICD-10 code for psoriatic arthritis, which is \"L40.52\". The drugs being studied in this trial are filgotinib and a placebo oral tablet. The eligibility criteria for participants in this trial include being at least 18 years old, having a diagnosis of psoriatic arthritis that meets the Classification Criteria for Psoriatic Arthritis (CASPAR), having a certain number of swollen and tender joints, and having a history of documented plaque psoriasis or currently active plaque psoriasis. There are also specific criteria regarding the use of certain medications and therapies, as well as requirements for contraception for subjects of childbearing potential. The exclusion criteria include the use of JAK inhibitors, prior use of multiple TNF inhibitors, use of high-dose oral steroids, recent intra-articular injections, use of multiple NSAIDs or COX-2 inhibitors, recent surgical treatment for psoriatic arthritis, poor functional status, and recent administration of live or attenuated vaccines.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 2 trial for the disease \"normal tension glaucoma\". The trial is associated with several ICD-10 codes related to the disease. The drugs being tested in this trial are \"php-201 0.25% ophthalmic solution\", \"php-201 0.5% ophthalmic solution\", and a placebo ophthalmic solution. The record also includes the eligibility criteria for participants in the trial. Inclusion criteria include being 19 years or older, having an intraocular pressure (IOP) of 21 mmHg or lower, showing open angle finding, glaucomatous optic nerve damage, and visual field defects, and having a best-corrected visual acuity (BCVA) of +0.2 or higher. Exclusion criteria include having certain diseases or surgery history that make the participant ineligible, being unable to discontinue contact lenses, and being unable to discontinue topical/systemic IOP lowering medication.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is Phase 2. The diseases being studied are cirrhosis and ascites hepatic. The corresponding ICD-10 codes for these diseases are K74.3, K74.4, K74.5, K74.60, K74.69, P78.81, and K70.30. The drug being tested is terlipressin acetate continuous infusion. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Patients with cirrhosis and refractory ascites who required 3 or more large volume (4 liters and more) paracenteses in the previous 60 days.\n\nExclusion Criteria:\n- Ascites with causes other than cirrhosis such as nephrogenic ascites or malignant ascites due to peritoneal carcinomatosis.\n- Total bilirubin > 5 mg/dL.\n- Blood clotting International normalized ratio (INR) > 2.5.\n- Serum creatinine > 2.0 mg/dL.\n- Current or recent (within 3 months of consent) renal dialysis.\n- Hepatic encephalopathy grade 3 or 4.\n- Superimposed acute liver failure/injury due to factors other than alcoholic hepatitis, including acute viral hepatitis, drugs, medications (e.g., acetaminophen), or other toxins (e.g., mushroom [Amanita] poisoning).\n- Current or recent treatment (within 7 days) with octreotide, midodrine, vasopressin, dopamine, or other vasopressors.\n- Respiratory failure requiring positive airway pressure devices or intubation.\n- SIRS/sepsis episode in the previous 28 days from consent.\n- Episode of spontaneous bacterial peritonitis or gastrointestinal hemorrhage within 28 days of consent.\n- Ongoing documented or suspected infection.\n- Severe cardiovascular disease that are contraindication to terlipressin therapy such as advanced arteriosclerosis, arrhythmia, coronary insufficiency, or uncontrolled hypertension.\n- Findings suggestive of organic renal disease (severe proteinuria/hematuria, or abnormal renal ultrasound suggestive of obstructive or other renal pathology).\n- Severe comorbidity that in the opinion of the Investigator would affect short-term prognosis and/or disallow safe participation in the trial (such as for example, severe anemia or pancytopenia, advanced neoplasia, hepatocellular carcinoma [confirmed with serum alpha1-fetoprotein testing], severe chronic obstructive pulmonary disease or asthma).\n- Alcoholics who have not been abstinent for the past 6 months.\n- Transjugular intrahepatic portosystemic shunt or other surgical shunt.\n- For female patients: Confirmed pregnancy.\n- Known allergy or hypersensitivity to terlipressin.\n- Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of consent.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of asthma. The trial focuses on patients who have a documented physician diagnosis of asthma and are currently receiving daily treatment with an inhaled corticosteroid at a low or medium dose. These patients must have been on a stable regimen for at least 4 weeks prior to screening.\n\nThe inclusion criteria also require patients to have a pre-bronchodilator FEV1 (forced expiratory volume in one second) between 60% and 100% of the predicted normal value during screening. Additionally, patients must demonstrate an increase in FEV1 of at least 12% and 200 mL after the administration of a specific dose of salbutamol/albuterol at screening.\n\nVital signs, including blood pressure, pulse rate, and oral body temperature, are assessed in both sitting and standing positions. The specified ranges for these vital signs are provided. Hypertensive patients must have been on stable antihypertensive therapy for at least 4 weeks prior to screening to be included in the trial. Patients must also weigh at least 50 kg and have a body mass index (BMI) within the range of 18 to 40 kg/m2.\n\nExclusion criteria include contraindications or a history of hypersensitivity to any of the drugs in a similar class. Patients who have had an asthma attack/exacerbation requiring systemic steroids, hospitalization, or emergency room visit within 1 year of screening are also excluded. Patients with a history of clinically relevant bronchoconstriction or paradoxical bronchospasm in response to inhaled medicines are excluded as well.\n\nFurthermore, patients who require the use of a certain amount of rescue medication or have a decline in peak expiratory flow (PEF) readings during the run-in period prior to randomization are excluded. Patients who do not maintain regular day/night, waking/sleeping cycles (e.g., night shift workers) are also excluded from the trial.",
    "The sample from the table represents a clinical trial for a drug called selumetinib. The trial is in phase 2 and is focused on treating patients with certain diseases, including neoplasms, nerve tissue, neurofibromatosis 1, heredodegenerative disorders of the nervous system, and peripheral nervous system diseases. The diseases are identified by their corresponding ICD-10 codes. The trial aims to evaluate the effectiveness of selumetinib in treating these diseases.\n\nThe eligibility criteria for the trial include age requirements, diagnosis of NF1 or a germline NF1 mutation, confirmation of NF1 mutation in patients without NF1 syndrome, histologically or cytologically confirmed measurable GIST without PDGFRA or KIT mutations, and normal organ and marrow function. Patients must also have measurable GIST as defined by RECIST v1.1 and a performance status of ECOG less than or equal to 2.\n\nPrior therapy, including chemotherapy and radiation therapy, is allowed as long as certain conditions are met. Patients must also meet various other criteria related to their medical history, cardiac conditions, ophthalmological conditions, ability to swallow capsules, and other factors. Pregnant women and HIV-positive patients on antiretroviral therapy are excluded from the trial.\n\nThe sample also includes information on the exclusion criteria, which specify conditions or circumstances that would make a patient ineligible for the trial. These include evidence of another malignancy or benign tumor requiring chemotherapy or radiation therapy, prior therapy with selumetinib or another specific MEK inhibitor, certain cardiac conditions, ophthalmological conditions, and other factors.\n\nOverall, the sample provides detailed information about the phase 2 clinical trial, including the diseases being targeted, the eligibility criteria, and the exclusion criteria.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of intraoperative bleeding. The associated ICD-10 codes for this disease are 'D78.81', 'E36.8', 'G97.81', 'I97.710', 'I97.711', 'I97.810', and 'I97.811'. The drugs being studied in this trial are tranexamic acid and adrenaline. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n1. The patient must be a candidate for ear exploration surgery.\n2. The patient must have an ASA (American Society of Anesthesiologists) classification of I or II.\n3. The patient must be willing to participate in the study.\n4. The patient's hemoglobin (Hb) level must be greater than 10 mg/dl.\n5. The patient must have a normal coagulation profile, as indicated by normal INR (International Normalized Ratio) and PTT (Partial Thromboplastin Time) values.\n\nExclusion Criteria:\n1. The patient refuses to participate in the study.\n2. The patient has an allergy to tranexamic acid.\n3. The patient has a bleeding disorder.\n4. The patient has a psychiatric illness.\n5. The patient has acute or chronic renal failure.\n6. The patient has used heparin within 48 hours before surgery.\n7. The patient is pregnant.\n8. The patient has cirrhosis.\n9. The patient has color blindness.\n10. The patient has a cardiac stent.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The diseases being studied are acute myeloid leukemia and myelodysplastic syndromes. The corresponding ICD-10 codes for these diseases are provided. The drugs being used in the trial are decitabine and digoxin. The sample also includes the eligibility criteria for participants in the trial. This includes requirements such as having a confirmed diagnosis of the specified diseases, being at least 18 years old, having a certain performance status, and having normal organ function. There are also exclusion criteria, such as recent chemotherapy or radiotherapy, receiving other investigational agents, and having certain medical conditions or prior exposure to certain drugs. The sample concludes with the statement that pregnant or breastfeeding individuals are not eligible for the trial.",
    "The sample is a phase 2 trial for the treatment of ankylosing spondylitis, a type of arthritis that primarily affects the spine. The trial is testing the effectiveness of the drug filgotinib compared to a placebo oral tablet. The eligibility criteria for participants include being at least 18 years old, having a diagnosis of moderate to severe ankylosing spondylitis that meets the Modified New York criteria, experiencing active symptoms such as high BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) scores and spinal pain, and having an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs). Participants must also meet certain requirements regarding the use of other medications and contraception. There are also exclusion criteria, such as prior use of JAK inhibitors or multiple TNF inhibitors, use of high-dose oral steroids, recent intra-articular injections, and contraindications to MRI. The sample does not provide information on the number of participants or the duration of the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the ICD-10 codes associated with the diseases, \"drugs\" which lists the names of the drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this particular sample, the phase of the trial is phase 2. The disease being studied is multiple myeloma. The associated ICD-10 codes for multiple myeloma are \"C90.01\", \"C90.02\", and \"C90.00\". The drugs being used in the trial are plitidepsin, bortezomib, and dexamethasone. The eligibility criteria for the trial include requirements such as written informed consent, age of 18 years or older, a confirmed diagnosis of multiple myeloma according to specific criteria, measurable disease as defined by certain parameters, previous treatment with bortezomib and lenalidomide and refractory to both, Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower, recovery from previous adverse events, and specific laboratory data within certain ranges. There are also exclusion criteria listed, such as previous treatment with plitidepsin, presence of other active or metastatic primary malignancies, certain serious concomitant systemic disorders, relevant cardiac conditions, history of hypersensitivity reactions to certain drugs, and other major illnesses that may increase the risk associated with participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are hyperuricemia, albuminuria, and type 2 diabetes. The corresponding ICDCodes for these diseases are 'E79.0' for hyperuricemia and a list of codes for type 2 diabetes. The drugs being tested in this trial are 'verinurad 9 mg+febuxostat 80 mg' and 'placebo'. The eligibility criteria for inclusion in the trial include having a serum uric acid level of at least 6.0 mg/dL, an estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73 m2, a urine albumin-to-creatinine ratio (UACR) between 30 mg/g and 3500 mg/g, and a diagnosis of type 2 diabetes. The exclusion criteria include recent treatment with drugs for hyperuricemia, a history of gout (unless prophylaxis therapy is not required), pregnancy or lactation, and being unsuitable or unable to undergo MRI assessment.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"cystic fibrosis\". The ICD-10 codes associated with this disease are \"E84.9\", \"Z14.1\", \"E84.0\", \"E84.11\", \"E84.8\", \"E84.19\", and \"P09.4\". The drugs being studied in this trial are \"glpg2222 50 mg\", \"glpg2222 100 mg\", \"placebo\", \"glpg2222 200 mg\", and \"glpg2222 400 mg\". \n\nThe eligibility criteria for this trial are as follows:\n- The subject must be at least 18 years old.\n- They must have a confirmed clinical diagnosis of cystic fibrosis and be homozygous for the F508del CFTR mutation.\n- The subject must weigh at least 40 kg.\n- They must have been on stable concomitant treatment for at least 4 weeks prior to baseline.\n- The forced expiratory volume in 1 second (FEV1) must be at least 40% of the predicted normal for age, gender, and height at screening.\n\nThere are also exclusion criteria, which include:\n- Having a history of clinically meaningful unstable or uncontrolled chronic disease that would make the subject unsuitable for the study.\n- Having unstable pulmonary status or a respiratory tract infection requiring a change in therapy within 4 weeks of baseline.\n- Needing supplemental oxygen during the day, and more than 2 liters per minute (LPM) while sleeping.\n- Having used CFTR modulator therapy (e.g., lumacaftor or ivacaftor) within 4 weeks prior to the first study drug administration.\n- Having a history of hepatic cirrhosis with portal hypertension.\n- Having abnormal liver function tests at screening, defined as AST and/or ALT and/or alkaline phosphatase and/or gamma-glutamyl transferase (GGT) being 3 times the upper limit of normal (ULN), and/or total bilirubin being greater than 1.5 times ULN.\n- Having an estimated creatinine clearance less than 60 mL/min using the Cockcroft-Gault formula at screening.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is Hodgkin lymphoma. The ICDCodes associated with this disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drug being used in the trial is atezolizumab. The eligibility criteria for this trial include various factors such as signed informed consent, age above 18 years, confirmed diagnosis of Hodgkin lymphoma, prior treatment regimens, and specific laboratory results within 14 days prior to the first treatment. The sample also includes exclusion criteria, medication-related exclusion criteria, and other specific conditions that would make a patient ineligible for the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on knee osteoarthritis. The trial involves the use of a drug called sm04690 and a placebo. The eligibility criteria for participants are listed, including requirements such as being ambulatory, having a diagnosis of femorotibial OA in the target knee, experiencing pain compatible with knee OA for at least 26 weeks, and being willing to use an electronic diary. Exclusion criteria are also listed, such as being pregnant or lactating, having a BMI over 35, having undergone joint replacement surgery, or having certain comorbid conditions. The sample also includes information about previous participation in a clinical trial, history of malignancy, psychiatric conditions, and recent treatments or procedures related to knee OA.",
    "The sample is a phase 2 trial for the treatment of primary biliary cholangitis (PBC). The trial is testing the effectiveness of three drugs: elafibranor 80 mg, elafibranor 120 mg, and a placebo. The eligibility criteria for participants include having a definite or probable PBC diagnosis, elevated ALP levels for at least 6 months, positive Anti-Mitochondrial Antibodies (AMA) titers, and a liver biopsy consistent with PBC. Other criteria include specific ranges for ALP, creatine phosphokinase (CPK), alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin, and serum creatinine levels. Participants must also not have certain liver diseases, renal disease, hepatic impairment, or clinical complications of PBC. Females must either be of non-childbearing potential or use highly efficient contraception throughout the study. Additionally, participants must not be pregnant, lactating, have HIV infection, or have medical conditions that may cause non-hepatic increases in ALP.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease called diabetic macular edema. The ICD-10 codes associated with this disease are ['E10.311', 'E10.319', 'E11.311', 'E11.319', 'E13.311', 'E13.319', 'E10.3513']. The drugs being studied in this trial are ivt aflibercept, sham sc, and sc cls-ta. The sample also includes the eligibility criteria for the trial, including inclusion criteria such as having a clinical diagnosis of type 1 or type 2 diabetes, having DME with central involvement, and being naive to local pharmacologic treatment for DME. The exclusion criteria include factors such as high intraocular pressure, previous treatment with an ocular corticosteroid implant, and a history of glaucoma or optic nerve damage.",
    "The sample is a phase 2 clinical trial for patients with nasopharyngeal carcinoma. The trial aims to evaluate the effectiveness of apatinib mesylate tablet in treating this type of cancer. The eligibility criteria for participants include being between 18 and 70 years old, having newly diagnosed or recurrent nasopharyngeal carcinoma, and having evidence of local residue or distant metastases after previous treatment. Other criteria include having a good performance status, adequate hematological and liver function, and a life expectancy of more than 3 months. Exclusion criteria include certain medical conditions such as high-risk tumors, uncontrolled high blood pressure, and abnormal coagulation. Participants must also provide informed consent and be willing to comply with the study requirements.",
    "The sample from the table represents a clinical trial with different phases (phase I, phase II, or phase III) for various diseases. The diseases mentioned in the sample include alk-positive non-small cell lung cancer (NSCLC), ret-positive non-small cell lung cancer (NSCLC), and ret-positive thyroid cancer. The diseases are associated with specific ICD-10 codes. The trial involves the use of a drug called alectinib. \n\nThe eligibility criteria for the trial are described in detail. Inclusion criteria include having a confirmed diagnosis of the specified diseases, specific disease status requirements, having measurable target lesions, and meeting certain organ and marrow function requirements. Other criteria include age, performance status, and pregnancy status for women. Exclusion criteria include recent chemotherapy or immunotherapy, recent targeted therapy, prior alectinib therapy, certain medications, recent radiation therapy, recent major surgery, receiving other investigational agents, liver disease, symptomatic CNS metastases, hypersensitivity to the drug formulation, and various other medical conditions.\n\nThe sample provides a comprehensive description of the trial, including the diseases targeted, the drug used, and the criteria for eligibility and exclusion.",
    "The sample from the table represents a phase 2 trial for the treatment of bleeding. The diseases being studied are bleeding-related conditions. The icd-10 codes associated with these diseases are N92.3, N95.0, K29.80, K29.81, I85.00, I85.01, and K20.80. The drugs being tested in this trial are peprostat and saline. \n\nThe eligibility criteria for this trial include being a male or female aged 18 or older, undergoing a planned open liver/soft tissue surgery, vascular surgery, or spine surgery, and being able to provide written informed consent. Other criteria include being willing and able to comply with all protocol requirements, using adequate contraception for males and highly effective contraception for women of childbearing potential, having a target bleeding site that is suitable for the study, and meeting certain health criteria such as not having emergency surgical procedures, specific blood test results, severe renal failure, or other conditions that may affect blood clotting. \n\nExclusion criteria include being a recipient of an organ transplant, having certain medical conditions or diseases, having a known history of allergic reactions to certain substances, participating in another investigational drug or device research study within 30 days before and after enrollment, having current alcohol or drug abuse or dependence, having concurrent medical, surgical, or psychiatric conditions that may affect the ability to meet study requirements, having HIV, Hepatitis B virus, or Hepatitis C Virus infection, having severe bleeding during surgery where the use of a topical haemostat would be inappropriate, and being on certain medications such as anti-platelets or oral anticoagulants. Additionally, pregnant or breastfeeding individuals are also excluded from the trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 2. The diseases being studied are salivary gland carcinoma, metastatic cancer, and recurrent cancer. The icd-10 codes associated with these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being used in the trial is nivolumab. The eligibility criteria include requirements such as having confirmed carcinoma of the salivary glands, availability of pre-treatment tumor tissue for analysis, having measurable lesions, and meeting certain laboratory values. There are also exclusion criteria, such as having stable disease, active brain metastases, or a history of certain autoimmune diseases.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"eczema\". The ICD-10 codes associated with eczema are provided. The trial involves two drugs, \"zl-3101\" and \"placebo\". The eligibility criteria for participants are listed, including age range, specific symptoms and characteristics of the disease, and general health requirements. There are also exclusion criteria, such as the presence of other health conditions or allergies to the test medications. The sample includes detailed information about the exclusion criteria, including specific timeframes for previous treatments and therapies that would disqualify a participant. The sample also mentions that certain medications and birth control methods are allowed during the study. Finally, there is a criterion related to the EASI score, which measures the severity of eczema.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The sample data includes a specific trial phase (phase 2), a disease (neonatal abstinence syndrome), ICDCodes associated with the disease, drugs used in the trial (methadone and morphine), and the eligibility criteria for participants in the trial.\n\nThe eligibility criteria are divided into two groups: the Methadone Treatment Group and the Comparison Group. The Methadone Treatment Group includes criteria such as the baby being diagnosed with neonatal abstinence syndrome, the mother being under the care of Operation PAR, residing in Pinellas or Pasco county, being compliant with the detoxification program, and meeting certain gestational age and weight requirements. The Comparison Group also includes criteria related to neonatal abstinence syndrome, gestational age, weight, and informed parental consent, but does not include the requirement for the baby to be in the Methadone Treatment Group.\n\nThere are also exclusion criteria listed for both groups, such as major congenital anomalies, concomitant medical illness, infants being placed for adoption, infants in significant pain, and maternal UDS (urine drug screen) positive for drugs other than opiates. Additionally, the Methadone Treatment Group excludes mothers with hearing or language impairment, while the Comparison Group excludes infants known upon admission who will be placed into state custody or sheltered.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 designation. The trial focuses on the treatment of renal cell carcinoma, a type of kidney cancer. The trial includes patients with metastatic renal cell carcinoma who have not been previously treated with the drugs tivozanib or nivolumab. The eligibility criteria for the trial include being at least 18 years old, having histologically or cytologically documented renal cell carcinoma with a clear cell component, having measurable or evaluable disease according to RECIST 1.1 criteria, having an ECOG performance status of 1 or lower, and having a life expectancy of at least 3 months. In addition, sexually active participants must use adequate contraceptive measures during the study and for at least 160 days after the last dose of the study drugs. The exclusion criteria include being pregnant or lactating, having symptomatic CNS metastases, having certain hematologic or serum chemistry abnormalities, having significant cardiovascular disease, having delayed healing of wounds, ulcers, or bone fractures, having a serious or active infection, having inadequate recovery from a prior surgical procedure, being unable to comply with protocol requirements, having a currently active second primary malignancy other than non-melanoma skin cancers, having a concomitant genetic or acquired immune suppression disease such as HIV, having received systemic hormonal therapy within 3 weeks prior to the start of the trial (with some exceptions), and having taken herbal preparations/supplements or certain medications within 2 weeks prior to the start of the trial.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on patients with rheumatoid arthritis (RA). The ICD-10 codes associated with the disease are M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, and M06.019. The trial involves two drugs, namely mbs2320 and placebo. The eligibility criteria for inclusion in the trial include being a male or female patient with active RA who is receiving stable once-weekly methotrexate and is between 18 and 75 years old. Exclusion criteria include being pregnant or breastfeeding, currently undergoing treatment with biological or non-biological disease-modifying anti-rheumatic drugs, and having a history of any other inflammatory or arthritic disease in addition to RA that may interfere with the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is phase 2. The disease being studied is thyroid cancer. The corresponding ICD-10 codes for the disease are \"C73\", \"D34\", \"D44.0\", and \"Z85.850\". The drugs being tested are lenvatinib and everolimus. The eligibility criteria for the trial include being 18 years old or older, having a confirmed diagnosis of metastatic or unresectable differentiated thyroid cancer, having received prior treatments with radioactive iodine and non-lenvatinib MKI treatments, having documented progression while on lenvatinib treatment, having measurable disease, having a life expectancy greater than 3 months, and meeting certain organ function requirements.\n\nThe exclusion criteria for the trial include having received any intervening systemic cancer treatment since the prior lenvatinib treatment, having significant medical diseases such as uncontrolled congestive heart failure or active infection, having organ allografts, having uncontrolled high blood pressure, being pregnant or nursing, having known HIV-infection, and having a history of certain medical conditions or intolerances to the drugs being tested.\n\nOverall, this sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for a specific clinical trial related to thyroid cancer.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is ankylosing spondylitis. The ICD-10 codes associated with this disease are M08.1, M45.6, M45.2, M45.3, M45.4, M45.5, and M45.7. The drugs being tested in this trial are nanocurcumin and placebo. The eligibility criteria for participants in this trial include willingness to cooperate, being aged 22 to 50 years, having a diagnosis of ankylosing spondylitis by a rheumatologist, having active disease with a BASDAI score greater than 4, and having a disease duration of 5-8 years. The exclusion criteria include not taking nutritional supplements or antioxidant alpha-lipoic acid a month before the study, being pregnant or lactating, having a history of diabetes or other chronic diseases, having a history of other autoimmune diseases, experiencing relapses during the study period, accepting less than 70% of supplements, and being unwilling to continue to cooperate.",
    "The sample is a phase 2 trial for prostate adenocarcinoma. The diseases being studied are stage I and stage II prostate adenocarcinoma. The ICD-10 codes associated with these diseases are provided. The drugs being used in the trial are bicalutamide and raloxifene hydrochloride. The eligibility criteria for participants include having histologically confirmed adenocarcinoma of the prostate with a Gleason score of 6 or higher, being in clinical stage T1a-T2c, and planning to undergo radical prostatectomy. Other criteria include specific performance status, platelet count, hemoglobin level, and creatinine level. Participants must also provide informed written consent and be willing to return to the enrolling institution for follow-up. There are also exclusion criteria, such as having uncontrolled intercurrent illness, receiving other investigational agents, and having a history of certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The diseases being studied are melanoma stage III and melanoma stage IV. The corresponding ICDCodes for these diseases are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4. The drug being used in the trial is ipilimumab. The eligibility criteria for this trial include various factors such as the patient's age, performance status, organ function, and previous treatments. There are also exclusion criteria listed, which specify conditions or situations that would disqualify a patient from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is rheumatoid arthritis (RA), and the corresponding ICDCodes for this disease are M05.9, M06.08, M06.00, M06.011, M06.012, M06.019, and M06.021. \n\nThe drugs being tested in this trial are placebo, niclosamide, and etanercept. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Patients must have RA, as defined by the American College of Rheumatology (ACR) 1987 revised criteria or ACR/EULAR 2010.\n- Patients must have severely active RA, determined by calculating either DAS28 or SDAI or CDAI.\n- Patients must have started etanercept treatment within the last 3 months and still be active.\n\nExclusion Criteria:\n- Patients who have taken nonsteroidal anti-inflammatory drugs (NSAIDs) or methotrexate (MTX) within 2 days before entering the study.\n- Patients with hypersensitivity or severe adverse effects to niclosamide.\n- Patients with renal impairment.\n- Patients with hepatic impairment.\n- Patients who are pregnant or have a desire to become pregnant.\n- Patients who are breastfeeding.\n- Patients with Juvenile RA (16 years old or younger).\n- Patients using other conventional disease modifying antirheumatic drugs (DMARDs).\n- Patients on steroid medication.\n- Patients with coexistence of other connective tissue diseases or hypothyroid disease.\n- Patients with mild or inactive RA.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"amyotrophic lateral sclerosis\" (ALSO). The corresponding ICD-10 code for ALSO is \"G12.21\". The drugs being studied are \"reldesemtiv\" and \"placebo\". \n\nThe eligibility criteria for this trial include:\n- Diagnosis of familial or sporadic ALSO within the past 24 months\n- Upright Slow Vital Capacity (SVC) of at least 60% of predicted for age, height, and sex\n- Ability to swallow tablets\n- Availability of a caregiver if needed\n- Ability to perform reproducible pulmonary function tests\n- Pre-study clinical laboratory findings within the normal range or deemed not clinically significant\n- Male patients who have not had a vasectomy and confirmed zero sperm count must agree to use acceptable methods of contraception or abstain from sex\n- Female patients must be post-menopausal or sterilized, have a negative pregnancy test, have no intention to become pregnant during the study, and use acceptable methods of contraception or abstain from heterosexual intercourse\n- Patients must either be on riluzole for at least 30 days prior to screening or have not taken riluzole for at least 30 days prior to screening and not planning to start riluzole during the study\n- Patients on edaravone must have completed at least 2 cycles of dosing with edaravone at the time of screening or have not taken edaravone for at least 30 days prior to screening and not planning to start edaravone during the study\n\nThe exclusion criteria for this trial include:\n- Use of non-invasive ventilation (NIV) or mechanical ventilation via tracheostomy or any form of oxygen supplementation at the time of screening\n- Neurological impairment due to a condition other than ALSO\n- Presence of any medically significant cardiac, pulmonary, gastrointestinal, musculoskeletal, or psychiatric illness that might interfere with study procedures or confound the interpretation of clinical safety or efficacy data\n- Recent use of any investigational study drug\n- Previous participation in a clinical trial involving CK-2127107 or tirasemtiv\n- Consideration or receipt of stem cell therapy, gene therapy, or a diaphragmatic pacing system during the study\n- History of substance abuse within the past 2 years\n- Use of certain medications\n\nThis information provides an overview of the phase, disease, drugs, and eligibility/exclusion criteria for this particular sample in the clinical trial table.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is rectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being used in the trial is folfoxiri. \n\nThe eligibility criteria for this trial include a diagnosis of adenocarcinoma of the rectum, age between 18 and 70 years old, signed informed consent, ability to comply with study and follow-up procedures, stage of the primary tumor determined by MRI as CRM positive, tumor amenable to curative resection, and adequate bone marrow, hepatic, and renal function as assessed by specific laboratory requirements. \n\nThere are also exclusion criteria, such as hypersensitivity to fluorouracil, oxaliplatin, or irinotecan, recent participation in any investigational drug study, history of invasive rectal malignancy, uncontrolled hypertension, cardiovascular disease that would preclude study treatment or follow-up, lack of upper gastrointestinal tract integrity or malabsorption syndrome, synchronous colon cancer, pregnancy or nursing, other malignancies within the past 5 years (except for specific types), psychiatric or addictive disorders, or any other conditions that, in the opinion of the investigator, would preclude study participation.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of clear cell renal cell carcinoma. The trial includes a list of ICDCodes, which are specific codes used to classify diseases. The drugs being tested in the trial are \"cb-839 plus everolimus\" and \"placebo plus everolimus\". \n\nThe eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include a Karnofsky Performance Score of at least 70%, an estimated life expectancy of at least 3 months, a documented diagnosis of renal cell carcinoma with a clear-cell component, measurable disease as determined by the Investigator, and having received at least two prior lines of systemic therapy, including at least one VEGFR-targeting TKI. \n\nExclusion criteria include prior treatment with mTOR inhibitors or CB-839, recent receipt of anticancer therapy, inability to receive oral medications, recent major surgery, presence of active or untreated central nervous system cancer, requirement for continued proton pump inhibitor use, chronic treatment with corticosteroids or other immunosuppressive agents, among others.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is multiple myeloma. The ICD-10 codes associated with the disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are elotuzumab, lenalidomide, dexamethasone, and bortezomib. The eligibility criteria for the trial include being between 18 and 75 years old, having completed a stem cell transplant regimen for newly diagnosed multiple myeloma within the past eight months, achieving at least a partial response to the transplant regimen, having an ECOG score of 2 or lower, and meeting certain blood count and liver function requirements. There are also specific criteria for female and male patients regarding contraception. The sample also includes exclusion criteria such as pregnancy, poorly controlled medical conditions, history of cardiac disease, prior malignancies, and allergies or intolerances to certain medications.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on pulmonary disease, specifically chronic obstructive pulmonary disease (COPD). The trial involves the use of drugs such as danirixin 35 mg tablets, placebo, and rescue medication. The eligibility criteria for participants are listed, including age requirements, lung function criteria, and other medical conditions that may exclude individuals from participating. The sample also includes exclusion criteria, such as the presence of other lung diseases, recent use of certain medications, and abnormal medical test results. The sample provides detailed information about the trial and the requirements for potential participants.",
    "The sample is from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being tested, and \"criteria\" which provides the eligibility criteria for participants.\n\nIn this specific sample, the phase of the trial is phase 2 and the disease being studied is \"smoking cessation\". The corresponding ICD-10 codes for this disease are listed as well. The drugs being tested are \"cqss2\" and \"nicoderm cq patch\". The eligibility criteria for participants are then provided, including requirements such as being able to fully participate in the study, understanding and signing the informed consent form, being an English-speaking literate individual, being at least 18 years old, and being a smoker who consumes more than 10 cigarettes per day for the past 6 months. Other criteria include having a certain level of carbon monoxide in the breath, being in good health, having regular access to Verizon Wireless or home wifi, and meeting various exclusion criteria such as not having certain medical conditions, not having recent substance abuse history, and not having certain psychiatric conditions. The sample also includes additional exclusion criteria related to physical examination findings, tattoos, infections, and other factors.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"ulcerative colitis.\" The ICD-10 codes associated with this disease are \"K51.80,\" \"K51.813,\" \"K51.814,\" \"K51.90,\" \"K51.913,\" \"K51.914,\" and \"K51.811.\" The drugs being studied in this trial are \"cobitolimod\" and \"placebo.\" \n\nThe eligibility criteria for participants in this trial include being at least 18 years old, having a confirmed diagnosis of ulcerative colitis, having moderately to severely active left-sided ulcerative colitis as assessed by central reading, and currently using or having a history of using oral 5-Aminosalicylic Acid (5-ASA)/ Sulphasalazine (SP) or Glucocorticosteroids (GCS). Participants must also have demonstrated an inadequate response, loss of response, or intolerance to immunomodulators and/or tumor necrosis factor alpha (TNF-\u03b1) inhibitors and/or anti-integrins.\n\nThere are also exclusion criteria, which include suspicion of a differential diagnosis, acute fulminant ulcerative colitis or signs of systemic toxicity, ulcerative colitis limited to the rectum, history of malignancy, history or presence of any clinically significant disorder, concomitant treatment with certain medications, treatment with rectal GCS, 5-ASA/SP or tacrolimus, long-term treatment with antibiotics or non-steroidal anti-inflammatory drugs (NSAIDs), serious active infection, gastrointestinal infections, current parenteral nutrition or blood transfusions, lactating females or those with a positive pregnancy test, women of childbearing potential not using reliable contraceptive methods, concurrent participation in another clinical study, and previous exposure to cobitolimod.",
    "The sample from the table is for a phase 2 clinical trial for the treatment of epilepsy. The trial is looking at the effectiveness of a drug called diazepam buccal film 12.5 mg. The eligibility criteria for participants include being scheduled for admission to an Epilepsy Monitoring Unit (EMU) or similar facility, being between 18 to 65 years old, having a body weight of at least 40 kg, having a clinical diagnosis of epilepsy, and having a certain frequency of seizures. Female participants must have a negative pregnancy test and use contraception. Participants must also be currently receiving at least one antiepileptic medication and be willing to comply with all study procedures. There are also exclusion criteria, such as having certain neurological or respiratory disorders, being pregnant or lactating, having severe psychiatric disease, or having certain medical conditions. The sample also includes a list of diseases, icd-10 codes, and the phase of the trial.",
    "The sample is a phase 2 clinical trial for the treatment of major depressive disorder. The trial is evaluating the effectiveness of the drugs \"anyu peibo\" and \"placebo\" in adults with a primary diagnosis of major depressive disorder. The inclusion criteria for the trial include meeting the criteria of DSM-5 for major depressive disorder, having a certain score on the MADRS and HAMD-17 scales, and having a certain score on the CGI-S scale. The subjects must also understand and consent to participate in the trial. The exclusion criteria include recent suicide attempts or significant risk of suicide, current psychiatric diagnoses other than depression, certain changes in HAMD-17 scores, known hypersensitivity to certain drugs, and various medical and neurological conditions. Other exclusion criteria include a history of mania episodes, current diagnosis of depression due to a somatic disease, inability to take medication, and various abnormal laboratory values. The sample also includes exclusion criteria related to previous antidepressant treatment, use of certain drugs or therapies, history of substance abuse, pregnancy or plans to become pregnant, recent participation in another drug clinical trial, and the investigator's judgment of unsuitability for enrollment.",
    "The sample is a phase 2 trial for breast carcinoma. The eligibility criteria for participants include having biopsy-proven invasive breast carcinoma stages T1cN0 to T3N0, being ER or PR positive with tumors larger than 1cm without lymph node spread, and having a mammographic breast composition category (density) of c or d. Participants must also be willing to participate and provide signed informed consent, have no immediate requirements for chemotherapy, radiotherapy, or hormonal therapy, and be willing to discontinue the use of NSAIDs like aspirin or ibuprofen until the tumor is removed. There are also specific medications that participants cannot be taking due to major pharmacokinetic interactions with celecoxib, the drug being studied. Participants should pass an MRI screening questionnaire. \n\nExclusion criteria include a prior history of cancer, neo-adjuvant chemotherapy, and radiation therapy, no daily NSAIDs intake within the past 4 weeks (intermittent non-daily NSAIDs is allowed under PI discretion), current or prior systemic use of corticosteroids in the past month, history of hypertension, congestive heart failure, edema, stroke, or other cardiac disease or condition, type 2 diabetes, documented stomach ulcers, and pulmonary embolism. Participants with aspirin or other NSAIDs-induced asthma or hypersensitivity reaction, sulfonamide allergy, current pregnancy, known HIV infection, hepatitis B carrier state, or clinical evidence of hepatitis B are also excluded. Participants who are not able to understand or provide written informed consent, have standard contraindications to non-contrast MRI (such as claustrophobia and metallic implants incompatible with MRI), whose girth exceeds the bore of the MRI scanner, or require conscious sedation for MR imaging are also excluded.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease called eosinophilic esophagitis. The ICD-10 code for this disease is K20.0. The trial involves two drugs, apt-1011 and placebo. The eligibility criteria for participants are listed, including age requirements, evidence of EoE, history of dysphagia, symptom scores, and willingness to adhere to the study procedures. There are also exclusion criteria, such as contraindications to corticosteroids, certain medical conditions, and recent use of specific medications. The sample also includes criteria related to cortisol levels, previous treatments, and esophageal conditions.",
    "The sample from the table is for a phase 2 clinical trial. The trial is focused on menopause and hot flashes. The diseases column lists these two conditions. The icdcodes column contains the corresponding ICD-10 codes for the diseases. The drugs column includes the names of the drugs being tested, which are fezolinetant and two placebos. The criteria column provides the eligibility criteria for participants in the trial. It includes various requirements such as age, body mass index, amenorrhea duration, vasomotor symptoms, general health, mammogram results, willingness to undergo certain tests, negative alcohol and drug tests, negative pregnancy test, signed informed consent, normal Pap smear, and exclusion of certain medical conditions. The exclusion criteria list factors that would disqualify a participant from the trial, such as use of prohibited therapies, history of drug or alcohol abuse, presence of malignant tumors, uncontrolled hypertension, unsuitability based on physical examination or vital signs, severe allergies or intolerances, unacceptable endometrial biopsy results, history of certain conditions or diseases, liver or kidney disease, concurrent participation in another study, recent suicide attempt, inability or unwillingness to complete the study procedures, and involvement in the study as a staff member or relative.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is female infertility. The ICDCodes associated with this disease are 'N97.9', 'N97.0', 'N97.1', 'N97.2', 'N97.8', and 'Z31.81'. The drug being tested is sildenafil vaginal suppositories. \n\nThe eligibility criteria for this trial are as follows:\n- Women with normal ovarian reserve and had at least two prior cycles with FSH (follicle-stimulating hormone) levels below 10 mIu/ml.\n- Women who have a history of two or three consecutive failed IVF/ICSI attempts using at least two good quality fresh or frozen-thawed embryos.\n- The endometrial thickness on the day of hCG (human chorionic gonadotropin) injection was less than 9 mm in all prior IVF/ICSI attempts.\n- Women with a normal endometrial appearance in hysteroscopy or hysterosonography or hysterosalpingography.\n\nThe exclusion criteria for this trial are as follows:\n- Women who have a history of polycystic ovary syndrome (PCOS), myomectomy, Asherman's Syndrome, and mullerian anomalies.",
    "The sample in the table is for a phase 2 clinical trial focused on hypercholesterolemia. The trial is investigating the effectiveness of two drugs, bempedoic acid 180mg and evolocumab. The eligibility criteria for participants include being at least 18 years old, having a fasting calculated LDL-C level of at least 160 mg/dL at screening and at least 70 mg/dL after previous PCSK9i therapy, and being male or a nonpregnant, nonlactating female. \n\nThe exclusion criteria include having heterozygous or homozygous familial hypercholesterolemia, having a total fasting TG level of at least 500 mg/dL, having renal dysfunction or a glomerulonephropathy with an eGFR less than 30 mL/min/1.73 m2, having known cardiovascular disease, peripheral arterial disease, or cerebrovascular disease, having a history of type 1 or type 2 diabetes, having uncontrolled hypertension or hypothyroidism, having liver disease or dysfunction, having gastrointestinal conditions or procedures, having a history of hematologic or coagulation disorders, having a history of malignancy (except non-metastatic basal or squamous cell carcinoma of the skin and cervical carcinoma in situ), having unexplained creatine kinase levels greater than 3 times the upper limit of normal, and having used a cholesterylester transfer protein inhibitor in the last 12 months prior to screening. \n\nAdditionally, participants who are pregnant, breastfeeding, or planning to become pregnant during treatment or within 30 days after the end of treatment are also excluded from the trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is major depressive disorder. The icd-10 codes associated with this disease are F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, and F33.40. The drugs being tested in this trial are \"btrx-246040 oral capsule(s)\" and \"placebo oral capsule(s)\". The eligibility criteria for this trial include having a diagnosis of MDD according to DSM-5 criteria, having had at least 1 prior major depressive episode in the past 10 years, presenting with a new current episode of MDD lasting between 4 weeks and 18 months, having clinically significant depressive symptoms, and having a CGI-S score of at least 4. There are also exclusion criteria, such as having any current DSM-5 disorder other than MDD, being homicidal or at suicidal risk, having a history of substance or alcohol use disorder within the past 12 months, and having a clinically significant comorbid disease.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is rheumatoid arthritis. The corresponding ICD-10 codes for this disease are M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, and M06.019. The drug being tested in this trial is etanercept. The eligibility criteria for this trial state that subjects must be between the ages of 18 and 55 and can be either male or female. The exclusion criteria specify that individuals who have previously been treated with any monoclonal antibody agent, including tumor necrosis factor inhibitors other than SB4, are not eligible for this trial.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is motor neuron disease, specifically including Amyotrophic Lateral Sclerosis (ALSO), Primary Lateral Sclerosis (PLS), or Progressive Muscular Atrophy (PMA). The ICD-10 codes associated with these diseases are 'G12.20', 'G12.24', and 'G12.29'. The drugs being tested in the trial are 'flx-787-odt (orally disintegrating tablet)' and 'placebo odt'. \n\nThe eligibility criteria for inclusion in the trial are:\n- Documented diagnosis of Motor Neuron Disease (MND) including ALSO, PLS, or PMA\n- Expected survival of more than 6 months\n- Weekly muscle cramping\n- Exclusion criteria include:\n- Presence of major gastrointestinal disorders\n- Presence of laryngospasm or significant swallowing problems\n- Presence of certain medical procedures or devices\n- Inability or unwillingness to discontinue certain medications\n- Inability to tolerate a spicy sensation in the mouth or stomach\n- History of substance abuse or current illicit drug use\n- Intention to change tobacco use or use of nicotine-containing products\n- Participation in another clinical study within 30 days prior to screening.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is \"nonproliferative diabetic retinopathy.\" The ICDCodes associated with this disease are \"E10.3213, E10.3293, E10.3313, E10.3393, E10.3413, E10.3493, E11.3213.\" The drugs being tested in this trial are \"akb-9778\" and \"placebo.\" The eligibility criteria for this trial include specific age requirements, the severity of the disease, visual acuity, and exclusion criteria related to other ocular diseases, neovascularization, HbA1C levels, and medical or psychiatric conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 1/Phase 2. The disease being studied is HIV infections, which is represented by the ICD-10 code 'Z21'. The drugs being used in the trial are disulfiram and vorinostat, along with their respective National Drug Codes (NDC). The eligibility criteria for participants are listed, including age, HIV status, CD4+ T cell count, ability to provide informed consent, and various other factors. There are also exclusion criteria listed, such as current alcohol use disorder, certain medication use, significant medical conditions, and pregnancy. Additionally, there are specific laboratory values that need to be within acceptable ranges for participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease of hypertension. The ICD-10 codes associated with this disease are ['I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', 'I10']. The drug being studied is called qgc001. The eligibility criteria for participants in this trial are listed, including requirements such as providing informed consent, being at least 18 years old, having a diagnosis of primary hypertension for at least 3 months, and meeting specific blood pressure measurements. There are also criteria related to body mass index, successful ambulatory blood pressure monitoring, and contraception use for sexually active participants. The sample also includes exclusion criteria, such as having secondary hypertension, certain medical conditions, recent history of certain diseases or surgeries, and other factors that may interfere with the study or pose risks to participants.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a trial in phase 2/phase 3, focusing on the treatment of polycystic ovarian syndrome and infertility. The associated ICD-10 codes for the diseases are E28.2 for polycystic ovarian syndrome and N46.8, N46.9, N97.9, N97.0, N97.1, N97.2, N97.8 for infertility.\n\nThe trial involves the use of two drugs, namely d-chiro-inositol and myoinositol. The eligibility criteria for participants are as follows:\n\nInclusion Criteria:\n- Being diagnosed with PCOS according to Rotterdam criteria.\n- Undergoing in vitro fertilization treatment.\n- Having a body mass index less than 30 kg/m2.\n- Willing to participate in the study and signing the informed consent document.\n\nExclusion Criteria:\n- Having contraindications to perform assisted reproduction techniques or ovulation stimulation.\n- Being in an advanced stage of endometriosis (III or IV).\n- Being classified as a poor responder in fertility treatment.\n- Having premature ovarian failure.\n- Having a severe male factor (cryptozoospermia).\n- Having low expectations of compliance and/or collaboration.\n\nThis information provides a detailed description of the trial's phase, diseases being studied, associated ICD-10 codes, drugs used, and the eligibility criteria for participants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of acute pain. The trial includes patients with specific ICD-10 codes related to acute pain. The drugs being tested in the trial are vx-150, hb/apap, and placebo. The sample also includes the eligibility criteria for the trial, which are divided into inclusion and exclusion criteria. The inclusion criteria specify requirements such as a specific BMI range and the need for a specific type of surgery. The exclusion criteria include factors such as a history of certain medical conditions, intolerance to specific medications, and pregnancy or planning to become pregnant. There is also a specific exclusion criterion related to the type of deformity or complications during the surgery. The sample concludes by mentioning that there may be additional inclusion/exclusion criteria defined by the trial protocol.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of diabetic peripheral neuropathy. The trial involves the use of the drugs \"nyx-2925\" and \"placebo\". The eligibility criteria for participants include being between 18 and 75 years old, having a diagnosis of Type 2 diabetes, and experiencing a score of 4 to 9 on a pain intensity scale. Other criteria include specific laboratory values, stable use of diabetic medications, and a body mass index of less than 40 kg/m^2. Exclusion criteria include having certain psychiatric disorders, pain conditions that could interfere with the assessment of neuropathy, and various medical conditions that could affect participation in the study. Waivers to the inclusion and exclusion criteria are not allowed.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on hepatocellular carcinoma and liver cirrhosis. The diseases are represented by their names and corresponding ICD-10 codes. The trial involves the use of two drugs, pravastatin pill and placebo oral tablet. The eligibility criteria for participants are listed, including age, confirmed diagnosis of liver cirrhosis, specific criteria for the diagnosis of hepatocellular carcinoma, initiation of LRT (locoregional therapy) within 24 months prior to the screening visit, ECOG performance status, AST and ALT levels, AFP level, ability to understand and sign informed consent, contraception use, and willingness to comply with the trial protocol. The exclusion criteria include current use of statin medication, use of medications known to interact with statins, history of adverse effects to similar medications, use of other investigational agents, pregnancy or breastfeeding, prior liver transplant, high MELD score, history of chronic myopathy, active malignancy (excluding HCC, basal/squamous cell skin cancer, or low-grade prostate cancer), HIV infection, hemophilia, concurrent illnesses that may compromise the patient or data integrity, and excessive alcohol consumption.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and the disease being studied is \"healthy\" (which seems to be a placeholder value). The associated ICD-10 codes for the disease are \"Z76.3\" and \"Z76.2\". The drugs being used in the trial include \"dexmedetomidine perineurally\", \"ropivacaine 5mg/ml\", \"ropivacaine 7.5mg/ml\", \"dexmedetomidine systemically\", and \"isotonic saline\". \n\nThe eligibility criteria for participants in the trial are as follows:\n- Participants must fully understand the protocol and provide written informed consent.\n- Participants must have an ASA (American Society of Anesthesiologists) classification of 1 or 2.\n- Participants must have a BMI (Body Mass Index) between 18 and 30.\n- For fertile women, they must have been using safe contraceptives for the last month and have a negative urine HCG (Human Chorionic Gonadotropin) test.\n\nThe exclusion criteria for participants in the trial are as follows:\n- Participants who are unable to cooperate in the trial.\n- Participants who are unable to speak or read Danish.\n- Participants who have allergies to the study medication.\n- Participants who consume more than 21 units of alcohol per week (for men) or more than 14 units per week (for women).\n- Participants who have taken prescription painkillers daily within the last 4 weeks.\n- Participants who have taken over-the-counter painkillers within the last 48 hours.\n- Participants who have neuromuscular defects or wounds on their arms or hands that would prevent them from performing the required tests.\n- Participants who have Diabetes Mellitus.\n- Participants who have 2nd-degree heart block.\n- Participants who have a sick sinus node.\n- For fertile women, a positive urine HCG test is an exclusion criterion.\n\nThis information provides details about the phase, diseases, ICDCodes, drugs, and eligibility criteria for participants in the clinical trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is cystic fibrosis. The ICDCodes associated with this disease are E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, and P09.4. The drugs mentioned in the sample are tez/iva, vx-659, iva, matched placebos, tez, and vx-561. The eligibility criteria include specific requirements such as a body weight of at least 35 kg, having an eligible CFTR genotype (heterozygous for F508del and an MF mutation for Part 1 and Part 3, and homozygous for F508del for Part 2), and FEV1 value between 40% and 90% of the predicted mean for age, sex, and height. There are also exclusion criteria mentioned, such as a history of clinically significant cirrhosis, glucose-6-phosphate dehydrogenase (G6PD) deficiency, lung infection with certain organisms, and a history of solid organ or hematological transplantation.",
    "The sample provided is a record from a clinical trial database. It pertains to a phase 2 trial for the treatment of primary biliary cirrhosis. The eligibility criteria for participants are listed, including age requirements, diagnosis confirmation, specific liver enzyme levels, and previous treatment history. Inclusion criteria also mention the use of contraception for female participants and the use of condoms for male participants with female partners. Exclusion criteria are also listed, such as pregnancy, hepatic complications, abnormal liver function, and certain medical conditions. The sample concludes with a general exclusion for any condition that may pose a risk or interfere with the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is \"depressive disorder, major.\" The ICDCodes associated with this disease are ['F33.0', 'F33.1', 'F33.9', 'F32.0', 'F32.1', 'F32.9', 'F33.40']. The drugs being tested in this trial are 'placebo' and 'jnj-42847922'. \n\nThe eligibility criteria for participants in this trial include being men or women of non-childbearing potential aged 18 to 70 years. They must meet the diagnostic criteria for major depressive disorder (MDD) based on the DSM-5 and confirmed by the SCID-CT. The length of their current depressive episode must be less than or equal to 18 months. Participants must have had an inadequate response to 1 to 3 antidepressants, as measured by the MGH-ATRQ. They must also be receiving monotherapy treatment with specific SSRI/SNRI antidepressants at a stable dose for at least 4 weeks but no longer than 12 months. \n\nAdditionally, participants must have a Montgomery-Asberg Depression Rating Scale (MADRS) total score of 25 or higher at screening and must not demonstrate a clinically significant improvement from screening to baseline visit. They must be otherwise healthy based on physical examination, medical history, vital signs, ECG, and clinical laboratory tests. \n\nExclusion criteria include severe renal insufficiency, moderate to severe hepatic insufficiency, significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic, or endocrine disorders. Participants with well-controlled non-insulin dependent diabetes mellitus may be eligible if otherwise medically healthy. Participants with certain medical disorders of the hypothalamic-pituitary-adrenal (HPA) axis, lack of response to multiple antidepressant treatments, history or current diagnosis of certain psychiatric disorders, and significant primary sleep disorders are also excluded from the trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is cystic fibrosis, and the corresponding ICDCodes are E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, and P09.4. The drugs being tested in the trial include iva, tez/iva, vx-445, matched placebo, tez, and vx-561. The eligibility criteria for the trial include specific age ranges, body mass index requirements, body weight thresholds, and FEV1 values. There are also exclusion criteria related to drug absorption, recent febrile illness, glucose-6-phosphate dehydrogenase deficiency, cirrhosis, lung infections, and history of organ or hematological transplantation.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of depression and related disorders in postpartum women. The diseases listed include depression, depressive disorder, postpartum depression, behavioral symptoms, mood disorders, mental disorders, puerperal disorders, pregnancy complications, postpartum, and postpartum depression. The corresponding ICD-10 codes for these diseases are also provided. The drugs being studied in the trial are ganaxolone and a placebo. The eligibility criteria for participants are listed, including requirements such as experiencing a major depressive episode during the third trimester or within 4 weeks after delivery, giving birth within the last 6 months, having a certain HAMD17 score, and agreeing to stop breastfeeding or temporarily cease giving breast milk. There are also exclusion criteria, such as a history of psychotic illness, suicide attempts, bipolar I disorder, and seizure disorder.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of biliary tract cancer. The diseases column specifies the disease being studied, while the icdcodes column provides the corresponding ICD-10 codes for the disease. The drugs column lists the names of the drugs being used in the trial, which in this case are varlitinib and capecitabine. The criteria column contains the eligibility criteria for patients to participate in the trial. The inclusion criteria include having histologically or cytologically confirmed advanced or metastatic biliary tract cancer, having received and failed one prior line of systemic treatment, and having radiographically measurable disease. The exclusion criteria include being currently on or having received anti-cancer therapy within the past 3 weeks, having major surgical procedures within 14 days prior to study entry, and having a known positive test for HIV or hepatitis B or C infection.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested in this trial is trametinib. The eligibility criteria for this trial include various conditions such as having a confirmed diagnosis of metastatic or unresectable locally advanced non-squamous NSCLC, having specific somatic mutations, having received prior cancer therapy, and meeting certain organ function and performance status requirements. The sample also includes exclusion criteria, such as having certain mutations, having untreated brain metastases, being pregnant or breastfeeding, having a history of other malignancies, and having certain medical disorders or conditions that could interfere with the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of primary open angle glaucoma or ocular hypertension. The diseases column lists the names of the diseases being studied, while the icdcodes column contains the corresponding ICD-10 codes for those diseases. The drugs column specifies the drug being used in the trial, which is \"netarsudil ophthalmic solution 0.02%\". The criteria column provides the eligibility criteria for participants in the trial, including both inclusion and exclusion criteria. The inclusion criteria state that participants must be 18 years or older, have a diagnosis of primary open angle glaucoma or ocular hypertension in both eyes, have a specific range of unmedicated intraocular pressure, have a certain level of visual acuity, and be able to give informed consent and follow study instructions. The exclusion criteria list various factors that would disqualify a participant, such as having certain ocular diseases, a history of certain types of glaucoma, high intraocular pressure, use of multiple ocular medications, hypersensitivity to the drug formulation, previous eye surgeries, recent eye injuries or infections, and certain systemic diseases or medications. Additionally, women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is dermatitis, specifically atopic dermatitis. The ICDCodes associated with this disease are \"L20.89\" and \"L20.9\". The drugs being tested in this trial are \"crisaborole ointment 2% bid\" and \"placebo ointment (vehicle)\". The eligibility criteria for participants in this trial include having a confirmed diagnosis of active atopic dermatitis with a minimum 6-month history, a stable condition for at least 1 month, a mild to moderate severity level, a certain percentage of body surface area affected by the disease, and specific lesion characteristics. There are also exclusion criteria, such as having clinically infected dermatitis, a history of allergic reactions to topical products or the specific drug being tested, a history of cancer (except certain types), and previous treatment with certain inhibitors.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 2.\n- Diseases: The trial is focused on muscle-invasive bladder cancer.\n- ICD Codes: The ICD-10 codes associated with the disease are ['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4'].\n- Drugs: The drugs being tested in the trial are 'durvalumab (imfinzi)' and 'tremelimumab'.\n- Criteria: The eligibility criteria for participants in the trial are listed, including age, performance status, confirmed diagnosis, measurable disease, and various laboratory results. There are also exclusion criteria, such as prior treatments, autoimmune diseases, pregnancy or breastfeeding, and certain medical conditions.\n\nThis record provides specific information about the phase, diseases, drugs, and eligibility criteria for a clinical trial focused on muscle-invasive bladder cancer.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is esophageal cancer. The ICDCodes associated with this disease are \"K22.2\", \"K22.81\", \"Q39.4\", \"P78.83\", \"I85.00\", \"I85.01\", and \"I85.10\". The drug being used in the trial is chemotherapy. The eligibility criteria for this trial include being at least 18 years old, having pathologically confirmed esophageal adenocarcinoma or squamous cell carcinoma of the thoracic esophagus or esophagogastric junction, and having a preliminary cancer stage of cT1b-T4, N0-N3 according to the AJCC 7th edition staging. There are also exclusion criteria listed, such as not having cervical esophageal carcinoma, not having received prior radiotherapy with fields overlapping the current esophageal cancer, not having cT1a disease, not having evidence of tracheoesophageal fistula, and not having distant metastatic disease.",
    "The sample provided is for a phase 2 clinical trial. The specific disease being studied is stress urinary incontinence. The associated ICD-10 codes for this disease are N39.41, N39.46, N39.490, N39.491, N39.492, R32, and R39.81. The drugs being tested in this trial are gtx 024 and a placebo. \n\nThe eligibility criteria for participants in this trial include having symptoms of stress urinary incontinence for at least 6 months, being predominantly affected by stress urinary incontinence as determined by the MESA urinary questionnaire, having a 24-hour pad weight of more than 3 grams during the screening period, experiencing a minimum of 1 and no more than 15 episodes of stress urinary incontinence on any single day, and having a total of at least 9 episodes of stress urinary incontinence over 3 days during the screening period. Additionally, participants must have a positive bladder stress test conducted during the screening visit.\n\nThere are also exclusion criteria for this trial. These include a history of pelvic radiation treatment, urethral diverticula, urethral sling or anterior prolapse repair, treatment with urethral bulking agents or other stress urinary incontinence procedures or surgeries within the 6 months prior to the screening visit, known vesicoureteral reflux, vaginal prolapse beyond the introitus, or other significant pelvic floor abnormalities, urinary incontinence of neurogenic etiology, being morbidly obese (defined as 100 pounds over ideal body weight or having a body mass index of 40 or greater), chronic hepatitis, hepatic cirrhosis, evidence of active infection with hepatitis B or hepatitis C, history of human immunodeficiency virus (HIV) infection, and a history of breast or endometrial cancer.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is Phase 2.\n- Diseases: The specific disease being studied, which in this case is \"type 2 diabetes mellitus.\"\n- ICD Codes: The ICD-10 codes associated with the disease, which are \"E11.65,\" \"E11.9,\" \"E11.21,\" \"E11.36,\" \"E11.41,\" \"E11.42,\" and \"E11.44.\"\n- Drugs: The drugs being used in the trial, which are \"medi0382\" and \"placebo.\"\n- Criteria: The eligibility criteria for participants in the trial, which are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\"\n\nThe inclusion criteria include factors such as age, BMI, HbA1c range, and specific requirements for individuals with type 2 diabetes mellitus. The exclusion criteria include factors such as existing medical conditions, participation in other studies, allergies, and various health conditions that may interfere with the trial or put the participant at risk.\n\nOverall, this sample provides a snapshot of a Phase 2 clinical trial focused on type 2 diabetes mellitus, including the specific criteria for participant eligibility.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2. The diseases being studied are acute pain, bunion, and abdominoplasty. The corresponding ICDCodes for these diseases are G89.12, G89.18, G89.11, G89.3 for acute pain, and M21.611, M21.612, M21.619, M21.621, M21.622, M21.629 for bunion. The drugs being tested in this trial are wafermine\u2122 50 mg, wafermine\u2122 75 mg, placebos, and wafermine\u2122 25 mg. The eligibility criteria for inclusion include being scheduled for a bunionectomy or mini abdominoplasty with no additional planned procedures, and being in good general health without significant renal, hepatic, cardiac, or respiratory disease. The exclusion criteria include having other painful conditions involving the surgical foot for those undergoing bunionectomy, and having positive lab values for Hepatitis B or C or HIV.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease called fibromyalgia. The ICD-10 code for fibromyalgia is \"M79.7\". The trial involves the use of two drugs, nyx-2925 and a placebo oral capsule. The eligibility criteria for participants in the trial are listed, including meeting the 2010 American College of Rheumatology criteria for fibromyalgia, having a certain level of self-reported clinical pain, being on a stable fibromyalgia treatment plan, and meeting various other medical and demographic requirements. The exclusion criteria are also listed, which include restrictions on the use of certain medications, presence of certain medical conditions, and other factors that may interfere with the study.",
    "The sample from the table is for a clinical trial in phase 2/phase 3. The trial is focused on the disease \"tardive dyskinesia\" and the associated ICD-10 codes are \"K22.4\" and \"G24.01\". The drugs being studied are \"propranolol hydrochloride\" and a \"placebo oral tablet\". \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- Age between 18 and 75 years\n- Diagnosis of classical TD by a movement disorder expert for at least 6 months with a baseline score of at least 2 on two of the seven items on the AIMS severity scale\n- Stable on medication (either on or off dopamine blocking agents) for at least six months\n\nThe exclusion criteria for the trial are as follows:\n- Breastfeeding\n- Pregnant\n- Unstable psychiatric disease\n- History of asthma or COPD\n- Baseline heart rate less than 60\n- History of orthostatic hypertension or its presence at screening\n- History of congestive heart failure or unstable angina pectoris\n- Resting SBP <100 and DBP < 60\n- AV-block II or III without pacemaker\n- History of diabetes mellitus\n- Previous adverse effects from use of beta-blockers\n- Current use of a \u03b2-blocker and the other following drugs: quinidine, amiodarone, propafenone, digoxin, verapamil, diltiazem, clonidine, and warfarin\n- Tremor, dystonia, akathisia, or other non-tardive movement disorder\n- Any medical illness that precludes treatment with propranolol.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on two diseases: type 2 diabetes mellitus and overweight and obesity. The corresponding ICD-10 codes for these diseases are provided as well. The trial involves two drugs, namely \"zgn-1061\" and \"placebo\". The eligibility criteria for participants are listed, including age requirements, body mass index (BMI), HbA1c levels for diabetes, stability of antidiabetes medication doses, and a minimum time since weight-loss surgery. The exclusion criteria are also mentioned, which include recent use of other study drugs or devices, certain prescribed medications, consistent use of insulin, recent major surgery or bed rest, bleeding disorders or risk factors for blood clotting, difficulty giving blood, and a history of drug and/or alcohol abuse.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on patients with esophageal neoplasms, specifically esophageal squamous cell carcinoma. The trial requires patients to have a definitive diagnosis of this type of cancer through pathological evaluation and to have non-metastatic esophageal cancer. Patients should also be candidates for chemo-radiation treatment and have normal blood count, kidney function, liver function, and fasting blood sugar levels.\n\nThere are certain exclusion criteria as well. Patients with a previous history of chest wall radiotherapy or chemotherapy are excluded, as well as those with a medical history of hypertension, diabetes mellitus, renal failure, or liver failure. Patients with a pathological report of adenocarcinoma or small cell carcinoma, neoplasm of other organs, or those who are discontent or unwilling to undergo daily radiotherapy or esophagectomy are also excluded from the study.\n\nThe drugs being used in the trial include enoxaparin sodium 40 mg/0.2 ml subcutaneous injectable and chemotherapeutic combinations. The icd-10 codes associated with the disease are ['K22.2', 'K22.81', 'Q39.4', 'P78.83', 'I85.00', 'I85.01', 'I85.10'].",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is non-alcoholic fatty liver disease. The ICDCodes associated with this disease are Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, and K70.0. The drugs being tested in this trial are placebo, pf-06835919 low dose, and pf-06835919 high dose. The eligibility criteria for this trial include having a BMI of at least 28 kg/m2, having type 2 diabetes and/or metabolic syndrome, and not having liver disease, type 1 diabetes, recent heart attack or stroke, or an inability to have an MRI scan.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is chronic obstructive pulmonary disease (COPD), and the corresponding ICD-10 codes for COPD are J44.9, J44.1, and J44.0. The drugs being tested in this trial are glycopyrronium mdi 28.8 micrograms, glycopyrronium mdi 14.4 micrograms, glycopyrronium mdi 7.2 micrograms, and a placebo mdi. \n\nThe eligibility criteria for this trial are as follows:\n- The participant must have a clinical history of COPD with a moderate to severe classification.\n- They must be current or former smokers with a history of at least 10 pack-years of cigarette smoking.\n- Their post-bronchodilator FEV1 (forced expiratory volume in 1 second) must be between 30% and 80% of the predicted normal value.\n\nThe exclusion criteria for this trial are:\n- Pregnancy\n- Primary asthma diagnosis\n- Poorly controlled COPD, defined as acute worsening of COPD that required treatment with corticosteroids or antibiotics in the 6-week interval prior to screening or between screening and visit 2\n- Clinically significant abnormal ECG (electrocardiogram)\n- Other active pulmonary diseases such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung disease, and uncontrolled sleep apnea\n- Cancer that has not been in complete remission for at least 5 years\n- Diagnosis of angle closure glaucoma\n- A documented myocardial infraction (heart attack) within 1 year of screening.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of nonsmall cell lung cancer. The trial is specifically targeting patients who have previously received no more than one line of treatment. The trial is evaluating the effectiveness of two drugs, apatinib/docetaxel/pemetrexed and docetaxel/pemetrexed, in treating the disease.\n\nThe eligibility criteria for the trial are as follows:\n1. Age: 18-75 years.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n3. Patients must have histologically or cytologically confirmed locally advanced or advanced NSCLC.\n4. Patients must have at least one measurable lesion as defined by RECIST (version 1.1).\n5. Patients must test negative for EGFR and ALK mutations.\n6. Patients must not have brain metastases or asymptomatic brain metastases requiring treatment.\n7. Patients must have a life expectancy of at least 3 months.\n8. Patients must have normal organ function.\n9. Females of childbearing potential must have a negative pregnancy test within 7 days before participating.\n10. Patients must provide written informed consent and be willing and able to comply with the protocol.\n\nThe exclusion criteria for the trial are as follows:\n1. Patients with small cell lung cancer.\n2. Patients with symptomatic brain metastases.\n3. Patients with a life expectancy of less than 3 months.\n4. Patients who require blood transfusion within 14 days of the first dose of drug treatment.\n5. Patients who have received chemotherapy, biotherapy, radiotherapy, or other anticancer therapies within 21 days of the first dose of drug treatment (excluding palliative radiotherapy).\n6. Patients at risk of active bleeding.\n7. Patients with uncontrolled blood pressure (140/90 mmHg) despite medication.\n8. Patients with abnormal laboratory values or organ dysfunction, including hematologic insufficiency, liver function insufficiency, renal function insufficiency, positive for HBV surface antigen or anti-HCV, interstitial lung disease, and impairment of heart function.\n9. Patients with liver fibrosis or hepatic cirrhosis.\n10. Patients with other active malignancy, except for certain treated non-melanoma skin cancer, carcinoma in-situ of the cervix, or other cancers that have been treated with curative intent and have no signs of recurrence for at least 5 years.\n11. Patients with dysphagia, malabsorption, chronic gastrointestinal diseases, or other medical history that may hinder compliance or drug absorption.\n12. Patients who have undergone major surgery within 28 days of the first dose of drug treatment.\n13. Patients who test positive for known human immunodeficiency virus (HIV).",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is respiratory syncytial virus infections. The corresponding ICD-10 codes for this disease are R09.2, A15.7, A15.8, A15.9, J98.9, R06.03, and J12.1. The drugs being tested in this trial are rv521 and placebo. The sample also includes the eligibility criteria for participants. The inclusion criteria state that participants must be between the ages of 18 and 45, in good health with no major medical conditions, and have a body weight of at least 50 kg and a BMI between 18 and 30 kg/m2. The exclusion criteria state that participants should not have any clinically significant or currently active major medical conditions, should not test positive for HIV or active Hepatitis A, B, or C, should not have significant nose or nasopharynx abnormalities, should not have abnormal lung function, and should not have a history or currently active symptoms of upper or lower respiratory tract infection.",
    "The sample from the table is a clinical trial for patients with myelodysplastic syndromes (MDS) in phase 1/phase 2. The trial is testing the effectiveness of multiple drugs including nivolumab, azacitidine, fludarabine, cyclophosphamide, cytarabine, all trans retinoic acid, sildenafil, and melphalan. The eligibility criteria for the trial include having MDS with up to 20% blasts, being 18 years or older, having no severe organ dysfunction, having a Karnofsky index of at least 70%, and meeting certain requirements for females of childbearing potential and males with partners of childbearing potential. The exclusion criteria include having another malignancy requiring treatment, a history of interstitial lung disease or pneumonitis, having any other severe and/or uncontrolled medical condition, having an active autoimmune disease requiring treatment, being pregnant or breastfeeding, being unwilling or unable to comply with the protocol, having a somatic or psychiatric disorder that prevents signing informed consent, and having prior treatment with certain therapies.",
    "The sample provided is a record from a table that contains information about a clinical trial. The table has several columns, including \"phase\" which indicates the phase of the trial (in this case, phase 2), \"diseases\" which lists the disease names (in this case, \"castration-resistant prostate cancer\"), \"icdcodes\" which lists the ICD-10 codes associated with the diseases, \"drugs\" which lists the drug names (in this case, \"calcitriol, ketoconazole, hydrocortisone\"), and \"criteria\" which provides the eligibility criteria for the trial.\n\nThe eligibility criteria are listed in a structured format, with each criterion numbered and described. The criteria include age requirements, confirmation of the specific type of prostate cancer, presence of measurable or evaluable disease, restrictions on previous chemotherapy, discontinuation of certain therapies, organ and marrow function requirements, ability to receive oral medications, and other factors such as life expectancy, performance status, and the need for contraception.\n\nThe exclusion criteria are also listed, which include hypersensitivity to certain medications, history of allergic reactions, presence of significant clinical disorders or laboratory findings, history of certain conditions or diseases, and other factors that may make it undesirable for a patient to participate in the trial.\n\nThe sample also includes information about the dosage and mode of administration for the drugs used in the trial, including ketoconazole, calcitriol, and hydrocortisone.\n\nOverall, the sample provides detailed information about the phase, diseases, drugs, eligibility criteria, and dosage of a clinical trial for castration-resistant prostate cancer.",
    "The sample provided is for a phase 2 clinical trial for attention deficit hyperactivity disorder (ADHD). The trial is investigating the effectiveness of the drug \"aevi-001\" compared to a placebo. The eligibility criteria for participants include being between 6 and 17 years old, having a primary diagnosis of ADHD based on DSM-5 criteria, and having a minimum score of 28 on the ADHD-RS-5 assessment. Participants must also be fluent in English, provide written informed consent, and comply with contraceptive requirements if of childbearing potential. Exclusion criteria include having significant emotional problems, having a co-morbid major psychiatric diagnosis (aside from ADHD), having autism spectrum disorder, currently taking medication that may affect safety assessments, and having a history of cardiovascular disease or other serious cardiac problems.",
    "The sample from the table is for a phase 2 clinical trial. The diseases being studied are marginal zone lymphoma, recurrent marginal zone lymphoma, recurrent waldenstrom macroglobulinemia, refractory marginal zone lymphoma, refractory waldenstrom macroglobulinemia, and waldenstrom macroglobulinemia. The corresponding ICD-10 codes for these diseases are provided as well. The drug being tested in the trial is carfilzomib. The eligibility criteria for the trial include specific disease diagnoses, measurable disease criteria, certain blood counts, kidney and liver function requirements, informed consent, expected survival of more than 90 days, and contraception for females of childbearing potential and male subjects. The exclusion criteria include certain infections, candidacy for curative antibiotic therapy for gastric MALT lymphoma, poor performance status, active central nervous system involvement, pregnancy or lactation, inadequate cardiac function, significant neuropathy, uncontrolled inter-current illness, and recent non-hematologic malignancy.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"beta-thalassemia\". The associated ICD-10 codes for this disease are \"D56.1\", \"D56.2\", \"D56.5\", \"D57.42\", \"D57.44\", \"D57.432\", and \"D57.439\". The drug being studied in this trial is \"bitopertin\". \n\nThe eligibility criteria for this trial include a confirmed diagnosis of beta-thalassemia, non-transfusion-dependent anemia with specific hemoglobin concentration levels, completion of a previous 16-week treatment with bitopertin, and a favorable benefit-risk ratio as assessed by the investigator. \n\nThere are also exclusion criteria, such as a history of gene therapy, hemolytic anemia (except for beta-thalassemia), severe symptomatic splenomegaly and/or hepatomegaly, recent use of erythropoiesis-stimulating agents or iron chelation therapy, presence of depression or psychiatric illnesses/drug abuse, significant comorbid diseases, pregnancy or breastfeeding, recent use of specific medications, active hepatitis B or C, positive HIV test result, recent cancer diagnosis, major illness or febrile illness prior to the study, and pulmonary hypertension requiring oxygen therapy (only applicable to Part 1 of the study).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is HIV-1 infection. The ICDCodes associated with this disease are \"B20\", \"Z71.7\", \"O98.72\", \"Z21\", \"O98.73\", \"R75\", and \"Z11.4\". The drugs being tested in this trial include islatravir, doravirine, lamivudine, and combinations of these drugs. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having HIV-1 infection, being na\u00efve to anti-retroviral therapy, being clinically stable, and following contraceptive guidance. Exclusion criteria include a history of drug or alcohol abuse, hypersensitivity to study drugs, history of malignancy, pregnancy, breastfeeding, positive pregnancy test, previous treatment for viral infections other than HIV-1, use of prohibited medications, participation in other clinical trials, virologic resistance to HIV-1 inhibitors, and co-infections with hepatitis C or hepatitis B. Additionally, previous participation in a study involving the mentioned drugs is also an exclusion criterion.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on two diseases: non-alcoholic fatty liver disease and diabetes mellitus type 2. The diseases are associated with specific ICD-10 codes. The trial involves the use of a drug called levothyroxine sodium. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Male between 21 to 60 years of age\n- Diagnosed with stable Type II diabetes mellitus with no recent changes in medication\n- If on insulin, there should be no more than a 10-unit change in dosage\n- No recent changes in statin medication\n- Baseline ALT (liver enzyme) should be within a certain range and a liver ultrasound should show the presence of fatty liver\n- The IHL content on the MRI/MRS should be more than 10%\n- Baseline TSH levels (thyroid-stimulating hormone) should be between 1 - 10 mIU/L\n- Baseline heart rate should be less than 90 beats/min\n- Ability to provide informed consent\n\nExclusion criteria for participants are as follows:\n- History of certain medical conditions such as viral hepatitis, liver cirrhosis, heart disease, osteoporosis, hyper/hypothyroidism, anxiety disorder, Graves' disease, thyroid/liver surgery, lactose intolerance, or malabsorption\n- Baseline estimated glomerular filtration rate (eGFR) less than 60 ml/min\n- Currently taking certain medications such as thyroxine, thiazolidinedione (TZD), anticoagulants, antiviral drugs, phenytoin, colestyramine, aluminum-containing drugs, salicylates, dicumarol, furosemide, or sevelamer\n- Consumption of more than 30g of ethanol per day\n- Advanced liver disease with a specific fibrosis score\n- Presence of an unsafe implant or device for MRI scan\n- Clinically significant ECG findings\n- History of claustrophobia\n- Baseline free T4 levels outside the specified reference range, unless deemed clinically insignificant by the investigator.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is \"refractory chronic cough.\" The ICDCodes associated with this disease are \"D46.4,\" \"D46.1,\" \"D46.A,\" \"D46.0,\" \"D46.20,\" \"D46.21,\" and \"D46.22.\" The drugs mentioned are \"5 mg serlopitant tablets\" and \"matching placebo tablets.\" The eligibility criteria include age requirements, a diagnosis of treatment refractory chronic cough, normal chest radiograph or CT scan, specific scores on the Cough Severity WAS, and the use of effective contraception for female subjects of childbearing potential. There are also exclusion criteria listed, such as prior treatment with serlopitant, certain medical conditions, hypersensitivity to serlopitant, pregnancy, smoking, and various other factors that may interfere with the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is indicated as \"phase 2/phase 3\". The disease being studied in this particular trial is \"dry eye disease\". The corresponding ICD-10 codes for this disease are listed as \"['H04.121', 'H04.122', 'H04.123', 'H04.129', 'H35.3111', 'H35.3112', 'H35.3121']\". The drugs being tested in the trial are \"cyclasol topical ocular, eye drops\" and \"vehicle topical ocular, eye drops\". \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Signed ICF (Informed Consent Form) and HIPAA (Health Insurance Portability and Accountability Act)\n- Patient-reported history of DEAD in both eyes\n- Current use of OTC (over-the-counter) and/or artificial tears for dry eye symptoms\n- Ability and willingness to follow instructions, including participation in all study assessments and visits\n\nExclusion Criteria:\n- Women who are pregnant, nursing, or planning a pregnancy\n- Unwillingness to submit a urine pregnancy test at screening and the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control\n- Clinically significant slit-lamp findings or abnormal lid anatomy at screening\n- Ocular/periocular malignancy\n- History of herpetic keratitis\n- Active ocular allergies or ocular allergies that may become active during the study period\n- Ongoing ocular or systemic infection at screening or baseline\n- Wear of contact lenses within 3 months prior to screening or anticipated use of contact lenses during the study\n- History of no response to previous topical Cyclosporine A and/or use of topical Cyclosporine A or Liftigrast within 2 months prior to screening\n- Intraocular surgery or ocular laser surgery within the previous 6 months, or have any planned ocular and/or lid surgeries over the study period\n- Presence of uncontrolled systemic diseases\n- Presence of known allergy and/or sensitivity to the study drug or its components",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is \"painful diabetic neuropathy.\" The ICDCodes associated with this disease are \"G58.0, G61.1, A52.15, G60.3, G61.82, H46.2, H46.3.\" The drugs being tested in this trial are \"ema401\" and \"placebo.\" The eligibility criteria for participants in this trial include having a documented diagnosis of Type I or Type II diabetes mellitus with painful distal symmetrical sensorimotor neuropathy for more than 6 months, experiencing neuropathic symptoms or decreased distal sensation, suffering from moderate to severe neuropathic pain, and scoring \u22654 on the Douleur Neuropathique en 4 Questions (DN4) questionnaire. There are also exclusion criteria, such as being a woman of child-bearing potential without using highly effective contraception, having certain medical conditions or abnormalities, and being unwilling or unable to complete daily eDiary.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is influenza. The ICD-10 codes associated with the disease are 'J11.81', 'J11.82', 'J10.01', 'J10.81', 'J10.82', 'J11.08', and 'J11.2'. The drugs being tested in the trial are the seasonal influenza vaccine, mva-np+m1, and sodium chloride. \n\nThe eligibility criteria for participants in the trial are as follows:\n- The volunteer must be willing and able to provide written informed consent.\n- The volunteer must be an adult aged 65 years or above.\n- The volunteer must be willing and able to comply with all study requirements.\n- The investigators should be allowed to discuss the volunteer's medical history with their General Practitioner.\n- The volunteer must be eligible to receive the seasonal influenza vaccine.\n\nThe exclusion criteria for participants in the trial are as follows:\n- Any history of anaphylaxis or allergic reactions likely to be exacerbated by the vaccine.\n- Ongoing terminal illness with a life expectancy of less than 6 months.\n- Continuous use of certain oral anticoagulants.\n- Presence of any other significant disease, disorder, or finding that may put the volunteer at risk or influence the study results.\n- Participation in another clinical trial of an investigational medicinal product within the past 30 days or planned use during the study period.\n- Prior receipt of an investigational vaccine that may impact the interpretation of trial data.\n- Receipt of the annual seasonal influenza vaccine prior to enrollment for the same influenza season.\n- Not willing to comply with study procedures.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 trial phase. The trial focuses on smoking cessation as the disease. The ICD-10 codes associated with the disease are ['Y36.881S', 'Y36.891S', 'Y36.880S', 'Y36.881A', 'Y36.881D', 'Y36.890S', 'Y36.891A']. The drug being tested is cytisine. \n\nThe eligibility criteria for the trial include being a regular moderate cigarette smoker (at least 10 cigarettes per day) who wants to quit smoking. Other criteria include having a urine cotinine level greater than 500 ng/mL, expired air carbon monoxide (CO) level greater than 11 parts per million, and being a healthy male or female between the ages of 18 and 65+. \n\nFemale subjects of childbearing potential must have a negative pregnancy test and be willing to use contraception during the study. Female subjects of non-childbearing potential must also have a negative pregnancy test and meet specific criteria related to menopausal status. Male subjects must also be willing to use contraception during the study. \n\nAdditional criteria include having no clinically significant abnormal serum biochemistry, haematology, or urine examination values, negative urinary drugs of abuse screen, negative HIV, Hep B, and Hep C results, no clinically significant abnormalities in 12-lead ECG and vital signs, and being available to complete the study and comply with study restrictions. Written informed consent is also required to participate in the study.\n\nExclusion criteria include recent treatment with smoking cessation medications or other forms of nicotine, known hypersensitivity/allergy reactions to certain medications, current treatment with specific medicinal products, history of certain medical or surgical conditions, breastfeeding, difficulty in donating blood, history of alcoholism or drug abuse, recent use of non-prescription drugs, participation in other clinical trials, recent blood donation or significant blood loss, inability to communicate well, and any other condition that the Principal Investigator deems unsuitable for the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied include anemia, asxl1 gene mutation, ezh2 gene mutation, idh1 gene mutation, idh2 gene mutation, plasma cell myeloma, primary myelofibrosis, recurrent plasma cell myeloma, secondary myelofibrosis, and thrombocytopenia. The corresponding ICDCodes for these diseases are also listed. The drugs being used in the trial are busulfan, cyclophosphamide, and fludarabine. The eligibility criteria for participants include specific performance status, documented diagnoses of multiple myeloma or myelofibrosis, and various risk factors or characteristics related to the diseases. Additionally, there are exclusion criteria listed, such as certain medical conditions or infections, and requirements for contraception for female subjects.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has the following columns: phase, diseases, icdcodes, drugs, and criteria.\n\nIn the sample, the phase is described as \"phase 1/phase 2\". The diseases listed are \"cough\". The ICDCodes associated with the disease are \"['R05.1', 'R05.2', 'R05.3', 'R05.4', 'R05.9', 'G44.83', 'J45.991']\". The drugs mentioned are \"bay1817080\" and \"matching placebo\". The eligibility criteria are provided in the \"criteria\" column.\n\nThe eligibility criteria are divided into two parts. In Part 1, the criteria include being a healthy male between the ages of 18-45, a non-smoker for at least 6 months, and agreeing to use contraception if sexually active. In Part 2, the criteria include being over 18 years old, having refractory chronic cough for at least one year, and having a score of >40 mm on the Cough Severity visual analogue scale (WAS) at screening.\n\nThere are also specific criteria for male and female patients regarding contraception and childbearing potential. The exclusion criteria include relevant diseases potentially interfering with the study's aims, febrile illness, taste dysfunction, and recent use of over-the-counter cough mixture in Part 1. In Part 2, the exclusion criteria include respiratory tract infection, smoking history, and significant pulmonary status changes.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"type 2 diabetes\". The associated ICD-10 codes for this disease are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\". The drugs being studied in this trial are \"tirzepatide\" and \"placebo\". \n\nThe record also includes eligibility criteria for participants. The inclusion criteria state that participants must have had type 2 diabetes for at least 6 months, have an HbA1c level between 7.0% and 10.5%, have been on stable doses of metformin for at least 3 months (if taking metformin), and have a body mass index (BMI) between 23 and 45 kilograms per square meter.\n\nThe exclusion criteria state that participants with type 1 diabetes, those who have used glucose-lowering medications other than metformin within the past 3 months or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the past 12 months, and those with certain cardiovascular conditions (such as acute myocardial infraction, heart failure, or stroke) are not eligible. Other exclusion criteria include having certain liver or pancreatic conditions, a low estimated glomerular filtration rate (eGFR), high serum calcitonin levels, or any condition that contraindicates the use of GLP-1 RA medications.\n\nOverall, this record provides information about a phase 2 clinical trial for type 2 diabetes, including the diseases being studied, the drugs involved, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating recurrent epithelial cancer of the ovary, primary peritoneal carcinoma, and fallopian tube cancer. The trial is testing the drug avelumab. The eligibility criteria for participants include being a female aged 18 or older, having a performance status of 0-2, and being able to comply with the study procedures. Other criteria include having adequate physiological function, a negative pregnancy test, and a histologic diagnosis of the specified cancers. Participants must have progressed through at least one prior treatment regimen for their cancer. The sample also includes a list of exclusion criteria, such as current use of immunosuppressive medication, active autoimmune disease, and prior organ transplantation. It also specifies that patients must not be pregnant or nursing, and should not have a history of prior treatment with inhibitors of PD-1 or PD-L1 or PDL2. The sample also includes additional exclusion criteria related to medical conditions, recent surgeries or radiation therapy, and the use of corticosteroids or other immunosuppressive medications.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, the disease is obesity, the ICDCodes are ['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99.215', 'O99.210', 'O99.211'], the drugs are ['lik066', 'placebo'], and the eligibility criteria are provided for both inclusion and exclusion.\n\nThe inclusion criteria state that patients must have obesity and inadequately controlled body weight despite diet and/or exercise. They must have a BMI of at least 25 kg/m^2 combined with at least two obesity-related comorbidities, or a BMI of at least 35 kg/m^2 with at least one obesity-related comorbidity. Additionally, patients must have FPG (fasting plasma glucose) levels of at least 110 mg/dL and/or HbA1c levels between 5.6% and 10.0%, or have T2DM (Type 2 Diabetes Mellitus) with HbA1c levels \u2264 10.0%. Waist circumference at the umbilical level must be at least 85 cm for males and 90 cm for females, and the visceral fat area must be at least 100 cm^2. Patients must also agree to comply with the study-required lifestyle intervention and treatment throughout the study duration.\n\nThe exclusion criteria state that pregnant or lactating women are not eligible. Patients who use pharmacologically active weight-loss medications or have undergone bariatric surgery are also excluded. Additionally, patients with conditions such as ketoacidosis, lactic acidosis, hyperosmolar coma, symptomatic genital infection or urinary tract infection in the 4 weeks prior to screening, gastrointestinal disorders associated with chronic diarrhea, or congestive heart failure classified as New York Heart Association (NYHA) class III or IV are not eligible.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of pruritus and psoriasis vulgaris. The diseases are represented by their names and corresponding ICD-10 codes. The drugs being studied are \"sna-120\" and \"vehicle\". The eligibility criteria for participants are listed, including requirements such as informed consent, stable PV for at least 6 months, presence of chronic pruritus, and mild to moderate PV. There are also specific criteria related to the target plaques, treatment with a topical ointment, and willingness to comply with study instructions. Exclusion criteria are also provided, such as underlying conditions other than psoriasis that influence pruritus, positive hepatitis serology, and thyroid abnormalities. The sample also includes criteria related to specific types of psoriasis, bacterial infections, major medical illnesses, and hypersensitivity to certain substances. Additionally, it states that participants should not be currently enrolled in other investigational studies or be pregnant or lactating.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is renal cell carcinoma. The ICDCodes associated with this disease are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']. The drugs being used in the trial are propranolol and sunitinib. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having a histological diagnosis of clear-cell renal cell carcinoma or mixed-type RCC with more than 60% clear-cell component, being diagnosed with stage IV RCC, having undergone prior nephrectomy, having measurable disease, having a Karnofsky performance status score of 80-100%, meeting certain organ function requirements, having normal thyroid function, being 18 years or older, and providing written informed consent.\n\nExclusion criteria include having prior systemic pharmacotherapy of RCC, recent treatment with propranolol, having metastases in the central nervous system (unless surgically resected or treated with radiotherapy in the past), being pregnant or breastfeeding, having other malignancies (with exceptions), having severe or uncontrolled medical conditions, receiving certain concomitant treatments, having known allergies/sensitivities to the drugs being used, having certain gastrointestinal or bleeding conditions, having had major surgery or significant traumatic injury recently, having contraindications to propranolol, and being unable or unwilling to provide written informed consent.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on Tourette Syndrome. The ICD-10 code for Tourette Syndrome is \"F95.2\". The drugs being studied are valbenazine and a placebo oral capsule. The eligibility criteria for participants include having a clinical diagnosis of Tourette Syndrome, moderate tic severity, impaired school, occupational, and/or social function due to TS symptoms, being on stable doses of medication if already using them, being in good general health, and having a negative urine drug screen for certain substances. There are also exclusion criteria, such as having unstable medical conditions, a history of certain cardiac conditions, or substance dependence. The sample provides a detailed list of both inclusion and exclusion criteria for potential participants in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of sunburn. The diseases column lists the disease names, with 'sunburn' being the specific disease in this case. The icdcodes column contains the corresponding ICD-10 codes for the diseases, with the code for sunburn being ['L55.9', 'L55.0', 'L55.1', 'L55.2']. The drugs column lists the names of the drugs being used in the trial, including 'sp160412 ibuprofen 400 mg and chlorpheniramine maleate 4 mg', '2 capsules ibuprofen and 1 placebo', and 'capsule chlorpheniramine 4mg and 1 placebo'. The criteria column provides the eligibility criteria for participants in the trial, including inclusion and exclusion criteria. The inclusion criteria specify that participants must be 18 years or older, have experienced sunburn in the past 18 hours, provide informed consent, be able to administer the investigational medicinal product as directed, have a Fitzpatrick skin type I, II, or III, and be in good general health. The exclusion criteria include factors such as routine tanning, pregnancy or lactation, enrollment in another investigational study, certain medical conditions or medications, allergies to specific drugs, recent use of pain relievers or psychoactive substances, and various other factors that may affect the participant's eligibility or safety in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating patients with recurrent or refractory plasma cell myeloma. The diseases are listed along with their corresponding ICD-10 codes. The only drug mentioned in this sample is lenalidomide. The eligibility criteria for the trial are also provided, including requirements for measurable disease, prior therapy, blood counts, liver function, renal function, and other factors. The sample also includes exclusion criteria, such as peripheral neuropathy, concurrent use of certain medications, cardiac risk factors, recent surgery, and other medical conditions that may interfere with the trial.",
    "The sample provided is for a phase 2 clinical trial. The trial is focused on a single disease, which in this case is \"healthy.\" The corresponding ICD-10 codes for this disease are \"Z76.3\" and \"Z76.2.\" The drug being tested in this trial is a placebo. \n\nThe eligibility criteria for participants in this trial include signing an Informed Consent Form (ICF), being in good health without any significant medical illness, and being willing to comply with all study procedures. Participants must also have a normal physical examination, including vital signs and clinical laboratory tests. Additionally, participants must have a non-clinically significant electrocardiogram (ECG) and be sero-suitable for respiratory syncytial virus (RSV). \n\nExclusion criteria for participants include having an acute illness or a temperature of 37.8 degrees Centigrade or higher within 24 hours prior to vaccination. Participants with a history of malignancy, chronic active hepatitis B or hepatitis C infection are also excluded. \n\nThere are additional exclusion criteria specifically related to viral challenge, such as having donated or lost a significant amount of blood or plasma within a certain time frame, as well as having an active acute respiratory infection.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for participants in the trial.\n\nIn this specific sample, the phase of the trial is phase 2, and the disease being studied is the common cold. The ICD-10 codes associated with the common cold are also provided. The drugs being tested include a new formulation of phenylephrine HCl, marketed phenylephrine HCl, and a placebo. The eligibility criteria for participants are listed, including requirements such as providing informed consent, being 18 years or older, experiencing cold symptoms within 72 hours, having specific symptom severities, being in a certain blood pressure and pulse rate range, having a specific BMI, agreeing to use only the study treatment, and meeting other medical and lifestyle criteria. The exclusion criteria are also listed, which include conditions or medications that may interfere with the study or pose risks to participants.\n\nOverall, this sample provides a detailed description of a specific clinical trial, including the phase, diseases, drugs, and eligibility criteria involved.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of plaque psoriasis. The ICD-10 codes associated with this disease are ['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']. The drugs being studied are 'agn-242428' and 'placebo'. The sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include having a confirmed diagnosis of plaque psoriasis, a certain severity level of the disease, being a candidate for phototherapy or systemic therapy, and having a minimum body weight. Exclusion criteria include having non-plaque forms of psoriasis, unstable psoriasis, certain medical conditions, recent vaccinations, positive drug/alcohol tests, recent use of certain biologic therapies, and abnormal liver function.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease called cryptosporidiosis. The disease is identified by the ICD-10 code A07.2. The trial involves the use of two drugs, clofazimine and placebo. The eligibility criteria for participants are listed, including being HIV positive, having stable anti-retroviral therapy treatment, and presenting with diarrhea. Female participants must either be not of reproductive potential or using highly effective contraception. The sample also includes exclusion criteria, such as having certain medical conditions, fever, active tuberculosis, or allergies to clofazimine. It also mentions electrocardiogram exclusions and history of risk factors for Torsade de Points. The use of certain medications and pregnancy or lactation are also exclusion criteria. The sample is divided into two parts, with Part B having the same eligibility criteria as Part A, except without diarrhea and being Cryptosporidium negative.",
    "The sample from the table is for a phase 2 clinical trial. The trial is focused on the treatment of pruritus and psoriasis. The diseases included in the trial are pruritus and psoriasis. The corresponding ICD-10 codes for pruritus are L29.0, L29.1, L29.2, L29.8, L29.9, and L29.3, while for psoriasis, the codes are L40.0, L40.4, L40.8, L40.9, L40.1, and L40.50. The drugs being tested in the trial are 5 mg serlopitant tablets and matching placebo tablets. The eligibility criteria for the trial include age between 18-80 years, a diagnosis of plaque psoriasis for at least 6 months, presence of pruritus for at least 4 weeks, willingness to discontinue other psoriasis therapies, severe pruritus, and willingness to practice contraception for female subjects of childbearing potential. There are also exclusion criteria, such as prior treatment with serlopitant or other neurokinin-1 receptor antagonists, clinical worsening of psoriasis, presence of non-plaque forms of psoriasis, presence of other medical conditions causing pruritus, recent treatment with biologic or non-biologic psoriasis therapies, recent use of certain topical treatments, and various other medical conditions or disabilities that could interfere with the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a trial for the treatment of Hodgkin's lymphoma in patients who have relapsed or are refractory to previous treatments. The trial is in phase 1/phase 2. The diseases column specifies the disease being targeted, which in this case is Hodgkin's lymphoma. The icdcodes column contains a list of ICD-10 codes associated with the disease. The drugs column lists the drugs being used in the trial, which are nivolumab and bendamustine hydrochloride. The criteria column provides the eligibility criteria for participants in the trial, including the diagnosis, previous treatment history, age range, and other factors. The inclusion criteria specify the requirements for participation, while the exclusion criteria list the conditions that would disqualify a patient from participating in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of colorectal cancer. The trial is testing the effectiveness of a combination of raltitrexed and apatinib. The eligibility criteria for participants include being 18 years or older, having histologically confirmed advanced colorectal adenocarcinoma with at least one measurable lesion, and having failed at least two lines of standard chemotherapy. Other criteria include having an ECOG performance status of 0-2, a life expectancy of more than 3 months, and normal organ function. Exclusion criteria include factors that could affect oral medication, such as inability to swallow or chronic diarrhea. Participants must also provide signed informed consent and have good compliance with the trial requirements.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease mentioned is \"pulmonary disease, chronic obstructive.\" The ICDCodes associated with this disease are \"J44.9,\" \"J44.1,\" and \"J44.0.\" The drugs being studied in this trial include \"placebo ellipta,\" \"nemiralisib ellipta 50 \u00b5g,\" \"nemiralisib ellipta 100 \u00b5g,\" \"nemiralisib ellipta 250 \u00b5g,\" \"nemiralisib ellipta 500 \u00b5g,\" \"nemiralisib ellipta 750 \u00b5g,\" \"albuterol (salbutamol) mdi or nebules,\" and \"standard of care therapy.\" The eligibility criteria for participants in this trial include age range, smoking history, COPD exacerbation history, body weight and BMI requirements, gender eligibility, and various exclusion criteria related to medical conditions, allergies, medications, and other factors.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is triple negative breast cancer. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs mentioned are vinorelbine tartrate and capecitabine 500 mg. The eligibility criteria for this trial include various conditions such as being female and aged 18 years or older, having a certain performance status, having locally advanced or metastatic triple-negative breast cancer, having received previous chemotherapy, having measurable lesions, and being willing to comply with the study protocol. There are also exclusion criteria listed, such as previous treatment with vinorelbine or capecitabine, presence of brain metastases, and inadequate bone marrow, hepatic, or renal function.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes information about the diseases being studied, the associated ICD-10 codes, the drugs being tested, and the eligibility criteria for participants.\n\nIn this particular trial, the diseases being studied are \"plaque psoriasis\" and \"skin diseases\". The corresponding ICD-10 codes for \"plaque psoriasis\" are 'L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', and 'L40.50', while the codes for \"skin diseases\" are 'L99', 'O99.711', 'O99.712', 'O99.713', 'O99.719', 'O99.72', and 'O99.73'.\n\nThe drugs being tested in this trial are \"jte-051\" and \"placebo\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being diagnosed with moderate to severe plaque psoriasis at least 6 months prior to Visit 1, having plaque-type psoriasis covering at least 10% of the body surface area at Visit 1 and Visit 2, having a Psoriasis Area and Severity Index (PASI) score of at least 12 at Visit 1 and Visit 2, having a Static Physician's Global Assessment (sPGA) score of at least 3 at Visit 1 and Visit 2, and having a Body Mass Index (BMI) of 38 or less at Visit 1.\n\nExclusion criteria include a medical history of treatment failure to any systemic agents for plaque psoriasis, prior exposure to more than one biologic agent treatment, presence of certain types of psoriasis or other skin conditions that could interfere with study evaluations, presence or history of itch due to underlying conditions other than plaque psoriasis, history of clinically-significant infections within a certain timeframe, history of infections requiring hospitalization or specific therapies, and history of or at risk for destructive arthropathy.\n\nOverall, this sample provides specific details about the phase 2 trial, the diseases being studied, the drugs being tested, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of low back pain. The diseases column lists \"low back pain\" as the primary condition. The icdcodes column contains the corresponding ICD-10 codes for the disease, which are \"M54.50\", \"M54.51\", and \"M54.59\". The drugs column includes the names of the drugs being used in the trial, which are \"duloxetine\", \"propranolol\", and \"placebo treatment\". \n\nThe eligibility criteria for participants in the trial are listed in the criteria column. These criteria include being male or female aged 18 or above, having chronic low back pain as the primary condition, having an average pain score of at least 4 at the time of recruitment, and being willing to comply with the study procedures. Other criteria include having a stable drug regimen for at least 1 month prior to the study, being able to follow the study protocol, and being able to write and speak in English and/or French. Participants must also provide signed and dated informed consent forms.\n\nThe exclusion criteria are also listed in the criteria column. These criteria include having uncontrolled medical or psychiatric conditions, a history of major depressive disorder or psychotic disorder within the past year, being pregnant or breastfeeding, having pain due to cancer, and receiving disability compensation or involved in litigation. Other exclusion criteria include having neurologic signs of lumbosacral radiculopathy, radiographic or electrophysiology evidence of radicular compression, clinical signs of lumbar stenosis, and clinical signs of back pain that require urgent intervention. Participants who have had certain surgeries or procedures, have known hypersensitivity to certain medications, or are currently taking certain medications are also excluded. Additionally, participants with a history of alcoholism or recent recreational drug abuse, as well as those with certain medical conditions, are excluded. Finally, participants with specific heart rate or blood pressure measurements during the initial visit are also excluded.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on patients with asthma. The ICD-10 codes associated with the disease are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The trial involves testing various drugs such as 'as mdi 90 \u03bcg', 'as mdi 180 \u00b5g', 'proventil 90 \u03bcg', and 'proventil 180 \u03bcg'. The eligibility criteria for participants include being between 12 and 65 years old, having a stable diagnosis of asthma for at least 6 months, and currently receiving specific inhaled asthma therapies. Participants must also meet spirometry performance criteria and have a pre-bronchodilator FEV1 within a specific range. The sample also includes exclusion criteria, such as having other significant lung diseases, recent oral corticosteroid use, or a history of life-threatening asthma episodes. Participants must also not have certain clinically significant diseases or recent hospitalizations for psychiatric disorders or attempted suicide. Additionally, participants must be able to abstain from prohibited medications during the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are knee osteoarthritis, blood clot, transfusion-related complication, and blood loss. The corresponding ICDCodes for these diseases are provided as well. The drugs being investigated are oral tranexamic acid and oral aminocaproic acid.\n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being over 18 years old, having undergone total replacement of the primary knee due to primary Osteoarthrosis, having a two-compartment prosthesis, undergoing a unilateral procedure, having a cemented prosthesis, and voluntarily agreeing to participate in the study. Additionally, the patient's pre-operative assessment should fall under ASA I, ASA II, or ASA III, and the patient should be able to take the drug orally.\n\nExclusion criteria include having a history of thrombotic or embolic events in the last 6 months, having a clinical history of coagulopathy, having previous surgeries in the knee, recent use of certain medications, history of myocardial infraction, arteriopathy or unstable angina in the past 12 months, having an ASA IV preoperative assessment or contraindication for the procedure, having total revision knee replacement, total replacement of tumoral knee, or total bilateral knee replacement, having cognitive deficit, not wishing to participate in the study despite meeting the inclusion criteria, having terminal chronic kidney disease or high serum creatinine levels, inability to ingest the drug orally, being pregnant or breastfeeding, or having a history of seizures or hypersensitivity to the active substance or excipients.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample is a phase 2 trial with a focus on kidney diseases. The diseases being studied include IgA nephropathy, chronic kidney disease associated with type 1 diabetes, focal segmental glomerulosclerosis, and autosomal dominant polycystic kidney. The trial is investigating the effectiveness of bardoxolone methyl capsules as a potential treatment. \n\nThe eligibility criteria for participants include being between the ages of 18 and 65, having a screening estimated glomerular filtration rate (eGFR) between 30 and 90 mL/min/1.73 m2, and an albumin to creatinine ratio (ACR) of less than or equal to 2500 mg/g. Patients already taking angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) should be on the maximum tolerated labeled daily dose (MTLDD) for at least 6 weeks prior to screening. \n\nAdditional criteria depend on the specific cohort being enrolled in. For the type 1 diabetes cohort, patients must have a confirmed diagnosis of type 1 diabetes and be on a stable insulin dose for at least 6 months. For the IgA nephropathy cohort, patients must have biopsy-confirmed IgA nephropathy. For the focal segmental glomerulosclerosis cohort, patients must have biopsy-confirmed focal segmental glomerulosclerosis not due to known secondary causes. For the autosomal dominant polycystic kidney cohort, patients must have genetic confirmation of a PKD1 mutation. \n\nPatients must also have adequate bone marrow reserve and organ function, as well as meet certain exclusion criteria such as having had a kidney or solid organ transplant, having certain levels of B-type natriuretic peptide (BNP) or serum albumin, or having certain medical conditions or history of certain events. \n\nParticipants must also be willing to practice acceptable methods of birth control if applicable. Pregnant or breastfeeding women are not eligible to participate.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is asthma. The ICD-10 codes associated with the disease are 'J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', and 'J45.40'. The drugs being used in the trial are 'as mdi' and 'proventil'. \n\nThe inclusion criteria for participants in the trial include having a stable diagnosis of asthma for at least 6 months, currently receiving specific inhaled asthma therapies for the past 30 days, meeting acceptable spirometry performance criteria, having a pre-bronchodilator FEV1 (forced expiratory volume in 1 second) value between 50% and less than 80% of the predicted normal value, and demonstrating a significant increase in FEV1 after using Ventolin.\n\nThe exclusion criteria for participants include having chronic obstructive pulmonary disease or other significant lung diseases, recent use of oral corticosteroids, recent use of certain biologic medications, current or recent smoking history, history of life-threatening asthma episodes, presence of clinically significant diseases, recent history of psychiatric hospitalization or attempted suicide, and inability to abstain from prohibited medications during the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is divided into different phases, such as phase I, phase II, or phase III. The sample focuses on a trial with the phase labeled as \"phase 1/phase 2\". The trial is related to the disease \"cough\", which is associated with specific ICD-10 codes. The codes provided are \"R05.1\", \"R05.2\", \"R05.3\", \"R05.4\", \"R05.9\", \"G44.83\", and \"J45.991\". The trial involves the use of two drugs, namely \"gsk2798745\" and \"placebo\". The eligibility criteria for participants are also provided, including age requirements, duration of cough, chest imaging results, lung function, cough severity, body weight and BMI, contraception requirements for males, childbearing potential for females, and the ability to provide informed consent. The exclusion criteria are also listed, which include various medical conditions, history of certain diseases or procedures, recent respiratory tract infection, suicide risk, abnormal liver function, cardiac abnormalities, medication usage, blood loss, recent exposure to new chemical entities, participation in other clinical studies, positive HIV or hepatitis test results, and other factors that may contraindicate participation in the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"endometriosis\". The associated ICD-10 codes for endometriosis are ['N80.8', 'N80.9', 'N80.0', 'N80.1', 'N80.5', 'N80.2', 'N80.3']. The trial involves two drugs, \"bay1128688\" and \"placebo\". The eligibility criteria for participants are listed, including age requirements, confirmation of endometriosis through surgery or imaging, pelvic pain assessment, willingness to use ibuprofen for pain relief, and the use of non-hormonal contraception. The exclusion criteria include pregnancy or lactation, liver function issues, use of pain medications for reasons other than endometriosis, contraindications to using ibuprofen, signs of hyperandrogenism, abnormal vaginal bleeding, history of certain surgeries, and uncontrolled thyroid disorder.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease mentioned is pancreatic ductal adenocarcinoma. The ICDCodes associated with this disease are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drugs being studied in this trial are cpi-613 and mfolfirnox. The eligibility criteria for this trial include having cytologically confirmed pancreatic adenocarcinoma, being diagnosed with locally advanced pancreatic cancer, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and having an expected survival of more than 3 months. There are also specific criteria related to age, gender, contraceptive methods, laboratory values, infection history, mental competence, and willingness to sign the informed consent form. The exclusion criteria include age restrictions, specific types of pancreatic carcinoma, resectable or metastatic pancreatic cancer, prior treatment for pancreatic cancer, recent treatment with other cancer therapies, serious medical illnesses, bleeding disorders, pregnancy or lactation, unwillingness to practice contraceptive methods, short life expectancy, conditions that may compromise patient safety, inability to follow protocol requirements, and certain cardiac conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied include various gene mutations (such as ATM, ATR, BRCA1, etc.) and recurrent squamous cell lung carcinoma. The ICDCodes associated with these diseases are listed as \"D02.20\", \"D02.21\", and \"D02.22\". The drug being used in the trial is talazoparib. The eligibility criteria for this sample include specific biomarker-positive groups, eligibility alterations, and restrictions on prior exposure to PARP inhibitors. Additionally, patients must have achieved stable disease, a partial response, or a complete response after initiating first-line platinum-based chemotherapy. There are also requirements related to gastrointestinal function, ability to take oral medications, and restrictions on certain medications. Finally, patients must agree to have blood specimens submitted for pharmacokinetic analysis.",
    "The sample from the table represents a clinical trial in phase 2. The trial focuses on treating metastatic renal cell carcinoma, a type of kidney cancer. The trial uses a combination of testosterone undecanoate and either sunitinib or pazopanib as the drugs for treatment. The eligibility criteria for participants include having histologically proven clear cell renal cell carcinoma, confirmed metastatic measurable disease through CT scan, experiencing fatigue as a result of first-line sunitinib or pazopanib treatment, having a low level of testosterone, being male and 18 years or older, and having a normal PSA level. The exclusion criteria include a history of prostate and other cancers, hypothyroidism, and serious cardiovascular diseases.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is acute myeloid leukemia. The ICDCodes associated with this disease are C92.A1, C92.A2, C92.61, C92.62, C92.A0, and C92.60. The drugs being used in the trial are cytarabine and nivolumab. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Patients must have a diagnosis of acute myeloid leukemia with the confirmed first or second complete remission.\n- Patients must be 55 years of age or older.\n- Patients must not be candidates for allogeneic stem cell transplantation, as determined by a panel of hematologists at the transplant center.\n- Patients must have a HLA-haploidentical donor who can provide informed consent for peripheral blood apheresis.\n- Patients must not have any severe concurrent illness that limits life expectancy to less than 2 years.\n\nExclusion Criteria:\n- Patients must not have an uncontrolled bacterial or fungal infection at the time of enrollment.\n- Patients must have a Karnofsky index of at least 70%.\n- Patients must not have acute promyelocytic leukemia.\n- Patients must not have any other tumor requiring treatment at the time of enrollment.\n- Patients must not have an active or prior documented autoimmune disease requiring systemic treatment.\n- Patients must not have a somatic or psychiatric disorder that would make them unable to sign informed consent.",
    "The sample from the table is for a phase 2 clinical trial. The diseases being studied are breast neoplasm female and arthralgia. The corresponding ICD-10 codes for these diseases are C50.011, C50.012, C50.019, C50.111, C50.112, C50.119, C50.611 for breast neoplasm female, and M26.621, M26.622, M26.623, M26.629 for arthralgia. The drug being tested is hyaluronic acid (HA). The eligibility criteria for participants include being at least 18 years old, having discontinued anastrazole or letrozole within the past 90 days due to pain and/or stiffness, having ER and/or PR positive tumors, and meeting other specific criteria related to previous treatments, surgery, menopausal status, performance score, and renal and hepatic function. The exclusion criteria include the presence of residual or recurrent cancer, certain medical conditions or abnormalities, consumption of HA-containing supplements in the four weeks prior to the study, known allergy to microcrystalline cellulose or HA, prolonged systemic corticosteroid treatment, self-reported compliance issues, and previous diagnosis of fibromyalgia and/or rheumatoid arthritis.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is \"stable coronary artery disease,\" and its corresponding ICDCodes are ['I25.84', 'I25.41', 'I25.42', 'Z98.61', 'Q24.5', 'T46.3X6S', 'I25.82']. The drugs being studied are 'act-246475' and 'placebo'. The eligibility criteria for this trial include various conditions such as signed informed consent, age between 18-85 years, negative pregnancy test for women of childbearing potential, stable coronary artery disease, stable antiplatelet background therapy, and a minimum body weight of 40.0 kg. The exclusion criteria include recent acute coronary syndrome, recent acute ischemic stroke or transient ischemic attack, active internal bleeding or bleeding disorders, low hemoglobin levels, recent blood loss, use of anticoagulants or fibrinolytic therapy, known platelet disorders, and pregnancy or breastfeeding.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"asthma\". The ICD-10 codes associated with this disease are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being studied in this trial are \"sar440340\", \"dupilumab\", \"fluticasone or fluticasone/salmeterol combination\", \"placebo for sar440340\", and \"placebo for dupilumab\". \n\nThe eligibility criteria for participants in this trial include being an adult with a physician diagnosis of asthma for at least 12 months, having existing treatment with medium to high dose ICS in combination with a LABA for at least 3 months, having a certain level of lung function, and having experienced certain events related to asthma within the past year. Participants must also meet certain exclusion criteria, such as age restrictions, specific medical conditions, recent use of certain medications, and smoking history.\n\nIt is important to note that the provided information is not exhaustive and there may be additional considerations for potential participants in the clinical trial.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The disease being studied is melanoma. The ICD-10 codes associated with the disease are \"C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4\". The drugs being used in the trial are \"apr-246\" and \"dabrafenib\". The eligibility criteria for the trial are listed, including requirements such as confirmed BRAF V600 mutation-positive unresectable and/or metastatic malignant cutaneous melanoma, measurable disease according to RECIST 1.1 criteria, ECOG Performance Status of 0 or 1, and signed informed consent. The exclusion criteria are also listed, including the presence of uveal melanoma or other non-cutaneous melanomas, current use of prohibited medications, unresolved toxicity from previous anti-cancer therapy, and various medical conditions that may interfere with the assessment of toxicity. Pregnant or lactating women are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease mentioned is \"progressive supranuclear palsy (psp)\". The ICDCodes associated with this disease are ['G23.1']. The drugs mentioned in this sample are 'abbv-8e12' and 'placebo solution for iv infusion on day 15'. \n\nThe eligibility criteria for this sample include several inclusion and exclusion criteria. Inclusion criteria state that the participant must have completed the 52-week treatment period in a previous study (NCT02985879), be compliant during that study, and have an identified, reliable study partner. Exclusion criteria include participants weighing less than 44 kg, any contraindication or inability to tolerate brain MRI, significant changes in medical condition that could interfere with participation, more than 8 weeks since the last dose of study drug in the previous study, and being considered an unsuitable candidate or unable to comply with the dosing schedule or study evaluations by the investigator.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is breast cancer. The ICDCodes associated with breast cancer are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are liposomal bupivacaine, bupivacaine, patient-controlled analgesia pump, and oral narcotic. The eligibility criteria for this sample include patients who are scheduled to have a unilateral, immediate breast reconstruction. Exclusion criteria include being pregnant, having concurrent or recent medical conditions that could interfere with the study, having a body weight of less than 50 kg, participating in another study involving an investigational medication within the prior 30 days, and taking certain medications within 3 days before surgery.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on bladder cancer and urothelial carcinoma, specifically metastatic urothelial carcinoma, renal pelvis carcinoma, ureter carcinoma, urinary bladder carcinoma, and urethra carcinoma. The trial also includes patients with muscle invasive bladder cancer. The ICD-10 codes associated with these diseases are provided as well.\n\nThe drug being tested in this trial is rucaparib. The eligibility criteria for participants include having histologically or cytologically confirmed locally advanced unresectable or metastatic transitional cell carcinoma of the urothelium. Participants must have received 1 or 2 prior treatment regimens for advanced or metastatic disease and must have confirmed radiologic disease progression during or following recent treatment. A mandatory biopsy is required during screening, and participants must have measurable disease per RECIST v1.1. Adequate organ function and an ECOG performance status of 0 or 1 are also required.\n\nExclusion criteria for the trial include prior treatment with a PARP inhibitor, symptomatic and/or untreated CNS metastases, and any gastrointestinal disorder that may interfere with the absorption of rucaparib, including the presence of a duodenal stent.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on non-small cell lung cancer. The trial is specifically targeting patients with activating EGFR mutations in exon 18 through exon 21, excluding T790M. The drug being studied is gefitinib.\n\nThe inclusion criteria for this trial include patients who have histologically confirmed stage IIIB/IV or recurrent NSCLC with the specified EGFR mutation. Additionally, patients must have achieved a complete or partial response for at least 4 months or stable disease for at least 6 months with first-line or second-line gefitinib. Other criteria include being at least 18 years old, having an ECOG performance status of 0 to 2, and having adequate organ function.\n\nThe exclusion criteria for this trial include prior treatment with EGFR TKI, requiring dose reduction of gefitinib, recent surgery or localized radiotherapy, uncontrolled systemic illnesses, pregnancy or nursing, uncontrolled symptomatic brain metastasis, prior history of malignancy within 5 years (with some exceptions), concomitant use of certain medications, prolonged QT interval in ECG, and inability to take medication orally or having a gastrointestinal absorption disorder.\n\nOverall, this record provides specific details about the phase 2 trial, the targeted disease, the drug being studied, and the eligibility criteria for potential participants.",
    "The sample provided is for a clinical trial in phase 2. The trial is focused on the disease called non-alcoholic steatohepatitis. The corresponding ICD-10 code for this disease is K75.81. The trial involves two drugs, namely bms-986036 and placebo. The eligibility criteria for participants include being between 21 and 75 years old, having a body mass index (BMI) of 25 or more. The exclusion criteria include having chronic liver disease other than NASH, uncontrolled diabetes, recent major surgery, inability to self-administer under the skin injections, and any bone trauma or surgery within 8 weeks of screening. For more information about participating in this clinical trial, individuals can visit www.BMSStudyConnect.com.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is \"extensive stage small cell lung carcinoma.\" The ICDCodes associated with this disease are \"D02.20,\" \"D02.21,\" and \"D02.22.\" The drug mentioned is \"epacadostat.\" The eligibility criteria for this trial include various medical conditions and requirements such as providing informed consent, having confirmed small cell lung cancer with extensive stage disease, previous treatment with platinum-based therapy, specific blood counts and levels, performance status, and other factors. There are also exclusion criteria listed, which include factors such as participation in other studies, immunodeficiency, active tuberculosis, hypersensitivity to certain medications, and various medical conditions that may affect eligibility.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on various diseases, including testicular neoplasms, neoplasms, germ cell and embryonal, and gonadal disorders. The trial is investigating the use of the drug avelumab. The eligibility criteria for participants are listed, including age, performance status, confirmed diagnosis of certain types of cancer, and specific laboratory values. The sample also includes exclusion criteria, such as prior malignancy, concurrent cancer treatments, and certain medical conditions. Additionally, it mentions the requirement for effective contraception for participants of reproductive age. The sample provides detailed information about the inclusion and exclusion criteria for the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of dry eye syndrome. The associated ICD-10 codes for the disease are 'H04.121', 'H04.122', 'H04.123', and 'H04.129'. The drugs being studied are 'reproxalap ophthalmic solution (0.25%)', 'reproxalap ophthalmic solution (0.1%)', and 'vehicle ophthalmic solution'. The eligibility criteria for participants are listed, including requirements such as being at least 18 years old, having a history of dry eye for at least 6 months, and having used or desired to use eye drops for dry eye symptoms within the past 6 months. There are also exclusion criteria, such as having certain eye conditions or infections, recent eye surgeries, or using certain medications.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is Type 2 Diabetes Mellitus. The ICD-10 codes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are opk-88003 and placebo. The sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being men or women aged 18 to 80 years with Type 2 Diabetes Mellitus treated with diet and exercise alone or on a stable dose of metformin, having a BMI between 27 and 45 kg/m2, and having an HbA1c level between 7.0% and 10.5% at screening. Exclusion criteria include having Type 1 Diabetes Mellitus, previous treatment with incretin mimetic drugs, using insulin for diabetic control for more than 6 consecutive days within the prior year, having two or more emergency room visits or hospitalizations due to poor glucose control within the prior 6 months, and having a history of acute or chronic pancreatitis or elevation in serum lipase/amylase.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The diseases being studied in this trial are breast cancer, lymphoma, and pain. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being used in the trial are pregabalin and placebo. The eligibility criteria for participants are listed, including age requirements, specific diagnoses, and the ability to accommodate the initiation of pregabalin prior to receiving pegfilgrastim. There are also exclusion criteria, such as a history of pregabalin use, high baseline pain scores, and the use of certain medications.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of sarcoma, a type of cancer. The trial is investigating the effectiveness of two drugs, epacadostat and pembrolizumab. The eligibility criteria for participants include being at least 18 years old, providing written informed consent, and having a confirmed diagnosis of metastatic and/or locally advanced sarcoma. Participants must also have a certain level of performance status, have received at least one prior line of systemic therapy for their sarcoma, and have measurable disease according to RECIST v1.1 criteria. Other criteria include adequate organ function, negative pregnancy test for women of childbearing potential, and willingness to use contraception during the study. Exclusion criteria include uncontrolled illness, active central nervous system metastases, significant immunosuppression, active autoimmune disease, HIV or hepatitis B/C infection, recent live vaccination, active tuberculosis, recent participation in another study, recent chemotherapy or radiation therapy, gastrointestinal conditions affecting drug absorption, known allergies to study drugs, pregnancy or breastfeeding, and inability to comply with study procedures. The sample also includes specific criteria related to electrocardiogram results, use of certain medications, prior therapy with IDO1 inhibitors or checkpoint pathway-targeting drugs, and concurrent active malignancy.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on heart failure. The ICD-10 codes associated with heart failure are provided. The drug being studied is valsartan. The sample also includes the eligibility criteria for participants, which include age, NYHA class, ejection fraction, and stable doses of ACE inhibitors and beta-blockers. Other criteria include being in sinus rhythm, understanding the risks and benefits of the trial, and meeting certain requirements for women of childbearing potential. The sample also lists the exclusion criteria, such as hypersensitivity to study drugs, recent acute decompensated heart failure, low blood pressure, and certain medical conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"dry eye.\" The ICD-10 codes associated with this disease are \"H04.121,\" \"H04.122,\" \"H04.123,\" \"H04.129,\" \"H35.3111,\" \"H35.3112,\" and \"H35.3121.\" The drugs being studied in this trial are \"brimonidine,\" \"brimonidine mono therapy,\" \"sodium carboxymethylcellulose,\" and \"corticosteroid eye drop.\" \n\nThe eligibility criteria for participants in this trial include being 18 years or older, having a history of dry eye disease, and showing objective evidence of dry eye disease through specific signs and symptoms. In addition, participants must have a certain level of intraocular pressure, meet certain criteria for women of child-bearing potential, and not have certain exclusion criteria such as allergies to specific medications or ocular infections.\n\nOverall, this sample provides a snapshot of the phase 2 trial focusing on dry eye disease, including the specific criteria that potential participants must meet to be eligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 2, and the disease being studied is psoriasis. The icd-10 codes associated with psoriasis are 'L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', and 'L40.50'. The drugs being tested in this trial are 'ppc-06 400 mg qd', 'ppc-06 400 mg bid', 'ppc-06 600 mg', and 'placebo'. The eligibility criteria for participants in this trial include being generally healthy individuals aged 18 years or older, having stable moderate-to-severe plaque psoriasis for at least 6 months, meeting specific severity criteria for psoriasis, and being a candidate for phototherapy and/or systemic therapy for psoriasis. There are also exclusion criteria listed, such as not having non-plaque psoriasis, not having drug-induced or drug-exacerbated psoriasis, and not having received certain types of psoriasis treatments within specific timeframes.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is non-alcoholic steatohepatitis (NASH). The ICD-10 code for NASH is K75.81. The drugs being tested in the trial are edp-305 dose 1, edp-305 dose 2, and a placebo. \n\nThe eligibility criteria for the trial include:\n- The subject must sign and date an informed consent document.\n- The subject can be male or female of any ethnic origin, between the ages of 18 and 75 years.\n- The subject must have evidence of NASH either through a histologic liver biopsy or a phenotypic diagnosis based on elevated ALT and a diagnosis of T2DM or pre-diabetes.\n- The subject must have a body mass index (BMI) greater than 25 kg/m2 (or greater than 23 kg/m2 for Asian-Americans).\n- Female subjects of childbearing potential must agree to use two effective methods of contraception.\n- The subject must be willing and able to adhere to the assessments, visit schedules, and restrictions outlined in the protocol.\n\nThe exclusion criteria for the trial include:\n- Certain laboratory screening results outside of the normal range.\n- Known history of alpha-1-antitrypsin deficiency.\n- Use of experimental treatments for NASH within the past 6 months.\n- Use of immunosuppressant drugs for more than 2 weeks within 1 year prior to screening and during the study.\n- Use of experimental or unapproved drugs within a year of screening.\n- Any other condition(s) that would compromise the subject's safety or the quality of the study, as determined by the Principal Investigator.\n- Pregnant or nursing females.\n- Recipients of liver or other organ transplantation or anticipated need for transplantation in one year.\n- Clinical suspicion of advanced liver disease or cirrhosis.\n- Coexisting liver or biliary diseases.\n- Suspicion of cancer (except basal cell carcinoma that has been resected).\n- Cirrhosis with or without complications.\n- Hepatorenal syndrome or high serum creatinine levels.\n- Prior variceal hemorrhage, uncontrolled encephalopathy, or other complications within the previous 6 months.\n- Any condition possibly affecting drug absorption.\n- Recent use of investigational agents, vaccines, or biological products.\n- Use of a new statin regimen or current use of fibrates.\n- Clinically significant history of drug sensitivity or allergy.\n- Uncontrolled diabetes mellitus.\n- Subjects with contraindications to MRI imaging or unable to have an MRI performed.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested is azd9291. \n\nThe eligibility criteria for this trial include:\n- The patient must have histologically confirmed metastatic or recurrent stage IV NSCLC with an activating EGFR mutation other than deletion in exon 19, L858R, T790M, and insertion in exon 20.\n- The patient must have metastatic or recurrent NSCLC.\n- The patient must be at least 19 years old at the time of signing the informed consent.\n- The patient's ECOG performance status should be between 0 and 2.\n- The patient must have at least one measurable lesion according to RECIST 1.1, excluding lesions treated with radiation therapy in the palliative setting.\n- The patient must have untreated asymptomatic brain metastasis or symptomatic brain metastasis treated with local treatment such as operation, whole brain radiotherapy, or gamma-knife surgery.\n- The patient must have undergone whole brain radiotherapy at least 2 weeks prior or palliative thoracic radiotherapy at least 4 weeks prior.\n- The patient must have adequate organ function, including absolute neutrophil count, Hb level, platelet count, total bilirubin level, AST and/or ALT levels, and CCr level.\n- The patient must provide written informed consent.\n\nThe exclusion criteria for this trial include:\n- Prior treatment with EGFR TKI.\n- Major surgery undertaken less than 4 weeks before the study.\n- Localized palliative radiotherapy completed less than 2 weeks before the study.\n- Uncontrolled systemic illnesses such as diabetes mellitus, congestive heart failure, unstable angina, hypertension, or arrhythmia.\n- Pregnant or nursing women (women of reproductive potential must agree to use adequate contraceptive methods).\n- Uncontrolled symptomatic brain metastasis.\n- Prior history of malignancy within 5 years, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or well-treated thyroid cancer.\n- Concomitant use of CYP3A4 inducers/inhibitors.\n- Prolonged QT interval in ECG (QTc >450 msec).\n- Prior history of interstitial lung disease.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is non-small cell lung cancer. The ICD-10 codes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being tested in this trial are ipilimumab and nivolumab. The eligibility criteria for participants include having stage IV NSCLC with no prior systemic anti-cancer therapy, having measurable disease, being at least 18 years old, having an ECOG performance status of 1 or lower, and having normal organ and marrow function. Participants must also have a tumor tissue sample available and be willing to undergo pre-treatment and on-treatment tumor tissue biopsies. There are also exclusion criteria, such as having known EGFR mutations or ALK rearrangements, prior treatment with certain antibodies or drugs, and having untreated brain metastases. Other exclusion criteria include having certain allergies, previous malignancies (unless in complete remission for at least 2 years), active autoimmune diseases, and certain medical conditions. Pregnant women are also excluded from the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the diseases being studied are \"clostridium difficile\" and \"pseudomembranous colitis\". The corresponding ICD-10 codes for these diseases are \"A04.71\" and \"A04.72\" respectively. The drug being used in the trial is \"vancomycin (before randomization)\". \n\nThe record also includes eligibility criteria for participants. The inclusion criteria state that participants must have recurrent C. difficile infection with a severe clinical picture, be able to undergo standard antimicrobial therapy, provide informed consent, and be able to undergo protocol diagnostic and therapeutic procedures. They must also test negative for parasites, as well as for specific microorganisms except for C. difficile, and negative for certain blood tests related to hepatitis, HIV, and venereal diseases.\n\nThe exclusion criteria state that participants must be over 18 years old, not have had a prior colectomy, test negative for C. difficile toxin in stools, have a mild clinical picture of C. difficile infection, not be at high risk of post-colonoscopy complications, not have other main gastrointestinal diseases such as Crohn's disease or ulcerative colitis, test negative for parasites and specific microorganisms except for C. difficile, and test negative for certain blood tests related to hepatitis, HIV, and venereal diseases. Additionally, pregnancy or breastfeeding, as well as the inability to follow protocol procedures, are also exclusion criteria.",
    "The sample is a phase 2 clinical trial for the treatment of non-alcoholic fatty liver disease (NAFLD). The trial is evaluating the effectiveness of a drug called gemcabene. The eligibility criteria for participants include being between the ages of 12-17, having a history of clinical diagnosis of NAFLD, and meeting certain laboratory and diagnostic criteria. Participants must also have a specific range of ALT levels, body weight of at least 60 kg, and be able to take oral medication. They must have attempted lifestyle modifications for at least three months prior to the study and agree to continue these modifications throughout the study. \n\nExclusion criteria include having heart disease, seizure disorder, coagulopathy, renal dysfunction, active malignant disease, significant alcohol intake, recent use of medications or supplements for NAFLD, history of bariatric surgery, clinically significant depression, pregnancy or planning to become pregnant, and certain liver disease criteria. Participants must also not have poorly controlled diabetes, type I diabetes, or other chronic liver diseases. Certain medications are also excluded. Participants must be willing to comply with the study protocol and not have any conditions that would impede compliance or hinder completion of the study, as determined by the investigator.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of non-small-cell lung carcinoma. The trial is specifically targeting patients with evidence of ROS1 rearrangement. The drug being tested in this trial is lorlatinib. \n\nThe sample also includes the eligibility criteria for participating in the trial. Inclusion criteria include having written informed consent, being 18 years or older, having a confirmed diagnosis of NSCLC with evidence of ROS1 rearrangement, and having evidence of disease progression during previous treatment with crizotinib. Other criteria include having measurable disease, previous standard chemotherapy, a performance status of 0-2, and compliance with trial procedures. Adequate bone marrow and liver function are also required. Female participants must have either undergone surgery, radiation, or menopause, or use an approved contraceptive method. \n\nExclusion criteria include not having ROS1 rearrangement, no previous therapy with crizotinib, no evidence of crizotinib failure, and no available post-crizotinib tumor tissue. Other exclusion criteria include not having measurable lesions, no previous chemotherapy, concurrent radiotherapy or chemotherapy, symptomatic brain metastases, and a diagnosis of any other malignancy within the last 5 years (except for certain types). Predisposing factors for acute pancreatitis, history of extensive lung diseases, pregnancy or lactation, and other serious illnesses or medical conditions that could interfere with the study are also exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is atopic dermatitis. The ICDCodes associated with this disease are \"L20.89\" and \"L20.9\". The drug being used in this trial is a placebo. \n\nThe eligibility criteria for participants in this trial are as follows:\n- Participants must be male or female, 18 years or older.\n- They must have chronic atopic dermatitis as defined by Hanifin and Rajka (1980) for at least one year before the screening visit.\n- The Eczema Area and Severity Index (EASI) score must be equal to or greater than 16 at both the screening and baseline visits.\n- The Investigator Global Assessment (IGA) score must be equal to or greater than 3 (on a scale of 0 to 4) at both the screening and baseline visits.\n- At least 10% of the participant's body surface area must be affected by atopic dermatitis at both the screening and baseline visits.\n\nThere are also exclusion criteria for participants in this trial, including recent treatment with certain drugs or therapies, such as immunosuppressive/immunomodulating drugs, phototherapy, topical corticosteroids, investigational drugs, dupilumab, cell-depleting biologics, and other biologics. Additionally, the use of prescription moisturizers within 7 days of the baseline visit is not allowed.",
    "The sample provided is for a phase 2 clinical trial for the treatment of seasonal allergic rhinitis. The trial is testing several drugs, including \"molo 1 (also referred as gsp 301-2 ns)\", \"molo 2 (also referred as gsp 301-1 ns)\", \"placebo nasal spray\", \"dymista nasal spray\", and \"patanase nasal spray\". The eligibility criteria for inclusion in the trial are being a male or female patient between the ages of 18 and 65 with a clinical history of seasonal allergic rhinitis for at least 2 years and a positive skin prick test. Exclusion criteria include being pregnant or lactating, having known hypersensitivity to any of the components of the formulation, a history of seasonal asthma during ragweed season, requiring chronic use of corticosteroids, having perennial rhinitis, non-allergic rhinitis, or ocular infection within 3 weeks before screening, a history of acute or significant chronic sinusitis or chronic purulent post-nasal drip, or having certain medical conditions such as narrow-angle glaucoma, increased intraocular pressure, posterior subcapsular cataract, urinary retention, uncontrolled hypertension, severe coronary artery disease, ischemic heart disease, uncontrolled diabetes mellitus, hyperthyroidism, renal impairment, prostatic hypertrophy, or receiving MAO inhibitor therapy.",
    "The sample is from a table that contains information about clinical trials. The sample shows a phase 2 trial for the treatment of geographic atrophy and age-related macular degeneration. The diseases are listed along with their corresponding ICD-10 codes. The drugs being tested are \"ionis-fb-lrx\" and a placebo called \"sterline saline 0.9%\". The eligibility criteria for participants are also provided, including requirements for informed consent, gender-specific conditions, and specific medical conditions. Exclusion criteria are also listed, such as certain medical history, immunodeficiencies, diabetes or thyroid disease that is not well controlled, abnormal laboratory values, and history of adverse reactions to vaccines. The sample does not mention any other diseases being present in the study eye.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is \"diabetic kidney disease\". The ICDCodes associated with this disease are ['E10.22', 'E11.22', 'E13.22', 'E08.22', 'E09.22']. The drugs being tested in this trial are 'tmx-049' and 'placebo'. The eligibility criteria for inclusion in the trial include having Type 2 diabetes treated with at least one glucose-lowering medication for at least 12 months, having a UACR (urine albumin-to-creatinine ratio) between 200 and 3000 mg/g, having an eGFR (estimated glomerular filtration rate) of at least 30 ml/min/1.73m2, and being treated with either an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB), but not both. The exclusion criteria include having a history of Type 1 diabetes, currently breastfeeding, recent treatment with any uric acid-lowering therapy, intolerance to any XO inhibitor, history of a gout flare requiring treatment, history or presence of tophaceous gout, history of immunosuppressant treatment for renal disorder, history of a non-diabetic form of renal disease, HbA1c (glycosylated hemoglobin) level above 11%, sUA (serum uric acid) level below 4.0 mg/dL or above 10.0 mg/dL, positive urinary pregnancy test, recent dialysis for acute renal failure, having a renal allograft in place or a scheduled kidney transplant within the next 22 weeks, and having a congenital or acquired solitary kidney.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is melanoma. The ICD-10 codes associated with the disease are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4. The drug being tested is palbociclib. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n1. Age between 18 and 75 years.\n2. ECOG performance status of 0 or 1 before treatment.\n3. Metastatic melanoma or unresectable acral melanoma.\n4. Histologically confirmed melanoma.\n5. Presence of gene aberrations in cell cycle pathways, including CDK4 amplification, CCND1 amplification, and P16 (CDKN2A) loss.\n6. Anticipated life expectancy of at least 3 months.\n7. Adequate organ function, including platelets, hemoglobin, absolute neutrophils, serum bilirubin, AST, ALT, BUN, creatinine, left ventricular ejection fraction, and QTc interval.\n8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.\n9. Written informed consent.\n\nThe exclusion criteria for the trial are as follows:\n1. Previous or current administration of any CDK4/6 inhibitors.\n2. Administration of any other anti-tumor therapy within 4 weeks before inclusion.\n3. Non-treated brain metastasis.\n4. Presence of uncontrollable third space fluid.\n5. Requirement of long-term steroid therapy.\n6. Uncorrectable hypokalemia or hypomagnesemia.\n7. Concurrent administration of drugs with potential QT interval prolongation.\n8. Allergies or previous history of severe allergies.\n9. Active HBV or HCV infection.\n10. NCICTCAE Grade 2 toxicity before inclusion.\n11. Diagnosed with any second primary malignant tumor within 5 years before inclusion.\n12. Presence of severe/unstable angina pectoris, myocardial infraction, congestive heart failure, cerebrovascular accident, pulmonary embolism, \u2265 grade II renal dysfunction, or other severe diseases within 6 months before drug administration.\n13. Administration of potent CYP3A4 inhibitors within 7 days before inclusion or within 12 days before randomization.\n14. NCICTCAE Grade \u2265 2 active arrhythmias.\n15. Hypertension that cannot be controlled by medication.\n16. No recommendation to receive >2 mg Warfarin treatment in 2 weeks before study beginning.\n17. Presence of any disease affecting drug absorption.\n18. Known infection of HIV or AIDS-related illness, or congenital immune deficiency diseases, organ transplantation history.\n19. Pregnancy, breastfeeding, or reluctance to take effective contraceptive measures throughout the trial period.\n20. Presence of other severe acute or chronic physiological or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results.\n21. Current treatment on another clinical trial. Supportive care or non-therapeutic clinical trials are allowed.",
    "The sample provided is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 2 and focuses on depressive disorders, including postpartum depression and mood disorders. The trial is investigating the effectiveness of the drug ganaxolone compared to a placebo. \n\nThe eligibility criteria for participants in this trial include experiencing a major depressive episode during the third trimester of pregnancy or within 4 weeks after delivery. The diagnosis of the major depressive episode is done using the Mini International Neuropsychiatric Interview (MINI) 7.0. Participants must have given birth within the last 6 months and have a HAMD17 score of at least 20 but less than 26. They must also agree to stop breastfeeding or temporarily cease giving breast milk to their infants during the study.\n\nExclusion criteria for this trial include a current history of any psychotic illness, a history of suicide attempt within the past 3 years, a history of bipolar I disorder, and a history of seizure disorder.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is lymphoma. The ICD-10 codes associated with the disease are 'S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', and 'S33.140S'. The drug being tested is atezolizumab. The eligibility criteria for the trial include being at least 18 years old, having relapsed or refractory follicular lymphoma grade 1, 2, or 3A, having stage III/IV disease, having received at least one prior treatment for follicular lymphoma, having a site of disease amenable to low-dose, local radiotherapy, and meeting certain hematologic and end organ function requirements. There are also exclusion criteria, such as having follicular lymphoma grade 3B, having concurrent aggressive non-Hodgkin lymphoma, having received any anticancer therapy within 3 weeks prior to the study, and having certain medical conditions or infections. The sample also includes medication-related exclusion criteria, such as prior treatment with certain immunotherapy drugs and recent use of immunosuppressive medications.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease called eosinophilic asthma. The ICD-10 code for this disease is J82.83. The trial involves two drugs, anb020 and placebo. The eligibility criteria for participants are listed, including age, diagnosis of eosinophilic asthma, severe asthma according to GINA guidelines, specific body mass index and weight requirements, negative pregnancy test for women of childbearing potential, use of effective contraception, being on high dose ICS plus LABA medication, willingness to comply with the study protocol, ability to understand study procedures and communicate with the investigator and staff. The exclusion criteria are also listed, including medical conditions that may interfere with evaluation, history of severe anaphylactic reactions, recent use of investigational products or high dose systemic corticosteroids, recent treatment with biologics, abnormal ECG assessment, uncontrolled hypertension or acute ischemic cardiovascular diseases, pregnancy or lactation, history of alcohol or substance abuse, contraindications to study participation, other physical, mental, or medical conditions that could confound study assessments, planned surgery, and history of malignancy within the past 5 years (except for fully treated non-melanoma skin cancer).",
    "The sample is a phase 2 trial that focuses on smoking cessation. The diseases being studied include smoking cessation, smoking, and nicotine dependence. The corresponding ICD-10 codes for these diseases are provided. The drugs being tested in this trial are axs-05 and bupropion sr. The eligibility criteria for participants include being 18 years or older, being a daily smoker of 10 or more cigarettes per day, and being willing to be smoke-free for 7 days. Participants must also be able to provide written informed consent, understand the study procedures, and meet other requirements outlined in the informed consent form. Exclusion criteria include current use of smoking cessation medications or tobacco products other than cigarettes, pregnancy or breastfeeding, and contraindications to the use of bupropion. Additional criteria may also apply.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease cystic fibrosis. The ICD-10 codes associated with this disease are ['E84.9', 'Z14.1', 'E84.0', 'E84.11', 'E84.8', 'E84.19', 'P09.4']. The drugs being studied are glpg2737 and placebo. The sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being at least 18 years old, having a confirmed clinical diagnosis of CF and being homozygous for the F508del CFTR mutation, stable intake of the drug Orkambi for at least 12 weeks prior to the study, and meeting certain lung function and sweat chloride concentration requirements. Exclusion criteria include a history of serious allergic reactions to drugs, unstable or uncontrolled chronic diseases, recent respiratory tract infections, hepatic cirrhosis with portal hypertension, and abnormal liver function test results.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is overactive bladder. The corresponding ICD-10 code for the disease is N32.81. The drugs being tested are solabegron immediate release tablets, low dose; solabegron immediate release tablets, high dose; and a matching placebo. \n\nThe eligibility criteria for the trial are as follows:\n- Adult female subjects between the ages of 18 and 80 with a history of overactive bladder symptoms for at least 6 months, including frequency, urgency, and urgency urinary incontinence. \n- Subjects must provide written informed consent and meet specific criteria for either non-childbearing potential or childbearing potential (e.g., negative pregnancy test, sexual inactivity, acceptable methods of birth control, and use of hormonal contraceptives).\n\nThe exclusion criteria for the trial are as follows:\n- Subjects with a history of pelvic or bladder disease, such as Grade 3/4 uterine prolapse, urogenital malignancy within the past 2 years, recent surgery for stress incontinence or pelvic prolapse repair, or bladder injections with botulinum toxin.\n- Subjects with diabetes insipidus or poorly controlled Type 1 or Type 2 diabetes mellitus.\n- Subjects with cardiac conditions, including prior cardiovascular events or procedures within 6 months, congestive heart failure, abnormal ECG findings (QTc > 470 msec), high blood pressure, or high heart rate.\n- Subjects with abnormal liver function tests.\n- Subjects with a history of prior infection due to HIV or hepatitis B or hepatitis C virus.\n- Subjects with allergy or hypersensitivity to solabegron or mirabegron.\n- Women of childbearing potential who are breastfeeding, pregnant, or actively trying to become pregnant.\n- Subjects who have participated in a trial of an investigational or marketed drug within 30 days prior to the screening visit or any clinical trial of an investigational drug that may affect urinary function within 3 months prior to the screening visit.\n- Subjects who are unable to read, understand, or complete study-related materials.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied include emesis, vomiting, nausea post chemotherapy, nausea, and chemotherapy-induced nausea and vomiting. The corresponding ICDCodes for these diseases are provided as well.\n\nThe drugs being investigated in this trial are olanzapine, aprepitant pill, ondansetron, and dexamethasone. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include requirements such as high-emetogenic chemotherapy regimen, no previous chemotherapy or radiotherapy, ECOG PS \u22642, and adequate hepatic and renal function, among others. The exclusion criteria include factors such as previous chemotherapy or radiotherapy, moderate- or low-emetogenic chemotherapy, ECOG PS >2, and history of brain metastases, among others.\n\nOverall, this sample provides specific details about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on the treatment of depression in adults with Parkinson's disease (PD). The disease is identified by the ICD-10 code \"G20\". The drug being studied is pimavanserin. \n\nThe eligibility criteria for participants include being able to understand and provide informed consent, having a clinical diagnosis of idiopathic Parkinson's disease for at least 1 year, meeting clinical criteria for depression with Parkinson's disease, and being on a stable dose of anti-Parkinson's medication for 1 month prior to screening. \n\nExclusion criteria include recent use of antipsychotics, recent myocardial infraction, known personal or family history or symptoms of long QT syndrome, severe hepatic or renal impairment, history of PD psychosis, schizophrenia, or other psychotic disorder, actively suicidal, pregnant or breastfeeding, previous treatment with pimavanserin, sensitivity to pimavanserin or its excipients, and being deemed inappropriate for the study by the investigator or medical monitor.\n\nAdditional inclusion/exclusion criteria may apply, and subjects will be evaluated during screening to ensure they meet all criteria for study participation.",
    "The sample in the table represents a clinical trial in phase 2. The trial focuses on diseases such as diabetes mellitus, diabetic retinopathy, and macular edema. The corresponding ICD-10 codes for these diseases are provided. The trial involves the use of drugs like ranibizumab 0.5mg, thr-317 8mg, and sham injection. The eligibility criteria for participants include being 18 years or older, having type 1 or type 2 diabetes mellitus, and having central subfield thickness above a certain threshold in the study eye. Other criteria include being treatment-na\u00efve or having a poor response to prior ranibizumab treatment, having reduced vision primarily due to diabetic macular edema, and having non-proliferative diabetic retinopathy. Exclusion criteria include having concurrent diseases that could affect vision, previous treatments or procedures that could confound the results, ocular infections or inflammation, being aphakic, having poorly controlled diabetes or uncontrolled hypertension, and being pregnant or not using adequate contraception.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include coronary artery disease, coronary artery bypass, cardiopulmonary bypass, nitric oxide, and reperfusion injury, myocardial. The corresponding ICDCodes for these diseases are also provided.\n\nThe drug being investigated in this trial is nitric oxide. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria state that participants must have coronary artery disease requiring coronary artery bypass grafting with cardiopulmonary bypass. Exclusion criteria include non-elective surgery, age over 70 years, left ventricular ejection fraction less than 35%, recent history of myocardial infraction, chronic atrial fibrillation, diabetes mellitus, and elevated levels of cardiac specific markers prior to the intervention.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 2. The disease being studied is chronic hepatitis C. The icd-10 codes associated with this disease are B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, and K71.4. The drugs being used in the trial are cdi-31244 and sof/vel. The eligibility criteria for participants include having documented chronic HCV GT 1 infection, serum HCV RNA level greater than 1,000 IU/mL during screening, and the absence of advanced fibrosis or cirrhosis. Some key exclusion criteria are being a nursing or pregnant woman, having active hepatitis B infection, being infected with HIV, or having a history of using any HCV direct-acting antiviral therapy.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes information about the diseases being studied, the associated ICD-10 codes, the drug being tested, and the eligibility criteria for participants.\n\nIn this particular trial, the diseases being studied are glaucoma, cataract, and wound healing. The ICD-10 codes associated with these diseases are provided as well. The drug being tested in this trial is mitomycin c.\n\nThe eligibility criteria for participants are listed under both inclusion and exclusion criteria. Inclusion criteria include having cataract and either primary open angle glaucoma or pseudoexfoliation glaucoma with progression of visual field loss and/or uncontrolled intraocular pressure levels with medication. Exclusion criteria include difficulty in reading or speaking Polish, previous ocular surgery, being pregnant or breastfeeding, having angle closure glaucoma, having secondary glaucoma (except pseudoexfoliation glaucoma), having ocular diseases with excessive scarring, and having an allergy to collagen or mitomycin c.",
    "The sample provided is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is stress urinary incontinence. The corresponding ICD-10 codes for this disease are N39.41, N39.46, N39.490, N39.491, N39.492, R32, and R39.81. The drugs being used in the trial are gtx-024 and a matching placebo. The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being one of the first 225 subjects who were randomly assigned to treatment in a previous Phase 2 study, being able to provide informed consent, and agreeing to maintain a stable dose of any medication known to affect lower urinary tract function. Exclusion criteria include starting any new treatment that may affect lower urinary tract function after completing the previous study, and having a physical condition that may put the subject at risk or interfere with the interpretation of study results.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include familial partial lipodystrophy, hypertriglyceridemia, fatty liver, and nonalcoholic steatohepatitis (NASH). The corresponding ICDCodes for these diseases are E88.1, K70.0, K76.0, and K75.81, respectively.\n\nThe drugs being tested in this trial are gemcabene, with two different dosages: 300mg and 600mg. The eligibility criteria for participants in this trial include a clinical diagnosis of lipodystrophy based on a lack of body fat in a partial fashion, low skinfold thickness in the anterior thigh, historic genetic diagnosis of familial partial lipodystrophy, hepatic steatosis, specific alcohol intake limits, fasting triglyceride levels, stable background lipid lowering medications, contraception requirements for women, weight and BMI restrictions, restrictions on the use of certain medications, and the absence of any conditions or findings that would compromise the patient's safety or participation in the study.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, the disease is Influenza A, the ICDCodes are J09.X1, J09.X3, J09.X9, J09.X2, A41.3, A49.2, B96.3, the drugs are ct-p27 dose1, ct-p27 dose2, and placebo, and the eligibility criteria include being between the ages of 19 and 65, being diagnosed with influenza A, and having a body temperature of at least 38\u00b0C. The exclusion criteria include not taking antiviral treatment for influenza or having a history of using these antivirals within 14 days prior to the study, and not having a positive influenza B or A+B infection.",
    "The sample from the table is for a clinical trial that is in phase 1/phase 2. The trial is focused on castration-resistant prostate cancer. The ICD-10 codes associated with this disease are 'C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', and 'Z12.5'. The drug being studied in this trial is cyclophosphamide. \n\nThe inclusion criteria for this trial include having histologically or cytologically confirmed adenocarcinoma of the prostate, radiographically documented metastatic disease with evidence of disease progression, being surgically or medically castrate, and having progressed following certain therapies. The exclusion criteria include having neuroendocrine or small cell cancer of the prostate, a history of other malignant diseases (except for primary prostate cancer and non-melanoma skin tumors) in the past 5 years, and various other factors such as recent experimental therapy, immunotherapy, radiopharmaceutical drugs, oncolytic virus treatment, and organ transplantation.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"atopic dermatitis\". The corresponding ICD-10 codes for this disease are \"L20.89\" and \"L20.9\". The drugs being studied in this trial are \"placebo\" and \"zpl389\". The eligibility criteria for participants are listed, including requirements such as having a written informed consent, having chronic atopic dermatitis for at least 1 year, and having moderate to severe atopic dermatitis as defined by EASI, IGA, and BSA. The criteria also mention that participants should have a documented recent history of inadequate response to topical medications or be unable to use topical treatments. Exclusion criteria are also listed, such as having any other skin disease that could affect the evaluation of atopic dermatitis, recent use of other investigational drugs, hypersensitivity to the study drugs or similar drugs, and previous participation in ZPL389 studies.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating metastatic colorectal cancer. The trial includes patients who have been diagnosed with colorectal adenocarcinoma and have unresectable metastatic disease. The patients must have at least one measurable tumor lesion that meets specific size criteria.\n\nThe patients must have previously received treatment with fluoropyrimidine, oxaliplatin, irinotecan, and at least one targeted therapy. They must also have adequate hematopoietic, hepatic, and renal function. Other eligibility criteria include being 20 years of age or older, having an ECOG performance status of 0-2, having a life expectancy of at least 12 weeks, being able to take oral medication, and being willing to sign an informed consent document.\n\nExclusion criteria for the trial include a history or presence of brain metastasis, mental disease or psychotic manifestation, significant medical conditions that contraindicate the study medication or pose a high risk of treatment complications, diarrhea of grade 2 or higher, and other malignancies within the past 5 years (except for certain types of adequately treated cancers). Patients who have recently received treatment with another investigational drug or are pregnant or nursing are also excluded from the trial. Female patients of childbearing potential must use effective contraception during the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of Tourette Syndrome. The diseases column specifies the disease being studied, which in this case is Tourette Syndrome. The icdcodes column provides the ICD-10 code associated with the disease, which is \"F95.2\" for Tourette Syndrome. The drugs column lists the drugs being used in the trial, which are \"valbenazine\" and \"placebo oral capsule\". The criteria column includes both inclusion and exclusion criteria for participants in the trial. The inclusion criteria state that participants must have a clinical diagnosis of Tourette Syndrome, moderate tic severity, impaired school, occupational, and/or social function due to TS symptoms, be on stable doses of any maintenance medication for TS or related diagnoses, be in good general health, have a negative urine drug screen, and agree to use contraception if of childbearing potential. The exclusion criteria state that participants must not have any active, clinically significant unstable medical condition, a history of long QT syndrome or cardiac arrhythmia, neuroleptic malignant syndrome, cancer diagnosis within the past 3 years (with some exceptions), allergy or intolerance to VMAT2 inhibitors, recent blood loss or blood donation, history of substance dependence or abuse, significant risk of suicidal or violent behavior, initiation of Comprehensive Behavioral Intervention for Tics (CBIT) during the screening period or study, recent participation in another clinical study involving NBI-98854 (except for specific studies), or HIV, hepatitis B, or hepatitis C.",
    "The sample from the table represents a clinical trial for a drug called IRL790 being conducted in patients with Parkinson's disease. The trial is a combination of phase 1 and phase 2. The inclusion criteria for the trial include patients aged 50-85 years, with a diagnosis of idiopathic Parkinson's disease and a clear peak-dose dyskinetic response to regular L-Dopa medication. The patients should also be on stable doses of anti-parkinson treatment for at least one month prior to inclusion. The exclusion criteria include a history of clinically significant diseases or disorders that could put the patient at risk or influence the results, a history of seizures, hepatic or renal disease, and any major surgery planned during the study. Other exclusion criteria include prolonged QTcF, cardiac arrhythmias, severe allergies or hypersensitivity, recent administration of another new chemical entity or participation in another clinical study with drug treatment, history of alcohol abuse or drug use, and patient's likelihood to comply with study procedures.",
    "The sample is a phase 2 trial for a drug targeting diabetes and cholesterolemia. The trial is looking for participants who have had type 2 diabetes for at least 6 months and are currently taking stable diabetes medication for at least 3 months. The participants should have an HbA1c level between 7-10% and LDL-cholesterol levels greater than 70 mg/dL. Women who are pregnant, lactating, or planning to become pregnant within 30 days after the last dose of the study medication are not eligible. They must also be postmenopausal, surgically sterile, or willing to use a form of birth control during the study. Exclusion criteria include a body mass index over 40 kg/m2, a history of clinically significant cardiovascular disease, fasting triglycerides over 400 mg/dL, type 1 diabetes, uncontrolled hypothyroidism, liver or renal dysfunction, gastrointestinal conditions that may affect drug absorption, hematologic or coagulation disorders, active malignancy, and a history of drug or alcohol abuse within the past 2 years.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being tested is a combination of apatinib and oral etoposide. The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include age requirements, HER2 negativity, ECOG score, previous treatments, measurable lesions, organ function, pregnancy test, ability to swallow oral drugs, compliance, and understanding of the study protocol. The exclusion criteria include factors such as pregnancy, previous treatments, oral administration and absorption issues, previous anti-VEGF or anti-VEGFR therapies, rapid progression of viscera invasion, mental illness, adverse effects or allergies to etoposide, bone metastasis without other measurable lesions, severe cardiovascular diseases, upper gastrointestinal ulcer or malabsorption syndrome, abnormal bone marrow, renal or liver function, uncontrollable brain metastasis, and poor compliance.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is \"lymphoma, large b-cell, diffuse.\" The corresponding ICDCodes for this disease are \"['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S'].\" The drugs being used in the trial are \"ngr-htnf,\" \"doxorubicin,\" \"cyclophosphamide,\" \"vincristine,\" and \"prednisone.\" \n\nThe eligibility criteria for this trial are as follows:\n- The patient must have a histological or cytological diagnosis of (D)LBCL.\n- The disease should be exclusively localized into the CNS (brain, meninges, cranial nerves, eyes, and/or spinal cord) both at first diagnosis and failure.\n- The patient must have progressive or recurrent disease.\n- Previous treatment with high-dose-methotrexate-based chemotherapy \u00b1 WBRT is required.\n- The patient must have at least one target lesion that is bidimensionally measurable.\n- The age range for inclusion is 18 - 80 years.\n- The patient's ECOG performance status should be between 0-3.\n- Adequate bone marrow, renal, cardiac, and hepatic function is required.\n- The patient must provide written informed consent prior to any study-specific procedures, with the understanding that they have the right to withdraw from the study at any time.\n\nThe exclusion criteria for this trial are as follows:\n- Known HIV disease or other chronic immunodeficiency.\n- Patients with positive flow cytometry examination of the CSF but negative results in CSF conventional cytology, and without any other evidence of CNS disease.\n- Patients with concomitant extra-CNS disease at presentation or relapse.\n- Symptomatic coronary artery disease, cardiac arrhythmias not well controlled with medication, or myocardial infraction within the last 6 months (New York Heart Association Class III or IV heart disease).\n- Any other serious medical condition that could impair the patient's ability to participate in the trial.\n- Concurrent treatment with other antineoplastic drugs.\n- Therapy with PPI (Proton Pump Inhibitors) is not allowed, but H2-blockers (i.e., ranitidine) are allowed for gastroprotective therapy.\n- Pregnant and lactating female patients are excluded. Sexually active patients of childbearing potential must implement adequate contraceptive measures during study participation.\n- Previous or concurrent malignancies at other sites diagnosed or relapsed within the last 3 years of follow-up, except for surgically cured in situ carcinomas and basal cell carcinoma of the skin.\n- Presence of any psychological, familial, sociological, or geographical condition that could potentially hamper compliance with the study protocol and follow-up schedule.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on chronic hepatitis D infection with hepatitis B. The ICD-10 codes associated with this disease are B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, and B17.2. The drugs being studied in this trial are myrcludex b, myrcludex-b, myrcludex-b, and tenofovir. The eligibility criteria for participants in this trial include being between the ages of 18 and 65, having positive serum HBsAg and anti-HDV antibody for at least 6 months, positive PCR results for serum HDV RNA, and certain liver conditions. There are also criteria related to previous treatment, pregnancy, contraception, and donation of sperm. The exclusion criteria include specific liver and kidney conditions, coinfection with HCV or HIV, certain bilirubin levels, and previous or current malignant neoplasms.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"stress urinary incontinence.\" The associated ICD-10 codes for this disease are ['N39.41', 'N39.46', 'N39.490', 'N39.491', 'N39.492', 'R32', 'R39.81']. The drug being studied is \"gtx-024\". \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being a subject from a previous study (G201002) and meeting certain completion requirements. Participants must also be able to provide informed consent, comply with the study protocol, and communicate with study personnel about adverse events and other important information. They must also agree to maintain a stable dose of any medication known to affect lower urinary tract function throughout the study.\n\nExclusion criteria include starting any new treatment that affects lower urinary tract function after completing the previous study, currently taking systemic sex-hormone products (excluding certain vaginal applications), having a current cancer diagnosis (excluding nonmelanoma skin cancer), and having a history or current episode of certain cardiovascular conditions.\n\nOverall, the sample provides specific details about the phase, disease, associated codes, drug, and eligibility criteria for participants in the clinical trial.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is acute cough, which is identified by the ICD-10 code R05.1. The drugs being tested in this trial are gefapixant and placebo. \n\nThe eligibility criteria for participants in this trial include being in good general health, being susceptible to human rhinovirus type 16 (HRV-16), and being male or a non-pregnant and non-breastfeeding female. If a female participant is of reproductive potential, she must agree to use one form of acceptable birth control.\n\nThe exclusion criteria for participants include having donated blood within 56 days or donated plasma within 7 days prior to dosing, having a history of significant multiple and/or severe allergies, having a recent history of respiratory tract infection, having a history of cancer, having a body mass index (BMI) less than 18 kg/m^2 or greater than or equal to 40 kg/m^2, having a history of major surgery or loss of 1 unit of blood, having a history of allergic reaction to sulfonamides, having received medications within 14 days prior to randomization, having significantly abnormal laboratory tests at screening, being a current smoker, having smoked within 5 years of screening, or having a significant past smoking history, and having a history of alcohol or drug abuse.",
    "The sample from the table represents a phase 2 clinical trial for prostate adenocarcinoma without neuroendocrine differentiation. The trial includes patients with stage I and stage II prostate cancer who are eligible for radical prostatectomy. The trial aims to evaluate the effectiveness of the drug olaparib. The eligibility criteria for the trial include providing informed consent, having confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, and having evidence of homologous recombination deficiency. Other criteria include being considered surgically resectable, having no evidence of metastatic or nodal disease, and meeting certain health requirements such as hemoglobin levels, platelet count, and liver function. The sample also includes exclusion criteria, such as previous treatment with PARP inhibitors, involvement in the study planning or conduct, and certain medical conditions or medications that may interfere with the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are prostate cancer and endometrial cancer. The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are rucaparib and nivolumab. The eligibility criteria for patients to participate in the trial are listed, including requirements related to consent, disease confirmation, biopsy, previous treatments, medical conditions, and reproductive status. There are also exclusion criteria listed, which specify conditions or situations that would disqualify a patient from participating in the trial.",
    "The sample is a phase 2 trial for the treatment of idiopathic pulmonary fibrosis. The trial is evaluating the effectiveness of a drug called bg00011 compared to a placebo. The eligibility criteria for participants include being diagnosed with IPF based on specific guidelines, having certain lung function measurements within a certain range, and being on a stable dose of certain medications if applicable. There are also exclusion criteria, such as having certain medical conditions or being unsuitable for enrollment for unspecified reasons.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is Parkinson's disease. The ICDCodes associated with the disease are ['G20']. The drugs mentioned are \"accordion pill carbidopa/levodopa\" and \"sinemet cr 25mg-100mg extended-release tablet\". The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include a diagnosis of Parkinson's disease, stable dose of levodopa/carbidopa IR, and stable use of all anti-PD medications. The exclusion criteria include conditions such as atypical or secondary parkinsonism, significant cardiac, pulmonary, hepatic, or renal disease, severe dyskinesia, cognitive impairment, psychiatric illness, history of certain surgeries or gastrointestinal conditions, allergies to study drugs, inability to swallow large pills, active GERD with regular use of PPIs, and pregnancy or nursing without contraception.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of inguinal hernia. The ICD-10 codes associated with the disease are ['K40.11', 'K40.41', 'K40.01', 'K40.21', 'K40.31', 'K40.91', 'K40.10']. The drugs being studied are 'tlc590' and 'naropin'. The sample also includes the eligibility criteria for participants in the trial. The inclusion criteria include being able to provide informed consent, being between 18 and 65 years old, scheduled for a primary, unilateral Lichtenstein inguinal hernia repair, having an ASA Physical Status Classification of 1 or 2, and meeting certain requirements for female and male subjects regarding pregnancy and birth control. The exclusion criteria include having abnormal clinical laboratory test values, evidence of clinically significant 12-lead ECG, history or evidence of certain medical conditions, history of seizures or taking anticonvulsants, hypersensitivity to certain medications, and other specific conditions.",
    "The sample is a phase 2 trial for the treatment of type 1 diabetes mellitus and hypoglycemia unawareness. The trial involves the use of the drugs amitriptyline and placebo. The eligibility criteria for participants include having type 1 diabetes for at least 5 years, being between the ages of 21 and 60, having a HbA1c level of less than or equal to 9% within the last 3 months, and using real-time continuous glucose monitoring (rtCGM) for at least 3 months with at least 80% of readings available over the last 2 weeks. Participants must also be able to provide informed consent and meet certain exclusion criteria, such as not having a history of major depressive disorder, not using antidepressants within the last three months, and not having certain medical conditions. The sample also mentions a \"Run-in Period\" for participants who meet the initial criteria, and additional exclusion criteria are applied before randomization for the study drug. These additional criteria include the percentage of CGM readings available and the time spent in hypoglycemia.",
    "The sample is a record from a table that contains information about clinical trials. It is for a phase 2 trial and the disease being studied is \"dementia with lewy bodies\". The corresponding ICD-10 code for this disease is \"G31.83\". The trial involves two drugs, \"htl0018318\" and \"placebo\". The eligibility criteria for this trial include being diagnosed with probable DLB according to specific diagnostic criteria, having clinical imaging evidence consistent with a DLB diagnosis, and having a partner or caregiver to support the patient throughout the trial. There are also exclusion criteria listed, such as having a diagnosis of Parkinson's disease, severe extrapyramidal symptoms, or any other illness that could contribute to cognitive dysfunction. Other exclusion criteria include poorly controlled hypertension, recurrent episodes of syncope related to orthostatic hypotension, pulmonary disease, taking prohibited or restricted medication, undergoing cognitive rehabilitation in the past 6 months, and having any known condition that may interfere with the completion of nuclear imaging scans.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is Major Depressive Disorder. The ICDCodes associated with this disease are F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, and F33.40. The drugs mentioned in this sample are axs-05 and bupropion. The eligibility criteria for this trial include meeting the DSM-5 criteria for MDD, having a body mass index (BMI) between 18 and 40 kg/m^2, agreeing to use adequate contraception during the study, and meeting other additional criteria. The exclusion criteria include having a suicide risk, a history of treatment resistance in the current depressive episode, a history of certain treatments, being pregnant or breastfeeding, and meeting other additional criteria.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the treatment of stage IV non-small cell lung cancer. The trial is specifically targeting patients who have already received first-line chemotherapy and achieved stable disease or a partial response. Additionally, patients who have been receiving specific drugs for EGFR mutant-positive cases and have achieved stable disease, partial response, or complete response are also eligible.\n\nThe inclusion criteria for this trial include patients aged 18 to 75 years old, with measurable disease at baseline, a limited amount of metastatic focus (less than 5), and an ECOG score of 0-2. Adequate normal organ and marrow function for TKI treatment and radiotherapy is also required. Furthermore, patients must have a sensitizing EGFR mutation (such as exon 19 deletion or exon 21 L858R) and provide written informed consent.\n\nOn the other hand, the exclusion criteria state that patients who have previously received radiotherapy to the primary site, those who cannot tolerate radiotherapy or targeted therapy, and pregnant or nursing women are not eligible for this trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is dry eye. The ICDCodes associated with this disease are \"H04.121\", \"H04.122\", \"H04.123\", \"H04.129\", \"H35.3111\", \"H35.3112\", and \"H35.3121\". The drugs being used in the trial are \"voclosporin ophthalmic solution\" and \"restasis\u00ae\". \n\nThe eligibility criteria for this trial include having a best corrected visual acuity (BCVA) of +0.7 logarithm of the Minimum Angle of Resolution (logMAR) or better in both eyes, a documented history of dry eye in both eyes, and ongoing dry eye symptoms in at least one eye. The symptoms include a symptom severity score of \u226530 for Eye Dryness on a Visual Analog Scale (WAS), an unanesthetized Schirmer Tear Test (STT) score of \u22651 mm and \u226410 mm per 5 minutes, and evidence of ocular surface staining. Additionally, participants must have normal lid anatomy.\n\nThere are also exclusion criteria listed, which include hypersensitivity or contraindication to study treatments, inability to demonstrate correct instillation of over-the-counter ocular lubricant, discomfort from instillation of ocular lubricant, recent use of Restasis\u00ae or Xiidra\u00ae, corneal graft surgery within the past year, evidence of ocular infection or inflammation, and clinically significant blepharitis, conjunctivitis, or a history of herpes simplex or zoster keratitis.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the trial is in phase 2 and focuses on the disease called vulvodynia. The ICD-10 codes associated with this disease are 'N94.818' and 'N94.819'. The drug being tested in this trial is a placebo. The sample also includes the eligibility criteria for participants. Inclusion criteria include being premenopausal, having vulvodynia for at least 6 months but no more than 15 years, and experiencing provoked pain at the vestibule during a Q tip test. Exclusion criteria include experiencing deep pain during intercourse, having genitourinary or gastrointestinal conditions that may interfere with the study, and having previous surgeries or genital trauma that may impact the study outcome.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of photosensitive epilepsy. The ICD-10 codes associated with the disease are provided. The drugs being studied include a placebo and a drug called e2730. The eligibility criteria for participants are listed, including age requirements, diagnosis and history of a specific type of seizure, current medication usage, specific EEG results, body mass index, and weight. The exclusion criteria are also listed, which include restrictions for pregnant or breastfeeding females, history of nonepileptic seizures, recent generalized tonic-clonic seizures, previous clinical seizures during assessments, use of certain antiepileptic drugs, allergies or severe reactions to medications, certain neurological conditions, use of cannabinoids, inability to follow restrictions on screen usage, history of prolonged QT syndrome or risk factors, suicidal ideation or behavior, psychotic or affective disorders, and abnormal EEG activity.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"tumor lysis syndrome,\" and its corresponding ICDCodes is \"E88.3.\" The drug being studied is \"febuxostat.\" \n\nThe eligibility criteria for this trial sample include:\n- Participants must be male and female children aged 6 to less than 12 years, adolescents aged 12 to less than 18 years, and adults aged 18 years and above.\n- Participants must be scheduled for their first cytotoxic chemotherapy cycle due to hematologic malignancies.\n- Participants must be at intermediate or high risk of tumor lysis syndrome (TLS).\n- Participants must not have access to rasburicase.\n\nThe exclusion criteria for this trial sample include:\n- Patients with contraindications as per the febuxostat summary of product characteristics.\n- Patients with severe renal insufficiency.\n- Patients with severe hepatic insufficiency.\n- Patients diagnosed with Laboratory TLS (LTLS) or Clinical TLS (CTLS).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are ixazomib, thalidomide, and dexamethasone. The eligibility criteria for participants in this trial include specific medical conditions and laboratory values that need to be met. Additionally, there are exclusion criteria that specify conditions or circumstances that would disqualify a participant from the trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease is \"diabetic macular edema\". The ICDCodes associated with this disease are ['E10.311', 'E10.319', 'E11.311', 'E11.319', 'E13.311', 'E13.319', 'E10.3513']. The drugs being tested in this trial are 'intravitreous dexamethasone solution 4mg/ml - vol 0,01 ml', 'intravitreous dexamethasone solution 4mg/ml - vol 0,03 ml', and 'intravitreous dexamethasone solution 4mg/ml - vol 0,05 ml'. The eligibility criteria for this trial include age greater than or equal to 18 years, a diagnosis of DM type 2, pseudophakic patients, presence of clinically significant DME according to ETDRS guidelines, best correct visual acuity (BCVA) between 20/400 and 20/40, central macular thickness (CMT) greater than or equal to 300 \u00b5m measured by spectral domain optical coherence tomography (Spectralis\u00ae Heidelberg). There are also exclusion criteria such as recent treatment of DME, recent pan retinal photocoagulation (PRP), recent ophthalmologic surgery, history of pars plana vitrectomy, history of open-angle glaucoma or intraocular pressure elevation induced by corticosteroids, intraocular pressure greater than or equal to 21 mmHg, and refusal to sign the written general consent.",
    "The sample provided is for a phase 2 clinical trial for attention deficit hyperactivity disorder (ADHD). The trial is investigating the effectiveness of the drug \"aevi-001\" compared to a placebo. The eligibility criteria for participants include being between 6 and 17 years old, having a primary diagnosis of ADHD based on DSM-5 criteria, and having a minimum score of 28 on the ADHD-RS-5 assessment. Participants must also be fluent in English, provide written informed consent, and comply with contraceptive requirements if of childbearing potential. Exclusion criteria include having significant emotional problems, having a co-morbid major psychiatric diagnosis (aside from ADHD), having autism spectrum disorder, currently taking medication that may affect safety assessments, and having a history of cardiovascular disease or other serious cardiac problems.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 2. The disease being studied is non-small cell lung cancer. The corresponding ICD-10 codes for this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being tested in this trial are endostar and placebos. The eligibility criteria for participants include having brain metastasis related to NSCLC as an inclusion criteria, and having a KPS (Karnofsky Performance Status) score less than 60 as an exclusion criteria.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the recurrence of Clostridium difficile infection. The associated ICD-10 codes for the disease are A05.2, A04.71, A04.72, and B96.7. The drugs being studied are fmt oral capsule, oral vancomycin, fmt oral placebo, and oral vancomycin placebo. \n\nThe eligibility criteria for participants are listed under \"Inclusion Criteria\" and include requirements such as providing written informed consent, being willing to comply with study procedures, being able to take oral medication, being a solid organ transplant recipient, and having experienced recurrent C. difficile infection within 180 days after completing treatment for a prior episode. Other criteria include a history of positive IgG test for cytomegalovirus (CMV) and Epstein-Barr Virus (EBV), negative pregnancy test for women of childbearing potential, and clinical response to oral antibiotic treatment for the current episode of CDI.\n\nThe \"Exclusion Criteria\" list factors that would disqualify potential participants, such as having active intestinal diseases, recent major bowel resection surgery, known or suspected toxic megacolon or small bowel ileus, history of total colectomy or bariatric surgery, dysphagia, neutropenia, expected life expectancy of less than 6 months, taking concomitant antibiotics within 48 hours of visit 2 (except for specific cases), unwillingness to withhold probiotics, concurrent intensive induction chemotherapy or radiation therapy for active malignancy, severe food allergy, gastroparesis, symptomatic co-infection with another intestinal pathogen, pregnancy, lactation, or plans to become pregnant during the study, and being deemed unsuitable for study participation for other reasons at the discretion of the investigators.",
    "The sample is a phase 2 trial for thyroid cancer. The diseases included in the trial are thyroid cancer, thyroid cancer, medullary, differentiated thyroid cancer, papillary thyroid cancer, follicular thyroid cancer, and poorly differentiated thyroid gland carcinoma. The corresponding ICD-10 codes for these diseases are C73, D34, D44.0, and Z85.850. The drugs being studied in the trial are lenvatinib, sorafenib, cabozantinib, and vandetanib. The eligibility criteria for participants include having a confirmed diagnosis of thyroid cancer (excluding anaplastic or stromal-cell derived cancers), measurable disease, evidence of disease progression, being radioiodine-refractory/resistant, and meeting various other criteria related to disease status, prior treatments, and overall health. There are also exclusion criteria, such as recent anticancer treatment, major surgery, significant cardiovascular impairment, active infections, and intolerance to the study drugs.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of glioma and diffuse intrinsic pontine glioma. The diseases are identified by their corresponding ICD-10 codes. The drugs being studied in the trial are panobinostat and everolimus. The eligibility criteria for participants are listed, including age restrictions, functional status requirements, and various health parameters that need to be met. The criteria also specify the need for histological confirmation of the type of tumor and the time that needs to have elapsed since previous treatments. The sample also includes exclusion criteria, such as pregnancy, uncontrolled infection, and certain medication restrictions.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"dry eye disease\". The ICD-10 codes associated with this disease are \"H04.121\", \"H04.122\", \"H04.123\", \"H04.129\", \"H35.3111\", \"H35.3112\", and \"H35.3121\". The drugs being studied are \"oc-02\" and \"placebo\". The eligibility criteria for this trial include having used or desired to use an artificial tear substitute for dry eye symptoms within the past 60 days. There are also exclusion criteria listed, such as having had recent eye surgeries, having certain ocular disorders or conditions, having unstable systemic conditions or diseases, having hypersensitivity to any of the procedural agents or study drug components, and having any condition or history that may interfere with study compliance or safety.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of plaque psoriasis. The ICD-10 codes associated with this disease are ['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']. The drugs being tested in this trial are 'arq-151 cream 0.3%', 'arq-151 cream 0.15%', and 'arq-151 vehicle cream'. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being legally competent to give informed consent, being 18 years or older, having a clinical diagnosis of psoriasis vulgaris for at least 6 months, having a negative pregnancy test for females of childbearing potential, and being in good health. Participants must also be reliable and capable of adhering to the trial protocol and visit schedule.\n\nExclusion criteria include planned excessive exposure of treated areas to sunlight or tanning beds, pregnancy or breastfeeding for females, previous treatment with ARQ-151 or its active ingredient, any serious medical condition or laboratory abnormality that would prevent participation or pose significant risk, a history of chronic alcohol or drug abuse within the past 6 months, and inability to communicate or understand the local language or any other condition that makes them unsuitable for the trial according to the investigator's judgment.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the diseases mentioned are \"cognitive dysfunction\" and \"Alzheimer's disease.\" The ICDCodes associated with these diseases are \"G30.8,\" \"G30.9,\" \"G30.0,\" and \"G30.1.\" The drugs being studied are \"aducanumab\" and \"placebo.\" The eligibility criteria include various requirements such as the participant's ability to understand the study's purpose and risks, having at least 6 years of education or work experience, evidence of cerebral A\u03b2 accumulation, consent for ApoE genotyping, and meeting specific clinical criteria for MCI due to AD or mild AD dementia. There are also exclusion criteria listed, such as uncontrolled medical or neurological conditions, unstable psychiatric illness, recent transient ischemic attack or stroke, recent vaccinations, and pregnancy or breastfeeding for female participants.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of metastatic or locally recurrent and inoperable triple negative breast cancer. The trial is focused on evaluating the effectiveness of the drug cisplatin. The eligibility criteria for participants include having a confirmed diagnosis of triple negative breast cancer, providing informed consent, having measurable disease, and meeting certain medical criteria such as blood counts, liver and kidney function, and performance status. Participants must also not have received more than 3 lines of cytotoxic chemotherapy for metastatic breast cancer and must not have documented disease progression on prior cisplatin therapy. Exclusion criteria include having received certain types of prior treatments, having certain medical conditions or infections, and being pregnant or breastfeeding. The sample provides detailed inclusion and exclusion criteria for potential participants.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 2 and focuses on two diseases: glaucoma, open-angle, and hypertension, ocular. The corresponding ICD-10 codes for these diseases are provided as well. The trial involves two drugs: ncx 470 and latanoprost 0.005%. The eligibility criteria for this trial are listed under both inclusion and exclusion criteria. Inclusion criteria include a diagnosis of open-angle glaucoma or ocular hypertension in both eyes, specific intraocular pressure (IOP) measurements, qualifying best-corrected visual acuity (BCVA), and the ability to provide informed consent and follow study instructions. Exclusion criteria include certain types of glaucoma, narrow anterior chamber angles or disqualifying corneal thickness, clinically significant ocular disease, previous complicated surgery or certain types of glaucoma surgery, recent ocular surgery or severe trauma, and uncontrolled systemic disease.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is nonalcoholic steatohepatitis. The corresponding ICDCodes for this disease are K75.81. The drugs being tested in this trial are sgm-1019 and placebo. The eligibility criteria for participants include being male or female, aged between 18 and 75 years, having elevated ALT levels, having F1-F3 NASH, and having a BMI of 25 or higher. The exclusion criteria include the use of prohibited medication/supplements, poorly controlled type 2 diabetes, hepatic decompensation, chronic liver disease, and planned surgeries/procedures.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on urinary tract infections. The associated ICD-10 codes for the diseases are listed. The drugs being studied are cefepime 1g - 2g / aai101 0.5g - 0.75g and cefepime 1 g or cefepime 2 g. The eligibility criteria for the trial are also provided, including inclusion and exclusion criteria. Inclusion criteria state that male or female patients with clinical signs and/or symptoms of cUTI or acute pyelonephritis that require hospitalization and at least 7 days of intravenous antibiotics are eligible. Exclusion criteria include patients with concurrent infections that would interfere with the evaluation of response to the study antibiotics, patients needing additional systemic antimicrobial agents, patients who have received effective antibacterial drug therapy within the previous 72 hours, patients likely to require antibiotic prophylaxis during the study, patients with confirmed fungal urinary tract infection, and patients with intractable urinary infection that would require more than 10 days of study drug therapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"multiple myeloma in relapse,\" \"multiple myeloma progression,\" and \"multiple myeloma with failed remission.\" The ICDCodes associated with these diseases are \"C90.02.\" The drug being used in the trial is \"tinostamustine.\" \n\nThe eligibility criteria for this trial include having received prior ASCT (autologous stem cell transplantation) after standard first-line induction treatment, evidence of disease progression with a certain progression-free interval, receiving treatment with a limited number of prior therapy lines, and having a certain response to the latest salvage chemotherapy. Other criteria include being a candidate for consolidation therapy with tinostamustine followed by ASCT, having a sufficient number of available autologous peripheral blood stem cells, being within a certain age range, having a specific performance status score, and meeting certain requirements for kidney, heart, lung, and liver function. \n\nThere are also exclusion criteria, such as a history of central nervous system disease involvement, plasma cell leukemia, recent myocardial infraction or stroke, uncontrolled acute infection, high HCT-CI score, concurrent malignant disease (with some exceptions), major coagulopathy or bleeding disorder, other serious medical conditions that could interfere with treatment, lack of cooperation, pregnancy or lactation, recent use of investigational agents, treatment with drugs known to prolong the QT/QTc interval, and a prolonged QTc interval based on ECG readings.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of generalized anxiety disorder. The disease is identified by the ICD-10 code \"F41.1\". The drug being tested is alprazolam 1mg. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being of both sexes, being 18 years of age or older, having a clinical diagnosis of generalized anxiety disorder, scoring 18 points or more on the Hamilton Anxiety Scale, not having received previous treatment for the disease for at least one month, not being pregnant or lactating (for women of reproductive age), and signing an informed consent letter to participate in the investigation.\n\nExclusion criteria include having received treatment for the condition, having another mental disorder, having alcoholism, smoking or drug addiction, living alone, taking drugs for insomnia, taking drugs of the Monoamine Oxidase Inhibitors group, having epilepsy, operating dangerous machinery, and having to drive for a long time as part of work (car, truck, or other motor vehicle).",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of psoriasis. The diseases column lists the disease names, with 'psoriasis' being the disease for this particular record. The icdcodes column contains the corresponding ICD-10 codes for the diseases, with the codes for psoriasis being ['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']. The drugs column lists the drug names being tested in the trial, which are 'mp1032' and 'placebo'. The criteria column provides the eligibility criteria for participants in the trial, including age range, specific disease severity criteria, BMI range, pregnancy and contraception requirements, health status criteria, laboratory criteria, and other exclusion criteria.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease is \"smoking cessation\". The ICDCodes associated with this disease are ['Y36.881S', 'Y36.891S', 'Y36.880S', 'Y36.881A', 'Y36.881D', 'Y36.890S', 'Y36.891A']. The drugs being studied are \"cytisine\" and \"placebo comparator\". The eligibility criteria are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\", which include factors such as age, smoking habits, previous attempts to quit smoking, willingness to participate, and various medical conditions or medications that may exclude a person from participating in the trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is \"cutaneous t-cell lymphoma/mycosis fungoides.\" The ICDCodes associated with this disease are \"S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S.\" The drugs mentioned in this sample are \"cobomarsen\" and \"vorinostat.\" The eligibility criteria for this trial include specific inclusion and exclusion criteria, such as having a biopsy-proven CTCL, MF subtype, a minimum mSWAT score of 10 at screening, and having received at least one prior therapy for CTCL. Some of the exclusion criteria include previous enrollment in a cobomarsen study, prior therapy with vorinostat or other HDAC inhibitors, and evidence of large cell transformation.",
    "The sample from the table is for a phase 2 trial. The disease being studied is respiratory syncytial virus infections. The corresponding ICD-10 codes for this disease are 'R09.2', 'A15.7', 'A15.8', 'A15.9', 'J98.9', 'R06.03', and 'J12.1'. The drugs being tested in the trial are 'pc786', 'placebo', and 'soc'. The eligibility criteria for inclusion in the trial include having received a hematopoietic stem cell transplant, experiencing respiratory symptoms within the past 5 days, testing positive for RSV, and providing written informed consent. The exclusion criteria include being intubated and requiring invasive ventilation, recent receipt of investigational RSV vaccine or monoclonal anti-RSV antibodies, treatment with intravenous ribavirin, testing positive for influenza or parainfluenza, having untreated bacteraemia or fungaemia, having untreated bacterial, fungal, or viral pneumonia, being precluded from participating in another clinical trial or taking another investigational drug, having a disease or condition that would prevent participation in a clinical trial, receiving an antiretroviral protease inhibitor, having chronic, active hepatitis infection, or having known alcohol or drug abuse.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and is related to the treatment of complications in perfusion. The ICD-10 codes associated with the diseases are ['A36.89', 'B01.89', 'B02.9', 'B05.89', 'B06.89', 'B26.89', 'K94.30']. The drug being studied is nitroglycerin. The eligibility criteria for the trial are listed under inclusion and exclusion criteria. Inclusion criteria include being a female patient between the ages of 18 and 99, undergoing mastectomy with possible immediate breast reconstruction, and having the ability to understand and sign an informed consent document. Exclusion criteria include being under 18 or over 99 years old, undergoing mastectomy without immediate breast reconstruction, having certain pre-existing conditions, being pregnant, and having conditions that contraindicate the use of nitroglycerin paste or incisional negative pressure wound therapy.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is anaplastic large cell lymphoma with ALK-positive status. The trial is investigating the drug brigatinib. The eligibility criteria for the trial include having a confirmed diagnosis of relapsed or refractory ALCL with ALK+ status, measurable disease, resolved toxicities from prior therapy, age over 18, ECOG performance status 0-2, and normal organ and marrow function. Patients with a known history of HIV are also permitted if certain criteria are met. The sample also includes exclusion criteria such as a history of another active primary malignancy, recent chemotherapy or radiation therapy, symptomatic CNS metastases, and certain medical conditions. Pregnant or breastfeeding individuals are also excluded from the trial.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The diseases being studied include \"total intravenous anesthesia,\" \"desflurane,\" \"obesity,\" \"pain, postoperative,\" and \"nausea, postoperative.\" The corresponding ICD-10 codes for these diseases are ['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99.215', 'O99.210', 'O99.211']. The drug being tested is \"desflurane.\" The eligibility criteria for this trial include having a BMI of at least 35 kg/m2 with at least one comorbid condition, or a BMI of at least 40 kg/m2. The exclusion criteria include drug abuse, severe mental illness, age below 18, and having serious medical conditions such as cancer, end-stage lung disease (ASA>3), or allergies to any drugs used in the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of Tourette Syndrome. The ICDCodes column contains the ICD-10 code for Tourette Syndrome, which is \"F95.2\". The drug being studied is called \"nbi-98854\". \n\nThe eligibility criteria for participants are listed under the \"criteria\" column. In order to be included in the trial, participants must have a clinical diagnosis of Tourette Syndrome and have previously participated in the NBI-98854-TS2004 or NBI 98854-TS2005 Phase 2 studies. If they are taking medication for Tourette Syndrome or related conditions, they must be on stable doses. Participants must also be in good general health and agree to use contraception if they are of childbearing potential.\n\nThere are also exclusion criteria listed, which specify conditions or circumstances that would disqualify someone from participating in the trial. These include having an unstable medical condition, a history of long QT syndrome or cardiac arrhythmia, a history of neuroleptic malignant syndrome, a cancer diagnosis within the past 3 years (with some exceptions), allergies or intolerance to VMAT2 inhibitors, recent blood loss or blood/plasma donation, substance dependence or abuse, significant risk of suicidal or violent behavior, recent use of investigational drugs (other than NBI-98854), current participation in another NBI-98854 clinical study, and pregnancy for females.",
    "The sample from the table is for a phase 2 clinical trial focused on schizophrenia. The diseases column specifies that the trial is targeting schizophrenia. The icdcodes column provides a list of ICD-10 codes associated with schizophrenia. The drugs column lists the drugs being tested in the trial, including \"lu af11167 (1-2 mg/day)\", \"lu af11167 (3-4 mg/day)\", and \"placebo\". The criteria column contains the eligibility criteria for participants in the trial.\n\nThe inclusion criteria include having a confirmed diagnosis of schizophrenia according to DSM-5, being treated by the site or investigator for at least the last 6 months, experiencing persistent negative symptoms, being on stable doses of an oral antipsychotic within the approved dose range, and having no psychiatric admissions due to clinical deterioration in the last 6 months. Other criteria include being in a clinically stable phase of schizophrenia, having no significant acute extrapyramidal side effects or tardive dyskinesia, having prominent negative symptoms, and having a caregiver or responsible person for support.\n\nThe exclusion criteria include recent acute exacerbation requiring hospitalization or change in antipsychotic medication, current or history of substance use disorder (with some exceptions), significant risk of self-harm or harm to others, positive tests for certain viruses (hepatitis A, hepatitis B, hepatitis C, and HIV), liver function compromise, and any other disorder that may interfere with the study treatment or compliance.\n\nIt is important to note that there may be additional in- and exclusion criteria not mentioned in the provided sample.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied include epithelial ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma, high-grade serous carcinoma, and endometrioid adenocarcinoma. The corresponding ICDCodes for these diseases are also listed.\n\nThe drugs being used in the trial are rucaparib and nivolumab. The eligibility criteria for participants in this trial include being at least 18 years old, having adequate organ function, having a life expectancy of at least 16 weeks, and having a negative serum pregnancy test for women of childbearing potential.\n\nOther criteria include having high-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, having received 1 or 2 prior regimens including platinum-based therapy, and having relapsed or progressive disease confirmed by radiologic assessment.\n\nParticipants must also be willing and able to have a tumor biopsy at screening and after 4 weeks of treatment. Additional criteria include having measurable disease (RECIST v1.1) for Cohort A1, having an ECOG performance status of 0 to 1, and meeting certain exclusion criteria such as not having active second malignancy, central nervous system brain metastases, or interstitial lung disease.\n\nParticipants should not have a history of myocarditis or active autoimmune diseases, and should not have received prior treatment with a PARP inhibitor or immune checkpoint inhibitor. Non-epithelial tumors or ovarian tumors with low malignant potential are excluded, but mixed Mullerian tumors/carcinosarcomas are allowed.",
    "The sample provided is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 2. The disease being studied is atopic dermatitis, and the corresponding ICD-10 codes for this disease are 'L20.89' and 'L20.9'. The drugs being tested in this trial are 'ly3375880' and 'placebo'. The eligibility criteria for participants are listed, including having a diagnosis of atopic dermatitis for at least 12 months, having moderate to severe atopic dermatitis at screening and randomization, and having an inadequate response to topical medications within 6 months of screening or a history of intolerance. Participants who are currently receiving topical or systemic treatments for atopic dermatitis are excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is pancreatic cancer. The ICDCodes associated with this disease are C25.3. The drug being used in the trial is gemcitabine. The eligibility criteria for this trial include having histologically or cytologically confirmed adenocarcinoma of the pancreas, being a candidate for gemcitabine chemotherapy, being at least 18 years old, having an ECOG performance status of 0-2, consenting to donate 12 tubes of peripheral blood, having adequate organ function, understanding and willingness to sign a consent document, and meeting certain time requirements for prior chemotherapy and radiation therapy. The exclusion criteria include never being immunized with tetanus toxoid, not receiving any investigational agents, being pregnant, and having HIV.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are castration-resistant prostate cancer, metastatic cancer, and bone metastases. The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are Xgeva and Xtandi. The eligibility criteria for participants in this trial are listed, including age, performance status, disease confirmation, disease progression, prior treatments, medical conditions, and various laboratory values. There are also exclusion criteria listed, which specify conditions or circumstances that would disqualify a participant from the trial.",
    "The sample is a phase 2 clinical trial for colorectal cancer. The trial is looking for patients with locally advanced or metastatic colorectal cancer who have undergone testing for MGMT promoter methylation and have confirmed MGMT promoter methylation. The trial also requires patients to be refractory or intolerant to at least 2 lines of standard chemotherapy. Patients must have at least one measurable index lesion based on RECIST 1.1 criteria. Other eligibility criteria include being 18 years or older, having an ECOG performance status of 0 or 1, and demonstrating adequate organ function. The trial excludes patients who are currently participating in or have participated in another investigational study within 4 weeks of the first dose of treatment, have immunodeficiency or are receiving systemic steroid therapy, have received prior chemotherapy or targeted therapy within 2 weeks prior to the study, have active central nervous system metastases, have active autoimmune disease requiring systemic treatment, have interstitial lung disease or active pneumonitis, have an active infection requiring systemic therapy, have psychiatric or substance abuse disorders, are pregnant or breastfeeding, have received prior anti-PD-1, anti-PDL-1, anti-PDL-2, anti-CTLA-4 antibody, have a known history of HIV or active Hepatitis B or C, have received a live vaccine within 30 days prior to the trial, or are prisoners or compulsory detained.",
    "The sample is a phase 2 clinical trial for prostate cancer. The eligibility criteria for patients to participate in the trial include having histologically confirmed adenocarcinoma of the prostate, with specific requirements for the stage and grade of the cancer. The patients must also be scheduled for radical prostatectomy at Johns Hopkins Hospital and meet certain age and performance status criteria. Adequate bone marrow, hepatic, and renal function is required, as well as willingness to provide informed consent and HIPAA authorization. Barrier contraception is also required during the study period. There are exclusion criteria, such as the presence of lymph node involvement or distant metastases, prior treatments for prostate cancer, use of certain medications, history of autoimmune disease, and other significant medical conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and is focused on Duchenne muscular dystrophy. The ICD-10 code associated with this disease is G71.01. The trial involves two drugs, namely \"wve-210201 (suvodirsen)\" and \"placebo\". The eligibility criteria for participants include a diagnosis of DMD based on clinical phenotype with increased serum creatine kinase, a documented mutation in the Dystrophin gene associated with DMD that is amenable to exon 51 skipping, being an ambulatory male able to walk independently for at least 10 meters in 10 seconds or less, and having stable pulmonary and cardiac function. Participants must also be on a stable corticosteroid therapy regimen. The exclusion criteria include severe cardiomyopathy, any evidence of clinically significant structural or functional heart abnormality, a cardiac troponin I value greater than 0.2 ng/mL, the need for daytime mechanical or non-invasive ventilation, prior treatment with drisapersen or an investigational peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO), prior treatment with gene therapy for DMD, and recent treatment with ataluren or eteplirsen. Additionally, participants should not have received any investigational drug within a certain timeframe prior to the planned baseline biopsy collection.",
    "The sample from the table represents a phase 2 clinical trial. The diseases being studied include metastatic bladder urothelial carcinoma, metastatic renal pelvis urothelial carcinoma, metastatic ureter urothelial carcinoma, metastatic urethral urothelial carcinoma, unresectable renal pelvis urothelial carcinoma, and unresectable ureter urothelial carcinoma. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being used in the trial are cyclophosphamide, fludarabine, and fludarabine phosphate. \n\nThe eligibility criteria for the trial include the subjects having a histologically confirmed unresectable TCC (transitional cell carcinoma), having failed one line of cisplatin-based chemotherapy, having a measurable target lesion, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less. Other criteria include adequate bone marrow and organ function, negative HIV status, recovered from prior anticancer therapy-related adverse events, negative pregnancy test for female subjects, and willingness to comply with the study requirements.\n\nExclusion criteria include having had another primary malignancy within the previous 3 years (with some exceptions), prior treatment with certain therapies, ongoing chemotherapy or radiotherapy, severe infections, autoimmune or inflammatory disorders, HIV infection, severe liver disease, obstructive or restrictive pulmonary disease, known primary central nervous system malignancy or symptomatic CNS metastases, pregnancy or breastfeeding, active infections, and recent treatment with other investigational agents.",
    "The sample is a phase 2 clinical trial for patients with resectable stage III or IV cutaneous melanoma. The trial is testing the effectiveness of the drugs nivolumab, bms-986205, and ipilimumab. The eligibility criteria include having a histologic or cytologic diagnosis of melanoma, being at least 18 years old, having a performance status of 2 or lower, and having normal organ and marrow function. Participants must also have measurable disease and have not received prior targeted therapy or immunotherapy, except for adjuvant ipilimumab or interferon-\u03b1-2b. Other criteria include the ability to understand and sign a consent form, ability to swallow pills, and agreement to follow contraception methods for women of childbearing potential. The exclusion criteria include a history of prior treatment with certain inhibitors, uveal or mucosal melanoma, active brain metastases, and certain allergies or medical conditions. Pregnant women, those with active HIV or hepatitis, and those with certain autoimmune diseases or hemolytic disorders are also excluded. The sample also includes additional exclusion criteria related to prior immune therapy, use of botanical preparations, history of other malignancies, recent major surgery or trauma, conditions that interfere with medication absorption, uncontrolled adrenal insufficiency, and prior history of serotonin syndrome.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are metastatic hepatocellular carcinoma and hepatocellular carcinoma. The ICDCodes associated with these diseases are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drug being used in the trial is vancomycin. The eligibility criteria for this trial include various requirements such as histopathological confirmation of FLC, ineligibility for curative resection, transplantation or ablation, age greater than or equal to 18, evaluable or measurable hepatic disease, willingness to undergo biopsies, ECOG performance status of less than or equal to 2, adequate renal function, adequate hepatic function, adequate hematological function, co-enrollment onto another protocol, ability to understand and sign informed consent, and exclusion of certain treatments, medications, and medical conditions. Pregnant women are also excluded from this study due to the potential abortifacient effect of the mandatory biopsies.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on two diseases: \"bclc stage c hcc\" and \"cp-b liver cirrhosis\". The diseases are associated with specific ICD-10 codes. The trial is testing the drug \"sorafenib\". The eligibility criteria for participants are listed, including age, diagnosis criteria for HCC, advanced stage of HCC, cancer-related symptoms, and liver cirrhosis. There are also exclusion criteria, such as certain liver cirrhosis conditions, mental conditions, concurrent antitumoral treatment, and specific health conditions. Additionally, there are additional exclusion criteria for a cocktail test, including restrictions on consuming certain fruits and medications.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on non-small cell lung cancer (NSCLC). The trial is specifically targeting patients who have undergone surgery to remove stage II or III NSCLC and have recovered adequately. The trial requires the presence of ctDNA (circulating tumor DNA) in the plasma after surgery and before starting adjuvant platinum-doublet therapy. Participants must have received at least two cycles of adjuvant platinum-doublet chemotherapy regimens for resected NSCLC and should show no evidence of disease after surgery and chemotherapy. Other criteria include age, Eastern Cooperative Oncology Group (ECOG) Performance Status, adequate hematologic and end-organ function, and negative HIV, hepatitis B, and hepatitis C tests.\n\nExclusion criteria include participants with specific mutations in epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) or reactive oxygen species (ROS) alteration. Participants with a history of malignancy other than the disease under study within the past 5 years are also excluded, except for certain low-risk malignancies. Other exclusion criteria include prior systemic therapy, certain medications, autoimmune diseases, significant cardiovascular disease, recent surgeries, tuberculosis infection, and pregnancy or lactation.\n\nThis sample provides a detailed description of the inclusion and exclusion criteria for participants in the clinical trial.",
    "The sample is a phase 2 trial for COVID-19. The trial is investigating the use of hydroxychloroquine sulfate as a potential treatment. The eligibility criteria for participants include being 18 years or older, competent to provide informed consent, having access to a smart device with internet accessibility, and meeting specific criteria based on the sub-study they are enrolled in.\n\nSub-Study 1 focuses on individuals aged 40 or older who have tested positive for the SARS-CoV2 virus and have symptoms such as fever, cough, or shortness of breath. They should not be taking azithromycin, not require hospitalization, and must live within 30 miles of HUP or Penn Presbyterian Medical Center. They must also own a working computer or smartphone, be willing to fill out a daily symptom diary, be available for a daily phone call, and take their temperature twice a day. Additionally, they should report any observed symptoms and the development of COVID-19 in their co-inhabitants.\n\nSub-Study 2 includes hospitalized non-ICU service patients who are PCR-positive for SARS-CoV-2. They should have one or more risk factors for severe disease progression and be admitted to Hospital of the University of Pennsylvania or Penn Presbyterian. \n\nSub-Study 3 focuses on health care workers, specifically emergency medicine or infectious disease team physicians or nurses at HUP or PPMC. They should work at least 20 hours per week during the COVID-19 pandemic, have no fever, cough, or shortness of breath in the past 2 weeks, and be willing to report compliance with hydroxychloroquine in a diary. They should also be able to swallow and retain oral medication and not have any gastrointestinal abnormalities.\n\nThe exclusion criteria include being under 18 years of age, prisoners or detained persons, having an allergy to hydroxychloroquine, being pregnant or lactating, receiving any treatment drug for COVID-19 within 14 days prior to screening, and having a history of retinal disease or taking medications that prolong Qtc. Other exclusion criteria include having a history of interstitial lung disease, porphyria, psoriasis, or serious intercurrent illness. Patients who have undergone major surgery or are receiving certain anticonvulsant drugs are also excluded. Additionally, patients with increased cardiovascular risk or congestive heart failure are not eligible for the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease COVID-19. The ICD-10 codes associated with the disease are 'U07.1', 'Z86.16', 'U09.9', 'Z11.52', and 'Z20.822'. The drugs being studied are 'rtb101' and 'placebo'. The sample also includes the eligibility criteria for the trial. The inclusion criteria state that informed consent must be obtained, the subjects must be adults aged 65 years and over, and they must reside in a nursing home where COVID-19 infection has been confirmed. The exclusion criteria list various conditions and circumstances that would make a subject ineligible for the trial, such as smoking history, chronic obstructive pulmonary disease, being in hospice or receiving comfort care, having symptomatic COVID-19, having unstable medical disorders, receiving immunosuppressive therapy, having an immunodeficiency disease, or being a sexually active male with a partner of child-bearing potential.",
    "The sample from the table represents a phase 2 clinical trial. The diseases being studied in this trial are thrombocytopenia, cancer, and liver diseases. The corresponding ICD-10 codes for these diseases are provided as well. The drug being tested in the trial is avatrombopag. \n\nThe eligibility criteria for the trial include patients with a history of locally advanced or metastatic solid tumors who are planning to initiate cancer-directed systemic therapy. Patients must be 18 years of age or older and have a known liver disease attributed to various causes listed in the criteria. There is no specific Child-Pugh Score requirement for eligibility. Patients with liver involvement in primary or metastatic cancer are also eligible if they meet the diagnosis criteria.\n\nOther inclusion criteria include a platelet count of less than 80,000/mcL at the time of enrollment, no prior cytotoxic or marrow suppressive cancer therapy in the past 12 months, and an ECOG Performance status of 2 or lower.\n\nExclusion criteria for the trial include a history of immune causes of thrombocytopenia, presence of leukemia or myelodysplastic syndrome, known bone metastases, previous use of thrombopoietin mimetics, and the need for emergent systemic cancer therapy or radiation therapy. Other exclusion criteria include pancytopenia, low serum sodium levels, known bleeding disorder or platelet dysfunction, certain genetic prothrombotic conditions, recent use of anticoagulation or NSAIDs, concurrent lymphoma, and pre-existing non-tumor-related thrombus in specific locations.\n\nThe sample also mentions potential drug interactions and the use of contraception during the study period for female participants. It specifies that pregnant or breastfeeding women, or those planning to become pregnant or breastfeed during treatment, will be excluded from the trial. Male participants must agree to use adequate contraception methods as deemed appropriate by the investigator.\n\nOverall, the sample provides detailed information about the phase 2 clinical trial, including the diseases being studied, the drug being tested, and the eligibility and exclusion criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied include advanced lymphoma, advanced malignant solid neoplasm, hematopoietic and lymphoid cell neoplasm, refractory lymphoma, refractory malignant solid neoplasm, and refractory plasma cell myeloma. The corresponding ICDCodes for these diseases are also listed.\n\nThe drug being used in the trial is dasatinib. The eligibility criteria for participants in this trial include meeting applicable criteria in the Master MATCH Protocol, having specific missense mutations in DDR2 (S768R, I638F, L239R), having a normal electrocardiogram (ECG) and echocardiogram (ECHO) within specified timeframes, and not having any known hypersensitivity to dasatinib or prior use of the drug. Additionally, the presence of certain medications (STRONG CYP 3A4 inhibitors/inducers, H2-antagonists, proton pump inhibitors) may make patients ineligible for treatment with dasatinib.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drug, and eligibility criteria for a specific clinical trial."
]
